Document:

EX-4.8

 Exhibit 4.8 
 CONFIDENTIAL TREATMENT REQUESTED 
 EXECUTION VERSION 

29 May 2014 

NOVARTIS AG 
 and

 GLAXOSMITHKLINE PLC 
 and 
 LEO CONSTELLATION LIMITED 

 
  

 
 DEED OF AMENDMENT AND
RESTATEMENT 
 relating to the 
 CONTRIBUTION AGREEMENT 
 relating to the Consumer Healthcare Joint
Venture 
 dated 22 April 2014 
  

 
  

 
 

 
 Freshfields Bruckhaus Deringer LLP 

65 Fleet Street 

London EC4Y 1HS 

 This Deed (the “Deed”) is made on 29 May 2014 between: 

 

	(1)	NOVARTIS AG, a corporation (Aktiengesellschaft) incorporated in Switzerland whose registered office is at Lichtstrasse 35, 4056 Basel, Switzerland
(“Novartis”); 

  

	(2)	GLAXOSMITHKLINE PLC, a public limited company incorporated in England and Wales whose registered office is at 980 Great West Road, Brentford, Middlesex, TW8 9GS
(“GSK”); and 

  

	(3)	LEO CONSTELLATION LIMITED, a company incorporated in England and Wales whose registered office is at 980 Great West Road, Brentford, Middlesex, TW8 9GS (the
“Purchaser”). 

 each a “party” and together the “parties”. 

Whereas: 
  

	(A)	The parties entered into the Original Agreement (as defined below) on 22 April 2014 (the “Signing Date”). 

 

	(B)	In connection with the Original Agreement, GSK provided the Original GSK Disclosure Letter (as defined below) to the Purchaser and Novartis provided the Original
Novartis Disclosure Letter (as defined below) to the Purchaser. 

  

	(C)	The parties now wish to amend and restate the Original Agreement, in the form of the Amended Agreement (as defined below). 

 

	(D)	GSK and the Purchaser now wish to amend and restate the Original GSK Disclosure Letter, in the form of the Amended GSK Disclosure Letter (as defined below).

  

	(E)	Novartis and the Purchaser now wish to amend and restate the Original Novartis Disclosure Letter, in the form of the Amended Novartis Disclosure Letter (as defined
below). 

 It is agreed as follows: 
  

	1	Definitions and Interpretation 

 In this Deed, unless the context otherwise requires, the provisions in this clause 1 apply. 
  

	1.1	Incorporation of defined terms 

 Unless otherwise stated, terms defined in the Original Agreement shall have the same meaning in this Deed. 
  

	1.2	Definitions 

“Amended Agreement” means the Original Agreement, as amended and restated in the form set out in Schedule 1 to this Deed;

 “Amended GSK Disclosure Letter” means the Original GSK Disclosure Letter, as amended and restated in the form
set out in Schedule 2 to this Deed; 
 Amended Novartis Disclosure Letter” means the Original Novartis Disclosure
Letter, as amended and restated in the form set out in Schedule 3 to this Deed; 
 “Original Agreement” means
the Contribution Agreement relating to the Consumer Healthcare Joint Venture, dated 22 April 2014; 

  
 2 

 “Original GSK Disclosure Letter” means the letter given on the Signing Date
from GSK to the Purchaser disclosing information constituting exceptions to the Seller’s Warranties; and 

“Original Novartis Disclosure Letter” means the letter given on the Signing Date from Novartis to the Purchaser
disclosing information constituting exceptions to the Seller’s Warranties. 
  

	1.3	Interpretation Clauses 

  

	 	1.3.1	The principles of interpretation set out in Clause 1 of the Original Agreement shall have effect as if set out in this Deed, save that references to “this
Agreement” shall be construed as references to “this Deed”. 

  

	 	1.3.2	References to this Deed include the Schedules. 

  

	2	Amendment 

  

	2.1	In accordance with Clauses 15.5.3 and 15.6.1 of the Original Agreement, the parties agree that the Original Agreement shall be amended and restated as set out in
Schedule 1 to this Deed. 

  

	2.2	GSK and the Purchaser agree that the Original GSK Disclosure Letter shall be amended and restated as set out in Schedule 2 to this Deed. 

 

	2.3	Novartis and the Purchaser agree that the Original Novartis Disclosure Letter shall be amended and restated as set out in Schedule 3 to this Deed.

  

	2.4	The amendment and restatement of: 

  

	 	2.4.1	the Original Agreement pursuant to clause 2.1; 

  

	 	2.4.2	the Original GSK Disclosure Letter pursuant to clause 2.2; and 

  

	 	2.4.3	the Original Novartis Disclosure Letter pursuant to clause 2.3, 

 shall take effect from the Signing Date, as if the Amended Agreement, the Amended GSK Disclosure Letter and the Amended Novartis Disclosure Letter had been entered into on the Signing Date. Therefore,
upon this Deed being entered into: 
  

	 	(i)	the Amended Agreement shall supersede the Original Agreement in its entirety; 

 

	 	(ii)	the Amended GSK Disclosure Letter shall supersede the Original GSK Disclosure Letter in its entirety; and 

 

	 	(iii)	the Amended Novartis Disclosure Letter shall supersede the Original Novartis Disclosure Letter in its entirety. 

 

	2.5	GSK and Novartis agree that the Agreed Terms of the Shareholders’ Agreement and the Articles of Association and the Agreed Terms of the Completion Board
Resolutions (as defined in the Shareholders’ Agreement) have been amended in the form initialled for identification purposes by GlaxoSmithKline’s Lawyers and Novartis’s Lawyers on the date of this Deed. 

  
 3 

	3	Miscellaneous 

  

	3.1	Each party represents and warrants that it has full power and authority to enter into this Deed and to perform its obligations under it. 

 

	3.2	The provisions of Clauses 12, 15.3 to 15.6 and 15.14 to 15.18 of the Amended Agreement shall apply to this Deed as if set out in full in this Deed and as if references
in that clause to “this Agreement” are references to this Deed and references to “party” or “parties” are references to parties to this Deed. 

  
 4 

 In witness whereof this Deed has been delivered on the date first stated above. 

 

					
	Executed as a DEED by	  		  	
	  
 Roy Papatheodorou and
	  	}	  	  
 /s/ Roy Papatheodorou

	  
 Jonathan Emery
	  	  	  
 /s/ Jonathan Emery

	on behalf of NOVARTIS AG	  	  	

  
 5 

					
	Executed as a DEED by	 	)	    	
	GLAXOSMITHKLINE PLC acting by its	 	)	    	/s/ David Redfern
	duly appointed attorney	 	)	    	(Signature of attorney)
		 	)	    	
	in the presence of:	 	)	    	
			
	Witness’s signature:	 		    	/s/ Claire Jackson
			
	Name (print):	 		    	Claire Jackson
			
	Occupation:	 		    	Solicitor
			
	Address:	 		    	One Bunhill Row, London

  
 6 

					
	Executed as a DEED by	 	)	    	
	LEO CONSTELLATION LIMITED	 	)	    	/s/ David Redfern
	acting by its duly appointed attorney	 	)	    	(Signature of attorney)
		 	)	    	
	in the presence of:	 	)	    	
			
	Witness’s signature:	 		    	/s/ Claire Jackson
			
	Name (print):	 		    	Claire Jackson
			
	Occupation:	 		    	Solicitor
			
	Address:	 		    	One Bunhill Row, London

  
 7 

 Schedule 1 
 Amended Agreement 

  
 8 

 Dated 22 April 2014 

as amended and restated on 29 May 2014 
 GLAXOSMITHKLINE PLC 
 and 

NOVARTIS AG 
 and 
 LEO CONSTELLATION LIMITED 

 
  

CONTRIBUTION AGREEMENT  
 relating to the Consumer Healthcare Joint Venture 
  

 
  

  
 9 

 CONTENTS 

 

							
	 	 	 	  	Page	 
			
	 1.
	 	 Interpretation
	  	 	12	  
			
	 2.
	 	 Sale and Purchase of the Target Groups
	  	 	46	  
			
	 3.
	 	 Consideration
	  	 	53	  
			
	 4.
	 	 Conditions
	  	 	55	  
			
	 5.
	 	 Pre-Closing
	  	 	62	  
			
	 6.
	 	 Closing
	  	 	65	  
			
	 7.
	 	 Post-Closing Adjustments
	  	 	69	  
			
	 8.
	 	 Post-Closing Obligations
	  	 	71	  
			
	 9.
	 	 Warranties
	  	 	80	  
			
	 10.
	 	 Limitation of Liability
	  	 	81	  
			
	 11.
	 	 Claims
	  	 	85	  
			
	 12.
	 	 Confidentiality
	  	 	87	  
			
	 13.
	 	 Insurance
	  	 	88	  
			
	 14.
	 	 France Business and the Netherlands Business
	  	 	89	  
			
	 15.
	 	 Other Provisions
	  	 	92	  
		
	 Schedule 1 Details of the Share Sellers, Shares etc.
	  	 	102	  
		
	 Schedule 2 The Properties
	  	 	108	  
		
	 Schedule 3 Excluded Assets
	  	 	128	  
		
	 Schedule 4 Product Approvals etc.
	  	 	129	  
		
	 Schedule 5 Certificate
	  	 	137	  
		
	 Schedule 6 Transferred Contracts and Certain Other Business
	  	 	139	  
		
	 Schedule 7 Employees
	  	 	149	  
		
	 Schedule 8 Employee Benefits
	  	 	166	  

  
 10 

							
		
	 Schedule 9 Products
	  	 	176	  
		
	 Schedule 9 Products
	  	 	176	  
		
	 Schedule 10 VAT
	  	 	0	  
		
	 Schedule 11 Closing Obligations
	  	 	2	  
		
	 Schedule 12 Post Closing Adjustments
	  	 	6	  
		
	 Schedule 13 Warranties given under Clause 9.1
	  	 	16	  
		
	 Schedule 14 Warranties given by the Purchaser under Clause 9.3
	  	 	31	  
		
	 Schedule 15 Pre-Closing Obligations
	  	 	33	  
		
	 Schedule 16 Key Personnel
	  	 	38	  
		
	 Schedule 17 Reorganisations
	  	 	39	  
		
	 Schedule 18 Statement of Net Assets
	  	 	42	  
		
	 Schedule 19 Novartis International Assignees
	  	 	51	  
		
	 Schedule 20 Clearances, Approvals etc.
	  	 	52	  
		
	 Schedule 21 Seller Marks
	  	 	54	  

  
 11 

 Contribution Agreement 
 This Agreement is made on 22 April 2014 and amended and restated on      May 2014 
 between: 
  

	(1)	Novartis AG, a corporation (Aktiengesellschaft) registered in the Commercial Register of the Canton of Basel-Stadt, Switzerland under number CHE-103.867.266 and
whose registered office is at Basel Switzerland and whose address is Lichtstrasse 35, 4056 Basel (“Novartis”); 

  

	(2)	GlaxoSmithKline Plc, a company registered in England under number 03888792 and whose registered office is at 980 Great West Road, Brentford, Middlesex TW8 9GS
(“GlaxoSmithKline”, with each of Novartis and GlaxoSmithKline being, a “Seller” and together, the “Sellers”); and 

 

	(3)	Leo Constellation Limited, a company registered in England under number 08998608 whose registered office is at 980 Great West Road, Brentford, Middlesex TW8 9GS
(the “Purchaser”), 

 each a “party” and together the “parties”. 

Whereas: 
  

	(A)	Each Seller and certain of its Affiliates (as defined below), including that Seller’s Target Group Companies (as defined below), are engaged in that Seller’s
Contributed Business (as defined below). 

  

	(B)	As of the date of this Agreement, each Seller and certain of its Affiliates directly or indirectly own shares or other equity interests in that Seller’s Target
Group Companies. 

  

	(C)	Each Seller has agreed to sell (or procure the sale of) its Target Group (as defined below) and to assume the obligations imposed on it as a Seller under this
Agreement, in each case, on the terms and subject to the conditions of this Agreement. 

  

	(D)	The Purchaser has agreed to purchase (or procure the purchase of) the Target Groups and to assume the obligations imposed on the Purchaser under this Agreement, in each
case, on the terms and subject to the conditions of this Agreement. 

  

	(E)	In connection with the transactions contemplated by this Agreement, the Purchaser and GlaxoSmithKline and/or Novartis, and/or certain of their respective Affiliates,
have entered into or will enter into the Ancillary Agreements (as defined below). 

 It is agreed as follows: 

 

	1.	Interpretation 

 In this
Agreement, unless the context otherwise requires, the provisions in this Clause 1 apply: 
  

	1.1	Definitions 

“2012 Accounts” means, for each Target Group Company, the audited financial statements of that Target Group Company,
prepared in accordance with legislation as in force and applicable to that Target Group Company for the accounting reference period ended on the 2012 Accounts Date, comprising the balance sheet, the profit and loss account and the notes to the
accounts; 

  
 12 

 “2012 Accounts Date” means 31 December 2012; 

“2013 Operating Income” means the operating income for 2013 annexed to the Disclosure Letter at Annex B. 

“A Shares” means the A ordinary shares in the capital of the Purchaser, having the rights and restrictions set out in the
articles of association of the Purchaser as at Closing, and which, immediately following Closing, will represent 63.5 per cent. of the ordinary share capital of the Purchaser; 

“Action” means the taking of any steps by any Governmental Entity to seek a Judgment which would have the effect of
preventing the consummation of the transactions contemplated by this Agreement by the Purchaser; 
 “Affiliate”
means, 
  

	 	(i)	with respect to the parties, any other person that is Controlled by such person; or 

 

	 	(ii)	with respect to any other person, any other person that Controls, is Controlled by or is under common Control with such person, and “Affiliates” shall
be interpreted accordingly; 

 “Affiliate Contract” means: 

 

	 	(i)	in respect of GlaxoSmithKline, any Contract between or among any member of GlaxoSmithKline’s Group (other than its Target Group Company) on the one hand, and its
Target Group Company on the other hand, to the extent that it relates to any services that will be and, as at Closing are, provided under the Ancillary Agreements, but excluding, for the avoidance of doubt: (i) any Ancillary Agreement; and
(ii) any Contract comprising or related to any Intra-Group Trading Payables or Intra-Group Trading Receivables; or 

  

	 	(ii)	in respect of Novartis, any Contract between or among any member of Novartis’s Group (other than its Target Group Company) on the one hand, and its Target Group
Company on the other hand, but excluding (i) any Ancillary Agreement; (ii) any Contract comprising or related to any Intra-Group Trading Payables or Intra-Group Trading Receivables; (iii) any Novartis Services Contract; and
(iv) any Novartis Distribution and Sales Products Contract; 

 “Agreed Terms” means, in
relation to a document, such document in the terms agreed between GlaxoSmithKline and Novartis and initialled for identification purposes by GlaxoSmithKline’s Lawyers and Novartis’s Lawyers, with such alterations as may be agreed in
writing between the parties from time to time; 
 “Agreed UK Restructuring Arrangement” means the pension
augmentation (or cash in lieu of augmentation) policy applying on redundancy to UK employees of the GlaxoSmithKline Group who joined service prior to 1 April 2005 as disclosed to Novartis prior to the date of this Agreement via a document which
was signed on 22 April 2014 by Eleanor Hart of Slaughter and May and Andrew Murphy of Freshfields Bruckhaus Deringer LLP for identification purposes; 
 “Agreement” means this contribution agreement as it may have been amended or restated from time to time; 
 “Ancillary Agreements” means the Implementation Agreement, the Local Transfer Documents, the Disclosure Letters, the Tax Indemnity, the France Offer Letters, the France SAPAs, the
Netherlands Offer Letter, the Netherlands SAPA, the Transitional Services Agreements, the Manufacturing, Distribution and Supply Agreements, the Seller Intellectual Property Licence Agreement, the Purchaser Trademark Licence Agreement, the Seller
Trademark Licence Agreement, the Intellectual Property Assignment Agreements, the Pharmacovigilance Agreement, the Services Agreement and the Shareholders’ Agreement; 

  
 13 

 “Animal Health Term Sheet” has the meaning given to it in Clause 5.2.3(i);

 “Anti-Bribery Law” means any Applicable Law that relates to bribery or corruption, including the US Foreign
Corrupt Practices Act of 1977 and the UK Bribery Act 2010, in each case, as amended, re-enacted or replaced from time to time; 

“Applicable Law” means any supra-national, federal, national, state, municipal or local statute, law, ordinance,
regulation, rule, code, order (whether executive, legislative, judicial or otherwise), judgment, injunction, notice, decree or other requirement or rule of law or legal process (including common law), or any other order of, or agreement issued,
promulgated or entered into by, any Governmental Entity or any rule or requirement of any national securities exchange, including all Healthcare Laws, and GCP, GLP, and GMP, each as may be amended, re-enacted or replaced from time to time;

 “Appointment Notice” has the meaning given to it in paragraph 1.4 of Schedule 12; 

“Articles of Association” means the articles of association of the Purchaser in the Agreed Terms, as amended from time to
time in accordance with the provisions of the Shareholders’ Agreement; 
 “Associated Person” means, in
relation to a Seller’s Group, a person (including any director, officer, employee, agent or other intermediary) who performs services for or on behalf of any member of that Seller’s Group or who holds shares of capital stock, partnership
interests, limited liability company membership interests or units, shares, interests or other participations in any member of that Seller’s Group (in each case, when performing such services or acting in such capacity); 

“Assumed Liabilities” means all Liabilities relating to the Target Group Businesses other than: (i) the Excluded
Liabilities; (ii) any Assumed Pension and Employment Liabilities; and (iii) any Liabilities in respect of Tax (other than Tax which has been provided for or reflected in the Closing Statement and Tax which has been assumed by a member of
the Purchaser’s Group under an express provision of this Agreement); 
 “Assumed Pension and Employment
Liabilities” means (i) any Liabilities assumed by the Purchaser or a member of the Purchaser’s Group as contemplated by Schedule 7; and (ii) any Transferred Employee Benefit Liabilities (as defined in Schedule 8) which the
Purchaser agrees to assume in accordance with Schedule 8; 
 “B Shares” means the B ordinary shares in the
capital of the Purchaser, having the rights and restrictions set out in the articles of association of the Purchaser as at Closing, and which, immediately following Closing, will represent 36.5 per cent. of the ordinary share capital of the
Purchaser; 
 “Base Working Capital Range” means, in respect of a Seller, the range between its Minimum Working
Capital Amount and its Maximum Working Capital Amount; 
 “Benefit Plans” means the US Benefit Plans and the
Non-US Benefit Plans; 
 “Brand” means the primary name of a Product; 

“Business Day” means a day which is not a Saturday, a Sunday or a public holiday in the canton of Basel-Stadt
(Switzerland) or London (United Kingdom); 
 “Business Information” means, in respect of a Seller:
(i) Commercial Information; (ii) Medical Information; and (iii) any other information Predominantly Related to its Contributed Business; 

  
 14 

 “Business Sellers” means, in respect of a Seller, the members of that
Seller’s Group (other than its Target Group Companies) that own assets of or otherwise conduct any of its Target Group Businesses; 
 “Call for New Tender” means, in respect of a Seller, any calls for a tender (including any tender for a basket of products), whether a new tender or the renewal of an existing tender,
which includes its Products and which is published after Closing of which that Seller and/or any of its Affiliates become aware and which relates in whole or in part to the sale of its Products; 

“Cash Balances” means cash in hand or credited to any account with a financial institution and securities which are
readily convertible into cash; 
 “Cash Pooling Arrangements” means, in respect of a Seller, the cash pooling
arrangements of that Seller’s Group in which any of its Target Group Companies participate; 
 “Cash
Portion” means, in respect of GlaxoSmithKline, £190,500,000 and, in respect of Novartis, £109,500,000; 

“Certificate” means, in the case of a Seller, a certificate signed by a director, officer or an authorised signatory of
that Seller in the form set out in Schedule 5 to be provided to the Purchaser immediately prior to Closing; 

“CFIUS” means the Committee on Foreign Investment in the United States; 

“CFIUS Approval” means written notice from CFIUS that any review or investigation of the Transaction under
Section 721 of the Defense Production Act of 1950 of the United States, as amended (50 U.S.C. App. Section 2170), has been concluded and there are no unresolved national security concerns with respect to the Transaction or the President
shall have determined not to take action with respect to the Transaction; 
 “CFIUS Filing” has the meaning
given to it in Clause 4.2.3(ii); 
 “Chinese JV Contracts” means the joint venture contract between Tianjin
Pharmaceutical Corporation and SmithKline Beckman Corporation dated April 1984, as amended from time to time, and any other ancillary agreements thereto; 
 “Chinese JV Interests” means all of the shares or other equity interests held by SmithKline Beckman Corporation in The Sino-American Tianjin Smith Kline & French Laboratories,
Ltd, a joint venture company governed by the Chinese JV Contracts; 
 “Clinical Trials/Data Liability” means any
Liability arising out of, relating to or resulting from any breach of Applicable Law in connection with the conduct of, or reporting or data in relation to, clinical studies or trials (including post-approval studies) sponsored or supported by or in
relation to a Target Group or otherwise recommended by a Governmental Entity; 
 “Closing” means the completion
of the sale of (i) the Shares and (ii) the Target Group Businesses in respect of each of GlaxoSmithKline and Novartis, in each case, pursuant to this Agreement and any Ancillary Agreement, and Closing shall be deemed to have taken place
even if some of the Shares in relation to the Joint Venture Entities only or other elements of the Contributed Businesses have not transferred to the Purchaser pursuant to Schedule 6 to which the provisions of Schedule 6 shall then apply;

 “Closing Date” means the date on which Closing takes place in accordance with Clause 6.1; 

“Closing Statement” means, in respect of a Seller, the statement setting out the Working Capital, the Working Capital
Adjustment, the Target Group Companies’ Cash Balances, the Intra-Group Non-Trade Receivables, the Third Party Indebtedness, the Intra-Group Non-Trade Payables and the Tax Adjustment, to be prepared by that Seller and agreed or determined in
accordance with Clause 7 and Schedule 12; 

  
 15 

 “COBRA” means the Consolidated Omnibus Budget Reconciliation Act of 1985 of
the United States, as amended, section 4980B of the Code, Title I Part 6 of ERISA and any similar US state group health plan continuation law, together with its implementing regulations; 

“Code” means the U.S. Internal Revenue Code of 1986, as amended, together with its implementing regulations; 

“Commercial Information” means, in respect of a Seller, information that is, as of the Closing Date, owned by that Seller
and/or its Affiliates and Predominantly Related to that Seller’s Contributed Business; 
 “Commercial Practices
Liability” means any Liability arising out of, relating to or resulting from any breach of Applicable Law in connection with Commercialisation; 
 “Commercialise” means to promote, market, distribute, sell and/or otherwise commercialise a product and “Commercialising” and “Commercialisation” shall
be construed accordingly; 
 “Company Lease” has the meaning given to it in paragraph 1.1 of Part 3 of Schedule
2; 
 “Company Leased Properties” has the meaning given to it in paragraph 1.1 of Part 3 of Schedule 2;

 “Company Owned Properties” has the meaning given to it in paragraph 1.1 of Part 3 of Schedule 2; 

“Company Properties” means the Company Owned Properties and the Company Leased Properties, and “Company
Property” means any one of them; 
 “Consumer Healthcare Product” means, in respect of any
jurisdiction, any oral care, nutritional care, skin care or other cosmetic or healthcare product or device of any kind, in each case, for the treatment of, or use by, human beings which is available without, or both with and without, a prescription,
but excluding any such product or device that is subject to the same regulatory classification and/or regulatory treatment (including in relation to advertising) as a product or device that is available only with a prescription; 

“Contract” means any binding contract, agreement, instrument, lease, licence or commitment, excluding: (i) any lease
or other related or similar agreements, undertakings and arrangements with respect to the leasing or ownership of the Properties (to which the provisions set out in Schedule 2 shall apply); and (ii) any contract with any Employee; 

“Contracts Liabilities” means Liabilities relating to: (i) the Transferred Contracts; (ii) the Transferred
Intellectual Property Contracts; and (iii) all other contracts (or any part thereof) transferred, assigned, novated or assumed by the Purchaser pursuant to this Agreement or to which a Target Group Company is or was a party or under which a
Target Group Company has any Liability, and “Contracts Liability” shall be construed accordingly; 

“Contributed Business” means, in respect of GlaxoSmithKline, the GlaxoSmithKline Consumer Business and, in respect of
Novartis, the Novartis OTC Business; 
 “Control” means the power to direct the management and policies of a
person (directly or indirectly), whether through ownership of voting securities, by Contract or otherwise (and the term “Controlled” shall be interpreted accordingly); 

  
 16 

 “Co-Owned Target Group Intellectual Property Rights” means any Target Group
Intellectual Property Right that is owned in part by a third party; 
 “Copyright” means any works of
authorship, copyrights, database rights, mask work rights and registrations and applications thereof; 
 “December
Presentation” means, in the case of GlaxoSmithKline, the GlaxoSmithKline December 2013 Presentation and, in the case of Novartis, the Novartis December 2013 Presentation; 

“Decision” means the issuing of any decision by a competition, antitrust, foreign investment, national, local,
supranational or supervisory or other government, governmental, quasi-governmental, trade, or regulatory body, agency, branch, subdivision, department, commission, official or authority, including any Tax Authority and any governmental department
and any court or other tribunal, that would have the effect of prohibiting the acquisition of the Target Groups by the Purchaser; 
 “Deferred Employee” means, in respect of GlaxoSmithKline, any GlaxoSmithKline Deferred Employee and, in respect of Novartis, any Novartis Deferred Employee; 

“Disclosure Letter” means, in respect of GlaxoSmithKline, the letter dated on the same date as this Agreement from
GlaxoSmithKline to the Purchaser and, in respect of Novartis, the letter dated on the same date as this Agreement from Novartis to the Purchaser; 
 “Draft Closing Statement” has the meaning given to it in Clause 7.1.1; 
 “Effective Time” means 11.59 p.m. (local time in the relevant location) on the Closing Date or, if the Closing Date is not the last day of a month but the first Business Day of a month,
11.59 p.m. on the last day of the immediately preceding month; 
 “Election Date” has the meaning given to it in
Clause 4.2.3(ii); 
 “Employee Benefit Indemnification Amount” has the meaning given to it in Schedule 8;

 “Employee Benefits” has the meaning given to it in Schedule 8; 

“Employees” means, in respect of GlaxoSmithKline, the GlaxoSmithKline Employees and, in respect of Novartis, the Novartis
Employees; 
 “Encumbrance” means any claim, charge, mortgage, lien, option, equitable right, power of sale,
pledge, hypothecation, usufruct, retention of title, right of pre-emption, right of first refusal or other security interest of any kind or an agreement, arrangement or obligation to create any of the foregoing, and for the avoidance of doubt, shall
exclude any licences of, or claims of infringement in relation to, Intellectual Property Rights; 
 “Endo Excluded
Contract” means the license and supply agreement between Novartis, Novartis Consumer Health, Inc. and Endo Pharmaceuticals Inc. dated 4 March 2008, in relation to, among other things, a license to Commercialise Voltaren Gel as a
Prescription Product; 
 “Environmental Laws” means any and all Applicable Law regulating or imposing Liability
or standards of conduct concerning pollution or protection of the environment (including surface water, groundwater or soil); 

“Environmental Liabilities” means any Liability arising out of, relating to or resulting from any Environmental Law or
environmental, health or safety matter or condition, including natural resources, but excluding any Product Liability; 

  
 17 

 “Environmental Permit” means any permit, licence, consent or authorisation
required by Environmental Laws issued by any relevant competent authority and used in relation to the operation or conduct of Manufacturing at any Property; 
 “ERISA” means the Employee Retirement Income Security Act of 1974 of the United States, as amended, together with its implementing regulations; 

“Estimated Employee Benefit Adjustment” means, in respect of a Seller, that Seller’s reasonable estimate (in so far
as practicable), made in good faith after consulting with the other Seller, of 95 per cent of the anticipated aggregate of its Employee Benefit Indemnification Amounts, to be notified by that Seller to the Purchaser pursuant to Clause 6.4;

 “Estimated Intra-Group Non-Trade Payables” means, in respect of a Seller, that Seller’s reasonable
estimate of its Intra-Group Non-Trade Payables, to be notified by that Seller to the Purchaser pursuant to Clause 6.4; 

“Estimated Intra-Group Non-Trade Receivables” means, in respect of a Seller, that Seller’s reasonable estimate of
its Intra-Group Non-Trade Receivables, to be notified by that Seller to the Purchaser pursuant to Clause 6.4; 

“Estimated Intra-Group Trade Balances” means, in respect of a Seller, that Seller’s reasonable estimate of its
Intra-Group Trade Balances, to be notified by that Seller to the Purchaser pursuant to Clause 6.4; 
 “Estimated
Intra-Group Trade Payables” means, in respect of a Seller, that Seller’s reasonable estimate of its Intra-Group Trade Payables, to be notified by that Seller to the Purchaser pursuant to Clause 6.4; 

“Estimated Intra-Group Trade Receivables” means, in respect of a Seller, that Seller’s reasonable estimate of its
Intra-Group Trade Receivables, to be notified by that Seller to the Purchaser pursuant to Clause 6.4; 
 “Estimated
Target Group Companies’ Cash Balances” means, in respect of a Seller, that Seller’s reasonable estimate of its Target Group Companies’ Cash Balances, to be notified by that Seller to the Purchaser pursuant to Clause 6.4;

 “Estimated Tax Adjustment” means, in respect of a Seller, that Seller’s reasonable estimate of its Tax
Adjustment, to be notified by that Seller to the Purchaser pursuant to Clause 6.4; 
 “Estimated Third Party
Indebtedness” means, in respect of a Seller, that Seller’s reasonable estimate of its Third Party Indebtedness, to be notified by that Seller to the Purchaser pursuant to Clause 6.4; 

“Estimated Transferred Accounts Payables” means, in respect of a Seller, that Seller’s reasonable estimate of its
Transferred Accounts Payables, to be notified by that Seller to the Purchaser pursuant to Clause 6.4; 
 “Estimated
Transferred Accounts Receivables” means, in respect of a Seller, that Seller’s reasonable estimate of its Transferred Accounts Receivables, to be notified by that Seller to the Purchaser pursuant to Clause 6.4; 

“Estimated Working Capital” means, in respect of a Seller, that Seller’s reasonable estimate of its Working Capital,
to be notified by that Seller to the Purchaser pursuant to Clause 6.4; 
 “Estimated Working Capital Adjustment”
means, in respect of a Seller: 

  
 18 

	 	(i)	if its Estimated Working Capital is no less than its Minimum Working Capital Amount and no greater than its Maximum Working Capital Amount, zero;

  

	 	(ii)	if its Estimated Working Capital is less than its Minimum Working Capital Amount, the amount by which its Estimated Working Capital is less than its Minimum Working
Capital Amount, such amount being treated as a negative amount; or 

  

	 	(iii)	if its Estimated Working Capital is greater than its Maximum Working Capital Amount, the amount by which its Estimated Working Capital exceeds its Maximum Working
Capital Amount, such amount being treated as a positive amount; 

 “Excluded Assets” means, in
respect of GlaxoSmithKline, the GlaxoSmithKline Excluded Assets and, in respect of Novartis, the Novartis Excluded Assets; 

“Excluded Contracts” means, in respect of a Seller, each Contract that is not Exclusively Related to that Seller’s
Contributed Business; 
 “Excluded Employees” means, in respect of GlaxoSmithKline, GlaxoSmithKline Excluded
Employees and, in respect of Novartis, the Novartis Excluded Employees; 
 “Excluded Liabilities” means, in
respect of a Seller: 
  

	 	(i)	all Liabilities: 

  

	 	(a)	relating to that Seller’s Target Group Businesses; and 

  

	 	(b)	of that Seller’s Target Group Companies (other than Liabilities in respect of Tax), 

in either case, to the extent that they have arisen or arise (whether before or after Closing) as a result of, or otherwise relate to,
any act, omission, fact, matter, circumstance or event undertaken, occurring, in existence or arising before Closing, and in either case, other than (a) any Assumed Pension and Employment Liabilities, (b) any Liabilities to the extent
taken into account, provided for or reflected in the Closing Statement (including in respect of Tax), (c) any Intra-Group Trade Payables and (d) Transferred Accounts Payables between any member of that Seller’s Group (other than a
Target Group Company) and a Business Seller of that Seller’s Group; and 
  

	 	(ii)	all Liabilities relating to its Seller’s Retained Business; 

 “Exclusively Related to” means, in respect of a Seller’s Contributed Businesses, exclusively related to, or used or held for use exclusively in connection with, that Contributed
Business; 
 “FCA” means the Financial Conduct Authority; 

“FDA” means the United States Food and Drug Administration (or its successor); 

“Final Payment Date” means five Business Days after the date on which the process described in Part 1 of Schedule 12 for
the preparation of its Closing Statement is complete; 
 “France Assumed Liabilities” means, in respect of a
Seller, the Assumed Liabilities to the extent they relate to that Seller’s France Business; 
 “France
Business” means, in respect of Novartis, that part of its Contributed Business that is conducted in France, including Novartis Santé Familiale S.A.S, its France Assumed Liabilities and its France Employees and, in respect of
GlaxoSmithKline, that part of its Contributed Business that is conducted in France, its France Assumed Liabilities and its France Employees; 

  
 19 

 “France Closing” has, in respect of a Seller, the meaning given to it in
that Seller’s France SAPA; 
 “France Employees” means, in respect of Novartis, the Employees employed by
Novartis Santé Familiale S.A.S. and, in respect of GlaxoSmithKline, those of the GlaxoSmithKline Employees who are employed in France; 
 “France Offer Letter” means, in respect of a Seller, the letter from the Purchaser to that Seller in respect of the binding offer from the Purchaser to acquire that Seller’s France
Business dated on the date hereof; 
 “France Put Option Exercise” means, in respect of a Seller, the meaning
given to it in that Seller’s France Offer Letter; 
 “France SAPA” means, in respect of a Seller, the
meaning given to it in that Seller’s France Offer Letter; 
 “FSAs” has the meaning given to it in
paragraph 7 of Schedule 7; 
 “FSMA” means the Financial Services and Markets Act 2000; 

“Full Title Guarantee” means, in respect of a Seller on the basis that the covenants implied under Part 1 of the Law of
Property (Miscellaneous Provisions) Act 1994 where a disposition is expressed to be made with full title guarantee are deemed to be given by that Seller (on behalf of its relevant Share Seller or Business Seller) on Closing; 

“GlaxoSmithKline’s Articles of Association” means the articles of association of GlaxoSmithKline in force and effect
from time to time; 
 “GlaxoSmithKline Business Employees” means the employees of any member of
GlaxoSmithKline’s Group who work wholly or substantially in the GlaxoSmithKline Consumer Business from time to time including, for the avoidance of any doubt, the GlaxoSmithKline International Assignees other than the GlaxoSmithKline Company
Employees and the GlaxoSmithKline Excluded Employees and provided that, in relation to the Seller’s Warranties only, the words “from time to time” shall be deemed to be replaced by “at the date of this Agreement”, and
“GlaxoSmithKline Business Employee” means any one of them; 
 [***] 

“GlaxoSmithKline Company Employees” means the employees from time to time of any of the GlaxoSmithKline Consumer Group
Companies other than the GlaxoSmithKline Excluded Employees, and provided that, in relation to the Seller’s Warranties only, the words “from time to time” shall be deemed to be replaced by “at the date of this Agreement”,
and “GlaxoSmithKline Company Employee” means any one of them; 
 “GlaxoSmithKline Consumer
Business” means: 
  

	 	(i)	the business of researching and developing, manufacturing, distributing, marketing, selling, promoting and/or otherwise Commercialising the GlaxoSmithKline Products in
the GlaxoSmithKline Territories; 

  

	 	(ii)	the business of researching and developing the GlaxoSmithKline Pipeline Products; 

 

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission 

  
 20 

	 	(iii)	all rights, title and interest in relation to researching and developing, manufacturing, distributing, marketing, selling, promoting and/or otherwise Commercialising
GlaxoSmithKline’s In-Scope Switch Product, in any jurisdiction, as a Consumer Healthcare Product only; 

  

	 	(iv)	the business of manufacturing, distributing, marketing, selling, promoting and/or otherwise Commercialising the Prescription Products which are managed by and reported
for financial purposes in the GlaxoSmithKline Consumer Healthcare Division for, or since, the year ended December 2013 and, in respect of any such Prescription Product, in the territories in which sales are reported for such Prescription Product for
financial purposes in the GlaxoSmithKline Consumer Healthcare Division for, or since, the year ended December 2013; and 

  

	 	(v)	any royalty streams in respect of any products received by and reported for financial purposes in the GlaxoSmithKline Consumer Healthcare Division for, or since, the
year ended 31 December 2013, 

 in each case, conducted by GlaxoSmithKline’s Group, but excluding the
GlaxoSmithKline Excluded Assets; 
 “GlaxoSmithKline Consumer Group” means the GlaxoSmithKline Consumer Group
Companies and the GlaxoSmithKline Consumer Group Businesses; 
 “GlaxoSmithKline Consumer Group Businesses”
means the businesses of the GlaxoSmithKline Consumer Business (but excluding the businesses carried on by the GlaxoSmithKline Consumer Group Companies) as set out in Clause 2.3.1, but subject always to Clause 2.3.2, and “GlaxoSmithKline
Consumer Group Business” means any of them; 
 “GlaxoSmithKline Consumer Group Companies” means those
members of GlaxoSmithKline’s Group whose operations, assets and/or businesses are Exclusively Related to the GlaxoSmithKline Consumer Business, an indicative list of which are set out in the table in Part A of Part 1 of Schedule 1, including
any Intermediate Holdco as defined in Schedule 17 (Reorganisations), but excluding any such members whose operations, assets and/or businesses form any part of the GlaxoSmithKline Excluded Assets and “GlaxoSmithKline Consumer Group
Company” shall mean any one of them; 
 “GlaxoSmithKline December 2013 Presentation” means the
management presentation entitled Project Constellation Consumer Healthcare and dated 3 December 2013 and attached to this Agreement as Attachment 1; 
 “GlaxoSmithKline Deferred Employee” means any person to whom GlaxoSmithKline, any GlaxoSmithKline Consumer Group Company or any other member of GlaxoSmithKline’s Group has made an
offer of employment for a role in the GlaxoSmithKline Consumer Business in compliance with Clause 5 and who has accepted such offer in writing and whose employment in the GlaxoSmithKline Consumer Business will take effect on a date following the
Closing Date, save that no person shall become a GlaxoSmithKline Deferred Employee unless and until GlaxoSmithKline has provided to Novartis a copy of the offer letter setting out the agreed principal terms of employment and/or employment agreement
(if executed) applicable to such person; 
 “GlaxoSmithKline Employees” means the GlaxoSmithKline Business
Employees and the GlaxoSmithKline Company Employees, and “GlaxoSmithKline Employee” means any one of them; 

  
 21 

 “GlaxoSmithKline Excluded Assets” means the property, rights, businesses
and assets referred to in Clause 2.3.2 in respect of the GlaxoSmithKline Consumer Group Businesses and the assets and businesses set out in Part 1 of Schedule 3; 
 “GlaxoSmithKline Excluded Businesses” means: 
  

	 	(i)	the business(es) (from time to time) of or reported for financial purposes in the business(es) of GlaxoSmithKline Consumer Healthcare Limited, an Indian listed company,
and its successors and assigns and any person Controlled by GlaxoSmithKline Consumer Healthcare Limited from time to time; 

  

	 	(ii)	the business(es) (from time to time) of or reported for financial purposes in the business(es) of GlaxoSmithKline Consumer Nigeria plc, a Nigerian listed company, and
its successor and assigns and any person Controlled by GlaxoSmithKline Consumer Nigeria plc from time to time; 

  

	 	(iii)	the business(es) (from time to time) of the GlaxoSmithKline Pharmaceutical Division, including the business of researching and developing, manufacturing, distributing,
marketing, selling, promoting and/or otherwise Commercialising any Consumer Healthcare Products which are managed by and reported for financial purposes in the GlaxoSmithKline Pharmaceutical Division on or prior to the date of this Agreement
(including any development of such products); 

  

	 	(iv)	any business(es) (from time to time) of or reported for financial purposes in the business(es) of: (i) Asia Private Limited, a private limited company incorporated
in India; and/or (ii) its successors and assigns and any person Controlled by Asia Private Limited from time to time, in each case, to the extent that such business(es) are part of the business(es) conducted by the business(es) referred to in
paragraph (i) of this definition; and 

  

	 	(v)	any assets or liabilities that are deemed to constitute GlaxoSmithKline Excluded Assets pursuant to paragraph 10.1 of Schedule 6; 

“GlaxoSmithKline Excluded Employees” means the employees of any member of GlaxoSmithKline’s Group (including the
GlaxoSmithKline Consumer Group Companies) as may be agreed in writing between GlaxoSmithKline and Novartis after the date of this Agreement but before the Closing Date; 
 “GlaxoSmithKline’s Group” means GlaxoSmithKline and its Affiliates from time to time, provided that, for the purposes of this Agreement, the Purchaser and any person Controlled by
the Purchaser (whether directly or indirectly) from time to time shall not be included in GlaxoSmithKline’s Group; 

“GlaxoSmithKline International Assignees” means the employees of any member of GlaxoSmithKline’s Group (including
the GlaxoSmithKline Consumer Group Companies) as may be agreed in writing between GlaxoSmithKline and Novartis after the date of this Agreement but before the Closing Date; 
 “GlaxoSmithKline Joint Venture Entities” means all entities in which GlaxoSmithKline’s Group holds equity interests of less than 100 per cent. but whose operations, assets
and/or businesses are Exclusively Related to the GlaxoSmithKline Consumer Business, an indicative list of which are set out in the relevant part of the table in Part B of Part 1 of Schedule 1, excluding any such entity whose operations, assets
and/or businesses form part of the GlaxoSmithKline Excluded Assets; 

  
 22 

 “GlaxoSmithKline Key Personnel” means the GlaxoSmithKline Employees listed
in Part 1 of Schedule 16; 
 “GlaxoSmithKline’s Lawyers” means Slaughter and May of One Bunhill Row, London
EC1Y 8YY; 
 “GlaxoSmithKline Material Employee Jurisdictions” means Brazil, China, Germany, the United Kingdom
and the United States of America; 
 “GlaxoSmithKline Pakistan” means GlaxoSmithKline Pakistan Limited, a
company incorporated in Pakistan as a limited liability company and listed on the Karachi and Lahore Stock Exchanges; 

“GlaxoSmithKline Pakistan Business” means that part of the GlaxoSmithKline Consumer Business conducted by GlaxoSmithKline
Pakistan or any person Controlled by GlaxoSmithKline Pakistan from time to time; 
 “GlaxoSmithKline Pakistan
Consent” has the meaning given in paragraph 8.1 of Schedule 6; 
 “GlaxoSmithKline Pipeline Products”
means each product that the GlaxoSmithKline Consumer Healthcare Division is researching and developing; 

“GlaxoSmithKline Products” means, in respect of any territory, any Consumer Healthcare Products which are managed by and
reported for financial purposes in the GlaxoSmithKline Consumer Healthcare Division in that territory for the year ended 31 December 2013 or since, an indicative list of which is set out in Part 1 of Schedule 9; 

“GlaxoSmithKline Shareholder Meeting” has the meaning given to it in Clause 4.1.6; 

“GlaxoSmithKline Shareholder Resolution” has the meaning given to it in Clause 4.1.6; 

“GlaxoSmithKline Shareholders” means the holders of ordinary shares in the capital of GlaxoSmithKline from time to time;

 “GlaxoSmithKline Shares” means the shares and other ownership interests in the capital of: (i) the
GlaxoSmithKline Consumer Group Companies; and (ii) the GlaxoSmithKline Joint Venture Entities that are owned by any member of GlaxoSmithKline’s Group; 
 “GlaxoSmithKline Statement of Net Assets” has the meaning given to it in Part 1 of Schedule 18; 
 “GlaxoSmithKline Territories” means, in respect of any GlaxoSmithKline Product, each of the territories in which sales are reported for such GlaxoSmithKline Product for financial purposes
in the GlaxoSmithKline Consumer Healthcare Division for the year ended 31 December 2013 or since; 

“GlaxoSmithKline US RX Products” means all rights, title and interest in and to any Prescription Products that are
researched or developed, manufactured, distributed, marketed, sold, promoted or otherwise Commercialised by GlaxoSmithKline’s Seller’s Group in the United States of America and which are managed by and reported for financial purposes in
the GlaxoSmithKline Consumer Healthcare Division for the year ended 31 December 2013 or since; 
 “Good Clinical
Practices” or “GCP” means the then-current standards, practices and procedures promulgated or endorsed by: (i) the ICH Harmonised Tripartite Guidelines for Good Clinical Practice (CPMP/ICH/135/95) and any other
guidelines for good clinical practices for trials on medicinal products in the European Union; (ii) the FDA as set forth in the guidelines entitled “Guidance for Industry E6 Good Clinical Practice: Consolidated Guidance,” including
related regulatory requirements imposed by the FDA; and (iii) the equivalent Applicable Law in any relevant country; 

  
 23 

 “Good Laboratory Practices” or “GLP” means the
then-current standards, practices and procedures promulgated or endorsed by: (i) the European Commission Directive 2004/10/EC relating to the application of the principles of good laboratory practices as well as “The rules governing
medicinal products in the European Union,” Volume 3, Scientific guidelines for medicinal products for human use (ex - OECD principles of GLP); (ii) the then-current standards, practices and procedures promulgated or endorsed by the FDA as
defined in 21 C.F.R. Part 58; and (iii) the equivalent Applicable Law in any relevant country; 
 “Good
Manufacturing Practices” or “GMP” means the then-current standards, practices and procedures promulgated or endorsed by: (i) the European Commission Directive 91/356/EEC, as amended by Directives 2003/94/EC and
91/412/EEC respectively, as well as “The rules governing medicinal products in the European Union,” Volume 4, Guidelines for good manufacturing practices for medicinal products for human and veterinary use; (ii) the FDA and the
provisions of 21 C.F.R. Parts 210 and 211; (iii) the principles detailed in the ICH Q7A guidelines; and (iv) all Applicable Law with respect to each of (i) through (iii); 

“Governmental Entity” means any supra-national, federal, national, state, county, local, municipal or other governmental,
regulatory or administrative authority, agency, commission or other instrumentality, any court, tribunal or arbitral body with competent jurisdiction, or any national securities exchange or automated quotation service, including any governmental
regulatory authority or agency responsible for the grant, approval, clearance, qualification, licensing or permitting of any aspect of the research, development, manufacture, marketing, distribution, promotion, sale or other commercialisation of the
relevant Products including the FDA, the European Medicines Agency, or any successor agency thereto; 
 “Governmental
Liability” means any Liability arising out of, relating to or resulting from any claim, demand, action, suit, proceedings or investigation by a Governmental Entity (other than a Tax Authority) brought or undertaken in connection with
products sold or developed by, or operations or practices of, the relevant Target Group prior to Closing; 
 “Hazardous
Substance” means any gasoline or petroleum products, polychlorinated biphenyls, urea-formaldehyde insulation, hazardous wastes, toxic substances, asbestos, pollutants, or contaminants defined as such in or regulated under any applicable
Environmental Law; 
 “Healthcare Laws” means the federal Anti-kickback Statute (42 U.S.C. § 1320a-7b(b));
the Anti-Inducement Law (42 U.S.C. § 1320a-7a (a)(5)); the civil False Claims Act (31 U.S.C. §§ 3729 et seq.); the administrative False Claims Law (42 U.S.C. § 1320a-7b(a)); the Exclusion Laws (42 U.S.C. § 1320a-7); the
Medicare statute (Title XVIII of the Social Security Act), including Social Security Act §§ 1860D-1 to 1860D-43 (relating to Medicare Part D and the Medicare Part D Coverage Gap Program); the Medicaid statute (Title XIX of the Social
Security Act); the Physician Payment Sunshine Act (42 U.S.C. § 1320a-7h) and any analogous state laws; the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. § 1320d et seq.), as amended by the Health Information
Technology for Economic and Clinical Health Act of 2009, and any other similar law, including the price reporting requirements and the requirements relating to the processing of any applicable rebate, chargeback or adjustment, under applicable rules
and regulations relating to the Medicaid Drug Rebate Program (42 U.S.C. § 1396r-8), any state supplemental rebate program, Medicare average sales price reporting (42 U.S.C. § 1395w-3a); the Public Health Service Act (42 U.S.C. §
256b); the Veterans Health Care Act (38 U.S.C. § 8126), regulatory requirements applicable to sales on the Federal Supply Schedule or under any state pharmaceutical assistance program or United States Department of Veterans Affairs agreement,
all legal requirements relating to the billing or submission of claims, collection of accounts receivable, underwriting the cost of, or provision of management or administrative services in connection with, any and all of the foregoing, by the
relevant Seller’s Group and any successor government programmes, and all foreign equivalents of the foregoing; 

  
 24 

 “HSR Act” means the Hart-Scott Rodino Antitrust Improvements Act of 1976,
as amended, together with its implementing regulations; 
 “IFRS” means International Financial Reporting
Standards, comprising the accounting standards and interpretations issued, adopted and/or approved by the International Accounting Standards Board; 
 “Implementation Agreement” means the implementation agreement dated the date of this Agreement between Novartis and GlaxoSmithKline relating to, amongst other things, the implementation
of the Transaction; 
 “In-Market Inventory” means, in respect of a Seller, all inventory of the Products for
Commercialisation that, at any particular time: (i) is beneficially owned by a member of that Seller’s Group; (ii) is in finished packed form and released for Commercialisation; and (iii) is located: (a) in (or in transit
to) the relevant market; or (b) in (or in transit to) a multi-market warehouse owned or operated by a member of that Seller’s Group or by a third party; or (c) at a Property pending despatch following release by the relevant qualified
person to the relevant market or multi-market warehouse; 
 “In-Scope Switch Product” means, in respect of
GlaxoSmithKline, Flonase /Flixonase and, in respect of Novartis, Voltaren, but, in each case, only to the extent relating to the rights to research and develop, manufacture, distribute, market, sell, promote and/or otherwise Commercialise the same
as a Consumer Healthcare Product, and “GlaxoSmithKline’s In-Scope Switch Product” and “Novartis’s In-Scope Switch Product” shall be construed accordingly; 

“Indebtedness” means all loans and other financing liabilities and obligations in the nature of borrowed moneys and
overdrafts, but excluding trade debt and liabilities arising in the ordinary course of business; 
 “Information
Technology” means computer hardware, software and network; 
 “Intellectual Property Assignment
Agreements” means the assignments between a Seller and/or one or more of its Affiliates and the Purchaser and/or one or more of its Affiliates on terms consistent with the Agreed Terms, to be entered into at Closing, in respect of the
transfer of certain Intellectual Property Rights in each of the relevant jurisdictions; 
 “Intellectual Property
Rights” means all (i) Patents; (ii) Know-How; (iii) Trademarks; (iv) internet domain names; (v) Copyrights; (vi) rights in designs; (vii) database rights; and (viii) all rights or forms of protection,
anywhere in the world, having equivalent or similar effect to the rights referred to in paragraphs (i) to (vii) above, in each case, whether registered or unregistered and including applications for registration of any such thing;

 “International Assignees” means, in respect of GlaxoSmithKline, the GlaxoSmithKline International Assignees
and, in respect of Novartis, the Novartis International Assignees; 
 “Intra-Group Non-Trade Payables” means, in
respect of a Seller, all outstanding loans or other financing liabilities or obligations (including, for the avoidance of doubt, interest accrued, dividends declared or payable but not paid) owed by its Target Group Company to a member of that
Seller’s Group (other than its Target Group Company) as at the Effective Time as derived from the Closing Statement, but excluding: (i) Intra-Group Trade Payables and Intra-Group Trade Receivables; and (ii) any item which falls to be
included in calculating the Target Group Companies’ Cash Balances or the Third Party Indebtedness; 

  
 25 

 “Intra-Group Non-Trade Receivables” means, in respect of a Seller, all
outstanding loans or other financing liabilities or obligations (including, for the avoidance of doubt, interest accrued, dividends declared or payable but not paid) owed by a member of that Seller’s Group (other than its Target Group Company)
to its Target Group Company as at the Effective Time as derived from the Closing Statement, but excluding: (i) Intra-Group Trade Payables and Intra-Group Trade Receivables; and (ii) any item which falls to be included in calculating the
Target Group Companies’ Cash Balances or the Third Party Indebtedness; 
 “Intra-Group Trade Payables”
means, in respect of a Seller, all trade accounts and notes payable to any member of any Seller’s Group (excluding a Target Group Company) on the one hand, by any Target Group Company, on the other hand, in each case, to the extent related to
its Target Group, arising in the ordinary course, together with any unpaid financing charges accrued thereon; 

“Intra-Group Trade Receivables” means, in respect of a Seller, all trade accounts and notes receivable from any member of
any Seller’s Group (excluding a Target Group Company) on the one hand, to any Target Group Company, on the other hand, in each case, to the extent related to its Target Group, arising in the ordinary course, together with any unpaid financing
charges accrued thereon; 
 “Intra-Group Trading Balances” means, in respect of a Seller, the aggregate of its
Intra-Group Trade Payables and its Transferred Accounts Payables payable to any member of that Seller’s Group (other than a Target Group Company) by a Business Seller of that Seller’s Group less the aggregate of its Intra-Group Trade
Receivables and its Transferred Accounts Receivables payable by any member of that Seller’s Group (other than a Target Group Company) to a Business Seller of that Seller’s Group; 

“IP Liability” means any Liability arising out of, relating to or resulting from any actual or alleged infringement,
misappropriation or other violation of Intellectual Property Rights of third parties; 
 “Joint Venture
Entities” means, in respect of GlaxoSmithKline, the GlaxoSmithKline Joint Venture Entities and, in respect of Novartis, the Novartis Joint Venture Entities; 
 “Judgment” means any order, writ, judgment, injunction, decree, decision, stipulation, determination or award entered by or with any Governmental Entity of competent jurisdiction;

 “Key Personnel” means, in respect of GlaxoSmithKline, the GlaxoSmithKline Key Personnel and, in respect of
Novartis, the Novartis Key Personnel; 
 “Know-How” means all existing and available technical information,
know-how and data, including inventions (whether patentable or not), discoveries, trade secrets, specifications, instructions, processes and formulae, including all biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical,
physical, safety, quality control, preclinical and clinical data; 
 “Lease” has the meaning given to it in
paragraph 1.1 of Part 4 of Schedule 2; 
 “Liabilities” means all liabilities, claims, damages, proceedings,
demands, orders, suits, costs, losses and expenses, in each case, of every description, whether deriving from contract, common law, statute or otherwise, whether present or future, actual or contingent, ascertained or unascertained or disputed and
whether owed or incurred severally or jointly or as principal or surety; 
 “LIBOR” means the London interbank
offered rate, being the interest rate offered in the London inter-bank market for three month US dollar deposits as displayed on pages LIBOR01 or LIBOR02 of the Reuters screen at 11 a.m. (London) on the second Business Day prior to the Closing Date;

  
 26 

 “Licensed Intellectual Property Contract” means any Target Group
Intellectual Property Contract constituting or containing a licence of Intellectual Property Rights in respect of the Contributed Business or Products; 
 “Listing Rules” means the listing rules made by the FCA under section 73A of FSMA; 
 “Local Transfer Document” has the meaning given to it in Clause 2.6.1; 
 “Long Stop Date” has the meaning given to it in Clause 4.3; 

“Losses” means all losses, liabilities, costs (including legal costs and experts’ and consultants’ fees),
charges, expenses, actions, proceedings, claims and demands; 
 “MA Costs” has the meaning given to it in
paragraph 4 of Part 2 of Schedule 4; 
 “MA Documentation” has the meaning given to it in paragraph 1.4 of Part
2 of Schedule 4; 
 “Manufacture” or “Manufacturing” or “Manufactured” means,
as applicable, the planning, purchasing of materials for, production, processing, compounding, storage, filling, packaging, labelling, leafleting, warehousing, quality control testing, waste disposal, quality release, sample retention and stability
testing of any products of the relevant Seller’s Contributed Business; 
 “Manufacturing Inventory” means,
in respect of a Seller, any packed inventory of Products for Commercialisation that is: (i) in finished form (save for any secondary packaging undertaken outside of a primary manufacturing site); (ii) beneficially owned by any member of
that Seller’s Group; (iii) held at a primary manufacturing site; and (iv) not yet released by the qualified person at a primary manufacturing site, and excluding in each case, for the avoidance of doubt, any In-Market Inventory and
Manufacturing Stocks; 
 “Manufacturing Liability” means any Liability arising out of, relating to or resulting
from any breach of Applicable Law in connection with the Manufacturing of products of the relevant Seller’s Contributed Business; 
 “Manufacturing Licences” means any certificates, permits, licences, consents and approvals issued by any Governmental Entity, used in the operation or conduct of Manufacturing at each
relevant Property, and “Manufacturing Licence” shall be construed accordingly; 
 “Manufacturing
Stocks” means, in respect of a Seller, all stocks of raw materials, active pharmaceutical ingredients, ingredients, adjuvants, drug substances, intermediates, packaging materials, components, devices and other production and pre-production
consumables and work-in-progress that are beneficially owned by any member of that Seller’s Group for use in the Manufacture of Products or Pipeline Products, respectively, and held at a primary manufacturing Property; 

“Manufacturing, Supply and Distribution Agreement” means, in respect of a Seller, the manufacturing, supply and
distribution agreement expected to be entered into between that Seller and the Purchaser at Closing on terms consistent with the Agreed Terms; 
 “Marketing Authorisation Data” means, in respect of a Seller, the existing and available dossiers containing the relevant Know-How used by that Seller and/or its Affiliates to obtain and
maintain the Marketing Authorisations; 

  
 27 

 “Marketing Authorisation Holder” means the holder of a Marketing
Authorisation; 
 “Marketing Authorisation Re-Registration” has the meaning given to it in
paragraph 1.1(ii) of Part 2 of Schedule 4; 
 “Marketing Authorisation Re-Registration Date” means the date
on which the Governmental Entity approves, or is deemed to approve, the Marketing Authorisation Re-Registration; 

“Marketing Authorisation Transfer” has the meaning given to it in paragraph 1.1(i) of Part 2 of Schedule 4; 

“Marketing Authorisation Transfer Date” means the date on which the Governmental Entity approves, or is deemed to
approve, the Marketing Authorisation Transfer; 
 “Marketing Authorisation Transferee” means the member of the
Purchaser’s Group or, where no member of the Purchaser’s Group satisfies the requirements under Applicable Law to be transferred the relevant Marketing Authorisation, such third party as is nominated by the Purchaser, in either case, to
whom the relevant Marketing Authorisation is to be transferred; 
 “Marketing Authorisations” means, in respect
of a Seller, the marketing authorisations issued or applications for marketing authorisations with respect to its Products, and all supplements, amendments and revisions thereto; 

“Markets” means, in respect of a Seller, the markets in which its Products are marketed and sold under the relevant
Marketing Authorisation and “Market” shall be construed accordingly; 
 “Material Adverse
Effect” means, in respect of a Seller, any matter, change, event or circumstance arising or discovered on or after the date of this Agreement and prior to Closing (including a breach of that Seller’s obligations under Clause 5 or
Clause 9.1) (a “Relevant Matter”) that, individually or in aggregate with other Relevant Matters, if known to the Purchaser prior to the date of this Agreement, could reasonably have been expected to have resulted in the Purchaser
reducing the number of A Shares or B Shares (as the case may be) to be issued by 30 per cent. or more, and, in determining such reduction regard shall be had to the actual basis on which the number of A Shares to be issued or the number of B
Shares to be issued (as the case may be) was calculated. A Relevant Matter shall not constitute or count towards a “Material Adverse Effect” to the extent resulting or arising from: 

 

	 	(i)	any change that is generally applicable to, or generally affects, the industries or markets in which the relevant Seller’s Target Group operates (including changes
arising as a result of usual seasonal variations) or arises from or relates to changes in Applicable Law or accounting rules or changes in any authoritative interpretation of any Applicable Law by any Governmental Entity; 

 

	 	(ii)	any change in financial, securities or currency markets or general economic or political conditions or changes in prevailing interest rates or exchange rates;

  

	 	(iii)	the execution of this Agreement, the public announcement thereof or the pendency or consummation of the transactions contemplated hereby (including any cancellations of
or delays in customer orders or other decreases in customer demand, any reduction in revenues and any disruption in supplier, distributor, customer or similar relationships); or 

 

	 	(iv)	the taking of any action expressly required by this Agreement or by any Ancillary Agreement or otherwise taken with the advance written consent of the Purchaser,

  
 28 

 except, in relation to either paragraph (i) or paragraph (ii) above, if that
change adversely affects that Seller’s Target Group in a disproportionate manner relative to other comparable businesses operating in the same industry and geographic markets as that Seller’s Target Group (in which case it may constitute
or count towards a “Material Adverse Effect”); 
 “Material Employee Jurisdictions” means, in respect
of GlaxoSmithKline, the GlaxoSmithKline Material Employee Jurisdictions and, in respect of Novartis, the Novartis Material Employee Jurisdictions; 
 “Maximum Working Capital Amount” means, in respect of GlaxoSmithKline, £600,000,000 and, in respect of Novartis, US$600,000,000; 

“Medical Information” means, in respect of each Seller, information Predominantly Related to its Contributed Business
which is available to or used by it and/or its Affiliates as of the Closing Date relating to clinical and technical matters, such as therapeutic uses for the approved indications, drug-disease information, and other product characteristics;

 “Minimum Working Capital Amount” means, in respect of GlaxoSmithKline, £500,000,000 and, in respect of
Novartis, US$500,000,000; 
 “Minority Notification” has the meaning given in clause 4.2.10; 

“Netherlands Assumed Liabilities” means the Assumed Liabilities to the extent that they relate to the Netherlands
Business; 
 “Netherlands Business” means that part of GlaxoSmithKline’s Contributed Business that is
conducted in the Netherlands, the Netherlands Assumed Liabilities and the Netherlands Employees; 
 “Netherlands
Closing” has the meaning given to it in the Netherlands SAPA; 
 “Netherlands Employees” means those of
the GlaxoSmithKline Employees who are employed in the Netherlands; 
 “Netherlands Offer Letter” means the
letter from the Purchaser to the Seller in respect of the binding offer from the Purchaser to acquire the Netherlands Business dated on or around the date hereof; 
 “Netherlands Put Option Exercise” has the meaning given to it in the Netherlands Offer Letter; 
 “Netherlands SAPA” has the meaning given in the Netherlands Offer Letter; 
 “Non-US Benefit Plans” has the meaning given to it in paragraph 17.3.1 of Schedule 13; 
 “Notice” has the meaning given to it in Clause 15.14.1; 

“Notifier” has the meaning given in paragraph 1.1 of Schedule 17; 

“Novartis Animal Health Business” means the business conducted by any member of Novartis’s Group of researching and
developing, manufacturing, distributing, marketing, selling, promoting and/or otherwise Commercialising the Novartis Animal Health Products; 
 “Novartis Animal Health Products” means any products which are managed by the Novartis Animal Health Division and reported in the Animal Health reporting segment of Novartis’s
Consumer Health Division; 

  
 29 

 “Novartis Business Employees” means the employees of any member of
Novartis’s Group who work wholly or substantially in the Novartis OTC Business from time to time including, for the avoidance of any doubt, the Novartis International Assignees other than the Novartis Company Employees and the Novartis Excluded
Employees and provided that, in relation to the Seller’s Warranties only, the words “from time to time” shall be deemed to be replaced by “at the date of this Agreement”, and “Novartis Business Employee”
means any one of them; 
 “Novartis Company Employees” means the employees from time to time of any of the
Novartis OTC Group Companies other than the Novartis Excluded Employees, and provided that, in relation to the Seller’s Warranties only, the words “from time to time” shall be deemed to be replaced by “at the date of this
Agreement”, and “Novartis Company Employee” means any one of them; 
 “Novartis December 2013
Presentation” mean the management presentation entitled “Gazelle Management Presentation: NOTC” and dated December 2013 and attached to this Agreement as Attachment 2; 

“Novartis Deferred Employee” means any person to whom Novartis, any Novartis OTC Group Company or any other member of
Novartis’s Group has made an offer of employment for a role within the Novartis OTC Business in compliance with clause 5 and who has accepted such offer in writing and whose employment within the Novartis OTC Business will take effect on a date
following the Closing Date, save that no person shall become an Novartis Deferred Employee unless and until Novartis has provided to GlaxoSmithKline a copy of the offer letter setting out the agreed principal terms of employment and/or employment
agreement (if executed) applicable to such person; 
 “Novartis Distribution and Sales Products Contracts” means
any contract between a member of Novartis’s Group (other than a Novartis OTC Group Company) on the one hand, and any Novartis OTC Group Company on the other hand, relating to the distribution and sale by the Novartis OTC Business of products
owned, managed and reported by the Seller’s Retained Business; 
 “Novartis Employees” means the Novartis
Business Employees and the Novartis Company Employees, and “Novartis Employee” means any one of them; 

“Novartis Excluded Assets” means the property, rights, businesses and assets referred to in Clause 2.3.2 in respect of
the Novartis OTC Group Businesses and the assets and businesses set out in Part 2 of Schedule 3; 
 “Novartis Excluded
Businesses” means: 
  

	 	(i)	the Novartis Animal Health Business; 

  

	 	(ii)	the Novartis US NRT Business; 

  

	 	(iii)	the Novartis Pharmaceutical Division’s business of researching and developing, manufacturing, distributing, marketing, selling, promoting and/or otherwise
Commercialising any Consumer Healthcare Products which are managed by and reported for financial purposes in the Novartis Pharmaceutical Division on or prior to the date of this Agreement (including any development of such products);

  

	 	(iv)	the business(es) (as conducted from time to time) owned or managed by, or reported for financial purposes in, Novartis’s: 

 

	 	(a)	Alcon division (including for the avoidance of doubt, Ciba-Giegy); or 

  
 30 

	 	(b)	Sandoz division (excluding, for the avoidance of doubt, Sandocal and Calcium Sandoz, which are included within the definition of the Novartis OTC Business); and

  

	 	(v)	any assets or liabilities that are deemed to constitute Novartis Excluded Assets pursuant to paragraph 9.2 of Schedule 6; 

“Novartis Excluded Employees” means the employees of any member of Novartis’s Group (including the Novartis OTC
Group Companies) as may be agreed in writing between Novartis and GlaxoSmithKline after the date of this Agreement but before the Closing Date; 
 “Novartis’s Group” means Novartis and its Affiliates from time to time, provided that, for the purposes of this Agreement, the Purchaser and any person Controlled by the Purchaser
(whether directly or indirectly) from time to time shall not be included in Novartis’s Group; 
 “Novartis
IndiaCo” means Novartis India Ltd, an Indian listed company; 
 “Novartis Indian Business” means that
part of the Novartis OTC Business conducted by Novartis IndiaCo or any person Controlled by Novartis IndiaCo from time to time; 

“Novartis Indian Consent” has the meaning given in paragraph 7.1 of Schedule 6; 

“Novartis International Assignees” means the employees of any member of Novartis’s Group (including
the Novartis OTC Group Companies) who are listed in Schedule 20, and such other employees as may be agreed in writing between GlaxoSmithKline and Novartis after the date of this Agreement but before the Closing Date; 

“Novartis Joint Venture Entities” means an entity in which Novartis’s Group holds equity interests of less than
100 per cent. but whose operations, assets and/or businesses are Exclusively Related to the Novartis OTC Business, an indicative list of which are set out in Part B of Part 2 of Schedule 1, excluding any such entity whose operations, assets
and/or businesses form part of the Novartis Excluded Assets; 
 “Novartis Key Personnel” means the Novartis
Employees listed in Part 2 of Schedule 16; 
 “Novartis’s Lawyers” means Freshfields Bruckhaus Deringer LLP
of 65 Fleet Street, London EC4Y 1HS; 
 “Novartis Material Employee Jurisdictions” means United States,
Switzerland, Russia, China and India; 
 “Novartis OTC Business” means: 

 

	 	(i)	the business of researching and developing, manufacturing, distributing, marketing, selling, promoting and/or otherwise Commercialising the Novartis Products in the
Novartis Territories; 

  

	 	(ii)	the business of researching and developing any Novartis Pipeline Products; 

 

	 	(iii)	all rights, title and interest in relation to researching and developing, manufacturing, distributing, marketing, selling, promoting and/or otherwise Commercialising
Novartis’s In-Scope Switch Product, in any jurisdiction, as a Consumer Healthcare Product only; 

  
 31 

	 	(iv)	the business of manufacturing, marketing, distributing, selling, promoting and/or otherwise Commercialising the Prescription Products which are managed by the Novartis
OTC Division and which have been reported for financial purposes in the OTC reporting segment of the Novartis Consumer Health Division for, or since, the year ended 31 December 2013 and, in respect of any such Prescription Product, in the
territories in which sales are reported for such Prescription Product in the OTC reporting segment of the Novartis Consumer Health Division for the year ended 31 December 2013 or since; and 

 

	 	(v)	any royalty streams in respect of any products received by and reported for financial purposes in the OTC reporting segment of the Novartis Consumer Healthcare Division
for, or since, the year ended 31 December 2013, 

 in each case, conducted by Novartis’s Group, but
excluding the Novartis Excluded Assets; 
 “Novartis OTC Group” means the Novartis OTC Group Companies and the
Novartis OTC Group Businesses, taken as a whole; 
 “Novartis OTC Group Businesses” means the businesses of the
Novartis OTC Business (but excluding the businesses carried on by the Novartis OTC Group Companies) as set out in Clause 2.3.1, but subject always to Clause 2.3.2, and “Novartis OTC Group Business” means any of them; 

“Novartis OTC Group Companies” means the members of Novartis’s Group whose operations, assets and/or businesses are
Exclusively Related to the Novartis OTC Business, a non-exhaustive list of which are set out in Part A of Part 2 of Schedule 1, but excluding any such members whose operations, assets and/or businesses form part of the Novartis Excluded Assets, and
“Novartis OTC Group Company” means any one of them; 
 “Novartis Pipeline Product” means each
product that the Novartis OTC Division is researching and developing, with the intention of that product becoming a Consumer Healthcare Product (but excluding, in any event, Diovan), an indicative list of which is set out in Schedule 9, Part 3;

 “Novartis Products” means, in respect of any territory, any Consumer Healthcare Products which are managed by
the Novartis OTC Division and which have been reported for financial purposes in the OTC reporting segment of the Novartis Consumer Health Division in that territory for the year ended 31 December 2013 or since, an indicative list of which is
set out in Schedule 9, Part 2; 
 “Novartis Services Contracts” means any Contract between or among any member
of Novartis’s Group (other than its Target Group Company and its Business Seller) on the one hand, and its Target Group Company or Business Seller on the other hand which, in addition to the Ancillary Agreements and any other assets to be
transferred pursuant to this Agreement, is necessary to enable the Purchaser and/or any other member of the Purchaser’s Group to carry on Novartis’s Contributed Business (or the relevant part thereof) in substantially the same manner as it
has been during the twelve months prior to the date of this Agreement; 
 “Novartis Shares” means the shares and
other equity, partnership or similar interests in the capital of: (i) the Novartis OTC Group Companies; and (ii) the Novartis Joint Venture Entities that are owned by any member of Novartis’s Group; 

“Novartis Statement of Net Assets” has the meaning given to it in Part 2 of Schedule 18; 

  
 32 

 “Novartis Territories” means, in respect of any Novartis Product, each of
the Territories in which sales are reported for such Novartis Product in the OTC reporting segment of the Novartis Consumer Healthcare Division for the year ended 31 December 2013 or since; 

“Novartis US NRT Business” means the business of researching and developing, manufacturing, distributing, marketing,
selling, promoting and/or otherwise Commercialising any nicotine related products of any nature whatsoever in the United States of America, conducted by Novartis’s Group, including those commercialised under the Habitrol brand and any other
private label nicotine related products; 
 “Novartis US RX Products” means all rights, title and interest in
and to any Prescription Products that are developed or researched, manufactured, distributed, marketed, sold, promoted or otherwise Commercialised by Novartis’ Seller’s Group in the United States of America and which are managed by the
Novartis OTC Division and which have been reported for financial purposes in the OTC reporting segment of the Novartis Consumer Health Division in that territory for the year ended 31 December 2013 or since, but excluding any Prescription
Product that is governed by the Endo Excluded Contract; 
 [***] 

“Oncology Sale and Purchase Agreement” means the sale and purchase agreement dated the date of this agreement between
GlaxoSmithKline and Novartis relating to the sale and purchase of certain oncology products; 
 “Ongoing Clinical
Trials” means, in respect of a Seller, the ongoing clinical studies sponsored or supported by that Seller’s Group (including post-approval studies) or otherwise recommended by a Governmental Entity in respect of the relevant Products;

 “Owned Information Technology” means, in respect of a Seller, the Information Technology Exclusively Related
to its Contributed Business and owned by any of its Target Group Companies; 
 “Owned Intellectual Property
Contracts” means, in respect of a Seller, the Contracts Exclusively Related to its Contributed Business which relate to Intellectual Property Rights and that are held by any of its Target Group Companies; 

“Owned Intellectual Property Rights” means, in respect of a Seller, the Intellectual Property Rights Exclusively Related
to its Contributed Business and owned by any of its Target Group Companies; 
 “PA Transfer Date” means, in
relation to a Product or Product Application, the date upon which the relevant Governmental Entity approves and notifies such Product Approval or Product Application (as applicable) naming the Purchaser or the relevant Affiliate of the Purchaser (or
designee thereof) as the holder of such Product Approval or Product Application in the relevant country or territory covered by that Product Approval or Product Application; 
 “Patents” means patents, design patents, patent applications, and any reissues, re-examinations, divisionals, continuations, continuations-in-part, provisionals, and extensions thereof or
any counterparts to any of the foregoing (including rights resulting from any post-grant proceedings relating to any of the foregoing); 
 “Payment” has the meaning given to it in Clause 1.9; 

“Payee” has the meaning given in Clause 15.11.1; 

“Payer” has the meaning given in Clause 15.11.1; 

 

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission 

  
 33 

 “Permit” has the meaning given to it in paragraph 10.2 of Schedule 13;

 “Permitted Encumbrance” means, in respect of a Seller: 

 

	 	(i)	Encumbrances imposed by Applicable Law; 

  

	 	(ii)	Encumbrances imposed in the ordinary course of business which are not yet due and payable or which are being contested in good faith; 

 

	 	(iii)	pledges or deposits to secure obligations under Applicable Law relating to workers’ compensation, unemployment insurance or to secure public or statutory
obligations; and 

  

	 	(iv)	liens, title retention arrangements or deposits to secure the performance of bids, trade contracts (other than for borrowed money), conditional sales contracts, leases,
statutory obligations, surety and appeal bonds, performance bonds and other obligations of a like nature incurred in the ordinary course of its Contributed Business; 

“Pharmacovigilance Agreement” means the agreement between each of the Sellers and the Purchaser, to be entered into at
Closing, in respect of pharmacovigilance and regulatory matters; 
 “Pipeline Product Approvals” means, in
respect of a Seller, the approvals in relation to its Pipeline Products; 
 “Pipeline Products” means the
GlaxoSmithKline Pipeline Products and the Novartis Pipeline Products; 
 “Predominantly Related to” means, in
respect of a Seller’s Contributed Business, exclusively or predominantly related to, or used or held for use predominantly in connection with, that Seller’s Contributed Business; 

“Prescription Product” means, in respect of any jurisdiction, any oral care, nutritional care, skin care or other
cosmetic or healthcare product or device of any kind, in each case, for the treatment of, or use by, human beings, which is (i) only available with a prescription, or (ii) available without, or both with and without, a prescription but is
subject to the same regulatory classification and/or regulatory treatment (including in relation to advertising) as a product or device that is only available with a prescription; 

“Proceedings” means any legal actions, proceedings, suits, litigations, prosecutions, investigations, enquiries,
mediations or arbitrations; 
 “Product Applications” means, in respect of a Seller, all applications for
Product Approval filed with respect to the relevant Products Under Registration, with each individual application being a “Product Application”; 
 “Product Approvals” means, in respect of a Seller, all permits, licences, certificates, registrations or other authorisations or consents issued by any Governmental Entity to that Seller
or one of its Affiliates with respect to its Products or the use, research, development, marketing, distribution or sale thereof, including the Marketing Authorisations; 
 “Product Filings” means, in respect of any Seller, all filings, written representations, declarations, listings, registrations, reports or submissions with or to any Governmental Entity,
including adverse event reports and all submitted data relating to each relevant Product; 

  
 34 

 “Product Liabilities” means any Liability arising out of, relating to or
resulting from actual or alleged harm, injury, damage or death to persons in connection with the use of any product (including in any clinical trial or study); 
 “Product Partners” means, in respect of a Seller, any third parties which, pursuant to a Contract with that Seller or any of its Affiliates, co-develop, co-promote, co-market, or
otherwise have a licence or other right to research, develop, manufacture, promote, distribute, market, or sell any Product, including all manufacturers and suppliers of that Product; 

“Products” means, in respect of GlaxoSmithKline, the GlaxoSmithKline Products and, in respect of Novartis, the Novartis
Products; 
 “Products Under Registration” means, in respect of a Seller, the Products of that Seller which are
pending Product Approval as of the date hereof; 
 “Properties” means the Company Properties and the Transferred
Properties, and “Property” means any one of them; 
 “Proprietary Information” means, in
respect of a Seller, all confidential and proprietary information of that Seller or its Affiliates that is Predominantly Related to its Contributed Business, including relevant confidential Medical Information, confidential Know-How and confidential
Commercial Information; 
 “Purchase Consideration” has the meaning given to it in Clause 3.1.1; 

“Purchaser’s Bank Account” means the account notified by the Purchaser to each of the Sellers no later than two
Business Days prior to the Closing Date; 
 “Purchaser’s Disagreement Notice” has the meaning given to it
in paragraph 1.4 of Schedule 12; 
 “Purchaser’s Group” means the Purchaser and its Affiliates from time to
time, excluding any member of GlaxoSmithKline’s Group or Novartis’s Group; 
 “Purchaser Trademark Licence
Agreement” means the agreement between a Seller and/or one or more of its Affiliates and the Purchaser and/or one or more of its Affiliates on terms consistent with the Agreed Terms, to be entered into at Closing, in respect of the grant of
licences from that Seller to the Purchaser of certain Intellectual Property Rights; 
 “Recipient” has the
meaning given in paragraph 1.1 of Schedule 17; 
 “Registered Intellectual Property Rights” means all
Intellectual Property Rights that are registered, issued, filed, or applied for under the authority of any Governmental Entity; 

“Registered Target Group Intellectual Property Rights” means all Target Group Intellectual Property Rights that are
Registered Intellectual Property Rights; 
 “Regulation” has the meaning given to it in Clause 4.1.1;

 “Relevant Employees” means, in respect of GlaxoSmithKline, the Relevant GlaxoSmithKline Employees and, in
respect of Novartis, the Relevant Novartis Employees; 
 “Relevant Employers” means, in respect of each Seller,
the Business Seller’s and such other members of that Seller’s Group that employ that Seller’s Relevant Employees; 

“Relevant Employer’s FSAs” has the meaning given to it in paragraph 7 of Schedule 7; 

  
 35 

 “Relevant GlaxoSmithKline Business Employees” means the GlaxoSmithKline
Business Employees immediately prior to the Closing Date, and “Relevant GlaxoSmithKline Business Employee” means any one of them; 
 “Relevant GlaxoSmithKline Company Employees” means the GlaxoSmithKline Company Employees immediately prior to the Closing Date (excluding any who do not work wholly or substantially in
the GlaxoSmithKline Consumer Business), and “Relevant GlaxoSmithKline Company Employee” means any one of them; 

“Relevant GlaxoSmithKline Employees” means the Relevant GlaxoSmithKline Business Employees and the Relevant
GlaxoSmithKline Company Employees, and “Relevant GlaxoSmithKline Employee” means any one of them; 

“Relevant Novartis Business Employees” means the Novartis Business Employees immediately prior to the Closing Date, and
“Relevant Novartis Business Employee” means any one of them; 
 “Relevant Novartis Company
Employees” means the Novartis Company Employees immediately prior to the Closing Date (excluding any who do not work wholly or substantially in the Novartis OTC Business), and “Relevant Novartis Company Employee” means any
one of them; 
 “Relevant Novartis Employees” means the Relevant Novartis Business Employees and the Relevant
Novartis Company Employees, and “Relevant Novartis Employee” means any one of them; 
 “Relevant
Part” means, in respect of a Shared Business Contract, the part of it which Exclusively Relates to the relevant Contributed Business (or the part of the relevant Contributed Business that is transferred to the Purchaser at Closing);

 “Relevant Period” means the period of two years prior to the date of this Agreement; 

“Relevant Persons” has the meaning given to it in Clause 8.2.2(vi); 

“Relevant Target Business Employees” means, in respect of GlaxoSmithKline, the Relevant GlaxoSmithKline Business
Employees and, in respect of Novartis, the Relevant Novartis Business Employees, and “Relevant Target Business Employee” means any one of them; 
 “Relevant Target Company Employees” means, in respect of GlaxoSmithKline, the Relevant GlaxoSmithKline Company Employees and, in respect of Novartis, the Relevant Novartis Company
Employees, and “Relevant Target Company Employee” means any one of them; 
 “Relevant Tax
Deduction” has the meaning given in Clause 15.11.2; 
 “Reorganisation” has the meaning given to
it in Clause 2.3.5; 
 “Reporting Accountants” means the London office of Ernst & Young or, if that
firm is unable or unwilling to act in any matter referred to them under this Agreement, the London office of Deloitte or, if that firm is also unable or unwilling to act in any matter referred to them under this Agreement, an internationally
recognised and independent firm of accountants who does not act as auditor to the relevant Seller or the Purchaser, to be agreed by the Seller and the Purchaser within seven days of a notice by one to the other requiring such agreement or, failing
such agreement, to be nominated on the application of either of them by or on behalf of the Institute of Chartered Accountants of England and Wales; 
 “Required Notifications” has the meaning given to it in Clause 4.2.1; 

  
 36 

 “Sanctions Law” has the meaning given to it in paragraph 10.5 of Schedule
13; 
 “Select Equity Plans” means the Novartis Restricted Stock Plan of 1 November 2007 (Rest of the
World), the Novartis Restricted Stock Plan of 1 November 2007 (Switzerland), the Novartis Restricted Stock Unit Plan of November 2007 (Rest of the World and Switzerland), the Novartis Stock Option Plan of September 2003 (Rest of the World), the
Novartis Stock Option Plan of February 2005 (Switzerland) and the Novartis Corporation 2011 Stock Incentive Plan for North American Employees effective 1 January 2011, and a “Select Equity Plan” means any one of them;

 “Seller Intellectual Property Licence Agreement” means the agreement between the relevant Seller and/or one
or more of its Affiliates and the Purchaser and/or one or more of its Affiliates on terms consistent with the Agreed Terms, to be entered into at Closing, in respect of the grant of licences from the Purchaser to the relevant Seller of certain
Target Group Intellectual Property Rights; 
 “Seller Marks” means: 

 

	 	(i)	with respect to GlaxoSmithKline, any Trademark of GlaxoSmithKline containing the mark “GlaxoSmithKline”, and any other mark listed in Part 1 of Schedule 21,
or any variants of the foregoing; and 

  

	 	(ii)	with respect to Novartis, any Trademark of Novartis containing the mark including the names “Novartis”, “Sandoz”, “Alcon” or “Ciba
Vision” or any of the variants of the foregoing; 

 “Seller Partner” means, in respect of a
Seller, any counterparty to a development, contract research, commercialisation, manufacturing, distribution, sales, marketing, supply, consulting or other collaboration contract with that Seller or any of its Affiliates; 

“Seller Trademark Licence Agreement” means the agreement between the relevant Seller and/or one or more of its Affiliates
and the Purchaser and/or one or more of its Affiliates on terms consistent with the Agreed Terms, to be entered into at Closing, in respect of the grant of licences from the relevant Seller to the Purchaser of certain Intellectual Property Rights;

 “Seller’s Bank Account” means, in respect of a Seller, the account notified by such Seller to the
Purchaser no later than two Business Days prior to the Closing Date; 
 “Seller’s Disagreement Notice” has
the meaning given to it in paragraph 1.5 of Schedule 12; 
 “Seller’s Group” means, in respect of a Seller,
that Seller and its Affiliates from time to time, provided that, for the purposes of this Agreement, the Purchaser and any person Controlled by the Purchaser (whether directly or indirectly) from time to time shall not be included in any
Seller’s Group; 
 “Seller’s Group Insurance Policy” means, in respect of a Seller, all insurance
policies (whether under policies maintained with third party insurers or any member of that Seller’s Group), other than the Target Group Insurance Policies, maintained by that Seller or any member of that Seller’s Group in relation to its
Contributed Business or under which, immediately prior to Closing, any of that Seller’s Target Group Companies or that Seller or member of that Seller’s Group in relation to its Contributed Business is entitled to any benefit, and
“Seller’s Group Insurance Policy” means any one of them; 
 “Seller’s Knowledge” has the
meaning given to it in Clause 9.1.4; 
 “Seller’s Retained Business” means, in respect of a Seller, all
businesses of that Seller’s Group from time to time, including its Excluded Assets, but excluding its Contributed Business; 

  
 37 

 “Seller’s Warranties” means, in respect of a Seller, the warranties
given by that Seller pursuant to Clause 9 and Schedule 13, and “Seller’s Warranty” means any one of them; 
 “Service Provider” means an Associated Person who is a legal person; 
 “Services Agreement” means the services agreement expected to be entered into between GlaxoSmithKline and the Purchaser at Closing on the terms consistent with the Agreed Terms;

 “Share Sellers” means, in respect of a Seller, the members of that Seller’s Group (other than its Target
Group Companies and Joint Venture Entities) that own shares or other equity interests in any of that Seller’s Target Group Companies or Joint Venture Entities, an indicative list of which is set out in column (1) of Schedule 1, Part A (in
respect of GlaxoSmithKline) or Part B (in respect of Novartis); 
 “Shared Business Contracts” means, in respect
of a Seller, any Contract which relates both: 
  

	 	(i)	to its Contributed Business; and 

  

	 	(ii)	to any other business of its Group, any part of its Contributed Business which is not transferred to the Purchaser at Closing (until it is so transferred), or any of
its Excluded Assets, 

 and to which a member of the Seller’s Group is a party or in respect of which a member
of the Seller’s Group has any right liability or obligation at Closing, and “Shared Business Contract” shall mean any of them; 
 “Shareholders’ Agreement” means the shareholders’ agreement to be entered into by the parties and certain of the Sellers’ Affiliates on Closing in the Agreed Terms;

 “Shares” means, together, the GlaxoSmithKline Shares and the Novartis Shares; 

“Statement of Net Assets” means, in respect of GlaxoSmithKline, the GlaxoSmithKline Statement of Net Assets and, in
respect of Novartis, the Novartis Statement of Net Assets; 
 “Statement of Net Assets Date” means
31 December 2013; 
 “Statement of Net Asset Rules” means, for each Seller, the rules in accordance with
which its Statement of Net Assets was prepared, as set out in Part 1 (in the case of GlaxoSmithKline) or Part 2 (in respect of Novartis) of Schedule 18; 
 “Target Asset Agreement” has the meaning given in the Implementation Agreement; 
 “Target Business Employees” means, in respect of GlaxoSmithKline, the GlaxoSmithKline Business Employees and, in respect of Novartis, the Novartis Business Employees, and “Target
Business Employee” means any of them; 
 “Target Company Employees” means, in respect of
GlaxoSmithKline, the GlaxoSmithKline Company Employees and, in respect of Novartis, the Novartis Company Employees, and “Target Company Employee” means any one of them; 

“Target Group” means, in respect of GlaxoSmithKline, the GlaxoSmithKline Consumer Group Companies and the GlaxoSmithKline
Consumer Group Businesses, and, in respect of Novartis, the Novartis OTC Group Companies and the Novartis OTC Group Businesses, in each case, taken as a whole, and “Target Groups” shall mean both of them; 

  
 38 

 “Target Group Businesses” means, in respect of GlaxoSmithKline, the
GlaxoSmithKline Consumer Group Businesses and, in respect of Novartis, Novartis OTC Group Businesses, and “Target Group Business” means any one of them; 
 “Target Group Companies” means, in respect of GlaxoSmithKline, the GlaxoSmithKline Consumer Group Companies, and, in respect of Novartis, the Novartis OTC Group Companies, and
“Target Group Company” means any one of them; 
 “Target Group Companies’ Cash Balances”
means, in respect of a Seller, an amount equal to the sum of the aggregate amount of Cash Balances held by or on behalf of the Target Group Companies within that Seller’s Group at the Effective Time, as derived from the Closing Statement;

 “Target Group Goodwill” means all goodwill of the Target Group Businesses, but excluding any Trademark
goodwill; 
 “Target Group Information Technology” means the Transferred Information Technology and the Owned
Information Technology; 
 “Target Group Insurance Policies” means all insurance policies held exclusively by
and for the benefit of the relevant Target Group Companies, and “Target Group Insurance Policy” means any one of them; 
 “Target Group Intellectual Property Contracts” means the Transferred Intellectual Property Contracts and the Owned Intellectual Property Contracts; 

“Target Group Intellectual Property Rights” means the Transferred Intellectual Property Rights and the Owned Intellectual
Property Rights; 
 “Taxation” or “Tax” has the meaning given to it in the Tax Indemnity;

 “Tax Adjustment” means, in respect of a Seller, the amount by which: 

 

	 	(i)	the aggregate amount of the income taxes and sales taxes payable by the Target Group Companies, as at the Effective Time, as derived from the Closing Statement;

 exceeds or is less than 
  

	 	(ii)	the aggregate amount of the current income tax and sales tax receivables of the Target Group Companies, as at the Effective Time, as derived from the Closing Statement,

 and any such excess amount shall be treated as a positive number and any shortfall shall be treated as a
negative amount; 
 “Tax Authority” has the meaning given to it in the Tax Indemnity; 

“Tax Group” has the meaning given to it in the Tax Indemnity; 

“Tax Indemnity” means the deed of covenant against taxation, on terms consistent with the Agreed Terms, to be entered
into on the Closing Date between each Seller and the Purchaser; 
 “Tax Return” has the meaning given to it in
the Tax Indemnity; 
 “Tax Warranties” means, in respect of a Seller, the Seller’s Warranties set out in
paragraph 14 of Schedule 13; 
 “Third Party Claim” has the meaning given to it in Clause 11.4; 

  
 39 

 “Third Party Consents” means all consents, licences, approvals, permits,
authorisations or waivers required from third parties, and “Third Party Consent” means any one of them; 

“Third Party Indebtedness” means the aggregate amount as at the Effective Time of all outstanding Indebtedness owed by
the Target Group Companies to any third party less any Indebtedness owed by any third party to any Target Group Company as derived from the Closing Statement (but excluding any item included in respect of any Target Group Companies’ Cash
Balances or Intra-Group Non-Trade Payables), and, for the purposes of this definition, third party shall exclude any member of either Seller’s Group; 
 “Time-Limited Excluded Liability” means an Excluded Liability which is: 
  

	 	(i)	a Contracts Liability; 

  

	 	(ii)	an Environmental Liability; 

  

	 	(iii)	a Manufacturing Liability; or 

  

	 	(iv)	a Commercial Practices Liability, 

but excludes an IP Liability; 
 “Trademarks” means trademarks, service marks, trade names, certification marks, service names, industrial designs, brand names, brand marks, trade dress rights, identifying symbols,
logos, emblems, and signs or insignia and all goodwill of the business in relation to which any of the foregoing are used (but no other or greater goodwill); 
 “Transaction” has the meaning given to it in Clause 4.1.1; 

“Transfer Regulations” means the relevant national measure by which the employment of a Relevant Target Business Employee
automatically transfers to the Purchaser or a relevant member of the Purchaser’s Group; 
 “Transferred Accounts
Payables” means, in respect of a Seller, all trade accounts and notes payable of that Seller’s Group (other than its Target Group Companies) to the extent related to its Contributed Business, and outstanding at the Effective Time,
arising in the ordinary course, together with any unpaid financing charges accrued thereon; 
 “Transferred Accounts
Receivables” means, in respect of a Seller, all trade accounts and notes receivable of that Seller’s Group (other than its Target Group Companies) to the extent related to its Contributed Business, and outstanding at the Effective
Time, arising in the ordinary course, together with any unpaid financing charges accrued thereon; 
 “Transferred Books
and Records” means, in respect of a Seller, all books, ledgers, files, reports, plans, records, manuals and other materials (in any form or medium) to the extent of, or maintained predominantly for, that Seller’s Contributed Business
by that Seller’s Group (excluding its Target Group Companies) (other than emails), but excluding: 
  

	 	(i)	any such items to the extent that: (A) they are related to any Excluded Assets or Excluded Liabilities; (B) they are related to any corporate, Tax, human
resources or stockholder matters of that Seller or its Affiliates (other than its Target Group Companies); (C) any Applicable Law prohibits their transfer; or (D) any transfer thereof otherwise would subject that Seller or any of its
Affiliates to any material liability; and 

  
 40 

	 	(ii)	any laboratory notebooks to the extent containing research and development information unrelated to its Contributed Business and any books and records that are more
than five years old containing, in whole or in part, research and development information (other than any laboratory notebooks, books or records described in this paragraph (ii) that are maintained for its Contributed Business by its Target
Group Companies); 

 “Transferred Contracts” means: (i) in respect of a Seller, the
Contracts, other than its Transferred Intellectual Property Contracts, that are Exclusively Related to that Seller’s Contributed Business between a Business Seller of that Seller’s Group, on the one hand, and any third party, on the other
hand (other than this Agreement and any Ancillary Agreement); and (ii) in the case of Novartis, the Novartis Distribution and Sales Products Contracts and the Novartis Services Contracts; and (iii) in the case of GlaxoSmithKline, any
Contracts between a member of its Group (other than its Target Group Company and its Business Seller) on the one hand and its Business Seller, on the other hand, that are Exclusively Related to GlaxoSmithKline’s Contributed Business, other than
any contracts that relate to any services that will be and, as at Closing are, provided under the Ancillary Agreements; 

“Transferred Employees” means, in relation to a Seller: (i) any Target Business Employees of that Seller to whom the
Purchaser (or a member of the Purchaser’s Group) offers employment and who accept such employment and become employed by the Purchaser (or a member of the Purchaser’s Group) in accordance with Schedule 7; (ii) any Relevant Target
Business Employees of that Seller who transfer to the Purchaser (or a member of the Purchaser’s Group) by operation of the Transfer Regulations and do not object to such transfer (to the extent permitted by the Transfer Regulations) in
accordance with Schedule 7; and (iii) the Relevant Target Company Employees of that Seller, and “Transferred Target Business Employees” means the employees in (i) and (ii), “Transferred Target Company
Employees” means the employees in (iii), and “Transferred Employee”, “Transferred Target Business Employee” and “Transferred Target Company Employee” respectively means any one of them;

 “Transferred Information Technology” means, in respect of a Seller, all Information Technology of any member
of that Seller’s Group (other than its Target Group Company) to the extent Exclusively Related to that Seller’s Contributed Business; 
 “Transferred Intellectual Property Contracts” means, in respect of a Seller, Contracts Exclusively Related to its Contributed Business which relate to Intellectual Property Rights (but
excluding the rights under any such Contracts that are held by its Target Group Companies); 
 “Transferred Intellectual
Property Rights” means, in respect of a Seller, the Intellectual Property Rights of any member of that Seller’s Group (other than a Target Group Company) Exclusively Related to its Contributed Business. For the avoidance of doubt,
whether a Trademark is Exclusively Related to a Contributed Business will be assessed on a Brand basis rather than a country by country basis, so that a Brand (and the Trademarks used or registered for use with a Product to which that Brand is
associated) shall be deemed not to be Exclusively Related to a Contributed Business where, as at the date of this Agreement, a Brand is Commercialised by a Seller or its Affiliates in relation to both (i) a Product and (ii) a product of
that Seller’s Retained Business, in any part of the world; 
 “Transferred Inventory” means, in respect of
a Seller, all inventories (including its Manufacturing Inventory, Manufacturing Stocks and In-Market Inventory), wherever located, including all raw materials, work in progress, finished GlaxoSmithKline Products or Novartis Products (as the case may
be), and packaging and labelling material in respect of the GlaxoSmithKline Products or Novartis Products (as the case may be) and otherwise, in each case, that are, Predominantly Related to its Contributed Business (but excluding any such items
held by its Target Group Companies), whether held at any location or facility of a member of that Seller’s Group or in transit to a member of that Seller’s Group, in each case, as of the Effective Time; 

  
 41 

 “Transferred Leased Properties” has the meaning given to it in paragraph
1.1 of Part 4 of Schedule 2; 
 “Transferred Owned Properties” has the meaning given to it in paragraph 1.1 of
Part 4 of Schedule 2; 
 “Transferred Plant and Equipment” means, in respect of a Seller: 

 

	 	(i)	its Transferred Information Technology; and 

  

	 	(ii)	all plant, furniture, furnishings, vehicles, equipment, tools and other tangible personal property (other than its Transferred Inventory or its Transferred Information
Technology) of that Seller’s Group that are Predominantly Related to its Contributed Business (but excluding any such items owned by its Target Group Companies); 

“Transferred Properties” means, in respect of a Seller: 

 

	 	(i)	its Transferred Owned Properties; 

  

	 	(ii)	its Transferred Leased Properties; 

  

	 	(iii)	all other freehold, leasehold or other immovable property comprising research and development, production or manufacturing facilities Exclusively Related to its
Contributed Business, other than any freehold, leasehold or other immovable property within the definition of “Excluded Assets”; and 

  

	 	(iv)	all other freehold, leasehold or other immovable property comprising warehousing, distribution or office facilities Predominantly Related to its Contributed Business,
other than any freehold, leasehold or other immovable property within the definition of “Excluded Assets”, 

 and “Transferred Property” means any one of them; 

“Transitional Services Agreement” means, in respect of a Seller, the transitional services agreement expected to be
entered into between it and the Purchaser at Closing on terms consistent with the Agreed Terms; 
 “US Benefit
Plans” means all United States “employee benefit plans” (within the meaning of section 3(3) of ERISA), severance, change in control or employment, vacation, incentive, bonus, stock option, stock purchase, or restricted stock
plans, programmes, agreements or policies benefiting the relevant Target Business Employees; 
 “US RX Product
Disposal” has the meaning given to it in paragraph 10.3 of Schedule 6; 
 “US RX Products” means any of
the GlaxoSmithKline US RX Products or the Novartis US RX Products; 
 “US Transferred Employees” has the meaning
given to it in paragraph 7.1 of Schedule 7; 
 “Vaccines Sale and Purchase Agreement” means the sale and
purchase agreement dated the date of this agreement between Novartis and GlaxoSmithKline relating to the sale and purchase of Novartis’s vaccines business (excluding Novartis’s Influenza vaccines business); 

  
 42 

 “VAT” means, within the European Union, such Taxation as may be levied in
accordance with (but subject to derogations from) Council Directive 2006/112/EC and, outside the European Union, any Taxation levied by reference to added value or sales; 
 “WARN Act” means the Worker Adjustment and Retraining Notification Act of 1988 of the United States; 
 “Wholly-Owned Subsidiary” means, in respect of GlaxoSmithKline, any body corporate that is a 100 per cent. owned and controlled subsidiary of GlaxoSmithKline and, in respect of
Novartis, any body corporate that is a 100 per cent. owned and controlled subsidiary of Novartis (where “subsidiary” has the meaning given in section 1159 of the Companies Act 2006); 

“Working Capital” means, in respect of a Seller, the aggregate amount of the working capital items of its Target Group
falling into the categories set out in Part A of Part 4 of Schedule 12 (in respect of Novartis) or Part B of Part 4 of Schedule 12 (in respect of GlaxoSmithKline) as set out in its Closing Statement (which shall not include any amount in respect of
Tax), at the Effective Time, as derived from its Closing Statement; 
 “Working Capital Adjustment” means, in
respect of a Seller: 
  

	 	(i)	if its Working Capital is no less than its Minimum Working Capital Amount and no greater than its Maximum Working Capital Amount, zero; 

 

	 	(ii)	if its Working Capital is less than its Minimum Working Capital Amount, the amount by which its Working Capital is less than its Minimum Working Capital Amount, such
amount being treated as a negative amount; or 

  

	 	(iii)	if its Working Capital is greater than its Maximum Working Capital Amount, the amount by which its Working Capital exceeds its Maximum Working Capital Amount, such
amount being treated as a positive amount; 

 “Withholding Seller” has the meaning given in
Clause 15.11.2; and 
 “Workstream Lead” has the meaning given to it in the Implementation Agreement.

  

	1.2	Shares 

 References to
shares shall include, where relevant, quotas. 
  

	1.3	Singular, plural, gender 

References to one gender include all genders and references to the singular include the plural and vice versa. 

 

	1.4	References to persons and companies 

 References to: 
  

	 	1.4.1	a person include any individual, company, partnership or unincorporated association (whether or not having separate legal personality); and 

 

	 	1.4.2	a company include any company, corporation or any body corporate, wherever incorporated. 

  
 43 

	1.5	Schedules etc. 

References to this Agreement shall include any Recitals and Schedules to it and references to Clauses and Schedules are to Clauses of, and
Schedules to, this Agreement. References to paragraphs and Parts are to paragraphs and Parts of the Schedules. 
  

	1.6	Reference to documents 

References to any document (including this Agreement), or to a provision in a document, shall be construed as a reference to such document
or provision as amended, supplemented, modified, restated or novated from time to time. 
  

	1.7	References to enactments 

Except as otherwise expressly provided in this Agreement, any express reference to an enactment (which includes any legislation in any
jurisdiction) includes references: (i) to that enactment as amended, consolidated or re-enacted by or under any other enactment before or after the date of this Agreement; (ii) any enactment which that enactment re-enacts (with or without
modification); and (iii) any subordinate legislation (including regulations) made before or after the date of this Agreement under that enactment as amended, consolidated or re-enacted as described in paragraph (i) or paragraph
(ii) above, except to the extent that any of the matters referred to in paragraph (i) to paragraph (iii) (inclusive) above occurs after the date of this Agreement and increases or alters the liability of a Seller or the Purchaser
under this Agreement. 
  

	1.8	Information 

 References
to books, records or other information mean books, records or other information in any form including paper, electronically stored data, magnetic media, film and microfilm. 

 

	1.9	References to “indemnify” 

 Unless specified to the contrary, references to “indemnify” and “indemnifying” any person against any circumstance include indemnifying and holding that person harmless on an after-Tax
basis and: 
  

	 	1.9.1	references to the Purchaser indemnifying each member of a Seller’s Group shall constitute undertakings by the Purchaser to that Seller for itself and on behalf of
each other member of that Seller’s Group; 

  

	 	1.9.2	references to the relevant Seller indemnifying each member of the Purchaser’s Group shall constitute undertakings by that Seller to the Purchaser for itself and on
behalf of each other member of the Purchaser’s Group; 

  

	 	1.9.3	to the extent that the obligation to indemnify relates to any Shares (including any Target Group Companies) or other assets or liabilities transferred by a Share Seller
or Business Seller (as the case may be) to a member of the Purchaser’s Group pursuant to this Agreement, references to the Seller indemnifying the Purchaser and references to the Seller indemnifying the Purchaser or any member of the
Purchaser’s Group shall constitute undertakings by the Seller to indemnify or procure the indemnification of the relevant purchaser of the Shares transferred by that Share Seller or the relevant purchaser of the assets or liabilities
transferred by that Business Seller (as the case may be), and references to the Purchaser indemnifying the Seller and references to the Purchaser indemnifying the Seller and each member of the Seller’s Group shall constitute undertakings by the
Purchaser to indemnify or procure the indemnification of the relevant member of the Seller’s Group; and 

  
 44 

	 	1.9.4	where under the terms of this Agreement one party is liable to indemnify or reimburse another party in respect of any costs, charges or expenses, the payment
shall include an amount equal to any VAT thereon not otherwise recoverable by the other party or any member of any group or consolidation of which it forms part for VAT purposes, subject to that party using reasonable endeavours to recover or to
procure recovery of such amount of VAT as may be practicable. 

 For the purposes of this Clause 1.9, indemnifying
and holding harmless a person on an “after-Tax basis” means that the amount payable pursuant to the indemnity (the “Payment”) shall be calculated in such a manner as will ensure that, after taking into account: 

 

	 	(i)	any Tax required to be deducted or withheld from the Payment and any additional amounts required to be paid by the payer of the Payment in consequence of such
withholding; 

  

	 	(ii)	the amount and timing of any additional Tax which becomes (or would, but for the use of any credit or other relief which would otherwise have been available to reduce
the Tax liabilities of any member of a Seller’s Group or of the Purchaser’s Group, as the case may be, have become) payable by the recipient of the Payment (or a member of a Seller’s Group or the Purchaser’s Group, as the case
may be) as a result of the Payment’s being subject to Tax in the hands of that person; and 

  

	 	(iii)	the amount and timing of any Tax benefit which is obtained by the recipient of the Payment (or a member of a Seller’s Group or the Purchaser’s Group, as the
case may be) to the extent that such Tax benefit is attributable to the matter giving rise to the indemnity payment or to the receipt of the Payment, 

 which amount and timing is to be determined by the auditors of the recipient at the shared expense of both relevant parties and is to be certified as such to the party making the Payment, the recipient of
the Payment is in no better and no worse after Tax position as that in which it would have been if the matter giving rise to the indemnity payment had not occurred, provided that if any party to this Agreement shall have assigned or novated the
benefit of this Agreement in whole or in part or shall, after the date of this Agreement, have changed its Tax residence or the permanent establishment to which the rights under this Agreement are allocated then no Payment to that party shall be
increased by reason of the operation of paragraphs (i) to (iii) above to any greater extent than would have been the case had no such assignment, novation or change taken place. 

 

	1.10	References to wholly or substantially in the Contributed Business 

References to any employee employed by a member of a Seller’s Group working “wholly or substantially” in a
Contributed Business (whether the GlaxoSmithKline Consumer Business or the Novartis OTC Business, as the case may be) means that such employee spends more than 70 per cent. of their time working in the Contributed Business at the relevant
time. 

  
 45 

	1.11	Legal terms 

 References
to any English legal term shall, in respect of any jurisdiction other than England and Wales, be construed as references to the term or concept which most nearly corresponds to it in that jurisdiction. 

 

	1.12	Non-limiting effect of words 

 The words “including”, “include”, “in particular” and words of similar effect shall not be deemed to limit the general effect of the words that precede them. 

 

	1.13	Currency conversion 

  

	 	1.13.1	Subject to Clause 1.13.1, any amount to be converted from one currency into another currency for the purposes of this Agreement shall be converted into an equivalent
amount at the Conversion Rate prevailing at the Relevant Date. For the purposes of this Clause 1.13: 

“Conversion Rate” means the spot reference rate for a transaction between the two currencies in question as quoted by
the European Central Bank on the Business Day immediately preceding the Relevant Date or, if no such rate is quoted on that date, on the preceding date on which such rates are quoted; 

“Relevant Date” means, save as otherwise provided in this Agreement, the date on which a payment or an assessment is to
be made, save that, for the following purposes, the date shall mean: 
  

	 	(i)	for the purposes of Clause 5, the date of this Agreement; 

  

	 	(ii)	for the purposes of Clause 7 and Schedule 12 and Schedule 18, the Closing Date; or 

 

	 	(iii)	for the purposes of Clause 10, the date of this Agreement; and 

  

	 	(iv)	for the purposes of the monetary amounts set out in Schedule 13, the date of this Agreement. 

 

	 	1.13.2	For the purposes of Schedule 12, the conversion of an amount from one currency into another shall be carried out in accordance with the accounting policies and
practices of the Purchaser’s Group in operation from time to time. 

  

	2.	Sale and Purchase of the Target Groups 

  

	2.1	Sale and Purchase of the Target Groups 

 On and subject to the terms of this Agreement and the Local Transfer Documents: 
  

	 	2.1.1	GlaxoSmithKline undertakes to Novartis and the Purchaser to procure that its Share Sellers and Business Sellers shall sell the GlaxoSmithKline Target Group;

  
 46 

	 	2.1.2	Novartis undertakes to GlaxoSmithKline and the Purchaser to procure that its Share Sellers and Business Sellers shall sell the Novartis Target Group; and

  

	 	2.1.3	the Purchaser undertakes to GlaxoSmithKline and Novartis to purchase (or procure the purchase by a member(s) of the Purchaser’s Group of) each of the Target
Groups, 

 in each case, as a going concern. 

 

	2.2	Sale of the Shares 

  

	 	2.2.1	GlaxoSmithKline shall procure that its Share Sellers shall sell the GlaxoSmithKline Shares, and Novartis shall procure that its Share Sellers shall sell the Novartis
Shares, and the Purchaser shall purchase (or procure the purchase of) the Shares, in each case, with Full Title Guarantee free from Encumbrances (other than any rights of first refusal that exist as at the date of this Agreement in relation to any
Shares in any Joint Venture Entities) and together with all rights and advantages attaching to them as at Closing (including the right to receive all dividends or distributions declared, made or paid on or after Closing), subject to and in
accordance with the provisions of Schedule 6. 

  

	 	2.2.2	GlaxoSmithKline shall procure that, on or prior to Closing, any and all rights of pre-emption over the GlaxoSmithKline Shares (other than such rights of pre-emption
that exist at the date of this Agreement in respect of its Joint Venture Entities) and Novartis shall procure that, on or prior to Closing, any and all rights of pre-emption over the Novartis Shares (other than in respect of its Joint Venture
Entities), in each case, are waived irrevocably by the persons entitled thereto. 

  

	2.3	Sale of the Target Group Businesses 

  

	 	2.3.1	Each Seller shall sell (or procure the sale of) the assets comprising its Target Group Businesses and the Purchaser shall purchase (or procure the purchase of), each
Seller’s Target Group Businesses, in each case, under this Agreement or, where relevant, the Local Transfer Documents. Each of those assets shall be sold by that Seller or Business Seller (as the case may be) with Full Title Guarantee (save in
respect of the Transferred Intellectual Property Rights) and free from Encumbrances other than Permitted Encumbrances (save for the Transferred Properties, which shall be sold free from Encumbrances other than as provided in paragraph 1.9 of Part 4
of Schedule 2) and shall comprise, in respect of each Target Group Business of each Seller (unless otherwise expressly provided below): 

  

	 	(i)	the Transferred Properties; 

  

	 	(ii)	the Transferred Plant and Equipment; 

  

	 	(iii)	the Transferred Inventory; 

  
 47 

	 	(iv)	the Transferred Accounts Receivables; 

  

	 	(v)	the Transferred Books and Records; 

  

	 	(vi)	subject to and in accordance with Schedule 6, the Transferred Intellectual Property Rights; 

 

	 	(vii)	subject to and in accordance with Schedule 6, the Transferred Intellectual Property Contracts; 

 

	 	(viii)	the Transferred Information Technology; 

  

	 	(ix)	subject to and in accordance with Schedule 6, its Transferred Contracts and the Relevant Part of the Shared Business Contracts; 

 

	 	(x)	subject to and in accordance with Clause 6.2 and Schedule 4, all Product Approvals and all Product Applications and all other permits, licences, certificates,
registrations, marketing or other authorisations or consents issued by a Governmental Entity Predominantly Related to that Seller’s Contributed Business and not held by its Target Group Companies; 

 

	 	(xi)	subject to and in accordance with Schedule 4, all Marketing Authorisation Data not held by its Target Group Companies; 

 

	 	(xii)	all Business Information not held at Closing by its Target Group Companies; 

 

	 	(xiii)	all rights of the Purchaser, its Affiliates and its Target Group Companies as contemplated by Schedule 7 and Schedule 8; 

 

	 	(xiv)	the Target Group Goodwill; and 

  

	 	(xv)	all other property, rights and assets owned or held by that Seller’s Group (other than its Target Group Companies) and Predominantly Related to that Seller’s
Contributed Business at Closing (other than any property, rights and assets of that Seller’s Target Group expressly excluded from the sale under this Agreement). 

 

	 	2.3.2	There shall be excluded from the sale of each Target Group Business by a Seller under this Agreement and the Local Transfer Documents the following:

  

	 	(i)	the Seller’s Retained Business; 

  

	 	(ii)	any Intellectual Property Right that is not a Target Group Intellectual Property Right; 

 

	 	(iii)	any Information Technology other than the Target Group Information Technology; 

  
 48 

	 	(iv)	the Seller Marks; 

  

	 	(v)	any product and any permits, licences, certificates, registrations, marketing or other authorisations or consents issued by any Governmental Entity in respect of any
products, or any applications therefor, other than: (a) products to the extent included in the relevant Seller’s Contributed Business (including the Products), Product Approvals, Products Under Registration and Pipeline Product Approvals;
and (b) Permits Predominantly Related to that Seller’s Contributed Business; 

  

	 	(vi)	all cash, marketable securities and negotiable instruments, and all other cash equivalents, of that Seller’s Group (other than its Target Group Companies);

  

	 	(vii)	the land and buildings of Novartis’s Group at 4560 Horton Street, Emeryville CA, United States of America, together with all fixtures and improvements erected
thereon; 

  

	 	(viii)	the land and buildings of the Novartis’s Group at Jaboatão dos Guarapas, State of Pernambuco, Brazil, together with all fixtures and improvements erected
thereon and any other assets, rights and Contracts related thereto; 

  

	 	(ix)	all real property and any leases therefor and interests therein other than the Properties; 

 

	 	(x)	the company seal, minute books, charter documents, stock or equity record books and such other books and records pertaining to that Seller or its Affiliates (other than
the Target Group Companies and the Transferred Books and Records), as well as any other records or material relating to that Seller or its Affiliates (other than its Target Group Companies) generally and not involving or related to that
Seller’s Target Group; 

  

	 	(xi)	any right of that Seller or its Affiliates to be indemnified in respect of Assumed Liabilities; 

 

	 	(xii)	all Tax assets (including Tax refunds and prepayments), other than Tax assets of any Target Group Company; 

 

	 	(xiii)	all Tax Returns of that Seller’s Group (other than its Target Group Companies) and all Tax Returns relating to Tax Groups of which persons other than Target Group
Companies are members and, in each case, all books and records (including working papers) related thereto; 

  

	 	(xiv)	any rights in respect of any insurance policies of that Seller’s Group as provided in and subject to Clause 13; 

  
 49 

	 	(xv)	all artwork, paintings, drawings, sculptures, prints, photographs, lithographs and other artistic works of that Seller’s Group that are not embodiments of the
Target Group Intellectual Property Rights; 

  

	 	(xvi)	any rights of that Seller’s Group (other than its Target Group Companies) under any of its Intra-Group Non-Trade Payables or Intra-Group Non-Trade Receivables
(excluding its Transferred Accounts Receivables); 

  

	 	(xvii)	any rights of that Seller or its Affiliates (other than its Target Group Companies) contemplated by Schedule 7 and Schedule 8; 

 

	 	(xviii)	any equity interest in any person other than a Target Group Company or the Joint Venture Entities; 

 

	 	(xix)	the Excluded Contracts, including the Endo Excluded Contract; 

  

	 	(xx)	all rights of that Seller’s Group under this Agreement and the Ancillary Agreements; 

 

	 	(xxi)	the Seller’s Bank Account; 

  

	 	(xxii)	in the case of GlaxoSmithKline only, those items, assets and businesses set out in Part 1 of Schedule 3; and 

 

	 	(xxiii)	in the case of Novartis only, those items, assets and businesses set out in Part 2 of Schedule 3. 

 

	 	2.3.3	Each Seller agrees to procure the transfer of (to the extent it is able so to do) and the Purchaser agrees to accept or procure the acceptance by another member of the
Purchaser’s Group of the transfer of, and to assume, duly and punctually pay, satisfy, discharge, perform or fulfil or procure that another member of the Purchaser’s Group will assume, duly and punctually pay, satisfy, discharge, perform
or fulfil, the Assumed Liabilities relating to that Seller’s Contributed Business, with effect from Closing. 

  

	 	2.3.4	Clause 2.3.3 shall not apply to, and the Purchaser shall not be obliged to accept (or procure the acceptance by another member of the Purchaser’s Group of), the
transfer of or to assume, duly and punctually pay, satisfy, discharge, perform or fulfil (or procure that another member of the Purchaser’s Group will assume, duly and punctually pay, satisfy, discharge, perform or fulfil):

  

	 	(i)	any Excluded Liability; or 

  

	 	(ii)	any Liability to the extent it relates to an Excluded Asset. 

  

	 	2.3.5	 Each Seller shall comply with its obligations in Schedule 17 (Reorganisations) in respect of any reorganisation of that Seller’s Group carried out
prior to Closing involving its Target Group (including assigning or otherwise transferring assets, liabilities and (only where in compliance with Clause 5 other than Clause 5.2.5)

  
 50 

	 	
employees between members of that Seller’s Group and including, without limitation, transferring all or part of its Target Group into or (directly or indirectly) beneath, as the case may be,
a single newly incorporated company or holding company, as the case may be, with the intention of that new company being transferred to the Purchaser on Closing) (each a “Reorganisation”). In the event that a Seller carries out a
Reorganisation such that the structure of the Target Group has been altered, the provisions of this Agreement shall apply to such altered structure mutatis mutandis. 

 

	 	2.3.6	Promptly after the date of this Agreement: 

  

	 	(i)	the project manager of each of GlaxoSmithKline and Novartis shall appoint a Workstream Lead who shall be generally responsible for the implementation of this Agreement;
and 

  

	 	(ii)	GlaxoSmithKline, Novartis and each Workstream Lead appointed in accordance with Clause 2.3.6(i) shall use their reasonable endeavours to further identify the assets and
liabilities comprising GlaxoSmithKline’s and Novartis’s respective Target Group and make any amendments or updates to Schedule 1, Schedule 2, Schedule 3, Schedule 6, Schedule 9, Schedule 16, Schedule 19 and Schedule 21 as may be necessary
to ensure that such Schedules accurately reflect the scope of each of GlaxoSmithKline’s and Novartis’s respective Target Group, 

 provided that nothing in this Clause 2.3.6 shall be construed as a right or obligation to amend or update the scope of each of GlaxoSmithKline’s and Novartis’s respective Target Group as defined
in this Agreement. 
  

	2.4	Employees and Employee Benefits 

  

	 	2.4.1	The provisions of Schedule 7 shall apply in respect of the Employees. 

  

	 	2.4.2	The provisions of Schedule 8 shall apply in respect of Employee Benefits. 

  

	2.5	Properties 

 The
provisions of Schedule 2 shall apply in respect of the Properties. 
  

	2.6	Local Transfer Documents 

  

	 	2.6.1	On Closing or at such other time as agreed between the parties, each Seller shall procure that its Share Sellers and Business Sellers execute, and the Purchaser shall
execute (or procure the execution by one or more other members of the Purchaser’s Group of), such agreements, transfers, conveyances and other documents, as may be required pursuant to the relevant local law and otherwise as may be agreed
between such Seller and the Purchaser to implement the transfer of (i) the Shares held by such Share Sellers and (ii) the Target Group Businesses held by such Business Sellers, in each case on Closing subject to the provisions of Schedule
6 (the “Local Transfer Documents” and each, a “Local Transfer Document”). The parties do not intend this Agreement to transfer title to any of the Shares. Title shall be transferred by the applicable Local Transfer
Document. 

  
 51 

	 	2.6.2	To the extent that the provisions of a Local Transfer Document are inconsistent with or (except to the extent they implement a transfer in accordance with this
Agreement) additional to the provisions of this Agreement: 

  

	 	(i)	the provisions of this Agreement shall prevail; and 

  

	 	(ii)	so far as permissible under the laws of the relevant jurisdiction, the relevant Seller and the Purchaser shall procure that the provisions of the relevant Local
Transfer Document are adjusted, to the extent necessary to give effect to the provisions of this Agreement or, to the extent this is not permissible, that Seller shall indemnify the Purchaser against all Liabilities suffered by the Purchaser or its
Affiliates or, as the case may be, the Purchaser shall indemnify that Seller against all Liabilities suffered by that Seller or its Affiliates, in either case, through or arising from the inconsistency between the Local Transfer Document and this
Agreement or the additional provisions (except to the extent they implement a transfer in accordance with this Agreement). 

  

	 	2.6.3	If there is an adjustment to the Purchase Consideration under Clause 7.3 which relates to a part of the Target Group which is the subject of a Local Transfer Document,
then, if required to implement the adjustment and so far as permissible under Applicable Law, the Purchaser shall (or shall procure that the relevant member of the Purchaser’s Group will), and the relevant Seller shall procure that its relevant
Affiliate shall, enter into a supplemental agreement reflecting such adjustment and the allocation of such adjustment. 

  

	 	2.6.4	Neither Seller shall, and each Seller shall procure that none of its Affiliates shall, bring any claim against the Purchaser or any member of the Purchaser’s Group
in respect of or based upon the Local Transfer Documents save to the extent necessary to implement any transfer of the Shares or Target Group Businesses as contemplated by this Agreement. To the extent that any Seller or a member of that
Seller’s Group does bring a claim in breach of this Clause, that Seller shall indemnify the Purchaser and each member of the Purchaser’s Group against all Liabilities which the Purchaser or that member of the Purchaser’s Group may
suffer through or arising from the bringing of such a claim. 

  

	 	2.6.5	The Purchaser shall not, and shall procure that none of its Affiliates shall, bring any claim against any Seller or any member of any Seller’s Group in respect of
or based upon the Local Transfer Documents save to the extent necessary to implement any transfer of the Shares or the Target Group Businesses as contemplated by this Agreement. To the extent that the Purchaser or a member of the Purchaser’s
Group does bring a claim in breach of this Clause, the Purchaser shall indemnify the relevant Seller and each member of that Seller’s Group against all Liabilities which that Seller or any member of that Seller’s Group may suffer through
or arising from the bringing of such a claim. 

  
 52 

	3.	Consideration 

  

	3.1	Amount 

  

	 	3.1.1	The aggregate consideration for the purchase of each of the GlaxoSmithKline Consumer Group and the Novartis OTC Group under this Agreement and the Local Transfer
Documents (together with any payment required to be made pursuant to clause 3.1.3, the “Purchase Consideration”) shall be: 

  

	 	(i)	in the case of the GlaxoSmithKline Consumer Group, the allotment and issue by the Purchaser to GlaxoSmithKline (and/or such other of its Affiliates as are Wholly-Owned
Subsidiaries as GlaxoSmithKline may direct prior to Closing, provided that no more than two members of GlaxoSmithKline’s Group shall be issued A Shares at Closing) of the A Shares in accordance with the provisions of this Agreement; and

  

	 	(ii)	in the case of the Novartis OTC Group, the allotment and issue by the Purchaser to Novartis (and/or such other of its Affiliates as are Wholly-Owned Subsidiaries as
Novartis may direct prior to Closing, provided that no more than two members of Novartis’s Group shall be issued B Shares at Closing of the B Shares in accordance with the provisions of this Agreement). 

 

	 	3.1.2	The Sellers and the Purchaser acknowledge and agree that the Purchase Consideration has been determined on the basis of the Base Working Capital Range, with the
intention that for each of the Target Groups, the sum of the amounts set out in Clause 3.1.3(i) to 3.1.3(vii) will equal zero. 

  

	 	3.1.3	If, in respect of the GlaxoSmithKline Consumer Group or the Novartis OTC Group, the sum of the following: 

 

	 	(i)	the Target Group Companies’ Cash Balances and the Intra-Group Non-Trade Receivables; 

minus 
  

	 	(ii)	the Third Party Indebtedness 

minus 
  

	 	(iii)	the Intra-Group Non-Trade Payables; 

 minus 
  

	 	(iv)	any Employee Benefit Indemnification Amount paid in accordance with Schedule 8; 

 minus 

	 	(v)	the excess over US$20,000,000, if any, of the Intra-Group Trading Balances; 

  
 53 

 minus 
  

	 	(vi)	the Tax Adjustment; and 

 plus
(if it is zero or a positive amount) or minus (if it is a negative amount) 
  

	 	(vii)	the Working Capital Adjustment, 

does not equal zero, balancing payments shall be made between GlaxoSmithKline and the Purchaser (in the case of the GlaxoSmithKline
Consumer Group) or Novartis and the Purchaser (in the case of the Novartis OTC Group) in accordance with Clauses 6.3 and 7.3 to 7.6 (inclusive). 
  

	3.2	Satisfaction of Purchase Consideration 

  

	 	3.2.1	The Purchaser shall allot and issue the A Shares and the B Shares credited as fully paid. The amount payable under Clause 3.1.3 shall be paid in cash to the relevant
Seller’s Bank Account(s) or the Purchaser’s Bank Account, as the case may be, pursuant to Clauses 6.3 and 7.6. 

  

	 	3.2.2	Any cash payment required to be made by the Purchaser pursuant to Clauses 3.1.3, 3.2.1, 3.3, 6.3 and/or 7.3 to 6 (inclusive), shall be funded through Shareholder Loans
(as defined in the Shareholders’ Agreement), made pro rata to each Seller’s Group’s shareholding in the Purchaser (and each Seller shall procure its relevant Affiliates make such Shareholder Loans required by this Clause 3.2.2).

  

	3.3	VAT 

  

	 	3.3.1	The provisions of Schedule 10 shall apply in respect of VAT. 

  

	 	3.3.2	Each Seller and the Purchaser agree that the consideration given under this Agreement in respect of the sale of the Target Group Businesses and the Shares is exclusive
of any VAT. 

  

	 	3.3.3	To the extent that VAT is chargeable in respect of that sale or any part thereof, the Purchaser shall, against delivery of a valid VAT invoice (or equivalent, if any),
in addition to any other amount expressed in this Agreement to be payable by the Purchaser, pay or procure the payment to the relevant Seller (on behalf of its relevant Business Seller or Share Seller as applicable) any amount of any VAT so
chargeable for which that Seller (or the relevant member of that Seller’s Group, as the case may be) is liable to account, in accordance with Schedule 10. 

 

	3.4	Treatment of Payments 

 If any payment is
made or procured (i) by a Seller to the Purchaser or relevant member of the Purchaser’s Group, or (ii) by a Purchaser to a member of a Seller’s Group, in either case, in respect of any claim under or for any breach of this
Agreement or pursuant to an indemnity (or equivalent covenant to pay) under this Agreement, the payment shall be treated, so far as possible, as an adjustment of the Purchase Consideration paid by the relevant member of the Purchaser’s Group
for the particular part of the Target Group to which the payment and/or claim relates under this Agreement and the Purchase Consideration shall be deemed to be increased or reduced (as applicable) by the amount of such payment, 

  
 54 

 PROVIDED THAT this Clause 3.4 shall not require any amount to be treated as an amount in respect of the
Purchase Consideration for the purposes of Clause 15.11 (Grossing-up) if it would not otherwise have been so treated. 
  

	4.	Conditions 

  

	4.1	Conditions Precedent 

 The
sale and purchase of each Target Group is conditional upon satisfaction of the following conditions, or their satisfaction subject only to Closing: 
  

	 	4.1.1	to the extent that the proposed transaction contemplated under this agreement (the “Transaction”) either constitutes (or is deemed to constitute under
Article 4(5) or Article 5(2)) a concentration with a Community dimension within the meaning of Council Regulation (EC) 139/2004 (as amended) (the “Regulation”) or is to be examined by the European Commission as a result of a
decision under Article 22(3) of the Regulation: 

  

	 	(i)	the European Commission taking a decision (or being deemed to have taken a decision) under Article 6(1)(b) or, if the Commission has initiated proceedings pursuant to
Article 6(1)(c), under Article 8(1) or 8(2) of the Regulation declaring the Transaction compatible with the common market; or 

  

	 	(ii)	the European Commission taking a decision (or being deemed to have taken a decision) to refer the whole or part of the Transaction to the competent authorities of one
or more Member States under Article 4(4) or 9(3) of the Regulation; and 

  

	 	(a)	each such authority taking a decision with equivalent effect to Clause 4.1.1(i) with respect to those parts of the Transaction referred to it; and

  

	 	(b)	the European Commission taking any of the decisions under Clause 4.1.1(i) with respect to any part of the Transaction retained by it; 

 

	 	4.1.2	any waiting period (and any extension thereof) under the HSR Act applicable to the Transaction having expired; 

 

	 	4.1.3	to the extent required or otherwise agreed between the parties as appropriate to permit the parties to consummate the Transaction in the jurisdictions listed in
Schedule 20, any additional clearances, approvals, waivers, no-action letters and consents having been obtained and any additional waiting periods having expired under applicable antitrust, merger control or foreign investment rules set forth in
Schedule 20; 

  
 55 

	 	4.1.4	receipt of CFIUS Approval if CFIUS has initiated a review of the transactions contemplated by this Agreement, whether pursuant to Clause 4.2.3 or otherwise;

  

	 	4.1.5	no Governmental Entity having enacted, issued, promulgated, enforced or entered any Applicable Law or Judgment (whether temporary, preliminary or permanent) that is in
effect at the Closing Date and that has the effect of making the transactions contemplated by this Agreement illegal or otherwise restraining or prohibiting the consummation of such transactions; 

 

	 	4.1.6	the passing at a duly convened and held general meeting of GlaxoSmithKline’s Shareholders (as defined in the Implementation Agreement) of an ordinary resolution
validly approving the sale and purchase under each of the Target Asset Agreements and any sale and purchase under the Put Option Agreement (as defined in the Implementation Agreement) in accordance with GlaxoSmithKline’s Articles of
Association, the Listing Rules (as defined in the Implementation Agreement) and all other Applicable Law and regulation (such resolution being the “GlaxoSmithKline Shareholder Resolution” and such meeting being the
“GlaxoSmithKline Shareholder Meeting”); 

  

	 	4.1.7	Novartis not delivering, in accordance with Clause 3 of the Implementation Agreement, a Novartis Board Certificate (as defined in the Implementation Agreement) prior to
the conclusion of the vote on the GlaxoSmithKline Shareholder Resolution at the GlaxoSmithKline Shareholder Meeting; and 

  

	 	4.1.8	each of the other Target Asset Agreements having become unconditional in accordance with its terms (save for any condition in those agreements relating to this
Agreement or the other of those agreements having become unconditional). 

  

	4.2	Responsibility for Satisfaction 

  

	 	4.2.1	The Sellers shall prepare and file the notifications necessary for the fulfilment of the conditions in Clauses 4.1.1 to 4.1.3 (the “Required
Notifications”) as soon as reasonably practicable (with notifications under the HSR Act to be filed by 29 May 2014). Notwithstanding anything to the contrary contained in this Agreement, GlaxoSmithKline shall have primary responsibility
for obtaining all consents, approvals or actions of any Governmental Entity which are required in connection with the Required Notifications (with the exception of the Minority Notifications addressed in Clause 4.2.10, for which Novartis shall have
such responsibility). 

  

	 	4.2.2	GlaxoSmithKline shall be responsible for payment of all filing and other fees and expenses in connection with the Required Notifications and the satisfaction of the
conditions in Clauses 4.1.1 to 4.1.3, (with the exception of the Minority Notifications addressed in Clause 4.2.10, for which Novartis shall have such responsibility). 

 

	 	4.2.3	CFIUS: 

  
 56 

	 	(i)	The Sellers and the Purchaser shall consult, cooperate and keep each other reasonably informed regarding communications with, and requests for additional information
from, CFIUS with respect to the Transaction. The Sellers and the Purchaser shall use their respective reasonable best efforts to provide promptly all information that is pursuant to a request by CFIUS. 

 

	 	(ii)	Within 30 calendar days after the execution of this Agreement, any party wishing to submit a formal joint voluntary notice to CFIUS pursuant to 31 C.F.R.
Section 800.401, et. seq. (“CFIUS Filing”) shall provide the other parties with written notice of its intent to make a CFIUS Filing (“Election Date”). Prior to making its election to submit a CFIUS Filing, the
party wishing to make a CFIUS Filing shall consult in good faith with senior executives of the other parties. If neither of the Sellers nor the Purchaser provide notice to submit a formal joint voluntary notice to CFIUS, a CFIUS Filing will not be
made unless requested by CFIUS. 

  

	 	(iii)	If any one or more of the parties elects to make a CFIUS Filing following the procedures and consultations in Clause 4.2.3(ii) or if CFIUS requires a filing, then:

  

	 	(a)	the Sellers and the Purchaser shall use their respective reasonable best efforts to submit a draft CFIUS Filing no later than 15 Business Days following the Election
Date, and a final CFIUS Filing the earlier of (1) five Business Days after submitting the draft CFIUS filing or (2) five calendar days after the receipt of any comments from CFIUS staff regarding the draft CFIUS Filing;

  

	 	(b)	the Sellers and the Purchaser will provide each other with the reasonable opportunity to review and comment on any information provided to CFIUS to the extent permitted
by Applicable Law, with the exception of personal identifier information required under Section 800.402(c)(6)(vi)(B) of the CFIUS regulations, 31 C.F.R. competitively sensitive information, or information not related to the transactions
contemplated by this Agreement, may be restricted to each party’s external counsel to the extent reasonably considered necessary or advisable by the providing party; 

 

	 	(c)	the Sellers and the Purchaser shall each have an opportunity to approve and mutually agree on the joint contents of the CFIUS Filing and shall be jointly responsible
for the accuracy of such contents. The Sellers and the Purchaser respectively, shall each be responsible for the accuracy of contents of the CFIUS Filing that exclusively relate to itself, its business, and any subsidiaries, parents or other related
parties; and 

  
 57 

	 	(d)	the Sellers and the Purchaser shall use their respective reasonable best efforts to obtain CFIUS Approval as promptly as practicable and shall consult with each other
on strategic matters related to obtaining such CFIUS Approval, provided that the Purchaser shall have no obligation to agree to any mitigation or other restrictive provision that could reasonably be considered to have a substantial impact on either
of the Contributed Business or the Purchaser. 

  

	 	4.2.4	Notwithstanding any other provision of this Agreement to the contrary, GlaxoSmithKline shall and, shall cause its subsidiaries and affiliates to:

  

	 	(i)	propose, negotiate, offer to commit and effect (and if such offer is accepted, commit to and effect), by consent decree, undertaking, hold separate order, or otherwise,
the sale, divestiture, licence or disposition of such combination of assets or businesses of: (i) the GlaxoSmithKline Target Group; (ii) GlaxoSmithKline’s other assets, businesses, subsidiaries or affiliates; and (ii) the
Novartis Target Group; and/or 

  

	 	(ii)	otherwise offer to take or offer to commit to take any action (including any action that limits its freedom of action, ownership or control with respect to, or its
ability to retain or hold, any of the businesses, assets, product lines, properties or services of: the GlaxoSmithKline Target Group; GlaxoSmithKline’s other assets, businesses, subsidiaries or affiliates; or the Novartis Target Group) and, if
the offer is accepted, take or commit to take such action; and/or 

  

	 	(iii)	use its best efforts to defend through litigation on the merits any claim asserted in court by any party in order to avoid entry of, or to have vacated or terminated,
any decree, order or Judgment (whether temporary, preliminary or permanent) that would restrain, prevent, or delay the Closing, 

 in each case, as may be required or desirable in order to procure the satisfaction of the conditions in Clauses 4.1.1 to 4.1.3 as soon as reasonably possible (and, in any event, not later than the
Longstop Date) or to avoid the commencement of any Action or the issuing of any Decision to prohibit the Transaction, or if such Action is already commenced, to avoid the entry of, or to effect the dissolution of, any injunction, temporary
restraining order or other order in any Action so as to enable the Closing to occur as soon as reasonably possible (and, in any event, not later than the Longstop Date). 

 

	 	4.2.5	GlaxoSmithKline, after reasonably and in good faith consulting with Novartis and considering Novartis’s views, shall make all decisions, lead all discussions,
negotiations and other proceedings, and coordinate all activities and any requests that may be made by, or any actions, consents, undertakings, approvals, waivers or authorizations that may be sought by or from, any Governmental Entity, including
determining the strategy and manner in which to contest or otherwise respond, by litigation or otherwise, to objections to, or proceedings or other actions challenging, the consummation of the Transaction. 

  
 58 

	 	4.2.6	At GlaxoSmithKline’s request, Novartis shall, and shall cause the Novartis Target Group to take all reasonable actions GlaxoSmithKline deems prudent in order to
reasonably assist GlaxoSmithKline in obtaining any actions, consents, undertakings, approvals, waivers or authorizations by or from any Governmental Entity for or in connection with consummating the Transaction including, inter alia:

  

	 	(i)	providing to GlaxoSmithKline such information with respect to the Novartis Target Group as GlaxoSmithKline may reasonably require in connection with satisfaction of its
obligations under this Clause; 

  

	 	(ii)	effecting the sale, divestiture, licence or disposition of such assets or businesses of the Novartis Target Group or any of its subsidiaries or affiliates as may be
reasonably necessary to consummate the Transaction; 

  

	 	(iii)	reasonably assisting GlaxoSmithKline in litigating or otherwise contesting any objections to or proceedings or other actions challenging, the consummation of the
Transaction; and/or 

  

	 	(iv)	assisting to ensure that any proposal or offer made (or intended to be made) by GlaxoSmithKline to a Governmental Entity pursuant to Clause 4.2.4 can also be proposed
or offered to a Governmental Entity which examines the transaction pursuant to a Minority Notification. 

  

	 	4.2.7	GlaxoSmithKline will, to the extent practicable and subject to Applicable Law: (i) consult with Novartis in advance of participating in any substantive meeting or
discussion with any Governmental Entity with respect to any filings, investigation or inquiry concerning the Transaction and, to the extent permitted by such Governmental Entity, give Novartis the opportunity to attend and participate in any such
meeting or discussion; (ii) discuss with and permit Novartis to review in advance, and consider in good faith Novartis’s reasonable comments in connection with, any proposed filing or communication to any Governmental Entity concerning the
Transaction, or relating to any investigation, inquiry or other proceeding in connection with the Transaction; and (iii) furnish Novartis with copies of all written correspondence and communications between GlaxoSmithKline and its Affiliates
and their respective representatives on the one hand, and any Governmental Entity or members of their respective staffs on the other hand, with respect to the Transaction. 

 

	 	4.2.8	Novartis shall not participate in or permit any of its representatives to participate in any meeting with any Governmental Entity in respect of any filings,
investigation, proceeding or other matters relating to the Transaction unless Novartis consults with GlaxoSmithKline in advance and, to the extent permitted by such Governmental Entity, gives GlaxoSmithKline the opportunity to attend and lead the
discussions at such meeting. 

  

	 	4.2.9	 Novartis shall (i) discuss with and permit GlaxoSmithKline to review in advance, and consider in good faith GlaxoSmithKline’s reasonable
comments in connection with, any proposed filing or communication to any Governmental Entity concerning the Transaction, or relating to any investigation, inquiry or other proceeding

  
 59 

	 	
in connection with the Transaction; and (ii) furnish GlaxoSmithKline with copies of all written correspondence and communications between Novartis and its Affiliates and their respective
representatives on the one hand, and any Governmental Entity or members of their respective staffs on the other hand, with respect to the Transaction. 

  

	 	4.2.10	In respect of any filings or notifications to Governmental Entities that are related solely to Novartis’s non-controlling minority stake in the Purchaser (the
“Minority Notifications”), Novartis shall be responsible for all filing fees and other fees and expenses and responsible for obtaining any necessary clearances, approvals, waivers, no action letters, consents or waiting period
expirations. 

  

	 	4.2.11	Clauses 4.2.5 to 4.2.10 (inclusive) shall not apply in respect of dealings with any Tax Authority in connection with any Tax matter. 

 

	 	4.2.12	The party responsible for satisfaction of each condition pursuant to this Clause 4.2 shall give notice to the other parties of the satisfaction of the relevant
condition within one Business Day of becoming aware of the same. 

  

	 	4.2.13	The Sellers shall cooperate to confirm, within 21 Business Days from signing of this Agreement, any additional merger notification requirements reasonably required or
advisable in respect of the Transaction in jurisdictions beyond those listed in Schedule 20, and shall cooperate with each other, in accordance with the other provisions of this Clause 4, in achieving any additional clearances, approvals, waivers,
no action letters, consents or waiting period expirations in such jurisdictions. For the avoidance of doubt, Closing shall not be conditional upon such additional clearances, approvals and consents or waiting period expirations.

  

	 	4.2.14	The Sellers shall cooperate, in accordance with the other provisions of this Clause 4, and use reasonable endeavours to ensure that no Governmental Entity shall enact,
issue, promulgate, enforce or enter any Applicable Law or Judgment as contemplated under Clause 4.1.5. In the event that any Governmental Entity enacts, issues, promulgates, enforces or enters any Applicable Law or Judgment as contemplated under
Clause 4.1.5, the parties shall cooperate and use reasonable endeavours to put in place arrangements that would allow the Transaction to complete to the greatest possible extent in compliance with the relevant Applicable Law or Judgment.

  

	4.3	Non-Satisfaction by the Long Stop Date 

 If the conditions in Clause 4.1 are not satisfied as of 22 October 2015 (the “Long Stop Date”), any party may, in its sole discretion, terminate this Agreement (other than Clauses 1,
12 and 15.1 to 15.17) and no party shall have any claim against any other under it, save for any claim arising from breach of any obligation contained in such Clauses or Clause 4.2. Neither of the Sellers nor the Purchaser may terminate this
Agreement after satisfaction of the conditions in Clause 4.1, except in accordance with this Agreement. 

  
 60 

	4.4	Termination 

  

	 	4.4.1	This Agreement may be terminated at any time prior to Closing: 

  

	 	(i)	by written consent of the parties; 

  

	 	(ii)	by any of the parties by notice to the other parties in the event that any Judgment restraining, enjoining or otherwise prohibiting the transactions contemplated by
this Agreement shall have become final and non-appealable, provided that the party seeking to terminate this Agreement pursuant to this Clause 4.4 has complied with the terms of the Implementation Agreement and this Agreement in connection with
having such Judgment vacated or denied; or 

  

	 	(iii)	by the Purchaser by notice to the Sellers if: 

  

	 	(a)	a Material Adverse Effect occurs in relation to any Seller prior to Closing (which shall include any breach or breaches of Clause 9.1 which alone or together constitute
a Material Adverse Effect); or 

  

	 	(b)	any Seller fails to provide a Certificate immediately prior to Closing; or 

 

	 	(iv)	in accordance with the terms of the Implementation Agreement. 

  

	 	4.4.2	This Agreement shall terminate automatically at any time prior to Closing if: 

 

	 	(i)	any other Target Asset Agreement terminates or is terminated in accordance with its terms; or 

 

	 	(ii)	the GSK Break Fee or the Novartis Break Fee (each as defined in the Implementation Agreement) becomes payable in accordance with clause 5.1 or clause 5.8, respectively,
of the Implementation Agreement. 

  

	 	4.4.3	Save as provided in this Clause 4, no party shall be entitled to terminate or rescind this Agreement, whether before or after Closing. If this Agreement is terminated
pursuant to this Clause 4.4, this Agreement shall be of no further force and effect and there shall be no further liability under this Agreement or any of the Ancillary Agreements on the part of any party, except that Clauses 1, 12 and 15.1 to
15.17, in each case, to the extent applicable, shall survive any termination. 

  

	 	4.4.4	Nothing in this Clause 4.4 shall be deemed to release any party from any liability for any breach by such party of the terms and provisions of this Agreement prior to
termination of this Agreement. 

  
 61 

	5.	Pre-Closing 

  

	5.1	The Sellers’ Obligations in Relation to the Conduct of Business 

 

	 	5.1.1	Each Seller undertakes to procure that between the date of this Agreement and Closing, it and the relevant members of that Seller’s Group shall, so far as
permitted by Applicable Law, carry on its Contributed Business as a going concern in the ordinary course as carried on immediately prior to the date of this Agreement save in so far as agreed in writing by the other Seller (such consent not to be
unreasonably withheld or delayed). 

  

	 	5.1.2	Without prejudice to the generality of Clause 5.1.1 and subject to Clause 5.2, each Seller undertakes to procure that, with respect to its Contributed Business, between
the date of this Agreement and Closing, no member of that Seller’s Group shall, except as may be required to comply with this Agreement, without the prior written consent of the other Seller (such consent not to be unreasonably withheld or
delayed) take any of the actions listed in Part 1 of Schedule 15. 

  

	 	5.1.3	Without prejudice to the generality of Clause 5.1.1, each Seller shall, in each case with respect to its Contributed Business only: (i) undertake to procure
the satisfaction of its obligations listed in paragraph 1, Part 2 of Schedule 15; and (ii) procure that that Seller’s Group shall, between the date of this Agreement and Closing, comply with the requirements of paragraph 2, Part 2 of
Schedule 15. 

  

	5.2	Exceptions to Sellers’ Obligations in Relation to the Conduct of Business 

Clause 5.1 shall not operate so as to prevent or restrict: 

 

	 	5.2.1	the disposal or transfer by one or more members of Novartis’s Group of any or all or part of the Novartis US NRT Business in accordance with Schedule 6;

  

	 	5.2.2	any US RX Product Disposal in accordance with Schedule 6; 

  

	 	5.2.3	the entry by Novartis or its Target Group Companies into any arm’s length transitional arrangements, contracts or agreements (including any transitional
services agreement, manufacturing and supply agreement, distribution or other similar agreement) in relation to the disposal to a third party purchaser of any of its Seller’s Retained Business (including its Novartis Animal Health Business,
and/or any of the Novartis US RX Products) with such a purchaser, any other member of the Seller’s Group that owns, or any successor in title to, any part of the Seller’s Retained Business being disposed of, provided that:

  

	 	(i)	 prior to entering into any such transitional arrangements, contracts or agreements, Novartis shall: (a) provide GlaxoSmithKline with a copy of the
substantially final draft of the written agreement(s) in relation to the same; (b) give GlaxoSmithKline a reasonable period of time to review the terms of such arrangements, contracts or agreements and provide any comments thereon; and
(c) take into account (acting reasonably and in good faith) any reasonable (in the context of, to the extent applicable, the terms of the term sheet agreed between Novartis and the purchaser of the

  
 62 

	 	
Novartis Animal Health Business upon entry into the sale agreement in respect of the Novartis Animal Health Business (the “Animal Health Term Sheet”) and the services to be
provided thereunder) comments of GlaxoSmithKline in relation to such transitional arrangements, contracts or agreements provided within that period of time; 

 

	 	(ii)	without prejudice to the above and other than in relation to any manufacturing and supply agreement or any arrangements to which Clause 5.2.3(iii) below applies, any
such transitional arrangement, contract or agreement terminates or is terminable by the relevant Target Group Company or the Business Seller (as the case may be) without any costs, losses, liabilities, expenses or penalties being incurred or payable
within a period of 12 months following closing of the relevant transaction; and 

  

	 	(iii)	the transitional services to be provided to the Novartis Animal Health Business pursuant to the terms of the Animal Health Term Sheet shall not be required to be
provided by the relevant Target Group Company or the Business Seller (as the case may be) for any longer term than the relevant service period as set out in the Animal Health Term Sheet and, in any event, not more than 24 months following the
closing of the sale and purchase of the Novartis Animal Health Business (subject to any extension that may be agreed by the relevant member of the Purchaser’s Group and the counterparty thereto); 

 

	 	5.2.4	the disposal or transfer by a Seller of any Seller’s Retained Business; 

 

	 	5.2.5	any matter undertaken by any member of the relevant Seller’s Group to facilitate or implement a Reorganisation in accordance with Clause 2.3.5;

  

	 	5.2.6	any action to the extent it is required to be undertaken to comply with Applicable Law; or 

 

	 	5.2.7	any matter reasonably undertaken by any member of the relevant Seller’s Group in an emergency or disaster situation with the intention of minimising any adverse
effect of such situation in relation to that Seller’s Group and where any delay arising by virtue of having to give notice to the other Seller and await consent would materially prejudice that Seller’s Group, 

provided that the relevant Seller shall, other than in respect of any action taken or proposed to be taken as described in Clause 5.2.5
(to which the provisions of Clause 2.3.5 and Schedule 17 (Reorganisations) shall apply), notify the other Seller as soon as reasonably practicable of any action taken or proposed to be taken as described in this Clause 5.2, shall provide to the
other Seller all such information as the other Seller may reasonably request in respect of any such action and shall use reasonable endeavours to consult with the Purchaser in respect of any such action. 

 

	5.3	The Sellers’ Obligations in relation to Cash, Intra-Group Payables and Receivables and Third Party Indebtedness 

Prior to Closing, each Seller shall seek to minimise the amounts which would, but for this Clause 5.3, otherwise fall to be treated as
its: 
  

	 	5.3.1	Intra-Group Non-Trade Payables; 

  
 63 

	 	5.3.2	Intra-Group Non-Trade Receivables; 

  

	 	5.3.3	Target Group Companies Cash Balances; and 

  

	 	5.3.4	Third Party Indebtedness, 

 in
each case: (i) including any such items which arise in connection with any Reorganisation; and (ii) to the extent reasonably possible, taking into account the consequences of any such reduction for the Seller’s Group. In addition,
each Seller shall use reasonable endeavours to minimise any adjustment payable by it in accordance with Clause 7.3.7. 
  

	5.4	Other Sellers’ Obligations Prior to Closing 

  

	 	5.4.1	Prior to Closing each Seller shall, and shall procure that its Target Group Companies and that Seller’s Affiliates shall, allow the other Seller and its respective
agents, upon reasonable notice, reasonable access to, and to take copies of, the books, records and documents of or relating in whole or in part to its Target Group, provided that the obligations of each Seller under this Clause shall not extend to
allowing access to information which is (i) reasonably regarded as confidential to the activities of that Seller and that Seller’s Group otherwise than in relation to its Target Group or (ii) commercially sensitive or other
information of its Target Group if such information cannot be shared with the other Seller prior to Closing in compliance with Applicable Law (though the Seller sharing the books, records and/or documents shall seek to share such information with
the other Seller to the extent and in such a manner as would comply with Applicable Law). 

  

	 	5.4.2	The parties shall comply with their respective obligations under Schedule 6. 

 

	5.5	Affiliate Contracts 

Other than as provided in and without prejudice to the provisions of the Ancillary Agreements, each Seller and the Purchaser shall procure
that: 
  

	 	5.5.1	the Cash Pooling Arrangements; and 

  

	 	5.5.2	each Affiliate Contract in force immediately prior to Closing, 

 shall terminate prior to Closing and each counterparty thereto shall, effective as of Closing, settle all outstanding financial obligations arising out of any such Affiliate Contract and unconditionally
release and irrevocably discharge each other party thereto from (i) any and all further obligations to perform or any further performance of the various covenants, undertakings, warranties and other obligations contained in such Affiliate
Contract and (ii) any and all claims and Liabilities whatsoever arising out of, in any way connected with, as a result of or in respect of such Affiliate Contract. 
  

	5.6	Tax Groups 

  

	 	5.6.1	Each Seller shall take all reasonable steps to procure that any Tax Group existing between any member of that Seller’s Group and any GlaxoSmithKline Consumer Group
Company or the Novartis OTC Group Company (as the case may be) is terminated on or before Closing, so far as permitted by Applicable Law, or otherwise on the earliest date on which such termination is permitted under Applicable Law, and that Seller
and the Purchaser shall take such action as is necessary to procure or effect this, including timely submitting any necessary Tax documents. 

  
 64 

	 	5.6.2	Pending the taking effect of the action referred to in Clause 5.6.1, and for so long thereafter as may be necessary, the Purchaser shall (subject to the provisions of
the Tax Indemnity) procure that such information is provided to each Seller as may reasonably be required to enable any relevant member of that Seller’s Group to make all Tax Returns and other filings required of it in respect of the Tax Group.

  

	 	5.6.3	Each Seller shall take, and shall procure that each member of that Seller’s Group takes, all reasonable procedural or administrative steps (including the making of
elections and filings with any relevant Tax Authority) which are reasonably necessary to procure the minimisation of the extent to which Tax liabilities of members of that Seller’s Group (other than the GlaxoSmithKline Consumer Group Companies
or Novartis OTC Group Companies (as the case may be)) can be assessed on the Purchaser or members of the Purchaser’s Group or on the relevant Target Group Companies by reason of having been members of a Tax Group. 

 

	5.7	US tax classification 

Between the date of this Agreement and Closing, the Purchaser shall not file any election to be treated as a partnership or disregarded
entity for US federal income tax purposes. 
  

	5.8	Insurance 

 Without
prejudice to the generality of this Clause 5, between the date of this Agreement and Closing, each Seller shall and shall procure that the relevant member of that Seller’s Group shall maintain in force all its Target Group Insurance Policies
and all Seller’s Group Insurance Policies for the benefit of its Target Group. 
  

	6.	Closing 

  

	6.1	Date and Place 

 Closing
shall take place simultaneously with closing under the other Target Asset Agreements at 11:59 pm (Central European Time) at the offices of Freshfields Bruckhaus Deringer LLP, 65 Fleet Street, London, EC4Y 1HS (other than in respect of any Local
Transfer Documents agreed between the parties to be executed in another jurisdiction) on the last Business Day of the month in which fulfilment of the condition(s) set out in Clause 4.1 takes place, except that: 

 

	 	6.1.1	where the last day of such month is not a Business Day, the Closing shall instead take place on the first Business Day of the following month; and

  

	 	6.1.2	where less than five Business Days remain between such fulfilment and the last Business Day of the month, Closing shall take place: 

  
 65 

	 	(i)	on the last Business Day of the following month; 

  

	 	(ii)	where the last day of such month is not a Business Day, the Closing shall instead take place on the first Business Day of the month following the month referred to in
Clause 6.1.2(i); or 

  

	 	(iii)	at such other location, time or date as may be agreed between the Sellers, 

 provided that Closing shall not take place and shall not be effective in any circumstances unless closing also takes place simultaneously under and in accordance with the terms of the other Target Asset
Agreements. 
  

	6.2	Closing Events 

  

	 	6.2.1	On Closing, the parties shall comply with their respective obligations specified in Schedule 11. GlaxoSmithKline may waive some or all of the obligations of Novartis
and/or of the Purchaser insofar as they relate to GlaxoSmithKline or its Affiliates as set out in Schedule 11 and Novartis may waive some or all of the obligations of GlaxoSmithKline and/or the Purchaser insofar as they relate to Novartis or its
Affiliates as set out in Schedule 11. 

  

	 	6.2.2	The parties acknowledge that the transfer of Product Approvals and Product Applications to the Purchaser or other members of the Purchaser’s Group may be subject
to the approval of applicable Governmental Entities, and that, notwithstanding anything in this Agreement to the contrary, each Product Approval and Product Application shall continue to be held by the relevant member of the relevant Seller’s
Group from the Closing Date until the relevant PA Transfer Date. 

  

	 	6.2.3	The parties shall perform their respective obligations with respect to: 

  

	 	(i)	the transfer of the Product Approvals, Product Applications and Pipeline Product Approvals as set out in Schedule 4; 

 

	 	(ii)	the transfer of Contracts (other than Product Approvals, Product Applications and Pipeline Product Approvals) and the Transferred Intellectual Property Contracts as set
out in Schedule 6; 

  

	 	(iii)	to the extent the Purchaser has elected to have the Relevant Part of a Shared Business Contract transferred to it, the separation and treatment of each Shared Business
Contract as set out in Schedule 6; 

  

	 	(iv)	the Chinese JV Interests and the Chinese JV Contracts, the Novartis US NRT Business, and the Novartis Indian Business, in each case, as set out in Schedule 6; and

  

	 	(v)	Novartis Consumer Health-Gebro GmbH, if Novartis does not hold its Shares in Novartis Consumer Health-Gebro GmbH through a Novartis Group Company at Closing, as set out
in Schedule 6. 

  
 66 

	6.3	Payment on Closing 

  

	 	6.3.1	On Closing the Purchaser shall pay (for itself and on behalf of each relevant member of the Purchaser’s Group) to a Seller (if such amount is positive) or that
Seller (for itself and on behalf of each other relevant member of that Seller’s Group) shall pay to the Purchaser (if such amount is negative), in each case, in accordance with Clause 15.7, an amount in cleared funds, to that Seller or the
Purchaser (as the case may be) to that Seller’s Bank Account or the Purchaser’s Bank Account (as the case may be), which is equal to the sum of the following, in respect of that Seller: 

 

	 	(i)	the Estimated Target Group Companies’ Cash Balances and the Estimated Intra-Group Non-Trade Receivables; 

minus 
  

	 	(ii)	the Estimated Third Party Indebtedness; 

 minus 
  

	 	(iii)	the Estimated Intra-Group Non-Trade Payables; 

 minus 
  

	 	(iv)	any Estimated Employee Benefit Adjustment; 

 minus 
  

	 	(v)	the Estimated Tax Adjustment; and 

 plus (if it is zero or a positive amount) or minus (if it is a negative amount) 
  

	 	(vi)	the Estimated Working Capital Adjustment. 

  

	 	6.3.2	On Closing each Seller shall pay to the Purchaser an amount equal to its Cash Portion in cleared funds to the Purchaser’s Bank Account. In the event that the
amount set out in Clause 6.3.1 is a positive amount in respect of any Seller, that Seller and the Purchaser may (but shall not be obliged to) agree to net off any or all of the amount owed by the Purchaser to that Seller under Clause 6.3.1 against
any or all of the Cash Portion owned by that Seller to the Purchaser under this Clause 6.3.2. The parties’ current intention is that the Cash Portion will be used to fund the short-term working capital requirements of the Purchaser’s
Group. 

  

	6.4	Notifications to determine payments on Closing 

  

	 	6.4.1	Five Business Days prior to Closing, each Seller shall notify the Purchaser of: 

 

	 	(i)	the Estimated Target Group Companies’ Cash Balances; 

  

	 	(ii)	the Estimated Third Party Indebtedness; 

  
 67 

	 	(iii)	the Estimated Intra-Group Non-Trade Receivables; 

  

	 	(iv)	the Estimated Intra-Group Non-Trade Payables; 

  

	 	(v)	any Estimated Employee Benefit Adjustment; 

  

	 	(vi)	the Estimated Tax Adjustment; 

  

	 	(vii)	the Estimated Working Capital; 

  

	 	(viii)	the Estimated Working Capital Adjustment; and 

  

	 	(ix)	the Estimated Intra-Group Trading Balances, 

 and shall at the same time provide to the Purchaser reasonable supporting calculations and information to enable the Purchaser to review the basis on which the estimates have been prepared. Each Seller
shall also provide the Purchaser with reasonable details (including the relevant debtor and creditor) in relation to the Intra-Group Trading Balances. 
  

	 	6.4.2	Each Seller’s notification pursuant to Clause 6.4.1 shall specify the relevant debtor and creditor for each Estimated Intra-Group Non-Trade Payable,
Estimated Intra-Group Non-Trade Receivable, Estimated Intra-Group Trade Payable, Estimated Intra-Group Trade Receivable, and Estimated Transferred Accounts Payable or Estimated Transferred Accounts Receivable included within the Estimated
Intra-Group Trading Balances. 

  

	 	6.4.3	Immediately following Closing: 

  

	 	(i)	the Purchaser shall procure that each Target Group Company repays to the relevant member of each Seller’s Group the amount of any Estimated Intra-Group Non-Trade
Payables and shall acknowledge on behalf of each Target Group Company the payment of the Estimated Intra-Group Non-Trade Receivables in accordance with Clause 6.4.3(ii); and 

 

	 	(ii)	each Seller shall procure that each relevant member of that Seller’s Group repays to the relevant Target Group Company the amount of any relevant Estimated
Intra-Group Non-Trade Receivables and shall acknowledge on behalf of each relevant member of that Seller’s Group the payment of the relevant Estimated Intra-Group Non-Trade Payables in accordance with Clause 6.4.3(i). 

 

	 	6.4.4	The repayments made pursuant to Clause 6.4.3 shall be adjusted in accordance with Clauses 7.3 and 7.4 when the Closing Statement becomes final and binding in accordance
with Clause 7.2.1. 

  

	6.5	Breach of Closing Obligations 

 Subject to Clause 6.2.1, if any party fails to comply with any material obligation in Clauses 6.2, 6.3 and 6.4, and Schedule 11 in relation to Closing, GlaxoSmithKline, in the case of non-compliance by
Novartis, or Novartis, in the case of 

  
 68 

 
non-compliance by GlaxoSmithKline or the Purchaser, shall be entitled (in addition to and without prejudice to all other rights or remedies available) by written notice to Novartis or
GlaxoSmithKline (as the case may be) to fix a new date for Closing (which, except as agreed by the parties, shall be the last day of the month next ending or, if that day is not a Business Day, the first Business Day falling after that day) in which
case the provisions of Schedule 11 shall apply to Closing as so deferred, but provided such deferral may only occur once. In all circumstances Closing shall only occur simultaneously with closing under the other Target Asset Agreements. 

 

	7.	Post-Closing Adjustments 

  

	7.1	Closing Statements 

  

	 	7.1.1	Each Seller shall procure that as soon as practicable following Closing there shall be drawn up a draft of its Closing Statement (the “Draft Closing
Statement”) in accordance with Schedule 12 in relation to its Target Group, on a combined basis. 

  

	 	7.1.2	The Closing Statements shall be drawn up as at the Effective Time. 

  

	7.2	Determination of Closing Statement 

  

	 	7.2.1	Any Draft Closing Statement as agreed or determined pursuant to paragraph 1 of Part 1 of Schedule 12: 

 

	 	(i)	shall constitute the Closing Statement as between the relevant Seller and the Purchaser for the purposes of this Agreement; and 

 

	 	(ii)	shall be final and binding on that Seller and the Purchaser. 

  

	 	7.2.2	The Working Capital, the Target Group Companies’ Cash Balances, the Third Party Indebtedness, the Intra-Group Non-Trade Receivables, the Intra-Group Non-Trade
Payables, the Employee Benefit Adjustment and the Tax Adjustment in respect of a Seller shall each be derived from its Closing Statement. 

  

	7.3	Adjustments to Consideration 

  

	 	7.3.1	Target Group Companies’ Cash Balances: 

  

	 	(i)	in respect of each Seller, if the Target Group Companies’ Cash Balances are less than the Estimated Target Group Companies’ Cash Balances, that Seller shall
repay to the Purchaser an amount equal to the deficiency; or 

  

	 	(ii)	in respect of each Seller, if the Target Group Companies’ Cash Balances are greater than the Estimated Target Group Companies’ Cash Balances, the Purchaser
shall pay to that Seller an additional amount equal to the excess. 

  

	 	7.3.2	Intra-Group Non-Trade Receivables: 

  
 69 

	 	(i)	in respect of each Seller, if the Intra-Group Non-Trade Receivables are less than the Estimated Intra-Group Non-Trade Receivables, that Seller shall repay to the
Purchaser an amount equal to the deficiency; or 

  

	 	(ii)	in respect of each Seller, if the Intra-Group Non-Trade Receivables are greater than the Estimated Intra-Group Non-Trade Receivables, the Purchaser shall pay to that
Seller an additional amount equal to the excess. 

  

	 	7.3.3	Third Party Indebtedness: 

  

	 	(i)	in respect of each Seller, if the Third Party Indebtedness is less than the Estimated Third Party Indebtedness, the Purchaser shall repay to that Seller an amount equal
to the deficiency; or 

  

	 	(ii)	in respect of each Seller, if the Third Party Indebtedness is greater than the Estimated Third Party Indebtedness, that Seller shall pay to the Purchaser an additional
amount equal to the excess. 

  

	 	7.3.4	Intra-Group Non-Trade Payables: 

  

	 	(i)	in respect of each Seller, if the Intra-Group Non-Trade Payables are greater than the Estimated Intra-Group Non-Trade Payables, that Seller shall repay to the Purchaser
an amount equal to the excess; or 

  

	 	(ii)	in respect of each Seller, if the Intra-Group Non-Trade Payables are less than the Estimated Intra-Group Non-Trade Payables, the Purchaser shall pay to that Seller an
additional amount equal to the deficiency. 

  

	 	7.3.5	Tax Adjustment 

  

	 	(i)	in respect of each Seller, if the Tax Adjustment is greater than the Estimated Tax Adjustment, that Seller shall repay to the Purchaser an amount equal to the
difference; or 

  

	 	(ii)	in respect of each Seller, if the Tax Adjustment is less than the Estimated Tax Adjustment, the Purchaser shall pay to that Seller an additional amount equal to the
difference. 

  

	 	7.3.6	Working Capital: 

  

	 	(i)	in respect of each Seller, if the Working Capital Adjustment is less than the Estimated Working Capital Adjustment, that Seller shall repay to the Purchaser an amount
equal to the deficiency; or 

  

	 	(ii)	in respect of each Seller, if the Working Capital Adjustment exceeds the Estimated Working Capital Adjustment, the Purchaser shall pay to that Seller an additional
amount equal to the excess. 

  
 70 

	 	7.3.7	Intra-Group Trading Balances: in respect of each Seller, if the amount of that Seller’s Intra-Group Trading Balances is greater than US$20,000,000, that Seller
shall pay to the Purchaser the amount of the excess. 

  

	7.4	Adjustments to repayment of Intra-Group Non-Trade Payables and Intra-Group Non-Trade Receivables 

Following the determination of any Closing Statement pursuant to Clause 7.1.2 and paragraph 1 of Part 1 of Schedule 12, if the amount of
any Intra-Group Non-Trade Payable and/or any Intra-Group Non-Trade Receivable contained in that Closing Statement is greater or less than the amount of the corresponding Estimated Intra-Group Non-Trade Payable or Estimated Intra-Group Non-Trade
Receivable, then the relevant Seller and the Purchaser shall procure that such adjustments to the repayments pursuant to Clause 6.4.3 are made as are necessary to ensure that (taking into account such adjustments) the actual amount of each
Intra-Group Non-Trade Payable and each Intra-Group Non-Trade Receivable has been repaid by each Target Group Company to the relevant member of that Seller’s Group or by the relevant member of that Seller’s Group to the relevant Target
Group Company, as the case may be. 
  

	7.5	Interest 

 Any payment to
be made in accordance with Clause 7.3 shall include interest thereon calculated from the Closing Date to the date of payment at a rate per annum of LIBOR. 
  

	7.6	Payment 

  

	 	7.6.1	Any payments pursuant to Clause 7.3 or 7.4, and any interest payable pursuant to Clause 7.5, shall be made on or before the Final Payment Date.

  

	 	7.6.2	Where any payment is required to be made pursuant to Clause 7.3 or Clause 7.5 (in relation to a payment pursuant to Clause 7.3) the payment made pursuant to clause
3.1.3 on account of the Purchase Consideration shall be reduced or increased accordingly. 

  

	8.	Post-Closing Obligations 

  

	8.1	Indemnities 

  

	 	8.1.1	Indemnity by Purchaser against Assumed Liabilities 

 The Purchaser hereby undertakes to each Seller (for itself and on behalf of each other member of such Seller’s Group and their respective directors, officers, employees and agents) that, with effect
from Closing, the Purchaser will indemnify on demand and hold harmless each member of that Seller’s Group and their respective directors, officers, employees and agents against and in respect of any and all Assumed Liabilities. 

 

	 	8.1.2	Indemnity by Sellers 

 Subject
to Clause 8.1.3, each Seller hereby undertakes to the Purchaser (for itself and on behalf of each other member of the Purchaser’s Group and their respective directors, officers, employees and agents) that, with effect from Closing, such Seller
will indemnify on demand and hold harmless each member of the Purchaser’s Group and their respective directors, officers, employees and agents against and in respect of any and all: 

  
 71 

	 	(i)	Excluded Liabilities; and 

  

	 	(ii)	Liabilities, including legal fees, to the extent they have arisen or arise (whether before or after Closing) as a result of or otherwise relate to any act, omission,
fact, matter, circumstance or event undertaken, occurring or in existence or arising before Closing so far as related to: (a) any anti-bribery warranty set out in this Agreement, including without limitation those set forth in paragraph 10 of
Schedule 13, not being true and correct when made; (b) any governmental inquiries or investigations involving that Seller, its Affiliates or its Associated Persons; (c) save to the extent in existence as at the date of this Agreement, any
limitation, restriction or other reduction in drug registrations, regulatory licenses, listings or market approvals, governmental pricing or reimbursement rates relating to any products of the relevant Seller’s Contributed Business and
affecting their future profits as a result of any such limitation, restriction or reduction; or (d) any other claim, litigation, investigation or proceeding to the extent related to any of the foregoing (a) to (c), including but not
limited to costs of investigation and defense and legal fees. 

  

	 	8.1.3	Limitations on Indemnities 

Subject to Clause 8.1.4, no Seller shall be liable under Clause 8.1.2 in respect of: 

 

	 	(i)	any Time-Limited Excluded Liability unless a notice of a claim in respect of the matter giving rise to such Liability is given by the Purchaser to that Seller within
ten years of Closing, provided that this Clause 8.1.3(i) shall not apply in respect of any claim by the Purchaser which relates to: 

  

	 	(a)	a Product Liability; 

  

	 	(b)	a Governmental Liability; 

  

	 	(c)	a Clinical Trials/Data Liability; or 

  

	 	(d)	an Excluded Asset; 

  

	 	(ii)	any claim if and to the extent that the relevant Liability is included in the Closing Statement; or 

 

	 	(iii)	any individual claim (or a series of claims arising from similar or identical facts or circumstances) where the Liability (disregarding the provisions of this Clause
8.1.3(iii)) in respect of any such claim or series of claims does not exceed US$10 million, provided that, for the avoidance of doubt, where the Liability in respect of any such claim or series of claims exceeds US$10 million, the Liability of such
Seller shall be for the whole amount of such claim(s) and not just the excess. 

  
 72 

	 	8.1.4	Disapplication of limitations 

None of the limitations contained in Clause 8.1.3 shall apply to any claim to the extent that such claim arises or is increased as the
consequence of, or which is delayed as a result of, fraud by any member of the relevant Seller’s Group or any director, officer or employee of any member of the relevant Seller’s Group. 

 

	 	8.1.5	Endo Excluded Contract 

  

	 	(i)	The parties acknowledge and agree that the Endo Excluded Contract is an Excluded Asset and is to remain with Novartis rather than transferring (in whole or in part) to
the Purchaser upon Closing. The parties further agree that all rights, title and interest in relation to researching and developing, manufacturing, distributing, marketing, selling, promoting and/or otherwise Commercialising Novartis’s In-Scope
Switch Product as a Consumer Healthcare Product will be transferred to the Purchaser upon Closing. 

  

	 	(ii)	With effect from Closing, Novartis shall within 15 Business Days of receipt pay to the Purchaser the amount of any royalties that Novartis or any member of the Novartis
Group receives under the Endo Contract of any nature whatsoever (net of any Taxes, costs and expenses incurred by any member of Novartis’s Group in connection with the receipt of such royalties, after taking account of any related deductions
available to offset such receipts, including any deduction in respect of the onward payments to the Purchaser). The parties, acting reasonably and in good faith, shall discuss structuring of the arrangements for the onward payments and shall take
commercially reasonable steps in relation to those arrangements to minimise the tax costs involved in aggregate for members of Novartis’s Group and the Purchaser (such steps to include Novartis’s consenting, if requested by the Purchaser
and such step is commercially reasonable, to an assignment by the Purchaser of the right to such royalties to another member of the Purchaser’s Group). 

 

	 	(iii)	In the event that, following a switch of Novartis’s In-Scope Switch Product in the United States of America from being a Prescription Product to being a Consumer
Healthcare Product and the Endo Excluded Contract terminates, the Purchaser shall indemnify Novartis in respect of any losses, liabilities, costs and expenses incurred by Novartis (or any of its Affiliates) in relation to the royalties payable under
clause 9.2 of the Endo Excluded Contract as it is as at the date of this Agreement. 

  
 73 

	8.2	Conduct of Claims 

  

	 	8.2.1	Assumed Liabilities 

  

	 	(i)	If the Seller becomes aware after Closing of any claim by a third party which constitutes or may constitute an Assumed Liability, the Seller shall as soon as reasonably
practicable: 

  

	 	(a)	give written notice thereof to the Purchaser and the other Seller setting out such information as is available to the Seller as is reasonably necessary to enable the
Purchaser and the other Seller to assess the merits of the potential claim; 

  

	 	(b)	take all appropriate actions to preserve evidence; and 

  

	 	(c)	provide the Purchaser and the other Seller with periodic updates on the status of the claim upon request and shall not admit, compromise, settle, discharge or otherwise
deal with such claim without the prior written agreement of the Purchaser and the other Seller (such agreement not to be unreasonably withheld or delayed). 

 

	 	(ii)	Each Seller shall, and shall procure that each of its Share Sellers and Business Sellers shall, take such action as the Purchaser may reasonably request to avoid,
dispute, resist, appeal, compromise, defend or mitigate any claim which constitutes or may constitute an Assumed Liability subject to that Seller and each of its Share Sellers and Business Sellers being indemnified and secured to their reasonable
satisfaction by the Purchaser against all Liabilities which may thereby be incurred. In connection therewith, that Seller shall make or procure to be made available to the Purchaser or its duly authorised agents on reasonable notice during normal
business hours all relevant books of account, records and correspondence relating to its Target Group Businesses which have been retained by that Seller’s Group (and shall permit the Purchaser to take copies thereof at its expense) for the
purposes of enabling the Purchaser to ascertain or extract any information relevant to the claim. 

  

	 	8.2.2	Excluded Liabilities 

  

	 	(i)	If the Purchaser becomes aware after Closing of any claim by a third party which constitutes or may constitute an Excluded Liability or relates to an Excluded Liability
or any investigations related thereto, regardless of whether the Purchaser believes that such claim would be made against a member of the Purchaser’s Group or a member of a Seller’s Group, the Purchaser shall as soon as reasonably
practicable: 

  

	 	(a)	give written notice thereof to the relevant Seller, setting out such information as is available to the Purchaser as is reasonably necessary to enable that Seller to
assess the merits of the potential claim; 

  
 74 

	 	(b)	take all appropriate actions to preserve evidence; and 

  

	 	(c)	provide the relevant Seller with periodic updates on the status upon request and shall not admit, compromise, settle, discharge or otherwise deal with such claim
without the prior written agreement of that Seller (such agreement not to be unreasonably withheld or delayed). 

  

	 	(ii)	The Purchaser shall take such action as the relevant Seller may reasonably request to avoid, dispute, resist, appeal, compromise, defend or mitigate any claim which
constitutes or may constitute an Excluded Liability subject to the Purchaser being indemnified and secured to its reasonable satisfaction by the relevant Seller against all Liabilities which may thereby be incurred. 

 

	 	(iii)	In addition, where any such claim or investigation involves a Governmental Entity, the Purchaser shall, subject to Applicable Law, the requirements of any relevant
Governmental Entity and the relevant Seller providing an appropriate confidentiality undertaking in favour of the Purchaser’s Group, provide to that Seller, at least five Business Days in advance (or, where not possible, as soon as reasonably
possible), any analyses, appearances, presentations, memoranda, briefs, arguments, opinions and proposals they or their agents make or submit to a Governmental Entity. Without limiting the foregoing, the parties agree, subject to Applicable Law and
the requirements of the relevant Governmental Entity and the Seller providing an appropriate confidentiality undertaking in favour of the Purchaser’s Group to: 

 

	 	(a)	give that Seller reasonable advance notice of all meetings with any Governmental Entity; 

 

	 	(b)	give that Seller an opportunity to participate in each of such meetings; 

  

	 	(c)	to the extent practicable, give that Seller reasonable advance notice of all substantive oral communications with any Governmental Entity; 

 

	 	(d)	if any Governmental Entity initiates a substantive oral communication, promptly notify that Seller of the substance of such communication; 

 

	 	(e)	provide that Seller with a reasonable advance opportunity to review and comment upon all substantive written communications (including any substantive correspondence,
analyses, presentations, memoranda, briefs, arguments, opinions and proposals) that the Purchaser or its agents intend to make or submit to a Governmental Entity in connection with such claim; 

  
 75 

	 	(f)	provide that Seller with copies of all substantive written communications to or from any Governmental Entity; and 

 

	 	(g)	not advance arguments with the Governmental Entity without prior agreement of that Seller that would reasonably be likely to have a significant adverse impact on the
Seller, 

 provided however, that the Purchaser shall not be required to comply with paragraph (b) above to
the extent that the Governmental Entity objects to the participation of a party, or with paragraph (e) or (f) above to the extent that such disclosure may raise regulatory concerns (in which case, the disclosure may be made on an outside
counsel basis). 
  

	 	(iv)	Other than in respect of any claim to the extent it relates to an IP Liability, a Commercial Practices Liability, or a Governmental Liability (other than in respect of
any Liability arising solely by virtue of a breach of Contract with any Governmental Entity which breach does not also constitute a breach of Applicable Law), the relevant Seller shall be entitled at its own expense and in its absolute discretion,
by notice in writing to the Purchaser, to take such action as it shall deem necessary to avoid, dispute, deny, defend, resist, appeal, compromise or contest any such claim (including making counterclaims or other claims against third parties) in the
name of and on behalf of the Purchaser or other member of the Purchaser’s Group concerned and to have the conduct of any related proceedings, negotiations or appeals. In taking action on behalf of any member of the Purchaser’s Group as
permitted by this Clause 8.2, the relevant Seller shall, in good faith, take into account and have due regard to any reputational matters or issues arising out of the claim for any member of the Purchaser’s Group or any of their respective
directors, officers, employees or agents which are brought to its attention by the Purchaser or a member of the Purchaser’s Group. 

  

	 	(v)	The Purchaser shall make or procure to be made available to the relevant Seller or its duly authorised agents on reasonable notice during normal business hours full and
free access to all relevant books of account, records and correspondence relating to its Target Group which are in the possession of the Purchaser or any member of the Purchaser’s Group (and shall permit the relevant Seller to take copies
thereof) for the purposes of enabling that Seller to ascertain or extract any information relevant to the claim. 

  

	 	(vi)	 The Purchaser shall, and shall procure that each other member of the Purchaser’s Group shall, on reasonable notice from the relevant Seller, give
such assistance to that Seller as it may reasonably require in relation to the claim including providing the relevant Seller or any member of that Seller’s Group and its representative and advisers with access to and assistance from directors,
officers, managers, employees, advisers, agents or consultants of the Purchaser and/or of each 

  
 76 

	 	
other member of the Purchaser’s Group (collectively, the “Relevant Persons”) and the Purchaser will use its reasonable endeavours to procure that such Relevant Persons
comply with any reasonable requests from that Seller and generally co-operate with and assist that Seller and other members of that Seller’s Group. 

  

	 	(vii)	When seeking assistance under Clauses 8.2.2(v) and 8.2.2(vi), the relevant Seller, or any other relevant member of that Seller’s Group, shall use reasonable
endeavours to minimise interference with the Purchaser and the Purchaser’s Group’s conduct of the relevant business or the performance by the Relevant Persons of their employment duties. 

 

	8.3	Release of Guarantees 

  

	 	8.3.1	The Purchaser shall use reasonable endeavours to procure as soon as reasonably practicable after Closing, the release of each Seller or any member of that Seller’s
Group from any securities, guarantees or indemnities given by or binding upon that Seller or any member of that Seller’s Group in respect of any Assumed Liabilities or in connection with a liability of any of the relevant Target Group Companies
(other than an Excluded Liability). Pending such release, the Purchaser shall indemnify that Seller and any member of that Seller’s Group against all amounts paid by any of them (acting reasonably) pursuant to any such securities, guarantees or
indemnities in respect of such Assumed Liabilities or such liability of the relevant Target Group Companies (other than an Excluded Liability). 

  

	 	8.3.2	Each Seller shall use reasonable endeavours to procure by Closing or, to the extent not done by Closing, as soon as reasonably practicable thereafter, the release of
its Target Group Companies from any securities, guarantees or indemnities given by or binding upon those Target Group Companies in respect of any liability of that Seller or any member of that Seller’s Group (other than those Target Group
Companies). Pending such release, that Seller shall pay to the Purchaser an amount equal to the sum that would have been payable to the Target Group Companies had that Seller indemnified the relevant Target Group Companies against all amounts paid
by any of them (acting reasonably) pursuant to any such securities, guarantees or indemnities in respect of such liability of that Seller which arises after Closing. 

 

	8.4	Transferred Accounts Payable 

 If at any time after Closing, a Seller or any of its Affiliates pays any monies in respect of any Transferred Accounts Payable, then the Purchaser shall pay or procure payment to that Seller (for the
relevant Business Seller), as soon as reasonably practicable the amount paid, plus any Taxation suffered or incurred by that Seller’s Group which would not have arisen but for the payment and receipt of such monies. 

  
 77 

	8.5	Transferred Accounts Receivable 

 If at any time after Closing, a Business Seller receives any monies in respect of any Transferred Accounts Receivables, then that Business Seller shall pay or procure payment to the Purchaser, as soon as
reasonably practicable the amount recovered, less any Taxation suffered or incurred by the relevant Seller’s Group which would not have arisen but for the receipt and payment of such monies. 

 

	8.6	Intra-Group Trading Balances 

 Any Intra-Group Trade Payables, any Intra-Group Trade Receivables and any Transferred Accounts Payables and Transferred Accounts Receivables, in each case, between a member of the Seller’s Group
(other than a Target Group Company) and a Business Seller of that Seller’s Group, shall be settled after Closing in the ordinary course of business and, in any event, within 60 days of Closing. 

 

	8.7	Wrong Pockets Obligations 

  

	 	8.7.1	Except as provided in Schedule 2, Schedule 4, Schedule 6, Schedule 7, or Schedule 8, if any property, right or asset forming part of a Target Group (other than any
property, right or asset expressly excluded from the sale under this Agreement) has not and should have been transferred to the Purchaser, or to another member of the Purchaser’s Group, pursuant to this Agreement, the relevant Seller shall
procure that such property, right or asset (and any related liability which is an Assumed Liability) is transferred to the Purchaser (or another member of the Purchaser’s Group as the Purchaser may nominate reasonably acceptable to the Seller)
as soon as practicable and at no cost to the Purchaser. 

  

	 	8.7.2	If, following Closing, any property, right or asset not forming part of a Target Group (other than any property, right or asset expressly included in the sale
under this Agreement) is found to have and should not have been transferred to the Purchaser or another member of the Purchaser’s Group pursuant to this Agreement, the Purchaser shall transfer (or procure the transfer of) such property, right
or asset as soon as practicable to the transferor or another member of the relevant Seller’s Group nominated by the relevant Seller reasonably acceptable to the Purchaser at no cost to the Seller. 

 

	8.8	Covenant not to sue 

  

	 	8.8.1	Each Seller hereby undertakes not to enforce any Intellectual Property Rights against the Purchaser or its Affiliates which qualify to be transferred pursuant to Clause
8.7.1 in relation to the period from Closing to the completion of the transfer under that Clause. 

  

	 	8.8.2	The Purchaser hereby undertakes not to enforce any Intellectual Property Rights against a Seller or its Affiliates which qualify to be transferred pursuant to Clause
8.7.2 in relation to the period from Closing to the completion of the transfer under that Clause. 

  
 78 

	8.9	The Purchaser’s Continuing Obligations 

  

	 	8.9.1	Except as provided in the GlaxoSmithKline Seller Intellectual Property Trademark Licence, or if the Purchaser is unable to obtain the necessary third party consent to
do so in relation to a Joint Venture Entity, the Purchaser shall procure that as soon as practicable after Closing, each of the Target Group Companies and Joint Venture Entities shall change its name so that it does not contain the Seller Marks or
any name which is likely to be confused with the same and shall provide the relevant Seller with appropriate evidence of such change of name. 

  

	 	8.9.2	Except as provided in the Ancillary Agreements, the Purchaser shall not, and shall procure that no member of the Purchaser’s Group shall, after Closing, use the
Seller Marks or any confusingly similar name or mark, any extensions thereof or developments thereto in any business which competes with the Seller’s business, or any other business of a Seller or any member of a Seller’s Group in which
the Seller Marks are used for a minimum period of five years following Closing and thereafter for so long as any member of a Seller’s Group continues to retain an interest in the name. 

 

	 	8.9.3	During the 90 calendar days following the Closing Date, the Purchaser shall provide and cause to be provided to each Seller the information reasonably required to
enable that Seller to prepare and audit the standard monthly reporting forms of the Seller’s Group, to the extent that such financial reporting relates to the Contributed Business, in respect of the period prior to the Closing and in respect of
the calendar month in which the Closing occurs. The Purchaser shall provide such financial reporting in respect of the calendar month in which Closing occurs to each Seller within six Business Days of the last day of the relevant month.

  

	8.10	The Sellers’ Continuing Obligations 

 For a period of ten years from Closing, each Seller shall make or procure to be made available to the Purchaser or their duly authorised agents on reasonable notice during normal business hours:

  

	 	8.10.1	all relevant books, accounts, other records and correspondence relating to that Seller’s Contributed Business which have been retained by that Seller’s Group
(and shall permit the Purchaser to take copies thereof); and 

  

	 	8.10.2	reasonable access to any employees of that Seller’s Group who have knowledge relating to products of the relevant Seller’s Contributed Business (including any
inventor of such products) for the purposes of the defence, prosecution or enforcement of any Target Group Intellectual Property Rights, or as required by law or a Governmental Entity, provided that the Purchaser shall promptly reimburse the
relevant Seller for expenses reasonably incurred by the Seller in relation to providing such access if it exceed 25 man hours in aggregate per annum. 

  
 79 

	8.11	Ancillary Agreements 

 If
any of the Seller Intellectual Property Licence Agreement, the Purchaser Trademark Licence Agreement or the Seller Trademark Licence Agreement have not been entered into at Closing, the provisions of the licences in the Agreed Terms shall be binding
on the relevant Seller and the Purchaser until the earlier of: (i) the date on which the relevant licence is entered into; or, if applicable, (ii) the date on which the relevant licence expires or terminates (if applicable) in accordance
with its Agreed Terms. 
  

	8.12	Transitional Services Agreement 

 In respect of each Seller, if the Transitional Services Agreement has not been entered into at Closing, the provision of the heads of terms in the Agreed Terms shall be binding on that Seller and the
Purchaser until the earlier of: (i) the date on which the Transitional Services Agreement is entered into; or (ii) the date on which that Seller no longer provides such transitional services to the Purchaser. 

 

	8.13	Manufacturing, Supply and Distribution Agreement 

 In respect of each Seller, if the Manufacturing, Supply and Distribution Agreement has not been entered into at Closing, the provisions of the heads of terms in the Agreed Terms shall be binding on that
Seller and the Purchaser until the earlier of: (i) the date on which the Manufacturing, Supply and Distribution Agreement is entered into; or (ii) the date on which the Seller no longer manufactures and supplies Products to that Seller for
distribution. 
  

	8.14	Services Agreement 

 In
respect of GlaxoSmithKline, if the Services Agreement has not been entered into at Closing, the provisions of the heads of terms in the Agreed Terms shall be binding on GlaxoSmithKline and the Purchaser until the earlier of: (i) the date on
which the Services Agreement is entered into; or (ii) the date on which GlaxoSmithKline no longer provides the relevant services to the Purchaser. 
  

	8.15	Transfer of Marketing Authorisations and Tenders 

  

	 	8.15.1	The transfer of the Marketing Authorisations following Closing shall take place in accordance with Part 2 of Schedule 4 and the terms of the Manufacturing, Supply and
Distribution Agreements. 

  

	 	8.15.2	Between the Closing Date and the Marketing Authorisation Transfer Date, the Seller agrees to assist the Purchaser in accordance with Part 3 of Schedule 4 in respect of
any tenders relating to the Products. 

  

	9.	Warranties 

  

	9.1	The Sellers’ Warranties 

  

	 	9.1.1	Subject to Clause 9.2, each Seller warrants (on behalf of the relevant Business Sellers or Share Sellers, as applicable) to the Purchaser and each member of the
Purchaser’s Group to which shares or assets are transferred pursuant to this Agreement or any Local Transfer Document, that the statements set out in Schedule 13 (save for paragraph 2.4.2 in the case of GlaxoSmithKline and 2.4.1 in the case of
Novartis) are true and accurate as of the date of this Agreement. 

  
 80 

	 	9.1.2	Each of the Seller’s Warranties shall be separate and independent and shall not be limited by reference to any other paragraph of Schedule 13 or by anything
in this Agreement or any Local Transfer Document or in the Tax Indemnity. 

  

	 	9.1.3	Neither of the Sellers gives or makes any warranty as to the accuracy of the forecasts, estimates, projections, statements of intent or statements of opinion provided
to the Purchaser or any of its directors, officers, employees, agents or advisers on or prior to the date of this Agreement. 

  

	 	9.1.4	Any Seller’s Warranty qualified by the expression “so far as the Seller is aware” or to the “Seller’s Knowledge” or any similar expression
shall, unless otherwise stated, be deemed to refer to the knowledge of: 

  

	 	(i)	in the case of GlaxoSmithKline, the following persons: [***] and 

  

	 	(ii)	in the case of Novartis, the following persons: [***], 

 in each case having made due and reasonable enquiry. 
  

	 	9.1.5	Each of the Seller’s Warranties shall be deemed to be repeated immediately before Closing by reference to the facts, circumstances and knowledge then existing as
if references in the Seller’s Warranties to the date of this Agreement were references to the Closing Date. Without prejudice to the provisions of Clause 4.4, no Seller shall have any liability for any breach of any Seller’s Warranty given
by it where such Seller’s Warranty was true as at the date of this Agreement unless (i) the fact, event or circumstances giving rise to the breach (i) constitutes a Material Adverse Effect and (ii) was not the result of an act or
omission expressly permitted by the terms of this Agreement or any other Ancillary Agreement. No Seller shall have any liability under this Clause 9.1.5 if the Purchaser has exercised its termination right in accordance with Clause 4.4.1(iii).

  

	9.2	Sellers’ Disclosures 

  

	 	9.2.1	Each Seller’s Warranties are subject to all matters which are fairly disclosed in this Agreement or in the Disclosure Letter. 

 

	 	9.2.2	References in a Disclosure Letter to paragraph numbers shall be to the paragraphs in Schedule 13 to which the disclosure is most likely to relate. Such references are
given for convenience only and, shall not limit the effect of any of the disclosures, all of which are made against the Seller’s Warranties as a whole. 

 

	9.3	The Purchaser’s Warranties 

 The Purchaser warrants to each Seller that the statements set out in Schedule 14 are true and accurate as of the date of this Agreement.Limitation of Liability 

 

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission. 

  
 81 

	9.4	Application 

  

	 	9.4.1	In respect of the Tax Indemnity, the provisions of this Clause 10 shall operate to limit the liability of a Seller only in so far as any provision in this Clause
10 is expressed to be applicable to the Tax Indemnity, and the provisions of the Tax Indemnity shall further operate to limit the liability of the Sellers in respect of any claims thereunder. 

 

	 	9.4.2	References to the Seller’s Warranties in Clauses 10.2 to 10.5 (inclusive), 10.7, 10.8 and 10.10 shall not include the Tax Warranties and the provisions of clauses
3 and 9 of the Tax Indemnity shall operate to limit the liability of the Sellers and to govern the claims procedure in respect of any claim under the Tax Warranties in respect of a liability for Tax as if such claim had been a claim in respect of a
Tax Liability (as defined in the Tax Indemnity) under the Tax Indemnity. 

  

	9.5	Time Limitation for Claims 

No Seller shall be liable under this Agreement or any Local Transfer Document for breach of any Seller’s Warranty, any Tax Warranty
or under the Tax Indemnity in respect of any claim unless a notice of the claim is given by the Purchaser to such Seller specifying the matters set out in Clause 11.2: 
  

	 	9.5.1	in the case of a claim under any of paragraphs 1, 2.1, 2.2.1, 2.2.3 or 2.5 of Schedule 13, within the applicable statutory limitation period; 

 

	 	9.5.2	in respect of claims under the Tax Warranties or the Tax Indemnity, before the date falling six months after the expiry of the period specified by statute during
which an assessment of the relevant liability to Tax may be issued by the relevant Tax Authority; and 

  

	 	9.5.3	in the case of any other claim, before the date falling two years following Closing. 

 

	9.6	Minimum Claims 

  

	 	9.6.1	No Seller shall be liable under: 

  

	 	(i)	this Agreement or any Local Transfer Document for breach of any Seller’s Warranty in respect of any individual claim (or a series of claims arising from similar or
identical facts or circumstances) where the liability agreed or determined (disregarding the provisions of this Clause 10.3) in respect of any such claim or series of claims does not exceed, in the case of Novartis, US$10.95 million, or, in the
case of GlaxoSmithKline, US$19.05 million; or 

  

	 	(ii)	this Agreement for breach of any Tax Warranty or under the Tax Indemnity in respect of any individual claim (or a series of claims arising from similar or identical
facts or circumstances) where the liability agreed or determined (disregarding the provisions of this Clause 10.3) in respect of any such claim or series of claims does not exceed US$1 million. 

  
 82 

	 	9.6.2	Where the liability agreed or determined in respect of any such claim or series of claims exceeds, in the case of claims falling within Clause 10.3.1(i),
US$10.95 million (in the case of Novartis) or US$19.05 million (in the case of GlaxoSmithKline) or, in the case of claims falling within Clause 10.3.1(ii), US$1 million, the liability of the relevant Seller shall be for the whole amount of such
claim(s) and not just the excess. 

  

	9.7	Aggregate Minimum Claims 

  

	 	9.7.1	No Seller shall be liable under this Agreement or any Local Transfer Document for breach of any Seller’s Warranty in respect of any claim unless the
aggregate amount of all claims for which such Seller would otherwise be liable under this Agreement or any Local Transfer Document for breach of any Seller’s Warranty (disregarding the provisions of this Clause 10.4) exceeds, in the case of
Novartis, US$109.5 million, or, in the case of GlaxoSmithKline, US$190.5 million, in which case the relevant Seller shall be liable for the aggregate amount of all claims as agreed or determined and not just the excess. 

 

	 	9.7.2	Where the liability agreed or determined in respect of all claims exceeds US$109.5 million (in the case of Novartis) or US$190.5 million (in the case of
GlaxoSmithKline) such Seller shall be liable for the aggregate amount of all claims as agreed or determined and not just the excess. 

  

	 	9.7.3	For the avoidance of doubt, the Purchaser may give notice of any single claim in accordance with and for the purposes of Clause 10.2, irrespective of whether, at
the time the notice is given, the amount set out in Clause 10.4.2 has been exceeded. 

  

	9.8	Maximum Liability 

 The
aggregate liability of a Seller in respect of: 
  

	 	9.8.1	any breaches of the Seller’s Warranties (other than the Seller’s Warranties contained in paragraphs 1, 2.1, 2.2.1, 2.2.3 or 2.5 of Schedule 13) shall
not exceed an amount equal to, in the case of Novartis, US$3.285 billion, or, in the case of GlaxoSmithKline, US$5.715 billion; and 

  

	 	9.8.2	any breaches of such Seller’s Warranties contained in paragraphs 1, 2.1, 2.2.1, 2.2.3 or 2.5 of Schedule 13 shall not exceed, in the case of Novartis,
US$10.95 billion, or, in the case of GlaxoSmithKline, US$19.05 billion. 

  

	9.9	Contingent Liabilities 

No Seller shall be liable under this Agreement or any Local Transfer Document for breach of any such Seller’s Warranties in respect
of which the liability is contingent, unless and until such contingent liability becomes an actual liability and is due and payable (but the Purchaser has the right under Clause 11.1 to give notice of such claim before such time). For the avoidance
of doubt, the fact that the liability may not have become an actual liability by the relevant date provided in Clause 10.2 shall not exonerate such Seller in respect of any claim properly notified before that date. 

  
 83 

	9.10	Provisions 

 No Seller
shall be liable under this Agreement or any Local Transfer Document in either case in respect of any claim for breach of any Seller’s Warranty in respect of any claim if and to the extent that any allowance, provision or reserve has been
properly made in the Closing Statement applicable to that Seller for the matter giving rise to the claim and such Seller can demonstrate that the allowance, provision or reserve so made was in respect of such matter. 

 

	9.11	Matters Arising Subsequent to this Agreement 

 Subject to Clause 8.1.2, no Seller shall be liable under this Agreement or any Local Transfer Document in either case in respect of any claim for breach of any Seller’s Warranty in respect of any
matter, act, omission or circumstance (or any combination thereof), to the extent that the same would not have occurred but for: 
  

	 	9.11.1	Agreed matters 

 any
matter or thing done or omitted to be done by such Seller or any member of such Seller’s Group before Closing pursuant to and in compliance with this Agreement or any Local Transfer Document or otherwise at the request in writing of the
Purchaser; or 
  

	 	9.11.2	Changes in legislation 

the passing of, or any change in, after the Closing Date, any Applicable Law or administrative practice of any government, governmental
department, agency or regulatory body having the force of the law including (without prejudice to the generality of the foregoing) any increase in the rates of Taxation or any imposition of Taxation or any withdrawal of relief from Taxation not in
force at the Closing Date. 
  

	9.12	Insurance 

 Without
prejudice to Clause 13, any Seller’s Liability under this Agreement for breach of any Seller’s Warranty shall be reduced by an amount equal to any loss or damage to which such claim related which has actually been recovered under a policy
of insurance held by the Purchaser or a Target Group Company (after deducting any reasonable costs incurred in making such recovery including the amount of any excess or deductible). 

 

	9.13	Purchaser’s Right to Recover 

 If any Seller has paid an amount in discharge of any claim under this Agreement for breach of any Seller’s Warranty and subsequently the Purchaser recovers (whether by payment, discount, credit,
relief, insurance or otherwise) from a third party a sum which indemnifies or compensates the Purchaser (in whole or in part) in respect of the loss or liability which is the subject matter of the claim, the Purchaser shall pay to such Seller as
soon as practicable after receipt an amount equal to (i) the sum recovered from the third party less any costs and expenses incurred in obtaining such recovery and any Tax on any amounts recovered (or Tax that would have been payable on such
amounts but for the availability of any Tax relief), or if less (ii) the amount previously paid by such Seller to the Purchaser. Any payment made by the Purchaser to such Seller under this Clause shall be made or procured by way of further
adjustment of the Purchase Consideration. 

  
 84 

	9.14	No Double Recovery and no Double Counting 

 A party shall be entitled to make more than one claim under this Agreement arising out of the same subject matter, fact, event or circumstance but shall not be entitled to recover under this Agreement or
any relevant Local Transfer Document or the Tax Indemnity or otherwise more than once in respect of the same Losses suffered or amount for which the party is otherwise entitled to claim (or part of such Losses or amount), regardless of whether more
than one claim arises in respect of it. No amount (including any relief) (or part of any amount) shall be taken into account, set off or credited more than once under this Agreement or any relevant Local Transfer Document or the Tax Indemnity or
otherwise, with the intent that there will be no double counting under this Agreement or any Local Transfer Document or the Tax Indemnity or otherwise. 
  

	9.15	Fraud 

 None of the
limitations contained in this Clause 10 shall apply to any claim to the extent that such claim arises or is increased as the consequence of, or which is delayed as a result of, fraud by any director or officer of any member of a Seller’s Group.

  

	10.	Claims 

  

	10.1	Notification of Potential Claims 

 Without prejudice to the obligations of the Purchaser under Clause 11.2, if the Purchaser becomes aware of any fact, matter or circumstance that may give rise to a claim against any Seller under this
Agreement or any Local Transfer Document for breach of any Seller’s Warranty other than a Tax Warranty (ignoring for these purposes the application of Clause 11.2 or 11.3), the Purchaser shall as soon as reasonably practicable give a notice in
writing to that Seller of such facts, matters or circumstances as are then available regarding the potential claim. Failure to give notice within such period shall not affect the rights of the Purchaser to make a relevant claim under this Agreement
or any Local Transfer Document for breach of any Seller’s Warranty, except that the failure shall be taken into account in determining the liability of that Seller for such claim to the extent that Seller establishes that the amount of it is
increased, or is not reduced, as a result of such failure. 
  

	10.2	Notification of Claims under this Agreement 

 Notices of claims under this Agreement or any relevant Local Transfer Document for breach of any Seller’s Warranty (other than a Tax Warranty) shall be given by the Purchaser to the relevant Seller
within the time limits specified in Clause 10.2 and shall specify information (giving reasonable detail) in relation to the basis of the claim and setting out the Purchaser’s estimate of the amount of Losses which are, or are to be, the subject
of the claim. 
  

	10.3	Commencement of Proceedings 

 Any claim notified pursuant to Clause 11.2 shall (if it has not been previously satisfied, settled or withdrawn) be deemed to be irrevocably withdrawn 9 months after the relevant time limit set out in
Clause 10.2 unless, at the relevant time, legal proceedings in respect of the relevant claim have been commenced by being both issued and served except: 
  

	 	10.3.1	where the claim relates to a contingent liability, in which case it shall be deemed to have been withdrawn unless legal proceedings in respect of it have been
commenced by being both issued and served with 9 months of it having become an actual liability; or 

  
 85 

	 	10.3.2	where the claim is a claim for breach of any Seller’s Warranty of which notice is given for the purposes of Clause 11.2 at a time when the amount set out in
Clause 10.4.1 has not been exceeded, in which case it shall be deemed to have been withdrawn unless legal proceedings in respect of it have been commenced by being both issued and served within 9 months of the date of any subsequent notification to
that Seller pursuant to Clause 11.1 of one or more claims which result(s) in the total amount claimed in all claims notified to that Seller pursuant to Clause 11.2 exceeding the amount set out in Clause 10.4.1 for the first time.

  

	10.4	Conduct of Third Party Claims 

 If the matter or circumstance that may give rise to a claim against a Seller under this Agreement or any relevant Local Transfer Document for breach of any Seller’s Warranty (other than a Tax
Warranty) is a result of or in connection with a claim by a third party (a “Third Party Claim”) then: 
  

	 	10.4.1	the Purchaser shall as soon as reasonably practicable give written notice thereof to that Seller and thereafter shall provide that Seller with periodic updates upon
reasonable request and shall consult with that Seller so far as reasonably practicable in relation to the conduct of the Third Party Claim and shall take reasonable account of the views of that Seller in relation to the Third Party Claim;

  

	 	10.4.2	the Third Party Claim shall not be admitted, compromised, disposed of or settled without the written consent of that Seller (such consent not to be unreasonably
withheld or delayed); and 

  

	 	10.4.3	subject to that Seller indemnifying the Purchaser or other member of the Purchaser’s Group concerned against all reasonable costs and expenses (including
legal and professional costs and expenses) that may be incurred thereby, the Purchaser shall, or the Purchaser shall procure that any other members of the Purchaser’s Group shall, take such action as that Seller may reasonably request to avoid,
dispute, deny, defend, resist, appeal, compromise or contest the Third Party Claim, provided that this Clause 11.4.3 shall not apply where the claim by the third party relates to matters or circumstances referred to in paragraph 4 or paragraph 9 of
Schedule 13 and the Purchaser shall then have the right to conduct the claim at its discretion (subject to Clauses 11.4.1 and 11.4.2), 

 provided that failure to give notice in accordance with Clause 11.4.1 shall not affect the rights of the Purchaser to make a relevant claim under this Agreement for breach of any Seller’s Warranty,
except that the failure shall be taken into account in determining the liability of that Seller for such claim to the extent that Seller establishes that the amount of it is increased, or is not reduced, as a result of that failure. 

  
 86 

	11.	Confidentiality 

  

	11.1	Announcements 

 No
announcement, communication or circular concerning the existence or the subject matter of this Agreement shall be made or issued by or on behalf of any member of any Seller’s Group or the Purchaser’s Group without the prior written
approval of the parties (such consent not to be unreasonably withheld or delayed). This shall not affect any announcement, communication or circular required by law or any governmental or regulatory body or the rules of any stock exchange on which
the shares of any party (or its holding company) are listed but the party with an obligation to make an announcement or communication or issue a circular (or whose holding company has such an obligation) shall consult with the other parties (or
shall procure that its holding company consults with the other parties) insofar as is reasonably practicable before complying with such an obligation. 
  

	11.2	Confidentiality 

  

	 	11.2.1	Subject to Clause 12.1 and Clause 12.2.2, each of the parties shall treat as strictly confidential and not disclose or use any information received or obtained
as a result of entering into this Agreement, any Ancillary Agreement (or any other agreement entered into pursuant to this Agreement, including the Ancillary Agreements) which relates to: 

 

	 	(i)	the existence and provisions of this Agreement, the Ancillary Agreements, or any other agreement entered into pursuant to this Agreement, including the Ancillary
Agreements; 

  

	 	(ii)	the negotiations relating to this Agreement, the Ancillary Agreements, or any other agreement entered into pursuant to this Agreement; 

 

	 	(iii)	(in the case of a Seller) any information relating to its Target Group Companies and Target Group Businesses following Closing and any other information relating to the
business, financial or other affairs (including future plans and targets) of the Purchaser’s Group; or 

  

	 	(iv)	(in the case of the Purchaser) any information relating to the business, financial or other affairs (including future plans and targets) of any Seller’s Group
including, prior to Closing, the Target Group Companies and Target Group Businesses, and, for the avoidance of doubt, the Purchaser shall not disclose any such information relating to a Seller Group to the other Seller Group.

  

	 	11.2.2	Clause 12.2.1 shall not prohibit disclosure or use of any information if and to the extent: 

 

	 	(i)	the disclosure or use is required by law, any governmental or regulatory body or any stock exchange on which the shares of any party (or its holding company) are
listed; 

  

	 	(ii)	the disclosure or use is required to vest the full benefit of this Agreement or the Ancillary Agreements in any party; 

  
 87 

	 	(iii)	the disclosure or use is required for the purpose of any arbitral or judicial proceedings arising out of this Agreement, the Ancillary Agreements, or any other
agreement entered into under or pursuant to this Agreement or to enable a determination to be made by the Reporting Accountants under this Agreement; 

  

	 	(iv)	the disclosure is made to a Tax Authority in connection with the Tax affairs of the disclosing party; 

 

	 	(v)	the disclosure is made on a confidential basis to a ratings agency in connection with the affairs of the disclosing party; 

 

	 	(vi)	the disclosure is made to professional advisers of any party on a need to know basis and on terms that such professional advisers undertake to comply with the
provisions of Clause 12.2.1 in respect of such information as if they were a party to this Agreement; 

  

	 	(vii)	the information was lawfully in the possession of that party without any obligation of secrecy prior to its being received or held, in either case as evidenced by
written records; 

  

	 	(viii)	the information is or becomes publicly available (other than by breach of this Agreement); 

 

	 	(ix)	the other party(ies) in respect of whom the information relates has given prior written approval to the disclosure or use; or 

 

	 	(x)	the information is independently developed, 

 provided that prior to disclosure or use of any information pursuant to Clause 12.2.2(i), (ii) or (iii), the party concerned shall, where not prohibited by law, promptly notify the other parties
of such requirement with a view to providing the other parties with the opportunity to contest such disclosure or use or otherwise to agree the timing and content of such disclosure or use. 

 

	12.	Insurance 

  

	12.1	No cover under any Seller’s Group Insurance Policies from Closing 

 Subject to the provisions of the Services Agreement, the Purchaser acknowledges and agrees that following Closing: 
  

	 	12.1.1	neither the Purchaser nor any Target Group Purchaser shall have or be entitled to the benefit of any Seller’s Group Insurance Policy in respect of any event, act
or omission that takes place after Closing and it shall be the sole responsibility of the Purchaser to ensure that adequate insurances are put in place for the Target Group Companies and the Target Group Businesses with effect from Closing;

  

	 	12.1.2	no Seller nor any member of its Group shall be required to maintain any Seller’s Group Insurance Policy for the benefit of the relevant Target Group; and

  
 88 

	 	12.1.3	no Target Group Company shall make or shall be entitled to make or notify a claim under any Seller’s Group Insurance Policy in respect of any event, act or
omission that occurred prior to the Closing Date. 

  

	12.2	Existing claims under any Seller’s Group Insurance Policies 

 With respect to any claim made before the Closing Date under any Seller’s Group Insurance Policy by or on behalf of any Target Group Company or in relation to any Target Group Business, to the extent
that: 
  

	 	12.2.1	neither the Purchaser nor the Target Group Companies have been indemnified by a Seller prior to the Closing Date in respect of the matter in respect of which the claim
was made; or 

  

	 	12.2.2	the Liability in respect of which the claim was made has not been properly provided for in the Closing Statement and reduced the Working Capital accordingly,

 that Seller shall use reasonable endeavours after Closing to recover all monies due from insurers and shall pay
any monies received (after taking into account any deductible under such Seller’s Group Insurance Policies and less any Taxation suffered on the proceeds and any reasonable out of pocket expenses suffered or incurred by such Seller or any
member of such Seller’s Group in connection with the claim) to the Purchaser or, at the Purchaser’s written direction, the relevant Target Group Company as soon as practicable after receipt. 

 

	12.3	GlaxoSmithKline and the Purchaser shall co-operate together after the date of this Agreement with a view to determining the most effective way of insuring the
Purchaser’s Group following Closing, taking into account the fact that the Purchaser’s Group will be consolidated with GlaxoSmithKline’s Group following Closing. In the event that they determine that it is preferable for
GlaxoSmithKline’s Group’s existing insurance arrangements to remain in place following Closing and for the Purchaser’s Group to be included within them, the provisions in this Cause 13.3 shall not apply to the extent they are no
longer relevant and the parties shall seek to agree the details in relation to such insurance arrangements to be included in the Services Agreement. 

  

	13.	France Business and the Netherlands Business 

  

	13.1	France Business 

Notwithstanding any other provision of this Agreement, this Agreement shall not constitute a binding agreement by a Seller to sell or
purchase its France Business, provided that: 
  

	 	13.1.1	in the event that a France Put Option Exercise occurs before Closing, this Clause 14.1 (other than this Clause 14.1.1) shall terminate and shall cease to have
effect, and the sale and purchase of the relevant France Business shall be subject to the terms of this Agreement as if it had been with effect from the date of this Agreement; 

 

	 	13.1.2	in the event that a France Put Option Exercise does not occur before Closing: 

  
 89 

	 	(i)	the provisions of Clauses 2, 6 and 9 (the “Disapplied Provisions”) shall not apply to the relevant France Business; 

 

	 	(ii)	prior to the relevant France Closing, the provisions of Schedule 7 and Schedule 8 (the “Suspended Provisions”) shall not apply to the relevant France
Business; and 

  

	 	(iii)	in respect of the Disapplied Provisions and, prior to the relevant France Closing, the Suspended Provisions only: 

 

	 	(a)	the term “Contributed Business” shall be deemed to exclude the relevant France Business; 

 

	 	(b)	the term “Target Group Companies” shall be deemed to exclude, in the case of Novartis, Novartis Santé Familiale S.A.S. and, in the case of
GlaxoSmithKline, any Target Group Companies that relate to its France Business; 

  

	 	(c)	Target Group Businesses shall be deemed to exclude, in the case of GlaxoSmithKline only, its France Business; 

 

	 	(d)	the term “Assumed Liabilities” shall be deemed to exclude the relevant France Assumed Liabilities; and 

 

	 	(e)	the term “Employees” shall be deemed to exclude the relevant France Employees; 

 

	 	13.1.3	with effect from a France Closing, the Suspended Provisions shall apply to the France Business mutatis mutandis save that in respect of the
Suspended Provisions only (A) the term “Closing” shall be deemed to refer to that France Closing and (B) the term “Closing Date” shall be deemed to refer to the date of that France Closing; 

 

	 	13.1.4	the parties shall negotiate in good faith to agree any amendments to this Agreement and any Ancillary Agreements as are required in order to give effect to the
principles set forth in this Clause 14.1 for the purposes of complying with the information and consultation requirements in respect of the relevant works council(s) in respect of GlaxoSmithKline’s France Business (in the case of
GlaxoSmithKline) and the Délégation Unique du Personnel (being the relevant works council in respect of Novartis France Business) (in the case of Novartis); and 

 

	 	13.1.5	the provisions of Clause 8 shall apply to the relevant France Business as if the remaining provisions of this Clause 14.1 did not have any force or effect.

  

	13.2	Netherlands Business 

Notwithstanding any other provision of this Agreement, this Agreement shall not constitute a binding agreement to sell or purchase the
Netherlands Business, provided that: 

  
 90 

	 	13.2.1	in the event that the Netherlands Put Option Exercise occurs before Closing, this Clause 14.2 (other than this Clause 14.2.1) shall terminate and shall cease to
have effect, and the sale and purchase of the Netherlands Business shall be subject to the terms of this Agreement as if it had been with effect from the date of this Agreement; 

 

	 	13.2.2	in the event that the Netherlands Put Option Exercise does not occur before Closing: 

 

	 	(i)	the Disapplied Provisions shall not apply to the Netherlands Business; 

  

	 	(ii)	prior to the Netherlands Closing, the Suspended Provisions shall not apply to the Netherlands Business; and 

 

	 	(iii)	in respect of the Disapplied Provisions and, prior to the Netherlands Closing, the Suspended Provisions only: 

 

	 	(a)	the term “Contributed Business” (when used in respect of GlaxoSmithKline) shall be deemed to exclude the Netherlands Business; 

 

	 	(b)	the term “GlaxoSmithKline Consumer Group Businesses” shall be deemed to exclude the Netherlands Business; 

 

	 	(c)	the term “Assumed Liabilities” (when used in respect of GlaxoSmithKline) shall be deemed to exclude the Netherlands Assumed Liabilities; and

  

	 	(d)	the term “Employees” (when used in respect of GlaxoSmithKline) shall be deemed to exclude the Netherlands Employees; 

 

	 	13.2.3	with effect from the Netherlands Closing, the Suspended Provisions shall apply to the Netherlands Business mutatis mutandis save that in respect of
the Suspended Provisions only (A) the term “Closing” shall be deemed to refer to the Netherlands Closing and (B) the term “Closing Date” shall be deemed to refer to the date of the Netherlands Closing;

  

	 	13.2.4	the parties shall negotiate in good faith to agree any amendments to this Agreement and any Ancillary Agreements as are required in order to give effect to the
principles set forth in this Clause 14.2 for the purposes of complying with such information and consultation requirements (if any) required under Applicable Law with the relevant works council or employee representative body (if any) in respect of
GlaxoSmithKline’s Netherlands Business; and 

  

	 	13.2.5	the provisions of Clause 8 shall apply to the Netherlands Business as if the remaining provisions of this Clause 14.2 did not have any force or effect.

  
 91 

	14.	Other Provisions 

  

	14.1	Further Assurances 

Without prejudice to any restriction or limitation on the extent of any party’s obligations under this Agreement, each of the parties
shall from time to time, so far as each is reasonably able, do or procure the doing of all such acts and/or execute or procure the execution of all such documents in a form reasonably satisfactory to the party concerned as it may reasonably consider
necessary to transfer the relevant Contributed Business to the Purchaser or otherwise to give the other parties the full benefit of this Agreement. 
  

	14.2	Ancillary Agreements 

 The
parties shall negotiate in good faith to agree definitive and legally binding documentation in respect of each of the Ancillary Agreements for which heads of terms are in Agreed Terms on the date of this Agreement, and shall duly execute and deliver
such definitive and legally binding documentation in respect of the Ancillary Agreements at Closing. 
  

	14.3	Whole Agreement 

  

	 	14.3.1	This Agreement and the Ancillary Agreements contain the whole agreement between the parties relating to the subject matter of this Agreement at the date hereof
to the exclusion of any terms implied by law which may be excluded by contract and supersedes any previous written or oral agreement between the parties in relation to the matters dealt with in this Agreement. 

 

	 	14.3.2	The Purchaser acknowledges that, in entering into this Agreement, it is not relying on any representation, warranty or undertaking not expressly incorporated
into it. 

  

	 	14.3.3	Each of the parties agrees and acknowledges that its only right and remedy in relation to any representation, warranty or undertaking made or given in connection
with this Agreement shall be for breach of the terms of this Agreement and each of the parties waives all other rights and remedies (including those in tort or arising under statute) in relation to any such representation, warranty or undertaking.

  

	 	14.3.4	In Clauses 15.3.1 to 15.3.3, “this Agreement” includes the Ancillary Agreements and all documents entered into pursuant to this Agreement.

  

	 	14.3.5	Nothing in this Clause 15.3 excludes or limits any liability for fraud. 

 

	14.4	No Assignment 

 No party
may, without the prior written consent of the other parties, assign, grant any security interest over, hold on trust or otherwise transfer the benefit of the whole or any part of this Agreement. 

  
 92 

	14.5	Third Party Rights 

  

	 	14.5.1	Subject to Clause 15.5.2, the parties do not intend that any term of this Agreement should be enforceable, by virtue of the Contracts (Rights of Third Parties)
Act 1999, by any person who is not a party to this Agreement. 

  

	 	14.5.2	Certain provisions of this Agreement confer benefits on the Affiliates of the Purchaser and the Affiliates of any Seller (each such Affiliate being, for the
purposes of this Clause 15.5, a “Third Party”) and, subject to Clause 15.5.3, are intended to be enforceable by each Third Party by virtue of the Contracts (Rights of Third Parties) Act 1999. 

 

	 	14.5.3	Notwithstanding Clause 15.5.2, this Agreement may be varied in any way and at any time without the consent of any Third Party. 

 

	14.6	Variation or waiver 

  

	 	14.6.1	No variation of this Agreement shall be effective unless in writing and signed by or on behalf of each of the parties. 

 

	 	14.6.2	No failure or delay by a party in exercising any right or remedy provided by Applicable Law or under this Agreement or any Ancillary Agreement shall impair such
right or remedy or operate or be construed as a waiver or variation of it or preclude its exercise at any subsequent time and no single or partial exercise of any such right or remedy shall preclude any further exercise of it or the exercise of any
other remedy. 

  

	14.7	Method of Payment and set off 

  

	 	14.7.1	Except as set out in Clause 15.7.2, payments (including payments pursuant to an indemnity, compensation or reimbursement provision ) made or expressed to be made by the
Purchaser or the Sellers pursuant to this Agreement or any claim for breach of this Agreement shall, insofar as the payment or claim relates to or affects any Shares (including the underlying Target Group Companies transferred (directly or
indirectly) by reason of the transfer of those Shares), assets or liabilities, transferred pursuant to this Agreement and the Local Transfer Documents, be made or received (as the case may be) by: 

 

	 	(i)	the relevant Seller, for itself or on behalf of its Share Seller or Business Seller (each in respect of the Shares and/or assets and liabilities to be transferred by it
pursuant to this Agreement and the relevant Local Transfer Documents); and 

  

	 	(ii)	the Purchaser, for itself and on behalf of the relevant members of the Purchaser’s Group (each in respect of the Shares and/or the assets and liabilities to be
transferred by it pursuant to this Agreement and the relevant Local Transfer Documents). 

  

	 	14.7.2	The repayment of the Estimated Intra-Group Non-Trade Receivables and the Estimated Intra-Group Non-Trade Payables pursuant to Clause 6.4.3 and any adjustments to
such repayment pursuant to Clause 7.4 shall be settled by payments between the Seller, for itself and on behalf of the relevant members of the Seller’s Group, and the Purchaser, for itself and on behalf of the relevant Target Group Companies.

  
 93 

	 	14.7.3	Without prejudice to Clause 6.3.2, any payments pursuant to this Agreement shall be made in full, without any set-off, counterclaim, restriction or condition and
without any deduction or withholding (save as may be required by law or as otherwise agreed), except that payments due between any Seller and the Purchaser: 

 

	 	(i)	in relation to repayments of the Estimated Intra-Group Non-Trade Payables and Estimated Intra-Group Non-Trade Receivables pursuant to Clause 6.4.3; or

  

	 	(ii)	in relation to adjustments to those repayments pursuant to Clause 7.4, 

 respectively, shall be discharged to the fullest extent possible by way of set-off against each other. 
  

	 	14.7.4	Any payments pursuant to this Agreement shall be effected by crediting for same day value the account specified by each Seller or the Purchaser (as the case may
be) on behalf of the party entitled to the payment (reasonably in advance and in sufficient detail to enable payment by telegraphic or other electronic means to be effected) on or before the due date for payment. 

 

	 	14.7.5	Payment of a sum in accordance with this Clause 15.7 shall constitute a payment in full of the sum payable and shall be a good discharge to the payer (and those
on whose behalf such payment is made) of the payer’s obligation to make such payment and the payer (and those on whose behalf such payment is made) shall not be obliged to see to the application of the payment as between those on whose behalf
the payment is received. 

  

	14.8	Costs 

  

	 	14.8.1	Subject to Clause 15.9, each Seller shall bear all costs incurred by it and its Affiliates in connection with the preparation and negotiation of, and the entry
into, this Agreement the relevant Ancillary Agreements and the sale of its Target Group. 

  

	 	14.8.2	The Purchaser shall bear all such costs incurred by it and its Affiliates in connection with the preparation and negotiation of, and the entry into, this
Agreement the relevant Ancillary Agreements and the purchase of Target Groups. 

  

	14.9	Notarial Fees, Registration, Stamp and Transfer Taxes and Duties 

 Each Seller shall bear the cost of all notarial fees and all registration, stamp and transfer taxes and duties or their equivalents in all jurisdictions where such fees, taxes and duties are payable as a
result of that Seller’s sale of its Target Group to the Purchaser pursuant to this Agreement. 

  
 94 

	14.10	Interest 

 If any party
defaults in the payment when due of any sum payable under this Agreement, the Local Transfer Documents or the Tax Indemnity the liability of that party shall be increased to include interest on such sum from the date when such payment is due until
the date of actual payment (as well after as before judgment) at a rate per annum of two per cent. above LIBOR. Such interest shall accrue from day to day. 
  

	14.11	Grossing-up 

  

	 	14.11.1	All sums payable under this Agreement, the Local Transfer Documents and the Tax Indemnity shall be paid free and clear of all deductions, withholdings, set-offs
or counterclaims whatsoever save only as may be permitted by Clause 15.7.3 or required by law. Subject to 15.11.2 to 15.11.7 (inclusive), if any deductions or withholdings are required by law, the party making the payment (the
“Payer”) shall (except in the case of any interest payable under this Agreement) be obliged to pay to the party to whom the payment is being made (the “Payee”) such sum as will after such deduction or withholding
has been made leave the Payee with the same amount as it would have been entitled to receive in the absence of any such requirement to make a deduction or withholding, provided that if the Payee shall have assigned or novated the benefit in whole or
in part of this Agreement or shall, after the date of this Agreement, have changed its tax residence or the permanent establishment to which the rights under this Agreement are allocated then the liability of the Payer under this Clause 15.11.1
shall be limited to that (if any) which it would have been had no such assignment, novation or change taken place. 

  

	 	14.11.2	If either Seller is or becomes aware of any facts making it reasonably likely that the Purchaser will be required to deduct or withhold any amount in respect of
the Purchase Consideration (a “Relevant Tax Deduction”) payable to a Seller (the “Withholding Seller”), then that Seller shall, as soon as reasonably practicable, give notice to the other Seller and the Purchaser
(including details of the relevant facts and, so far as possible, details of the rate and basis of such withholding). 

  

	 	14.11.3	The Sellers and the Purchaser shall, and shall procure that the members of their respective groups shall (at the Withholding Seller’s cost), co-operate with
each other in good faith and use all reasonable efforts to reduce or mitigate any Relevant Tax Deduction (or its amount) and /or to enable the Withholding Seller or the relevant Share Seller or Business Seller to obtain any available credit or
refund in respect of such Relevant Tax Deduction, including, without limitation, making any available claim under an applicable double taxation treaty. 

  

	 	14.11.4	Without prejudice to the generality of Clause 15.11.3, the Sellers and the Purchaser shall co-operate in good faith to establish or agree the amount or basis of
calculation of any Relevant Tax Deduction prior to Closing (and in this regard the Purchaser shall consider reasonably any relevant information or evidence provided or obtained by the Sellers) including, if requested by the Withholding Seller and at
the Withholding Seller’s expense, by seeking to obtain a ruling or confirmation from a relevant Tax Authority, or obtaining an opinion from reputable local tax counsel or a firm of accountants of international standing satisfactory to the
Purchaser (acting reasonably) and instructed jointly by the Withholding Seller and the Purchaser. 

  
 95 

	 	14.11.5	The Purchaser shall make any Relevant Tax Deduction in the minimum amount required by applicable law, provided that: 

 

	 	(i)	if a double taxation treaty between the jurisdiction under the laws of which the Relevant Tax Deduction is required and the jurisdiction of residence of the Withholding
Seller or the relevant Share Seller or Business Seller is in force, the Purchaser shall (and shall procure that any relevant member of the Purchaser’s Group shall) make any Relevant Tax Deduction in an amount not exceeding the rate specified in
such double taxation treaty (which may be nil), provided that the Withholding Seller has provided the Purchaser with such evidence as is required under applicable law to establish the entitlement of the Withholding Seller (or relevant Share Seller
or Business Seller) to the benefit of the applicable treaty; and 

  

	 	(ii)	if an opinion from reputable local counsel or a firm of accountants of international standing has been obtained at the request of the Withholding Seller as envisaged by
Clause 15.11.4, the Purchaser shall (and shall procure that any relevant member of the Purchaser Group shall) make such Relevant Tax Deduction in an amount or on a basis which is consistent with that opinion (which may result in no withholding or
deduction), provided that the Withholding Seller has indemnified the Purchaser and any relevant member of the Purchaser’s Group, to the Purchaser’s reasonable satisfaction, against any Liabilities arising (including any interest and
penalties) should such opinion be wholly or partly incorrect. 

  

	 	14.11.6	The Purchaser shall promptly provide the Withholding Seller with evidence reasonably satisfactory to the Withholding Seller that a Relevant Tax Deduction has
been made and an appropriate amount paid to the relevant Tax Authority. 

  

	 	14.11.7	If any Relevant Tax Deduction is required an additional sum shall be payable in accordance with Clause 15.11.1 only if and to the extent that such deduction
or withholding would not have been required had the Purchaser been resident for Tax purposes only in the United Kingdom. 

  

	14.12	Structure of indemnity payments 

 Where it is agreed or determined that an amount is payable by either Seller to the Purchaser or to another member of the Purchaser’s Group pursuant to any indemnity or covenant to pay in this
Agreement, or as damages in respect of a breach of this Agreement, then both Sellers and the Purchaser shall consult in good faith for a period of not less than ten Business Days (or such longer or shorter period as the parties may agree) with a
view to agreeing an acceptable arrangement for satisfying that obligation to pay the amount so claimed in an efficient manner that does not prejudice the interests of the Purchaser’s Group (which may involve, by way of example only, a
subscription for deferred shares in the Purchaser or making an additional contribution to the Purchaser in respect of existing shares in the Purchaser). If both Sellers and the Purchaser fail to agree on any particular manner of payment during the
course of such consultations (but not before), the Seller which is liable to make the payment under or in respect of this Agreement shall make that payment in cash to the person entitled to it. 

  
 96 

	14.13	Changes to share rights 

  

	 	14.13.1	GlaxoSmithKline shall be entitled, by written notice to Novartis and the Purchaser not less than 20 Business Days before the Closing Date, to stipulate that, subject to
the parties implementing the changes agreed pursuant to the final sentence of this clause 15.13.1, the A Shares which shall be issued to members of GlaxoSmithKline’s Group under this Agreement shall be split, before Closing, into two classes of
Shares, referred to as “A1” and “A2” shares. To the extent permitted by Applicable Law, GlaxoSmithKline shall be entitled to specify the rights attaching to each of these classes of shares, provided that the rights attaching to
the A1 and A2 shares, in aggregate, may not in any respect exceed the rights attaching to the A Shares as set out in the Agreed Terms Shareholders’ Agreement. If GlaxoSmithKline gives notice of the same, the parties shall promptly agree and
implement such changes to the Agreed Terms Shareholders’ Agreement as are necessary to give effect to the division of the A Shares into “A1” and “A2” shares and to ensure that both Sellers will be in the same relative
economic and governance position as they would have been in had the A Shares not been divided into two classes. 

  

	 	14.13.2	Novartis shall be entitled, by written notice to GlaxoSmithKline and the Purchaser not less than 20 Business Days before the Closing Date, to stipulate that, subject to
the parties implementing the changes agreed pursuant to the final sentence of this clause 15.13.2, the B Shares which shall be issued to members of Novartis’s Group under this Agreement shall be split, before Closing, into two classes of
Shares, referred to as “B1” and “B2” shares. To the extent permitted by Applicable Law, Novartis shall be entitled to specify the rights attaching to each of these classes of shares, provided that the rights attaching to the B1
and B2 shares, in aggregate, may not in any respect exceed the rights attaching to the B Shares as set out in the Agreed Terms Shareholders’ Agreement. If Novartis gives notice of the same, the parties shall promptly agree and implement such
changes to the Agreed Terms Shareholders’ Agreement as are necessary to give effect to the division of the B Shares into “B1” and “B2” shares and to ensure that both Sellers will be in the same relative economic and
governance position as they would have been in had the B Shares not been divided into two classes. 

  

	 	14.13.3	GlaxoSmithKline shall be entitled, by written notice to Novartis and the Purchaser not less than 20 Business Days before the Closing Date, to stipulate that it will
only have one shareholder in the Purchaser as at Closing. If GlaxoSmithKline gives notice of the same, the parties shall promptly agree such changes to the Agreed Terms Shareholders’ Agreement and Agreed Terms Articles of Association as are
necessary to give effect to the fact that the A Shares will be held by just one shareholder as at Closing. 

  

	 	14.13.4	 Novartis shall be entitled, by written notice to GlaxoSmithKline and the Purchaser not less than 20 Business Days before the Closing Date, to
stipulate that it will only have one shareholder in the Purchaser as at Closing. 

  
 97 

	 	
If Novartis gives notice of the same, the parties shall promptly consult each other in good faith with a view to agreeing such changes to the Agreed Terms Shareholders’ Agreement and Agreed
Terms Articles of Association as are necessary to give effect to the fact that the B Shares will be held by just one shareholder as at Closing 

  

	14.14	Notices 

  

	 	14.14.1	Any notice or other communication in connection with this Agreement (each, a “Notice”) shall be: 

 

	 	(i)	in writing in English; 

  

	 	(ii)	delivered by hand, fax, or by courier using an internationally recognised courier company. 

 

	 	14.14.2	A Notice to GlaxoSmithKline shall be sent to such party at the following address, or such other person or address as GlaxoSmithKline may notify to the Purchaser from
time to time: 

 GlaxoSmithKline 
 980 Great West Road 
 Brentford 

Middlesex TW8 9GS 
 United Kingdom 
 Fax: +44 (0)208 0476904 

Attention: Company Secretary and General Counsel of Consumer Healthcare 

with a copy to the GlaxoSmithKline’s Lawyers, marked for the urgent attention of Richard Smith (delivery of such copy shall not in
itself constitute valid notice). 
  

	 	14.14.3	A Notice to Novartis shall be sent to such party at the following address, or such other person or address as Novartis may notify to the Purchaser from time to time:

 Novartis 
 c/o Novartis International AG 
 Postfach 

CH-4002 Basel 

Switzerland 
  

					
	Fax:	  	+41 613244300
			
	Attention:	  		  	Head M&A and Head M&A Legal

 with a copy to Novartis’s Lawyers, marked for the urgent attention of Jennifer Bethlehem (delivery
of such copy shall not in itself constitute valid notice). 

  
 98 

	 	14.14.4	A Notice to the Purchaser shall, prior to Closing, be sent to each Seller at the addresses specified above, and, with effect from Closing, be sent to such party
at the following address, or such other person or address as the Purchaser may notify to the Sellers from time to time: 

 The Purchaser 
 980 Great West Road 

Brentford Middlesex TW8 9GS 
 United Kingdom 
 Fax: +44 (0)208 0476904 

Attention: Company Secretary and General Counsel of Consumer Healthcare 

with a copy to GlaxoSmithKline’s Lawyers, marked for the urgent attention of Richard Smith, and to Novartis’s Lawyers, marked
for the urgent attention of Jennifer Bethlehem (delivery of such copy shall not in itself constitute valid notice). 
  

	 	14.14.5	A Notice shall be effective upon receipt and shall be deemed to have been received: 

 

	 	(i)	at the time of delivery, if delivered by hand or courier; or 

  

	 	(ii)	at the time of transmission in legible form, if delivered by fax. 

  

	14.15	Invalidity or Conflict 

  

	 	14.15.1	If any provision in this Agreement shall be held to be illegal, invalid or unenforceable, in whole or in part, the provision shall apply with whatever deletion or
modification is necessary so that the provision is legal, valid and enforceable and gives effect to the commercial intention of the parties. 

  

	 	14.15.2	To the extent it is not possible to delete or modify the provision, in whole or in part, under Clause 15.15.1, then such provision or part of it shall, to the
extent that it is illegal, invalid or unenforceable, be deemed not to form part of this Agreement and the legality, validity and enforceability of the remainder of this Agreement shall, subject to any deletion or modification made under
Clause 15.15.1, not be affected. 

  

	 	14.15.3	If there is any conflict between the terms of this Agreement and any of the Ancillary Agreements this Agreement shall prevail (as between the parties between
this Agreement and as between any member of the relevant Seller’s Group and any member of the Purchaser’s Group) unless (i) such Ancillary Agreement expressly states that it overrides this Agreement in the relevant respect and
(ii) that Seller and the Purchaser are either also parties to that Ancillary Agreement or otherwise expressly agree in writing that such Ancillary Agreement shall override this Agreement in that respect. 

  
 99 

	14.16	Counterparts 

 This
Agreement may be entered into in any number of counterparts, all of which taken together shall constitute one and the same instrument. Any party may enter into this Agreement by executing any such counterpart. Delivery of a counterpart of this
Agreement by email attachment shall be an effective mode of delivery. 
  

	14.17	Governing Law and Submission to Jurisdiction 

  

	 	14.17.1	This Agreement and the documents to be entered into pursuant to it, save as expressly referred to therein, and any non-contractual obligations arising out of or in
connection with the Agreement and such documents shall be governed by and construed in accordance with English law. 

  

	 	14.17.2	Each of the parties irrevocably agrees that the courts of England and Wales are to have exclusive jurisdiction to settle any dispute which may arise out of or in
connection with this Agreement and the documents to be entered into pursuant to it, save as expressly referred to therein, and that accordingly any proceedings arising out of or in connection with this Agreement and the documents to be entered into
pursuant to it, save as expressly referred to therein, shall be brought in such courts. Each of the parties irrevocably submits to the jurisdiction of such courts and waives any objection to proceedings in any such court on the ground of venue or on
the ground that proceedings have been brought in an inconvenient forum. 

  

	14.18	Appointment of Process Agent 

  

	 	14.18.1	Novartis hereby irrevocably appoints Hackwood Secretaries Limited of One Silk Street, London EC2Y 8HQ as its agent to accept service of process in England and Wales in
any legal action or proceedings arising out of this Agreement, service upon whom shall be deemed completed whether or not forwarded to or received by Novartis. 

 

	 	14.18.2	Novartis agrees to inform the Purchaser in writing of any change of address of such process agent within 28 days of such change. 

 

	 	14.18.3	If such process agent ceases to be able to act as such or to have an address in England and Wales, Novartis irrevocably agrees to appoint a new process agent in England
and Wales and to deliver to the Purchaser within 14 days a copy of a written acceptance of appointment by the process agent. 

  

	 	14.18.4	Nothing in this Agreement shall affect the right to serve process in any other manner permitted by law. 

This Agreement has been entered into on the date stated at the beginning. 

  
 100

 GLAXOSMITHKLINE PLC 
  

 
  

 
 Name: 

Function: 
 NOVARTIS AG 

 
  
  

 
  

 
 Name: 

Name: 
 Function: Attorney

 Function: Attorney 

LEO CONSTELLATION LIMITED 
  

 
  

 
 Name: 

Function: 

  
 101

 Schedule 1 
 Details of the Share Sellers, Shares etc. 
 Part 1 

GlaxoSmithKline Shares 
 Part A 
  

					
	 (1)
	 	 (2)
	 	 (3)

	 Name

of Share Seller
	 	 Name of Target

Group Company
	 	 Shares

			
	Glaxo Group Limited	 	GlaxoSmithKline Argentina S.A.	 	84.2%
	  
 Setfirst Limited
	 	 	  
 15.8%

			
	Wellcome Limited (UK)	 	GlaxoSmithKline Consumer Healthcare S.A.	 	100%
			
	SmithKline Beecham Limited	 	GlaxoSmithKline Consumer Healthcare Inc. (Canada)	 	100% (common shares)
	  
 GlaxoSmithKline Inc.
	 	 	  
 100% (preference shares)

			
	Setfirst Limited	 	GlaxoSmithKline Consumer Healthcare A/S	 	100%
			
	Groupe GlaxoSmithKline SAS (France)	 	GlaxoSmithKline Sante Grand Public SAS	 	100%
			
	GlaxoSmithKline Beteiligungs GmbH (Germany)	 	GlaxoSmithKline GmbH & Co. KG	 	100%
			
	GlaxoSmithKline GmbH & Co. KG	 	GlaxoSmithKline Healthcare GmbH	 	100%
			
	GlaxoSmithKline Healthcare GmbH	 	GlaxoSmithKline Consumer Healthcare GmbH & Co. KG	 	88.89%
	  
 GlaxoSmithKline Consumer Holding B.V.
	 	 	  
 11.11%

			
	GlaxoSmithKline Consumer Healthcare GmbH & Co. KG	 	Panadol GmbH	 	100%
			
	GlaxoSmithKline Consumer Healthcare GmbH & Co. KG	 	Fink GmbH	 	100%

  
 102

					
	 (1)
	 	 (2)
	 	 (3)

	 Name

of Share Seller
	 	 Name of Target

Group Company
	 	 Shares

			
	Fink GmbH	 	Lingner-Produktion GmbH	 	100% (DM 2,500,000 shares)
	  
 Panadol GmbH
	 	 	  
 100% (DM 1,600,000 shares)

	  
 Panadol GmbH
	 	 	  
 100% (DM 1,500,000 shares)

	  
 Setfirst Limited
	 	 	  
 100% (DM 80,000 shares)

	  
 Setfirst Limited
	 	 	  
 100% (DM 40,000 shares)

	  
 Setfirst Limited
	 	 	  
 100% (DM 20,000 shares)

			
	Fink GmbH	 	Fink Naturarznei GmbH	 	100%
			
	GlaxoSmithKline Consumer Healthcare GmbH & Co. KG	 	Abtei Pharma Vertriebs GmbH	 	100%
			
	Setfirst Limited	 	GlaxoSmithKline Dungarvan Limited	 	100%
			
	Setfirst Limited	 	GlaxoSmithKline Consumer Healthcare (Ireland) Limited	 	100%
			
	Glaxo Group Limited	 	Stafford-Miller (Ireland) Limited	 	100%
			
	Glaxo Group Limited	 	GlaxoSmithKline Consumer Healthcare Investments (Ireland) Limited	 	100%
			
	Setfirst Limited	 	GlaxoSmithKline Consumer Healthcare Investments (Ireland) (No.2)	 	100%
			
	SmithKline Beecham Limited (UK)	 	GlaxoSmithKline Consumer Healthcare SpA	 	100%
			
	Beecham Group plc (UK)	 	GlaxoSmithKline Consumer Healthcare Sdn. Bhd.	 	100%
			
	S.R. One International B.V.	 	GlaxoSmithKline Consumer Holding B.V.	 	100%
			
	S.R. One International B.V.	 	GlaxoSmithKline Consumer Healthcare B.V.	 	100%
			
	Setfirst Limited	 	GlaxoSmithKline Consumer Healthcare S.p.z.o.o.	 	100%
			
	Glaxo Group Limited	 	GlaxoSmithKline Consumer Healthcare SRL	 	100%

  
 103

					
	 (1)
	 	 (2)
	 	 (3)

	 Name

of Share Seller
	 	 Name of Target

Group Company
	 	 Shares

			
	Glaxo Group Limited	 	GlaxoSmithKline Consumer Healthcare Pte. Limited	 	100%
			
	Glaxo Group Limited	 	GlaxoSmithKline South Africa (Pty) Limited	 	100%
			
	Setfirst Limited	 	GlaxoSmithKline Consumer Healthcare S.A.	 	100%
			
	Setfirst Limited	 	GlaxoSmithKline Consumer Healthcare A.B.	 	100%
			
	Setfirst Limited	 	GlaxoSmithKline Consumer Healthcare AG	 	100%
			
	Setfirst Limited	 	GlaxoSmithKline Consumer Trading Services Limited (UK)	 	100%
			
	The Wellcome Foundation Limited (UK)	 	Wellcome Consumer Products Limited	 	100%
			
	The Wellcome Foundation Limited (UK)	 	Wellcome Consumer Healthcare Limited (UK)	 	100%
			
	GlaxoSmithKline LLC	 	Block Drug Company Inc.	 	100%
			
	Block Drug Company Inc.	 	Block Drug Corporation	 	100%
			
	Block Drug Company Inc.	 	Stafford-Miller Limited (UK)	 	100% (common shares)
	  
 Wellcome Limited
	 	 	  
 100% (non-cumulative non-redeemable preference
shares)

			
	GlaxoSmithKline LLC	 	GlaxoSmithKline Consumer Healthcare LLC	 	100%
			
	Block Drug Company Inc.	 	Stafford-Miller Limited (UK) branches	 	100%

 Part B 
  

					
	 (1)
	 	 (2)
	 	 (3)

	 Name

of Share Seller
	 	 Name of

Joint Venture Entity
	 	 Shares

			
	GlaxoSmithKline Consumer Healthcare LLC	 	GlaxoSmithKline Consumer Healthcare L.P.	 	0.4%
	  
 GlaxoSmithKline LLC
	 	 	  
 87.6%

	  
 Sanofi-Aventis US
	 	 	  

12.0%

  
 104

					
			
	GSK (China) Investment Co. Limited	 	The Sino-American Tianjin Smith Kline & French Laboratories Limited	 	55%
	  
 Tianjin Pharmaceutical Group Co. Limited
	 	 	  
 20%

	  
 Tianjin Zhong Xin Pharmaceutical Group Corporation
Limited
	 	 	  
 25%

			
	Setfirst Limited	 	GlaxoSmithKline Algérie SPA	 	99%
	  
 Nominees / private individuals
	 	 	  
 1%

			
	Interpharma Dienstleistungen Gmbh	 	Laboratoire Pharmaceutique Algérien LPA Production SPA	 	99%
	  
 Private individuals
	 	 	  
 1%

			
	Laboratoire Pharmaceutique Algérien LPA Production SPA	 	Laboratoire Pharmaceutique Algérien SPA	 	66%
	  
 GlaxoSmithKline SAS
	 	 	33%
	  
 Nominees / private individuals
	 	 	1%

  
 105

 Part 2 
 Novartis Shares 
 Part A 

 

					
	 (1)
	 	 (2)
	 	 (3)

	 Name

of Share Seller
	 	 Name of

Company
	 	 Shares

			
	Novartis AG	 	Novartis Consumer Health Australasia Pty Ltd	 	100%
			
	Novartis AG	 	Novartis Consumer Health S.A.	 	100%
			
	Novartis AG	 	Novartis Consumer Health Schweiz AG	 	100%
			
	Novartis Consumer Health S.A.	 	N.V. Novartis Consumer Health S.A.	 	99.33%
	  
 Various minority shareholders
	 	 	  
 0.67%

			
	Novartis Deutschland GmbH	 	Novartis Consumer Health GmbH	 	51%
	  
 Novartis Consumer Health S.A.
	 	 	  
 49%

			
	Novartis Farma SpA	 	Novartis Consumer Health SpA	 	100%
			
	Novartis Farmacéutica S.A.	 	Novartis Consumer Health S.A.	 	100%
			
	Novartis Finance Corporation	 	Novartis Consumer Health, Inc.	 	80%
	  
 Novartis Consumer Health S.A.
	 	 	  
 20%

			
	Novartis Groupe France S.A.	 	Novartis Santé Familiale SAS	 	100%
			
	Novartis Holding AG	 	Ex-Lax, Inc.	 	100%
			
	Novartis Pharma AG	 	Novartis Consumer Health Canada	 	100%
			
	Novartis Portugal SGPS Lda	 	Novartis Consumer Health - Produtos Farmacêuticos	 	100%

  
 106

					
	 (1)
	 	 (2)
	 	 (3)

	 Name

of Share Seller
	 	 Name of

Company
	 	 Shares

			
	Novartis UK Limited	 	Novartis Consumer Health UK Limited	 	100%

 Part B 
  

					
	 (1)
	 	 (2)
	 	 (3)

	 Name

of Share Seller
	 	 Name of

Joint Venture Entity
	 	 Shares

			
	Novartis Consumer Health S.A.	 	Novartis Consumer Health-Gebro GmbH	 	60%
	  
 Gebro Pharma GmbH
	 	 	  
 40%

  
 107

 Schedule 2 
 The Properties 
 Part 1  

GlaxoSmithKline Properties 

Manufacturing and production facilities: 
 [***] 
 Research and development facilities: 

[***] 
  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission. 

  
 108

 Part 2 

Novartis Properties 

Manufacturing and production facilities: 
  

	 	1.	[***] 

  

	 	2.	[***] 

  

	 	3.	[***] 

  

	 	4.	[***] 

 Research and development facilities:

  

	 	1.	[***] 

  

	 	2.	[***] 

  

	 	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission. 

  
 109

 Part 3  

Terms Relating to the Company Properties 
  

	1	GENERAL PROVISIONS RELATING TO THE COMPANY PROPERTIES 

  

	1.1	Interpretation 

 The
following further definitions apply in this Part 3 of Schedule 2: 
 “Company Landlord” means the person for the
time being entitled to the reversion immediately expectant on the termination of the term granted by a Company Lease; 

“Company Leased Properties” means the properties identified in Parts 1 and 2 of this Schedule 2 which, as at Closing, are
held by a Target Group Company under a lease, licence or tenancy agreement, and “Company Leased Property” means any one of them; 
 “Company Leases” means the leases, licence documents or tenancy agreements under which the Company Leased Properties are held, including all documents supplemental to them, and
“Company Lease” means any one of them; 
 “Company Owned Properties” means the properties
identified in Parts 1 and 2 of this Schedule 2 in which the freehold estate (or nearest local law equivalent) is owned by a Target Group Company as at Closing, together (subject to Clause 2.3.2) with all buildings, structures, fixed plant, fixed
machinery and fixed equipment thereon (except as excluded in Clause 2.3.2, and “Company Owned Property” means any one of them; 
 “Company Property Longstop Date” means the date on which a court of competent jurisdiction finally determines that a Company Third Party Consent has been lawfully refused or cannot be
obtained and/or that the Purchaser may not acquire (directly or indirectly, acting through a subsidiary) the relevant Company Property; and 
 “Company Third Party Consents” means all consents, licences, approvals, permits, authorisations or waivers required from any Company Landlord, superior landlord and/or other third party,
including any consents, licences, approvals, permits, authorisations or waivers required by any legislation or regulation or by any statutory, governmental, state, provincial or municipal bodies or authorities which are required under a Company
Lease or otherwise in relation to any change of control, shareholders or directors of the relevant Target Group Company, and “Company Third Party Consent” means any one of them. 

 

	1.2	Company Third Party Consents 

  

	 	1.2.1	This paragraph 1.2.1 applies to those Company Properties in relation to which a Company Third Party Consent is required, and if such Company Third Party Consent remains
to be obtained as at the Closing Date this paragraph 1.2.1 shall continue to apply until the relevant Company Third Party Consent shall have been obtained or until the Company Property Longstop Date. If any Company Third Party Consents are required:

  

	 	(i)	the Seller in relation to the Target Group Company which owns the Company Property in question shall make an application for, and shall use all reasonable endeavours to
obtain each Company Third Party Consent as soon as reasonably practicable following the date of this Agreement and shall at all times keep the Purchaser informed of progress in obtaining such Company Third Party Consents; 

  
 110

	 	(ii)	the Purchaser and each Seller shall supply such information and references as may reasonably be required by a Company Landlord, any superior landlord or other relevant
third party in connection with a Company Third Party Consent; 

  

	 	(iii)	the Purchaser shall be responsible for and undertake to pay, or procure the giving of undertakings to pay the professional and other fees of any Company Landlord, any
superior landlord or other relevant person (including any Tax or disbursements in respect of such fees but excluding any Tax on the actual net income, profit or gains of the Company Landlord, any superior landlord or any other relevant person)
properly incurred in connection with any application for Company Third Party Consents, whether or not such Company Third Party Consents are given; and 

  

	 	(iv)	in respect of the period after Closing only, the Purchaser shall enter into such covenants for the payment of the rent under the Company Lease and for the observance
and performance of the covenants and conditions contained in the Company Lease as may reasonably be required by the Company Landlord, any superior landlord or other relevant third party. 

 

	 	1.2.2	Each Seller shall give written notice to the other Seller as soon as reasonably practicable after obtaining any Company Third Party Consents which shall
be accompanied by a copy of such consent. 

  

	 	1.2.3	Save as set out in paragraph 1.2.1(iii) of this Part 3 of Schedule 2, the Seller in relation to the Target Group Company which owns the Company Property in
question shall pay any moneys or provide or procure the giving of any guarantees or other security, in each case as may be lawfully required by a Company Landlord, superior landlord or other relevant third party in connection with the obtaining of
the Company Third Party Consents, provided that the Purchaser shall indemnify and keep indemnified that Seller in an amount equal to: 

  

	 	(i)	any moneys required to be paid by that Seller pursuant to this paragraph; and 

 

	 	(ii)	any Liabilities under any guarantees or other security given or procured by that Seller pursuant to this paragraph 1.2.3 and arising out of, or in connection with, an
act or omission on the part of the Purchaser or (following Closing) the relevant Target Group Company, 

 and
where the Company Landlord, superior landlord or other relevant third party lawfully requires any guarantees or other security to be given by the person who is acquiring a membership interest in respect of the relevant Target Group Company, the
Purchaser shall provide or procure the giving of any such guarantees or security. 

  
 111

 Company Third Party Consent not Obtained 

 

	 	1.2.4	If a Company Third Party Consent has been refused or otherwise not obtained within 12 months following the Closing Date, the Sellers may (acting
reasonably) agree that an application is to be made to a court of competent jurisdiction that the relevant Company Third Party Consent has been unreasonably withheld or delayed. 

 

	 	1.2.5	If an application is to be made to a court of competent jurisdiction pursuant to paragraph 1.2.4 of this Part 3 of Schedule 2: 

 

	 	(i)	the proceedings shall be brought by, and prosecuted at the expense of the Purchaser; 

 

	 	(ii)	the Sellers shall provide all such assistance in connection with such proceedings as the Purchaser (acting reasonably) may require in the interests of obtaining the
Company Third Party Consent; and 

  

	 	(iii)	provided that the Seller has complied with its obligation under paragraph 1.2.1(i) of this Part 3 of Schedule 2, the Purchaser shall indemnify and keep indemnified the
Seller for any costs and expenses properly incurred in connection with any such assistance provided by the Seller. 

  

	 	1.2.6	If a Company Third Party Consent has not been obtained by the Company Property Longstop Date then the relevant Seller in relation to the Target Group
Company which owns the Company Property in question shall indemnify and keep indemnified the Purchaser against all Losses arising out of or in connection with the failure to obtain such Company Third Party Consent. 

  
 112

 Part 4  

Terms Relating to the Transferred Properties 
  

	1	GENERAL PROVISIONS RELATING TO THE TRANSFERRED PROPERTIES 

  

	1.1	Interpretation 

 The
following further definitions apply in this Part 4 of Schedule 2: 
 “Expert” has the meaning given to it in
paragraph 1.3.2(i) of this Part 4 of Schedule 2; 
 “Landlord” means the person for the time being entitled
to the reversion immediately expectant on the termination of the term granted by a Lease; 
 “Leases” means the
leases, licences or tenancy agreements under which the Transferred Leased Properties are held by the relevant member of the Seller’s Group, including all documents supplemental to them, and “Lease” means any one of them;

 “Letting Document” means any lease, licence or tenancy agreement to which a Transferred Property is subject;

 “Licence” means a right in favour of the Purchaser and all persons authorised by it to occupy the Licensed
Premises during the Licence Period pursuant to this Part 4 of Schedule 2; 
 “Licence Fee” means the payments to
be made by the Purchaser to the Seller’s Group pursuant to paragraph 1.4.4 of this Part 4 of Schedule 2; 
 “Licence
Period” means a period, which may be different for each of the Licensed Premises, commencing on the Closing Date and ending on the earliest of the following dates: 

 

	 	(i)	the date on which this Agreement is terminated by whatever means whether in whole or in relation to the relevant Licensed Premises; 

 

	 	(ii)	the date immediately preceding the date on which the term of the relevant Lease ends by whatever means; 

 

	 	(iii)	the date of Property Transfer Completion in relation to the relevant Transferred Property; and 

 

	 	(iv)	the Property Longstop Date; 

“Licensed Premises” means any of the Transferred Properties for which all relevant Property Third Party Consents have not
been obtained prior to, or at, the Closing Date; 
 “President” has the meaning given to it in
paragraph 1.3.2(ii) of this Part 4 of Schedule 2; 
 “Property Agreed Terms” means a transfer in the terms
agreed between the Sellers, the Purchaser and any relevant third party or determined pursuant to paragraph 1.3.2 of this Part 4 of Schedule 2 and signed for identification by or on behalf of the Sellers and by or on behalf of the Purchaser from time
to time before or after the date of this Agreement, with such alterations as may be agreed from time to time in writing between the Sellers, the Purchaser and any relevant third party; 

“Property Longstop Date” means the date on which a court of competent jurisdiction finally determines that a Property
Third Party Consent has been lawfully refused; 

  
 113

 “Property Third Party Consents” means all consents, licences, approvals,
permits, authorisations or waivers required from any Landlord, superior landlord and/or other third party, including any consents, licences, approvals, permits, authorisations or waivers required by any legislation or regulation or by any statutory,
governmental, state, provincial or municipal bodies or authorities for or in connection with the transfer of a Transferred Property by the relevant member of the Seller’s Group to the Purchaser and includes (where the context so admits)
Sublease Consents; 
 “Property Transfer Completion” means the completion of the transfer of a Transferred
Property under this Agreement, where such completion does not take place on the Closing Date because any relevant Property Third Party Consents have not been obtained on or prior to such date; 

“Property Transfer Completion Date” means the date of Property Transfer Completion in accordance with paragraph 1.7 of
this Part 4 of Schedule 2; 
 “Registered Title” means the registered title relating to a Transferred Property;

 “Sublease Consent” has the meaning given to it in paragraph 1.11.2 of this Part 4 of Schedule 2; 

“transfer”, for the purposes of this Part 4 of Schedule 2 only, means in respect of a Transferred Leased Property, the
transfer or assignment of the relevant Lease or Leases, and in the case of a Transferred Owned Property the transfer thereof, and “a transfer” means and includes any instruments, deeds or agreements effecting such transfer;

 “Transferred Leased Properties” means the leasehold properties identified in Parts 1 and 2 of this Schedule 2
which are not owned by a Target Group Company as at Closing, and “Transferred Leased Property” means any one of them; and 
 “Transferred Owned Properties” means the properties identified in Parts 1 and 2 of this Schedule 2 in which the freehold estate (or nearest local law equivalent) is not owned by a Target
Group Company as at Closing, together (subject to Clause 2.3.2) with all buildings, structures, fixed plant, fixed machinery and fixed equipment thereon (except as excluded in Clause 2.3.2), and “Transferred Owned Property” mean any
one of them. 
  

	1.2	Each of the Transferred Properties and/or the Leases thereof shall be transferred subject to the terms set out in this Part 4 of Schedule 2 and all other
applicable terms of this Agreement. 

  

	1.3	Pre-Closing 

  

	 	1.3.1	Prior to Closing, the Business Sellers and the Purchaser shall agree (acting reasonably) the form of all documents on Property Agreed Terms necessary for the
transfer of each of the Transferred Properties pursuant to the terms set out in this Part 4 of Schedule 2 and all other applicable terms of this Agreement. 

 

	 	1.3.2	Any dispute arising out of or connected with paragraph 1.3.1 of this Part 4 of Schedule 2 which is not resolved by agreement between the parties within nine
months of such dispute arising shall be referred for and resolved by expert determination as follows: 

  

	 	(i)	either Seller may initiate an expert reference under this provision by proposing to the other Seller the appointment of an expert (the “Expert”);

  
 114

	 	(ii)	the Expert shall either be the nearest equivalent to a chartered surveyor in the relevant jurisdiction or (in relation to legal issues) a single QC (or equivalent), in
each case with no less than 15 years’ post-qualification experience in commercial real estate in the relevant jurisdiction chosen by agreement between the Sellers or, failing agreement within 14 days of the initiation of the reference, by the
President for the time being of the relevant professional body to which the Expert belongs (the “President”) on the application of either Seller; 

 

	 	(iii)	the Sellers shall request that the Expert determines the referred dispute within ten days of receiving the reference; 

 

	 	(iv)	if the Expert has been appointed but is unable or unwilling to complete the reference, another Expert shall be appointed by agreement between the Sellers or, failing
agreement within 7 days of the parties being notified that the Expert is unable or unwilling to complete the reference, by the President on the application of either party; 

 

	 	(v)	the Expert shall act as an expert and not as an arbitrator; 

  

	 	(vi)	the Sellers shall have the right to make representations and submissions to the Expert, but there will be no formal hearing; 

 

	 	(vii)	the Sellers shall make all relevant documents and information within their control available to the Expert; 

 

	 	(viii)	the costs of the Expert shall be borne by the Sellers in equal shares; and 

 

	 	(ix)	the decision of the Expert shall, in the absence of fraud or manifest error, be final and binding on the parties. 

 

	 	1.3.3	This paragraph 1.3.3 applies to those Transferred Properties in relation to which a Property Third Party Consent is required and if such Property Third Party Consent
remains to be obtained as at the Closing Date this paragraph 1.3.3 shall continue to apply until the relevant Property Third Party Consent shall have been obtained or until the Property Longstop Date. If any Property Third Party Consents are
required: 

  

	 	(i)	the Seller in relation to the Transferred Property in question shall make an application for, and shall use all reasonable endeavours to obtain each Property Third
Party Consent as soon as reasonably practicable following the date of this Agreement for the transfer of the Transferred Property and shall, at all times, keep the Purchaser and the other Seller informed of progress in obtaining such Property Third
Party Consents; 

  

	 	(ii)	the Purchaser and each Seller shall supply such information and references as may reasonably be required by a Landlord, any superior landlord or other relevant third
party in connection with a Property Third Party Consent; 

  
 115

	 	(iii)	in respect of the period after Closing only, the Purchaser shall enter into such covenants for the payment of the rent in respect of the Transferred Leased Properties
and for the observance and performance of the covenants and conditions on the part of the lessee contained in any Lease as may reasonably be required by the Landlord, any superior landlord or other relevant third party; 

 

	 	(iv)	if reasonably required by a Landlord, any superior landlord or any other relevant third party, the Purchaser shall provide a rent deposit or the Purchaser shall procure
that a surety acceptable to such person guarantees the Purchaser’s obligations under the Lease following the transfer of the relevant Transferred Leased Property; and 

 

	 	(v)	the Purchaser shall be responsible for and undertake to pay, or procure the giving of undertakings to pay the professional and other fees of any Landlord, any superior
landlord or other relevant person (including any Tax or disbursements in respect of such fees but excluding any Tax on the actual net income, profit or gains of the Landlord, any superior landlord or any other relevant person) properly in connection
with any application for Property Third Party Consents, whether or not such Property Third Party Consents are given. 

  

	 	1.3.4	Each Seller shall give written notice to each other Seller as soon as reasonably practicable after obtaining any Property Third Party Consents which shall
be accompanied by a copy of such consent. 

  

	 	1.3.5	Subject to the Purchaser complying with its obligations under paragraphs 1.3.3(iii) to (v) of this Part 4 of this Schedule 2, the Seller in relation
to the Transferred Property in question shall pay, or shall procure that a member of the Seller’s Group pays, any moneys or provide or procure the giving of any guarantees or other security, in each case as may be lawfully required by a
Landlord, superior landlord or other relevant third party in connection with the obtaining of the Property Third Party Consents, provided that the Purchaser shall indemnify and keep indemnified such Seller in an amount equal to:

  

	 	(i)	any moneys required to be paid or procured to be paid by the Seller pursuant to this paragraph; and 

 

	 	(ii)	any Liabilities under any guarantees or other security given or procured by the Seller pursuant to this paragraph and arising out of, or in connection with, an act or
omission on the part of the Purchaser. 

  

	1.4	Licence 

  

	 	1.4.1	In the event that any Property Third Party Consents are not obtained on or before the Closing Date, notwithstanding the terms of the Leases, the Seller
shall procure that the owner of the Transferred Property in question allows the Purchaser to occupy the Licensed Premises for the Licence Period relating to the relevant Licensed Premises on the terms set out in this paragraph 1.4.

  
 116

	 	1.4.2	The Purchaser acknowledges that the grant of each Licence may amount to a breach of the terms of the relevant Lease. 

 

	 	1.4.3	The Licence of each Licensed Premises is granted: 

  

	 	(i)	subject to all of the matters to which the relevant Leases relating to the Transferred Leased Property are subject; 

 

	 	(ii)	subject to the matters referred to in the Registered Title and the Letting Documents; 

 

	 	(iii)	out of whatever right, title and interest that the owner of the Transferred Property has in the Licensed Premises and/or under the relevant Lease;

  

	 	(iv)	in such state of repair and condition as the Licensed Premises may be in as at the date on which the relevant Licence is granted; and 

 

	 	(v)	without making any statement or representation that the owner of the Transferred Property is entitled to grant it. 

 

	 	1.4.4	From Closing and pending Property Transfer Completion, the Purchaser shall pay to the owner of the Transferred Property in question a “Licence
Fee” equivalent to: 

  

	 	(i)	all rents and other charges (including VAT due thereon under the relevant Lease where payable at the date of this Agreement by the relevant owner) payable in respect of
the Licensed Premises; and 

  

	 	(ii)	all outgoings (including VAT due thereon under the relevant Lease) (including, but not limited to, rates, service charges, management charges, levies, air-conditioning
charges, insurance, heating, electricity, gas, telecommunications and other services and the cost of complying with fire and other statutory regulations) payable by the relevant owner in respect of the Licensed Premises or charged upon the owner or
occupier of the Licensed Premises, 

 such payments to be made not less than ten Business Days before any such sum
falls due subject to the Seller in relation to the Transferred Property in question giving the Purchaser not less than ten Business Days’ prior written notice to that effect. To the extent that there has been a prepayment at the Closing Date of
the amounts in paragraphs 1.4.4(i) and (ii) of this Part 4 of Schedule 2 by the owner of the Transferred Property which is not otherwise accounted for in the Closing Statement, the Purchaser shall pay to such owner within ten Business
Days of written demand an amount equal to the amount of such prepayment in respect of any period after the Closing Date. 
  

	 	1.4.5	Throughout the Licence Period, the Purchaser shall, in respect of the Licensed Premises only: 

 

	 	(i)	keep the Licensed Premises in no worse a state of repair than they are in at the Closing Date, fair wear and tear excepted; 

  
 117

	 	(ii)	observe and perform the covenants and conditions on the part of the lessee in the relevant Lease under which the Licensed Premises are held (other than in relation to
the payment of rent and other charges paid as part of the Licence Fee and subject to paragraph 1.4.5(i) of this Part 4 of Schedule 2); and 

  

	 	(iii)	use the Licensed Premises only in accordance with the terms of the Lease of the relevant Licensed Premises and in compliance with the law and regulations where the
relevant Licensed Premises is located (save for any such law or regulation that prohibits the use of the Licensed Premises without a Property Third Party Consent having been obtained). 

 

	 	1.4.6	The Purchaser and each Seller agrees that: 

  

	 	(i)	the Licence is personal to the Purchaser and may only be exercised by the Purchaser and those authorised by it; 

 

	 	(ii)	(subject to paragraph 1.4.5 of this Part 4 of Schedule 2) the Purchaser and all persons authorised by it are permitted to have the unrestricted use and occupation of
the Licensed Premises; and 

  

	 	(iii)	no relationship of landlord and tenant is created as a result of the Licence. 

 

	 	1.4.7	If a Landlord or any other relevant third party commences proceedings, raises any lawful objection or takes any other action in connection with the
Purchaser’s occupation or use of any of the Licensed Premises pending the obtaining of the relevant Property Third Party Consents, the Purchaser and the Sellers shall meet and negotiate in good faith in order to determine which steps should be
taken in respect of the relevant Transferred Property. 

  

	 	1.4.8	Throughout the Licence Period, the Purchaser shall, in respect of the Licensed Premises only, indemnify and keep indemnified the owner of the Transferred
Property in question from and against any Licence Fee, any Losses arising from the Licence and/or as a result of the occupation of the Licensed Premises by the Purchaser. 

 

	 	1.4.9	The Purchaser and the Sellers shall each inform each other forthwith of any notice received by any of them in relation to any of the Licensed Premises from the Landlord
or any other third party. 

  

	1.5	Determination of Licence 

  

	 	1.5.1	The Licence in relation to any one or more of the Licensed Premises shall determine: 

 

	 	(i)	immediately if the Property Longstop Date occurs; 

  

	 	(ii)	 by the Seller in relation to the Transferred Property in question giving at least three months’ prior written notice to the Purchaser if the
Purchaser fails to make the payment of the Licence Fee for a period of one month or is otherwise in material breach of the provisions of the Licence for a 

  
 118

	 	
continuous period of one month following written notification by such Seller to the Purchaser of the same, and in either case the Purchaser has failed to remedy the relevant failure to pay or to
remedy the breach prior to the expiry of the three month notice period or, if the breach is not capable of remedy within such three month period, the Purchaser has failed to commence to remedy the breach within that period and thereafter failed
diligently to continue with such remedy; or 

  

	 	(iii)	if the relevant Landlord in relation to a Transferred Leased Property prosecutes forfeiture proceedings (or the nearest local law equivalent) as a result of
the occupation by the Purchaser of the Licensed Premises then the parties shall either: 

  

	 	(a)	agree that the Licence shall determine on a date to be agreed between the parties (acting reasonably); or 

 

	 	(b)	in the absence of such agreement, either party may require a QC (or equivalent) with no less than 15 years’ post-qualification experience in commercial real estate
in the relevant jurisdiction to be appointed (such appointment to be by agreement between the Sellers or, failing agreement, within 14 days, by the President (as defined in paragraph 1.3.2(ii) of this Part 4 of Schedule 2)). Should the QC determine
that there is more than a 50% chance of the proceedings in question resulting in the Lease in question being forfeited (or equivalent), then the Licence shall determine on a date to be agreed between the Sellers (acting reasonably) in order to
afford the relevant Seller the opportunity to apply for relief from forfeiture or otherwise challenge the proceedings in question on the basis that any breach resulting from the grant of the Licence has been cured, 

provided that this paragraph 1.5.1(iii) shall at all times operate without prejudice to paragraphs 1.4.7, 1.5.1(i) and 1.12. 

 

	 	1.5.2	If, for whatever reason, the Licence Period comes to an end in relation to any of the Licensed Premises then: 

 

	 	(i)	the Licence insofar as it relates to the relevant Licensed Premises shall be severable from the remainder of this Agreement and this Agreement shall otherwise remain in
full force and effect; 

  

	 	(ii)	the Purchaser shall be entitled to a refund in respect of any Licence Fee prior to the termination of the Licence for the Licensed Premises and which relates to the
period following termination of the Licence; 

  

	 	(iii)	it shall not prejudice or affect any claim in respect of any prior breach of this Agreement by the Purchaser in respect of that Licensed Premises; and

  
 119

	 	(iv)	unless the Licence Period comes to an end due to Property Transfer Completion in respect of the relevant Licensed Premises taking place, the Purchaser shall:

  

	 	(a)	vacate the Licensed Premises forthwith; 

  

	 	(b)	remove from the Licensed Premises all items belonging to it; 

  

	 	(c)	leave the Licensed Premises in a clean and tidy condition; and 

  

	 	(d)	at the request of the Seller in relation to the Transferred Property in question, reinstate the Licensed Premises or any part or parts thereof to at least as good a
state of repair or condition as at Closing, fair wear and tear excepted. 

  

	1.6	Closing 

  

	 	1.6.1	The transfer of the Transferred Property shall only take place on Closing to the extent that all necessary Property Third Party Consents in respect of the
relevant transfer have been obtained prior to the Closing Date. 

  

	 	1.6.2	Completion of the transfer of the Transferred Property shall take place at such place (or places) as the parties may agree. 

 

	1.7	Property Transfer Completion 

 Property Transfer Completion in respect of a Transferred Property shall take place on the date falling 15 Business Days following the grant of all relevant Property Third Party Consents for such
Transferred Property or on such other date as the parties shall agree acting reasonably (but not before the Closing Date). 
  

	1.8	General Transfer Provisions 

  

	 	1.8.1	Each Seller shall procure that each member of that Seller’s Group shall transfer the Transferred Property to the Purchaser subject to the terms set out in
this Part 4 of Schedule 2 and all other applicable terms of this Agreement on the Closing Date or (if later) Property Transfer Completion. 

  

	 	1.8.2	The Transferred Property is sold subject to the Letting Documents (if any) but otherwise with vacant possession together with all buildings, structures, fixed
plant, fixed machinery and fixed equipment thereon except as excluded in Clause 2.3.2. 

  

	 	1.8.3	The transfer of each Transferred Property shall contain covenants with the relevant transferor by the Purchaser to comply with the: 

 

	 	(i)	obligations arising from the matters mentioned in the Registered Title; and 

 

	 	(ii)	obligations on the part of the landlord arising under the Letting Documents (if any), 

  
 120

 insofar as the relevant transferor may remain liable directly or indirectly for them after
the Closing Date or Property Transfer Completion (as the case may be) and to indemnify and keep indemnified the relevant transferor against any non-compliance, and a further covenant by the Purchaser to indemnify the relevant transferor against any
liability arising under an authorised guarantee agreement (or equivalent) entered into by the relevant transferor. 
  

	 	1.8.4	The transfer of each Transferred Property shall be on the nearest equivalent terms that exist under local (national) law to a transfer of real property in
England and Wales made with full title guarantee save that where it is a Transferred Leased Property the covenant set out in Section 4(2)(b) of the Law of Property (Miscellaneous Provisions) Act 1994 shall not extend to the imposition on the
transferor of liability for any subsisting breach of obligation relating to the physical state of the Transferred Leased Property. 

  

	 	1.8.5	On the Closing Date or Property Transfer Completion (as the case may be) in respect of each of the Transferred Properties: 

 

	 	(i)	each Seller shall procure that each relevant transferor delivers to the Purchaser a duly executed transfer in respect of the relevant Transferred Property on Property
Agreed Terms; and 

  

	 	(ii)	the Purchaser shall deliver to the Seller a duly executed transfer in respect of the relevant Transferred Property on Property Agreed Terms. 

 

	 	1.8.6	The Purchaser shall procure that all transfers are duly stamped, filed or registered at the relevant registries on a timely basis and within the statutory period
(if any) and the Seller in relation to the Transferred Property in question shall promptly assist the Purchaser with any requisitions or enquiries raised in relation thereto. Any notarial fees and registration, stamp and transfer taxes and duties
(or their equivalents in any jurisdiction) in connection with such transfers shall be borne as provided in Clause 15.8. 

  

	1.9	Subjections 

Notwithstanding anything contained in this Agreement: 
  

	 	1.9.1	Each of the Transferred Properties is transferred subject to and (where appropriate) with the benefit of the following matters (to the extent applicable under
the laws of the relevant jurisdiction): 

  

	 	(i)	any unregistered interest which overrides first registration under Schedule 1 of the Land Registration Act 2002 (the “2002 Act”) and any interest which
fall within Section 11(4)(c) of the 2002 Act and any unregistered interests which override registered dispositions under Schedule 3 of the 2002 Act or their local jurisdiction equivalent (if any); 

 

	 	(ii)	such unregistered interests as may affect that Transferred Property to the extent and for so long as they are preserved by the transitional provisions of Schedule 12 of
the 2002 Act or its local jurisdiction equivalent (if any); 

  
 121

	 	(iii)	all matters contained or referred to in the Letting Documents; 

  

	 	(iv)	all matters contained or referred to in the Property, Proprietorship and Charges registers (or equivalent entries and registers) of the Registered Title relating to
that Transferred Property (except fixed and floating charges securing money or liabilities); 

  

	 	(v)	all exceptions, reservations, rights, easements, quasi-easements, wayleaves, rent charges, covenants, conditions, declarations, leases, tenancies (including statutory
tenancies), licences and agreements affecting the same; 

  

	 	(vi)	(in the case of a leasehold property) the rents, covenants and conditions reserved by or contained in the Lease under which the same is respectively held;

  

	 	(vii)	all local land charges (whether or not registered before the date of this Agreement) and all matters capable of registration as local land charges (whether or not
actually registered) or their local jurisdiction equivalent (if any); 

  

	 	(viii)	all notices served and orders, demands, proposals, or requirements made by any local or other public or competent authority; 

 

	 	(ix)	all actual or proposed orders, directions, plans, notices, instruments, charges, restrictions, conditions, agreements or other matters arising under any statute
relating to town and country planning and any laws and regulations intended to control or regulate the construction, demolition, alteration or change of use of land or buildings or to preserve or protect the environment; and

  

	 	(x)	matters which are fairly disclosed by the Disclosure Letter. 

  

	 	1.9.2	The Purchaser is deemed to acquire with full knowledge of the matters referred to in paragraph 1.9.1 of this Part 4 of Schedule 2. 

 

	 	1.9.3	Each Seller shall procure that any and all financial charges affecting the Transferred Properties will be discharged on or before the date on which such Transferred
Property is to be transferred to the Purchaser, and shall provide to the Purchaser and the other Seller such evidence as the Purchaser or the other Seller may reasonably require in order to satisfy itself that such discharge has been effected and to
remove any notices or entries in respect of such charges from any relevant register. 

  

	 	1.9.4	The Sellers do not give any warranty as to the use or area of any of the Transferred Properties and shall not be required to define the boundaries of any of the
Transferred Properties. The transfer of the Transferred Properties shall not be annulled, nor shall any compensation be allowed or payable, in respect of any error in respect of any such matters. 

  
 122

	 	1.9.5	On the date on which the transfer of each Transferred Property is completed, the Seller in relation to the Transferred Property in question shall deliver to the
Purchaser (or such other third party as the Purchaser may reasonably direct) all of the original documents in the possession of the Seller or the transferor of the Transferred Property in question in respect of each of the Transferred Properties.

  

	 	1.9.6	The Purchaser shall not raise any requisition on matters arising after the date of this Agreement, except where the subject matter of the requisition is
registered at the Land Registry (or equivalent local registry) after the date of this Agreement and does not relate to any matter referred to in paragraph 1.9.1 of this Part 4 of Schedule 2. 

 

	 	1.9.7	To the extent that deposit guarantees have been given by a Seller or any member of a Seller’s Group in respect of any Transferred Property and/or insofar as
a Seller or any member of a Seller’s Group retains any residual or ongoing liabilities or obligations including performance guarantees in connection with the Transferred Property, the Purchaser shall use all reasonable endeavours to procure
that the Seller or the relevant member of the Seller’s Group is released from all deposit guarantees and all other residual or ongoing liabilities or obligations and, insofar as the counterparties thereto shall properly and lawfully refuse to
give any such release, the Purchaser shall indemnify and keep indemnified that Seller (or the member of that Seller’s Group) in an amount equal to any Liabilities under any such residual or ongoing liabilities or obligations arising out of, or
in connection with, an act or omission on the part of the Purchaser. 

  

	1.10	Insurance 

 The Sellers
shall procure that any existing insurance (if any) on the Transferred Properties shall be maintained and that any such insurance will be cancelled with effect from the Closing Date or, if later, the date of Property Transfer Completion (as the case
may be) unless agreed otherwise with the Purchaser. 
  

	1.11	Grant of Sublease 

 If a
Seller is unable to obtain a Property Third Party Consent from a Landlord for the transfer of a Transferred Leased Property the provisions of this paragraph 1.11 of Part 4 of Schedule 2 shall apply: 

 

	 	1.11.1	where a Lease permits a sublease to be granted without the requirement for any Property Third Party Consent from the Landlord, the Seller shall procure that the owner
of the Transferred Property in question shall grant to the Purchaser a sublease of the Transferred Leased Property on the same rent and other terms and conditions as the Lease of the Transferred Leased Property with such changes as are appropriate
and agreed between the Seller in relation to the Transferred Leased Property in question and the Purchaser acting reasonably and the term of the sublease shall be the term of such Lease less one day; and 

  
 123

	 	1.11.2	where the Transferred Leased Property is held from a Landlord on terms which require the consent of the Landlord to: 

 

	 	(i)	the grant of a sublease; or 

  

	 	(ii)	the terms on which a sublease is granted, 

 the Seller in relation to the Transferred Leased Property in question shall use all reasonable endeavours to obtain such consent (“Sublease Consent”) from such Landlord. Where the Seller
is able to obtain the appropriate Sublease Consent (or, where applicable, the court of competent jurisdiction referred to in paragraph 1.12.1 of this Part 4 of Schedule 2 declares that the Sublease Consent has been unreasonably withheld or delayed),
the Seller shall procure that the owner of the Transferred Property in question shall grant to the Purchaser a sublease of the Transferred Leased Property on the same rent and other terms and conditions as the Lease of the Transferred Leased
Property with such changes as are appropriate and agreed between the Seller and the Purchaser acting reasonably and the term of the sublease shall be the term of such Lease less one day. 

 

	1.12	Property Third Party Consent not Obtained 

  

	 	1.12.1	If a Property Third Party Consent (and, where applicable, a Sublease Consent) has been refused or otherwise not obtained within 12 months following the Closing Date,
the Sellers may (acting reasonably) agree that an application is to be made to a court of competent jurisdiction that the relevant Property Third Party Consent has been unreasonably withheld or delayed. 

 

	 	1.12.2	If an application is to be made to a court of competent jurisdiction pursuant to paragraph 1.12.1 of this Part 4 of Schedule 2: 

 

	 	(i)	the proceedings shall be brought by, and prosecuted by the relevant Seller; 

 

	 	(ii)	the Purchaser and the other Seller shall provide all such assistance in connection with such proceedings as the relevant Seller (acting reasonably) may require in the
interests of obtaining the Property Third Party Consent; and 

  

	 	(iii)	provided that the Seller has complied with its obligations under paragraphs 1.3.3(i) and 1.11.2 of this Part 4 of this Schedule 2, the Purchaser shall indemnify and
keep indemnified the Sellers for any costs and expenses properly incurred in connection with any such assistance provided by them and in bringing and prosecuting proceedings under this paragraph. 

 

	 	1.12.3	If a Property Third Party Consent has not been obtained by the Property Longstop Date then the relevant Seller in relation to the Transferred Property in question shall
indemnify and keep indemnified the Purchaser against all Losses arising out of or in connection with the failure to obtain such Property Third Party Consent. 

  
 124

 Part 5 
 Site Separation 
  

	1.1	Interpretation 

 The
following further definition applies in this Part 5 of Schedule 2: 
 “Separation Properties” means any Property
or part of a Property which, as at the date of this Agreement, forms part of a wider building or site that is used by both the Target Group and a Seller’s retained business. 

 

	1.2	Separation 

  

	 	1.2.1	As soon as reasonably practicable following the date of this Agreement, and in any event prior to Closing, the Sellers and the Purchaser will agree the form of
transfers, leases, facilities services arrangements or other agreements (the “Separation Documents”) to reflect the arrangements described in this Part 5 of Schedule 2. 

 

	 	1.2.2	Without prejudice to the principles as to the preservation of arrangements existing at the date of this Agreement set out in the remainder of this paragraph, all
Separation Documents are to be negotiated between the parties in good faith, on an arm’s length basis and on reasonable commercial terms. 

  

	 	1.2.3	The Separation Documents will enable the owner of the Separation Property and the relevant Seller’s retained business to continue to use the Property and the
adjoining or neighbouring property of that Seller’s retained business respectively in the same manner (including as to terms of use/occupation and costs) as they are used at the date of this Agreement and will incorporate such other provisions
(including as to site security or physical site separation) as the Sellers may agree are fair and reasonable in all the circumstances. 

  

	 	1.2.4	Each Separation Document will grant and reserve rights to continue to use all roads, access ways and conduits used and enjoyed by the relevant Separation Property (or
the adjoining or neighbouring property of the relevant Seller’s retained business, as the case may be) at the date of this Agreement on terms reflecting as closely as possible their use at the date of this Agreement. 

 

	 	1.2.5	Each Separation Document is to be in a form appropriate to the jurisdiction in which the relevant Separation Property is situated and will comply with all formalities
and other requirements in the relevant jurisdiction. 

  

	 	1.2.6	The Separation Documents which are underleases will follow the form of the relevant headlease (other than in respect of the amount of rent and the length of term)
insofar as is reasonably appropriate. 

  

	 	1.2.7	 In the event of any disagreement under or in respect of this paragraph 1.2, the matter may be referred by either Seller to the person (or persons)
within each Seller with ultimate responsibility 

  
 125

	 	
(on a national level) for property matters within the jurisdiction in question, and in the event that the matter is not resolved by agreement between the parties within three months, may be
referred by either party to an independent lawyer in the relevant jurisdiction, being a partner in a reputable law firm with not less than ten years’ post-qualification experience in dealing with commercial property transactions (the
“Independent Lawyer”). In the absence of agreement between the Sellers, the Independent Lawyer is to be appointed by the President of the Law Society (or other body responsible for regulation of the legal profession in the relevant
jurisdiction) on the application of either party. 

  

	 	1.2.8	The Independent Lawyer will act as an expert and not as an arbitrator and his decision will be binding on the parties. 

 

	 	1.2.9	The Independent Lawyer may obtain any additional professional advice in order to reach a decision as he may deem necessary or desirable. 

 

	 	1.2.10	The cost of the determination by the Independent Lawyer will be met by the Sellers in equal shares. 

 

	1.3	Preservation of Rights 

  

	 	1.3.1	If following Closing the Purchaser or either Seller shall be of the view that a Separation Document omits the grant or reservation of any rights (including any rights
of access, rights to use facilities and/or rights in respect of any item of apparatus or equipment) which is required for the purposes of the business carried out at a Separation Property or the adjoining or neighbouring property of the relevant
Seller’s retained business (each such right being an “Omitted Right or Easement”), it shall give the notice referred to in paragraph 1.3.2 and the Sellers (acting reasonably and in the utmost good faith) will meet and attempt
to reach agreement with regard to any amendments needed to the relevant Separation Document, or any additional document or documents that are necessary. 

  

	 	1.3.2	If any party identifies any Omitted Rights or Easements, that party shall give written notice thereof to the other parties as soon as reasonably practicable and in any
event within two years of the Closing Date (time to be of the essence). 

  

	 	1.3.3	Any dispute or difference as to Omitted Rights or Easements shall be resolved in the manner set out in paragraph 1.2.7, and as soon as practicable following agreement
or determination as to any Omitted Rights or Easements (and in any case within two months of such agreement or determination) the Purchaser and the Sellers will procure to be executed any deeds or other documents required in order to give effect to
the agreed or determined position. 

  

	2	General 

  
 126

	2.1	The Purchaser and each of the Sellers acknowledge and undertake to each other that: 

 

	 	2.1.1	notwithstanding that certain of the arrangements provided for or envisaged by this Part 5 of Schedule 2 (including the reference to the grant or reservation of rights
in paragraph 1.3.1) may not be capable of being directly or appropriately applied in jurisdictions other than England and Wales (“Other Jurisdictions”) under the laws, established law practices and procedures of those jurisdictions,
the commercial principles underlying the provisions and intentions of this Part 5 of Schedule 2 shall be applied as closely as possible in the Other Jurisdictions to produce as nearly as possible the same commercial results (taking into account any
Applicable Laws) as would be achieved in England and Wales on the application of those arrangements; 

  

	 	2.1.2	to the extent necessary in order to achieve in Other Jurisdictions the commercial results intended by this Schedule, Clause 15.1 will apply; and

  

	 	2.1.3	to the extent required to give effect to these provisions each party agrees to ensure that any relevant local registration, filing or other requirement is complied with
as soon as practicable, and in any event within the requisite time period for such registration, filing or other requirement to be submitted, carried out or otherwise completed (as the case may be). 

  
 127

 Schedule 3 
 Excluded Assets 
 Part 1 

GlaxoSmithKline Excluded Assets 
  

	1	The GlaxoSmithKline Excluded Businesses and the shares in the companies mentioned in the definition of GlaxoSmithKline Excluded Businesses. 

 

	2	Any shares in, and assets of, Horlicks Limited, a private limited company incorporated in the UK, and its successors and assigns and any person Controlled by Horlicks
Limited from time to time, including any rights which relate to the Horlicks product in India, Nepal and/or Bhutan. 

  

	3	The shares that any member of GlaxoSmithKline’s Group holds in Aspen Pharmacare Holdings Limited. 

Part 2 

Novartis Excluded Assets 
  

	1	The Novartis Excluded Businesses. 

  

	2	The land and buildings of Novartis’s Seller’s Group at: 

  

	 	(i)	Plot Number (Parzelle) 329, Route de L’Etraz No 6, Switzerland; 

 

	 	(ii)	Plot Number (Parzelle) 330, Chemin du Coutelet No10, Switzerland; 

  

	 	(iii)	Plot Number (Parzelle) 331, Route de L’Etraz No 8, Switzerland; 

 

	 	(iv)	Plot Number (Parzelle) 332, Le Coutelet, Switzerland; and 

  

	 	(v)	Plot Number (Parzelle) 333, Le Coutelet Sur la CroixRoute de L’Etraz No 6, Switzerland. 

 

	3	The Endo Excluded Contract. 

  
 128

 Schedule 4 
 Product Approvals etc. 
 Part 1 

Terms Relating to the Product Approvals and Product Applications 

 

	1	General Provisions 

  

	1.1	The Purchaser shall do all things necessary to effect the transfer of each Product Approval and Product Application, including complying with requirements and
requests of Governmental Entities with respect to the transfer of each Product Approval and Product Application. 

  

	1.2	The Marketing Authorisations shall be transferred in accordance with Part 2 of this Schedule 4. 

 

	2	Product Applications 

  

	2.1	The Purchaser shall file or cause to be filed applications for the transfer of each Product Application in each country or territory in which such transfer is
required to be submitted as soon as possible after the Closing Date. 

  

	2.2	Pending the transfer of each Product Application each Seller shall, and shall cause the relevant members of its Group to: 

 

	 	2.2.1	upon reasonable request from the Purchaser and at the Purchaser’s expense, reasonably cooperate and coordinate with the Purchaser in relation to the
transfer of the Product Applications, including by providing the Purchaser with regulatory documentation concerning the Products owned or controlled by that Seller or any of its Affiliates; 

 

	 	2.2.2	perform such acts and services as may be requested by the Purchaser that are reasonably necessary or required by any Governmental Entity to maintain or renew any
Product Application or are reasonably necessary for the Purchaser to pursue the regulatory approval for any Product Application, including conducting any studies, including clinical and stability studies, concerning the Products; and

  

	 	2.2.3	notify the Purchaser as soon as is reasonably practicable of any written communication received by such Seller or any member of its Group with respect to any
Product Application and shall consult with the Purchaser with respect to such communication and take into account the Purchaser’s views as to the form and content of any communication with any Governmental Entity concerning such Product
Application. 

  

	3	Fees and Expenses 

 From
and after the Closing Date, the Purchaser shall promptly reimburse the relevant members of each Seller’s Group for all maintenance and renewal fees and similar fees paid, and all out of pocket expenses reasonably incurred in connection with the
satisfaction of any commitments or obligations by such members of such Seller’s Group with respect to each Product Approval and each Product Application. 

  
 129

	4	Notification 

 As soon as
a Seller or the Purchaser or any of their respective Affiliates receives notification, if any, of impending approval or approval of the transfer of a Product Application from a Governmental Entity, the notified party or the party whose Affiliate was
notified shall inform the other parties of the expected date of appointment or transfer and actual date of appointment or transfer of that Product Application. 
  

	5	Responsibility for Transfer 

 Notwithstanding any other provision of this Agreement, no Seller nor any of its Affiliates shall have any Liability to the Purchaser in the event that the transfer of any Product Application alone results
in any further obligations, commitments or Liabilities in relation to such Product Application. 
 Part 2 

Marketing Authorisations Transfer Provisions 
  

	1	Transfer of Marketing Authorisations 

 Marketing Authorisation Transfer and Marketing Authorisation Re-Registration 
  

	1.1	Each Seller and the Purchaser hereby agree they will each use, and will procure that their respective Affiliates will use, all reasonable endeavours to ensure that, as
soon as reasonably practicable after the Closing Date: 

  

	 	(i)	subject to paragraph 1.1(ii), each Marketing Authorisation shall be transferred in accordance with Applicable Law by the Marketing Authorisation Holder to the Marketing
Authorisation Transferee (“Marketing Authorisation Transfer”); and 

  

	 	(ii)	where Applicable Law does not permit Marketing Authorisation Transfer, a new marketing authorisation shall be registered in the name of the Marketing Authorisation
Transferee to replace the existing Marketing Authorisation (“Marketing Authorisation Re-Registration”) and such Seller shall procure that the relevant Marketing Authorisation Holder takes all necessary steps to withdraw, abandon,
cancel or allow to lapse the superseded Marketing Authorisation as soon as practicable after the Marketing Authorisation Re-Registration Date. 

  

	1.2	Any Marketing Authorisation Transfer or Marketing Authorisation Re-Registration (as applicable) shall each be effected on a Market-by-Market basis (such that there
shall not be any staggered Marketing Authorisation Transfer or Marketing Authorisation Re-Registration (as the case may be) on a Product-by-Product basis in any Market), unless otherwise agreed between the relevant Seller and the Purchaser.

  

	1.3	With effect from the Closing Date until the Marketing Authorisation Transfer Date or the Marketing Authorisation Re-Registration Date (as applicable), each Seller shall
procure that each Marketing Authorisation Holder shall hold the Marketing Authorisation(s) in its name but for the account, risk and benefit of the relevant Marketing Authorisation Transferee. 

  
 130

 Submission of MA Documentation 

 

	1.4	Without prejudice to paragraph 1.5 below, the Purchaser shall be responsible for preparing and submitting, or for procuring that there is prepared and submitted (in any
such case at the Purchaser’s cost and expense), all notices, applications, submissions, reports and any other instruments, documents, correspondence or filings necessary to complete Marketing Authorisation Transfer or Marketing Authorisation
Re-Registration (as applicable) (the “MA Documentation”). The MA Documentation shall be prepared in accordance with Applicable Law as soon as reasonably practicable. 

 

	1.5	At a Seller’s election, the Purchaser shall procure that advanced drafts of the MA Documentation are submitted to that Seller so as to allow that Seller and/or the
Marketing Authorisation Holder a reasonable opportunity to provide comments on such MA Documentation before it is submitted to the relevant Governmental Entity. The Purchaser shall incorporate all comments on such drafts as may reasonably be made by
that Seller and/or the Marketing Authorisation Holder PROVIDED THAT the Purchaser shall not be obliged to incorporate any comments if the Purchaser considers, acting reasonably that to do so would materially delay Marketing Authorisation Transfer or
Marketing Authorisation Re-Registration (as applicable). 

  

	1.6	Where under Applicable Law the MA Documentation is required to be submitted to the relevant Governmental Entity: 

 

	 	(i)	by the Marketing Authorisation Holder, the Purchaser shall procure that the finalised MA Documentation is provided to the relevant Seller after such MA Documentation is
finalised in accordance with paragraph 1.5 above and that Seller shall, in turn, procure that the Marketing Authorisation Holder submits such MA Documentation to the relevant Governmental Entity (the timing and date of such submission to be agreed
with the Purchaser) and that Seller shall promptly thereafter advise the Purchaser of such submission and provide a copy of the relevant MA Documentation (in the form submitted) to the Purchaser; and 

 

	 	(ii)	by the Marketing Authorisation Transferee, the Purchaser shall procure that the relevant Marketing Authorisation Transferee submits the finalised MA Documentation to
the relevant Governmental Entity as soon as reasonably after such MA Documentation is finalised in accordance with paragraph 1.5 above and the Purchaser shall promptly thereafter advise the relevant Seller of such submission and provide a copy of
the relevant MA Documentation (in the form submitted) to that Seller. 

  

	1.7	From the Closing Date, each Seller shall procure that the relevant Marketing Authorisation Holder shall, as soon as reasonably practicable, sign any notices,
applications, submissions, reports and other instruments, documents, correspondence or filings presented to it by the Purchaser or the relevant Marketing Authorisation Transferee that are necessary to effect Marketing Authorisation Transfer or
Marketing Authorisation Re-Registration (as applicable). The Marketing Authorisation Holder shall: 

  

	 	(i)	provide notice of its consent to a Marketing Authorisation Transfer or Marketing Authorisation Re-Registration if required by any Governmental Entity; and

  

	 	(ii)	provide to the Purchaser or the relevant Marketing Authorisation Transferee any information or other data or technical or other information in its possession that
relates to the relevant Marketing Authorisation and that is required by a relevant Governmental Entity or otherwise reasonably required by the Purchaser or the relevant Marketing Authorisation Transferee to assist the Purchaser or the relevant
Marketing Authorisation Transferee to effect the relevant Marketing Authorisation Transfer or Marketing Authorisation Re-Registration; and 

  
 131

	 	(iii)	in the event of any request for information or any query from any relevant Governmental Entity in respect of Marketing Authorisation Transfer or the Marketing
Authorisation Re-Registration (as applicable), the relevant party receiving such request or query shall provide copies of any such request or query to that Seller or, as the case may be, to the Purchaser. The Purchaser shall be responsible for
preparing, or shall be responsible for procuring that there is prepared, (at the Purchaser’s cost and expense) any response to such a request or query with the intention that such request or query shall be dealt with as promptly and efficiently
as possible. In advance of finalising any such response, the Purchaser shall procure that the relevant response is submitted to the that Seller so as to allow that Seller and/or the relevant Marketing Authorisation Holder a reasonable opportunity to
provide comments on such response before it is submitted to the Governmental Entity. The Purchaser shall procure that relevant Marketing Authorisation Transferee (i) shall submit the response to the relevant Governmental Entity as soon as
reasonably practicable after the same has been finalised in accordance with this paragraph 1.7(C) and (ii) shall provide a copy of the relevant response (in the form submitted) to such Seller. 

 

	2	Obligations pending Marketing Authorisation Transfer or Marketing Authorisation Re-Registration 

 

	2.1	Unless otherwise required by Applicable Law or a relevant Governmental Entity (or unless otherwise agreed in writing by a Seller and the Purchaser), from the Closing
Date until the applicable Marketing Authorisation Transfer Date or Marketing Authorisation Re-Registration Date: 

  

	 	(i)	each Seller shall: 

  

	 	(A)	maintain in force (or procure that there is maintained in force) each Marketing Authorisation, and shall not voluntarily amend, cancel or surrender any Marketing
Authorisation unless requested to do so in writing by the Purchaser or required to do so by any Applicable Law or any Governmental Entity; 

  

	 	(B)	with the Purchaser’s consent (not to be unreasonably withheld or delayed) progress (or procure that there is progressed) any registrations, variations or renewals
to Marketing Authorisations initiated by such Seller (or any other member of such Seller’s Group) prior to the Closing Date or withdraw them upon the request of the Purchaser; 

 

	 	(C)	procure that each Marketing Authorisation Holder shall comply with the terms of any Marketing Authorisation and shall notify the Purchaser as soon as reasonably
practicable of the details of any variations or renewals initiated following the Closing Date; 

  

	 	(D)	inform the Purchaser of any impending renewals of Marketing Authorisations as at the Closing Date and the parties shall discuss in good faith to what extent any such
renewal will be pursued or withdrawn (it being agreed that the Purchaser shall have the final decision in any such matter); 

  
 132

	 	(E)	not without the consent of the Purchaser, initiate any additional variations or amendments to the Marketing Authorisations, except to the extent required by any
Governmental Entity or where failure to do so would breach Applicable Law; and 

  

	 	(F)	consider in good faith any request by the Purchaser to apply for a new marketing authorisation in respect of a Product PROVIDED THAT if such Seller agrees to submit
such application, any costs or expenses incurred by such Seller in making such application shall be for the Purchaser’s account and shall constitute MA Costs; 

 

	 	(ii)	without prejudice to the generality of the foregoing paragraph 2.1(i)(c), the Purchaser acknowledges and agrees that each Marketing Authorisation Holder shall be
entitled to do (or to procure that there is done) any or all of the following (and the Purchaser acknowledges that, where the relevant Marketing Authorisation Holder so chooses and unless otherwise agreed, responsibility for each of the following
activities shall rest with the relevant Marketing Authorisation Holder): 

  

	 	(A)	pharmacovigilance activities related to the Marketing Authorisations, which activities shall be conducted in accordance with the Applicable Laws, the Pharmacovigilance
Agreement, and the standards, policies and procedures of the relevant Seller’s Group from time to time in force; and 

  

	 	(B)	conducting any and all communications with a Governmental Entity in respect of a Marketing Authorisation (including, without limitation to the generality of the
foregoing, attending any meetings with relevant Governmental Entities and filing and submitting all reports and other documents which it reasonably considers necessary to be submitted in order to comply with Applicable Law or its obligations under
this Agreement), PROVIDED THAT responsibility for (a) the costs of preparation of any such documents, reports and/or filings shall be borne by the Purchaser (or the relevant Marketing Authorisation Transferee) to the extent such costs are
reasonably necessary, and (b) the submission of MA Documentation shall be the responsibility of the Purchaser in accordance with paragraph 1.4 above, PROVIDED THAT the Seller shall ensure that the Purchaser is kept fully and promptly informed
of any such communications or submissions in advance, to the extent reasonably practicable; 

  

	 	(iii)	each Seller shall procure that each Marketing Authorisation Holder shall act in accordance with the reasonable instructions of the Purchaser or the Marketing
Authorisation Transferee in respect of each Marketing Authorisation in respect of which such Marketing Authorisation Holder is the holder, PROVIDED THAT no Marketing Authorisation Holder shall be obliged to comply with such instructions to the
extent the same: (i) infringe the terms of the relevant Marketing Authorisation(s); or (iii) are otherwise inconsistent with the provisions of the Pharmacovigilance Agreement relating to that Seller; 

  
 133

	 	(iv)	the Purchaser shall only request artwork changes to the extent such changes are required in order to comply with Applicable Law; 

 

	 	(v)	the Purchaser shall submit to the relevant Seller (or shall procure that there is submitted) written details (in such form and with such supporting materials as such
Seller may reasonably request) of any new, amended or proposed advertising and promotional activity or training materials in respect of any Product Commercialised pursuant to any Marketing Authorisation (including (without limitation) any material
reasonably requested by such Seller in order to validate new and/or amended promotional or training materials), and the Purchaser acknowledges and agrees that no such advertising, promotional or training activity shall be implemented, undertaken or
otherwise commenced without the prior written consent of that Seller (for itself and on behalf of the relevant Marketing Authorisation Holder), such consent not to be unreasonably withheld. The Purchaser further agrees and acknowledges that, if it
so chooses, the Seller shall be entitled to assume responsibility for obtaining (or procuring that there is obtained) the consent(s) and approval(s) of any relevant Governmental Entity required for such new, amended or proposed advertising and
promotional activity or training activity; and 

  

	 	(vi)	to the extent permitted by the terms of the relevant Marketing Authorisation, the Purchaser or any other member of the Purchaser’s Group shall Commercialise the
Product(s) which are the subject of such Marketing Authorisation (notwithstanding that such Marketing Authorisation is held in the name of the relevant Marketing Authorisation Holder and, for the avoidance of doubt, the proceeds of any such
Commercialisation shall be for the benefit of the Purchaser’s Group) and the Purchaser shall: 

  

	 	(A)	indemnify each member of the Seller’s Group against any and all actions, claims, demands, investigations, judgments, proceedings, liabilities, loss, damages,
payments, costs and expenses arising in relation to the Commercialisation of the Product(s) by the Purchaser or any other member of the Purchaser’s Group under this paragraph 2.1(vi); and 

 

	 	(B)	procure that such Product(s) are Commercialised in compliance with the terms of the relevant Marketing Authorisation and/or the requirements of the relevant
Governmental Entity. 

  

	3	New and Pending Marketing Authorisations in Respect of the Products 

 

	3.1	If, at any time prior to Closing, any member of any Seller’s Group is granted or otherwise comes to hold any marketing authorisation which relates exclusively to
one or more Products (a “New Marketing Authorisation”) then: 

  

	 	(i)	that Seller undertakes to the Purchaser to notify the Purchaser as soon as reasonably practicable following the date on which the relevant member of that Seller’s
Group is granted, or becomes entitled to, the New Marketing Authorisation; and 

  

	 	(ii)	the provisions of paragraphs 1 and 2 above shall apply to that new Marketing Authorisation. 

 

	3.2	Where a member of a Seller’s Group has submitted to any Governmental Entity any application relating to the grant of a new marketing authorisation in respect of
its Contributed Business which is pending or in process as at the date of this Agreement (a “Pending Marketing Authorisation”): 

  
 134

	 	(i)	that Seller shall continue to be responsible for preparation and submission of all documents required to register such Pending Marketing Authorisation but, following
Closing, it shall do so at the Purchaser’s cost and shall pass responsibility for such Pending Marketing Authorisation to the Purchaser (or such member of the Purchaser’s Group as the Purchaser may nominate) as soon reasonably possible
after Closing, subject to Applicable Law; and 

  

	 	(ii)	from the Closing Date, the provisions of paragraph 1 shall apply mutatis mutandis to any registration process for any Pending Marketing Approval.

  

	4	MA Costs 

 From the
Closing Date, the Purchaser shall be responsible for all necessary costs of preparation and submission of MA Documentation and, save as expressly provided in this Agreement, any other necessary costs incurred by any Seller or a member of such
Seller’s Group in connection with the maintenance and any variations, amendments and renewals of the Marketing Authorisations relating to the Products or for any matter requested by the Purchaser pursuant to this Part 2 of Schedule 4 and for
all fees and costs reasonably incurred by the relevant member of the Seller’s Group in complying with its obligations in respect of a Marketing Authorisation Transfer or Marketing Authorisation Re-Registration (“MA Costs”).

  

	5	Obligations Following Marketing Authorisation Transfer or Marketing Authorisation Re-Registration 

 

	5.1	On and from the relevant Marketing Authorisation Transfer Date or Marketing Authorisation Re-Registration Date (as applicable), the Purchaser shall procure that
each Marketing Authorisation Transferee shall assume and be solely responsible for: 

  

	 	(i)	all obligations as the holder of such Marketing Authorisation including (subject to the terms of the Pharmacovigilance Agreement) pharmacovigilance activities related
to such Marketing Authorisation; 

  

	 	(ii)	all activities and actions required by Applicable Law in connection with such Marketing Authorisation; and 

 

	 	(iii)	any and all outstanding commitments and obligations to the relevant Governmental Entities with respect to the relevant Marketing Authorisation, save for any such
commitments or obligations arising from a breach of this Agreement by the relevant Seller. 

  

	5.2	In the event that, following Marketing Authorisation Transfer or Marketing Authorisation Re-Registration in respect of any Product, any Seller wishes to apply for a
Marketing Authorisation in respect of a retained product, the Purchaser shall (and shall procure that the relevant Marketing Authorisation Transferee shall) co-operate with and provide all reasonable assistance to that Seller (or the relevant member
of the Seller’s Group) at that Seller’s costs as may be reasonably required for the purposes of applying for such New Marketing Authorisation, including (without limitation) providing that Seller (or the relevant member of the
Seller’s Group) and/or any Governmental Entity with such access to Marketing Authorisation Data or such other data or technical or other information as is reasonably requested by the relevant Governmental Entity or is otherwise reasonably
required by that Seller or the relevant member of that Seller’s Group. 

 Part 3 

Tenders 

  
 135

	1.1	From the Closing Date until the Marketing Authorisation Transfer Date in any Market, each Seller shall, and shall procure that each member of the Seller’s Group
and the relevant Marketing Authorisation Holder shall, to the extent permitted by Applicable Law: 

  

	 	1.1.1	inform the Purchaser in writing of any Call for New Tender as soon as reasonably practicable following receipt; 

 

	 	1.1.2	co-operate with and provide reasonable assistance to the Purchaser (or the relevant member of the Purchaser’s Group) for the purposes of responding to the Call for
New Tender or otherwise applying for a new tender; and 

  

	 	1.1.3	where Applicable Law requires such responses or applications to be made by the Marketing Authorisation Holder, the relevant Seller shall procure that the Marketing
Authorisation Holder submits such responses or applications on behalf of the Purchaser PROVIDED THAT the Purchaser shall indemnify the relevant Seller and/or the relevant Marketing Authorisation Holder (as the case may be) for any and all costs,
expenses and liabilities suffered or reasonably incurred by the relevant Seller and/or the Marketing Authorisation Holder in complying with or as a result of the provisions of this paragraph. 

  
 136

 Schedule 5 
 Certificate 
 To: Leo Constellation Limited (the “Purchaser”) 

[Date] 
 Certificate 

This Certificate is issued in accordance with Clause 4.4.1(iii)(b) and paragraph 1.1.4 of Schedule 11 of the sale and purchase agreement between
GlaxoSmithKline Plc, Novartis AG and the Purchaser dated 22 April 2014 (the “Agreement”). Unless otherwise defined, capitalised words used in this Certificate shall have the meanings given to them in the Agreement. 

We confirm that: 
 1. no Material Adverse
Effect has occurred in relation to us between the date of the Agreement and the date of this Certificate; 
 2. having made due and careful
enquiry, we are not aware of any breach or breaches of Clause 9.1 which alone or together give rise to a Material Adverse Effect having occurred in relation to us; and 
 [either] 
 3. having made due and careful enquiry, we are not aware of any breach or
breaches of the Seller’s Warranties that would have occurred and that would, alone or together, have given rise to a Material Adverse Effect in relation to us had the Seller’s Warranties been repeated immediately before Closing by
reference to the facts, circumstances and knowledge then existing as if references in the Seller’s Warranties to the date of this Agreement were references to the Closing Date. 
 [or] 
 3. having made due and careful enquiry, we are aware of the following material
breaches of the Seller’s Warranties that would, alone or together, be material and have occurred had the Seller’s Warranties been repeated immediately before Closing by reference to the facts, circumstances and knowledge then existing as
if references in the Seller’s Warranties to the date of this Agreement were references to the Closing Date. 
 [description of material
breaches.] 

  
 137

	
	  

	
	Director
	For an on behalf of [Novartis AG][GlaxoSmithKline Plc]

  
 138

 Schedule 6 
 Transferred Contracts and Certain Other Business 
  

	1	Separation of Shared Business Contracts 

  

	1.1	Prior to Closing, each Seller and the Purchaser shall discuss and agree in good faith a process to identify all material Shared Business Contracts.

  

	1.2	Each Seller shall use all reasonable efforts to maintain relationships under its Shared Business Contracts and continue to operate the Shared Business Contracts,
including without limitation fulfilling all its obligations under its Shared Business Contracts, in the same manner as it has for the 12 months prior to this Agreement. 

 

	1.3	The Purchaser may, by notice to the relevant Seller at any time prior to the Marketing Authorisation Transfer Date, elect to take the rights and obligations of the
Relevant Part of any Shared Business Contract. 

  

	1.4	If the Purchaser makes an election under paragraph 1.3 above, the relevant Seller and the Purchaser shall use all reasonable endeavours to procure that an arrangement
is entered into with the relevant counterparty to each Shared Business Contract, the effect of which shall be that, with effect from whichever is the later of Marketing Authorisation Transfer Date and the date of the relevant arrangement, the
benefit and burden of the Relevant Part is severed from such Shared Business Contract and an agreement or arrangement equivalent to such Shared Business Contract is entered into between the relevant counterparty and a member of the Purchaser’s
Group (or the Relevant Part of the Shared Business Contract is sub-licensed to such Purchaser) (a “Separation”). For the avoidance of doubt, no part of any such Shared Business Contract shall be severed and transferred to the
Purchaser in so far as it relates to the Seller’s Retained Business, any product other than the products to the extent included in the relevant Seller’s Contributed Business (including the Products) or any Excluded Asset.

  

	1.5	In addition, in relation to a Separation of a Shared Business Contract the Relevant Part of which contains any material non-compete provisions that, without
obtaining a Third Party Consent, are reasonably likely to be breached on Closing as a result of the Target Groups both being transferred to the Purchaser’s Group, the parties shall each use reasonable endeavours to procure that any arrangement
entered into with the relevant counterparty in respect of such Separation does not contain such material non-compete provisions or, if it does, that such material non-compete provisions are waived by the relevant counterparty.

  

	2	Obligation to Obtain Third Party Consents 

  

	2.1	In relation to any: 

  

	 	2.1.1	Transferred Contract or Transferred Intellectual Property Contract (excluding, for the purposes of this Schedule 6, any Product Approval or Product Application) or
Co-Owned Target Group Intellectual Property Right which is not assignable without a Third Party Consent, or a Separation of a Shared Business Contract which is not separable without a Third Party Consent; or 

  
 139

	 	2.1.2	Transferred Contract or Transferred Intellectual Property Contract (excluding, for the purposes of this Schedule 6 any Product Approval or Product Application) which
contains any material non-compete or change of control provisions that, without obtaining a Third Party Consent, are reasonably likely to be breached or triggered (as relevant) on Closing as a result of the Target Groups both being transferred or
the relevant Target Group being transferred (as relevant) to the Purchaser (and/or any member of the Purchaser’s Group) 

 this Agreement shall not be construed as an assignment or an attempted assignment, a sub-licensing or an attempted sub-licensing, and the relevant Seller and the Purchaser shall each use reasonable
endeavours both before and after Closing to obtain all necessary Third Party Consents as soon as possible and shall keep each other informed of progress in obtaining such Third Party Consents. The relevant Seller shall deliver to the Purchaser, on
Closing or, if later, as soon as possible after receipt, any Third Party Consent. 
  

	2.2	In addition, in relation to any Contract (excluding, for the purposes of this Schedule 6, any Product Approval or Product Application) which is transferred to the
Purchaser’s Group as part of the Target Group Companies and which contains any non-compete or change of control provisions that, without obtaining a Third Party Consent, are reasonably likely to be breached or triggered (as relevant) on Closing
as a result of the Target Groups both being transferred or the relevant Target Group being transferred (as relevant) to the Purchaser (and/or any other member of the Purchaser’s Group), the parties shall each use reasonable endeavours both
before and after Closing to obtain all such necessary Third Party Consents as soon as possible and shall keep each other informed of progress in obtaining such Third Party Consents. Each Seller shall deliver to the Purchaser, on Closing or, if
later, as soon as possible after receipt, any such Third Party Consent. 

  

	2.3	In connection with the obtaining of any Third Party Consent referred to in paragraph 2.1 and 2.2, the Purchaser shall supply to the relevant Seller such information as
may be reasonably requested by the relevant Seller or any relevant third party. 

  

	2.4	The cost of any fee demanded by the third party as consideration for giving the Third Party Consent shall be borne by the Purchaser, provided that:

  

	 	2.4.1	the cost is agreed in advance by the Purchaser (such agreement not to be unreasonably withheld or delayed); and 

 

	 	2.4.2	no party shall be required to bear any internal or administrative costs of the other parties in relation to any Third Party Consent. 

 

	3	Obligations until Third Party Consents are Obtained/where Third Party Consents are Refused 

 

	3.1	Subject to paragraph 3.2, the Purchaser shall assume, carry out, perform and discharge the relevant Seller’s and the relevant Business Sellers’
obligations arising under the Transferred Contracts, the Transferred Intellectual Property Contracts, the Co-Owned Target Group Intellectual Property Rights, and the Relevant Part of the Shared Business Contracts as from Closing.

  
 140

	3.2	In respect of any Transferred Contract, Transferred Intellectual Property Contract, the Co-Owned Target Group Intellectual Property Rights or Relevant Part of any
Shared Business Contract from Closing until the relevant Third Party Consent has been obtained as contemplated by paragraph 2.1 or where the Third Party Consent has been refused: 

 

	 	3.2.1	the relevant Business Seller shall hold on trust to the extent it is lawfully able to do so or, where it is not lawfully able to do so or where holding on trust is not
possible under local law, and to the extent that any such Transferred Contracts, Transferred Intellectual Property Contract for the Purchaser or Relevant Parts of the Shared Business Contract, includes licence of Intellectual Property Rights, the
relevant Business Seller and the Purchaser shall make such other arrangements between themselves to provide to the Purchaser, the benefits of the Contract (other than amounts corresponding to any Tax Liability of the relevant Business Seller, in
respect of amounts due under or in respect of the Transferred Contract or Transferred Intellectual Property Contract Co-Owned Target Group Intellectual Property Rights, or Relevant Part of the Shared Business Contract including the enforcement at
the cost and for the account of the Purchaser of all rights of the relevant Business Seller against any other party thereto; and 

  

	 	3.2.2	to the extent that the Purchaser is lawfully able to do so, the Purchaser shall perform (or procure the performance of) the relevant Business Seller’s
obligations under the Contract as agent or sub-contractor and shall indemnify the relevant Seller and the relevant Business Seller if the Purchaser fails to do so. To the extent that the Purchaser is not lawfully able to perform (or procure the
performance of) such obligations, the relevant Seller shall procure that the relevant Business Seller shall (subject to being indemnified by the Purchaser for any Liabilities the relevant Seller or the relevant Business Seller may incur in
connection therewith) do all such things as the Purchaser may reasonably require to enable due performance of the Transferred Contract or Transferred Intellectual Property Contract or Relevant Part of any Shared Business Contract and the Purchaser
shall indemnify the relevant Business Seller in respect thereof. 

  

	4	Failure to Obtain Third Party Consents 

  

	4.1	If a Third Party Consent is refused or otherwise not obtained on terms reasonably acceptable to the Purchaser within 18 months of Closing: 

 

	 	4.1.1	the relevant Seller shall be entitled to procure the termination of the Transferred Contract, Transferred Intellectual Property Contract or Relevant Part of the
Shared Business Contract and the obligations of the parties under this Agreement in relation to such Transferred Contract, Transferred Intellectual Property Contract, or the Relevant Part of the Shared Business Contract shall cease forthwith;

  
 141

	 	4.1.2	references in this Agreement to the Transferred Contracts, Transferred Intellectual Property Contract or Relevant Parts of the Shared Business Contracts (other
than in this paragraph 4) shall be construed as excluding such Transferred Contract, Transferred Intellectual Property Contract or Relevant Part of such Shared Business Contract; and 

 

	 	4.1.3	the relevant Seller and the Purchaser shall use all reasonable efforts to put in place alternative arrangements so as to give the Purchaser equivalent benefits
or rights as would have been enjoyed under the terminated Transferred Contract, Transferred Intellectual Property Contract, Co-Owned Target Group Intellectual Property Rights, or Relevant Part of the Shared Business Contract.

  

	5	Chinese Joint Venture 

  

	5.1	The parties acknowledge and agree that the Chinese JV Interests and the Chinese JV Contracts cannot be transferred to the Purchaser without the consent of
Tianjin Pharmaceutical Holdings Co. Ltd and Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (the “Tianjin Consents”) and that therefore this Agreement shall not be construed as a transfer or attempted transfer of the
Chinese JV Interests or the Chinese JV Contracts without such consent. 

  

	5.2	All parties shall use reasonable endeavours both before and after Closing to obtain the Tianjin Consents as soon as possible and shall keep each other informed of
progress in relation to the same. GlaxoSmithKline shall deliver to the Purchaser, on Closing or, if later, as soon as possible after receipt, the Tianjin Consents. 

 

	5.3	In connection with the obtaining of the Tianjin Consents, each of the parties shall supply to the other parties and any relevant third party such information as
may be reasonably requested by such other parties or any relevant third party. 

  

	5.4	In the event that the Tianjin Consents have not been obtained by Closing, from Closing until the Tianjin Consents have been obtained: 

 

	 	5.4.1	GlaxoSmithKline shall procure that the relevant member of GlaxoSmithKline’s Group shall hold on trust for the Purchaser to the extent it is lawfully able to
do so, or, where it is not lawfully able to do so or where holding on trust is not possible under local law, GlaxoSmithKline shall procure that the relevant member of GlaxoSmithKline’s Group and the Purchaser shall make such other arrangements
between themselves as are necessary to provide the Purchaser with, all of the benefits of the relevant member of GlaxoSmithKline’s Group in relation to the Chinese JV Interests and the Chinese JV Contracts so that the Purchaser is no worse (or
better) off than it would have been had the Chinese JV Interests and the Chinese JV Contracts been transferred to it (other than in respect of amounts corresponding to any Tax payable by GlaxoSmithKline or the relevant member of
GlaxoSmithKline’s Group), including the enforcement and exercise at the cost and for the account of the Purchaser of all rights of the relevant member of GlaxoSmithKline’s Group against or in respect of the Chinese JV Interests and/or any
other party to the Chinese JV Contracts; and 

  
 142

	 	5.4.2	to the extent that the Purchaser is lawfully able to do so, the Purchaser shall perform (or procure the performance of) the relevant member of GlaxoSmithKline’s
Group’s obligations in respect of the Chinese JV Interests (if any) and under the Chinese JV Contracts as agent or as agent or sub-contractor and shall indemnify GlaxoSmithKline and the relevant member of GlaxoSmithKline’s Group if the
Purchaser fails to do so. To the extent that the Purchaser is not lawfully able to perform (or procure the performance of) such obligations, GlaxoSmithKline shall procure that the relevant member of GlaxoSmithKline’s Group shall (subject to
being indemnified by the Purchaser for any Liabilities GlaxoSmithKline or the relevant GlaxoSmithKline’s Group may incur in connection therewith) do all such things as the Purchaser may reasonably require to enable due performance of the
obligations in respect of the Chinese JV Interests and/or the Chinese JV Contracts and the Purchaser shall indemnify the relevant member of GlaxoSmithKline’s Group in respect thereof. 

 

	6	Novartis US NRT Business 

  

	6.1	The parties acknowledge and agree that the Novartis US NRT Business is a Novartis Excluded Asset and therefore shall not be transferred to the Purchaser at
Closing or otherwise, except as agreed between the parties in writing. 

  

	6.2	Promptly following the date of this Agreement, Novartis shall commence the process in relation to the sale (which may include an out-licensing) of the Novartis US NRT
Business to a third party unconnected to the parties and shall use reasonable endeavours to effect such sale (or out-licensing as relevant) prior to Closing. 

 

	6.3	The parties agree that the following provisions shall apply in respect of the sale (or out-licensing as relevant) process referred to above in relation to the
Novartis US NRT Business (subject to Applicable Law): 

  

	 	6.3.1	Novartis shall inform the Purchaser of, and consult with the Purchaser in relation to, all material steps to be taken in respect of such sale and shall take
reasonable account of any views of the Purchaser so expressed in connection with the same; 

  

	 	6.3.2	prior to the first circulation of any material draft sale (or out-licensing as relevant) documentation in respect of such sale (or out-licensing as relevant),
Novartis shall provide the Purchaser with a reasonable opportunity to review and comment on such documentation and shall take reasonable account of any views of the Purchaser so expressed in connection with the same; 

  
 143

	 	6.3.3	with effect from Closing, and only if Closing occurs, all of the proceeds of any such sale shall (or out-licensing as relevant), unless such proceeds are
received by a Novartis OTC Group Company, be paid to the Purchaser to such account as it may direct promptly following receipt of the same by Novartis (or any of its Affiliates); and 

 

	 	6.3.4	the Purchaser shall indemnify Novartis for any reasonable costs and expenses incurred in connection with such sale process (or out-licensing process, as relevant),
excluding, for the avoidance of doubt, any costs and expenses arising out of, or in connection with the exercising of rights and/or obligations under any definitive documentation in respect of such sale (or out-licensing as relevant) (and the
parties shall work together to seek to avoid any potential double taxation of the proceeds). 

  

	7	Novartis Indian Business 

  

	7.1	The parties acknowledge and agree that Novartis’s Indian Business cannot be transferred to the Purchaser without the requisite consent of the non-Novartis
shareholders in Novartis IndiaCo pursuant to and in accordance with the rules and regulations of the Securities Exchange Board of India and any other Applicable Law (the “Novartis Indian Consent”) and that therefore this Agreement
shall not be constructed as a transfer or attempted transfer of the Novartis Indian Business without the Novartis Indian Consent. 

  

	7.2	Novartis agrees to use its reasonable endeavours to obtain the Novartis Indian Consent prior to Closing, and as soon as reasonably practicable following the date
of this Agreement. Without prejudice to the generality of the foregoing, Novartis shall, promptly following the date of this Agreement: 

  

	 	7.2.1	commence the process in relation to the obtaining of the Novartis Indian Consent; and 

 

	 	7.2.2	give the Purchaser a reasonable opportunity to take part in the process of, and to review and comment on any material documentation in relation to (with Novartis
to take reasonable account of any such comments), the obtaining of the Novartis Indian Consent. 

  

	7.3	In the event that the Novartis Indian Consent is not obtained prior to Closing, such that the Novartis Indian Business cannot be transferred to the Purchaser upon
Closing in accordance with the provisions of this Agreement: 

  

	 	7.3.1	for a maximum of two years, the parties shall use reasonable endeavours to obtain the Novartis Indian Consent and to procure that the Novartis Indian Business is
transferred to the Purchaser as soon as reasonably practicable after Closing; and 

  

	 	7.3.2	from Closing until such transfer (if any) takes place, Novartis shall procure that such arrangements are put in place between Novartis and the Purchaser as are
necessary to put the Purchaser in no worse (or better) position than it would have been had the Novartis Indian Business been transferred to it at Closing, and prior to Closing the parties shall enter into discussions (acting reasonably and in good
faith) with a view to reaching agreement on such arrangements. 

  
 144

	8	GlaxoSmithKline Pakistan Business 

  

	8.1	The parties acknowledge and agree that the GlaxoSmithKline Pakistan Business cannot be transferred to the Purchaser without the requisite consent of the
shareholders in GlaxoSmithKline Pakistan pursuant to and in accordance with the rules and regulations of the Security and Exchange Commission of Pakistan and any other Applicable Law and (if required) the approval of the Sindh High Court (the
“GlaxoSmithKline Pakistan Consent”) and that therefore this Agreement shall not be constructed as a transfer or attempted transfer of the GlaxoSmithKline Pakistan Business without the GlaxoSmithKline Pakistan Consent. To the extent
that the relevant member of GlaxoSmithKline’s Group is not able to vote its shares in favour of the transfer of the GlaxoSmithKline Pakistan Business (as confirmed by GlaxoSmithKline’s Pakistan legal adviser) or (if required) the approval
of the Sindh High Court is not granted, paragraph 8.3 below will apply. 

  

	8.2	GlaxoSmithKline agrees to use its reasonable endeavours to obtain the GlaxoSmithKline Pakistan Consent prior to Closing, and as soon as reasonably practicable following
the date of this Agreement. Without prejudice to the generality of the foregoing, GlaxoSmithKline shall, promptly following the date of this Agreement: 

  

	 	8.2.1	commence the process in relation to the obtaining of the GlaxoSmithKline Pakistan Consent; and 

 

	 	8.2.2	give the Purchaser a reasonable opportunity to take part in the process of, and to review and comment on any material documentation in relation to (with
GlaxoSmithKline to take reasonable account of any such comments), the obtaining of the GlaxoSmithKline Pakistan Consent. 

  

	8.3	In the event that the GlaxoSmithKline Pakistan Consent is not obtained prior to Closing, such that the GlaxoSmithKline Pakistan Business cannot be transferred to
the Purchaser upon Closing in accordance with the provisions of this Agreement: 

  

	 	8.3.1	for a maximum of two years, the parties shall use reasonable endeavours to obtain the GlaxoSmithKline Pakistan Consent and to procure that the GlaxoSmithKline
Pakistan Business is transferred to the Purchaser as soon as reasonably practicable after Closing; and 

  

	 	8.3.2	from Closing until such transfer (if any) takes place, GlaxoSmithKline shall procure that such arrangements are put in place between GlaxoSmithKline and the
Purchaser as are necessary to put the Purchaser in no worse (or better) position than it would have been had the GlaxoSmithKline Pakistan Business been transferred to it at Closing, and prior to Closing the parties shall enter into discussions
(acting reasonably and in good faith) with a view to reaching agreement on such arrangements. 

  

	9	Gebro Pharma Joint Venture 

  

	9.1	If, at Closing, (i) the relevant shares in Novartis Consumer Health-Gebro GmbH are not held by a Novartis OTC Group Company and (ii) consent or approval from
Gebro Pharma GmbH to the transfer of shares in Novartis Consumer Health-Gebro GmbH has not been obtained, then this Agreement shall not be construed as a transfer or attempted transfer of the relevant shares in Novartis Consumer Health-Gebro GmbH
without such consent and: 

  
 145

	 	9.1.1	Novartis shall procure that the relevant member of Novartis’s Group shall hold on trust for the Purchaser to the extent it is lawfully able to do so, or,
where it is not lawfully able to do so or where holding on trust is not possible under local law, Novartis shall procure that the relevant member of Novartis’s Group and the Purchaser shall make such other arrangements between themselves to
provide the Purchaser with, all of the benefits of the relevant shares in Novartis Consumer Health-Gebro GmbH so that the Purchaser is no worse (or better) off than it would have been had in Novartis Consumer Health-Gebro GmbH been transferred to it
(other than in respect of amounts corresponding to any Tax payable by Novartis or the relevant member of Novartis’s Group), including the enforcement and exercise at the cost and for the account of the Purchaser of all rights of the relevant
member of Novartis’s Group against or in respect of the relevant shares in Novartis Consumer Health-Gebro GmbH; and 

  

	 	9.1.2	to the extent that the Purchaser is lawfully able to do so, the Purchaser shall perform (or shall procure the performance of) the relevant member of
Novartis’s Group’s obligations in respect of Novartis’s Shares in Novartis Consumer Health-Gebro GmbH as agent or as agent or sub-contractor and shall indemnify Novartis and the relevant member of Novartis’s Group if the
Purchaser fails to do so. To the extent that the Purchaser is not lawfully able to perform (or shall procure the performance of) such obligations, Novartis shall procure that the relevant member of Novartis’s Group shall (subject to being
indemnified by the Purchaser for any Liabilities Novartis or the relevant member of Novartis’s Group may incur in connection therewith) do all such things as the Purchaser may reasonably require to enable due performance of the obligations in
respect of the relevant shares in Novartis Consumer Health-Gebro GmbH and the Purchaser shall indemnify the relevant member of Novartis’s Group in respect thereof. 

 

	10	US RX Products 

  

	10.1	The parties acknowledge and agree that they will effect Closing with respect to US RX Products that are included in the Contributed Business in a manner that
ensures that the Purchaser, its Affiliates, and their respective businesses shall not be subject to or bound by the terms of the [***] and that there is no breach of the [***] as a result of the transfer of Novartis US RX Products or GlaxoSmithKline
US RX Products at Closing. 

  

	10.2	Subject to paragraph 9.3 of this Schedule 6 but notwithstanding any other provision of this Agreement: 

 

	 	10.2.1	Novartis shall not transfer to the Purchaser at Closing any assets or liabilities of its Contributed Business relating (in whole or in part) to the Novartis US
RX Products; and 

  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission 

  
 146

	 	10.2.2	GlaxoSmithKline shall not transfer to the Purchaser at Closing any assets or liabilities of its Contributed Business relating (in whole or in part) to the
GlaxoSmithKline US RX Products, 

 in the case of each US RX Product, if, and only to the extent that, such
transfer would result in the Purchaser or any of its Affiliates or their respective businesses (including such US RX Product) being subject to or bound by the terms of the [***] post-Closing and/or would result in any breach of the [***]. Any assets
or liabilities excluded from being transferred to the Purchaser in accordance with this paragraph 9.2 shall be deemed to constitute Novartis Excluded Assets or GlaxoSmithKline Excluded Assets, as the case may be. 

 

	10.3	With effect from the date of this Agreement, the Sellers shall consult with one another (acting reasonably and in good faith) so as to determine whether the
assets and liabilities comprised in each of their Contributed Businesses relating (in whole or in part) to each GlaxoSmithKline US RX Product and each Novartis US RX Product, as applicable, can be transferred to the Purchaser (or another member of
its Group) at Closing without the transfer resulting in the Purchaser or any of its Affiliates or their respective businesses being subject to or bound by the terms of the [***] post-Closing and without the transfer resulting in any breach of the
[***]. 

  

	10.4	To the extent that, notwithstanding paragraph 9.3 of this Schedule 6, any assets and liabilities of a Seller’s Contributed Business are deemed to constitute
Novartis Excluded Assets or GlaxoSmithKline Excluded Assets pursuant to paragraph 9.2 of this Schedule 6, then the following provisions shall apply to such Novartis Excluded Assets or GlaxoSmithKline Excluded Assets (subject to Applicable Law):

  

	 	10.4.1	with effect from Closing, and only if Closing occurs, until the date of completion of any US RX Product Disposal (if any) the relevant Seller shall procure that
such arrangements are put in place between it and the Purchaser as are necessary to put the Purchaser in no worse (or better) position than it would have been had in such Novartis Excluded Assets or GlaxoSmithKline Excluded Assets (as the case may
be) been transferred to it at Closing, and prior to Closing, the parties shall enter into discussions (acting reasonably and in good faith) with a view to reaching agreement on such arrangements; and 

 

	 	10.4.2	the relevant Seller shall be entitled to dispose of, or out-licence, all or part of any such Novartis Excluded Assets or GlaxoSmithKline Excluded Assets at any
time prior to or after Closing (a “US RX Product Disposal”) and the following provisions shall apply in respect of any US RX Product Disposal (subject to Applicable Law): 

 

	 	(i)	the relevant Seller shall inform the Purchaser of, and consult with the Purchaser in relation to, all material steps to be taken in respect of such sale and shall take
reasonable account of any views of the Purchaser so expressed in connection with the same; 

  

	 	(ii)	prior to the first circulation of any material draft sale (or out-licensing as relevant) documentation in respect of such sale (or out-licensing as relevant), the
relevant Seller shall provide the Purchaser with a reasonable opportunity to review and comment on such documentation and shall take reasonable account of any views of the Purchaser so expressed in connection with the same; 

 

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission 

  
 147

	 	(iii)	with effect from Closing, and only if Closing occurs, all of the proceeds of any such sale (or out-licensing as relevant) shall, unless such proceeds are received by a
Target Group Company, be paid to the Purchaser to such account as it may direct promptly following receipt of the same by the relevant Seller (or any of its Affiliates); and 

 

	 	(iv)	the Purchaser shall indemnify the relevant Seller for any reasonable costs and expenses incurred in connection with such sale process (or out-licensing process, as
relevant), excluding, for the avoidance of doubt, any costs and expenses arising out of, or in connection with the exercising of rights and/or obligations under any definitive documentation in respect of such sale (or out-licensing, as relevant)
(and the parties shall work together to seek to avoid any potential double taxation of the proceeds). 

  
 148

 Schedule 7 
 Employees 
  

	1	INFORMATION AND CONSULTATION 

  

	1.1	At such time as the parties agree to be appropriate following the public announcement of the matters contemplated by this Agreement, each Seller and the
Purchaser or the relevant member of the Purchaser’s Group shall jointly communicate to the Employees an agreed notice which shall (other than to the extent the parties agree otherwise): 

 

	 	1.1.1	inform the Employees that following Closing those Employees who continue to be employed in the Contributed Business would be employed by the Purchaser or
relevant member of the Purchaser’s Group; and 

  

	 	1.1.2	comply with the requirements of any applicable national law. 

 For the avoidance of doubt, the parties may agree to issue such notice to different Employees or categories of Employees at different times and in different forms. 

 

	1.2	Notwithstanding the operation of paragraph 1.1 above, each Seller and the Purchaser agree to comply with any more onerous notice requirements imposed by local
laws. 

  

	1.3	Each Seller agrees that it shall be permitted to conduct its own information and consultation exercise in respect of the matters contemplated by this Agreement
with its own Employees without interference from the other Seller. Each Seller agrees to co-operate with the other Seller in respect of that other Seller’s information and consultation process to ensure as far as practicable that the
communications of a Seller with the Employees of that Seller are aligned with the communications of the other Seller with the Employees of that other Seller. 

 

	1.4	The Purchaser (on its own behalf and on behalf of any relevant member of the Purchaser’s Group) shall provide each Seller (for itself and any relevant
member of such Seller’s Group) with such information and assistance at such times as such Seller may reasonably request or as may be reasonably necessary for such Seller or any other member of such Seller’s Group to comply with any formal
or informal requirement to inform or consult with the Employees, a relevant trade union, a relevant works council, or any other employee representatives in connection with the matters contemplated by this Agreement (which formal or informal
requirements the Seller hereby undertakes to comply or procure compliance with). Where reasonably necessary to ensure compliance with any formal or informal requirements or obligations to inform or consult with Employees, a relevant trade union, a
relevant works council or any other employee representatives in connection with the matters contemplated by this Agreement, each Seller (for itself and for each member of its Group) and the Purchaser (for itself and for each member of its Group)
agree that the Purchaser or relevant member of the Purchaser’s Group shall cooperate with and participate in any information, negotiation and/or consultation process as reasonably required by that relevant Seller. 

  
 149

	1.5	As soon as practicable following the date of this Agreement each Seller agrees to provide on a timely basis such information, in writing, in respect of its existing
terms and conditions of employment as may reasonably be required by the other Seller so as to facilitate that other Seller’s information and consultation exercise with its Employees in respect of the matters set out in this Agreement.

  

	2	TARGET BUSINESS EMPLOYEES 

  

	2.1	General 

  

	 	2.1.1	The Purchaser shall (or shall procure that the relevant member of its Group shall) fulfil all its duties and obligations under Applicable Law in relation to the
Target Business Employees. Where the provisions of local law do not provide for an automatic transfer of the employment of the Target Business Employees to the Purchaser or a relevant member of its Group with effect from (and including) the Closing
Date, then paragraph 2.2 below shall apply. Where the provisions of local law do provide for an automatic transfer of employment of the Relevant Target Business Employees to the Purchaser or the relevant member of its Group with effect from (and
including) the Closing Date, then paragraph 2.3 below shall apply. 

  

	 	2.1.2	Each Seller and the Purchaser acknowledge and agree that, in relation to Deferred Employees of a member of that Seller’s Group: 

 

	 	(i)	any Deferred Employee shall be treated for all purposes under this Agreement as if such Deferred Employee were a Target Business Employee or a Target Company Employee
(as appropriate); 

  

	 	(ii)	the Purchaser’s obligations under this Schedule 7 shall apply in respect of each Deferred Employee in the same way as they do to each Target Business Employee or
Target Company Employee (as appropriate); and 

  

	 	(iii)	if any Deferred Employee accepts an offer of employment made by the Purchaser under paragraph 2.2.1 below or becomes an employee of a Target Group Company after the
Closing Date, such Deferred Employee shall further be treated for all purposes under this Agreement as a Transferred Employee. 

  

	 	2.1.3	For the avoidance of doubt, this paragraph 2 shall not apply to any Excluded Employee, who will remain employed by a Seller or the relevant member of that
Seller’s Group. 

  

	2.2	Where no Automatic Transfer of Employment 

  

	 	2.2.1	 In such timescale as each Seller and the Purchaser may agree, but in any event at least 30 Business Days prior to the Closing Date, the
Purchaser or relevant member of its Group shall make an offer to each Target Business Employee employed by that Seller or a member of its Group to employ him or her under a new contract of employment to commence with effect from (and including) the
Closing Date provided that such employee continues to be a Target Business Employee until the 

  
 150

	 	
Closing Date. Save as otherwise agreed with that Seller (such agreement not to be unreasonably withheld), the offer to be made will be on the same terms and conditions (including as to period of
continuous employment) as were provided to that Target Business Employee immediately prior to the Closing Date. The Purchaser shall keep each Seller updated throughout the offer process on when offers are made and accepted or rejected.

  

	 	2.2.2	If the Target Business Employee wishes to accept the offer of employment from the Purchaser or the relevant member of its Group, then the Seller who employs
(whether directly or indirectly) that person shall (or shall procure that the relevant member of its Group shall), insofar as it is permitted by Applicable Law, waive the requirement on the Target Business Employee concerned to give any period of
notice of termination of his or her employment under the terms of his or her employment so as to allow the Target Business Employee to commence employment with the Purchaser or relevant member of its Group with effect from (and including) the
Closing Date. 

  

	2.3	Where Automatic Transfer of Employment 

 If the Transfer Regulations do not or are found not to or are alleged not to apply to any person who is a Relevant Target Business Employee, and to whom paragraph 2.2 does not apply, the Purchaser agrees
that following Closing: 
  

	 	2.3.1	in consultation with the Seller who employs (whether directly or indirectly) that person, the Purchaser or relevant member of the Purchaser’s Group shall within
ten Business Days of being so requested by that Seller (as long as the request is made no later than three months after Closing) (or if the Purchaser so chooses) make such Relevant Target Business Employee an offer in writing to employ him or her
under a new contract of employment subject to, and to take effect upon, a date agreed between that Seller, the Purchaser and such employee; and 

  

	 	2.3.2	save as otherwise agreed with that Seller (such agreement not to be unreasonably withheld) the offer to be made will be on the same terms and conditions
(including as to period of continuous employment) as were provided to that Relevant Target Business Employee immediately prior to the Closing Date. 

  

	3	WRONG-POCKET ARRANGEMENTS FOR PERSONS OTHER THAN RELEVANT EMPLOYEES 

 

	3.1	If the contract of employment of any person other than a Relevant Employee is found or alleged to have effect upon Closing as if originally made with the
Purchaser or another member of its Group (including any Target Group Company) as a consequence of this Agreement, or if any Target Group Company employs any person who does not work wholly or substantially in the relevant Contributed Business, the
Seller whose Group had previously employed (whether directly or indirectly) such person agrees that following Closing: 

  
 151

	 	3.1.1	in consultation with the Purchaser, that Seller or relevant member of its Group may within ten Business Days of being so requested by the Purchaser (as long as
the request is made no later than three months after Closing) (or if that Seller so chooses), make to that person an offer in writing to employ him or her under a new contract of employment subject to, and to take effect upon, the termination
referred to below; and 

  

	 	3.1.2	the offer to be made will be on the same terms and conditions (including as to period of continuous employment) as were provided to that person immediately prior
to the Closing Date. 

  

	3.2	After the expiry of the ten Business Days referred to at paragraph 3.1 above, and provided that the relevant member of the Purchaser’s Group takes such
steps as are legally possible to terminate the employment of the person concerned as soon as reasonably practicable after becoming aware of the finding or allegation referred to at paragraph 3.1 above (either by giving notice or transferring the
person by agreement to be concluded between the relevant member of the Purchaser’s Group, the person concerned and the relevant member of that Seller’s Group), that Seller shall be responsible for and shall indemnify and keep indemnified
the Purchaser (for itself and as trustee for any relevant member of its Group) against all Losses from time to time made, suffered or incurred by the Purchaser (or any other member of its Group) as a result of: 

 

	 	3.2.1	the actual or alleged transfer to a member of the Purchaser’s Group and (regardless of whether there has been such a transfer) any employment liabilities
relating to such person; 

  

	 	3.2.2	employing such person on and from the Closing Date until such termination (up to the time reasonably expected to have achieved such termination in accordance with the
terms of the contract of employment and Applicable Law but subject to a maximum period of six months unless prevented by the terms of the contract of employment or Applicable Law); and 

 

	 	3.2.3	such termination. 

  

	3.3	Each Seller and the Purchaser agree to co-operate in good faith to minimise the Losses which are subject to the indemnity referred to in paragraph 3.2 above.

  

	4	EMPLOYMENT LIABILITIES 

  

	4.1	All wages, salaries, employer’s liabilities in respect of associated Taxes and other periodic outgoings in respect of the Transferred Employees which relate
to a period: 

  

	 	4.1.1	after the Closing Date shall be borne or discharged by the Purchaser or relevant member of the Purchaser’s Group; and 

 

	 	4.1.2	on or before the Closing Date shall be borne or discharged by the Seller or relevant member of its Group to which they relate. 

  
 152

	4.2	Each Seller shall (for itself and for each member of its Group) indemnify and keep indemnified the Purchaser (for itself and as trustee for each other member of
its Group) against all Losses (ignoring any amount in respect of Employee Benefits, as to which see Schedule 8) in respect of: 

  

	 	4.2.1	the employment of any Employee at any time prior to the Closing Date (excluding any Transferred Employee Benefit Liabilities (as defined in Schedule 8 of that
Seller) which the Purchaser agrees to assume in accordance with Schedule 8); 

  

	 	4.2.2	any termination of the employment of any Employees prior to the Closing Date, including, but not limited to, all claims relating to severance, termination pay,
pay in lieu of notice of termination and similar obligations (excluding any liability arising directly as a result of any breach of the commitments set out in paragraph 5 or 6 below by the Purchaser or a member of the Purchaser’s Group and any
act or omission by the Purchaser or any member of the Purchaser’s Group in relation to any Employee before Closing as a result of which that Employee treats his employment as having been terminated prior to the Closing Date);

  

	 	4.2.3	any amount which becomes payable to any Employee or benefit to which any Employee becomes entitled by reason of this Agreement or the matters it contemplates,
including any change of control or other payment or benefit (and including any enhancement of severance terms on a subsequent termination of employment but excluding any Losses relating to any share-based incentive schemes, as to which see paragraph
10 below); 

  

	 	4.2.4	any failure by such Seller or any other member of such Seller’s Group to comply with any obligation to inform or consult with employee representatives in
connection with the matters contemplated by this Agreement (other than as a result of any failure set out in paragraph 4.3.3 below); and 

  

	 	4.2.5	any breach by such Seller or any other member of such Seller’s Group of paragraph 4.1.2 above or paragraph 4.4, 4.5 or 9 below. 

Where this paragraph 4.2 refers to an ‘Employee’ this is a reference to an Employee employed prior to the Closing Date by the
Seller giving the indemnity (or a member of that Seller’s Group) and not to an Employee of the other Seller’s Group prior to the Closing Date. 
  

	4.3	The Purchaser shall (for itself and for each member of the Purchaser’s Group) indemnify and keep indemnified each Seller (for itself and as trustee for each
other member of such Seller’s Group) against all Losses (ignoring any amount in respect of Employee Benefits, as to which see Schedule 8) in respect of: 

 

	 	4.3.1	the employment of any of the Transferred Employees on and after the Closing Date (including, without limitation, any changes to terms and conditions of
employment by the Purchaser or any other member of the Purchaser’s Group); 

  
 153

	 	4.3.2	any termination of the employment of any Transferred Employees on and after the Closing Date including, but not limited to, all claims relating to severance,
termination pay, pay in lieu of notice of termination and similar obligations except as contemplated under paragraph 3.2 above; 

  

	 	4.3.3	any failure by the Purchaser or any other member of the Purchaser’s Group to provide information and reasonable assistance to such Seller to enable such
Seller or any other member of such Seller’s Group to comply with any obligation to inform or consult with employee representatives in connection with the matters contemplated by this Agreement; 

 

	 	4.3.4	any breach by the Purchaser or any other member of the Purchaser’s Group of paragraph 4.1.1 above or paragraphs 4.4 or 4.5 below; and

  

	 	4.3.5	any act or omission by the Purchaser or any member of the Purchaser’s Group in relation to any Employee before Closing as a result of which that Employee
treats his employment as having been terminated prior to the Closing Date. 

  

	4.4	Any amount payable to or in respect of any Transferred Employee after Closing (including without limitation amounts paid under paragraph 4.5 below) which
(ignoring vesting conditions and any amount payable in respect of Employee Benefits or otherwise in accordance with Schedule 8) is referable to the period prior to Closing is payable by the Seller to whom such Transferred Employee relates (for
itself or on behalf of the relevant Business Seller or relevant Share Seller). Responsibility for amounts payable which are only partly referable to the period prior to Closing (again ignoring vesting conditions) is to be shared between the relevant
Seller (for itself or on behalf of the relevant Business Seller or relevant Share Seller) and the Purchaser (for itself or on behalf of the relevant member of the Purchaser’s Group) such that that Seller bears S per cent. of the cost and the
Purchaser bears P per cent., where S is the percentage of the period by reference to which the amount was earned which fell on or before the Closing Date and P is the percentage of that period which falls after the Closing Date. The Purchaser shall,
or shall procure that such other member of the Purchaser’s Group shall, pay such amounts when due to the relevant Transferred Employees on or after Closing and shall deduct and/or pay and account for any Tax payable or accountable for by the
employer in respect of such amounts. Each Seller covenants to reimburse the Purchaser in respect of any such amount (or S per cent. of it where relevant), including any Tax due payable or accountable for by the employer in respect of such amount,
within 30 days of receiving notification that it has been paid, to the extent such amounts are not reflected in the Closing Statement. Each Seller will provide the Purchaser with all information and documentation reasonably necessary to allow such
payments to be made. 

  

	4.5	Following the Closing Date: 

  
 154

	 	4.5.1	the Purchaser shall, or shall procure that a member of the Purchaser’s Group shall, pay a pro-rated cash bonus of an amount advised by each Seller to the
Purchaser to each Transferred Employee formerly employed by that Seller’s Group and who participated in an annual cash bonus plan immediately before the Closing Date in their first payroll payment after the Closing Date; and

  

	 	4.5.2	where the Seller to whom such Transferred Employee relates is able to determine performance, any such bonus payment made to such eligible employees by the
Purchaser or a member of the Purchaser’s Group will be based on that Seller’s determination of performance to the Closing Date and pro-rated to the Closing Date; or 

 

	 	4.5.3	where that Seller is unable to determine performance (either business or individual), for example, because the Closing Date occurs near the start of the bonus
year, that Seller shall calculate any such bonus payment based on a deemed achievement of performance conditions at target level pro-rated to the Closing Date; and 

 

	 	4.5.4	as soon as reasonably practicable after the Closing Date, the Purchaser shall, or shall procure that such other member of the Purchaser’s Group shall,
provide such information as that Seller requires in order for that Seller to calculate the Tax payable or accountable for by the employer in respect of such bonus payments; and 

 

	 	4.5.5	the Purchaser shall, or shall procure that such other member of the Purchaser’s Group shall, deduct and/or account for any Tax payable or accountable for by
the employer in respect of such bonus payments; and 

  

	 	4.5.6	that Seller shall reimburse the Purchaser for the aggregate bonuses advised by that Seller to the Purchaser which are paid pursuant to this paragraph 4.5 along
with the employer’s social security contributions due in respect of such payments to the extent such amounts are not reflected in the Closing Statement. 

 

	5	PROTECTION OF TERMS AND CONDITIONS AND TERMINATION RIGHTS POST-CLOSING 

 

	5.1	Without prejudice to paragraph 5.4 below, the Purchaser shall procure that for a period of 24 months following the Closing Date: 

 

	 	5.1.1	each Transferred Employee will (for so long as such Transferred Employee continues in the same role with any member of the Purchaser’s Group save that the
Purchaser shall not seek to demote any Transferred Employee to avoid the application of this provision) continue to receive at least the same basic salary; 

 

	 	5.1.2	 each Transferred Employee will continue to receive contractual benefits (but excluding Employee Benefits and any share-based incentive schemes
or other long-term incentive plans) which the 

  
 155

	 	
Purchaser reasonably considers to be substantially comparable, taken as a whole, to the contractual benefits (but excluding Employee Benefits and any share-based incentive schemes or other
long-term incentive plans) of such Transferred Employee immediately prior to the Closing Date; and 

  

	 	5.1.3	no Transferred Employee will suffer a change to his overall employment terms (whether contractual or otherwise) and including, without limitation, any related to
length of service (but excluding Employee Benefits and any share-based incentive schemes or other long-term incentive plans) which, when taken as a whole viewed in the round (including to the extent relevant alongside any other changes being made at
the same time to that Transferred Employee’s employment terms), would in the Purchaser’s reasonable opinion acting in good faith be regarded as materially detrimental. 

 

	5.2	The Purchaser confirms that, following the Closing Date and for so long as the Transferred Employees continue in the employment of any member of the
Purchaser’s Group, the Transferred Employees will be eligible to participate in those share-based incentive schemes or other long-term incentive plans that are operated by the Purchaser or relevant members of the Purchaser’s Group from
time to time for employees of equivalent status, subject always to the rules of such share-based incentive schemes or long-term incentive plans and any qualifying conditions. 

 

	5.3	Each Seller shall provide or shall cause to be provided to any member of the Purchaser’s Group such information reasonably requested in writing by any
member of the Purchaser’s Group to enable the Purchaser to comply with its obligations in paragraph 5.1 above. 

  

	5.4	If the employment of any Transferred Employee is terminated by reason of redundancy within 24 months following the Closing Date, the Purchaser shall procure that
there shall be provided to such Transferred Employee benefits which are equivalent to those provided under such redundancy and severance policies and benefits (whether contractual or otherwise and giving due credit to the Transferred Employees for
any additional service or earnings from the Closing Date onwards) (but excluding Employee Benefits other than the Agreed UK Restructuring Arrangement) as were applicable in respect of the particular Transferred Employee immediately prior to the
Closing Date, to the extent that such policies and benefits are notified in writing to the Purchaser prior to the Closing Date. If, at any time during the 24 month period immediately following the Closing Date, the Purchaser places any Transferred
Employee into a redundancy selection process, the Purchaser undertakes that, in determining such selection, it will or will procure that the relevant member of the Purchaser’s Group will take no account of the costs of dismissal of any person
within the relevant selection pool (including such Transferred Employee). 

  

	5.5	For the avoidance of doubt, the provisions of this paragraph 5 are without prejudice to the operation of any rule of law in relation to the terms and conditions
of employment of the Transferred Employees. 

  
 156

	6	BENEFITS ARRANGEMENTS/SERVICE CONTINUITY 

  

	6.1	Each Transferred Employee shall have their service with the Seller’s Group and their respective predecessors recognised under any employee benefit plans or
arrangements of the Purchaser’s Group for all purposes of eligibility, vesting and accrual of benefits to the extent past service was recognised for such Transferred Employee under a comparable plan or arrangement immediately prior to the
Closing Date. Notwithstanding the foregoing, nothing in this paragraph 6.1 shall be construed to require recognition of service for the purposes of calculation of Employee Benefits or that would result in: 

 

	 	6.1.1	any additional liability being assumed by the Purchaser’s Group in respect of Employee Benefits other than subject to and in accordance with the provisions
of Schedule 8; 

  

	 	6.1.2	duplication of benefit; 

  

	 	6.1.3	recognition of service for any purposes under any plan or arrangement for which participation, service and/or benefits accrual is frozen or any post-retirement
medical plan; or 

  

	 	6.1.4	recognition of service under a newly established plan or arrangement for which prior service is not taken into account for employees of the Purchaser’s
Group generally. 

  

	6.2	Without limiting the foregoing, with respect to the Transferred Employees, the Purchaser shall, or shall cause such other member of the Purchaser’s Group
to, be responsible for all paid time off benefits, including vacation pay, sick pay, banked leave, flexitime and other payments for time off of normal work hours accrued by the Transferred Employees up to the Closing Date provided that if the value
of such matters (excluding normal accrued but untaken annual leave for the year current as at Closing) would exceed US$7.5 million if accrued for in a balance sheet in accordance with IFRS; then the Seller to whom such Transferred Employees relate
shall compensate the Purchaser for such matters (again excluding normal accrued but untaken annual leave for the year current as at Closing) by paying the Purchaser an amount equal to that value, less any amount actually accrued and transferred to
the Purchaser for such matters. 

  

	6.3	With respect to any welfare plan maintained by the Purchaser or any other member of the Purchaser’s Group in which Transferred Employees are eligible to
participate after the Closing Date, the Purchaser shall: 

  

	 	6.3.1	waive all limitations as to pre-existing conditions, exclusions, evidence of insurability provisions, waiting periods with respect to such participation and
coverage requirements or similar provisions under the Purchaser’s benefit plans that are welfare plans (as defined in section 3(1) of ERISA or any equivalent Applicable Law) applicable to such employees to the extent such conditions, exclusions
and waiting periods or other provisions were satisfied or did not apply to such employees under welfare plans maintained by the Seller to whom such Transferred Employees relate or other members of its Group prior to the Closing Date; and

  
 157

	 	6.3.2	provide each Transferred Employee with credit for any co-payments and deductibles paid prior to the Closing Date in satisfying any analogous deductible or
out-of-pocket requirements to the extent applicable under any such plan in the year in which Closing occurs, to the extent credited under the welfare plans maintained by the Seller to whom such Transferred Employees relate or other members of its
Group prior to the Closing Date. 

  

	7	US TRANSFERRED EMPLOYEES 

  

	7.1	To the extent the Purchaser or any other member of the Purchaser’s Group maintains a health care and dependent care flexible spending account arrangement
pursuant to section 125 or 129 of the Code (collectively “FSAs”), the Purchaser will use commercially reasonable efforts to honour the elections of all Transferred Employees who are employed in the United States and/or covered by US
Benefit Plans (“US Transferred Employees”) under the FSAs of any relevant member of the Seller’s Group to whom such Transferred Employees relate (“Relevant Employer’s FSAs”), as in effect immediately prior
to the Closing Date, and the Purchaser will use commercially reasonable efforts to assume responsibility for administering all reimbursement claims of US Transferred Employees with respect to the calendar year in which the Closing Date occurs that
are submitted for payment on or after the Closing Date, whether arising before, on or after the Closing Date, under the Purchaser’s FSAs. As soon as practicable but no more than 45 days following the Closing Date, the Seller will cause to be
transferred to the Purchaser an amount in cash equal to: (i) the sum of all contributions to the Relevant Employer’s FSAs with respect to the calendar year in which the Closing Date occurs by or on behalf of the US Transferred Employees
prior to the Closing Date, reduced by; (ii) the sum of all claims incurred in the calendar year in which the Closing Date occurs that are submitted to the Relevant Employer for payment prior to the Closing Date and paid by the Relevant
Employer’s FSAs with respect to such US Transferred Employees prior to the date of such cash transfer to the Purchaser; provided, however, if this calculation results in a negative number, then the Purchaser will pay to the relevant Seller (on
behalf of the Relevant Employer) as soon as practicable following the end of the calendar year in which the Closing Date occurs, the amount by which (ii) exceeds (i). 

 

	7.2	With effect on and from the Closing Date, the Purchaser shall, or shall procure that such other members of the Purchaser’s Group shall, assume the
responsibility and obligation to provide COBRA continuation coverage to all US Transferred Employees whose employment is terminated after the Closing Date and their eligible dependents. 

 

	8	INTERNATIONAL ASSIGNEES 

Where Applicable Law does not provide for the automatic transfer of employment of any International Assignee and/or the other terms
governing their international assignment, the Purchaser shall assume and agree to be bound by the individual contract of employment and such other terms governing their international assignment including any tax equalisation agreement entered into
between an International Assignee and a member of a Seller’s Group provided that such employee becomes a Transferred Employee and each Seller has disclosed to the other Seller the template international assignment terms of that Seller’s
Group prior to the Closing Date. 

  
 158

	9	LIABILITY FOR RETENTION ARRANGEMENTS 

 Each Seller or any other member of the Seller’s Group has or will put in place certain retention arrangements (in the form of cash) to retain key employees in connection with the matters contemplated
by this Agreement. To the extent that details of such retention arrangements are disclosed to the other Seller prior to the Closing Date, and in respect of arrangements put in place after the date of this Agreement, with the agreement of that other
Seller, the Purchaser shall, or shall procure that such other member of the Purchaser’s Group shall, make the cash retention payments when due to the relevant Transferred Employees on or after Closing and shall deduct and/or pay and account for
any Tax payable or accountable for by the employer in respect of such cash payments. Each Seller covenants to reimburse the Purchaser in respect of any cash retention payments, whether or not disclosed (including any Tax payable or accountable for
by the employer in respect of such payments), which are put in place prior to the Closing Date. Each Seller will provide the Purchaser with all information and documentation reasonably necessary to allow such payments to be made. 

 

	10	SHARE-BASED INCENTIVE SCHEMES 

 This
paragraph 10 applies notwithstanding any other provision of this Agreement. 
 Outstanding share-based awards under Novartis’s Group
plans 
  

	10.1	Subject to paragraph 10.10, Novartis undertakes to use its best endeavours to ensure that share-based awards held by Transferred Employees pursuant to a
share-based incentive scheme operated by Novartis or another member of Novartis’s Group (“Novartis Awards”) shall be treated in a manner consistent with the “good leaver treatment” in the share-based incentive schemes
operated by the Purchaser, to the extent possible under the relevant plan rules and any applicable law. Where Novartis Awards are subject to performance (or other) conditions and it is not possible to determine whether or not such conditions have
been met at the applicable early vesting date (or within a reasonable period thereafter), the Sellers agree that performance shall be deemed “on target”. 

For the avoidance of doubt: 
  

	 	(i)	where necessary and subject to (ii), Novartis shall rely on the exercise of existing discretions in the relevant plan rules and (provided the approval of
Novartis’s shareholders is not required) shall be expected to amend the relevant plan rules to achieve the “good leaver treatment”; 

  

	 	(ii)	Novartis (or relevant member of Novartis’s Group) shall not take any action which would require shareholder approval or which could trigger any significant legal,
Tax or operational issues for the relevant Transferred Employee (including the loss of any Tax-favourable treatment), GlaxoSmithKline’s Group, Novartis’s Group or the Purchaser’s Group. 

For the purposes of this paragraph 10.1, the “good leaver treatment” shall be that: 

 

	 	(iii)	Novartis Awards shall not lapse or be forfeited as a result of Closing except to the extent that they do not vest in accordance with (iv) and/or (v) below;

  

	 	(iv)	Novartis Awards shall vest early as a result of Closing and shall be time pro-rated to take account of the reduced period of time, as a proportion of the original
vesting period, that the relevant Transferred Employee worked within Novartis’s Group (calculated on the basis of the number of years of service as at the Closing Date, where part years of service are rounded up); and 

  
 159

	 	(v)	Novartis Awards that vest after the Closing Date shall remain subject to any relevant performance (or other) conditions, adjusted as necessary to take account of
Closing and measured up to the applicable early vesting date. 

  

	10.2	For the purposes of this paragraph 10.2, “on target” performance shall not be construed as permitting share-based awards to vest in full.

  

	10.3	Novartis agrees to indemnify the Purchaser (or relevant member of the Purchaser’s Group) for any Liabilities borne by the Purchaser’s Group in
connection with the Novartis Awards, including any Tax. The Sellers agree to use their best endeavours to ensure that the Purchaser seeks any applicable Tax relief in respect of the Novartis Awards and indemnifies Novartis in respect of any Tax
relief obtained, provided always that Novartis provides the Purchaser with any information that the Purchaser may reasonably request in this respect in a timely manner. 

 

	10.4	Subject to paragraph 10.5, Novartis undertakes to inform the Purchaser of the vesting or exercise (as applicable) of the Novartis Awards and to provide, in a
timely manner, details of the Novartis Awards that so vest or are exercised so that the Purchaser’s Group can make any applicable withholdings for Tax and pay any Tax for which the Purchaser’s Group is liable in respect of the Novartis
Awards to the relevant Tax Authority within any applicable timescale. 

  

	10.5	To the extent permitted under the relevant plan rules and any applicable law, Novartis undertakes to sell such number of the shares underlying the Novartis
Awards as may be necessary for the sale proceeds to satisfy any applicable Tax withholdings and to pay such amounts to the Purchaser in sufficient time for the Purchaser to pay such Tax to the relevant Tax Authority within any applicable timescale,
provided always that the Purchaser provides Novartis with any information that Novartis may reasonably request in this respect in a timely manner. 

  

	10.6	Novartis undertakes to pay any Tax for which Novartis’s Group is liable in respect of the Novartis Awards to the relevant Tax Authority within any
applicable timescale. 

  

	10.7	Novartis undertakes to complete any relevant Tax Return in respect of the Novartis Awards and to submit any such Tax Return to the relevant Tax Authority within
any applicable timescale. 

  

	10.8	 This paragraph shall apply where Novartis Awards lapse or are forfeited (or will lapse or be forfeited) either in whole or in part as a result
of Closing. As soon as practicable following Closing (and, in any event, by the later of 30 days from the Closing Date and 30 days from the first date after the Closing Date when the granting of share-based awards is not prevented by dealing
restrictions, subject in both cases to the relevant plan rules and any applicable law), GlaxoSmithKline (or member of GlaxoSmithKline’s Group) shall grant each relevant Transferred Employee a share-based award over shares in the capital of
GlaxoSmithKline substantially equal in value (valued as at the date of grant) to the value of the portion of their Novartis Awards which lapsed or was forfeited (or will lapse or be forfeited) as a result of Closing (valued as at the Closing Date),
where relevant, disregarding any loss (or expected loss) of Tax-favourable treatment (each a “Compensation Award”). To the extent that (i) it could reasonably have been expected that any related matching share award and/or free
share award would have been granted to a Transferred Employee following Closing in connection with 

  
 160

	 	
any Novartis Award which lapsed or was forfeited (or will lapse or be forfeited) as a result of Closing (each an “Novartis Matching Award”), and (ii) such Novartis Matching
Award has not been granted (or will not be granted) as a result of Closing, on or around the date on which such Novartis Matching Award would, in the ordinary course of business, have been made by Novartis (or member of Novartis’s Group),
GlaxoSmithKline (or member of GlaxoSmithKline’s Group) shall grant each relevant Transferred Employee a share-based award over shares in the capital of GlaxoSmithKline substantially equal in value (valued as at the date of grant) to the value
of such Novartis Matching Award (valued as at the date of grant of the related Matching Award, defined below), where relevant, disregarding any loss (or expected loss) of Tax-favourable treatment (each a “Matching Award”), subject
to the relevant plan rules and any applicable law. 

 Such Compensation Awards and Matching Awards shall be granted
pursuant to the rules of whichever share-based incentive plan operated by GlaxoSmithKline’s Group at the time of grant GlaxoSmithKline considers most closely aligned to the share-based incentive plan operated by Novartis’s Group pursuant
to which the related Novartis Award had been granted (or related Novartis Matching Award would have been granted) but will vest according to a vesting schedule substantially similar to the vesting schedule that would have otherwise applied to the
related Novartis Award or related Novartis Matching Award if Closing had not occurred. In such cases: 
  

	 	(i)	the Sellers agree to use their best endeavours to ensure that the Purchaser seeks any applicable Tax relief in respect of the Compensation Awards and Matching Awards
and indemnifies Novartis in respect of 50 per cent. of any Tax relief obtained, and GlaxoSmithKline undertakes to provide the Purchaser with any information that the Purchaser may reasonably request in this respect in a timely manner;

  

	 	(ii)	where a Compensation Award or Matching Award is granted in the form of a restricted share award, the Sellers agree to use their reasonable endeavours to ensure that the
Purchaser obtains a valid election pursuant to section 431 of the Income Tax (Earnings and Pensions) Act 2003 (or, as applicable, any similar Tax election that is available pursuant to any applicable law in another jurisdiction), provided that, if a
Seller makes representations to the other Seller to waive this obligation in respect of certain Compensation Awards or certain Matching Awards and the other Seller consents to such waiver (such consent not to be unreasonably withheld), this
paragraph (ii) shall not apply in respect of such Compensation Awards or Matching Awards; and 

  

	 	(iii)	Novartis agrees to indemnify GlaxoSmithKline (or relevant member of GlaxoSmithKline’s Group or the Purchaser’s Group) for any Liabilities borne by
GlaxoSmithKline’s Group or the Purchaser’s Group in connection with such Compensation Awards and Matching Awards, including any Tax, provided that: 

 

	 	(A)	Novartis shall not indemnify GlaxoSmithKline (or relevant member of GlaxoSmithKline’s Group or the Purchaser’s Group) to the extent that GlaxoSmithKline (or a
member of GlaxoSmithKline’s Group or the Purchaser’s Group) compensates Transferred Employees for any loss (or expected loss) of Tax-favourable treatment in respect of Novartis Awards or for any Liabilities to Tax as contemplated in
paragraph 10.9 below; 

  

	 	(B)	 Novartis only agrees to indemnify GlaxoSmithKline (or member of GlaxoSmithKline’s Group or the Purchaser’s Group) to a maximum of 50 per
cent. of the total of: (i) the value of the portion of such Novartis Awards that lapsed or was forfeited (or will lapse or be forfeited) as a result of Closing, (ii) the value of Novartis Matching Awards, and (iii) any related
Liabilities, including Tax; and 

  
 161

	 	(C)	for the avoidance of doubt, Novartis shall not indemnify GlaxoSmithKline (or member of GlaxoSmithKline’s Group or the Purchaser’s Group) for any lapse or
forfeiture (or expected lapse or forfeiture) due to a failure to meet any applicable performance (or other) conditions. 

 For these purposes, the compensation in respect of the portion of an Novartis Award which lapsed or was forfeited (or will lapse or be forfeited) as a result of Closing shall not exceed the difference
between (i) the value of the Novartis Award which could reasonably have been expected to vest on the normal vesting date but for Closing (subject, where applicable, to performance (or other) conditions), and (ii) the value of the Novartis
Award which actually vested (or will vest) as a result of Closing. 
 For the purposes of this paragraph 10.8: 

 

	 	(i)	the portion of an Novartis Award which lapsed or was forfeited (or will lapse or be forfeited) as a result of Closing shall be valued on the basis of the average price
of an ordinary share in the capital of Novartis over the five trading days immediately prior to Closing; 

  

	 	(ii)	the value of a Compensation Award to be granted shall be valued on the basis of the average price of an ordinary share in the capital of GlaxoSmithKline over the five
trading days immediately prior to the date of grant; 

  

	 	(iii)	the value of an Novartis Matching Award shall be valued on the basis of the average price of an ordinary share in the capital of Novartis over the five trading days
immediately prior to the date of grant of the related Matching Award; 

  

	 	(iv)	the value of a Matching Award to be granted shall be valued on the basis of the average price of an ordinary share in the capital of GlaxoSmithKline over the five
trading days immediately prior to the date of grant; and 

  

	 	(v)	any currency conversion shall be made in accordance with Clause 1.13.1. 

  

	10.9	To the extent that any payment to a Transferred Employee (whether by Novartis’s Group, GlaxoSmithKline’s Group or by the Purchaser’s Group) would trigger
Liabilities to Tax under section 280G of the United States Internal Revenue Code (“Section 280G”), the relevant Transferred Employee shall be allowed to choose whether to accept the full payment (and pay any relevant Section 280G
Tax) or to receive such lower payment as may be necessary in order to fall below the Section 280G threshold for Tax. To the extent that any similar Tax would arise pursuant to any applicable law in another jurisdiction, this paragraph 10.9 shall
apply mutatis mutandis. 

  

	10.10	This paragraph shall apply if any member of Novartis’s Group’s corporate executive team (or similar body) is a Transferred Employee (each a
“CET Member”). The treatment of share-based awards held by CET members shall be determined by the remuneration committee of the board of directors of Novartis (acting reasonably and in good faith and following informal consultation
with GlaxoSmithKline), subject to the rules of any relevant share-based incentive scheme and any applicable law, and the provisions of paragraphs 10.8 and 10.16 shall apply. 

  
 162

 Outstanding Share-Based Awards under GlaxoSmithKline’s Group Plans 

 

	10.11	GlaxoSmithKline agrees to indemnify the Purchaser (or relevant member of the Purchaser’s Group) for any Liabilities borne by the Purchaser’s Group in
connection with share-based awards held by Transferred Employees pursuant to a share-based incentive scheme operated by GlaxoSmithKline or another member of GlaxoSmithKline’s Group and which were granted prior to Closing
(“GlaxoSmithKline Awards”), including any Tax. The Sellers agree to use their best endeavours to ensure that the Purchaser seeks any applicable Tax relief in respect of the GlaxoSmithKline Awards and indemnifies GlaxoSmithKline in
respect of any Tax relief obtained, provided always that GlaxoSmithKline provides the Purchaser with any information that the Purchaser may reasonably request in this respect in a timely manner. 

 

	10.12	Subject to paragraph 10.13, GlaxoSmithKline undertakes to inform the Purchaser of the vesting or exercise (as applicable) of the GlaxoSmithKline Awards and to
provide, in a timely manner, details of the GlaxoSmithKline Awards that so vest or are exercised so that the Purchaser’s Group can make any applicable withholdings for Tax and pay any Tax for which the Purchaser’s Group is liable in
respect of the GlaxoSmithKline Awards to the relevant Tax Authority within any applicable timescale. 

  

	10.13	To the extent permitted under the relevant plan rules and any applicable law, GlaxoSmithKline undertakes to sell such number of the shares underlying the
GlaxoSmithKline Awards as may be necessary for the sale proceeds to satisfy any applicable Tax withholdings and to pay such amounts to the Purchaser in sufficient time for the Purchaser to pay such Tax to the relevant Tax Authority within any
applicable timescale, provided always that the Purchaser provides GlaxoSmithKline with any information that GlaxoSmithKline may reasonably request in this respect in a timely manner. 

 

	10.14	GlaxoSmithKline undertakes to pay any Tax for which GlaxoSmithKline’s Group is liable in respect of the GlaxoSmithKline Awards to the relevant Tax Authority within
any applicable timescale. 

  

	10.15	GlaxoSmithKline undertakes to complete any relevant Tax Return in respect of the GlaxoSmithKline Awards and to submit any such Tax Return to the relevant Tax
Authority within any applicable timescale. 

 2014 Performance Awards 

 

	10.16	 This paragraph 10.16 shall apply where: (i) a Transferred Employee would, in the ordinary course of business, have been granted a
share-based award pursuant to a share-based incentive scheme operated by the relevant Seller or another member of the relevant Seller’s Group on the basis of performance criteria linked to the relevant Seller’s Group’s 2014 financial
year (which may, for the avoidance of doubt, be business and/or individual performance criteria and assessment) (each a “2014 Performance Award”), and (ii) Closing occurs prior to the grant of such 2014 Performance Award. As
soon as practicable following Closing (and, in any event, by the later of 30 days from the Closing Date and 30 days from the date when the value of each 2014 Performance Award has been determined), the relevant Seller shall notify the Purchaser
(and, where the relevant Seller is Novartis, shall also notify GlaxoSmithKline) in writing of the value of each 2014 Performance Award and under which share-based incentive plan operated by the relevant Seller’s Group the related 2014
Performance 

  
 163

	 	
Award would have been granted. As soon as practicable following the receipt of such notice (and, in any event, by the later of 30 days from the receipt of such notice and 30 days from the first
date following the receipt of such notice when the granting of share-based awards is not prevented by dealing restrictions, subject in both cases to the relevant plan rules and any applicable law), GlaxoSmithKline (or member of
GlaxoSmithKline’s Group) shall grant each relevant Transferred Employee a share-based award over shares in the capital of GlaxoSmithKline substantially equal in value (valued as at the date of grant) to the value of the 2014 Performance Award
which would have been granted but for the occurrence of Closing. Such 2014 Performance Awards shall be granted pursuant to the rules of whichever share-based incentive plan operated by GlaxoSmithKline’s Group at the time of grant
GlaxoSmithKline considers most closely aligned to the share-based incentive plan operated by the relevant Seller’s Group pursuant to which the related 2014 Performance Award would have been granted. In such cases: 

 

	 	(i)	the Sellers agree to use their best endeavours to ensure that the Purchaser seeks any applicable Tax relief in respect of the 2014 Performance Awards and indemnifies
the relevant Seller in respect of any Tax relief obtained, and GlaxoSmithKline undertakes to provide the Purchaser with any information that the Purchaser may reasonably request in this respect in a timely manner; 

 

	 	(ii)	where a 2014 Performance Award is granted in the form of a restricted share award, the Sellers agree to use their reasonable endeavours to ensure that the Purchaser
obtains a valid election pursuant to section 431 of the Income Tax (Earnings and Pensions) Act 2003 (or, as applicable, any similar Tax election that is available pursuant to any applicable law in another jurisdiction), provided that, if a Seller
makes representations to the other Seller to waive this obligation in respect of certain 2014 Performance Awards and the other Seller consents to such waiver (such consent not to be unreasonably withheld), this paragraph (ii) shall not apply in
respect of such 2014 Performance Awards; and 

  

	 	(iii)	the relevant Seller agrees to indemnify GlaxoSmithKline (or relevant member of GlaxoSmithKline’s Group or the Purchaser’s Group) for any Liabilities borne by
GlaxoSmithKline’s Group or the Purchaser’s Group in connection with such 2014 Performance Awards, including any Tax. 

 The grant of a 2014 Performance Award to a Transferred Employee shall be taken into account by the Purchaser when determining the extent to which that Transferred Employee shall participate in incentive
arrangements (other than any Compensation Award or Matching Award) for employees of the Purchaser’s Group following Closing. 
 For the purposes of this paragraph 10.16: 
  

	 	(i)	the value of a 2014 Performance Award to be granted shall: (i) be determined by the relevant Seller acting reasonably and in good faith, (ii) be consistent
with both past practice and with the level of similar awards granted to employees (where Novartis is the relevant Seller) remaining in service within Novartis’s Group or (where GlaxoSmithKline is the relevant Seller) remaining in service within
GlaxoSmithKline’s Group, (iii) take into account the relevant business and/or individual performance criteria linked to the Seller’s Group’s 2014 financial year, and (iv) if Closing occurs before 31 December 2014, be
time pro-rated to take account of the reduced period of time, as a proportion of the relevant Seller’s Group’s 2014 financial year, that the relevant Transferred Employee worked within (where Novartis is the relevant Seller)
Novartis’s Group or (where GlaxoSmithKline is the relevant Seller) within GlaxoSmithKline’s Group (calculated on the basis of the number of complete months of service as at the Closing Date); 

  
 164

	 	(ii)	the number of shares to be placed under a 2014 Performance Award shall be valued on the basis of the average price of an ordinary share in the capital of
GlaxoSmithKline over the five trading days immediately prior to the date of grant; and 

  

	 	(iii)	any currency conversion shall be made in accordance with Clause 1.13.1. 

 Future share-based incentives 
  

	10.17	The Sellers confirm that it is envisaged that any share-based incentives to be provided to employees of the Purchaser’s Group following Closing will be
granted pursuant to share-based incentives schemes operated by GlaxoSmithKline or a member of GlaxoSmithKline’s Group (the “JV Awards”). Subject to paragraphs 10.8 and 10.16, the Sellers undertake to use their best endeavours
to ensure that the Purchaser indemnifies GlaxoSmithKline for any Liabilities borne by GlaxoSmithKline in connection with the JV Awards. 

  
 165

 Schedule 8 
 Employee Benefits 
 In this Schedule 8: 

“Employee Benefits” means benefits to or in respect of any current or former employee, including without limitation, any pension, early
retirement, disability, death benefit, long service awards, termination indemnity (such as Italian TFR) or post-retirement medical benefits or deferred compensation linked to retirement, disability or death benefits or old age part-time benefits
(such as German ATZ) and jubilee payments; 
 “Employee Benefit Liabilities” means liabilities and obligations (whether funded
or unfunded) in respect of any employee benefit promise, scheme, plan, fund, program, policy, practice or other individual or collective arrangement providing Employee Benefits; 
 “Oncology Funding Assumptions” means, in relation to any Transferred Employee Benefits which are similar or comparable to benefits in the same country which are Transferred
Employee Benefits under the Oncology Sale and Purchase Agreement (the “Equivalent Oncology Benefits”), the method and assumptions used under the Oncology Sale and Purchase Agreement to value those
Equivalent Oncology Benefits. For the avoidance of doubt, the Oncology Funding Assumptions are only available in respect of Transferred Employee Benefits for which there are Equivalent Oncology Benefits; 

“Other Party” means (i) where GlaxoSmithKline is the Seller, Novartis and (ii) where Novartis is the Seller, GlaxoSmithKline;

 “Other Party Group” means (i) where GlaxoSmithKline is the Other Party, GlaxoSmithKline’s Group and
(ii) where Novartis is the Other Party, Novartis’s Group; 
 “Other Party Funding Assumptions” means, in relation to
any Transferred Employee Benefits, where a member of the Other Party Group provides, in the same country, a similar or comparable benefit programme to the programme to which the Transferred Employee Benefits relate (regardless of differences in the
terms of entitlement of accrual etc.), and there is a local obligation or practice prior to the date of this Agreement to pre-fund or externally fund those similar or comparable benefits to a funding target which is determined by reference to a
method and assumptions other than IFRS (such as would, for example, be the case in relation to UK HMRC-registered defined benefit pension obligations), then that method and those assumptions as in force in relation to those similar or comparable
benefits immediately prior to the date of this Agreement (so, taking the example of UK defined benefit obligations, this would be the method and assumptions used to determine the relevant plan’s technical provisions as at the date of this
Agreement – regardless of whether the plan is in fact fully funded on that basis at any relevant time); 
 “Other Party IFRS
Assumptions” means, in relation to any Transferred Employee Benefits, where a member of the Other Party Group provides, in the same country, a similar or comparable benefit programme to the programme to which the Transferred Employee
Benefits relate (regardless of differences in the terms of entitlement of accrual etc.), the method and assumptions used most recently prior to the date of this Agreement to value those similar or comparable benefits by the Other Party Group (or any
relevant member thereof) for IFRS accounting purposes; 
 “Partial Liquidation Longstop Date” means, in relation to each of
Novartis Pensionskasse 1, Novartis Pensionskasse 2 and Kaderkasse Novartis and any similar plans operated by GlaxoSmithKline in Switzerland, the earlier of: (i) the date (if any) after Closing on which the plan undergoes partial liquidation;
and (ii) 12 months after Closing; 
 “Seller Funding Assumptions” means, in relation to any Transferred Employee Benefits,
if there is a local obligation or practice prior to the date of this Agreement to pre-fund or externally fund those Transferred Employee Benefits to a funding target which is 

  
 166

 
determined by reference to a method and assumptions other than IFRS (such as would, for example, be the case in relation to UK HMRC-registered defined benefit pension obligations), then that
method and those assumptions as in force in relation to those Transferred Employee Benefits immediately prior to the date of this Agreement (so, taking the example of UK defined benefit obligations, this would be the method and assumptions used to
determine the relevant plan’s technical provisions as at the date of this Agreement – regardless of whether the plan is in fact fully funded on that basis at any relevant time); 
 “Seller IFRS Assumptions” means, in relation to any Transferred Employee Benefits, the method and assumptions used by the Seller’s Group (or the most relevant member thereof) most
recently prior to the date of this Agreement to value those Transferred Employee Benefits for IFRS accounting purposes; 
 “Swiss
Actuary” means an actuary: (a) who can reasonably be viewed: (i) as independent of both the Other Party and each Seller; and (ii) as familiar with Swiss pension issues; and (b) whom the Other Party and each Seller have
agreed should be jointly appointed by them for the purposes of determining the Swiss Assumptions or who in default of such agreement has been appointed by the Swiss Association of Actuaries or other industry body of actuaries in Switzerland as
agreed by each Seller and the Other Party; 
 “Swiss Assumptions” means, in relation to any Transferred Employee Benefits in
Switzerland, Novartis’s Seller IFRS Assumptions adjusted: 
  

	 	(i)	by replacing – other than in so far as the Transferred Employee Benefits relate to any Swiss Potential Early Retirees – any assumed “cash balance”
annuity conversion rate in Novartis’s Seller IFRS Assumptions with a conversion rate which the Swiss Actuary certifies to GlaxoSmithKline and Novartis as representing a reasonable estimate of the likely effective overall blended conversion rate
which will apply in relation to the Transferred Employee Benefits in question, having regard to the changes to the rate which can (having regard to longevity projections, legal and governance constraints around Swiss pension structures and such
other matters as the Swiss Actuary considers relevant) in the Swiss Actuary’s opinion reasonably be expected to occur during the expected service lives of the Transferred Employees to whom the Transferred Employee Benefits relate, and weighting
the impact of those changes by reference to the ages of the relevant employees (and so the extent to which the changes will in fact operate to reduce the effective liability on GlaxoSmithKline); and 

 

	 	(ii)	by removing any reserve for death or disability benefits to the extent that the Swiss Actuary certifies to GlaxoSmithKline and Novartis that it constitutes a reserve
for liabilities to and in respect of the relevant Transferred Employees which could reasonably be externally insured by the Purchaser’s Group without introducing a new ongoing cost on the Purchaser’s Group which was not reflected in
Novartis’s ongoing cost base prior to the date of this Agreement; and 

 “Swiss Potential Early Retirees”
means those Transferred Employees employed in Switzerland who have “grandfathered” entitlements to a wholly or partly unreduced early retirement pension under the old final salary scheme operated by Novartis in Switzerland which closed at
the end of 2010; and 
 “Vaccines Funding Assumptions” means, in relation to any Transferred Employee Benefits which are
similar or comparable to benefits in the same country which are Transferred Employee Benefits under the Vaccines Sale and Purchase Agreement (the “Equivalent Vaccines Benefits”), the method and assumptions used under the
Vaccines Sale and Purchase Agreement to value those Equivalent Vaccines Benefits. For the avoidance of doubt, the Vaccines Funding Assumptions are only available in respect of Transferred Employee Benefits for which there are Equivalent
Vaccines Benefits. 

  
 167

 For the purposes of each of the Other Party Funding Assumptions, the Other Party IFRS Assumptions, the
Seller Funding Assumptions, the Seller IFRS Assumptions, the Swiss Assumptions (and, for the avoidance of doubt, the Vaccines Funding Assumptions and the Oncology Funding Assumptions), any economic and financial assumptions which are based (whether
expressly or implicitly) on yields, rates or indices shall be updated for the purposes of such definitions to take account of those yields, rates or indices as at Closing (or the latest practicable time prior to Closing). 

 

	1	Except to the extent otherwise requested by each Seller and expressly agreed by the Other Party before Closing (such Other Party agreement not to be unreasonably
withheld to the extent that it is not reasonably possible for such Seller or its Affiliates to retain the relevant Employee Benefit Liabilities – for example, where a relevant Target Group Company operates its own standalone arrangement,
liability for which cannot lawfully be assumed by another member of such Seller’s Group, or where liability unavoidably transfers by operation of law under European Council Directive 2001/23/EC or its local implementing legislation), any
Employee Benefit Liabilities in respect of service in the relevant Target Group or with any member of such Seller’s Group (including any relevant Target Group Company) or in any plan or arrangement in which any member of such Seller’s
Group (including any relevant Target Group Company) participates or has participated: 

  

	 	(a)	(in the case of a Transferred Employee) prior to Closing; or 

  

	 	(b)	(in the case of any other person) at any time, 

 (together, “Pre-Closing EB Liabilities”) will stay with or be assumed by such Seller or its Affiliates (excluding any relevant Target Group Company) and such Seller shall fully indemnify
the Purchaser and its Affiliates (which for the avoidance of doubt in the period from Closing includes any relevant Target Group Company) against any such Employee Benefit Liabilities and against any liabilities and obligations to or in respect of
any plan or arrangement for the provision of Employee Benefits in which any member of such Seller’s Group (including any relevant Target Group Company) participates or participated prior to Closing. For the avoidance of doubt, the Other
Party’s agreement under this paragraph 1 may, if the Other Party so determines, relate only to certain specified categories or tranches of relevant Pre-Closing EB Liabilities under a particular benefit programme (in other words, it does not
need to be “all or nothing”), in which case it is only those specified Pre-Closing EB Liabilities which are excluded from the scope of the Purchaser’s indemnity entitlement hereunder. 

 

	2	 Where and to the extent that the Other Party agrees under paragraph 1 that any Pre-Closing EB Liabilities may transfer to or remain with the Purchaser
and/or its Affiliates (which for the avoidance of doubt in the period from Closing includes any relevant Target Group Company), (such Pre-Closing EB Liabilities being the “Transferred Employee Benefit Liabilities” and the benefits
to which they relate being the “Transferred Employee Benefits”), the Purchaser will be compensated in respect of such Transferred Employee Benefit Liabilities as set out in the rest of this Schedule 8. Subject to being so
compensated but without prejudice to paragraphs 9 and 12, the Purchaser shall, or shall procure that its relevant Affiliate shall, assume, with a full discharge for each Seller and its Affiliates, the Transferred Employee Benefit Liabilities.
Without limiting the Other Party’s obligation not unreasonably to withhold consent under paragraph 1 above, the Seller and the Other Party hereby acknowledge that it would not be reasonably possible for the Seller or its Affiliates to retain
those Pre-Closing EB Liabilities which attach to the relevant Target Group Companies in Germany or Switzerland. So 

  
 168

	 	
subject to appropriate identification during the period before Closing of such liabilities and to the operation of the compensation mechanism set out in this Schedule 8 they will become
Transferred Employee Benefit Liabilities. The Other Party also acknowledges its agreement to the principle that the post-retirement medical healthcare plan to which it admits US Transferred Employees who immediately before Closing were members of
such a plan will take account of periods of employment with the Seller’s Group to the extent previously recognised under the equivalent Seller’s Group plan for the purposes of determining eligibility, contributions, and vesting; again,
therefore, subject to appropriate identification during the period before Closing of such liabilities and to the operation of the compensation mechanism set out in this Schedule 8, they will become Transferred Employee Benefit Liabilities.

 United Kingdom 
 For the avoidance of doubt, it is also agreed that, where the Seller is Novartis, no UK defined benefit pension liabilities are to be Transferred Employee Benefit Liabilities. Without limiting paragraph
1, this means that Novartis must prior to Closing procure that no Novartis OTC Group Company is a participating employer under the governing documents, or an ‘employer’ for the purposes of the Pensions Act 1995 and the Pensions Act 2004,
in the Chiron UK Pension Scheme or the Novartis UK Pension Scheme, and Novartis shall under paragraph 1 fully indemnify the Purchaser and its Affiliates (including any Target Group Company) against any liabilities and obligations to or in respect of
either of those plans, including any debt under section 75 of the Pensions Act 1995. 
 Switzerland 

For the avoidance of doubt, it is also agreed that the Purchaser shall procure that the Swiss Potential Early Retirees will as at Closing
be provided with equivalent early retirement benefit provisions under the replacement pension plan to be provided by the Purchaser for and in respect of the Transferred Employees employed in Switzerland under the terms of this Agreement, provided
that the Swiss Actuary confirms that such early retirement benefit provisions are allowed for in the Swiss Assumptions. 
  

	3	The value of the Transferred Employee Benefit Liabilities shall be determined on employee census data and plan provision as at Closing on the Vaccines Funding
Assumptions where available, failing which on the Oncology Funding Assumptions if those are available, failing which on: 

  

	 	(i)	in relation to any Transferred Employee Benefits in Switzerland, the Swiss Assumptions; and 

 

	 	(ii)	in relation to any other Transferred Employee Benefits, the Seller IFRS Assumptions, PROVIDED that if any of the following values is available then that value will be
used instead: 

  

	 	(A)	if a member of the Other Party Group provides, in the same country, a similar or comparable benefit programme to the programme to which the Transferred Employee
Benefits relate (regardless of differences in the terms of entitlement of accrual etc.) and neither (B) nor (C) below is available, the value which is midway between the value based on the Seller IFRS Assumptions and the Other Party IFRS
Assumptions; 

  

	 	(B)	 if (C) below is not available but there is a local obligation or practice prior to the date of this Agreement to pre-fund or externally fund the
Transferred Employee Benefits to a funding target which would lead to a greater value being placed on the Transferred Employee Benefit Liabilities than the Seller IFRS Assumptions, the value derived using the Seller Funding Assumptions; and

  
 169

	 	(C)	if there is both: (i) a local obligation or practice prior to the date of this Agreement to pre-fund or externally fund the Transferred Employee Benefits to a
funding target which would lead to a greater value being placed on the Transferred Employee Benefit Liabilities than the Seller IFRS Assumptions; and (ii) a member of the Other Party Group provides, in the same country, a similar or comparable
benefit programme to the programme to which the Transferred Employee Benefits relate (regardless of differences in the terms of entitlement of accrual etc.), the value which is midway between the value based on the Seller Funding Assumptions and the
Other Party Funding Assumptions. 

 The market value as at Closing of any underlying assets related to the
Transferred Employee Benefit Liabilities which are or are to be transferred as per paragraph 8 below will be deducted from the value of the Transferred Employee Benefit Liabilities to the extent such assets are or will be available to the Purchaser
or its Affiliates to meet such liabilities and the remaining value of the Transferred Employee Benefit Liabilities (if any) is the “Employee Benefit Indemnification Amount”. Such determination shall be carried out on a
country-by-country basis and, where necessary, on a plan-by-plan basis. For the avoidance of doubt, in relation to Switzerland, the calculation shall, if partial liquidation occurs in relation to any of the Transferred Employee Benefit Liabilities
by the Partial Liquidation Longstop Date, make allowance for the assets thereby transferred assuming that they will be available to meet such liabilities. If any Employee Benefit Indemnification Amount is greater than the estimate of such amount
determined for the purposes of the Estimated Employee Benefit Adjustment (or, where no such estimate was made, greater than zero), each Seller shall pay or procure payment so far as possible, by way of a reduction in the Purchase Consideration paid
for the particular part of the Target Group to which the payment relates, an amount equal to the difference (or, where no such estimate was made, such amount) to the Purchaser, or at the request of the Purchaser to an Affiliate of the Purchaser, as
compensation for the Transferred Employee Benefit Liabilities. If any Employee Benefit Indemnification Amount is less than the estimate of such amount determined for the purposes of the Estimated Employee Benefit Adjustment (if any), the Purchaser
shall pay an amount equal to the difference to the Seller. 
  

	4	 Each Seller and its Affiliates shall, within 45 days after Closing (or, in the case of Switzerland, 45 days after the Partial Liquidation Longstop
Date), provide its actuary, the Swiss Actuary and the actuary chosen by the Purchaser with all relevant plan, asset, assumptions and employee census information needed to calculate the Employee Benefit Indemnification Amounts in respect of any
Transferred Target Business Employees. The actuary chosen by the Seller shall provide the actuary chosen by the Other Party with its calculation of the Employee Benefit Indemnification Amounts (including, but not limited to, any supporting
documentation on which it relied as well as the methodologies it employed in calculating the Employee Benefit Indemnification Amounts), on a plan-by-plan basis, within 90 days following Closing (or, in the case of Switzerland, 90 days after the
Partial Liquidation Longstop Date). The actuary chosen by the Other Party shall review the calculation of the Employee Benefit Indemnification Amounts of the Seller’s actuary within 120 days following Closing (or, in the case of Switzerland,
120 days after the Partial Liquidation Longstop Date). The Employee Benefit Indemnification Amounts shall be determined, on a plan-by-plan basis, by mutual agreement between the Seller and the Other Party within 180 days following the Closing Date
(or, in the case of Switzerland, 180 days after the Partial Liquidation Longstop Date). 

  
 170

	5	If such Seller and the Purchaser cannot agree on any Employee Benefit Indemnification Amount within the 180-day period referred to in paragraph 4, such parties shall
appoint within five days an independent actuary acceptable to both parties, or such actuary shall be selected by the President of the Institute and Faculty of Actuaries in the UK if they cannot agree, and the independent actuary thus appointed shall
review their calculations and, within 75 days after appointment, render a final and binding decision on the amount of that Employee Benefit Indemnification Amount, and, in making such decision, shall be limited to adopting the position taken by
either one of that Seller or the Purchaser. The cost of any independent actuary shall be borne jointly by that Seller and the Purchaser. 

  

	6	In connection with the procedures referred to in this Schedule 8, each Seller and the Purchaser shall provide each other and the actuaries referred to in this Schedule
8 with access to the relevant business records and other relevant documents and information as may reasonably be requested. All documents, records and information provided for the purposes of this Schedule 8 must be accurate and complete in all
material respects. 

  

	7	Each Employee Benefit Indemnification Amount shall be paid by the relevant Seller so far as possible (by way of a reduction in the Purchase Consideration paid
for the particular part of the Target Group to which the payment relates) within 14 days following its final determination. Each Seller may make an accelerated or advance payment at its own discretion (which, for the avoidance of doubt, includes in
relation to each Employee Benefit Indemnification Amount so much (if any) of the Estimated Employee Benefit Adjustment as the Seller notified pursuant to Clause 6.4 was intended to relate to that Employee Benefit Indemnification Amount). Each
relevant Employee Benefit Indemnification Amount shall include interest calculated from (and including) the Closing Date to (and including) the date of payment at a rate per annum of LIBOR (but where amounts are prepaid or paid in stages or treated
as paid via inclusion in the Estimated Employee Benefit Adjustment then the interest will cease to accrue on so much of such Employee Benefit Indemnification Amount as has been paid). Such interest shall accrue from day to day. Any such payment
shall be made in US dollars (and any underlying values shall be expressed in US dollars) and any currency other than US dollars shall be converted into US dollars at the exchange rates determined in accordance with Clause 1.13 of this Agreement on
the Closing Date. 

  

	8	To the extent (if any) that there are any Transferred Employee Benefit Liabilities which prior to Closing were externally funded by assets held in a trust or other
vehicle established for the purposes of meeting such Transferred Employee Benefit Liabilities, the Purchaser will, if requested by a Seller before Closing and unless it is not reasonably practicable to do so, establish or nominate a trust or other
vehicle which is capable of receiving a transfer of assets from the pre-Closing trust or other vehicle to the extent that such assets relate to such Transferred Employee Benefit Liabilities. 

 

	9	If, within one year of Closing, a Seller or the Purchaser notifies the other that the membership or other benefit data (the “Data”) used for
calculating any Employee Benefit Indemnification Amount may be inaccurate, then a “Data Dispute” has arisen and the following provisions shall apply: 

  
 171

	 	(a)	On such notification, the Seller shall procure that its actuary and the Purchaser shall procure that its actuary consult each other with a view to agreeing whether the
Data is inaccurate and if so, what the accurate Data should be. If that Seller’s actuary and the Purchaser’s actuary agree that the Data is inaccurate, they will jointly certify this to be the case and advise on what the accurate Data
should be. The notification is deemed to have occurred on the date of the certification. 

  

	 	(b)	If that Seller’s actuary and the Purchaser’s actuary fail to agree whether the Data is inaccurate within 60 days of the notification by one party to the other
that the Data may be inaccurate, paragraph 5 shall apply mutatis mutandis. The notification is deemed to have occurred when the independent actuary advises that the Data is inaccurate and what the accurate Data should be.

  

	 	(c)	On the occurrence of the Data Dispute, such Seller and the Purchaser shall respectively procure that a valuation of the relevant Employee Benefit Indemnification Amount
is carried out in accordance with paragraphs 3 and 4 (mutatis mutandis) but on the basis of the accurate Data as agreed under sub-paragraph (a) or determined under sub-paragraph (b). 

 

	 	(d)	If as a consequence of sub-paragraph (c), such Seller has paid to the Purchaser an amount which on the basis of the further valuation is not payable, such amount (the
“Overpayment”) shall be repaid within 21 days of the amount of the Overpayment being agreed or determined. Any such payment shall bear interest calculated from (and including) the date the Overpayment was made to (and including) the
date the payment is made in full in accordance with this sub-paragraph (d) at a rate per annum of LIBOR. Such interest shall accrue from day to day. 

  

	 	(e)	If as a consequence of sub-paragraph (c), such Seller has not paid to the Purchaser an amount which on the basis of the further valuation is payable, such amount (the
“Outstanding Amount”) shall be paid within 21 days of the amount of the Outstanding Amount being agreed or determined. Any such payment shall bear interest calculated from (and including) the Closing Date to (and including) the date
the payment is made in full in accordance with this sub-paragraph (d) at a rate per annum of LIBOR. Such interest shall accrue from day to day. 

  

	10	Except as otherwise agreed by each Seller, the Purchaser shall where a trust or other vehicle has been established under paragraph 8, procure that all of the
assets transferred as envisaged by paragraph 8 are paid into such trust or other vehicle. If, after such payment or transfer, or after payment of an Employee Benefit Indemnification Amount or after making an Estimated Employee Benefit Adjustment,
the Purchaser and/or its Affiliates achieves a reduction in its liability to any Tax in respect of or in connection with payment or transfer, the Purchaser shall pay to that Seller (for itself and on behalf of the relevant Share Seller or Business
Seller, as applicable), within 30 days after the Purchaser would otherwise have been liable to pay the saved Tax, a sum equal to the amount of that Tax reduction so far as possible by way of an increase in the Purchase Consideration in respect of
the particular part of the Target Group to which the payment relates. This paragraph 10 applies for a period of four years following the later of the date on which a transfer of assets is made, or payment of any Employee Benefit Indemnification
Amount or Estimated Employee Benefit Adjustment is made to the Purchaser. 

  

	11	 Each Seller covenants with the Purchaser to pay to the Purchaser an amount equal to any cost, claim or liability incurred by any member of the
Purchaser’s Group which it is or becomes liable to make on or at any time after Closing by reason of 

  
 172

	 	
any change or purported change made to the terms of any relevant Transferred Employee Benefits prior to Closing proving to be or have been legally ineffective or by reason of such terms and/or
benefits failing to comply with any mandatory legal requirements (excluding any obligation to equalise guaranteed minimum pensions in the United Kingdom). The relevant Seller shall not be liable under this paragraph 11 in respect of any individual
claim (or a series of claims arising from similar or identical facts or circumstances) unless the liability in respect of such claim or series of claims exceeds US$100,000. If the Purchaser becomes aware of any fact, matter or circumstance that may
give rise to a claim against the relevant Seller under this paragraph 11, the Purchaser shall as soon as reasonably practicable give notice in writing to the relevant Seller of such facts, matters or circumstances as are then available regarding the
potential claim. Failure to give such notice within such period shall not affect the rights of the Purchaser to make a relevant claim under this paragraph 11, except that the relevant Seller shall not be liable for any increase in the amount of such
claim arising from such failure. The latest date on which the Purchaser may give notice of a claim under this paragraph 11 is the fourth anniversary of the Closing Date. 

 

	12	Notwithstanding any general provision to the contrary in Schedule 7 and subject to being compensated in accordance with this Schedule 8, the Purchaser shall admit
Transferred Employees in the United States who participated in a post-retirement medical plan immediately prior to Closing to its own post-retirement medical plan. Subject to being compensated in accordance with this Schedule 8, periods of
employment with the relevant Seller’s Group (including, without limitation, any current or former Affiliate of the relevant Seller, to the extent previously recognised under the applicable benefit plan arrangement provided by the relevant
Seller’s Group), shall be taken into account for the purposes of determining, as applicable, the eligibility for participation, contributions, and vesting for any employee under such post-retirement medical plan. 

 

	13	Notwithstanding any general provision to the contrary in Schedule 7, the US Transferred Employees shall, as of the Closing Date, become eligible to participate in a US
tax-qualified defined contribution plan to the extent such plan is sponsored by the Purchaser or a relevant member of the Purchaser’s Group. The Purchaser agrees that it will use commercially reasonable efforts to cause such plan to accept
rollovers of the account balances of the US Transferred Employees (including participant loan promissory notes) from the relevant employer’s tax-qualified retirement plans; provided that (i) the Purchaser will not be required to accept any
such rollovers that might result in material liability to the Purchaser or may otherwise cause the relevant plan to cease to qualify under Section 401(a) of the Code and (ii) the Purchaser will not be required to amend any plan to permit
participant loans. 

  

	14	 GlaxoSmithKline covenants to pay Novartis an amount equal to any payment Novartis or any member of Novartis’s Group (excluding, for the avoidance
of doubt, any Novartis OTC Group Companies – as to which, see paragraph 1 above) is or becomes liable to make on or at any time after Closing to or in respect of any post-retirement benefit plan or arrangement (whether funded or unfunded,
including without limitation any occupational pension scheme and any arrangement with only one member) in which the Purchaser, the GlaxoSmithKline Consumer Group Companies or GlaxoSmithKline’s Group participates or has at any time participated
(each a “GlaxoSmithKline Retirement Plan”). This covenant does not apply to liabilities in respect of any arrangement in which Novartis or a member of Novartis’s Group participates after

  
 173

	 	
Closing. If a financial support direction or contribution notice in respect of a pension scheme under the UK Pensions Act 2004 is received by Novartis or a member of Novartis’s Group in
respect of a GlaxoSmithKline Retirement Plan, Novartis shall, within five Business Days notify GlaxoSmithKline of the financial support direction, and will continue to pass on all related correspondence. Subject to that, however, Novartis will not
be required to take any positive action in respect of the financial support direction (including entering into any discussion or negotiations with the UK Pensions Regulator or GlaxoSmithKline as to possible financial support arrangements) in order
to benefit from the indemnity in respect of the direction or notice in this paragraph 14. 

  

	15	Novartis covenants to pay GlaxoSmithKline an amount equal to any payment GlaxoSmithKline or any member of GlaxoSmithKline’s Group (excluding, for the avoidance of
doubt, any GlaxoSmithKline Consumer Group Companies – as to which see paragraph 1 above) is or becomes liable to make on or at any time after Closing to or in respect of any post-retirement benefit plan or arrangement (whether funded or
unfunded, including without limitation any occupational pension scheme and any arrangement with only one member) in which the Purchaser, the Novartis OTC Group Companies or Novartis’s Group participates or has at any time participated (each an
“Novartis Retirement Plan”). This covenant does not apply to liabilities in respect of any arrangement in which GlaxoSmithKline or a member of GlaxoSmithKline’s Group participates after Closing. If a financial support direction
or contribution notice in respect of a pension scheme under the UK Pensions Act 2004 is received by GlaxoSmithKline or a member of GlaxoSmithKline’s Group in respect of an Novartis Retirement Plan, GlaxoSmithKline shall, within five Business
Days notify Novartis of the financial support direction, and will continue to pass on all related correspondence. Subject to that, however, GlaxoSmithKline will not be required to take any positive action in respect of the financial support
direction (including entering into any discussion or negotiations with the UK Pensions Regulator or Novartis as to possible financial support arrangements) in order to benefit from the indemnity in respect of the direction or notice in this
paragraph 15. 

  

	16	If, after Closing, the Purchaser or any member of the Purchaser’s Group participates in a GlaxoSmithKline Retirement Plan (as defined in paragraph 14 above),
unless otherwise agreed among GlaxoSmithKline, Novartis and the Purchaser, then the parties agree that the mechanism for giving effect to GlaxoSmithKline’s commitment at paragraph 1 above to the Purchaser in relation to such plan will be for
GlaxoSmithKline to procure that the only amounts (as certified by the actuary to the GlaxoSmithKline Retirement Plan) which the Purchaser or any member of the Purchaser’s Group is required to contribute to that GlaxoSmithKline Retirement Plan
will relate to the service of the employees of the Purchaser or any member of the Purchaser’s Group from and after Closing. The obligation in this paragraph 16 will continue to apply only for so long as Novartis retains a shareholding in the
Purchaser. 

  

	17	 By way of exception to the general principle at paragraph 1, where a Transferred Employee in the UK who had joined service with GlaxoSmithKline’s
Group before 1 April 2005 is made redundant within 24 months of Closing, then the Purchaser shall pay GlaxoSmithKline an amount equal to the cost of applying the Agreed UK Restructuring Arrangement to an employee of the employee’s actual
age at the date he is made redundant, but (unless the employee is prior to his redundancy still actively participating in a GlaxoSmithKline Retirement Plan) only to so much of the employee’s benefits

  
 174

	 	
in a GlaxoSmithKline Retirement Plan as were accrued prior to Closing and provided further that the Purchaser’s aggregate liability under this paragraph in respect of all such Transferred
Employees in the UK who are so made redundant is capped at £1,000,000. This cost shall be calculated on a basis consistent with that which is used across the GlaxoSmithKline’s Seller’s Retained Business for internal cross-charging
purposes in relation to the Agreed UK Restructuring Arrangement, and GlaxoSmithKline shall supply the Purchaser with such evidence as the Purchaser may reasonably require to verify that. Subject to receipt of such payment, GlaxoSmithKline shall
apply the Agreed UK Restructuring Arrangement to the relevant employee’s GlaxoSmithKline Retirement Plan benefits. GlaxoSmithKline’s commitments under paragraphs 1 and 16 above shall be amended accordingly. 

 

	18.	The parties agree that where any Transferred Employee has accrued defined contribution benefits prior to Closing in a Seller’s Group arrangement then:

 (a) that Seller shall use commercially reasonable efforts to procure the vesting of those benefits (if they
would otherwise lapse as a result of Closing); 
 (b) the parties shall, provided this will not impose unreasonable
administrative burdens on the Purchaser’s Group, co-operate in good faith to procure a transfer of the account balances of such Transferred Employee from that Seller’s Group arrangement to a Purchaser’s Group arrangement; and

 (c) for the avoidance of doubt, the Purchaser will comply with the provisions of paragraph 6.1 of Schedule 7. 

  
 175

 Schedule 9 
 Products 
 Part 1 

GlaxoSmithKline Products 
  

	
	Piriton / Piriteze
	
	Formigran
	
	Cholinex
	
	Fenbid
	
	Panadeine
	
	Panadol
	
	Panadol Cold
	
	Beechams Cold & Flu and Night/Day Nurse
	
	Coldrex
	
	Iodosan
	
	Abreva
	
	Eumovate
	
	Hinds
	
	Oilatum
	
	Physiogel
	
	Zovirax
	
	Citrucel
	
	ENO
	
	Gaviscon
	
	Tums
	
	Maxinutrition (parent company of Maximuscle, Maxifuel, Maxitone and Maxiraw)
	
	Committed Quitters
	
	Nicorette
	
	NiQuitin CQ/ Nicoderm CQ/ Nicabate
	
	Boost

  
 176

	
	
	Horlicks
	
	Maltova
	
	Aquafresh
	
	Astringosol
	
	Binaca
	
	Biotene
	
	Chlorhexamed
	
	Corega
	
	Corsodyl
	
	Dr. Best
	
	Macleans
	
	Odol
	
	Odol-med3
	
	Parodontax
	
	Polident
	
	Polident 5 minute
	
	Poligrip
	
	Poligrip Ultra
	
	Sensodyne
	
	Shumitect
	
	Super Poligrip
	
	Super Wernet’s
	
	Synthol
	
	Breathe Right
	
	Commit Lozenge
	
	Flu
	
	Cetebe
	
	Medacalm
	
	Oscal

  
 177

	
	
	Rutinoscorbin
	
	Scott’s Emulsion
	
	Viva
	
	alli

 Part 2 
 Novartis Products 
  

			
	4-Way	 	Comtrex
		
	Alca C	 	Coramin Gluc
		
	Ascriptin	 	Cruex
		
	Aseptal	 	Cuticura
		
	Balsamo	 	C-Vit Brause
		
	Benefiber	 	Degoran
		
	Benuron	 	Delsym
		
	Bialcol	 	Denavir/Vectavir
		
	Black Forest	 	Dermisone
		
	Bradoral	 	Dermo H Infantil
		
	Buckley	 	Desenex
		
	Bufferin	 	Detensor
		
	Calcium	 	Dlyanos
		
	Calcium Sandoz	 	Doans
		
	Calcium Vit. C	 	Do-Do
		
	Calcium Vit. D3	 	Doederlein
		
	Carreras/Zydermine	 	Doxiten
		
	Cibalgina	 	Dycholium
		
	Clearblue	 	Dynamisan Tonic

  
 178

			
		
	Dynamisan Vms	 	Lamisil Insoles
		
	Euceta	 	Lamisil Once
		
	Eurax	 	Lemocin
		
	Excedrin	 	Lipactin
		
	Ex-Lax	 	Locacorten Viofrom
		
	Fenistil Systemic	 	Loratadine
		
	Fenistil Topical	 	Lypsyl
		
	Flamigel	 	Lyseen
		
	Florvis	 	Maalox
		
	Gas-X	 	Macalvit
		
	Gaviscon	 	Magnesium
		
	Glyvenol	 	Magnogene
		
	Halibut	 	Mebucaine
		
	Halset	 	Med-V
		
	Hematrin	 	Merfen
		
	Hemeran	 	Meteozym
		
	Hermesetas	 	Mineral Ice
		
	Hova	 	Moisturel
		
	Idalprem	 	Myoflex
		
	Importal	 	Neda
		
	Iron	 	Neo-Citran / Theraflu
		
	Kcl-Retard	 	Neo-Intestopan
		
	Keri	 	Neotussan
		
	Kpp	 	Neril
		
	Lac-Hydrin	 	Nicotinell Gum (excluding the US)
		
	Lamisil Base	 	Nicotinell Lozenge (excluding the US) (excluding the US)

  
 179

			
		
	Nicotinell Patch (excluding the US)	 	Prorhinel
		
	Nitossil	 	Pulmex
		
	Nodoz	 	Pursennid
		
	Novafibra	 	Resoferon
		
	Novapirin	 	Resyl
		
	Nupercainal	 	Rhinomer
		
	Omniflora	 	Sancos
		
	Optalidon	 	Sandocal
		
	Optaliphen	 	Savlon
		
	Orofar	 	Selenix
		
	Osteomix	 	Senokot
		
	Otrivin	 	Sinecod
		
	Pantoloc	 	Slow-Fe
		
	Parsel	 	Spasmo Canulase
		
	Pdolocyl	 	Spasmo Cibalgin
		
	Perdiem	 	Strepsil
		
	Peristaltin	 	Sweatosan
		
	Pilka	 	Sympavagol
		
	Prevacid	 	Tavegyl / Tavist
		
	Private Label NRT Gum (excluding the US)	 	Termalgin
		
	Private Label NRT Lozenge (excluding the US)	 	Tessacof
		
	Private Label NRT Patch (excluding the US)	 	Tessalon
		
	Privin	 	Tixylix
		
	Procto-Glyvenol	 	Tonopan
		
	Proflex	 	Torres Munoz
		
		 	Tossamin

  
 180

			
		
	Tranquital	 	Verton / Venuton
		
	Transderm Scop	 	Vibrocil
		
	Triaminic	 	Vitaleyes
		
	Trimedil	 	Voltaren Cataflam Systemic
		
	Vagistat	 	Voltaren Cataflam Topical
		
	Valverde	 	Zaditen
		
	Varemoid	 	Zolben
		
	Venatural	 	Zyma D2
		
	Venoruton Systemic	 	Zymafluor
		
	Venoruton Topical	 	

 Part 3 
 Novartis Pipeline Products 
 [***] 

 

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission. 

  
 181

 Schedule 10 
 VAT 
  

	1	VAT: Records 

  

	1.1	Each Seller may, on or before the date of Closing, obtain a direction from the relevant Tax Authority for the retention and preservation by it of any VAT records
relating to its period of ownership of the relevant part of the Target Group and, where any such direction is obtained, that Seller shall: 

  

	 	1.1.1	preserve the records to which that direction relates in such a manner and for such period as may be required by the direction or by Applicable Law; and

  

	 	1.1.2	allow the Purchaser, upon the Purchaser giving reasonable notice, reasonable access to and copies of such records where reasonably required by the Purchaser for its Tax
purposes. 

  

	1.2	If no such direction as is referred to in paragraph 1.1 above is obtained on or before the date of Closing and any documents in the possession or control of a
member of a Seller’s Group are required by law to be preserved by the Purchaser, that Seller shall, as soon as reasonably practicable after Closing, deliver such documents to the Purchaser. 

 

	2	VAT: Going Concern - EU Member States 

  

	2.1	The Sellers and the Purchaser shall use reasonable endeavours (including, for the avoidance of doubt, the making of an election or application in respect of VAT
to any Tax Authority or entering into a written agreement) to secure that, to the extent reasonably possible, the sale of all or any part of the Target Group Businesses, so far as carried on in the European Union, is treated as neither a supply of
goods nor a supply of services for the purposes of the laws governing VAT in each relevant member state. 

  

	2.2	Each Business Seller shall have the right to seek a ruling from the relevant Tax Authority as to whether the sale of all or part of the Target Group Businesses,
so far as carried on in the relevant member state, should be treated as neither a supply of goods nor a supply of services for the purposes of the laws governing VAT in that member state and to account for VAT (and accordingly to seek an additional
payment from the Purchaser under Clause 3.3.3) in accordance with that ruling. The relevant Seller shall not be obliged to challenge (or to procure that any relevant Business Seller challenges) that ruling unless required to do so by the Purchaser.
If the Purchaser wishes to challenge, or to require the relevant Business Seller to challenge, any such ruling it may do so, provided that it bears the full cost of, and agrees to indemnify the relevant Business Seller in respect of any loss arising
from or in connection with, that challenge and that such challenge shall not affect the date on which VAT must be paid to the relevant Seller under paragraph 4 below. 

 

	2.3	Insofar as no ruling has been obtained from a relevant Tax Authority prior to Closing, each Seller shall determine in good faith if (or the extent to which) VAT
is payable in respect of the sale of the Target Group Businesses carried on by a member of that Seller’s Group and shall be entitled to charge (or not to charge) VAT to the Purchaser in accordance with such determination.

	3	VAT: Going Concern - non-EU Jurisdictions 

  

	3.1	To the extent that any state outside the European Union provides for relief or exemption from VAT on the transfer of a business or a company or treats such a
transaction as being non-taxable for VAT purposes, the Sellers and the Purchaser shall use reasonable endeavours (including, for the avoidance of doubt, the making of an election or application in respect of VAT to any Tax Authority or entering into
a written agreement) to secure such relief, exemption or treatment, to the extent reasonably possible, as regards the sale of all or part of the Target Group Businesses (insofar as the business of the Target Group is carried on in the relevant
state) under this Agreement. 

  

	3.2	The relevant Business Seller shall have the right to seek a ruling from the relevant Tax Authority as to whether the sale of all or part of the Target Group
Businesses, so far as the business of the Target Group is carried on in the relevant state, is eligible for a relief or exemption or is otherwise eligible to be treated as non-taxable for the purposes of the laws governing VAT in that state and to
account for VAT and accordingly seek an additional payment from the Purchaser under Clause 3.3.3) in accordance with that ruling. The relevant Seller shall not be obliged to challenge (or to procure then the relevant Business Seller challenges) that
ruling unless required to do so by the Purchaser. If the Purchaser wishes to challenge, or to require the relevant Business Seller to challenge, any ruling it may do so, provided that it bears the full cost of, and agrees to indemnify the relevant
Business Seller in respect of any loss arising from or in connection with, that challenge and that such challenge shall not affect the date on which VAT must be paid to the relevant Seller under paragraph 4 below. Insofar as no ruling has been
obtained from a relevant Tax Authority prior to Closing, each Seller shall determine in good faith if (or the extent to which) VAT is payable in respect of the sale of the Target Group Businesses carried on by a member of that Seller’s Group
and shall be entitled to charge (or not to charge) VAT to the Purchaser in accordance with such determination. 

  

	4	VAT: Time, Manner and Currency of Payment 

  

	4.1	Any amounts which the Purchaser is obliged to pay to a Seller under this Agreement in respect of VAT shall be paid by the Purchaser, on its own account or on
behalf of another member of the Purchaser’s Group, to that Seller or to such member of that Seller’s Group as that Seller may direct. Such amounts shall be paid in the currency in which the VAT in question must be accounted for to the
relevant Tax Authority. 

  

	4.2	Subject to any provision or express agreement to the contrary, any amounts in respect of VAT payable in any jurisdiction in respect of the transfer at Closing of
any of the Target Group Businesses or Shares shall be paid in accordance with paragraph 4.1 above at Closing against production of a valid VAT invoice (or equivalent, if any). 

 

	4.3	Notwithstanding any other provision of this Agreement, the Purchaser shall not be liable to account to a Seller or any member of a Seller’s Group for or in
respect of penalties or interest arising solely from the failure of that Seller or any other member of that Seller’s Group to account promptly for VAT to the relevant Tax Authority following that Seller having been placed in the appropriate
amount of funds for that purpose by the Purchaser. 

  
 Page 1

 Schedule 11 
 Closing Obligations 
  

	1	GENERAL OBLIGATIONS 

  

	1.1	The Sellers’ Obligations 

 On Closing, each Seller shall deliver or make available to the Purchaser the following: 
  

	 	1.1.1	the Tax Indemnity duly executed by that Seller; 

  

	 	1.1.2	the Ancillary Agreements (other than the France SAPA and the Netherlands SAPA, and any other Ancillary Agreements that have not been agreed and are subject to
any of Clauses 8.11, 8.12, 8.13 and 8.14) duly executed by the relevant members of that Seller’s Group; 

  

	 	1.1.3	evidence reasonably satisfactory to the Purchaser that that Seller, and each of its relevant Affiliates, is authorised to execute this Agreement, the Tax
Indemnity, the Ancillary Agreements and the Local Transfer Documents (including, where relevant, any notarial deeds referred to in this Schedule 11), in each case, to the extent that they are parties thereto; 

 

	 	1.1.4	the Certificate duly executed by that Seller; and 

  

	 	1.1.5	the statutory books of the Target Group Companies (which shall be written up to but not including the Closing Date), the certificate of incorporation (and
certificate of incorporation on change of name, if any) and common seal (if any) of each Target Group Company and share certificates (or other documents of title) in respect of all the issued share capital of each Target Group Company.

  

	1.2	Novartis’s Obligations 

 In addition, Novartis shall, on or before Closing: 
  

	 	1.2.1	if requested by the Purchaser by notice in writing not less than five Business Days prior to the Closing Date: 

 

	 	(i)	procure the present auditors of each Novartis OTC Group Company to resign their office as such, such resignations to take effect as at the Closing Date;

  

	 	(ii)	procure board meetings of the relevant Novartis OTC Group Companies are held, or written resolutions of the board are passed, at or by which it shall be resolved that
each of the transfers relating to the relevant Shares shall, so far as possible, be approved for registration; 

  
 Page 2

	 	(iii)	procure any then present directors and officers (if any) of each Novartis OTC Group Company that are not Novartis Employees resign their offices to take effect at the
Closing Date as such and to relinquish any rights which they may have under any contract of employment with any Novartis OTC Group Company or under any statutory provisions (including any right to damages or compensation for breach of contract, loss
of office, redundancy or unfair dismissal or any other account whatsoever) and to confirm that no agreement or arrangement is outstanding under which any Novartis OTC Group Company has or could have any obligation to any of them including in respect
of remuneration or expenses; and 

  

	 	1.2.2	procure that the First Novartis Shareholder and the Second Novartis Shareholder (as defined in the Shareholders’ Agreement) carry out the actions they are
required to do under clause 2.1 of the Shareholders’ Agreement prior to Closing. 

  

	1.3	GlaxoSmithKline’s Obligations 

 In addition, GlaxoSmithKline shall, on or before Closing, procure that: 
  

	 	1.3.1	a shareholder meeting of the Purchaser is held or a written resolution is passed at which it is resolved that: 

 

	 	(i)	the articles of association in the Agreed Terms are adopted; and 

  

	 	(ii)	the directors of the Purchaser are authorised to allot the Consideration A Shares and B Shares; and 

 

	 	(iii)	the name of the Purchaser is changed to GlaxoSmithKline Consumer Healthcare Holdings Limited; 

 

	 	1.3.2	the First GlaxoSmithKline Shareholder and the Second GlaxoSmithKline Shareholder (as defined in the Shareholders’ Agreement) carry out the actions they are
required to do under clause 2.1 of the Shareholders’ Agreement prior to Closing, 

 and, if requested by the
Purchaser by notice in writing not less than five Business Days prior to the Closing Date (it being the case that the Purchaser cannot issue a request of this nature to Novartis without making an equivalent request to GlaxoSmithKline, unless there
are valid reasons for treating them differently): 
  

	 	1.3.3	procure board meetings of the relevant GlaxoSmithKline Consumer Group Companies are held, or written resolutions of the board are passed, at or by which it shall
be resolved that each of the transfers relating to the relevant Shares shall, so far as possible, be approved for registration; and 

  

	 	1.3.4	 procure any then present directors and officers (if any) of each GlaxoSmithKline Consumer Group Company that are not GlaxoSmithKline Employees
resign their offices to take effect at the Closing Date as such and to relinquish any rights which they may have under any contract of employment with any GlaxoSmithKline Consumer Group Company or under any statutory provisions

  
 Page 3

	 	
(including any right to damages or compensation for breach of contract, loss of office, redundancy or unfair dismissal or any other account whatsoever) and to confirm that no agreement or
arrangement is outstanding under which any GlaxoSmithKline Consumer Group Company has or could have any obligation to any of them including in respect of remuneration or expenses. 

 

	1.4	The Purchaser’s Obligations 

 On Closing, the Purchaser shall deliver or make available to each Seller the following: 
  

	 	1.4.1	the Tax Indemnity duly executed by the Purchaser; 

  

	 	1.4.2	the Ancillary Agreements (other than the France SAPA and the Netherlands SAPA and, if they have not been agreed, the Transitional Services Agreements, the
Manufacturing, Supply and Distribution Agreements and the Services Agreement) duly executed by the relevant members of the Purchaser’s Group; and 

  

	 	1.4.3	evidence reasonably satisfactory to the Seller that the Purchaser, and each of its relevant Affiliates, are authorised to execute this Agreement, the Tax
Indemnity, the Ancillary Agreements and the Local Transfer Documents (including, where relevant, any notarial deeds referred to in this Schedule 11), in each case, to the extent that they are parties thereto. 

In addition, subject to GlaxoSmithKline and Novartis having done or procured to be done those things set out in paragraphs 1.1, 1.2 and
1.3, as relevant, at Closing the Purchaser shall: 
  

	 	1.4.4	allot and issue the A Shares to GlaxoSmithKline (or such other of GlaxoSmithKline’s Wholly-Owned Subsidiaries as GlaxoSmithKline may direct by notice in
writing to the Purchaser at least five Business Days prior to the Closing Date, provided that no more than two members of GlaxoSmithKline’s Group shall be issued A Shares at Closing); and 

 

	 	1.4.5	allot the B Shares to Novartis (or such other of Novartis’s Wholly-Owned Subsidiaries as Novartis may direct by notice in writing to the Purchaser at least
five Business Days prior to the Closing Date, provided that no more than two members of Novartis’s Group shall be issued B Shares at Closing). 

  

	2	TRANSFER OF THE SHARES AND TARGET GROUP BUSINESSES 

  

	2.1	General Transfer Obligations 

 On Closing or such other date as agreed between the parties, each Seller shall procure that its Share Sellers and its Business Sellers shall, and the Purchaser shall, execute and/or deliver and/or make
available Local Transfer Documents and take such steps as are required to transfer the Shares and relevant Target Group Businesses in accordance with this Agreement. 

  
 Page 4

	2.2	Specific Transfer Obligations 

 For the purposes of compliance with paragraph 2.1, each Seller and the Purchaser shall, between the date of this Agreement and Closing, negotiate in good faith any and all Local Transfer Documents and
other such steps as are required to transfer the Shares and Target Group Businesses in accordance with this Agreement. 

  
 Page 5

 Schedule 12 
 Post Closing Adjustments 
 Part 1 

Preparation of Closing Statement 
  

	1	PREPARATION 

  

	1.1	No later than 60 days following Closing, each Seller shall deliver to the Purchaser a Draft Closing Statement. Prior to such delivery, each Seller shall so far
as is practicable consult with the Purchaser with a view to reducing the potential areas of disagreement. 

  

	1.2	In order to enable each Seller to prepare its Draft Closing Statement, the Purchaser shall keep up-to-date and, subject to reasonable notice, make available to
that Seller’s representatives and to that Seller’s accountants all books and records relating to that Seller’s Target Group during normal office hours and co-operate with them with regard to the preparation, review and agreement or
determination of that Draft Closing Statement. The Purchaser agrees to make available the services of the employees of that Seller’s Target Group to assist that Seller in the preparation, review and agreement or determination of that Draft
Closing Statement. 

  

	1.3	In order to allow the Purchaser to review the Draft Closing Statements, each Seller shall, subject to reasonable notice, make available to the Purchaser’s
representatives and to the Purchaser’s accountants all books and records relating to the preparation of the relevant Draft Closing Statement during normal office hours and co-operate with them with regard to their review of that Draft Closing
Statement. Each Seller agrees to make available the services of its employees and its Affiliates to assist the Purchaser in its review of that Draft Closing Statement. 

 

	1.4	If the Purchaser does not within 60 days of presentation to it of a Draft Closing Statement give notice to the Seller that produced it that it disagrees with
that Draft Closing Statement or any item thereof, such notice stating the reasons for the disagreement in reasonable detail and specifying the adjustments which, in the Purchaser’s opinion, should be made to that Draft Closing Statement (the
“Purchaser’s Disagreement Notice”), that Draft Closing Statement shall be final and binding on that Seller and the Purchaser for all purposes. If the Purchaser gives a valid Purchaser’s Disagreement Notice within such 60
days, that Seller and the Purchaser shall attempt in good faith to reach agreement in respect of that Draft Closing Statement and, if they are unable to do so within 30 days of such notification, that Seller or the Purchaser may by notice to the
other require that that Draft Closing Statement be referred to the Reporting Accountants (an “Appointment Notice”). 

  

	1.5	Within 30 days of the giving of an Appointment Notice, the relevant Seller may by notice to the Purchaser indicate that, in the light of the fact that the
Purchaser has not accepted the Draft Closing Statement in its entirety, it wishes the Reporting Accountants to consider matters relating to the Draft Closing Statement in addition to those specified in the Purchaser’s Disagreement Notice,
provided that such matters as are related to the matters specified in the Purchaser’s Disagreement Notice and that the notice states in reasonable detail the reasons why and in what respects that Seller believes that the Draft Closing Statement
should be altered in respect of such matters (the “Seller’s Disagreement Notice”). 

  
 Page 6

	1.6	The Reporting Accountants shall be engaged jointly by that Seller and the Purchaser on the terms set out in this paragraph 1 and otherwise on such terms as
shall be agreed; provided that neither that Seller nor the Purchaser shall unreasonably (having regard, inter alia, to the provisions of this paragraph 1) refuse its agreement to terms proposed by the Reporting Accountants or by the other party. If
the terms of engagement of the Reporting Accountants have not been settled within 45 days of their identity having been determined (or such longer period as that Seller and the Purchaser may agree) then, unless that Seller or the Purchaser is
unreasonably refusing its agreement to those terms, those accountants shall be deemed never to have become the Reporting Accountants and new Reporting Accountants shall be selected in accordance with the provisions of this Agreement.

  

	1.7	Except to the extent that the relevant Seller and the Purchaser agree otherwise, the Reporting Accountants shall determine their own procedure but:

  

	 	1.7.1	apart from procedural matters and as otherwise set out in this Agreement shall determine only: 

 

	 	(i)	whether any of the arguments for an alteration to the relevant Draft Closing Statement put forward in the Purchaser’s Disagreement Notice or the Seller’s
Disagreement Notice is correct in whole or in part; and 

  

	 	(ii)	if so, what alterations should be made to that Draft Closing Statement in order to correct the relevant inaccuracy in it; 

 

	 	1.7.2	shall apply the accounting principles, policies, procedures, practices and estimation techniques as set out in Part 2 of this Schedule 12;

  

	 	1.7.3	shall make their determination pursuant to paragraph 1.7.1 as soon as is reasonably practicable; and 

 

	 	1.7.4	the procedure of the Reporting Accountants shall: 

  

	 	(i)	give that Seller and Purchaser a reasonable opportunity to make written and oral representations to them; 

 

	 	(ii)	require that each party supply the other with a copy of any written representations at the same time as they are made to the Reporting Accountants;

  

	 	(iii)	permit that Seller and the Purchaser to be present while oral submissions are being made by the other party; and 

 

	 	(iv)	for the avoidance of doubt, the Reporting Accountants shall not be entitled to determine the scope of their own jurisdiction. 

 

	1.8	The Reporting Accountants shall send that Seller and the Purchaser a copy of their determination pursuant to paragraph 1.7.1 within one month of their
appointment. Such determination: 

  
 Page 7

	 	1.8.1	shall be made available to that Seller and the Purchaser in writing; and 

 

	 	1.8.2	unless otherwise agreed by that Seller and the Purchaser, shall include reasons for each relevant determination. 

 

	1.9	The Reporting Accountants shall act as experts and not as arbitrators and their determination of any matter falling within their jurisdiction shall be final and
binding on that Seller and the Purchaser save in the event of manifest error (when the relevant part of their determination shall be void and the matter shall be remitted to the Reporting Accountants for correction). In particular, their
determination shall be deemed to be incorporated into the relevant Draft Closing Statement. 

  

	1.10	The expenses (including amounts in respect of VAT) of the Reporting Accountants shall be borne as they shall direct at the time they make any determination under
paragraph 1.7.1(i) or, failing such direction, equally between the Purchaser and that Seller. 

  

	1.11	That Seller and the Purchaser shall co-operate with the Reporting Accountants and comply with their reasonable requests made in connection with the carrying out
of their duties under this Agreement. In particular, each other party shall keep up-to-date and, subject to reasonable notice, make available to that Seller’s representatives, that Seller’s accountants and the Reporting Accountants all
books and records relating to the relevant Target Group during normal office hours as that Seller or the Reporting Accountants may reasonably request during the period from the appointment of the Reporting Accountants down to the making of the
relevant determination. 

  

	1.12	Nothing in this Schedule 12 shall entitle a party or the Reporting Accountants access to any information or document which is protected by legal professional or
litigation privilege, provided that neither the relevant Seller nor the Purchaser shall be entitled to refuse to supply such part or parts of documents as contain only the facts on which the relevant claim or argument is based.

  

	1.13	Each party and the Reporting Accountants shall, and shall procure that its accountants and other advisers shall, keep all information and documents provided to
them pursuant to this paragraph 1 confidential and shall not use the same for any purpose, except for disclosure or use in connection with the preparation of the Draft Closing Statement, the proceedings of the Reporting Accountants or another matter
arising out of this Agreement. 

 Part 2 

Closing Statement Principles 
 This Part 2 of Schedule 12 comprises the specific rules, principles, policies and practices, without limitation, for preparing each Closing Statement. 

Each Closing Statement sets out the Working Capital, the Working Capital Adjustment, the Target Group Companies’ Cash Balances, the Intra-Group
Non-Trade Receivables, the Third Party Indebtedness, the Intra-Group Non-Trade Payables, the Employee Benefits Adjustment and the Tax Adjustment for the relevant Seller, in each case, as prepared in accordance with the specific rules, principles,
policies and practices set forth in this Part 2 of Schedule 12. Each Closing Statement shall be prepared in the form of the Illustrative Closing Statement in Part A (in the case of GlaxoSmithKline) or Part B (in the case of Novartis) of Part 3 of
this Schedule 12. 

  
 Page 8

 For the avoidance of doubt, each Closing Statement as referred to in this Part 2 of Schedule 12 shall
inclusively apply to each of the Draft Closing Statement and the Closing Statement for each Seller. 
  

	1	Closing Statement Rules 

  

	1.1	Each Closing Statement shall be prepared as follows: 

  

	 	1.1.1	in accordance with the specific accounting treatments set out in paragraph 2 of this Part 2 of Schedule 12; and, subject thereto 

 

	 	1.1.2	adopting the same accounting principles, methods, procedures and practices utilized in preparing the Statement of Net Assets, as detailed in the Statement of Net
Asset Rules, applied on a consistent basis using consistent estimation methodologies and judgments and with consistent classifications as were used to prepare the Statement of Net Assets; and subject thereto 

 

	 	1.1.3	in accordance with IFRS. 

  

	1.2	For the avoidance of doubt, paragraph 1.1.1 shall take precedence over paragraphs 1.1.2 and 1.1.3, and paragraph 1.1.2 shall take precedence over paragraph
1.1.3. 

  

	2	Specific requirements 

  

	2.1	Cut-off 

 Each Closing
Statement (including each Draft Closing Statement) shall not take into account any additional events or any additional information that becomes available after the date that such Closing Statement is agreed or, if earlier, such time as the Purchaser
serves a Purchaser’s Disagreement Notice. 
  

	2.2	Change of Ownership 

 No
Closing Statement shall be adjusted for any charges, provisions, reserves or write-offs in respect of any costs, liabilities or charges that may be incurred by the relevant Contributed Business prior to or after the Closing as a consequence of the
change of ownership of the relevant Target Group or any changes in the management strategy, direction or priority or possible closure of any part of that Target Group by the Purchaser after Closing, whether or not resulting from the change in
ownership. 
  

	2.3	Deferred Tax 

 The Closing
Statement (including the Draft Closing Statement) shall not take into account or provide for deferred Tax. 
  

	2.4	Other Taxes 

 The Closing
Statement (including the Draft Closing Statement) shall take account of or provide for all income taxes and sales taxes, to which, in the case of Novartis, lines BS14_120 Taxes other than income taxes (Liability account) and BS13_108 Value added tax
receivable apply. 

  
 Page 9

	3	Supplementary Working Capital Rules 

  

	3.1	This paragraph 3 comprises supplementary specific rules, principles, policies and practices applicable to the preparation of the Working Capital to be set forth
in each Closing Statement. For the avoidance of doubt, each of the specific rules, principles, policies and practices set out in paragraph 1 and 2 shall be equally applicable to the Working Capital. 

 

	3.2	For each of the Sellers, the Working Capital of each of their Joint Venture Entities shall be included within the calculation of Working Capital only if such
Joint Venture Entities are consolidated into the relevant Seller’s Group accounts, and the amount of any such Joint Venture Entities Working Capital shall be calculated as if such Joint Venture Entity is wholly-owned by a member of that
Seller’s Group. 

  

	3.3	In relation to the France Business for each Seller and, in respect of GlaxoSmithKline only, the Netherlands Business, if one or, in respect of GlaxoSmithKline
only, both business(es) is (are) not transferred to the Purchaser under the terms of this Agreement at Closing, the Working Capital relating to such business (or businesses) shall not be included in the determination of Working Capital at the
Effective Time. If that France Business or, in respect of GlaxoSmithKline only, the Netherlands Business is (are) Transferred to the Purchaser after Closing, then a further adjustment shall be made to the Closing Statement on the assumption that the
France Business and/or, in respect of GlaxoSmithKline only, the Netherlands Business were included in the Closing Statement taking the relevant items for the relevant business as of the date they transferred to the Purchaser. Any adjustment arising
as a result of including the France Business or, in respect of GlaxoSmithKline only, the Netherlands Business in the Closing Statement after the date of Closing shall be agreed and paid on the same basis as the Closing Statement was agreed and
payment in respect thereof made. 

  

	3.4	Part 3 of this Schedule 12 sets forth, for illustrative purposes only a computation of the Working Capital of Novartis’s and GlaxoSmithKline’s Working
Capital as of the close of business on 31 December 2013. 

  
 Page 10

 Part 3 
 Illustrative Closing Statement 
 Part A - GlaxoSmithKline 

 

			
	 Target Group Companies’ Cash Balances (Cash & cash equivalents)
	  	[    ]
		
	 Intra-Group Non-Trade Receivables (Total
financing and loans to subsidiaries / JV), comprising:
	  	[    ]
	 [—]
	  	[    ]
		
	 Third Party Indebtedness, comprising:
	  	
	 Financial Debt – long term
	  	[    ]
	 Financial Debt – short term
	  	[    ]
		
	 Intra-Group Non-Trade Payables
	  	[    ]
	Financing from subsidiaries / JV:	  	[    ]
	 [—]
	  	[    ]
	Loans from subsidiaries / JV:	  	[    ]
	 [—]
	  	[    ]
		
	 Employee Benefit Indemnification Amount
	  	
		
	 Tax Adjustment, comprising
	  	[    ]
	 Current income tax receivables
	  	[    ]
	 Income taxes payable
	  	[    ]
	 VAT
	  	[    ]
		
	 Intra-Group Trading Balances
	  	
	 Intra-group Trade Receivables
	  	[    ]
	 Transferred Accounts Receivables1
	  	[    ]

  

	1 	 That are payable by any member of GlaxoSmithKline’s Group (other than a Target Group Company) by a Business Seller of GlaxoSmithKline’s Group

  
 Page 11

			
	 Intra-group Trade Payables
	  	[    ]
	 Transferred Accounts Payables2
	  	[    ]
		
	 Adjustment (if any)
	  	[    ]
		
	 Net Working Capital (*)
	  	[    ]
	 Inventory
	  	[    ]
	 Trade Receivables
	  	[    ]
	 Trade Payables
	  	[    ]
	 Working Capital Adjustment
	  	[    ]
		
	 Balancing payment required:
	  	

 Part B – Novartis 

 

			
	 Target Group Companies’ Cash Balances (BS01_180 Cash & cash equivalents)
	  	[    ]
		
	 Intra-Group Non-Trade Receivables (BS01_050 Total financing and loans to subsidiaries / JV), comprising:
	  	[    ]
	 [***]
	  	[    ]
		
	 Third Party Indebtedness, comprising:
	  	[    ]
	 BS01_511 Financial Debt – long term
	  	[    ]
	 BS01_651 Financial Debt – short term
	  	[    ]
		
	 Intra-Group Non-Trade Payables
	  	[    ]
	 BS01_516 Financing from subsidiaries / JV:
	  	[    ]

  

	2 	 That are payable to any member of GlaxoSmithKline’s Group (other than a Target Group Company) by a Business Seller of GlaxoSmithKline’s Group

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission. 

  
 Page 12

			
	 [***]
	  	[    ]
	 BS01_518 Loans from subsidiaries / JV:
	  	[    ]
	 [***]
	  	[    ]
		
	 Employee Benefit Indemnification Amount
	  	
		
	 Tax Adjustment, comprising
	  	[    ]
	 BS13_190 Current income tax receivables
	  	[    ]
	 BS01_660 Income taxes payable
	  	[    ]
	 BS14_120 Taxes other than income taxes
	  	[    ]
	 BS13_108 Value added tax receivable apply
	  	[    ]
		
	 Intra-Group Trading Balances
	  	
	 BS01_130 Receivables own BU – Corporate
	  	[    ]
	 BS01_140 Receivables other BU’s
	  	[    ]
	 BS01_620 Payables own BU – Corporate
	  	[    ]
	 BS01_630 Payables other BU’s
	  	[    ]
	 Transferred Accounts Receivables3
	  	[    ]
	 Transferred Accounts Payables4
	  	[    ]
	 Adjustment (if any)
	  	[    ]
		
	 Net Working Capital (*)
	  	[    ]
	 BS01_110 Total inventories
	  	[    ]
	 BS01_120 Trade receivables (3rd parties and AC)
	  	[    ]
	 BS01_610 Trade payables (3rd parties and AC)
	  	[    ]

  

	3 	That are payable by any member of Novartis’s Group (other than a Target Group Company) by a Business Seller of Novartis’s Group 

	4 	That are payable to any member of Novartis’s Group (other than a Target Group Company) by a Business Seller of Novartis’s Group 

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission. 

  
 Page 13

			
	 Net Working Capital
	  	[    ]
	 Working Capital Adjustment
	  	[    ]
		
	 Balancing payment required:
	  	[    ]

  
 Page 14

 Part 4 
 Illustrative Working Capital Statement 
 Part A – Novartis

 All amounts in US$ thousands 
  

					
	 	  	Illustrative Net Working
Capital as per Dec 31, 2013	 
	 BS01_110 Total inventories
	  	 	[***	] 
	 BS01_120 Trade receivables (3rd parties and AC)
	  	 	[***	] 
	 BS01_610 Trade payables (3rd parties and AC)
	  	 	[***	] 
		
	 Illustrative Net Working Capital
	  			

 Part B – GlaxoSmithKline 
 All amounts in GBP millions 
  

					
	 	  	Illustrative Net Working
Capital as per Dec 31, 2013	 
		
	 Inventory
	  	 	[***	] 
		
	 Third Party Trade Receivables
	  	 	[***	] 
		
	 Third Party Trade Payables
	  	 	[***	] 
		
	 Illustrative Net Working Capital
	  	 	[***	] 

  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission. 

  
 Page 15

 Schedule 13 
 Warranties given under Clause 9.1 
  

	1	Authority and Capacity 

  

	1.1	Incorporation 

 The Seller
and each Share Seller and Business Seller is validly existing and is a company duly incorporated and registered under the law of its jurisdiction of incorporation. 
  

	1.2	Authority to enter into Agreement 

  

	 	1.2.1	The Seller and each Share Seller and Business Seller has the legal right and full power and authority to enter into and perform this Agreement, any Ancillary Agreement
to which it is a party and any other documents to be executed by it pursuant to or in connection with this Agreement or any Ancillary Agreement. 

  

	 	1.2.2	The documents referred to in paragraph 1.2.1 will, when executed, constitute valid and binding obligations on the Seller and each Share Seller and Business Seller
within that Seller’s Group in accordance with their respective terms. 

  

	 	1.2.3	Except as referred to in this Agreement, the Seller: 

  

	 	(i)	is not required to make any announcement, consultation, notice, report or filing; and 

 

	 	(ii)	does not require any consent, approval, registration, authorisation or permit, 

 in each case in connection with the performance of this Agreement or any other document referred to in paragraph 1.2.1. 
  

	 	1.2.4	The execution and delivery of the documents referred to in paragraph 1.2.1 and the performance by the Seller, each Share Seller and each Business Seller within that
Seller’s Group of their respective obligations under them, will not: 

  

	 	(i)	result in a breach of any provision of the memorandum or articles of association or by laws or equivalent constitutional document of the relevant member of the
Seller’s Group; or 

  

	 	(ii)	result in a breach of, or constitute a default under, any instrument or contract to which the relevant member of the Seller’s Group is party or by which the
relevant member of the Seller’s Group is bound where such breach is material to their ability to perform their obligations under such documents; 

  

	 	(iii)	result in a breach of any existing order, judgment or decree of any court or Governmental Entity by which the relevant member of the Seller’s Group is bound and
where such breach is material to their ability to perform their obligations under such documents. 

  

	1.3	Authorisation 

 The Seller
and each Share Seller and Business Seller within its Group has taken, or will have taken by Closing, all corporate action required by it to authorise it to enter into and to perform this Agreement, any Ancillary Agreement to which it is a party and
any other documents to be executed by it pursuant to or in connection with this Agreement or any Ancillary Agreement. 

  
 Page 16

	2	Target Group 

  

	2.1	Organisation and Standing of the Target Group Companies 

  

	 	2.1.1	All of the equity interests in each of the Target Group Companies (other than the Joint Venture Entities) are held by the Seller or another member of the Seller’s
Group. 

  

	 	2.1.2	Each Target Group Company is duly incorporated, validly existing and in good standing, under the laws of its jurisdiction of organisation and has all necessary
corporate power under its constitutional documents to conduct its portion of its Contributed Business as at the date of this Agreement. 

  

	2.2	The Shares 

  

	 	2.2.1	Either the Seller or one of its Affiliates is the legal and beneficial owner of the GlaxoSmithKline Shares or the Novartis Shares, as the case may be (the
“Relevant Shares”). 

  

	 	2.2.2	There is no option, right to acquire, mortgage, charge, pledge, lien or other form of security or Encumbrance or equity on, over or affecting the Relevant Shares or any
of them and there is no agreement or commitment to give or create any. 

  

	 	2.2.3	All of the Relevant Shares have been duly authorised and validly issued and are fully paid and non-assessable. There are no options, warrants, rights, convertible,
exercisable or exchangeable securities, “phantom” stock rights, stock appreciation rights, stock-based performance units, commitments, Contracts, arrangements or undertakings of any kind to which any of the Target Group Companies is a
party or by which it is bound obligating any of the Target Group Companies to issue, deliver or sell, or cause to be issued, delivered or sold, additional shares of capital stock or other equity interests in, or any security convertible into, or
exercisable or exchangeable for, any capital stock of, or other equity interest in, such Target Group Company. 

  

	 	2.2.4	There are no outstanding Contracts to which any of the Target Group Companies is a party or is otherwise bound to repurchase, redeem or otherwise acquire any shares,
capital stock or other equity interest of such Target Group Company. 

  

	 	2.2.5	None of the Relevant Shares is subject to and was not issued in violation of any purchase option, call option, right of first refusal, pre-emptive right, subscription
right or similar right or any provision of Applicable Law or the constitutional documents of its Target Group Companies. 

  

	2.3	2012 Accounts 

 The 2012
Accounts of each Target Group Company: 
  

	 	2.3.1	were prepared in accordance with accounting practices generally accepted in the jurisdiction of incorporation of that Target Group Company at the time they were
audited; and 

  

	 	2.3.2	show in accordance with applicable legal requirements: 

  

	 	(i)	the assets and liabilities of that Target Group Company at the 2012 Accounts Date; and 

 

	 	(ii)	the profits and losses of the relevant Target Group Company for the accounting period ended on the 2012 Accounts Date. 

  
 Page 17

	2.4	Financial Information 

  

	 	2.4.1	The annual consolidated financial statements of GlaxoSmithKline plc for the year ended 31 December 2013 fairly present the operating profit for its Consumer
Healthcare Division (including, for this purpose, the Excluded Assets and the Ribena and Lucozade businesses that have been subsequently sold) in 2013, being £0.9 billion. 

 

	 	2.4.2	The 2013 Operating Income (defined below) fairly presents the operating income of the Novartis OTC Group (which, for this purpose, includes the Novartis US NRT
Business, the benefit of the Endo Excluded Contract, and any manufacturing, distributing, marketing, selling, promoting or otherwise Commercialising of Prescription Products in the United States of America carried out by the Novartis OTC Group
Companies) for the year ended 31 December 2013. 

 “2013 Operating Income” means the
operating income for 2013 annexed to the Disclosure Letter at Annex B. 
  

	2.5	The Assets 

 Save in
relation to the Transferred Intellectual Property Rights, either the Seller or another member of the Seller’s Group has good and valid title to the assets listed in Clause 2.3.1 free and clear of all Encumbrances other than Permitted
Encumbrances. 
  

	2.6	Changes Since 31 December 2013 

 Except as a result of the execution and delivery of this Agreement from 31 December 2013 to the date of this Agreement: 

 

	 	2.6.1	the Seller’s Contributed Business has been conducted in all material respects in the ordinary and usual course; 

 

	 	2.6.2	the Seller’s Contributed Business has not entered into any material contract or commitment outside the ordinary course of business as conducted prior to
31 December 2013; and 

  

	 	2.6.3	to the Seller’s knowledge, there has been no event or circumstance arising which is reasonably likely to have had a Material Adverse Effect (as if reference in the
definition of Material Adverse Effect to the date of this Agreement were to 31 December 2013). 

  

	3	Third Party Indebtedness and Financial Instruments 

 None of the Target Group Companies: (i) has any Third Party Indebtedness exceeding US$1million; or (ii) is a party to any financial instruments (including any swaps or derivatives). 

 

	4	Real Property 

  

	4.1	Company Properties 

  

	 	4.1.1	The Company Properties are the only material freehold, leasehold or other immovable property in any part of the world owned, used or occupied by the Target Group
Companies for the purpose of research and development, production or manufacturing facilities. 

  

	 	4.1.2	Each of the Company Properties is used and occupied for the purpose of the business of a Target Group Company. 

  
 Page 18

	 	4.1.3	A member of the Seller’s Group is solely legally and beneficially entitled to such Company Property. 

 

	 	4.1.4	No person has or will have any right to possession, occupation or use of such Company Property in a manner that has or will have a material adverse effect on the use
of, or operations at, such Company Property. 

  

	 	4.1.5	There are no mortgages or charges affecting any of the Company Properties other than those registered in the relevant Land Register. 

 

	 	4.1.6	There are no material outstanding disputes, actions, claims or demands in respect of any Company Property, nor has the Seller or any member of the Seller’s Group
received any notice threatening the same. 

  

	 	4.1.7	In respect of each Company Leased Property, all material covenants and conditions contained in the Company Lease have been observed and performed to date.

  

	4.2	Transferred Properties 

  

	 	4.2.1	The Transferred Leased Properties and the Transferred Owned Properties are the only material freehold, leasehold or other immovable property in any part of the world
owned or occupied by the Target Group Business for the purpose of research and development, production or manufacturing facilities. 

  

	 	4.2.2	Each of the Transferred Properties is used and occupied for the purposes of the Seller’s Contributed Business. 

 

	 	4.2.3	A member of the Seller’s Group is solely legally and beneficially entitled to such Transferred Property. 

 

	 	4.2.4	No person has or will have any right to possession, occupation or use of such Transferred Property in a manner that has or will have a material adverse effect on the
use of, or operations at, such Transferred Property. 

  

	 	4.2.5	There are no mortgages or charges affecting any of the Transferred Properties other than those registered in the relevant Land Register. 

 

	 	4.2.6	There are no material outstanding disputes, actions, claims or demands in respect of any Transferred Property, nor has the Seller or any member of the Seller’s
Group received any notice threatening the same. 

  

	 	4.2.7	In respect of each Transferred Leased Property, all material covenants and conditions contained in the Lease have been observed and performed to date.

  

	5	Intellectual Property 

  

	5.1	All renewal, application and other registry fees and steps required for the maintenance of the registrations of any of the Target Group Intellectual Property Rights
that are Registered Intellectual Property Rights and relate to products that are material to the Seller’s Contributed Business have been paid or taken. 

 

	5.2	Neither the Seller nor any of its Affiliates has given, or received, written notice to terminate any material Target Group Intellectual Property Contract, and neither
the Seller nor any Affiliate of the Seller is in breach or default of any material Target Group Intellectual Property Contract, except for any such breach or default which would not be material to the Contributed Business. To the Seller’s
Knowledge, no third party is in breach or default under any Target Group Intellectual Property Contract, except for any such breach or default which would not be material to the Business. 

  
 Page 19

	5.3	The Seller and its Affiliates own all Registered Target Group Intellectual Property Rights free of all Encumbrances except Permitted Encumbrances. The Seller and its
Affiliates have taken reasonable steps to protect the confidentiality of Proprietary Information. 

  

	5.4	To the Seller’s Knowledge: (i) the conduct of its Contributed Business as currently conducted does not infringe or misappropriate the Intellectual Property
Rights of any third party; and (ii) there is no material judicial, administrative or arbitral action, suit, hearing, inquiry, investigation or other proceeding (public or private) before any Governmental Entity pending against the Seller or any
of its Affiliates in which it is alleged that the conduct of its Contributed Business as currently conducted by the Seller and its Affiliates infringes or misappropriates any Intellectual Property Rights of any third party. 

 

	5.5	To the Seller’s Knowledge, no third party is infringing or misappropriating any Target Group Intellectual Property Rights or Proprietary Information.

  

	5.6	To the Seller’s Knowledge, the Target Group Intellectual Property Rights, the Intellectual Property Rights licensed under the Target Group Intellectual Property
Contracts, and the Intellectual Property Rights licensed under the Purchaser Intellectual Property Licence Agreement constitute all the material Intellectual Property Rights used in the conduct of the Contributed Business as currently conducted by
the Seller and its Affiliates; provided however, that the foregoing is not a representation of non-infringement, non-misappropriation, or any other non-violation of Intellectual Property Rights of any third party, which representation is solely set
out in paragraph 5.4 above. 

  

	5.7	All Information Technology necessary for the Contributed Business to be conducted in all material respects as it is carried on at the date of this Agreement:
(i) is Owned Information Technology; (ii) is Transferred Information Technology; or (iii) will be provided by the Seller and its Affiliates to the Purchaser and the Contributed Business under the Transitional Services Agreement.

  

	5.8	The Seller’s Contributed Business has not, in the 12 months prior to the date of this Agreement, experienced any material disruption in its operations as a result
of any failure of its Information Technology. 

  

	6	Contracts 

  

	6.1	No Target Group Company or Business Seller is a party to or subject to any Contract, transaction, arrangement, understanding or obligation (other than in relation to
any Property, lease, contract of employment, Information Technology or Intellectual Property Right) which is material to the Contributed Business and which: 

 

	 	6.1.1	is not in the ordinary course of business; 

  

	 	6.1.2	is not on an arm’s length basis; 

  

	 	6.1.3	has an unexpired term or likely duration of five years or more; 

  

	 	6.1.4	restricts its freedom to carry on its business in any part of the world in such manner as it thinks fit; 

 

	 	6.1.5	involves an aggregate outstanding expenditure by it of more than US$50 million, exclusive of VAT; 

 

	 	6.1.6	can be terminated in the event of a change of underlying ownership or control of a Target Group Company; or 

 

	 	6.1.7	involves the supply of goods and services, the aggregate sales value of which (exclusive of VAT) will be more than five per cent of turnover of the Contributed Business
(exclusive of VAT) for the preceding financial year. 

  
 Page 20

	6.2	All material supply contracts of the Contributed Business relating to ingredients are either contracts to which a Target Group Company is a party or are Transferred
Contracts. 

  

	6.3	Save in relation to any Target Group Intellectual Property Contract, no Target Group Company is in material default under any material Contract to which it is party and
no third party is in material default under any material Contract to which a Target Group Company is party and, to the Seller’s Knowledge, there are no circumstances in either case likely to give rise to such a material default.

  

	6.4	Save in relation to any Target Group Intellectual Property Contract, no Business Seller is in material default under any material Contract to which it is a party and,
to the Seller’s knowledge, no third party is in material default under any material Contract to which a Business Seller is a party and, to the Seller’s Knowledge, there are no circumstances in either case likely to give rise to such a
material default. 

  

	7	Joint Ventures etc. 

 No
Target Group Company or Business Seller is, or has agreed to become, a member of any joint venture, consortium, partnership or other unincorporated association (other than a recognised trade association in relation to which the Target Group
Purchaser or Business Seller has no liability or obligation except for the payment of annual subscription or membership fees). 
  

	8	Agreements with Connected Parties 

 There are no existing contracts or arrangements material to the business of the Target Group between, on the one hand, any Business Seller or Target Group Company and, on the other hand, the Seller or any
other member of the Seller’s Group (other than any Business Seller or Target Group Company), other than on normal commercial terms in the ordinary course of business. 

 

	9	Sufficiency of Assets 

  

	9.1	Each of the assets listed in Clause 2.3.1 is owned both legally and beneficially by the Seller or its Affiliates and each of those assets capable of possession is, save
where in the possession of third parties in the ordinary course of business, in the possession of the Seller or its Affiliates. 

  

	9.2	Save for Permitted Encumbrances, no option, right to acquire, mortgage, charge, pledge, lien or other form of security or Encumbrance (excluding licences of
Intellectual Property or Know-How) or equity on, over or affecting the whole or any part of the assets listed in Clause 2.3.1 is outstanding and, save in relation to Permitted Encumbrances, there is no agreement or commitment entered into by any
member of the Seller’s Group to give or create any and no claim has been made against any member of the Seller’s Group by any person entitled to any. 

 

	9.3	The Target Group Businesses and the assets of the Target Group Companies, when taken together with the rights and services under the Ancillary Agreements and for the
respective terms thereof: 

  

	 	(i)	comprise all of the assets required to carry on the Contributed Business in substantially the same manner as it has been during the 12 months prior to the date of this
Agreement and as it was reported in its December Presentation, save in relation to the Excluded Assets; and 

  

	 	(ii)	are sufficient in all material respects to carry out the Contributed Business after the Closing in substantially the same manner as it has been conducted by the Seller
and its Affiliates in the 12 months prior to the date of this Agreement and as it was reported in its December Presentation, save in relation to the Excluded Assets, provided however, that the foregoing is not a warranty of non-infringement,
non-misappropriation or any other non-violation of Intellectual Property Rights of any third party, which warranty is solely set out in paragraph 5.5. 

  
 Page 21

	10	Compliance with Laws, Permits and Anti-Bribery 

  

	10.1	None of the Seller or its Affiliates is in breach of any Applicable Law where such breach is reasonably likely to be material to the Target Group.

  

	10.2	Neither the Seller nor any of its Affiliates has received any written notice from any Governmental Entity that it is not in compliance (or any warning letter that it
may not be in compliance) with any Applicable Law or is not in possession of any permits, licences, certificates or other authorisations or consents of a Governmental Entity in each case as is necessary for the conduct of the Contributed Business in
all material respects as presently conducted (each a “Permit” and, collectively, the “Permits”), except where such non-compliance or non-possession does not remain outstanding or uncured as of Closing or would not
reasonably be expected to have a material effect on the Business. 

  

	10.3	With respect to its Contributed Business, since 1 January 2009, neither the Seller nor any of its Affiliates, nor any of their respective directors, officers or
employees and, to the Seller’s Knowledge, no Seller Partner has, directly or indirectly: (i) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity or to
influence official action; (ii) made or offered to make any unlawful payment to any foreign or domestic government official or employee, or agent, political party or any official of such party, or political candidate from corporate funds;
(iii) made or offered to make any bribe, rebate, payoff, influence payment, money laundering, kickback or other unlawful payment; or (iv) violated or is in violation of any provision of any applicable Anti-Bribery Law; and with respect to
the Contributed Business, the Seller and its relevant Affiliates have instituted and maintain policies and procedures reasonably designed to ensure compliance with applicable Anti-Bribery Law. 

 

	10.4	With respect to its Contributed Business, neither the Seller nor any of its Affiliates, nor any of their respective directors, officers or employees and, to the
Seller’s Knowledge, no Seller Partner: (i) is currently the subject of, nor has been since 1 January 2009 the subject of, any action alleging a violation, or possible violation, of any Anti-Bribery Law, nor has been, since
1 January 2009, the recipient of a subpoena, letter of investigation or other document alleging a violation, or possible violation, of any Anti-Bribery Law, or (ii) has, since 1 January 2009, improperly or inaccurately recorded in any
books and records (A) any payments, cash, contributions, gifts, hospitalities or entertainment to a foreign or domestic government official, employee of an enterprise owned or controlled in whole or in part by any foreign government, official
of a foreign or domestic political party or campaign, or a foreign or domestic candidate for political office; or (B) other expenses related to political activity or lobbying. 

 

	10.5	With respect to its Contributed Business, since 1 January 2009, neither the Seller nor any of its Affiliates, nor any of their respective directors or officers,
and, to the Seller’s Knowledge, none of their respective employees has received notice that any such person is or has been alleged to be in violation of any sanctions administered by the Office of Foreign Assets Control of the U.S. Department
of the Treasury or by the U.S. Department of State or equivalent measures of the United Kingdom, European Union, or the United Nations (the “Sanctions Law”). With respect to its Contributed Business, neither the Seller nor any of
its Affiliates, nor any of their respective directors or officers, and, to the Seller’s Knowledge, none of their respective employees has conducted any of their business activities whatsoever with, or for the benefit of, a government, national
or legal entity to the extent such actions would violate any Sanctions Law. None of the execution, delivery and performance of this Agreement and the direct or indirect use of proceeds from any transaction contemplated hereby or the fulfilment of
the terms hereof will result in a violation by any person of any Sanctions Law. 

  
 Page 22

	10.6	Each member of the Seller’s Group, in connection with any products of the relevant Seller’s Contributed Business, the Product Approvals, the Product
Applications, the Transferred Contracts and the Transferred Intellectual Property Contracts requires its Service Providers to act in accordance with the requirements of applicable Anti-Bribery Law and uses all reasonable endeavours to procure that
they do so. 

  

	11	Product Approvals 

  

	11.1	The Seller or one of its Affiliates is the registered holder of each of the Product Approvals. All material Product Approvals held by Seller or its Affiliates are in
full force and effect. No material deficiencies have been asserted by any applicable Government Entity with respect to any Product Approval or Product Filing, nor, to the Seller’s knowledge, are there any facts or circumstances that would be
likely to lead to such assertions being made. 

  

	11.2	Each Product was and is being researched, developed, manufactured, marketed or sold in all material respects in accordance with the specifications and standards
contained in the relevant Product Approval and the related Marketing Authorisation Data and in accordance with Applicable Laws. 

  

	11.3	Neither the Seller or any of its Affiliates has received any written notice that any Governmental Entity with jurisdiction over the Products has commenced or will
commence any action: (i) to withdraw the approval of any Product or otherwise revoke or materially amend any Product Approval or Marketing Authorisation Data; or (ii) enjoin production, marketing or sale of any Product and, to the
Seller’s Knowledge, no such action has been threatened. 

  

	11.4	All application and renewal fees due and payable with respect to all material Product Approvals have been paid. 

 

	11.5	All preclinical and clinical investigations with respect to the Products are being and have been conducted in compliance with Applicable Laws in all material respects.
The Seller and its Affiliates have not, and to the Seller’s Knowledge, none of its Product Partners or any other third party under any Licensed Intellectual Property Contract has received since 1 January 2009, any written notices or other
correspondence from any Governmental Entity with respect to any on-going clinical or pre-clinical studies or tests of any Product requiring the termination, suspension or material modification of such studies or tests. 

 

	11.6	None of the Seller or its Affiliates or, to the Seller’s Knowledge, any Product Partner or any other third parties pursuant to any Licensed Intellectual Property
Contract, has any knowledge of any adverse event, arising since the date three years prior to the date of this Agreement, reportable with respect to the safety or efficacy of any Product, which is reasonably expected to be material.

  

	12	Product Liability 

 The
Products sold by the Contributed Business during the Relevant Period have complied in all material respects with all applicable product specifications and have been Manufactured in all material respects in accordance with applicable requirements of
then current GMP and Applicable Laws, except for any such non-compliance that has not had, and would not reasonably be expected to have a materially adverse impact on any of the Seller’s Products. 

 

	13	Product Recall 

  

	13.1	No Product (or any component thereof) has been recalled, suspended, withdrawn, seized, discontinued or the subject of a refusal to file, clinical hold, deficiency or
similar action letter (including any correspondence questioning data integrity) as a result of any action by any Governmental Entity, by the Seller or any of its Affiliates; nor are any such actions pending or under consideration (or any facts,
conditions, or circumstance known) by the Seller or any of its Affiliates, or, to the Seller’s Knowledge, by any Governmental Entity. There is not, to the Seller’s Knowledge, pending or threatened litigation anywhere in the world seeking
the recall, withdrawal, suspension, seizure or discontinuance of any of the Products. 

  
 Page 23

	14	Taxes 

  

	14.1	Each Target Group Company and each Tax Group to which it belongs has, and every member of the Seller’s Group with an interest in the Contributed Business has, in
respect of the Contributed Business, duly, and within any appropriate time limits, filed all Tax Returns required to be filed and has maintained all records required to be maintained for Tax purposes in relation to the assets comprised in the
Contributed Business; all such information was and remains complete and accurate in all material respects and all such Tax Returns were complete and accurate in all material respects and were made on the proper basis. 

 

	14.2	There are no Tax liens on any asset comprised in the Target Group Business (other than Permitted Encumbrances). 

 

	14.3	No Target Group Company and no Tax Group to which a Target Group Company belongs is currently under audit or examination by a Tax Authority that could result in the
assessment of a material amount of Tax and neither the Seller nor any Target Group Company (nor any Tax Group to which a Target Group Company belongs) has received notice from a Tax Authority of any dispute or disagreement outstanding or
contemplated at the date of this Agreement with any Tax Authority regarding liability or potential liability to any Tax recoverable from any Target Group Company or regarding the availability of any relief from Tax to any Target Group Company and,
so far as the Seller is aware, there are no circumstances which make it likely that any such dispute or disagreement will commence. 

  

	14.5	No Target Group Company, and no Tax Group to which a Target Group Company belongs, has received or requested any extension of time to file a Tax Return that remains
unfiled or has granted or requested a waiver or extension of a limitation on any period for audit and examination or assessment and collection of Tax for any taxable period as to which Tax could be assessed. 

 

	14.6	No member of the Seller’s Group with an interest in the Contributed Business has received notice from a Tax Authority of, and so far as the Seller is aware, there
is not any dispute or disagreement outstanding at the date of this Agreement with any Tax Authority regarding the proper method of computing the profits of the Contributed Business (or any part of it) for Tax purposes or the proper treatment for VAT
purposes of any supplies of goods or services made (or treated as made) in the course of the Contributed Business and, so far as the Seller is aware, there are no circumstances which make it likely that any such dispute or disagreement will
commence. 

  

	14.7	So far as the Seller is aware, no Target Group Company benefits from any preferential Tax regime, granted by law or by special authorisation issued by any Tax Authority
or by any other authority, which would in whole or in part be withdrawn as a result of the signature of this Agreement. 

  

	14.8	So far as the Seller is aware, no Tax Authority has within the past three years operated or agreed to operate any special arrangement (being an arrangement which is not
based on relevant legislation or any published practice) in relation to any assets comprised in the Contributed Business. 

  

	14.9	In respect of all documents which establish or are necessary to establish the title of the relevant member of the Seller’s Group to each material asset comprised
in the Contributed Business, or by virtue of which the relevant member of the Seller’s Group has any right in respect of each such asset, all applicable stamp duties, transfer taxes, registration charges or similar duties or charges have been
duly paid. 

  
 Page 24

	14.10	So far as the Seller is aware, other than any payments which are of a nature or type (such as expenditure on business entertainment or marketing) which are not
deductible for Tax purposes by reason of a general restriction on deductibility applicable to payments of that nature or type under the laws of the jurisdiction in which the relevant Target Group Company is resident for Tax purposes or carries on
its business, no Target Group Company is under any obligation to make any future payment which will not be deductible for Tax purposes in an amount which, if the payment were deductible for Tax purposes, would reduce the Tax liability of the
relevant Target Group Company by an amount exceeding US$5 million. 

  

	15	Environmental Matters 

  

	15.1	To the Seller’s Knowledge, each Business Seller (with respect to its conduct of the Contributed Business and any Transferred Property) and Target Group Company is
in compliance in all material respects with all Environmental Laws. 

  

	15.2	To the Seller’s Knowledge, each Target Group Company and each Business Seller (with respect to its conduct of the Contributed Business and any Transferred
Property) possesses all material Permits required under applicable Environmental Laws necessary to conduct its portion of the Contributed Business. 

  

	15.3	To the Seller’s Knowledge, no Target Group Company nor any Business Seller (with respect to its conduct of the Contributed Business and any Transferred Property)
has received any written notice alleging a material violation of any Environmental Laws, other than matters that have been resolved in all material respects. 

 

	15.4	To the Seller’s Knowledge, no Target Group Company nor any Business Seller (with respect to its conduct of the Contributed Business and any Transferred Property)
has received any written notice or claim alleging that it is or may be liable to any person in any material respect under any applicable Environmental Law as a result of a release or threatened release of any Hazardous Substance at any Transferred
Property, other than matters that have been resolved in all material respects. 

  

	15.5	To the Seller’s Knowledge, no Target Group Company nor any Business Seller (with respect to its conduct of the Contributed Business and any Transferred Property)
is a party to any pending proceedings relating to any Environmental Laws, other than proceedings that would not reasonably be expected to have a relevant Material Adverse Effect. 

 

	16	Employees 

  

	16.1	The Disclosure Letter contains a true, complete and correct list of the following information in respect of each Target Business Employee and each Target Company
Employee as of 31 March 2014 (organised by country and, in relation to any Target Group Company, by legal employer): (A) employee identification details; (B) date of birth; (C) employment status (part-time or full-time);
(D) employment start date; (E) base salary as at 1 January 2014; (F) target annual incentive for 2014 (and amounts and/or details of approach to the calculation of the 2013 bonus amounts); and (G) target long-term incentive
for 2014 (and amounts and/or details of the approach to the calculations of the long-term incentive amounts for 2013). 

  

	16.2	In each of the Material Employee Jurisdictions except as would not be reasonably expected to have a Material Adverse Effect: 

 

	 	16.2.1	as of the date of this Agreement there is not, and in the two years prior to the date of this Agreement there has not been, nor to the Seller’s Knowledge is there
pending or threatened, any labour strike, dispute, work stoppage or lockout by any group of either Target Business Employees or Target Company Employees; 

  
 Page 25

	 	16.2.2	no trade union or works council is recognised in any way for bargaining, information or consultation purposes in relation to any of the Target Business Employees or
Target Company Employees and no collective bargaining negotiations, whether voluntary or mandatory, are currently taking place with respect to any of the Target Business Employees or Target Company Employees and, as of the date of this Agreement, no
Target Group Company or Business Seller is a party to any agreement (whether legally binding or not) with any such trade union or works council affecting any Target Business Employee or Target Company Employee and there is no existing dispute with
any such representative body (or, to the Seller’s Knowledge, pending or threatened) in relation to the Target Group Business; 

  

	 	16.2.3	there is no material litigation, claim or other dispute existing, nor to the Seller’s Knowledge, pending or threatened by or in respect of any Employees (or any
former employees of the Target Group Companies) in respect of their employment or any matter arising from their employment; and 

  

	 	16.2.4	no Target Group Company or Business Seller has, within the two years prior to the date of this Agreement, closed any plant or facility, effectuated any layoffs of
employees or implemented any early retirement, separation or similar programme in each case in violation of the WARN Act, nor has any Target Group Company or Business Seller announced any such action or programme for the future.

  

	16.3	No Key Personnel has given notice terminating his or her contract of employment, nor is under notice of dismissal. 

 

	16.4	To the Seller’s Knowledge, and subject to the next sentence, no Target Company Employee will, as a result of the entering into of this Agreement or Closing, be
entitled to receive any payment or benefit which he would not otherwise be entitled to receive (including, without limitation, an enhanced severance package on a subsequent termination) or be entitled to treat either such event as amounting to a
breach of his terms and conditions of employment or to treat himself as redundant or dismissed or released from any obligation. This warranty shall not apply to any retention arrangements (in the form of cash or shares) put in place by the Seller or
any member of the Seller’s Group to retain key employees in connection with the matters contemplated by this Agreement as described in paragraphs 9 and 10 of Schedule 7 or any arrangement relating to the share-based incentive schemes of
the Seller’s Group pursuant to paragraph 10 of Schedule 7. 

  

	16.5	Since the Statement of Net Assets Date, no material change has been made, announced or proposed to the emoluments or other terms of employment of any Employee, and no
such change, and no negotiation or request for such a change, is due or expected within 12 months from the date of this Agreement, and the employing company is under no obligation to make such a change (with or without retrospective operation) other
than any arrangement relating to the share-based incentive schemes of the Seller’s Group pursuant to paragraph 10 of Schedule 7. 

  

	17	Employee Benefits 

  

	17.1	 The Disclosure Letter contains a true, complete and correct list of all bonus, staff incentives (including any share-based incentive schemes),
redundancy or other benefits payable on termination of employment (whether voluntary or involuntary but excluding arrangements required in accordance with Applicable Law), ill-health, Employee Benefits or other benefits which are the material
benefits available to the Target Business Employees and the Target Company Employees in the Material Employee Jurisdictions. To the Seller’s Knowledge, other than any arrangement relating to the
share-based incentive schemes of the Seller’s Group pursuant to paragraph 10 of Schedule 7, no Target Group Company or Business

  
 Page 26

	 	
Seller has made any promises or commitments to make available any additional benefits to the Target Business Employees and the Target Company Employees in the Material Employee Jurisdictions, or
to modify or change in any material way any existing benefits in the Material Employee Jurisdictions, or to continue or maintain the level of any existing benefits generally for any period, which in each case could reasonably be expected to have a
Material Adverse Effect. 

  

	17.2	The Disclosure Letter contains true and complete copies of all documents of any written benefit schemes, plans or arrangements referred to in paragraph 17.1 above
applicable to either Target Business Employees or Target Company Employees in the Material Employee Jurisdictions containing material terms (including governing documents, and for benefit plans that are not share-based incentive schemes related
trust agreements or other funding documents) and a true, complete and correct summary of the material terms of any unwritten benefit schemes, plans or arrangements referred to in paragraph 17.1 above. 

 

	17.3	Benefit Plans 

  

	 	17.3.1	In the Material Employee Jurisdictions all benefit and compensation schemes, plans, funds, contracts, policies, agreements or arrangements (other than the US Benefit
Plans and any schemes, plans, funds, contracts, policies, agreements or arrangements operated by any Governmental Entity) (A) operated by or on behalf of a Target Group Company or Business Seller, with respect to Target Company Employees or
Target Business Employees or current or former employees or directors of a Target Group Company, (B) in respect of which any Target Group Company or Business Seller, with respect to Target Company Employees or Target Business Employees, the
Seller or any member of the Seller’s Group contributes or has contributed or (C) in respect of which any Target Group Company or Business Seller, with respect to Target Company Employees or Target Business Employees, has any liability
(whether actual or contingent), including, but not limited to, plans providing Employee Benefits or during periods of sickness or disablement, or any deferred or incentive compensation, welfare, healthcare, medical, stock or stock-related award
plans, including individual pension commitments, “jubilee” pension benefits and retirement and termination indemnity arrangements and, in relation to Switzerland, all plans, funds, contracts, policies, agreements or arrangements providing
pension or other benefits on retirement (such schemes, plans, funds, contracts, policies, agreements and arrangements hereinafter being referred to, for each Seller, as “Non-US Benefit Plans”)
and the US Benefit Plans have been administered in accordance with their terms and are in compliance with Applicable Law, except for any failures to so administer or be in compliance that, individually and in the aggregate, would not reasonably be
expected to have a Material Adverse Effect. All required filings for all Benefit Plans have been made on time and with the appropriate Governmental Entity, except for any failures to timely file that, individually and in the aggregate, would not
reasonably be expected to have a Material Adverse Effect. As of the date of this Agreement, there is no existing, pending or, to the Seller’s Knowledge, threatened material litigation, claim or other dispute relating to the Benefit Plans.

  

	 	17.3.2	 The Target Group Companies or Business Sellers, with respect to Target Company Employees or Target Business Employees in each Material Employee
Jurisdiction: (A) are in material compliance with all Applicable Law respecting employment, employment practices, terms and conditions of employment, occupational health, safety, wages and hours; (B) have withheld all amounts required by
Applicable Law, collective bargaining agreements or the Benefit Plans to be withheld from the wages, salaries or other payments to the Target Company Employees or the Target Business Employees and former employees of the Target Group Companies;
(C) in respect of the Target Company Employees or Target Business Employees or former employees of the Target Group Companies, are not liable under any applicable provisions of the

  
 Page 27

	 	
Benefit Plans and any Applicable Law for any arrears, wages, Taxes, other than payments not yet due, or any penalty for failure to comply with the foregoing; and (D) are not liable under any
applicable provisions of the Benefit Plans and any Applicable Law for any payment to any trust or other fund or to any Governmental Entity with respect to unemployment compensation benefits, workers compensation, social security or other benefits
for Target Company Employees or Target Business Employees or former employees of the Target Group Companies, other than payments not yet due, except, in each case, for any failures to comply, failures to withhold or liabilities that, individually
and in the aggregate, would not reasonably be expected to have a Material Adverse Effect. 

  

	 	17.3.3	All material contributions that the Target Group Companies or Business Sellers, with respect to Target Business Employees or the Target Company Employees in a Material
Employee Jurisdiction and Switzerland, are required to make to any Benefit Plan in respect of the period on or before the date of this Agreement have been fully and timely paid when due. 

 

	18	Litigation 

  

	18.1	No Target Group Company or Business Seller is involved whether as claimant or defendant or other party in any claim or Proceeding (other than as claimant in the
collection of debts arising in the ordinary course of its business none of which exceeds US$5 million) which is material to the Business. 

  

	18.2	To the Seller’s Knowledge, no such claim or Proceeding of material importance is pending or threatened by or against any Target Group Company or Business Seller.

  

	19	Insolvency 

  

	19.1	No order has been made and no resolution has been passed for the winding up of the Seller, any Share Seller or any Business Seller, or for the appointment of any
administrator, receiver (including administrative receiver) or liquidator (provisional or otherwise) over the whole or any part of the property, assets and/or undertaking of the Seller, any Share Seller or any Business Seller.

  

	19.2	No petition has been presented or meeting convened for the purpose of considering a resolution or resolution circulated for the winding up of the Seller, any Share
Seller or any Business Seller, or for the appointment of any administrator, receiver (including administrative receiver) or liquidator (provisional or otherwise) over the whole or any part of the property, assets and/or undertaking of the Seller,
any Share Seller or any Business Seller. 

  

	19.3	Neither the Seller, nor any Share Seller nor any Business Seller has stopped payment or suspended payment of its debts generally, is insolvent or deemed unable to pay
its debts as they fall due. 

  

	20	Insurance 

 All material
insurance policies relating to the Contributed Business are in full force and effect and, to the Seller’s Knowledge, no notice of cancellation, termination or default has been received with respect to any such insurance policy. All premiums due
and payable on such policies covering periods up to Closing have been paid in full or accrued. 
  

	21	Consents and Licences 

  

	21.1	All governmental and quasi-governmental licences, consents, permissions, waivers, exceptions and approvals required for carrying on the Contributed Business, the
absence of which, individually or in the aggregate, would be material to the Contributed Business, are in force and, to the Seller’s Knowledge, no written notice has been received by the Seller or any member of the Seller’s Group which
indicates that any such licence, consent, permission, waiver, exception or approval is likely to be revoked or which may confer a right of revocation. 

  
 Page 28

	22	Delinquent and Wrongful Acts 

  

	22.1	To the Seller’s Knowledge, no member of the Seller’s Group has, during the Relevant Period, committed any criminal or illegal act which relates to the Target
Group Companies or the Target Group Businesses. 

  

	22.2	No member of the Seller’s Group has, during the Relevant Period, received notification that any investigation or inquiry is being or has been conducted by any
supranational, national or local authority or governmental agency specifically related to the Contributed Business, which is material in respect of the Contributed Business. 

 

	23	Compliance 

  

	23.1	No member of the Seller’s Group has received in the Relevant Period any written notification or written claim (in each case, which remains outstanding) that it has
conducted the Contributed Business with respect to the research, development, manufacturing, distribution and sale of any products of the relevant Seller’s Contributed Business in a manner which does not in any respect comply with all
Applicable Law, or which in any respect is defective or dangerous, where the pursuit of any such notification or claim is, or would reasonably be expected to be, material in respect of the Contributed Business. 

 

	23.2	So far as the Seller is aware, the Contributed Business has, and has during the Relevant Period been, operated in all material respects in compliance with all
Applicable Law or standards and to the Seller’s Knowledge there are no circumstances that could involve or lead to a material violation of any material Applicable Law or standards. 

 

	24	Pipeline Products 

  

	24.1	The Seller or one of its Affiliates is the registered holder of each of the Pipeline Product Approvals, and the benefit of each Pipeline Product Approval can be
transferred to the Purchaser (or another member of the Purchaser’s Group) regardless as to whether such transfer occurs directly (whether by way of transfer, reissuance or any other equivalent mechanism under Applicable Law of the relevant
jurisdiction) or indirectly (through the transfer of the Target Group Companies). 

  

	24.2	All development activities in relation to the Pipeline Products have been conducted in the ordinary course and in accordance with all Applicable Law and standards and
to the Seller’s Knowledge there are no circumstances relating to the development of the Pipeline Products that could involve or lead to a material violation of any material Applicable Law or standards. 

 

	24.3	No material regulatory, clinical or safety event has occurred in relation to the Pipeline Products and no member of the Seller’s Group has received any
notification or claim from any person of any such event (or the possibility of any such event). 

  

	25	Manufacturing Licences and Manufacture 

  

	25.1	All Manufacturing Licences which are material to the Contributed Business, are in effect and are validly held by a member of the Seller’s Group and during the
Relevant Period, to the Seller’s Knowledge, no member of the Seller’s Group has received any written notice of any suit, action or proceeding regarding the revocation or modification of any such Manufacturing Licence.

  
 Page 29

	25.2	No directive, order or notice has been given to the Seller or any member of the Seller’s Group by any relevant regulatory authority to update, modify, amend, vary,
supplement or delete any process and/or methodology relevant to the manufacture at the Properties of any product currently manufactured at the Properties and, so far as the Seller is aware, no such directive, order or notice is pending.

  
 Page 30

 Schedule 14 
 Warranties given by the Purchaser under Clause 9.3 
  

	1	AUTHORITY AND CAPACITY 

  

	1.1	Incorporation 

 The
Purchaser is validly existing and is a Purchaser duly incorporated and registered under the law of its jurisdiction of incorporation. 
  

	1.2	Authority to enter into Agreement 

  

	 	1.2.1	The Purchaser has the legal right and full power and authority to enter into and perform this Agreement, any Local Transfer Document to which it is a party and
any other documents to be executed by it pursuant to or in connection with this Agreement or any Local Transfer Document. 

  

	 	1.2.2	The documents referred to in paragraph 1.2.1 will, when executed, constitute valid and binding obligations on the Purchaser in accordance with their respective terms.

  

	 	1.2.3	Except as referred to in this Agreement, the Purchaser: 

  

	 	(i)	is not required to make any announcement, consultation, notice, report or filing; and 

 

	 	(ii)	does not require any consent, approval, registration, authorisation or permit, 

 

	 	(iii)	in each case in connection with the performance of this Agreement or any other document referred to in paragraph 1.2.1. 

 

	 	1.2.4	The execution and delivery of the documents referred to in paragraph 1.2.1 and the performance by the Purchaser and each member of the Purchaser’s Group of their
respective obligations under them, will not: 

  

	 	(i)	result in a breach of any provision of the memorandum or articles of association or by laws or equivalent constitutional document of the relevant member of the
Purchaser’s Group; 

  

	 	(ii)	result in a breach of, or constitute a default under, any instrument or contract to which the relevant member of the Purchaser’s Group is party or by which the
relevant member of the Purchaser’s Group is bound where such breach is material to their ability to perform their obligations under such documents; 

  

	 	(iii)	result in a breach of any existing order, judgment or decree of any court, Governmental Entity by which the relevant member of the Purchaser’s Group is bound and
where such breach is material to their ability to perform their obligations under such documents. 

  
 Page 31

	1.3	Authorisation 

 The
Purchaser has taken, or will have taken by Closing, all corporate action required by it to authorise it to enter into and to perform this Agreement, any Local Transfer Document to which it is a party and any other documents to be executed by it
pursuant to or in connection with this Agreement or any Local Transfer Document. 

  
 Page 32

 Schedule 15 
 Pre-Closing Obligations 
 Part 1 

Seller Restrictions 
 The
actions for the purposes of Clause 5.1.2 are: 
  

	1.1	amend or otherwise modify the constitutional documents of any Target Group Company other than minor or administrative amendments or modifications which are not adverse
to its Contributed Business, the other Seller, or to the Purchaser in respect of its rights and obligations under this Agreement and the Ancillary Agreements; 

 

	1.2	create, allot or issue, or grant an option or right to subscribe for or purchase, any share capital or other securities or loan capital of any Target Group
Company; 

  

	1.3	repay, redeem or repurchase any share capital, or other securities of any Target Group Company; 

 

	1.4	make any acquisition or disposal which has a value in excess of US$150 million, in the case of GlaxoSmithKline, or US$85 million, in the case of Novartis,
exclusive of VAT; 

  

	1.5	grant any guarantee or indemnity for the obligations of any person (other than any Target Group Company) which has a value in excess of US$5 million (other than
in the ordinary course of trading); 

  

	1.6	dispose of, or agree to dispose of, any material asset or material stock at below market value other than in the ordinary course of business;

  

	1.7	acquire or agree to acquire any share, shares or other interest in any company, partnership or other venture, other than an investment of 5 per cent. or
less of the total shares or interest in such company, partnership or venture; 

  

	1.8	enter into, extend, amend, give notice to terminate or vary in any material respect any lease of real property or change the existing use of such property which
is material to its Contributed Business; 

  

	1.9	enter into any borrowing facility which constitutes Third Party Indebtedness which would not be repaid prior to Closing; 

 

	1.10	enter into any off-balance sheet finance arrangements; 

  

	1.11	sell, lease, license, transfer or dispose of, or create any Encumbrance over, any material assets of its Contributed Business other than (i) in the ordinary
course of business (including any sale of inventory) or (ii) a Permitted Encumbrance; 

  

	1.12	amend, terminate or grant any waiver with respect to any Owned Intellectual Property Contract or Transferred Intellectual Property Contract other than in the
ordinary course of business; 

  
 Page 33

	1.13	fail to comply in all material respects with all Applicable Laws, Product Approvals, Marketing Authorisations applicable to the operation of its Contributed
Business; 

  

	1.14	assign, licence or abandon any Owned Intellectual Property Rights or Transferred Intellectual Property Rights or rights in Proprietary Information, or cease to
prosecute or otherwise dispose of, fail to maintain, defend or pursue applications for any of its registered Owned Intellectual Property Rights or registered Transferred Intellectual Property Rights material to any Product or Pipeline Product in
each case other than in the ordinary course of business; 

  

	1.15	save where requested in writing by the other Seller or required by any applicable Governmental Entity, amend (other than in the ordinary course of business),
cancel or surrender any applications, submissions or filings with respect to its registered Owned Intellectual Property Rights or registered Transferred Intellectual Property Rights; 

 

	1.16	instigate, cease, compromise or settle any litigation or arbitration proceedings related to its Contributed Business in relation to a claim for which the
potential liability attaching thereto is in excess of US$150 million, in the case of GlaxoSmithKline, or US$85 million, in the case of Novartis; 

  

	1.17	make any material amendment to any Marketing Authorisation, Manufacturing Licence or Environmental Permit, in each case except to the extent required by:
(a) Applicable Law; (b) any Governmental Entity, or (c) the standards, policies and procedures of the Seller’s Group as then in force; 

  

	1.18	enter into, terminate, grant any waiver in respect of or amend in any material respect any Transferred Contract, or incur any commitment which is not capable of
being terminated without compensation at any time with twelve months’ notice or less or which is not in the ordinary course of business, or which involves or may involve total annual expenditure in excess of US$150 million, in the case of
GlaxoSmithKline, or US$85 million, in the case of Novartis, exclusive of VAT; 

  

	1.19	enter into any contract which would materially restrict the freedom of its Target Group to operate in any part of the world; 

 

	1.20	terminate (except for good cause) the employment of any Key Personnel; 

 

	1.21	take any steps to increase or reduce the proportion of time spent working in its Contributed Business by any employee of any member of its Group or to transfer
the employment of any Employee to another member of its Group or to employ or offer to employ or engage any new persons in its Contributed Business other than in ordinary course of business consistent with past practice and subject to an aggregate
increase of not more than 2.5 per cent. in total staff costs of its Contributed Business per annum, provided that this restriction shall not apply to the redeployment of any Target Group Company Employee who is not wholly or substantially
engaged in its Contributed Business before the Closing Date to employment with another member of its Group; 

  

	1.22	 make, or commit to make, any changes to the terms and conditions of employment (including pension fund commitments or any increase to remuneration) or
to any employee benefit plan of any Employee, other than (a) those required by Applicable Law or (b) pursuant to normal annual pay reviews in the ordinary course of business consistent with past

  
 Page 34

	 	
practice and subject to an aggregate increase of not more than 5 per cent. in total staff costs of the Contributed Business per annum or (c) retention arrangements (in the form of cash
or shares) to retain key employees in connection with the matters contemplated by this Agreement as described in paragraphs 9 and 10 of Schedule 7 or (d) those changes to share-based incentive
schemes made for the purpose of complying with paragraph 10 of Schedule 7; 

  

	1.23	make any promises or commitment to any Employees or employee representative body concerning the matters contemplated by this Agreement or offer or otherwise give
any assurances to any Employees as to the possibility of continued employment with the Purchaser’s Group after Closing; 

  

	1.24	make any change or commitment to make any change to the terms of any redundancy policy or practice applying to the Employees (including amounts payable on
redundancy); 

  

	1.25	enter into (where there is no existing agreement) or materially amend any collective bargaining agreement or other contract with a labour organisation, works
council or employee organisation to create new or additional obligations for any member of the Seller’s Group, in each case in relation to the Contributed Business or any Target Group Company; and 

 

	1.26	undertake any recall or withdrawal of any Product (other than in the ordinary course of business or to comply with Applicable Law). 

Part 2 

Seller Obligations 
  

	1	Obligations to be Satisfied prior to the Closing 

  

	1.1	At least five Business Days prior to the Closing Date, each Seller shall provide the other Seller with a list of any required actions that must be taken within three
months after Closing with respect to the payment of any registration, maintenance, or renewal fees or the filing of any documents, applications or certificates in order to maintain any Transferred Intellectual Property Rights that are Registered
Intellectual Property Rights in full force and effect. Upon the other Seller’s reasonable request, the relevant Seller shall execute and deliver assignment agreements and other transfer documentation, including, where applicable, duly executed
assignments of such Transferred Intellectual Property Rights for recording with the applicable Governmental Entity, and to take such further actions, in each case at the other Seller’s reasonable cost and expense and as may be required, to give
effect to the foregoing assignments. 

  

	2	Obligations from the Date of the Agreement to the Closing 

 The requirements for the purposes of Clause 5.1.3 are: 
  

	2.1	so far as permitted by Applicable Law, procure that each member of the Seller’s Group informs the other Seller promptly if the Seller becomes aware of, or has
reasonable grounds for suspecting any violation of Anti-Bribery Law which is reasonably likely to have an impact on the Target Group; 

  
 Page 35

	2.2	carry out capital expenditure in relation to any site operated by the Target Group where Products are manufactured in a manner materially consistent (and within a
variance of 10 per cent. in aggregate) with the Seller’s capital expenditure programme as at the date of this Agreement; 

  

	2.3	maintain and keep any Transferred Intellectual Property Rights and ensure that all filings and notifications required to be made in respect of the same are made in
accordance with past practice; 

  

	2.4	progress, in accordance with past practice any applications, submissions, filings or other correspondence relating to the grant of new Transferred Intellectual
Property Rights; 

  

	2.5	progress, in accordance with past practice during the Relevant Period, any applications, submissions, filings or other correspondence initiated by such member of
the Seller’s Group relating to the grant of new Manufacturing Licences and Environmental Permits in respect of the Contributed Business; 

  

	2.6	continue to Commercialise products of the relevant Seller’s Contributed Business in accordance with past practice during the Relevant Period and do not
materially accelerate or increase the quantity of such products distributed to the relevant distributors and/or wholesalers, in each case except in respect of a bona fide increase in demand for the relevant Product by the relevant distributor and/or
wholesaler which has not been stimulated in any way by discounts, rebates, claw-backs or the like outside of the ordinary course of business or the grant of preferred terms offered by the Seller’s Group outside of the ordinary course;

  

	2.7	not discontinue or cease to operate or materially reduce the resources applied to any part of the Contributed Business; 

 

	2.8	maintain the level of Manufacturing Stocks and Manufacturing Inventory held for use in its Contributed Business materially in accordance with the Seller’s
Group’s operating policies as applied to its Contributed Business from time to time in force; 

  

	2.9	maintain the level of In-Market Inventory held for use in its Contributed Business materially in accordance with the Seller’s Group’s operating
policies as applied to its Contributed Business from time to time in force; 

  

	2.10	use all reasonable efforts to ensure that the manufacture of all products of the relevant Seller’s Contributed Business by the Seller’s Group comply
with Applicable Law; 

  

	2.11	use all reasonable efforts to ensure that the products sold by its Contributed Business comply with Applicable Law; 

 

	2.12	continue to conduct the Ongoing Clinical Trials in accordance with GCP and the Seller Group’s policies and procedures; 

 

	2.13	notify the other Seller in writing of any actual safety or quality issue in respect of any Product or the manufacture of any Product (as soon as reasonably
practicable after becoming aware of the same) which issue the relevant member of the Seller’s Group, acting reasonably and in good faith, considers material in the context of the manufacture or commercialisation of such Product;

  
 Page 36

	2.14	so far as permitted by Applicable Law, report periodically to the Purchaser concerning the status of the Contributed Business, including delivering to the
Purchaser as soon as reasonably practicable each month: 

  

	 	2.14.1	an update on material commercial developments in relation to the Contributed Business during the previous month; 

 

	 	2.14.2	the gross profit for each relevant Product in respect of the previous month; and 

 

	 	2.14.3	a report on the month-end in-trade inventory in respect of each relevant Product for the previous month prepared in the ordinary course of business consistent with past
practice, together with a comparison against the comparable period of trading for the prior year. 

  
 Page 37

 Schedule 16 
 Key Personnel 
 [***] 

 

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission 

  
 Page 38

 Schedule 17 
 Reorganisations 
  

	1	Between signing of this Agreement and Closing, each Seller may carry out one or more Reorganisations, provided that: 

 

	1.1	if a Seller proposes to carry out a Reorganisation, that Seller (the “Notifier”) shall notify the other Seller (the “Recipient”) no
later than the end of 90 calendar days after the date of this Agreement (and at least three weeks in advance of the proposed Reorganisation being implemented) of its intention to carry out the proposed Reorganisation and the detailed steps proposed
to be implemented to effect the Reorganisation and, in respect of each Target Group Company, the country of incorporation, the country or countries of residence for Tax purposes and the location of any permanent establishments of that Target Group
Company; 

  

	1.2	the Notifier shall provide the Recipient with copies of all relevant legal documentation required to implement the Reorganisation in draft a reasonable period prior to
the Reorganisation being implemented and shall provide the Recipient with such other information as the Recipient may reasonably request regarding the implementation of the Reorganisation; 

 

	1.3	the Notifier shall consult in good faith with, and take into account the views of, and any requests made by, the Recipient in relation to any Reorganisation steps; and

  

	1.4	without prejudice to Clause 15.9 of this Agreement, all fees, costs and expenses of implementing any Reorganisation (or any part thereof) are borne by
GlaxoSmithKline’s Group in the case of a Reorganisation where GlaxoSmithKline is the Notifier of the Reorganisation and by Novartis’s Group in the case of a Reorganisation where Novartis is the Notifier of the Reorganisation.

  

	2	GlaxoSmithKline undertakes to the Purchaser (for itself and as trustee for each GlaxoSmithKline Consumer Group Company) that, with effect from Closing, GlaxoSmithKline
will indemnify on demand and hold harmless the relevant GlaxoSmithKline Consumer Group Company against and in respect of any and all Liabilities arising in connection with any Reorganisation (or part thereof) undertaken by GlaxoSmithKline, other
than: 

 (A) any Liabilities of a GlaxoSmithKline Consumer Group Company in respect of Tax (which shall be dealt
with under the Tax Indemnity); and 
 (B) any Liabilities in connection with any matter provided for or document entered into as
provided by this Agreement (including the provisions of Clause 8.11, but excluding this Schedule 17) or any Ancillary Agreement. 
  

	3	Novartis undertakes to the Purchaser (for itself and as trustee for each Novartis OTC Group Company) that, with effect from Closing, Novartis will indemnify on demand
and hold harmless the relevant Novartis OTC Group Company against and in respect of any and all Liabilities arising in connection with any Reorganisation (or part thereof) undertaken by Novartis, other than: 

  
 Page 39

 (A) any Liabilities of any Novartis OTC Group Company in respect of Tax (which shall be
dealt with under the Tax Indemnity); and 
 (B) any Liabilities in connection with any matter provided for or document entered
into as provided by this Agreement (including the provisions of Clause 8.11, but excluding this Schedule 17 ) or any Ancillary Agreement. 
  

	4	In this paragraph 4 and in paragraph 5 below: 

 (A) “GlaxoSmithKline RoW Consumer Assets” means the GlaxoSmithKline Consumer Group excluding the GlaxoSmithKline Consumer Group in the US and excluding the GlaxoSmithKline Transferring UK
Companies; and 
 (B) “GlaxoSmithKline Transferring UK Companies” means the GlaxoSmithKline Consumer Group
Companies incorporated in the UK which are held (directly or indirectly) by Glaxo Group Limited. 
  

	5	GlaxoSmithKline intends to carry out a Reorganisation (the “GlaxoSmithKline Reorganisation”) between signing of this Agreement and Closing involving
the following high-level steps: 

  

	5.1	GlaxoSmithKline will procure that a Jersey incorporated but solely UK tax resident company is incorporated as a (direct or indirect) subsidiary of Glaxo Group Limited
(the “Intermediate Holdco”); 

 GlaxoSmithKline Consumer Group in the US 

 

	5.2	the GlaxoSmithKline Consumer Group in the US is currently primarily held (directly or indirectly) underneath GlaxoSmithKline Holdings Americas Inc and Stiefel
Laboratories Inc; 

  

	5.3	if GlaxoSmithKline concludes that the conditions of section 355 of the Code should be met in respect of the GlaxoSmithKline Reorganisation, the GlaxoSmithKline Consumer
Group in the US will be distributed to GlaxoSmithKline Finance plc by way of a “qualifying spin-off” under section 355 of the Code prior to Closing. The GlaxoSmithKline Consumer Group in the US will then be transferred to the Intermediate
Holdco prior to Closing; 

  

	5.4	in any other case, the GlaxoSmithKline Consumer Group in the US will be transferred to the Purchaser on Closing in return for an issue of a portion of the A Shares to
the Second GlaxoSmithKline Shareholder (as defined in the Shareholders’ Agreement); 

 GlaxoSmithKline Consumer Group
outside the US 
  

	5.5	the GlaxoSmithKline RoW Consumer Assets are primarily held (directly or indirectly) underneath Glaxo Group Limited, Stiefel Laboratories Inc and Setfirst Limited;

  

	5.6	the GlaxoSmithKline RoW Consumer Assets will be transferred to the Intermediate Holdco (or a direct or indirect subsidiary of the Intermediate Holdco) prior to Closing;
and 

  

	5.7	on Closing, the Intermediate Holdco and the GlaxoSmithKline Transferring UK Companies will be contributed to the Purchaser in return for an issue of A Shares to the
First GlaxoSmithKline Shareholder (as defined in the Shareholders’ Agreement). 

  
 Page 40

	6	For the avoidance of doubt, the information set out in paragraph 5 above shall not constitute notification by GlaxoSmithKline to Novartis of a Reorganisation in
accordance with paragraph 1.1 above. 

  

	7	Novartis intends to achieve its contributions to the Purchaser through the following high-level steps: 

 

	7.1	shares in Novartis OTC Group Companies held from Switzerland would be contributed to the Purchaser in return for the issue shares; 

 

	7.2	an 80 per cent. shareholding in Novartis Consumer Health, Inc. will be contributed to the Purchaser for the issue of shares to Novartis Finance Corporation;

  

	7.3	shares in Novartis OTC Group Companies held by non-Swiss holding companies will be transferred to the Purchaser for cash; 

 

	7.4	Intellectual Property Rights may be transferred to the Purchaser for cash, either by way of sale or by way of fully paid-up licence; and 

 

	7.5	cash required by the Purchaser as envisaged in paragraphs 7.3 and 7.4 above would be provided by Novartis AG, and possibly also Novartis Finance Corporation,
subscribing cash for shares in the Purchaser. 

  

	8	For the avoidance of doubt, the information set out in paragraph 7 above shall not constitute notification by Novartis to GlaxoSmithKline of a Reorganisation in
accordance with paragraph 1.1 above. 

  

	9	The parties agree that although a Reorganisation may result in a change in the ownership structure of the relevant Target Group, it shall not, under any circumstances,
result in a change in scope of that Target Contributed Business as defined in this Agreement. 

  

	10	Between the date of this Agreement and Closing, the Purchaser shall be entitled to set up such wholly-owned (direct or indirect) subsidiary companies as it sees fit
and, in accordance with Clauses 2.1, 2.2 and 2.3, may procure that such subsidiary companies purchase the relevant Shares and/or Target Group Businesses in accordance with such Clauses. 

  
 Page 41

 Schedule 18 
 Statement of Net Assets 
 Part 1 

Statement of Net Assets Rules – GlaxoSmithKline 

 

	1	Preparation of the GlaxoSmithKline Statement of Net Assets 

  

	1.1	Period 

 The Statements of
Net Assets is prepared as of the close of business on the final day of the relevant calendar month. 
  

	1.2	Translation of Reporting Entity’s Statements of Net Assets 

 A reporting entity reports in local currency. All reports are translated into GBP by the Seller for reporting purposes. The GlaxoSmithKline Statement of Net Assets is translated at the period-end exchange
rates which are the rates published on the Finance Community and are based on exchange rates published by Reuters and are published on the GlaxoSmithKline intranet. 
  

	1.3	GlaxoSmithKline UNISON Reporting System and Materiality: 

  

	 	1.3.1	Financial information has been obtained from GlaxoSmithKline’s UNISON reporting system and prepared in accordance with GlaxoSmithKline’s Finance Manual.

  

	 	1.3.2	The GlaxoSmithKline Statement of Net Assets contains the business of GlaxoSmithKline Consumer division as included in GlaxoSmithKline’s segment reporting (column
A- “Per Annual Report”). Excluded assets and liabilities related to GlaxoSmithKline’s business in India and Nigeria and related to Lucozade and Ribena (which products were sold on 31 December 2013) are shown in columns B and C
(“Adjust out Nigeria and India” and Exclude Lucozade and Ribena”). A £5 million threshold was applied. 

  

	 	1.3.3	The GlaxoSmithKline Statement of Net Assets has been prepared as follows: 

  

	 	(i)	in accordance with the specific accounting treatments set out below; and, subject thereto; 

 

	 	(ii)	adopting the same accounting principles, methods, procedures and practices utilized in preparing the consolidated financial statements of GlaxoSmithKline plc as
described in the GlaxoSmithKline Finance Manual applied on a consistent basis using consistent estimation methodologies and judgments and with consistent classifications and, subject thereto; and 

 

	 	(iii)	in accordance with IFRS. 

  
 Page 42

	 	1.3.4	For the avoidance of doubt, paragraph 1.3.3(i) shall take precedence over paragraphs 1.3.3(ii) and 1.3.3(iii), and paragraph 1.3.3(ii) shall take precedence over
paragraph 1.3.3(iii). 

  

	2	Specific Policies 

 The
adjustment for exclusion of Lucozade and Ribena in the illustrative statement Net Assets represents an estimate based on balances at 31 December 2012 inflated by 2.8% for sales growth of the divested products. Other one-off adjustments relating to
the divestment have also been excluded from other payables and receivables. 

  
 Page 43

 Part 2 
 Statement of Net Assets Rules – Novartis 
 Part 3 of this Schedule 18 sets forth, for
illustrative purposes only, a computation of the statement of net assets as of the close of business on 31 December 2013 (the “Novartis Statement of Net Assets”). 

 

	1	Preparation of the Novartis Statement of Net Assets 

  

	1.1	Period 

 The Novartis
Statement of Net Assets is prepared as of the close of business on the final day of the relevant calendar month. 
  

	1.2	Translation of Reporting Entity’s Statements of Net Assets 

 A reporting entity reports in local currency. All reports are translated into US Dollars by the Seller for reporting purposes. The Novartis Statement of Net Assets is translated with the period-end
exchange rates which are the rates provided by Novartis Group Treasury and are based on Bloomberg’s mid-morning CET exchange rates and are published in the Group Treasury section of the Novartis intranet. 

 

	1.3	Novartis Reporting System and Materiality: 

  

	 	1.3.1	Financial information is obtained from the Financial Consolidation & Reporting System of Novartis and the supporting general ledgers are prepared in accordance
with Novartis’s Accounting Manual (the “NAM”). The Financial Consolidation & Reporting System is the system of record for Novartis external reporting. References in the Novartis Statement of Net Assets included as Part
2 of this Schedule 18 shown as “BS01 lines 010-671” relate to the groupings shown in Novartis’s monthly reporting form “BS01 – Balance sheet”. 

 

	 	1.3.2	For the Seller’s reporting purposes, the financial reporting of a legal entity is separated into a divisional part, which includes operating items and a corporate
part, which mainly captures the amounts related to taxes, post-employment benefit obligations and most of the financial assets and liabilities. The Novartis Statement of Net Assets contains the business of the OTC division as included in
Novartis’s segment reporting (column A- “OTC Divisional Reported Statement of Net Assets”), and items of the corporate Statement of Net Assets for the Novartis Group Companies (Column B – “OTC Statement of Net Assets of the
Corporate part of the Novartis Group Companies” as well as adjustments for certain items which are either excluded from or added to the transaction (columns C -“Excluded items”). A US$10 million threshold was applied.

  

	 	1.3.3	The Novartis Statement of Net Assets has been prepared as follows: 

  

	 	(i)	in accordance with the specific accounting treatments set out below; and, subject thereto; 

  
 Page 44

	 	(ii)	adopting the same accounting principles, methods, procedures and practices utilized in preparing the consolidated financial statements of Novartis AG as described in
the Novartis Accounting Manual applied on a consistent basis using consistent estimation methodologies and judgments and with consistent classifications and, subject thereto; and 

 

	 	(iii)	in accordance with IFRS. 

  

	 	1.3.4	For the avoidance of doubt, paragraph 1.3.3(i) shall take precedence over paragraphs 1.3.3(ii) and 1.3.3(iii), and paragraph 1.3.3(ii) shall take precedence over
paragraph 1.3.3(iii). 

  

	2	Specific Policies 

 The
following supplement the description in the NAM for certain items included in the Novartis Group Statement of Net Assets: 
  

	2.1	Non-Current assets 

  

	 	2.1.1	Property, plant and equipment (BS01_010) 

 An amount of US$1.1m has been excluded as it relates to assets, which will be retained. 
  

	 	2.1.2	Financial assets &– subsidiaries/JV (BS01_040) 

 This line reflects equity investments that Novartis Group Companies hold in other Novartis Group Companies. These relationships have been eliminated in the Novartis Statement of Net Assets (as reflected
in Column C). The equity investment in an entity which is not supposed to transfer in a share deal is maintained. Deferred tax assets (BS01_042). 
  

	 	2.1.3	Deferred tax assets (BS01_042) 

This line represents deferred tax assets included in the corporate part of Transferred Subsidiaries. In the US deferred taxes are
recognized in a member of the Seller’s Group US corporate entity and have therefore been added (as reflected in column C) in the Novartis Statement of Net Assets. 
  

	2.2	Current Assets: 

  

	 	2.2.1	Receivables own BU (BS01_130) 

Column B of the Novartis Statement of Net Assets represents receivables against other entities within the Novartis division, which are
offset by an equivalent amount in the line Payables own BU. These amounts have been eliminated in Column C of the Novartis Statement of Net Assets. 
  

	 	2.2.2	Prepaid share-based payments (BS01_161) 

  
 Page 45

 An asset for prepaid share-based compensation is recognized to reflect Novartis’s
internal charge-out mechanism for its equity settled share-based compensation plans. For entities settling the charge for the shares at the beginning of the vesting period, it reflects the expense yet to be recognized for the unvested part of a
share-based compensation plan. This asset has been excluded (as reflected in Column C) and is not reflected in the Novartis Statement of Net Assets. 
  

	2.3	Long-term Liabilities: 

  

	 	2.3.1	Deferred tax assets (BS01_535) 

This line represents deferred tax liabilities included in the corporate part of Transferred Subsidiaries. In the US deferred taxes are
recognized in a member of the Seller’s Group US corporate entity and have therefore been added (as reflected in column C) in the Novartis Statement of Net Assets. 
  

	 	2.3.2	Other non-current liabilities (BS01_540) 

 Column C excludes net liabilities for post-employment benefits of US$88 million included in the corporate part of the Novartis Group Companies as their treatment is addressed separately in Schedule 8.

  

	2.4	Current Liabilities: 

  

	 	2.4.1	Accrued share-based payments (BS01_671) 

 A liability for share-based compensation is recognized to reflect Novartis’s internal charge-out mechanism for its equity-settled share-based compensation plans. For entities settling the charge for
the shares after the vesting period, it reflects the expense recognized for the vested part of a share based compensation plan. This liability has been excluded (as reflected in Column C) and is not reflected in the Novartis Statement of Net Assets.

  
 Page 46

 Part 3 
 GlaxoSmithKline Statement of Net Assets 
  

																	
	GBP M	  	Per Annual
Report	 	 	Adjust Out
Nigeria and India	 	  	 Exclude
 Lucozade &
Ribena
	 	  	TOTAL	 
	 Fixed Assets
	  	 	2,964	  	 	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 Goodwill
	  	 	333	  	 	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 Computer Software
	  	 	15	  	 	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 Other intangibles
	  	 	1,669	  	 	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 Property, Plant and Equipment
	  	 	947	  	 	 	[***]	  	  	 	[***]	  	  	 	[***]	  
					
	 Inventory
	  	 	441	  	 	 	[***]	  	  	 	[***]	  	  	 	[***]	  
					
	 Receivables
	  	 	835	  	 	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 Trade Receivables*
	  	 	673	  	 	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 Other Receivables*
	  	 	162	  	 	 	[***]	  	  	 	[***]	  	  	 	[***]	  
					
	 Payables
	  	 	(1,363	) 	 	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 Trade Payables*
	  	 	(556	) 	 	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 Other Payables*
	  	 	(807	) 	 	 	[***]	  	  	 	[***]	  	  	 	[***]	  
					
	 Provisions
	  	 	(21	) 	 	 	[***]	  	  	 	[***]	  	  	 	[***]	  
		  	  
	  
	 	 	  
	  
	 	  	  
	  
	 	  	  
	  
	 
	 Net Operating Assets
	  	 	2,856	  	 	 	[***]	  	  	 	[***]	  	  	 	[***]	  
		  	  
	  
	 	 	  
	  
	 	  	  
	  
	 	  	  
	  
	 

  

	*	Adjustment for Lucozade and Ribena sales represents an estimate based on 2012 inflated at 2.8% for sales growth of divested portfolio. Other one off adjustments
relating to the divestment have also been excluded from other payables and receivables 

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission 

  
 Page 47

 Part 4 
 Novartis Statement of Net Assets 
 All amounts in US$ thousands 

 

																	
	 	  	OTC 
Divisional
Reported
Statement of 
Net
Assets at Dec 31,
2013	 	  	OTC Statement of
Net
Assets
including
Corporate part of
the OTC
Group
Companies	 	 	Excluded
items	 	 	OTC Group
Statement 
of
Net Assets
Dec 31, 2013	 
					
	 BS01_010 Property, plant and equipment
	  	 	306,208	  	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
					
	 BS01_020 Intangible assets
	  	 	585,066	  	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
					
	 BS01_035 Financial assets - 3rd parties and loans to AC
	  	 	2,983	  	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
					
	 BS01_040 Financial assets & subsidiaries//JV
	  				  	 	[***	] 	 	 	[***	] 	 	 	[***	]
					
	 BS01_040 Financial assets & subsidiaries//JV
	  				  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
					
	 BS01_042 Deferred tax assets
	  				  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
					
	 BS01_044 Other non-current non-financial assets
	  	 	15,128	  	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
					
	 BS01_050 Total financing and loans to subsidiaries / JV
	  				  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
					
	 BS01_110 Total inventories
	  	 	343,177	  	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
					
	 BS01_120 Trade receivables (3rd parties and AC)
	  	 	494,787	  	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
					
	 BS01_130 Receivables own BU
	  	 	1	  	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
					
	 BS01_130 Receivables own BU – Corporate
	  				  	 	[***	] 	 	 	[***	] 	 	 	[***	] 

  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission. 

  
 Page 48

																	
					
	 BS01_140 Receivables other BU’s
	  	 	13,319	  	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
					
	 BS01_160 Other current assets(3rd parties and AC)
	  	 	81,327	  	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
					
	 BS01_161 Prepaid share-based payments
	  	 	2,439	  	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
					
	 BS01_163 Marketable securities, Commodities and Derivative financial assets
	  				  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
					
	 BS01_180 Cash & cash equivalents
	  				  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
		  	  
	  
	 	  	  
	  
	 	 	  
	  
	 	 	  
	  
	 
					
	 Total Assets
	  	 	1,844,435	  	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
		  	  
	  
	 	  	  
	  
	 	 	  
	  
	 	 	  
	  
	 
					
	 BS01_511 Financial debt – long-term
	  				  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
					
	 BS01_516 Financing from subsidiaries / JV
	  				  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
					
	 BS01_518 Loans from subsidiaries / JV
	  				  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
					
	 BS01_535 Deferred tax liabilities
	  				  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
					
	 BS01_540 Other non-current liabilities (3rd parties and AC)
	  	 	30,675	  	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
					
	 BS01_610 Trade payables (3rd parties and AC)
	  	 	322,063	  	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
					
	 BS01_620 Payables own BU
	  				  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
					
	 BS01_620 Payables own BU – Corporate
	  				  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
					
	 BS01_630 Payables other BU’s
	  	 	35,113	  	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
					
	 BS01_651 Financial debt – Short-term (3rd parties and AC)
	  				  	 	[***	] 	 	 	[***	] 	 	 	[***	] 

  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission. 

  
 Page 49

																	
					
	 BS01_660 Income taxes payable
	  				  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
					
	 BS01_670 Accrued and other current liabilities (3rd parties and AC)
	  	 	302,075	  	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
					
	 BS01_671 Accrued share-based payments
	  	 	25,814	  	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
					
	 Total Liabilities
	  	 	715,740	  	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
		  	  
	  
	 	  	  
	  
	 	 	  
	  
	 	 	  
	  
	 
					
	 Net Assets
	  	 	1,128,695	  	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 
		  	  
	  
	 	  	  
	  
	 	 	  
	  
	 	 	  
	  
	 

  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission. 

  
 Page 50

 Schedule 19 
 Novartis International Assignees 
  

											
	 Unique No.
	  	 Assignment
	  	 Home
Division
	  	 Host
Division
	  	 Start Date
	  	 Estimated
End Date

						
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission. 

  
 Page 51

 Schedule 20 
 Clearances, Approvals etc. 
 Regulatory Approvals 

The following table provides the additional jurisdictions and applicable antitrust, merger control, or foreign investment rules referenced in Clause
4.1.3 of the Agreement. 
 This list of jurisdictions and statutes is not meant to be indicative of a known filing or approval requirement in
these jurisdictions. To the extent that clearances, approvals, waivers, no action letters or consents are not required to be obtained or not otherwise agreed by the parties to be appropriate and waiting periods are not required to have expired in
these jurisdictions, prior to closing of the transactions contemplated by the Agreement, such clearances, approvals, waivers, no action letters, consents, and waiting period expirations will not be conditions precedent to closing of the transactions
contemplated by the Agreement. 
  

			
	 Country
	  	 Statute Under Which Filing/Approval Is Required

	Australia	  	The Competition and Consumer Act of 2010
	Austria	  	Part I, chapter 3 of the Austrian Cartel Act of 2005
	Brazil	  	Law No. 12,529 of November 30, 2011
	Canada	  	The Competition Act
	China	  	The Chinese Anti-Monopoly Law
	Germany	  	Chapter VII of the Act against Restraints of Competition of 1958
	India	  	The Competition Act of 2002, as amended by The Competition (Amendment) Act of 2007
	Israel	  	Restrictive Trade Practices Law, 5748-1988
	Japan	  	The Act on Prohibition of Private Monopolisation and Maintenance of Fair Trade No. 54 of 1947
	Mexico	  	The Federal Law on Economic Competition
	New Zealand	  	The Commerce Act of 1986
	Russia	  	Federal Law No. 135-FZ of July 16, 2006 on Protection of Competition
	South Africa	  	The Competition Act 89 of 1998
	South Korea	  	The Monopoly Regulation and Fair Trade Act
	Taiwan	  	The Fair Trade Law of 1991

  
 Page 52

			
	Turkey	  	The Law on Protection of Competition No. 4054 of 1994
	United Kingdom	  	The Enterprise Act of 2002

  
 Page 53

 Schedule 21 
 Seller Marks 
 Part 1 

GlaxoSmithKline Seller Marks 
 GLAXOSMITHKLINE 
 GLAXO 
 GSK 
 SMITHKLINE 
 SMITHKLINE BEECHAM 
 SB 
 STERLING 
 STIEFEL 
 WELLCOME 
 GLAXO WELLCOME 
 GSK Logo 
 GLAXOSMITHKLINE Logo 
 STIEFEL Logo 

  
 Page 54

 Attachment 1 
 [***] 
  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions, consisting of 32 pages, have been
omitted from this filing and have been filed separately with the Securities and Exchange Commission. 

  
 Page 55

 Attachment 2 
 [***] 
  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions, consisting of 53 pages, have been
omitted from this filing and have been filed separately with the Securities and Exchange Commission. 

  
 Page 56

 Schedule 2 
 Amended GSK Disclosure Letter 
 [***] 

 

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions, consisting of 204 pages, have been
omitted from this filing and have been filed separately with the Securities and Exchange Commission 

  
 Page 57

 Schedule 3 
 Amended Novartis Disclosure Letter 
 [***] 

 

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions, consisting of 155 pages, have been
omitted from this filing and have been filed separately with the Securities and Exchange Commission 

  
 Page 58EX-4.9

 Exhibit 4.9 

CONFIDENTIAL TREATMENT REQUESTED 

EXECUTION VERSION 
 9 October 2014 

NOVARTIS AG 
 and 

GLAXOSMITHKLINE PLC 
 DEED OF
AMENDMENT 
 relating to the 

SHARE AND BUSINESS SALE AGREEMENT 

relating to the Vaccines Group, dated 22 April 2014 as amended and restated on 29 May 2014 

 
 

 
 Linklaters LLP 
 One Silk
Street 
 London EC2Y 8HQ 
 Telephone (+44) 20 7456 2000

 Facsimile (+44) 20 7456 2222 
 Ref L-220595 

 This Deed (the “Deed”) is made on 9 October 2014 between: 

 

	(1)	NOVARTIS AG, a corporation (Aktiengesellschaft) incorporated in Switzerland whose registered office is at Lichtstrasse 35, 4056 Basel, Switzerland (the “Seller”); and 

 

	(2)	GLAXOSMITHKLINE PLC, a public limited company incorporated in England and Wales whose registered office is at 980 Great West Road Brentford, Middlesex, TW8 9GS (the “Purchaser”),

 each a “party” and together the “parties”. 

Whereas: 
  

	(A)	The Seller and the Purchaser entered into the Original Agreement (as defined below) on 22 April 2014 (the “Signing Date”). 

 

	(B)	The Seller and the Purchaser entered into the Amended Agreement (as defined below) on 29 May 2014. 

  

	(C)	The Seller and the Purchaser now wish to amend and supplement the Amended Agreement on the terms set out herein. 

It is agreed as follows: 
  

	1	Definitions and Interpretation 

 In this Deed, unless the context otherwise requires, the
provisions in this Clause 1 apply. 
  

	1.1	Incorporation of defined terms 

 Unless otherwise stated, terms defined in the Amended
Agreement shall have the same meaning in this Deed. 
  

	1.2	Definitions 

 “Amended Agreement” means the Original Agreement, as
amended and restated on 29 May 2014; 
 “Original Agreement” means the Share and Business Sale Agreement relating to
the Vaccines Group, dated 22 April 2014; and 
  

	1.3	Interpretation clauses 

  

	 	1.3.1	The principles of interpretation set out in Clause 1 of the Amended Agreement shall have effect as if set out in this Deed, save that references to “this Agreement” shall be construed as references to
“this Deed”. 

  

	 	1.3.2	References to this Deed include the Schedule. 

  

	2	Amendment 

  

	2.1	In accordance with Clauses 16.4.3 and 16.5.1 of the Amended Agreement, the parties agree that the Amended Agreement shall be amended and supplemented as set out in the Schedule to this Deed. 

 

	2.2	The amendment and supplementation of the Amended Agreement pursuant to clause 2.1 shall take effect from the Signing Date, as if this Deed had been entered into on the Signing Date. Therefore, upon this Deed
being entered into, this Deed read together with the Amended Agreement shall supersede the Original Agreement in its entirety. 

	3	Miscellaneous 

  

	3.1	Each party represents and warrants that it has full power and authority to enter into this Deed and to perform its obligations under it. 

 

	3.2	The provisions of Clauses 13, 16.2 to 16.5 and 16.11 to 16.15 of the Amended Agreement shall apply to this Deed as if set out in full in this Deed and as if references in those Clauses to “this Agreement” are
references to this Deed and references to “party” or “parties” are references to parties to this Deed. 

 In witness whereof this Deed has been delivered on the date first stated above. 

 

					
	 Executed as a DEED by
  

Marvelle Sullivan and
  

Jonathan Emery on behalf of
 NOVARTIS AG
		 }
		 /s/ Marvelle Sullivan
  

/s/ Jonathan Emery

		

							
	 Executed as a DEED by
GLAXOSMITHKLINE PLC acting by its
duly appointed attorney

 
 in the presence of:
				 )
 )

)
 )

)
		 /s/ Subesh Williams
 (Signature of
attorney)

				
	Witness’s signature:						/s/ Richard Hilton
				
	Name (print):						Richard Hilton
				
	Occupation:						Solicitor, Slaughter and May
				
	Address:						One Bunhill Row, London, EC1Y8YY

 Schedule 

Amendments to the Amended Agreement 
  

	1	With effect from the Signing Date: 

  

	1.1	the definitions of Business and Influenza Business in clause 1.1 of the Amended Agreement are deleted in their entirety and replaced with the following: 

“Business” means the research, development, manufacture, sales, marketing and commercialisation of Vaccines for human use by
the Seller’s Group as recorded and reported by the Seller’s Group from time to time under the “Vaccines and Diagnostics” segment as described in and consistent with the Novartis 2013 Annual Report and, with respect only to the
Vaccines Institute for Global Health, through the Novartis Institutes for BioMedical Research, and including the fill-finish process undertaken at the Rosia Site and, to the extent relevant, the Siena Site, but excluding: 

 

	 	(i)	the Influenza Business; 

  

	 	(ii)	the Diagnostics Business; and 

  

	 	(iii)	any Non-strategic Assets if and to the extent disposed of or transferred otherwise than to the Purchaser or a member of the Purchaser’s Group in accordance with this Agreement; 

“Influenza Business” means the Cell-based Influenza Business, the Egg-based Influenza Business and the German Flu Operations,
taken together; 
  

	1.2	the following definitions are added to clause 1.1 of the Amended Agreement: 

 “FCC
Vaccines” means bulk influenza Vaccines produced using cell-based technologies; 
 “German Flu Operations” means
the operations for the manufacture of FCC Vaccines and MF59® adjuvant located at the Marburg Site; 
  

	1.3	the words “subject to the following sub-clause (iv) of this Clause 2.3.6,” are added at the beginning of sub-clause (iii) of clause 2.3.6 of the Amended Agreement; 

 

	1.4	a new sub-clause (iv) is added to clause 2.3.6 of the Amended Agreement as follows: 

“all out-of-pocket fees, costs and expenses which (x) are incurred by either party, whether before or after Closing,
(y) specifically relate to the separation of the German Flu Operations from the Vaccines Group, and (z) are incurred in respect of works council consultations (including court fees, notary fees and works council legal fees) or physical
separation at the Marburg Site (including IT systems workarounds, costs of new access cards and construction works), but excluding the parties’ own legal fees, shall, to the extent that such fees, costs and expenses arise solely as a result of
such works council consultations or physical separation, be split equally between the Seller and the Purchaser. For the avoidance of doubt, this Clause 2.3.6(iv) shall not affect the cost allocation of wider measures necessary to effect the
separation of the Business from the Influenza Business.” 
  

	1.5	existing sub-clauses (i) and (ii) of clause 2.3.8 of the Amended Agreement are renumbered (ii) and (iii) respectively, and a new sub-clause (i) is added as follows: 

“such Liabilities where the allocation has been, or is, otherwise agreed between the parties;” 

	1.6	the words “subject to Clause 8.6” in clause 5.6.1 of the Amended Agreement are deleted and replaced with “subject to Clauses 5.6.3 and 8.6”; 

 

	1.7	a new clause 5.6.3 is added to the Amended Agreement as follows: 

 “Any Affiliate
Contract between or among Sandoz GmbH or Novartis Pharma Stein AG on the one hand, and any Vaccines Group Company on the other hand, and entered into after the date hereof with the written consent of the Purchaser, shall not terminate prior to
Closing in accordance with Clause 5.6.1, and shall transfer to the Purchaser upon Closing pursuant to Clause 2.3.1(viii).” 
  

	1.8	paragraph 3.4 of part B of part 1 of schedule 3 of the Amended Agreement is deleted in its entirety and replaced with the following: 

 

					
	3.4		Property Description:		Behringwerke: Emil-von-Behring-Straße 76, 35041 Marburg, Germany
			
					Building M 481 (entire building)
			
			Date and parties to Lease:		4/17 May 2004
			
					 (1)             PharmaServ Marburg
GmbH & Co. KG
  

(2)             Novartis Vaccines and Diagnostics
GmbH

  

	1.9	paragraphs 3.7, 3.8 and 3.9 of part B of part 1 of schedule 3 of the Amended Agreement are deleted in their entirety and replaced with the following: 

 

					
	3.7		Property Description:		Behringwerke: Emil-von-Behring-Straße 76, 35041 Marburg, Germany
			
					Building H 043 (entire building)
			
			Date and parties to Lease:		05 January 2012
			
					 (1)             PharmaServ Marburg
GmBH & Co. KG
  

(2)             Novartis Vaccines and Diagnostics
GmbH

			
	3.8		Property Description:		Behringwerke: Emil-von-Behring-Straße 76, 35041 Marburg, Germany
			
					 Building H 001 (partially)
  

Building H 007 (partially)

			
			Date and parties to Lease:		19 / 20 July 2010
			
					 (1)             PharmaServ Marburg
GmbH & Co. KG
  

(2)             Novartis Vaccines and Diagnostics
GmbH

			
	3.9		Property Description:		Behringwerke: Emil-von-Behring-Straße 76, 35041 Marburg, Germany
			
					Building Z24 (partially)
			
			Date and parties to Lease:		21 December 2011
			
					 (1)             PharmaServ Marburg
GmbH & Co. KG
  

(2)             Novartis Vaccines and Diagnostics
GmbH

	1.10	the following definitions are added to paragraph 1.1 of part 3 of schedule 3: 

 “German
Carve-out Leases” means the leases of the Company Leased Real Properties referred to at paragraphs 3.2 and 3.3 of Part B of Part 1 of Schedule 3 and any other lease(s) of the Company Leased Real Properties at the Marburg Site where the
premises demised by such lease(s) are occupied by both the Business and the German Flu Operations; 
 “German Flu Lease(s)”
has the meaning set out in paragraph 2.1 of this Part 3 of Schedule 3; and 
 “German Vaccines Lease(s)” has the meaning set
out in paragraph 2.1 of this Part 3 of Schedule 3. 
  

	1.11	the following paragraphs are added as paragraph 2 of part 3 of schedule 3: 

  

	“2	Specific provisions relating to the Marburg Site 

  

	2.1	The Seller agrees to procure that Novartis Vaccines and Diagnostics GmbH shall use reasonable efforts to procure the contemporaneous surrender of the German Carve-out Leases and the grant of replacement leases, certain
of which shall relate to those parts of the premises demised by the German Carve-out Leases which are used by the Business (the “German Vaccines Lease(s)”), and certain other of which shall relate to the balance of the premises
demised by the German Carve-out Leases (the “German Flu Lease(s)”). 

  

	2.2	If Novartis Vaccines and Diagnostics GmbH is able to procure the surrender of the German Carve-out Leases and the grant of the German Vaccines Lease(s) and the German Flu Lease(s) prior to Closing, it is acknowledged
that: 

  

	 	2.2.1	the German Flu Lease(s) shall be entered into by, or assigned prior to Closing to, an entity in the Seller’s Group Retained Business; 

 

	 	2.2.2	the German Flu Lease(s) shall not constitute lease(s) of Company Leased Real Property; and 

  

	 	2.2.3	the demise of the relevant Company Leased Real Property set out in Part B of Part 1 of this Schedule 3 shall be deemed amended to exclude the premises demised by the German Carve-out Leases and the German Flu Lease(s)
and to include reference to the premises demised by the German Vaccines Lease(s). 

  

	2.3	If Novartis Vaccines and Diagnostics GmbH is not able to procure the surrender of the German Carve-out Leases and the grant of the German Vaccines Lease(s) and the German Flu Lease(s) prior to Closing, the Seller and
the Purchaser shall use reasonable efforts to give practical effect to the above-described separation following Closing, and shall consider (without limitation): 

	 	2.3.1	continued negotiations with the relevant Company Landlords to achieve a separation of each German Carve-out Lease into a German Vaccines Lease and a German Flu Lease, the latter of which shall be entered into by, or
immediately assigned to, an entity in the Seller’s Group Retained Business; or 

  

	 	2.3.2	if a separation pursuant to paragraph 2.3.1 of this Part 3 of Schedule 3 is not achievable, a sub-lease of those parts of the premises demised by the German Carve-out Leases which are used by the German Flu Operations
to an entity in the Seller’s Group Retained Business. 

  

	2.4	The Seller agrees to procure that Novartis Vaccines and Diagnostics GmbH shall not agree to any terms of any German Vaccines Lease(s) which are not substantially similar to the equivalent terms of the relevant
underlying German Carve-out Lease without the consent of the Purchaser (not to be unreasonably withheld or delayed), and shall not agree to any terms of any German Flu Lease(s) which are not substantially similar to the equivalent terms of the
relevant underlying German Carve-out Lease without the consent of the Seller (not to be unreasonably withheld or delayed). 

  

	2.5	In connection with the implementation of the arrangements set out in this paragraph 2 of Part 3 of Schedule 3, the parties agree to work together prior to Closing (or, where paragraph 2.3 of this Part 3 of Schedule 3
applies, after Closing) to agree the provision of any site engineering services reasonably required by the other in order to operate those premises demised by the German Vaccines Lease(s) or the German Flu Lease(s), as applicable, in substantially
the same manner as operated immediately prior to Closing. Such services may include, but are not limited to, supply of water, gas and electricity, the operation of clean utility systems (water for injection, clean steam, clean gases, etc.), facility
services contract management and administration, preventive and corrective maintenance, and shutdown coordination.” 

  

	1.12	the words “, the Influenza Business Transitional Services Agreement” are deleted in their entirety from paragraphs 1.1.2 and 1.2.2 of schedule 15 of the Amended Agreement; 

 

	1.13	the Illustrative Working Capital Statement in part 4 of schedule 16 of the Amended Agreement is deleted and replaced in its entirety with the following: 

All amounts in USD thousands 
  

					
	 	  	Vaccines Group (excl. Flu business)
Illustrative Net Working Capital as
per December 31, 2013	 
	 BS01_110 Total inventories
	  	 	400,663	  
	 BS01_120 Trade receivables (3rd parties and AC)
	  	 	335,387	  
	 BS01_130 Receivables own BU
	  	 	22,683	  
	 BS01_140 Receivables other BU’s
	  	 	20,419	  
	 BS01_610 Trade payables (3rd parties and AC)
	  	 	(176,115	) 
	 BS01_620 Payables own BU
	  	 	(18,295	) 
	 BS01_630 Payables other BU’s
	  	 	(40,675	) 
	 Illustrative Net Working Capital
	  	 	544,067	  

	1.14	the Statement of Net Assets in part 2 of schedule 23 of the Amended Agreement is deleted and replaced in its entirety with the following: 

All amounts in $ thousands 
  

																																					
	 	  	Column A	 	  	Column B	 	  	Column C	 	  	Column D	 	  	Column E	 	  	Column F	 	  	Column G	 	  	Column H	 	  	Column I	 
	 	  	Vaccines
Dataroom
balance
sheet
Dec 31,
2013	 	  	Adjustments*	 	  	Vaccines
Divisional
Reported
Statement
of Net
Assets at
Dec 31,
2013	 	  	Vaccines
Statement
of Net
Assets of
the
Corporate
part of the
Vaccines
Group
Companies	 	  	Statement
of Net
Assets of
the part of
Novartis
Vaccines
Institute for
Global
Health	 	  	Excluded
items	 	  	Vaccines
Group
Statement
of Net
Assets
Dec 31,
2013	 	  	Influenza
business	 	  	Vaccines
Group
(excl.
Influenza
business)
Statement
of Net
Assets
Dec 31,
2013	 
	 BS01_010 Property, plant and equipment
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	729,492	  
	 BS01_020 Intangible assets
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	1,853,635	  
	 BS01_034 Financial assets_ associated companies
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	777	  
	 BS01_035 Financial assets - 3rd parties and loans to AC
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	17,981	  
	 BS01_040 Financial assets & subsidiaries//JV
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	0	  
	 BS01_042 Deferred tax assets
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	78,951	  
	 BS01_044 Other non-current non-financial assets
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	23,129	  
	 BS01_050 Total financing and loans to subsidiaries / JV
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	58,563	  
	 BS01_110 Total inventories
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	400,663	  

  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

																																					
	 	  	Column A	 	  	Column B	 	  	Column C	 	  	Column D	 	  	Column E	 	  	Column F	 	  	Column G	 	  	Column H	 	  	Column I	 
	 BS01_120 Trade receivables (3rd parties and AC)
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	335,387	  
	 BS01_130 Receivables own BU
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	21,818	  
	 BS01_130 Receivables own BU – Corporate and Institute for Global Health
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	865	  
	 BS01_140 Receivables other BU’s
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	20,419	  
	 BS01_160 Other current assets (3rd parties and AC)
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	70,207	  
	 BS01_161 Prepaid share-based payments
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	0	  
	 BS01_180 Cash & cash equivalents
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	4,393	  
	 Total Assets
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	3,616,280	  
	 Bs01_511 Financial debt – long-term
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	8	  
	 BS01_520 Total financing and loans from subsidiaries// JV
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	680,633	  
	 BS01_535 Deferred tax liabilities
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	92,072	  
	 BS01_540 Other non-current liabilities (3rd parties and AC)
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	54,071	  
	 BS01_610 Trade payables (3rd parties and AC)
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	176,115	  
	 BS01_620 Payables own BU
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	15,056	  
	 BS01_620 Payables own BU – Corporate 
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	3,239	  

  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

																																					
	 	  	Column A	 	  	Column B	 	  	Column C	 	  	Column D	 	  	Column E	 	  	Column F	 	  	Column G	 	  	Column H	 	  	Column I	 
	 BS01_630 Payables other BU’s
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	40,675	  
	 BS01_651 Financial debt – Short-term (3rd parties and AC)
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	1,395	  
	 BS01_660 Income taxes payable
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	55,060	  
	 BS01_670 Accrued and other current liabilities (3rd parties and AC)
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	238,671	  
	 BS01_671 Accrued share-based payments
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	0	  
	 Total Liabilities
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	1,356,995	  
	 Net Assets
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	2,259,285	  

  

	*	The difference for BS01_010 Property, plant and equipment relates to the plant built in Pernambuco Brazil, which had been excluded in the dataroom balance sheet. 

The difference for BS01_160 Other current assets is composed of other current assets related to the Diagnostics Business, but which have not been transferred
to Grifols; these were excluded in the dataroom balance sheet. 
 Line BS01_620 and Line BS01_630 have been combined into the line Intercompany payable in
the dataroom balance sheet and items related to Pernambuco have been excluded. 
 The difference for BS01_670 Accrued and other current liabilities is
composed of items related to the Diagnostics business, which have not been transferred to Grifols and were therefore excluded in the dataroom balance and items related to the Plant in Pernambuco, which have also been excluded in the dataroom balance
sheet. 
  
  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

 EXECUTION VERSION 

29 May 2014 
 NOVARTIS AG

 and 
 GLAXOSMITHKLINE PLC

 DEED OF AMENDMENT AND RESTATEMENT 

relating to the 
 SHARE AND
BUSINESS SALE AGREEMENT 
 relating to the Vaccines Group, dated 22 April 2014 

 
 

 
 Linklaters LLP 
 One Silk
Street 
 London EC2Y 8HQ 
 Telephone (+44) 20 7456 2000

 Facsimile (+44) 20 7456 2222 
 Ref L-220595 

 This Deed (the “Deed”) is made on 29 May 2014 between: 

 

	(1)	NOVARTIS AG, a corporation (Aktiengesellschaft) incorporated in Switzerland whose registered office is at Lichtstrasse 35, 4056 Basel, Switzerland (the “Seller”); and 

 

	(2)	GLAXOSMITHKLINE PLC, a public limited company incorporated in England and Wales whose registered office is at 980 Great West Road Brentford, Middlesex, TW8 9GS (the “Purchaser”),

 each a “party” and together the “parties”. 

Whereas: 
  

	(A)	The Seller and the Purchaser entered into the Original Agreement (as defined below) on 22 April 2014 (the “Signing Date”). 

 

	(B)	In connection with the Original Agreement, the Seller provided the Original Disclosure Letter (as defined below) to the Purchaser. 

  

	(C)	The Seller and the Purchaser now wish to amend and restate: 

  

	 	(i)	the Original Agreement, in the form of the Amended Agreement (as defined below); and 

  

	 	(ii)	the Original Disclosure Letter, in the form of the Amended Disclosure Letter (as defined below). 

 It is
agreed as follows: 
  

	1	Definitions and Interpretation 

 In this Deed, unless the context otherwise requires, the
provisions in this Clause 1 apply. 
  

	1.1	Incorporation of defined terms 

 Unless otherwise stated, terms defined in the Original
Agreement shall have the same meaning in this Deed. 
  

	1.2	Definitions 

 “Amended Agreement” means the Original Agreement, as
amended and restated in the form set out in Schedule 1 to this Deed; 
 “Amended Disclosure Letter” means the Original
Disclosure Letter, as amended and restated in the form set out in Schedule 2 to this Deed; 
 “Original Agreement” means the
Share and Business Sale Agreement relating to the Vaccines Group, dated 22 April 2014; and 
 “Original Disclosure
Letter” means the letter given on the Signing Date from the Seller to the Purchaser disclosing information constituting exceptions to the Seller’s Warranties. 
  

	1.3	Interpretation clauses 

  

	 	1.3.1	The principles of interpretation set out in Clause 1 of the Original Agreement shall have effect as if set out in this Deed, save that references to “this Agreement” shall be construed as references to
“this Deed”. 

  

	 	1.3.2	References to this Deed include the Schedules. 

	2	Amendment 

  

	2.1	In accordance with Clauses 16.4.3 and 16.5.1 of the Original Agreement, the parties agree that the Original Agreement shall be amended and restated as set out in Schedule 1 to this Deed. 

 

	2.2	The parties agree that the Original Disclosure Letter shall be amended and restated as set out in Schedule 2 to this Deed. 

  

	2.3	The amendment and restatement of the Original Agreement pursuant to clause 2.1 and the amendment and restatement of the Original Disclosure Letter pursuant to clause 2.2 shall take effect from the Signing Date,
as if the Amended Agreement and the Amended Disclosure Letter had been entered into on the Signing Date. Therefore, upon this Deed being entered into: 

  

	 	2.3.1	the Amendment Agreement shall supersede the Original Agreement in its entirety; and 

  

	 	2.3.2	the Amended Disclosure Letter shall supersede the Original Disclosure Letter in its entirety. 

  

	3	Miscellaneous 

  

	3.1	Each party represents and warrants that it has full power and authority to enter into this Deed and to perform its obligations under it. 

 

	3.2	The provisions of Clauses 13, 16.2 to 16.5 and 16.11 to 16.15 of the Amended Agreement shall apply to this Deed as if set out in full in this Deed and as if references in those Clauses to “this
Agreement” are references to this Deed and references to “party” or “parties” are references to parties to this Deed. 

 In witness whereof this Deed has been delivered on the date first stated above. 

 

							
	 Executed as a DEED by
  

Roy Papatheodorou and
  

Jonathan Emery on behalf of NOVARTIS AG
		  
 }
				 /s/ Roy Papatheodorou
  

/s/ Jonathan Emery

							
	 Executed as a DEED by
 GLAXOSMITHKLINE
PLC acting by its
 duly appointed attorney
  

in the presence of:
		 )
 )

)
 )

)
				  
 /s/ David Redfern

(Signature of attorney)

				
	Witness’s signature:						/s/ Claire Jackson
				
	Name (print):						Claire Jackson
				
	Occupation:						Solicitor
				
	Address:						One Bunhill Row, London

 Schedule 1 

Amended Agreement 

 CONFORMED COPY 

Dated 22 April 2014 
 as
amended and restated on 29 May 2014 and further 
 amended on 9 October 2014 

NOVARTIS AG 
 and 

GLAXOSMITHKLINE PLC 
 SHARE AND
BUSINESS SALE AGREEMENT 
 relating to the Vaccines Group 
  

 
   Linklaters LLP 

  One Silk Street 
   London EC2Y 8HQ 

  United Kingdom 
   Telephone (+44 20) 7456
2000 
   Facsimile (+44 20) 7456 2222 

  Ref L-220595 

 Share and Business Sale Agreement 

This Agreement is made on 22 April 2014, amended and restated on 29 May 2014 and further amended on 9 October 2014. 

between: 
  

	(1)	NOVARTIS AG, a corporation (Aktiengesellschaft) incorporated in Switzerland whose registered office is at Lichtstrasse 35, 4056 Basel, Switzerland (the “Seller”); and 

 

	(2)	GLAXOSMITHKLINE PLC, a public limited company incorporated in England and Wales whose registered office is at 980 Great West Road Brentford, Middlesex, TW8 9GS, United Kingdom (the “Purchaser”),

 each a “party” and together the “parties”. 

Whereas: 
  

	(A)	the Seller and certain of the Seller’s Affiliates, including the Vaccines Group Companies (as defined below), are engaged in the Business; 

 

	(B)	as of the date of this Agreement, the Seller and certain of the Seller’s Affiliates directly or indirectly own shares and other equity interests in the Vaccines Group Companies; 

 

	(C)	the Seller has agreed to sell (or procure the sale of) the Vaccines Group (as defined below) and to assume the obligations imposed on the Seller under this Agreement; 

 

	(D)	the Purchaser has agreed to purchase (or procure the purchase of) the Vaccines Group and to assume the obligations imposed on the Purchaser under this Agreement; 

 

	(E)	the Seller and certain of the Seller’s Affiliates are also engaged in the Influenza Business, and shall retain the Influenza Business following the date hereof (such Influenza Business not to be the subject of the
transactions between the Seller and the Purchaser contemplated by this Agreement). The Seller may carry out a Re-organisation (as defined below) on or prior to Closing to facilitate separation of the business from the Influenza Business; and

  

	(F)	in connection with the transactions contemplated by this Agreement, the Purchaser and the Seller, or certain of their respective Affiliates, have or will enter into the Ancillary Agreements. 

It is agreed as follows: 
  

	1	Interpretation 

 In this Agreement, unless the context otherwise requires, the provisions
in this Clause 1 apply: 
  

	1.1	Definitions 

 “2013 DCOGS” means the highlighted sections of the COGS
analysis in the Agreed Terms; 
 “2013 Gross Profit” means US$274 million (being the difference between net sales (excluding
other revenue) of US$935 million and cost of goods sold of US$661 million); 
 “2013 Income Statement” means the 2013 income
statement of the Vaccines Group and the Influenza Business in the Agreed Terms; 

  
  

 
 1 

 “Accounts” means, for each Vaccines Group Company, the audited financial
statements of that Vaccines Group Company, prepared in accordance with legislation as in force and applicable to that Vaccines Group Company for the accounting reference period ended on the Accounts Date, comprising the balance sheet, the profit and
loss account and the notes to the accounts; 
 “Accounts Date” means, in respect of: 

 

	 	(vi)	Chiron Behring Vaccines Private Limited, 31 March 2013; and 

  

	 	(vii)	each other Vaccines Group Company, 31 December 2012; 

 “Action” means the
taking of any steps by any Governmental Entity to seek a Judgment which would have the effect of preventing the consummation of the transactions contemplated by this Agreement by the Purchaser; 

“Affiliate” means: 
  

	 	(viii)	with respect to any person (other than a party to this Agreement), any other person that Controls, is Controlled by or is under common Control with such person; or 

 

	 	(ix)	with respect to a party to this Agreement, any other person that is Controlled by such party, 

and “Affiliates” shall be interpreted accordingly; 

“Affiliate Contract” means a Contract between or among any member of the Seller’s Group (other than the Vaccines Group
Companies) on the one hand, and any Vaccines Group Company on the other hand, but excluding any Ancillary Agreement; 
 “Agreed
Terms” means, in relation to a document, such document in the terms agreed between the Seller and the Purchaser and signed for identification purposes by the Seller’s Lawyers and the Purchaser’s Lawyers, with such alterations as
may be agreed in writing between the Seller and the Purchaser from time to time; 
 “Agreement” means this share and
business sale agreement; 
 “Allocation” has the meaning given to it in paragraph 1 of Schedule 13; 

“Allowance” means any amount payable or repayable to customers in respect of a contractual allowance or discount due on the
sales of products; 
 “Ancillary Agreements” means the Implementation Agreement, the Local Transfer Documents, the
Disclosure Letter, the Tax Indemnity, the France Offer Letter, the France SPA, the Netherlands Offer Letter, the Netherlands APA, the Transitional Services Agreement, the Manufacturing, Supply and Distribution Agreement, the Influenza Business
Manufacturing and Supply Agreement, the Purchaser Intellectual Property Licence Agreement, the Intellectual Property Assignment Agreements and the Pharmacovigilance Agreement; 

“Anti-Bribery Law” means any Applicable Law that relates to bribery or corruption, including the US Foreign Corrupt Practices
Act of 1977 and the UK Bribery Act 2010, in each case as amended, re-enacted or replaced from time to time; 
 “Applicable
Law” means any supra-national, federal, national, state, municipal or local statute, law, ordinance, regulation, rule, code, order (whether executive, legislative, judicial or otherwise), judgment, injunction, notice, decree or other
requirement or rule of law or legal process (including common law), or any other order of, or agreement issued, promulgated or entered into by, any Governmental Entity or any rule or requirement of any national securities exchange, including all
Healthcare Laws, and GCP, GLP, and GMP, each as may be amended from time to time; 

  
  

 
 2 

 “Appointment Notice” has the meaning given to it in paragraph 1.3 of Schedule
16; 
 “Associated Person” means, in relation to the Seller’s Group, a person (including any director, officer,
employee, agent or other intermediary) who performs services for or on behalf of any member of the Seller’s Group or who holds shares of capital stock, partnership interests, limited liability company membership interests and units, shares,
interest and other participations in any member of the Seller’s Group (in each case when performing such services or acting in such capacity); 

“Assumed Liabilities” means all Liabilities relating to the Vaccines Group Businesses other than: (i) the Excluded
Liabilities; (ii) any Relevant Pension and Employment Liability; and (iii) any Liabilities in respect of Tax (other than Tax which has been provided for or reflected in the Closing Statement and Tax which has been assumed by the
Purchaser’s group under an express provision of this Agreement); 
 “Base Working Capital” means, in respect of the
Vaccines Group Companies and Vaccines Group Businesses, the amount shown in paragraph 4 of Part 2 of Schedule 16; 
 “Benefit
Plans” means the US Benefit Plans and the Non-US Benefit Plans; 
 “Beta Interferon Patent Rights” means the
Patents listed in Part 3 of Schedule 4 (the “Beta Interferon Patents”) together with the rights of Novartis Vaccines and Diagnostics, Inc. under the Merck 2012 Licence; 

“Business” means the research, development, manufacture, sales, marketing and commercialisation of Vaccines for human use by
the Seller’s Group as recorded and reported by the Seller’s Group from time to time under the “Vaccines and Diagnostics” segment as described in and consistent with the Novartis 2013 Annual Report and, with respect only to the
Vaccines Institute for Global Health, through the Novartis Institutes for BioMedical Research, and including the fill-finish process undertaken at the Rosia Site and, to the extent relevant, the Siena Site, but excluding: 

 

	 	(x)	the Influenza Business; 

  

	 	(xi)	the Diagnostics Business; and 

  

	 	(xii)	any Non-strategic Assets if and to the extent disposed of or transferred otherwise than to the Purchaser or a member of the Purchaser’s Group in accordance with this Agreement; 

“Business Day” means a day which is not a Saturday, a Sunday or a public holiday in the canton of Basel-Stadt (Switzerland) or
London; 
 “Business Information” means: (i) Commercial Information; (ii) Medical Information; and (iii) any
other information Predominantly Related to the Business; 
 “Business Sellers” means the members of the Seller’s Group
(other than the Vaccines Group Companies) that own assets of or otherwise conduct any of the Vaccines Group Business; 

  
  

 
 3 

 “Call for New Tender” means any calls for a tender (including any tender for a
basket of products), whether a new tender or the renewal of an existing tender, which includes the Products and which is published after Closing of which the Seller and/or any of the Seller’s Affiliates become aware and which relates in whole
or in part to the sale of Products; 
 “Cash Balances” means cash in hand or credited to any account with a financial
institution and securities which are readily convertible into cash; 
 “Cash Pooling Arrangements” means the cash pooling
arrangements of members of the Seller’s Group in which the Vaccines Group Companies participate; 
 “Cell-based Influenza
Business” means: 
  

	 	(xiii)	the business conducted by the Seller’s Group from time to time of research, development, manufacture, sales, distribution, marketing and commercialisation of: 

 

	 	(a)	influenza Vaccines using cell-based technologies, including such business conducted at the Holly Springs Site; 

  

	 	(b)	adjuvants conducted at the Holly Springs Site; and 

  

	 	(c)	other Vaccines products to the extent that such business is conducted or contemplated to be conducted by the Seller’s Group at the Holly Springs Site in accordance with its obligations to, or as requested by, the
US government or regulatory authorities; and 

  

	 	(xiv)	technical development, manufacturing and supply of Enoxaparin, Copaxone or any other pharmaceutical or biological products (other than Vaccines) at the Holly Springs Site, including, but not limited to, pursuant to
agreements or arrangements with Sandoz Inc. or its Affiliates; 

 “Certificate” means a certificate signed by
a director, officer or an authorised signatory of the Seller in the form set out in Schedule 9, to be provided to the Purchaser immediately prior to Closing; 

“CFIUS” means the Committee on Foreign Investment in the United States; 

“CFIUS Approval” means written notice from CFIUS that any review or investigation of the Transaction under Section 721 of
the Defense Production Act of 1950, as amended (50 U.S.C. App. Section 2170), has been concluded and there are no unresolved national security concerns with respect to the Transaction or the President shall have determined not to take action
with respect to the Transaction; 
 “Clinical Trials/Data Liability” means any Liability arising out of, relating to or
resulting from any breach of Applicable Law in connection with the conduct of, or reporting or data in relation to, clinical studies or trials (including post-approval studies) in relation to the Vaccines Group; 

“Closing” means the completion of the sale of the Shares and the Vaccines Group Businesses pursuant to this Agreement and any
Ancillary Agreement; 
 “Closing Date” means the date on which Closing takes place; 

“Closing Statement” means the statement setting out the Working Capital, the Working Capital Adjustment, the Vaccines Group
Companies’ Cash Balances, the Intra-Group Non-Trade Receivables, the Third Party Indebtedness, the Intra-Group Non-Trade Payables and the Tax Adjustment, to be prepared by the Seller and agreed or determined in accordance with Clause 7 and
Schedule 16; 

  
  

 
 4 

 “COBRA” means the Consolidated Omnibus Budget Reconciliation Act of 1985 of the
United States, as amended, section 4980B of the Code, Title I Part 6 of ERISA, and any similar US state group health plan continuation law, together with its implementing regulations; 

“Code” means the U.S. Internal Revenue Code of 1986, as amended, together with its implementing regulations; 

“Commercial Information” means information that is, as of the Closing Date, owned by the Seller and/or its Affiliates and
relates predominantly to the Commercialisation of any Products; 
 “Commercial Practices Liability” means any Liability
arising out of, relating to or resulting from any breach of Applicable Law in connection with the Commercialisation of products; 

“Commercialise” means to promote, market, distribute and/or sell a Product and “Commercialising” and
“Commercialisation” shall be construed accordingly; 
 “Companies” means the companies, details of which
are set out in paragraph 2 of Schedule 2, and “Company” means any one of them; 
 “Company Lease” has the
meaning given to it in paragraph 1.1 of Part 3 of Schedule 3; 
 “Company Leased Real Properties” has the meaning given to
it in paragraph 1.1 of Part 3 of Schedule 3; 
 “Company Owned Real Properties” has the meaning given to it in paragraph 1.1
of Part 3 of Schedule 3; 
 “Company Real Properties” means the Company Owned Real Properties and the Company Leased Real
Properties, and “Company Real Property” means any one of them; 
 “Consumer Contribution Agreement” means
the contribution agreement dated the date of this Agreement between Leo Constellation Limited, the Purchaser and the Seller, relating to the establishment of a joint venture between the Purchaser and the Seller; 

“Contract” means any binding contract, agreement, instrument, lease, licence or commitment, excluding: (i) any lease or
other related or similar agreements, undertakings and arrangements with respect to the leasing or ownership of the Properties (to which the provisions set out in Schedule 3 shall apply); and (ii) any contract with any Employee; 

“Contracts Liabilities” means Liabilities relating to the: (i) Transferred Contracts; (ii) Transferred Intellectual
Property Contracts; and (iii) all other contracts or parts thereof transferred, assigned, novated or assumed by the Purchaser pursuant to this Agreement or to which a Vaccines Group Company is or was a party or under which a Vaccines Group
Company has any Liability, and a “Contracts Liability” shall mean any one of them; 
 “Control” means the
power to direct the management and policies of a person (directly or indirectly), whether through ownership of voting securities, by Contract or otherwise (and the term “Controlled” shall be interpreted accordingly); 

“Co-Owned Vaccines Group Intellectual Property Right” means any Vaccines Group Intellectual Property Right that is owned in
part by a third party; 

  
  

 
 5 

 “Copyright” means any works of authorship, copyrights, database rights, mask
work rights and registrations and applications therefor; 
 [***] 
 “Decision”
means the issuing of any decision by a competition, antitrust, foreign investment, national, local, supranational or supervisory or other government, governmental, quasi-governmental, trade, or regulatory body, agency, branch, subdivision,
department, commission, official or authority, including any Tax Authority and any governmental department and any court or other tribunal, that would have the effect of prohibiting the acquisition of the Vaccines Group by the Purchaser; 

“Deferred Employee” means any person to whom the Seller, any Vaccines Group Company or any other member of the Seller’s
Group has made an offer of employment for a role in the Business (as carried on by the Vaccines Group) in compliance with Clause 5 and whose employment in the Business (as carried on by the Vaccines Group) will take effect on a date following the
Closing Date, save that no person shall become a Deferred Employee unless and until the Seller has provided to the Purchaser a copy of the offer letter setting out the agreed principal terms of employment and/or employment agreement (if executed)
applicable to such person; 
 “Diagnostics Business” means the human blood and blood products diagnostics business (and
certain related activities) sold by Novartis Vaccines and Diagnostics Inc. and its affiliates to G-C Diagnostics Corp. pursuant to a share and asset purchase agreement dated 10 November 2013; 

“Diagnostics GESA” means the Global Employee Services Agreement and Amendment No. 3 to Share and Asset Purchase Agreement
dated as of 9 January 2014 by and between Novartis Vaccines and Diagnostics, Inc., Novatis Corporation, G-C Diagnostics Corp., and Grifols, S.A.; 

“Diagnostics TSA Liabilities” means any Liability arising out of, relating to or resulting from the Diagnostics TSA; 

“Diagnostics TSA” means the Transition Services Agreement dated as of 9 January 2014 between Novartis Vaccines and
Diagnostics, Inc. and G-C Diagnostics Corp.; 
 “Disclosure Letter” means the letter dated on the same date as this
Agreement from the Seller to the Purchaser disclosing information constituting exceptions to the Seller’s Warranties; 
 “Draft
Closing Statement” has the meaning given to it in Clause 7.1; 
 “Effective Time” means 11.59 p.m. (local time in
the relevant location) on the Closing Date or, if the Closing Date is not the last day of a month but the first Business Day of a month, 11.59 p.m. on the last day of the immediately preceding month; 

“Egg-based Influenza Business” means the business conducted by the Seller’s Group from time to time of research,
development, manufacture, sales, distribution, marketing and commercialisation of influenza Vaccines and other products using egg-based technologies and related adjuvant technologies; 

 
  

	*** 	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
  

 
 6 

 “Employee Benefit Indemnification Amount” has the meaning given to it in
Schedule 12; 
 “Employee Benefits” has the meaning given to it in Schedule 12; 

“Employees” means the Vaccines Business Employees and the Vaccines Group Company Employees, and “Employee”
means any one of them; 
 “Encumbrance” means any claim, charge, mortgage, lien, option, equitable right, power of sale,
pledge, hypothecation, usufruct, retention of title, right of pre-emption, right of first refusal or other security interest of any kind or an agreement, arrangement or obligation to create any of the foregoing, and for the avoidance of doubt, shall
exclude any licences of or claims of infringement relating to, Intellectual Property Rights; 
 “Environmental Laws” means
any and all Applicable Law regulating or imposing Liability or standards of conduct concerning pollution or protection of the environment (including surface water, groundwater or soil); 

“Environmental Liabilities” means any Liability arising out of, relating to or resulting from any Environmental Law or
environmental, health or safety matter or condition, including natural resources, but excluding any Product Liability; 

“Environmental Permit” means any permit, licence, consent or authorisation required by Environmental Laws issued by any
relevant competent authority and used in relation to the operation or conduct of Manufacturing at each Property, and “Environmental Permit” shall be construed accordingly; 

“ERISA” means the Employee Retirement Income Security Act of 1974 of the United States, as amended, together with its
implementing regulations; 
 “Estimated Employee Benefit Adjustment” means the Seller’s reasonable estimate (in so far
as practicable), made in good faith after consulting with the Purchaser, of 95 per cent. of the anticipated aggregate of the Employee Benefit Indemnification Amounts, to be notified by the Seller to the Purchaser pursuant to Clause 6.4; 

“Estimated Intra-Group Non-Trade Payables” means the Seller’s reasonable estimate of the Intra-Group Non-Trade Payables,
to be notified by the Seller to the Purchaser pursuant to Clause 6.4; 
 “Estimated Intra-Group Non-Trade Receivables” means
the Seller’s reasonable estimate of the Intra-Group Non-Trade Receivables, to be notified by the Seller to the Purchaser pursuant to Clause 6.4; 

“Estimated Tax Adjustment” means the Seller’s reasonable estimate of the Tax Adjustment, to be notified by the Seller to
the Purchaser pursuant to Clause 6.4; 
 “Estimated Third Party Indebtedness” means the Seller’s reasonable estimate of
the Third Party Indebtedness, to be notified by the Seller to the Purchaser pursuant to Clause 6.4; 
 “Estimated Vaccines Group
Companies’ Cash Balances” means the Seller’s reasonable estimate of the aggregate of the Vaccines Group Companies’ Cash Balances, to be notified by the Seller to the Purchaser pursuant to Clause 6.4; 

“Estimated Working Capital” means the Seller’s reasonable estimate of the Working Capital, to be notified by the Seller
to the Purchaser pursuant to Clause 6.4; 

  
  

 
 7 

 “Estimated Working Capital Adjustment” means the amount by which the Estimated
Working Capital is greater or less than the Base Working Capital, any such excess amount being treated as a positive number and any shortfall being treated as a negative number; 

“Excluded Assets” means the property, rights and assets referred to in Clause 2.3.2 or Schedule 5; 

“Excluded Contracts” means, collectively, each Contract which is not Predominantly Related to the Business; 

“Excluded Employees” means the employees of any member of the Seller’s Group (including the Vaccines Group Companies) who
are listed in Schedule 5, any Vaccines Group Company Employees who do not work wholly or substantially in the Business (as carried on by the Vaccines Group), and such other employees as may be agreed in writing between the Seller and the Purchaser
after the date of this Agreement but before the Closing Date; 
 “Excluded Liabilities” means: 

 

	 	(xv)	all Liabilities: 

  

	 	(a)	relating to the Vaccines Group Businesses other than to the extent taken into account in the Closing Statement; 

  

	 	(b)	of the Vaccines Group Companies (other than Liabilities in respect of Tax), 

 in either case,
to the extent that they have arisen or arise (whether before or after Closing) as a result of, or otherwise relate to, an act, omission, fact, matter, circumstance or event undertaken, occurring, in existence or arising before Closing, other than
any Relevant Pension and Employment Liability and any Liabilities in respect of Tax provided for or reflected in the Closing Statement; and 
  

	 	(xvi)	all Liabilities relating to the Seller’s Group Retained Business and the Excluded Assets; and 

  

	 	(xvii)	any Seller Allowance Rebate and Royalty Amount; 

 “Exclusively Related to the
Business” means exclusively related to, or exclusively used or held for use exclusively, in connection with the Business; 

“FCA” means the Financial Conduct Authority; 

“FCC Vaccines” means bulk influenza Vaccines produced using cell-based technologies; 

“FDA” means the United States Food and Drug Administration (or its successor); 

“Final Allocation Schedule” has the meaning given to it in paragraph 8 of Schedule 13; 

“Final Payment Date” means five Business Days after the date on which the process described in Part 1 of Schedule 16 for the
preparation of the Closing Statement is complete; 
 “France Assumed Liabilities” means the Assumed Liabilities to the
extent they relate to the France Business; 
 “France Business” means that part of the Vaccines Group, comprising: 

 

	 	(xviii)	Novartis Vaccines and Diagnostics S.A.S. and the part of the Business conducted by Novartis Vaccines and Diagnostics S.A.S.; 

  
  

 
 8 

	 	(xix)	the France Assumed Liabilities; 

  

	 	(xx)	the France Employees; and 

  

	 	(xxi)	any other assets that are exclusively related to the France Business; 

 “France
Closing” has the meaning given to it in the France SPA; 
 “France Employees” means the Employees employed by
Novartis Vaccines and Diagnostics S.A.S.; 
 “France Offer Letter” means the letter from the Purchaser to the Seller in
respect of the binding offer from the Purchaser to acquire the France Business dated on or around the date hereof; 
 “France Put
Option Exercise” has the meaning given to it in the France Offer Letter; 
 “France SPA” has the meaning given to
it in the France Offer Letter; 
 “FSAs” has the meaning given to it in paragraph 7 of Schedule 11; 

“FSMA” means the Financial Services and Markets Act 2000; 

“Full Title Guarantee” means on the basis that the covenants implied under Part 1 of the Law of Property (Miscellaneous
Provisions) Act 1994 where a disposition is expressed to be made with full title guarantee are deemed to be given by the Seller (on behalf of the relevant Share Seller or Business Seller) on Closing; 

“German Flu Operations” means the operations for the manufacture of FCC Vaccines and MF59® adjuvant located at the Marburg Site; 
 “Good Clinical Practices” or
“GCP” means the then-current standards, practices and procedures promulgated or endorsed by (i) the ICH Harmonised Tripartite Guidelines for Good Clinical Practice (CPMP/ICH/135/95) and any other guidelines for good clinical
practices for trials on medicinal products in the European Union; (ii) the FDA as set forth in the guidelines entitled “Guidance for Industry E6 Good Clinical Practice: Consolidated Guidance,” including related regulatory requirements
imposed by the FDA; and (iii) the equivalent Applicable Law in any relevant country; 
 “Good Laboratory Practices” or
“GLP” means the then-current standards, practices and procedures promulgated or endorsed by: (i) the European Commission Directive 2004/10/EC relating to the application of the principles of good laboratory practices as well as
“The rules governing medicinal products in the European Union,” Volume 3, Scientific guidelines for medicinal products for human use (ex—OECD principles of GLP); (ii) the then-current standards, practices and procedures
promulgated or endorsed by the FDA as defined in 21 C.F.R. Part 58; and (iii) the equivalent Applicable Law in any relevant country; 

“Good Manufacturing Practices” or “GMP” means the then-current standards, practices and procedures
promulgated or endorsed by: (i) the European Commission Directive 91/356/EEC, as amended by Directive 2003/94/EC and 91/412/EEC respectively, as well as “The rules governing medicinal products in the European Union,” Volume 4,
Guidelines for good manufacturing practices for medicinal products for human and veterinary use; (ii) the FDA and the provisions of 21 C.F.R. Parts 210 and 211; (iii) the principles detailed in the ICH Q7A guidelines; and (iv) all
Applicable Law with respect to each of (i) through (iii); 
 “Governmental Entity” means any supra-national, federal,
national, state, county, local, municipal or other governmental, regulatory or administrative authority, agency, commission or other instrumentality, any court, tribunal or arbitral body with competent jurisdiction, or any national securities
exchange or automated quotation service including, any governmental regulatory authority or agency responsible for the grant approval, clearance, qualification, licensing or permitting of any aspect of the research, development, manufacture,
marketing distribution or sale of the Products including the FDA, the European Medicines Agency, or any successor agency thereto; 

  
  

 
 9 

 “Governmental Liability” means any Liability arising out of, relating to or
resulting from any claim, demand, action, suit, proceedings or investigation by a Governmental Entity (other than a Tax Authority) brought or undertaken in connection with products sold or developed by, or operations or practices of, the Vaccines
Group prior to Closing; 
 “GSK Break Fee” has the meaning given to it in the Implementation Agreement; 

“Hazardous Substance” means any gasoline or petroleum products, polychlorinated biphenyls, urea-formaldehyde insulation,
hazardous wastes, toxic substances, asbestos, pollutants, or contaminants defined as such in or regulated under any applicable Environmental Law; 

“Headline Price” has the meaning given to it in Clause 3.1.1(i); 

“Healthcare Laws” means the federal Anti-kickback Statute (42 U.S.C. § 1320a-7b(b)); the Anti-Inducement Law (42 U.S.C.
§ 1320a-7a (a)(5)); the civil False Claims Act (31 U.S.C. §§ 3729 et seq.); the administrative False Claims Law (42 U.S.C. § 1320a-7b(a)); the Exclusion Laws (42 U.S.C. § 1320a-7); the Medicare statute (Title XVIII of the
Social Security Act), including Social Security Act §§ 1860D-1 to 1860D-43 (relating to Medicare Part D and the Medicare Part D Coverage Gap Program); the Medicaid statute (Title XIX of the Social Security Act); the Physician Payment
Sunshine Act (42 U.S.C. § 1320a-7h) and any analogous state laws; the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. § 1320d et seq.), as amended by the Health Information Technology for Economic and Clinical Health
Act of 2009, and any other similar law, including the price reporting requirements and the requirements relating to the processing of any applicable rebate, chargeback or adjustment, under applicable rules and regulations relating to the Medicaid
Drug Rebate Program (42 U.S.C. § 1396r-8), any state supplemental rebate program, Medicare average sales price reporting (42 U.S.C. § 1395w-3a), the Public Health Service Act (42 U.S.C. § 256b), the Veterans Health Care Act (38 U.S.C.
§ 8126), regulatory requirements applicable to sales on the Federal Supply Schedule or under any state pharmaceutical assistance program or United States Department of Veterans Affairs agreement, all legal requirements relating to the billing
or submission of claims, collection of accounts receivable, underwriting the cost of, or provision of management or administrative services in connection with, any and all of the foregoing, by the Seller’s Group and any successor government
programs, and all foreign equivalents of the foregoing; 
 “Holly Springs Site” means properties located in Holly Springs,
North Carolina, United States of America at which the Influenza Business undertakes Manufacturing activities; 
 “HSR Act”
means the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, together with its implementing regulations; 

“IFRS” means International Financial Reporting Standards, comprising the accounting standards and interpretations issued,
adopted and/or approved by the International Accounting Standards Board; 

  
  

 
 10 

 “Illustrative Working Capital Statement” has the meaning given to it in Part 2
of Schedule 16; 
 “Implementation Agreement” means the implementation agreement dated the date of this Agreement between
the Seller and the Purchaser relating to, amongst other things, the implementation of the Transaction; 
 “In-Market
Inventory” means all inventory of Products for Commercialisation that, at any particular time: (i) is beneficially owned by a member of the Seller’s Group; and (ii) is in finished packed form and released for
Commercialisation; and (iii) is located: (a) in (or in transit to) the relevant Market; or (b) in (or in transit to) a multi-market warehouse owned or operated by a member of the Seller’s Group or by a third party; or (c) at
a Property pending despatch following release by the relevant qualified person to the relevant market or multi-market warehouse; 

“Indebtedness” means all loans and other financing liabilities and obligations in the nature of borrowed moneys and overdrafts
and moneys borrowed, but excluding trade debt and liabilities arising in the ordinary course of business; 
 “Influenza
Business” means the Cell-based Influenza Business, the Egg-based Influenza Business and the German Flu Operations, taken together; 

“Influenza Business Manufacturing and Supply Agreement” means the manufacturing and supply agreement expected to be entered
into between the Seller or a member of the Seller’s Group and the Purchaser or a member of the Purchaser’s Group on Closing on terms consistent with the heads of terms in the Agreed Terms, pursuant to which the Purchaser will manufacture
and supply certain products to the Influenza Business; 
 “Information Technology” means computer, hardware, software and
network; 
 “Intellectual Property Assignment Agreements” means the assignments between the Seller and/or one or more of its
Affiliates and the Purchaser and/or one or more of its Affiliates on terms consistent with the Agreed Terms, to be entered into at Closing, in respect of the transfer of certain Intellectual Property Rights in each of the relevant jurisdictions;

 “Intellectual Property Rights” means all: (i) Patents; (ii) Know-How; (iii) Trademarks; (iv) internet
domain names; (v) Copyrights; (vi) rights in designs; (vii) database rights; and (viii) all rights or forms of protection, anywhere in the world, having equivalent or similar effect to the rights referred to in paragraphs
(i) to (vii) above, in each case whether registered or unregistered and including applications for registration of any such thing; 

“International Assignees” means the employees of any member of the Seller’s Group (including the Vaccines Group
Companies) who are listed in Schedule 6 (as updated after the date of this Agreement as noted in Schedule 6 to exclude any international assignees working in the Influenza Business), and such other employees as may be agreed in writing between the
Seller and the Purchaser after the date of this Agreement but before the Closing Date; 
 “Intra-Group Non-Trade Payables”
means all outstanding loans or other financing liabilities or obligations (including, for the avoidance of doubt, interest accrued, dividends declared or payable but not paid) owed by a Vaccines Group Company to a member of the Seller’s Group
(other than a Vaccines Group Company) as at the Effective Time as derived from the Closing Statement, but excluding: (i) Intra-Group Trading Balances; and (ii) any item which falls to be included in calculating the Vaccines Group
Companies’ Cash Balances or the Third Party Indebtedness; 

  
  

 
 11 

 “Intra-Group Non-Trade Receivables” means all outstanding loans or other
financing liabilities or obligations (including, for the avoidance of doubt, interest accrued, dividends declared or payable but not paid) owed by a member of the Seller’s Group (other than a Vaccines Group Company) to a Vaccines Group Company
as at the Effective Time as derived from the Closing Statement, but excluding: (i) Intra-Group Trading Balances; and (ii) any item which falls to be included in calculating the Vaccines Group Companies’ Cash Balances or the Third
Party Indebtedness; 
 “Intra-Group Trading Balances” means all trade accounts and notes receivable or payable arising in
the ordinary course between any two members of the Seller’s Group, in each case to the extent related to the Vaccines Group, to which lines “BS01_630 Payables Other BU’s”, “BS01_140 Receivables Other BU’s”,
“BS01_620 Payables Own BU” and “BS01_130 Receivables Own BU” of the Statement of Net Assets apply, together with any unpaid financing charges accrued thereon; 

“IP Liability” means any Liability arising out of, relating to or resulting from any actual or alleged infringement,
misappropriation or other violation of Intellectual Property Rights of third parties; 
 “Judgment” means any order, writ,
judgment, injunction, decree, stipulation, determination, decision or award entered by or with any Governmental Entity of competent jurisdiction; 

“Key Personnel” means the Employees listed in Schedule 21; 

“Key Sites” means the Marburg Site, the Rosia Site and the Siena Site; 

“Know-How” means all existing and available technical information, know-how and data, including inventions (whether patentable
or not), discoveries, trade secrets, specifications, instructions, processes and formulae, including all biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical, physical, safety, quality control, preclinical and clinical
data; 
 “Lease” has the meaning given to it in paragraph 1.1 of Part 4 of Schedule 3; 

“Liabilities” means all liabilities, claims, damages, proceedings, demands, orders, suits, costs, losses and expenses of every
description, whether deriving from contract, common law, statute or otherwise, whether present or future, actual or contingent, ascertained or unascertained or disputed and whether owed or incurred severally or jointly or as principal or surety;

 “LIBOR” means the London interbank offered rate, being the interest rate offered in the London inter-bank market for
three month US dollar deposits as displayed on pages LIBOR01 or LIBOR02 of the Reuters screen at 11 a.m. (London) on the second Business Day prior to the Closing Date; 

“Licensed Intellectual Property Contract” means any Vaccines Group Intellectual Property Contract constituting or containing a
licence of Intellectual Property Rights in respect of the Business or Products; 
 “Listing Rules” means the listing rules
made by the FCA under section 73A of FSMA; 
 “Local Transfer Document” has the meaning given to it in Clause 2.6.1; 

  
  

 
 12 

 “Long Stop Date” has the meaning given to it in Clause 4.3; 

“Losses” means all losses, liabilities, costs (including legal costs and experts’ and consultants’ fees), charges,
expenses, actions, proceedings, claims and demands; 
 “MA Costs” has the meaning given to it in paragraph 4 of Part 2 of
Schedule 8; 
 “MA Documentation” has the meaning given to it in paragraph 1.4 of Part 2 of Schedule 8; 

“Manufacture”, “Manufacturing” or “Manufactured” means the planning, purchasing of materials
for, production, processing, compounding, storage, filling, packaging, labelling, leafleting, warehousing, quality control testing, waste disposal, quality release, sample retention and stability testing of products; 

“Manufacturing Inventory” means any packed inventory of Products and/or products for Commercialisation that is: (i) in
finished form (save for any secondary packaging undertaken outside of a Property); (ii) beneficially owned by any member of the Seller’s Group; (iiii) held at a Property; and (iv) not yet released by the qualified person at a
Property; and excluding in each case, for the avoidance of doubt, any In-Market Inventory and Manufacturing Stocks; 
 “Manufacturing
Liability” means any Liability arising out of, relating to or resulting from any breach of Applicable Law in connection with the manufacturing of products; 

“Manufacturing Licences” means any certificates, permits, licences, consents and approvals issued by any Governmental Entity,
used in the operation or conduct of Manufacturing at each Property, and “Manufacturing Licence” shall be construed accordingly; 

“Manufacturing Stocks” means, as at Closing, all stocks of raw materials, active pharmaceutical ingredients, ingredients,
adjuvants, drug substances, intermediates, packaging materials, components, devices and other production and pre-production consumables and work-in-progress that are beneficially owned by any member of the Seller’s Group for use in the
Manufacture of Products or Pipeline Products and held at a Property; 
 “Manufacturing, Supply and Distribution Agreement”
means the manufacturing, supply and distribution agreement to be entered into between the Seller and the Purchaser at Closing on terms consistent with the heads of terms in the Agreed Terms; 

“Marburg Site” means the Properties located in Marburg (Germany) at which the Vaccines Group undertakes Manufacturing
activities; 
 “Marketing Authorisation Data” means the existing and available dossiers containing the relevant Know-How
used by the Seller and/or its Affiliates to obtain and maintain the Marketing Authorisations; 
 “Marketing Authorisation
Holder” means the holder of the relevant Marketing Authorisation; 
 “Marketing Authorisation Re-registration” has
the meaning given to it in paragraph 1.1.2 of Part 2 of Schedule 8; 
 “Marketing Authorisation Re-Registration Date” means
the date on which the relevant Governmental Entity approves, or is deemed to approve, the relevant Marketing Authorisation Re-registration; 

  
  

 
 13 

 “Marketing Authorisation Transfer Date” means the date on which the relevant
Governmental Entity approves, or is deemed to approve, the relevant Marketing Authorisation Transfer; 
 “Marketing Authorisation
Transfer” has the meaning given to it in paragraph 1.1.1 of Part 2 of Schedule 8; 
 “Marketing Authorisation
Transferee” means the member of the Purchaser’s Group or, where no member of the Purchaser’s Group satisfies the requirements under Applicable Law to be transferred the relevant Marketing Authorisation, such Third Party as is
nominated by the Purchaser, in either case to whom the relevant Marketing Authorisation is to be transferred; 
 “Marketing
Authorisations” means the marketing authorisations issued or applications for Marketing Authorisations with respect to the Products and all supplements, amendments and revisions thereto; 

“Markets” means the markets in which the Products are marketed and sold under the relevant Marketing Authorisation, and
“Market” shall be construed accordingly; 
 “Material Adverse Effect” means any matter, change, event or
circumstance arising or discovered on or after the date of this Agreement and prior to Closing (including a breach of the Seller’s obligations under Clause 5 or Clause 9.1) (a “Relevant Matter”) that, individually or in the
aggregate with other Relevant Matters, if known to the Purchaser prior to the date of this Agreement, could reasonably have expected to have resulted in the Purchaser offering to acquire the Vaccines Group on the terms of this Agreement at a
discount to the Headline Price of 30 per cent. or more and, in determining such reduction, regard shall be had to the actual basis on which the Purchaser determined the Headline Price. A Relevant Matter shall not constitute or count towards a
“Material Adverse Effect” to the extent resulting or arising from: 
  

	 	(xxii)	any change that is generally applicable to, or generally affects, the industries or markets in which the Vaccines Group operates (including changes arising as a result of usual seasonal variations) or arises from or
relates to changes in Applicable Law or accounting rules or changes in any authoritative interpretation of any Applicable Law by any Governmental Entity; 

  

	 	(xxiii)	any change in financial, securities or currency markets or general economic or political conditions or changes in prevailing interest rates or exchange rates; 

 

	 	(xxiv)	the execution of this Agreement, the public announcement thereof or the pendency or consummation of the transactions contemplated hereby (including any cancellations of or delays in customer orders or other decreases in
customer demand, any reduction in revenues and any disruption in supplier, distributor, customer or similar relationships); or 

  

	 	(xxv)	the taking of any action expressly required by this Agreement or by any Ancillary Agreement or otherwise taken with the advance written consent of the Purchaser, 

except, in relation to either paragraph (i) or paragraph (ii) above, if that change adversely affects the Vaccines Group in a
disproportionate manner relative to other comparable businesses operating in the same industry and geographic markets as the Vaccines Group (in which case it may constitute or count towards a “Material Adverse Effect”); 

  
  

 
 14 

 “Material Employee Jurisdictions” means China, Germany, India, Italy, the United
Kingdom and the United States of America; 
 “Medical Information” means information relating to clinical and technical
matters, such as therapeutic uses for the approved indications, drug-disease information, and other product characteristics Predominantly Related to the Business which is available to or used by the Seller and/or its Affiliates as of the Closing
Date; 
 “Merck 2012 Licence” means the Settlement and Licence Agreement between Novartis Vaccines and Diagnostics Inc. and
Merck KGaA and Ares Trading SA dated 14 November 2012; 
 “Milestone Payments” has the meaning given to it in paragraph
10 of Schedule 17; 
 “Minority Interest Entities” means the entities, details of which are set out in paragraph 3 of
Schedule 2, and “Minority Interest Entity” means any one of them; 
 “Netherlands APA” has the meaning
given to it in the Netherlands Offer Letter; 
 “Netherlands Assumed Liabilities” means the Assumed Liabilities to the
extent they relate to the Netherlands Business; 
 “Netherlands Business” means that part of the Vaccines Group, comprising:

  

	 	(xxvi)	the Vaccines Group Businesses that relate predominantly to the part of the Business conducted in the Netherlands; 

  

	 	(xxvii)	the Netherlands Assumed Liabilities; 

  

	 	(xxviii)	the Netherlands Employees; and 

  

	 	(xxix)	any other assets that are exclusively related to the Netherlands Business; 

“Netherlands Closing” has the meaning given to it in the Netherlands APA; 

“Netherlands Employees” means the Employees employed in the Netherlands; 

“Netherlands Offer Letter” means the letter from the Purchaser to the Seller in respect of the binding offer from the
Purchaser to acquire the Netherlands Business dated on or around the date hereof; 
 “Netherlands Put Option Exercise” has
the meaning given to it in the Netherlands Offer Letter; 
 “Non-strategic Assets” means the assets of the Vaccines Group
exclusively related to the Products Encepur and Ixiaro and any Liabilities relating to those Products; 
 “Non-US Benefit
Plans” has the meaning given to it in paragraph 16.3.1 of Schedule 18; 
 “Notice” has the meaning given to it in
Clause 16.11.1; 
 “Novartis 2013 Annual Report” means the 2013 annual report of Novartis AG, including the consolidated
financial statements of the Seller’s Group for the financial year ending on 31 December 2013; 
 “Novartis Break
Fee” has the meaning given in the Implementation Agreement; 
 “Ongoing Clinical Trials” means the ongoing clinical
studies sponsored or supported by the Seller’s Group (including post-approval studies) or otherwise recommended by a Governmental Entity, and regulatory commitments in respect of the Products and the Pipeline Products, listed in Schedule 22 and
“Ongoing Clinical Trial” shall mean any one of them; 

  
  

 
 15 

 “Out-Licensing Programme” means the out-licensing and enforcement of
Intellectual Property Rights that are not used in or developed for the Business and generally relate to base technology useful in drug discovery and/or manufacturing processes, including any contracts or Intellectual Property Rights related thereto
but excluding the Beta Interferon Patent Rights; 
 “Out-Licensing Programme Intellectual Property Rights” means the
Intellectual Property Rights used in relation to the Out-Licensing Programme; 
 “Out of Scope Patent” means any Patent of
the Seller’s Group at the date of Closing, but excluding (i) the Transferred Intellectual Property Rights; (ii) any Patents licensed under the Purchaser Intellectual Property Licence Agreement; (iii) Out-Licensing Programme
Intellectual Property Rights; and (iii) any Patents in any Non-strategic Assets; 
 “Owned Information Technology”
means all Information Technology of any Vaccines Group Company to the extent Exclusively Related to the Business; 
 “Owned
Intellectual Property Contracts” means the Contracts Exclusively Related to the Business which relate to Intellectual Property Rights and that are held by the Vaccines Group Companies, including any such Contracts set out in Part 2 of
Schedule 4; 
 “Owned Intellectual Property Rights” means the Intellectual Property Rights of any Vaccines Group Company to
the extent Exclusively Related to the Business, including the Intellectual Property Rights of any Vaccines Group Company set out in Part 1 of Schedule 4; 

“Patent Term Extensions” means any and all extensions of a term of a Patent granted under the Patent laws or regulations of
any country, the European Union, or any other Governmental Entity; 
 “Patents” means patents, design patents, patent
applications, and any reissues, re-examinations, divisionals, continuations, continuations-in-part, provisionals, and extensions thereof or any counterparts to any of the foregoing (including rights resulting from any post-grant proceedings relating
to any of the foregoing); 
 “PA Transfer Date” means, in relation to a Product or Product Application, the date upon which
the relevant Governmental Entity approves and notifies the Product Approval or Product Application (as applicable) naming the Purchaser or the relevant Affiliate of the Purchaser (or designee thereof) as the holder of such Product Approval or
Product Application in the relevant country or territory covered by that Product Approval or Product Application; 

“Payment” has the meaning given to it in Clause 1.9; 

“Permit” has the meaning given to it in paragraph 9.2 of Schedule 18; 

“Permitted Encumbrance” means: 
  

	 	(xxx)	Encumbrances imposed by Applicable Law; 

  

	 	(xxxi)	Encumbrances imposed in the ordinary course of business which are not yet due and payable or which are being contested in good faith; 

 

	 	(xxxii)	Encumbrances which are listed in Schedule 7; 

  
  

 
 16 

	 	(xxxiii)	pledges or deposits to secure obligations under Applicable Law relating to workers’ compensation, unemployment insurance or to secure public or statutory obligations; and 

 

	 	(xxxiv)	liens, title retention arrangements or deposits to secure the performance of bids, trade contracts (other than for borrowed money), conditional sales contracts, leases, statutory obligations, surety and appeal bonds,
performance bonds and other obligations of a like nature incurred in the ordinary course of the Business; 

 “Personal
Property” means all tangible personal property legally and beneficially owned by the Seller’s Group which is Predominantly Related to the Business and is located at a Property at Closing; 

“Pharmacovigilance Agreement” means the agreement between the Seller and the Purchaser, to be entered into at Closing, in
respect of pharmacovigilance and regulatory matters relating to the Products; 
 “Pipeline Product” means: 

 

	 	(xxxv)	each product in development by the Business set out under the heading “Pipeline Products” in Part 3 of Schedule 8; and 

  

	 	(xxxvi)	any other product in development Exclusively Related to the Business; 

 “Pipeline
Product Approvals” means the approvals in relation to the Pipeline Products; 
 “Predominantly Related to the
Business” means exclusively or predominantly related to, or used or held for use exclusively or predominantly, in connection with the Business; 

“Proceedings” means any legal actions, proceedings, suits, litigations, prosecutions, investigations, enquiries, mediations or
arbitrations; 
 “Product Applications” means all applications for Product Approval filed with respect to Products Under
Registration, with each individual application being a “Product Application”; 
 “Product Approvals” means
all permits, licences, certificates, clearances, registrations or other authorisations or consents issued by any Governmental Entity to the Seller or one of its Affiliates with respect to the Products or the use, research, development, marketing,
distribution or sale thereof, including the Marketing Authorisations; 
 “Product Filings” means all filings, written
representations, declarations, listings, registrations, reports or submissions with or to any Governmental Entity, including adverse event reports and all submitted data relating to each Product; 

“Product Liabilities” means any Liability arising out of, relating to or resulting from actual or alleged harm, injury, damage
or death to persons in connection with the use of any product (including in any clinical trial or study); 
 “Product
Partners” means any third parties which pursuant to a Contract with Seller or any Affiliate of Seller co-develop, co-promote, co-market, or otherwise have a licence or other right to research, develop, manufacture, promote, distribute,
market, or sell any Product, including all manufacturers and suppliers of any such Product; 
 “Products” means: 

 

	 	(xxxvii)	the products set out under the heading “Products” in Part 3 of Schedule 8; and 

  
  

 
 17 

	 	(xxxviii)	any other products Exclusively Related to the Business; 

 “Products Under
Registration” means: 
  

	 	(xxxix)	the products set out under the heading “Products Under Registration” in Part 3 of Schedule 8, which are pending Product Approval as of the date hereof; and 

 

	 	(xl)	any other products under registration Exclusively Related to the Business; 

“Properties” means the Company Real Properties and the Transferred Real Properties and “Property” means any
one of them; 
 “Proprietary Information” means all confidential and proprietary information of the Seller or its Affiliates
that is Predominantly Related to the Business, including confidential Medical Information, confidential Know How and confidential Commercial Information; 

“Purchase Price” has the meaning given to it in Clause 3.1.1; 

“Purchase Price Bank Account” means the account notified by the Seller to the Purchaser no later than two Business Days prior
to the Closing Date; 
 “Purchaser Articles of Association” means the articles of association of the Purchaser in force and
effect from time to time; 
 “Purchaser Intellectual Property Licence Agreement” means the agreement between the Seller
and/or one or more of its Affiliates and the Purchaser and/or one or more of its Affiliates on terms consistent with the Agreed Terms, to be entered into at Closing, in respect of the grant of licences from the Seller to the Purchaser of certain
Intellectual Property Rights; 
 “Purchaser’s Disagreement Notice” has the meaning given to it in paragraph 1.3 of
Schedule 16; 
 “Purchaser’s Group” means the Purchaser and its Affiliates from time to time; 

“Purchaser’s Lawyers” means Slaughter and May of One Bunhill Row, London EC1Y 8YY, United Kingdom; 

“Purchaser Shareholder Meeting” has the meaning given to it in Clause 4.1.6; 

“Purchaser Shareholder Resolution” has the meaning given to it in Clause 4.1.6; 

“Purchaser Shareholders” means the holders of ordinary shares in the capital of the Purchaser from time to time; 

“Rebate” means any amount payable or repayable to customers or Governmental Entities in respect of a contractual rebate or
other rebate including under applicable Healthcare Laws (or under similar laws or regulations) due on sales of products; 

“Registered Intellectual Property Rights” means Intellectual Property Rights that are registered, issued, filed, or applied
for under the authority of any Governmental Entity; 
 “Registered Vaccines Group Intellectual Property Rights” means all
Vaccines Group Intellectual Property Rights that are Registered Intellectual Property Rights; 
 “Regulation” has the
meaning given to it in Clause 4.1.1; 

  
  

 
 18 

 “Relevant Employees” means the Relevant Vaccines Business Employees and the
Relevant Vaccines Group Company Employees and “Relevant Employee” means any one of them; 
 “Relevant
Employers” means the Business Sellers and such other members of the Seller’s Group who employ the Relevant Vaccines Business Employees; 

“Relevant Employer’s FSAs” has the meaning given to it in paragraph 7 of Schedule 11; 

“Relevant Matter” has the meaning given to it in the definition of Material Adverse Effect; 

“Relevant Part” means the relevant part of the Shared Business Contracts which relates exclusively to the Business (or the
relevant part of the Business that is transferred to the Purchaser at Closing); 
 “Relevant Parties” has the meaning given
to it in paragraph 1.1.1 of Schedule 17; 
 “Relevant Pension and Employment Liability” means (i) any Liabilities
assumed by the Purchaser or a member of the Purchaser’s Group as contemplated by Schedule 11; and (ii) any Transferred Employee Benefit Liabilities (as defined in Schedule 12) which the Purchaser agrees to assume in accordance with
Schedule 12; 
 “Relevant Period” means the period of two years prior to the date of this Agreement; 

“Relevant Persons” has the meaning given to it in Clause 8.2.2; 

“Relevant Vaccines Business Employees” means the Vaccines Business Employees immediately prior to the Closing Date and
“Relevant Vaccines Business Employee” means any one of them; 
 “Relevant Vaccines Group Company Employees”
means the Vaccines Group Company Employees immediately prior to the Closing Date (excluding any who do not work wholly or substantially in the Business (as carried on by the Vaccines Group)) and “Relevant Vaccines Group Company
Employee” means any one of them; 
 “Reorganisation” has the meaning given to it in Clause 2.3.5; 

“Reporting Accountants” means the London office of Ernst & Young or, if that firm is unable or unwilling to act in
any matter referred to them under this Agreement, the London office of Deloitte or, if that firm is also unable or unwilling to act in any matter referred to them under this Agreement, an internationally recognised and independent firm of
accountants who does not act as auditor to the Seller or the Purchaser, to be agreed by the Seller and the Purchaser within seven days of a notice by one to the other requiring such agreement or, failing such agreement, to be nominated on the
application of either of them by or on behalf of the Institute of Chartered Accountants of England and Wales; 
 “Required
Item” has the meaning given to it in paragraph 2 of Schedule 13; 
 “Required Notifications” has the meaning given
to it in Clause 4.2.1; 
 “Rosia Site” means the Properties located in Rosia (Italy) at which the Vaccines Group undertakes
Manufacturing activities; 
 “Royalty” means any royalty payable in respect of sales of the products; 

“Royalty Payments” has the meaning given to it in paragraph 10 of Schedule 17; 

“Sanctions Laws” has the meaning given to it in paragraph 9.5 of Schedule 18; 

  
  

 
 19 

 “Seller Allowance Rebate and Royalty Amount” means any Allowance, Rebate or
Royalty payable after Closing by the Purchaser or any member of the Purchaser’s Group, to the extent it relates to the sales of any products made prior to Closing; 

“Seller Marks” means any of the marks (including in either or both logo and local script form) “Novartis”,
“Sandoz”, “Alcon” and “Ciba Vision” used alone or in combination with other words or marks; 
 “Seller
Restricted Marks” means any of the marks (including in either or both logo and local script form) “Novartis”, “Sandoz”, “Alcon” and “Ciba Vision”; 

“Seller Partner” means any counterparty to a development, contract research, commercialisation, manufacturing, distribution,
sales, marketing, supply, consulting or other collaboration Contract with the Seller or any Affiliate of the Seller; 

“Seller’s Disagreement Notice” has the meaning given to it in paragraph 1.4 of Schedule 16; 

“Seller’s Group” means the Seller and its Affiliates from time to time; 

“Seller’s Group Insurance Policies” means all insurance policies (whether under policies maintained with third party
insurers or any member of the Seller’s Group), other than Vaccines Group Insurance Policies, maintained by the Seller or any member of the Seller’s Group in relation to the Vaccines Group or under which, immediately prior to Closing, any
Vaccines Group Company or the Seller or member of the Seller’s Group in relation to the Vaccines Group Businesses is entitled to any benefit, and “Seller’s Group Insurance Policy” means any one of them; 

“Seller’s Group Retained Business” means, from time to time, all businesses of the Seller’s Group, including, the
Influenza Business, but excluding the Business; 
 “Seller’s Knowledge” has the meaning given to it in Clause 9.1.4;

 “Seller’s Lawyers” means Linklaters LLP of One Silk Street, London EC2Y 8HQ, United Kingdom; 

“Seller’s Warranties” means the warranties given by the Seller pursuant to Clause 9 and Schedule 18, and
“Seller’s Warranty” means any one of them; 
 “Service Provider” means an Associated Person who is a
legal person; 
 “Share Seller” means, in relation to each of the Companies and Minority Interest Entities referred to in
column (2) of Schedule 1, the company whose name is set out opposite that Company or Minority Interest Entity in column (1); 

“Shared Business Contracts” means any Contract which relates both: 

 

	 	(xli)	to the Business or any part of the Business to be transferred to the Purchaser at Closing; and 

  

	 	(xlii)	to any part of the Seller’s Group Retained Business, any product other than the Products, or any Excluded Asset, 

and to which a member of the Seller’s Group is a party or in respect of which a member of the Seller’s Group has any liability or
obligation at Closing, and “Shared Business Contract” shall mean any of them; 

  
  

 
 20 

 “Shared Employees” means employees of any member of the Seller’s Group who
work wholly or substantially in the Business (as carried on by the Vaccines Group) pursuant to service level agreements with the Vaccines Group Companies and other members of the Seller’s Group but excluding, for the avoidance of any doubt, any
Vaccines Group Company Employee and any employees included on the list of employees provided pursuant to paragraph 15.2 of Schedule 18; 

“Shares” means the shares in the capital of the Companies and the Minority Interest Entities specified in Schedule 1; 

“Siena Site” means the Properties located in Siena (Italy) at which the Vaccines Group undertakes Manufacturing activities;

 “Statement of Net Assets” means the statement of net assets as at the Statement of Net Assets Date, as set out in Part 2
of Schedule 23; 
 “Statement of Net Assets Date” means 31 December 2013; 

“Statement of Net Assets Rules” means the rules in accordance with which the Statement of Net Assets was prepared, as set out
in Part 2 of Schedule 23; 
 “Subsidiaries” means the companies listed in paragraph 3 of Schedule 2 and
“Subsidiary” means any one of them; 
 “Target Asset Agreements” has the meaning given to it in the
Implementation Agreement; 
 “Taxation” or “Tax” means all supra-national, federal, state, county, local,
municipal, foreign and other taxes, assessments, duties or similar charges of any kind whatsoever (other than deferred tax), including all corporate franchise, income, gross receipts, sales, use, ad valorem, receipts, value added, profits, licence,
withholding, payroll, employment, excise, premium, property, net worth, capital gains, transfer, stamp, documentary, social security, alternative minimum, occupation, recapture and other taxes regardless as to whether any such taxes, assessments,
duties or similar charges are chargeable directly or primarily against or attributable directly or primarily to a Vaccines Group Company or any other person, and including all interest, penalties and additions imposed with respect to such amounts by
any Tax Authority or with respect to any failure to file any Tax Return; 
 “Tax Adjustment” means the amount by which: 

 

	 	(a)	the aggregate amount of the income taxes and sales taxes payable by the Vaccines Group Companies, as at the Effective Time and as derived from the Closing Statement; 

exceeds or is less than 
  

	 	(b)	the aggregate amount of the current income tax and sales tax receivables of the Vaccines Group Companies as at the Effective Time as derived from the Closing Statement, 

and any such excess amount shall be treated as a positive number and any shortfall shall be treated as a negative amount; 

“Tax Authority” has the meaning ascribed to it in the Tax Indemnity; 

“Tax Consolidation” has the meaning ascribed to it in the Tax Indemnity; 

“Tax Group” has the meaning ascribed to it in the Tax Indemnity; 

  
  

 
 21 

 “Tax Indemnity” means the deed of covenant against taxation, in the Agreed
Terms, to be entered into on the Closing Date between the Seller and the Purchaser; 
 “Tax Return” has the meaning ascribed
to it in the Tax Indemnity; 
 “Tax Warranties” means the Seller’s Warranties set out in paragraph 13 of Schedule 18;

 “Third Party” has the meaning given to it in Clause 16.4.2; 

“Third Party Claim” has the meaning given to it in Clause 11.4; 

“Third Party Consents” means all consents, licences, approvals, permits, authorisations or waivers required from third parties
for the assignment or transfer to the Purchaser of any of the Transferred Contracts, Transferred Intellectual Property Contracts or Shared Business Contracts or Co-Owned Vaccines Group Intellectual Property Rights or Transferred Plant and Equipment,
and “Third Party Consent” means any one of them; 
 “Third Party Indebtedness” means the aggregate amount
as at the Effective Time of all outstanding Indebtedness owed by the Vaccines Group Companies to any third party less any Indebtedness owed by any third party to any Vaccines Group Company as derived from the Closing Statement (but excluding any
item included in respect of any Vaccines Group Companies’ Cash Balances or Intra-Group Non-Trade Payables), and, for the purposes of this definition, third party shall exclude any member of the Seller’s Group; 

“Threshold Amount” means, in the case of Ixiaro, US$ 50 million, and in the case of Encepur, US$ 200 million; 

“Time-Limited Excluded Liability” means an Excluded Liability which is: 

 

	 	(xliii)	a Contracts Liability; 

  

	 	(xliv)	an Environmental Liability; 

  

	 	(xlv)	a Manufacturing Liability; or 

  

	 	(xlvi)	a Commercial Practices Liability; 

 “Trademarks” means trademarks, service
marks, trade names, certification marks, service names, industrial designs, brand names, brand marks, trade dress rights, identifying symbols, logos, emblems, and signs or insignia and all goodwill of the business in relation to which any of the
foregoing are used (but no other or greater goodwill); 
 “Transaction” has the meaning given to it in Clause 4.1.1; 

“Transfer Regulations” means the relevant national measure by which the employment of a Relevant Vaccines Business Employee
automatically transfers to the Purchaser or a relevant member of the Purchaser’s Group; 
 “Transferred Accounts
Payable” means all trade accounts and notes payable arising in the ordinary course of the Seller’s Group (other than any Vaccines Group Company) to the extent related to the Business, and outstanding at the Effective Time, together
with any unpaid financing charges accrued thereon; 
 “Transferred Accounts Receivable” means all trade accounts and notes
receivable arising in the ordinary course of the Seller’s Group (other than any Vaccines Group Company) to the extent related to the Business, and outstanding at the Effective Time, together with any unpaid financing charges accrued thereon;

  
  

 
 22 

 “Transferred Books and Records” means all books, ledgers, files, reports, plans,
records, manuals and other materials (in any form or medium) to the extent of, or maintained predominantly for, the Business by the Seller’s Group (excluding the Vaccines Group Companies) (other than emails), but excluding: 

 

	 	(xlvii)	any such items to the extent that: (A) they are related to any Excluded Assets or Excluded Liabilities, (B) they are related to any corporate, Tax, human resources or stockholder matters of the Seller or its
Affiliates (other than the Vaccines Group Companies), (C) any Applicable Law prohibits their transfer or (D) any transfer thereof otherwise would subject the Seller or any of its Affiliates to any material liability; and 

 

	 	(xlviii)	any laboratory notebooks to the extent containing research and development information unrelated to the Business; 

“Transferred Contracts” means: 
  

	 	(xlix)	the Contracts, other than Transferred Intellectual Property Contracts, that are Predominantly Related to the Business between a member of the Seller’s Group (excluding the Vaccines Group Companies), on the one
hand, and any third party, on the other hand (other than this Agreement and any Ancillary Agreement), but excluding any Excluded Contract; 

  

	 	(l)	subject to paragraph 1 of Schedule 10 the Relevant Part of the Shared Business Contracts; and 

  

	 	(li)	the Diagnostics TSA; 

 “Transferred Employees” means (i) the Vaccines
Business Employees to whom the Purchaser (or a member of the Purchaser’s Group) offers employment and who accept such employment and become employed by the Purchaser (or a member of the Purchaser’s Group) in accordance with Schedule 11;
(ii) any Relevant Vaccines Business Employees who transfer to the Purchaser (or a member of the Purchaser’s Group) by operation of the Transfer Regulations and do not object to such transfer (to the extent permitted by the Transfer
Regulations) in accordance with Schedule 11; and (iii) the Relevant Vaccines Group Company Employees, and “Transferred Vaccines Business Employees” means the employees in (i) and (ii), “Transferred Vaccines Group
Company Employees” means the employees in (iii) and “Transferred Employee”, “Transferred Vaccines Business Employee” and “Transferred Vaccines Group Company Employee” respectively
means any one of them; 
 “Transferred Information Technology” means all Information Technology of any member of the
Seller’s Group (other than a Vaccines Group Company) to the extent Exclusively Related to the Business; 
 “Transferred
Intellectual Property Contracts” means Contracts Exclusively Related to the Business which relate to Intellectual Property Rights (but excluding the rights under any such Contracts that are held by the Vaccines Group Companies), including
any such Contracts set out in Part 2 of Schedule 4 and the Merck 2012 Licence; 
 “Transferred Intellectual Property Rights”
means the Intellectual Property Rights of any member of the Seller’s Group (other than a Vaccines Group Company) Exclusively Related to the Business, including the Intellectual Property Rights of any member of the Seller’s Group (other
than a Vaccines Group Company) set out in Parts 1 and 3 of Schedule 4; 

  
  

 
 23 

 “Transferred Inventory” means all inventories (including Manufacturing Inventory
and Manufacturing Stocks and In-Market Inventory), wherever located, including all raw materials, work in progress, finished Products and packaging and labelling material in respect of the Products and otherwise Predominantly Related to the Business
(but excluding any such items held by the Vaccines Group Companies) whether held at any location or facility of a member of the Seller’s Group or in transit to a member of the Seller’s Group, in each case as of the Effective Time; 

“Transferred Leased Real Properties” has the meaning given to it in paragraph 1.1 of Part 4 of Schedule 3; 

“Transferred Owned Real Properties” has the meaning given to it in paragraph 1.1 of Part 4 of Schedule 3; 

“Transferred Plant and Equipment” means: 
  

	 	(lii)	the Transferred Information Technology; and 

  

	 	(liii)	all plant, furniture, furnishings, vehicles, equipment, tools and other tangible Personal Property (other than Transferred Inventory or Transferred Information Technology) of the Seller’s Group that are
Predominantly Related to the Business (but excluding any such items owned by the Vaccines Group Companies); 

“Transferred Real Properties” means: 
  

	 	(liv)	the Transferred Owned Real Properties; 

  

	 	(lv)	the Transferred Leased Real Properties; and 

  

	 	(lvi)	all other freehold, leasehold or other immovable property Predominantly Related to the Business, other than any freehold, leasehold or other immovable property within the definition of “Excluded Assets”,

 and “Transferred Real Property” means any one of them; 

“Transitional Services Agreement” means the transitional services agreement to be entered into between the Seller and the
Purchaser at Closing on terms consistent with the heads of terms in the Agreed Terms, pursuant to which: (i) the Seller will provide or procure the provision of certain transitional services to the Purchaser; and (ii) the Purchaser will
provide or procure the provision of certain transitional services to the Influenza Business; 
 “US Benefit Plans” means all
United States “employee benefit plans” (within the meaning of section 3(3) of ERISA), severance, change in control or employment, vacation, incentive, bonus, stock option, stock purchase, or restricted stock plans, programmes, agreements
or policies benefiting the Vaccines Business Employees; 
 “US Transferred Employees” has the meaning given to it in
paragraph 7.1 of Schedule 11; 
 “Vaccines” means a preparation comprising (i) an antigen, (ii) an epitope of an
antigen, or (iii) a polynucleotide encoding an antigen derived directly or indirectly from, or mimicking, an agent (including, but not limited to, a compound, a toxin, a microbe including a pathogen or component thereof), wherein such
preparation may further comprise a composition capable of modulating an immune response, including preparations intended to improve a human’s immune response to a microbe that has been linked to cancer, wherein said preparation is intended for
purposes of inducing an immune response in a human, including, but not limited to, a functional immune response or immunological memory to the particular or related antigen or agent, thereby causing or improving an immune response to a challenge by
the particular or related agent. “Vaccines” shall not include preparations intended to improve a human’s immune response to or to treat other non-infectious conditions, whether or not related to pathogens, such as certain autoimmune
diseases, Alzheimer’s disease and certain cancers, or non-antigen preparations comprising immune system components intended to function analogous to corresponding native components within the patient, such as antibodies or white blood cells
(both unmodified or modified to better treat disease); 

  
  

 
 24 

 “Vaccines Business Employees” means the employees of any member of the
Seller’s Group who work wholly or substantially in the Business (as carried on by the Vaccines Group) from time to time including, for the avoidance of any doubt, the International Assignees other than the Vaccines Group Company Employees, the
Excluded Employees and the Shared Employees and provided that, in relation to the Seller’s Warranties only, the words “from time to time” shall be deemed to be replaced by “at the date of this Agreement” and
“Vaccines Business Employee” means any one of them; 
 “Vaccines Group” means the Vaccines
Group Companies and the Vaccines Group Businesses, taken as a whole; 
 “Vaccines Group Businesses” means the
businesses of the Business (but excluding the businesses of the Business carried on by the Vaccines Group Companies) as set out in Clause 2.3.1, but subject always to Clause 2.3.2, and “Vaccines Group Business” means any one of
them; 
 “Vaccines Group Companies” means the Companies and the Subsidiaries, and “Vaccines Group
Company” means any one of them; 
 “Vaccines Group Companies’ Cash Balances” means the aggregate
amount of the Cash Balances held by or on behalf of the Vaccines Group Companies (excluding 50 per cent. of the Cash Balances held by Chiron Behring Vaccines Private Limited and Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.) at the Effective
Time; 
 “Vaccines Group Company Employees” means the employees from time to time of any of the Vaccines Group
Companies other than the Excluded Employees, and provided that, in relation to the Seller’s Warranties only, the words “from time to time” shall be deemed to be replaced by “at the date of this Agreement”, and
“Vaccines Group Company Employee” means any one of them;  
 “Vaccines Group Goodwill” means
all goodwill of the Vaccines Group Businesses, but excluding any Trademark goodwill; 
 “Vaccines Group Information
Technology” means the Transferred Information Technology and the Owned Information Technology; 
 “Vaccines
Group Insurance Policies” means all insurance policies held exclusively by and for the benefit of the Vaccines Group Companies and “Vaccines Group Insurance Policy” means any one of them; 

“Vaccines Group Intellectual Property Contracts” means the Transferred Intellectual Property Contracts and the Owned
Intellectual Property Contracts; 
 “Vaccines Group Intellectual Property Rights” means the Transferred
Intellectual Property Rights and the Owned Intellectual Property Rights; 

  
  

 
 25 

 “Vaccines Patent” means any Vaccines Group Intellectual Property Right
which is a Patent; 
 “VAT” means within the European Union such Taxation as may be levied in accordance with
(but subject to derogations from) Council Directive 2006/112/EC and outside the European Union any Taxation levied by reference to added value or sales; 

“WARN Act” means the Worker Adjustment and Retraining Notification Act of 1988 of the United States; 

“Working Capital” means the aggregate amount of the working capital of the Vaccines Group Companies and Vaccines Group
Businesses set out in the Closing Statement (which shall not include any amount in respect of Tax), at the Effective Time, as derived from the Closing Statement; and 

“Working Capital Adjustment” means the amount by which the Working Capital exceeds or is less than the Base Working
Capital, any such excess being treated as a positive amount and any such shortfall being treated as a negative amount. 
  

	1.2	Shares 

 References to shares shall include, where relevant, quotas. 

 

	1.3	Singular, plural, gender 

 References to one gender include all genders and references to
the singular include the plural and vice versa. 
  

	1.4	References to persons and companies 

 References to: 

 

	 	1.4.1	a person include any individual, company, partnership or unincorporated association (whether or not having separate legal personality); and 

 

	 	1.4.2	a company include any company, corporation or any body corporate, wherever incorporated. 

  

	1.5	Schedules etc. 

 References to this Agreement shall include any Recitals and Schedules to it and
references to Clauses and Schedules are to Clauses of, and Schedules to, this Agreement. References to paragraphs and Parts are to paragraphs and Parts of the Schedules. 
  

	1.6	Reference to documents 

 References to any document (including this Agreement), or to a
provision in a document, shall be construed as a reference to such document or provision as amended, supplemented, modified, restated or novated from time to time. 
  

	1.7	References to enactments 

 Except as otherwise expressly provided in this Agreement, any express
reference to an enactment (which includes any legislation in any jurisdiction) includes references (i) to that enactment as amended, consolidated or re-enacted by or under any other enactment before or after the date of this Agreement;
(ii) any enactment which that enactment re-enacts (with or without modification); and (iii) any subordinate legislation (including regulations) made before or after the date of this Agreement under that enactment as amended, consolidated
or re-enacted as described in paragraph (i) or (ii) above, except to the extent that any of the matters referred to in paragraphs (i) to (iii) above occurs after the date of this Agreement and increases or alters the liability of
the Seller or Purchaser under this Agreement. 

  
  

 
 26 

	1.8	Information 

 References to books, records or other information mean books, records or
other information in any form including paper, electronically stored data, magnetic media, film and microfilm. 
  

	1.9	References to “indemnify” 

 Unless specified to the contrary, references to
“indemnify” and “indemnifying” any person against any circumstance include indemnifying and holding that person harmless on an after-Tax basis and: 
  

	 	1.9.1	references to the Purchaser indemnifying each member of the Seller’s Group shall constitute undertakings by the Purchaser to the Seller for itself and on behalf of each other member of the Seller’s Group;

  

	 	1.9.2	references to the Seller indemnifying each member of the Purchaser’s Group shall constitute undertakings by the Seller to the Purchaser for itself and on behalf of each other member of the Purchaser’s Group;

  

	 	1.9.3	to the extent that the obligation to indemnify relates to any Shares (including any Vaccines Group Companies) or other assets or liabilities transferred by a Share Seller or Business Seller (as the case may be) to a
member of the Purchaser’s Group pursuant to this Agreement, references to the Seller indemnifying the Purchaser and references to the Seller indemnifying the Purchaser or any member of the Purchaser’s Group shall constitute undertakings by
the Seller, to indemnify or procure the indemnification of the relevant purchaser of the Shares transferred by that Share Seller or the relevant purchaser of the assets or liabilities transferred by that Business Seller (as the case may be), and
references to the Purchaser indemnifying the Seller and references to the Purchaser indemnifying the Seller and each member of the Seller’s Group shall constitute undertakings by the Purchaser to indemnify or procure the indemnification of the
relevant member of the Seller’s Group; and 

  

	 	1.9.4	where under the terms of this Agreement one party is liable to indemnify or reimburse another party in respect of any costs, charges or expenses, the payment shall include an amount equal to any VAT thereon not
otherwise recoverable by the other party or any member of any group or consolidation of which it forms part for VAT purposes, subject to that party using reasonable endeavours to recover or to procure recovery of such amount of VAT as may be
practicable. 

 For the purposes of this Clause 1.9, indemnifying and holding harmless a person on an “after-Tax
basis” means that the amount payable pursuant to the indemnity (the “Payment”) shall be calculated in such a manner as will ensure that, after taking into account: 

  
  

 
 27 

	 	(i)	any Tax required to be deducted or withheld from the Payment and any additional amounts required to be paid by the payer of the Payment in consequence of such withholding; 

 

	 	(ii)	the amount and timing of any additional Tax which becomes (or would, but for the use of any credit or other relief which would otherwise have been available to reduce the Tax liabilities of any member of the
Seller’s Group, have become) payable by the recipient of the Payment (or a member of the Seller’s Group or the Purchaser’s Group, as the case may be) as a result of the Payments being subject to Tax in the hands of that person; and

  

	 	(iii)	the amount and timing of any Tax benefit which is obtained by the recipient of the Payment (or a member of the Seller’s Group or the Purchaser’s Group, as the case may be) to the extent that such Tax benefit
is attributable to the matter giving rise to the indemnity payment or to the receipt of the Payment, 

 which amount and timing
is to be determined by the auditors of the recipient at the shared expense of both relevant parties and is to be certified as such to the party making the Payment, the recipient of the Payment is in no better and no worse after Tax position as that
in which it would have been if the matter giving rise to the indemnity payment had not occurred, provided that if either party to this Agreement shall have assigned or novated the benefit of this Agreement in whole or in part or shall, after the
date of this Agreement, have changed its Tax residence or the permanent establishment to which the rights under this Agreement are allocated then no Payment to that party shall be increased by reason of the operation of paragraphs (i) to
(iii) above to any greater extent than would have been the case had no such assignment, novation or change taken place. 
  

	1.10	References to wholly or substantially in the Business (as carried on by the Vaccines Group) 

References to “wholly or substantially in the Business (as carried on by the Vaccines Group)” in relation to any employee employed by
a member of the Seller’s Group means that such employee spends more than 70 per cent. of their time working in the Business (as carried on by the Vaccines Group) at the relevant time. 

 

	1.11	Legal terms 

 References to any English legal term shall, in respect of any jurisdiction other
than England and Wales, be construed as references to the term or concept which most nearly corresponds to it in that jurisdiction. 
  

	1.12	Non-limiting effect of words 

 The words “including”, “include”, “in
particular” and words of similar effect shall not be deemed to limit the general effect of the words that precede them. 
  

	1.13	Currency conversion 

  

	 	1.13.1	Subject to Clause 1.13.2, any amount to be converted from one currency into another currency for the purposes of this Agreement shall be converted into an equivalent amount at the Conversion Rate prevailing at the
Relevant Date. For the purposes of this Clause 1.13: 

  
  

 
 28 

 “Conversion Rate” means the spot reference rate for a transaction between the
two currencies in question as quoted by the European Central Bank on the Business Day immediately preceding the Relevant Date or, if no such rate is quoted on that date, on the preceding date on which such rates are quoted; 

“Relevant Date” means, save as otherwise provided in this Agreement, the date on which a payment or an assessment is
to be made, save that, for the following purposes, the date shall mean: 
  

	 	(i)	for the purposes of Clause 5, the date of this Agreement; 

  

	 	(ii)	for the purposes of Clause 7 and Schedules 16 and 23, the Closing Date; or 

  

	 	(iii)	for the purposes of Clause 10, the date of this Agreement; and 

  

	 	(iv)	for the purposes of the monetary amounts set out in Schedule 18, the date of this Agreement. 

  

	 	1.13.2	The conversion of an amount from one currency into another as may be required in connection with the matters contemplated in Schedule 17 shall be carried out in accordance with the accounting policies and practices of
the Purchaser’s Group in operation from time to time. 

  

	2	Sale and Purchase of the Vaccines Group 

  

	2.1	Sale and Purchase of the Vaccines Group 

 On and subject to the terms of this Agreement and the
Local Transfer Documents: 
  

	 	2.1.1	the Seller shall procure that the Share Sellers and Business Sellers shall sell, and 

  

	 	2.1.2	the Purchaser shall purchase or shall procure the purchase by one or more other members of the Purchaser’s Group of, 

the Vaccines Group as a going concern. 
  

	2.2	Sale of the Shares 

  

	 	2.2.1	The Seller shall procure that the Share Sellers shall sell the Shares, which shall be sold with Full Title Guarantee free from Encumbrances and together with all rights and advantages attaching to them as at Closing
(including the right to receive all dividends or distributions declared, made or paid on or after Closing). 

  

	 	2.2.2	The Seller shall procure that, on or prior to Closing, any and all rights of pre-emption over the Shares and the Shares or equity interests in any subsidiaries are waived irrevocably by the persons entitled thereto.

  

	2.3	Sale of the Vaccines Group Businesses 

  

	 	2.3.1	The Seller shall sell, or shall procure that the Business Sellers shall sell, the assets comprising the Vaccines Group Businesses, under this Agreement or, where relevant, the Local Transfer Documents with Full
Title Guarantee (save in respect of the Transferred Intellectual Property Rights which are not Registered Intellectual Property Rights) and free from Encumbrances other than Permitted Encumbrances (save for the Transferred Real Properties, which
shall be sold free from Encumbrances other than as provided in paragraph 1.9 of Schedule 3), such assets being: 

  
  

 
 29 

	 	(i)	the Transferred Real Properties; 

  

	 	(ii)	the Transferred Plant and Equipment; 

  

	 	(iii)	the Transferred Inventory; 

  

	 	(iv)	the Transferred Accounts Receivable; 

  

	 	(v)	the Transferred Books and Records; 

  

	 	(vi)	subject to and in accordance with Schedule 10, the Transferred Intellectual Property Rights; 

  

	 	(vii)	subject to and in accordance with Schedule 10, the Transferred Intellectual Property Contracts; 

  

	 	(viii)	subject to and in accordance with Schedule 10, the Transferred Contracts; 

  

	 	(ix)	subject to and in accordance with Schedule 8, all Product Approvals and all Product Applications and all other permits, licences, certificates, registrations, marketing or other authorisations or consents issued by a
Governmental Entity Predominantly Related to the Business and not held by the Vaccines Group Companies; 

  

	 	(x)	subject to and in accordance with Schedule 8, all Marketing Authorisation Data not held by the Vaccines Group Companies; 

  

	 	(xi)	all Business Information not held at Closing by the Vaccines Group Companies; 

  

	 	(xii)	all rights of the Purchaser, its Affiliates and the Vaccines Group Companies as contemplated by Schedule 11 and Schedule 12; 

  

	 	(xiii)	the Vaccines Group Goodwill; and 

  

	 	(xiv)	all other property, rights and assets owned or held by the Seller’s Group (other than the Vaccines Group Companies) and Predominantly Related to the Business at Closing (other than any property, rights and assets
of the Vaccines Group expressly excluded from the sale under this Agreement). 

  

	 	2.3.2	There shall be excluded from the sale of the Vaccines Group under this Agreement and the Local Transfer Documents the following: 

  

	 	(i)	the Seller’s Group Retained Business, including the Influenza Business; 

  

	 	(ii)	the Non-strategic Assets to the extent not transferred to the Purchaser or a member of the Purchaser’s Group at Closing; 

  

	 	(iii)	the Out-Licensing Programme; 

  

	 	(iv)	any Intellectual Property Right that is not a Vaccines Group Intellectual Property Right (subject to the Purchaser Intellectual Property Licence Agreement and any Contract relating to Intellectual Property Rights that
is not a Vaccines Group Intellectual Property Contract or the Relevant Part of a Shared Business Contract); 

  
  

 
 30 

	 	(v)	any Information Technology other than Vaccines Group Information Technology; 

  

	 	(vi)	the Seller Marks; 

  

	 	(vii)	any product and any permits, licences, certificates, registrations, marketing or other authorisations or consents issued by any Governmental Entity in respect of any products, or any applications therefor, other than
(a) the Products, Product Approvals, Products Under Registration and Pipeline Product Approvals; and (b) Permits Predominantly Related to the Business; 

  

	 	(viii)	all cash, marketable securities and negotiable instruments, and all other cash equivalents, of the Seller’s Group (other than the Vaccines Group Companies); 

 

	 	(ix)	all real property and any leases therefor and interests therein, other than the Properties; 

  

	 	(x)	the land and buildings of the Seller’s Group at 4560 Horton Street, Emeryville CA, United States of America; 

  

	 	(xi)	the land and buildings of the Seller’s Group at Jaboatão dos Guararapes, State of Pernambuco (Brazil), together with all buildings, fixtures, and improvements erected thereon, and any other assets, rights
and Contracts related thereto; 

  

	 	(xii)	the company seal, minute books, charter documents, stock or equity record books and such other books and records pertaining to the Seller or its Affiliates (other than the Vaccines Group Companies and the Transferred
Books and Records), as well as any other records or material relating to the Seller or its Affiliates (other than Vaccines Group Companies) generally and not involving or related to the Vaccines Group; 

 

	 	(xiii)	any right of the Seller or its Affiliates to be indemnified in respect of Assumed Liabilities; 

  

	 	(xiv)	all Tax assets (including Tax refunds and prepayments), other than Tax Assets of any Vaccines Group Company); 

  

	 	(xv)	all Tax Returns of the Seller’s Group (other than the Vaccines Group Companies) and all Tax Returns relating to Tax Groups of which persons other than Vaccines Group Companies are members and, in each case, all
books and records (including working papers) related thereto; 

  

	 	(xvi)	any rights in respect of any insurance policies of the Seller’s Group as provided in Clause 14; 

  

	 	(xvii)	all artwork, paintings, drawings, sculptures, prints, photographs, lithographs and other artistic works of the Seller’s Group that are not embodiments of Vaccines Group Intellectual Property Rights;

  

	 	(xviii)	any rights of the Seller’s Group (other than the Vaccines Group Companies) under any Intra-Group Non-Trade Payables or Intra-Group Non-Trade Receivables (excluding Transferred Accounts Receivable);

  
  

 
 31 

	 	(xix)	any rights of the Seller or its Affiliates (other than the Vaccines Group Companies) contemplated by Schedule 11 and Schedule 12; 

  

	 	(xx)	any equity interest in any person other than a Vaccines Group Company or a Minority Interest Entity; 

  

	 	(xxi)	the Excluded Contracts; 

  

	 	(xxii)	all rights of the Seller’s Group under this Agreement and the Ancillary Agreements; 

  

	 	(xxiii)	the Purchase Price Bank Account; 

  

	 	(xxiv)	the Manufacturing, production and research activity carried on by the Seller’s Group at the Holly Springs Site; and 

  

	 	(xxv)	the Diagnostics GESA. 

  

	 	2.3.3	The Seller agrees to procure the transfer (to the extent it is able so to do) and the Purchaser agrees to accept (or procure the acceptance by another member of the Purchaser’s Group of) the transfer of, and to
assume, pay, satisfy, discharge, perform or fulfil (or procure that another member of the Purchaser’s Group will assume, pay, satisfy, discharge, perform or fulfil) the Assumed Liabilities with effect from Closing. 

 

	 	2.3.4	Clause 2.3.3 shall not apply to, and the Purchaser shall not be obliged to accept (or procure the acceptance by another member of the Purchaser’s Group of), the transfer of or to assume, pay, satisfy, discharge,
perform or fulfil, or procure that another member of the Purchaser’s Group will assume, pay, satisfy, discharge, perform or fulfil: 

  

	 	(i)	any Excluded Liability; or 

  

	 	(ii)	any Liability to the extent it relates to an Excluded Asset. 

  

	 	2.3.5	With prejudice to Clauses 2.1, 2.2, 2.3.1 to 2.3.4, 2.4 and 2.5 on or prior to Closing, the Seller may: 

  

	 	(i)	assign or otherwise transfer assets, liabilities and (only where in compliance with Clause 5 (other than Clause 5.2.2)) employees between members of the Seller’s Group as may be reasonably required to facilitate
separation of the Business from the Influenza Business; and 

  

	 	(ii)	otherwise, carry out or procure one or more reorganisations of the Seller’s Group (including assigning or otherwise transferring assets and liabilities between members of the Seller’s Group but excluding
assigning or otherwise transferring assets or liabilities to Vaccines Group Companies) as may reasonably be required to facilitate the Transaction, 

each, a “Reorganisation”. 
  

	 	2.3.6	In respect of any Reorganisation: 

  

	 	(i)	the Seller shall notify the Purchaser of any proposed Reorganisation, the steps proposed to be implemented and such other information as the Purchaser may reasonably request regarding the proposed Reorganisation in
advance of it being implemented; 

  
  

 
 32 

	 	(ii)	the Seller shall, in good faith, consult with, and take into account the reasonable views of, and any reasonable requests made by, the Purchaser in relation to any Reorganisation before it is implemented, including any
proposals to reduce or avoid Liability or cost being suffered or incurred by any member of the Purchaser’s Group or any Vaccines Group Company; 

  

	 	(iii)	subject to the following sub-clause 0 of this Clause 2.3.6, all fees, costs and expenses of implementing any Reorganisation (or any part thereof) shall be borne by the Seller’s Group; and 

 

	 	(iv)	all out-of-pocket fees, costs and expenses which (x) are incurred by either party, whether before or after Closing, (y) specifically relate to the separation of the German Flu Operations from the Vaccines
Group, and (z) are incurred in respect of works council consultations (including court fees, notary fees and works council legal fees) or physical separation at the Marburg Site (including IT systems workarounds, costs of new access cards and
construction works), but excluding the parties’ own legal fees, shall, to the extent that such fees, costs and expenses arise solely as a result of such works council consultations or physical separation, be split equally between the Seller and
the Purchaser. For the avoidance of doubt, this Clause 2.3.60 shall not affect the cost allocation of wider measures necessary to effect the separation of the Business from the Influenza Business. 

 

	 	2.3.7	In respect of the separation of the Influenza Business from the Vaccines Group, the parties shall work together in good faith to facilitate such separation. 

 

	 	2.3.8	The Seller undertakes to the Purchaser (for itself and as trustee for each other member of the Purchaser’s Group and each Vaccines Group Company) that, with effect from Closing, the Seller will indemnify on demand
and hold harmless the relevant member of the Purchaser’s Group (including each Vaccines Group Company) against and in respect of any and all Liabilities arising in connection with any Reorganisation (or part thereof) undertaken by the Seller,
other than: 

  

	 	(i)	such Liabilities where the allocation has been, or is, otherwise agreed between the parties; 

  

	 	(ii)	any Liabilities of any Vaccines Group Company in respect of Tax (which shall be dealt with under the Tax Indemnity); and 

  

	 	(iii)	any Liabilities in connection with this Agreement or any document entered into as provided by this Agreement (including the provisions of Clause 8.12) or any Ancillary Agreement. 

 

	2.4	Employees and Employee Benefits 

  

	 	2.4.1	The provisions of Schedule 11 shall apply in respect of the Employees. 

  

	 	2.4.2	The provisions of Schedule 12 shall apply in respect of Employee Benefits. 

  

	2.5	Properties 

 The provisions of Schedule 3 shall apply in respect of the Properties. 

  
  

 
 33 

	2.6	Local Transfer Documents 

  

	 	2.6.1	On Closing or at such other time as agreed between the parties, the Seller shall procure that the Share Sellers and Business Sellers execute, and the Purchaser shall execute (or procure the execution by one or more
other members of the Purchaser’s Group of), such agreements, transfers, conveyances and other documents, as may be required pursuant to the relevant local law and otherwise as may be agreed between the Seller and the Purchaser to implement the
transfer of (i) the Shares and (ii) the Vaccines Group Businesses, in each case on Closing (the “Local Transfer Documents” and each, a “Local Transfer Document”). The parties do not intend this Agreement
to transfer title to any of the Shares. Title shall be transferred by the applicable Local Transfer Document. 

  

	 	2.6.2	To the extent that the provisions of a Local Transfer Document are inconsistent with or (except to the extent they implement a transfer in accordance with this Agreement) additional to the provisions of this Agreement:

  

	 	(i)	the provisions of this Agreement shall prevail; and 

  

	 	(ii)	so far as permissible under the laws of the relevant jurisdiction, the Seller and the Purchaser shall procure that the provisions of the relevant Local Transfer Document are adjusted, to the extent necessary to give
effect to the provisions of this Agreement or, to the extent this is not permissible, the Seller shall indemnify the Purchaser against all Liabilities suffered by the Purchaser or its Affiliates or, as the case may be, the Purchaser shall indemnify
the Seller against all Liabilities suffered by the Seller or its Affiliates, in either case through or arising from the inconsistency between the Local Transfer Document and this Agreement or the additional provisions (except to the extent they
implement a transfer in accordance with this Agreement). 

  

	 	2.6.3	If there is an adjustment to the Purchase Price under Clause 7.3 which relates to a part of the Vaccines Group which is the subject of a Local Transfer Document, then, if required to implement the adjustment and so far
as permissible under Applicable Law, the Purchaser shall (or shall procure that the relevant member of the Purchaser’s Group will), and the Seller shall procure that its relevant Affiliate shall, enter into a supplemental agreement reflecting
such adjustment and the allocation of such adjustment. 

  

	 	2.6.4	The Seller shall not, and shall procure that none of its Affiliates shall bring any claim against the Purchaser or any member of the Purchaser’s Group in respect of or based upon the Local Transfer Documents save
to the extent necessary to implement any transfer of the Shares or Vaccines Group Businesses as contemplated by this Agreement. To the extent that the Seller or a member of the Seller’s Group does bring a claim in breach of this Clause, the
Seller shall indemnify the Purchaser and each member of the Purchaser’s Group against all Liabilities which the Purchaser or that member of the Purchaser’s Group may suffer through or arising from the bringing of such a claim.

  

	 	2.6.5	The Purchaser shall not, and shall procure that none of its Affiliates shall, bring any claim against the Seller or any member of the Seller’s Group in respect of or based upon the Local Transfer Documents save to
the extent necessary to implement any transfer of the Shares or Vaccines Group Businesses as contemplated by this Agreement. To the extent that the Purchaser or a member of the Purchaser’s Group does bring a claim in breach of this Clause, the
Purchaser shall indemnify the Seller and each member of the Seller’s Group against all Liabilities which the Seller or any member of the Seller’s Group may suffer through or arising from the bringing of such a claim. 

  
  

 
 34 

	3	Consideration 

  

	3.1	Amount 

  

	 	3.1.1	The aggregate consideration for the purchase of the Vaccines Group under this Agreement and the Local Transfer Documents (the “Purchase Price”) shall be an amount in US dollars equal to the sum of:

  

	 	(i)	US$5,255,000,000 (the “Headline Price”); 

 plus 

 

	 	(ii)	the Vaccines Group Companies’ Cash Balances and the Intra-Group Non-Trade Receivables; 

minus 
  

	 	(iii)	the Third Party Indebtedness; 

 minus 

 

	 	(iv)	the Intra-Group Non-Trade Payables; 

 minus 

 

	 	(v)	any Employee Benefit Indemnification Amount paid in accordance with Schedule 12; 

 minus 

 

	 	(vi)	the Tax Adjustment; 

 plus 

 

	 	(vii)	the Working Capital Adjustment; and 

 plus 

 

	 	(viii)	the Milestone Payments and the Royalty Payments. 

  

	3.2	Payment of Purchase Price 

 The Purchase Price shall be paid by the Purchaser (for itself and on
behalf of each relevant member of the Purchaser’s Group): 
  

	 	(lvii)	other than in the case of the Milestone Payments and the Royalty Payments, by way of cash payments to the Purchase Price Bank Account pursuant to Clauses 6.3 and 7.6; and 

 

	 	(lviii)	in the case of the Milestone Payments and the Royalty Payments, pursuant to and in accordance with Schedule 17. 

  
  

 
 35 

	3.3	Allocation of Purchase Price 

 The Purchase Price shall be allocated in accordance with Schedule
13. 
  

	3.4	VAT 

  

	 	3.4.1	The provisions of Schedule 14 shall apply in respect of VAT. 

  

	 	3.4.2	The Seller and the Purchaser agree that the consideration given under this Agreement in respect of the sale of the Vaccines Group Businesses and the Shares is exclusive of any VAT. To the extent that VAT is chargeable
in respect of that sale or any part thereof, the Purchaser shall, against delivery of a valid VAT invoice (or equivalent, if any), in addition to any other amount expressed in this Agreement to be payable by the Purchaser, pay or procure the payment
to the Seller (on behalf of the relevant Business Seller or Share Seller as applicable) any amount of any VAT so chargeable for which the Seller (or the relevant Share Seller or Business Seller, as the case may be) is liable to account, in
accordance with Schedule 14. 

  

	3.5	Treatment of Payments 

  

	 	3.5.1	If any payment is made or procured (i) by the Seller to the Purchaser or relevant member of the Purchaser’s Group, or (ii) by a Purchaser to the Seller or a member of the Seller’s Group, in either
case in respect of any claim under or for any breach of this Agreement or pursuant to an indemnity (or equivalent covenant to pay) under this Agreement, the payment shall be treated, so far as possible, as an adjustment of the consideration paid by
the relevant member of the Purchaser’s Group for the Shares or the particular part of the Vaccines Group to which the payment and/or claim relates under this Agreement and the consideration shall be deemed to be increased or reduced (as
applicable) by the amount of such payment, provided that this Clause 3.5.1 shall not require any amount to be treated as an amount in respect of the Purchase Price for the purposes of Clause 16.10 if it would not otherwise have been so treated

  

	 	3.5.2	If: 

  

	 	(i)	the payment and/or claim relates to the shares in more than one Vaccines Group Company or to more than one category of Vaccines Group Business, it shall be allocated in a manner which reflects the impact of the matter
to which the payment and/or claim relates, failing which it shall be allocated rateably to the shares in the Vaccines Group Companies or Vaccines Group Businesses concerned by reference to the proportions in which the consideration is allocated in
accordance with Schedule 13; or 

  

	 	(ii)	the payment and/or claim relates to no particular shares in any Vaccines Group Company or no particular category of Vaccines Group Business, it shall be allocated rateably to all the Shares and all the Vaccines Group
Businesses by reference to the proportions in which the consideration is allocated in accordance with Schedule 13, 

 and in
each case the consideration shall be deemed to have been reduced by the amount of such payment. 

  
  

 
 36 

	3.6	Non-strategic Assets 

  

	 	3.6.1	If, prior to Closing, any member of the Seller’s Group completes the disposal of a Non-strategic Asset to a third party in accordance with clause 5.2.1, the Seller shall pay to the Purchaser at Closing the greater
of: 

  

	 	(i)	the relevant Threshold Amount; or 

  

	 	(ii)	an amount equal to the consideration (less any Taxes, costs and expenses incurred by any member of the Seller’s Group in connection with such disposal) received for the relevant Non-strategic Asset.

 Any payment obligation of the Seller arising pursuant to this clause 3.6.1 shall be set-off against the Purchaser’s
payment obligation pursuant to clause 6.3.1. 
  

	 	3.6.2	If, following Closing, any member of the Seller’s Group receives consideration for the disposal of a Non-strategic Asset, the Seller shall pay to the Purchaser, within five Business Days of the date of receipt of
the consideration, the greater of: 

  

	 	(i)	the Threshold Amount; or 

  

	 	(ii)	an amount equal to the consideration (less any Taxes, costs and expenses incurred by any member of the Seller’s Group in connection with such disposal) received for the relevant Non-strategic Asset.

  

	4	Conditions 

  

	4.1	Conditions Precedent 

 The sale and purchase of the Vaccines Group is conditional upon
satisfaction or, where applicable, waiver of the following conditions, or their satisfaction subject only to Closing: 
  

	 	4.1.1	to the extent that the proposed acquisition of all or any of the Shares or Vaccines Group Businesses (the “Transaction”) either constitutes (or is deemed to constitute under Article 4(5) or Article
5(2)) a concentration with a Community dimension within the meaning of Council Regulation (EC) 139/2004 (as amended) (the “Regulation”) or is to be examined by the European Commission as a result of a decision under Article 22(3) of
the Regulation: 

  

	 	(i)	the European Commission taking a decision (or being deemed to have taken a decision) under Article 6(1)(b) or, if the Commission has initiated proceedings pursuant to Article 6(1)(c), under Article 8(1) or 8(2) of the
Regulation declaring the Transaction compatible with the common market; or 

  

	 	(ii)	the European Commission taking a decision (or being deemed to have taken a decision) to refer the whole or part of the Transaction to the competent authorities of one or more Member States under Articles 4(4) or 9(3) of
the Regulation; and 

  

	 	(a)	each such authority taking a decision with equivalent effect to Clause 4.1.1(i) with respect to those parts of the Transaction referred to it; and 

 

	 	(b)	the European Commission taking any of the decisions under Clause 4.1.1(i) with respect to any part of the Transaction retained by it. 

  
  

 
 37 

	 	4.1.2	any waiting period (and any extension thereof) under the HSR Act applicable to the Transaction having expired; 

  

	 	4.1.3	to the extent required or otherwise agreed between the parties as appropriate to permit the parties to consummate the Transaction in the jurisdictions listed in Schedule 24, any additional clearances, approvals,
waivers, no-action letters and consents having been obtained and any additional waiting periods having expired under applicable antitrust, merger control or foreign investment rules set forth in Schedule 24; 

 

	 	4.1.4	receipt of CFIUS Approval if CFIUS has initiated a review of the transactions contemplated by this Agreement, whether pursuant to Clause 4.2.3 or otherwise; 

 

	 	4.1.5	no Governmental Entity having enacted, issued, promulgated, enforced or entered any Applicable Law or Judgment (whether temporary, preliminary or permanent) that is in effect at the Closing Date and that has the effect
of making the transactions contemplated by this Agreement illegal or otherwise restraining or prohibiting the consummation of such transactions; 

  

	 	4.1.6	the passing at a duly convened and held general meeting of the Purchaser Shareholders of an ordinary resolution validly approving the Target Asset Agreements (as defined in the Implementation Agreement) and any sale and
purchase under the Put Option Agreement (as defined in the Implementation Agreement) in accordance with the Purchaser Articles of Association, the Listing Rules and all other Applicable Law (such resolution being the “Purchaser Shareholder
Resolution” and such meeting being the “Purchaser Shareholder Meeting”; 

  

	 	4.1.7	the Seller not delivering a Novartis AG Board Certificate (as defined in the Implementation Agreement), in accordance with clause 3 of the Implementation Agreement, prior to the conclusion of the vote on the Purchaser
Shareholder Resolution at the Purchaser Shareholder Meeting; 

  

	 	4.1.8	none of the Key Sites (each taken as a whole) being, or being reasonably likely to be, from or after Closing: 

  

	 	(i)	incapable of operation in whole or part by the Purchaser’s Group without a member of the Purchaser’s Group being in breach of any Applicable Law or any other material duty or obligation; or 

 

	 	(ii)	otherwise incapable of operation in whole or part by virtue of some other event, matter, or circumstance, 

but only where the circumstances giving rise to the inability of the Purchaser’s Group to operate a Key Site would, or would be
reasonably likely to (whether alone or together with any other such circumstances), result in: 
  

	 	(a)	a Key Site being prohibited from, or otherwise being substantially incapable of, operation for a period of at least three consecutive or non-consecutive months in the 12 month period immediately following the Closing
Date; and 

  

	 	(b)	the manufacturing output of that Key Site in the 12 month period following the Closing Date falling by 30 per cent. or more as compared to the manufacturing output at that Key Site in the 12 month period ending on
the corresponding date in the immediately preceding year; and 

  
  

 
 38 

	 	4.1.9	the obtaining in form and substance satisfactory to the Purchaser of any consent, amendment, waiver or approval that the Purchaser, acting reasonably and in good faith, notifies to the Seller prior to 21 May 2014
that it wishes to obtain or be obtained for its benefit prior to Closing in relation to the [***]; and 

  

	 	4.1.10	each of the other Target Asset Agreements having become unconditional in accordance with its terms (save for any condition in those agreements relating to this Agreement or the other of those agreements having become
unconditional). 

  

	4.2	Responsibility for Satisfaction 

  

	 	4.2.1	The Purchaser and the Seller shall prepare and file the notifications necessary for the fulfilment of the conditions in Clauses 4.1.1 to 4.1.3 (the “Required Notifications”) as soon as reasonably
practicable (with notifications under the HSR Act to be filed by 29 May 2014). Notwithstanding anything to the contrary contained in this Agreement, the Purchaser shall have primary responsibility for obtaining all consents, approvals or
actions of any Governmental Entity which are required in connection with the Required Notifications. 

  

	 	4.2.2	The Purchaser shall be responsible for payment of all filing and other fees and expenses in connection with the Required Notifications and the satisfaction of the conditions in Clauses 4.1.1 to 4.1.3. 

 

	 	4.2.3	CFIUS: 

  

	 	(i)	The Seller and the Purchaser shall consult, cooperate and keep each other reasonably informed regarding communications with, and requests for additional information from, CFIUS with respect to the Transaction. The
Seller and the Purchaser shall use their respective reasonable best efforts to provide promptly all information that is pursuant to a request by CFIUS. 

  

	 	(ii)	Within 60 calendar days after the execution of this Agreement, any party wishing to submit a formal joint voluntary notice to CFIUS pursuant to 31 C.F.R. Section 800.401, et. seq. (“CFIUS Filing”)
shall provide the other party with written notice of its intent to make a CFIUS Filing (“Election Date”). Prior to making its election to submit a CFIUS Filing, the party wishing to make a CFIUS Filing shall consult in good faith
with senior executives of the other party. If neither the Seller nor the Purchaser provides notice to submit a formal joint voluntary notice to CFIUS, a CFIUS Filing will not be made unless requested by CFIUS. 

 

	 	(iii)	If either the Seller or the Purchaser elects to make a CFIUS Filing following the procedures and consultations in Clause 4.2.3(i) or if CFIUS requires a filing, then: 

 

	 	(a)	the Seller and the Purchaser shall use their respective reasonable best efforts to submit a draft CFIUS Filing no later than 15 Business Days following the Election Date, and a final CFIUS Filing the earlier of
(1) five business days after submitting the draft CFIUS filing or (2) five calendar days after the receipt of any comments from CFIUS staff regarding the draft CFIUS Filing; 

 

	***	 Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted
from this filing and have been filed separately with the Securities and Exchange Commission. 

  
  

 
 39 

	 	(b)	the Seller and the Purchaser will provide each other with the reasonable opportunity to review and comment on any information provided to CFIUS to the extent permitted by Applicable Law, with the exception of personal
identifier information required under Section 800.402(c)(6)(vi)(B) of the CFIUS regulations, 31 C.F.R.. Competitively sensitive information, or information not related to the transactions contemplated by this Agreement, may be restricted to
each party’s external counsel to the extent reasonably considered necessary or advisable by the providing party; 

  

	 	(c)	the Seller and the Purchaser shall each have an opportunity to approve and mutually agree on the joint contents of the CFIUS Filing and shall be jointly responsible for the accuracy of such contents. The Seller and the
Purchaser respectively, shall each be responsible for the accuracy of contents of the CFIUS Filing that exclusively relate to itself, its business, and any subsidiaries, parents or other related parties; and 

 

	 	(d)	The Seller and the Purchaser shall use their respective reasonable best efforts to obtain CFIUS Approval as promptly as practicable and shall consult with each other on strategic matters related to obtaining such CFIUS
Approval, provided that the Purchaser shall have no obligation to agree to any mitigation or other restrictive provision that could reasonably be considered to have a substantial impact on either the Business or the Purchaser. 

 

	 	4.2.4	The party responsible for satisfaction of each condition pursuant to this Clause 4.2 shall give notice to the other party of the satisfaction of the relevant condition within one Business Day of becoming aware of the
same. 

  

	 	4.2.5	The parties shall cooperate with each other in connection with the satisfaction of the conditions in Clauses 4.1.1 to 4.1.3. The parties will consult and cooperate reasonably with one another, consider in good faith the
views of one another, and provide to the other party in advance any analyses, appearances, presentations, memoranda, briefs, arguments, opinions and proposals they or their agents make or submit to a Governmental Entity. Without limiting the
foregoing, the parties agree to: (a) give each other reasonable advance notice of all meetings with any Governmental Entity; (b) give each other an opportunity to participate in each of such meetings; (c) to the extent practicable,
give each other reasonable advance notice of all substantive oral communications with any Governmental Entity; (d) if any Governmental Entity initiates a substantive oral communication, promptly notify the other party of the substance of such
communication; (e) provide each other with a reasonable advance opportunity to review and comment upon all written communications (including any analyses, presentations, memoranda, briefs, arguments, opinions and proposals) with a Governmental
Entity; (f) provide each other with copies of all written communications to or from any Governmental Entity; and (g) not advance arguments in connection with any regulatory review or litigation proceeding related to this Agreement (other
than litigation between the parties) over the objection of the other party that would reasonably be likely to have a significant adverse impact on that other party, provided however, that neither party shall be required to comply with paragraph
(b) above to the extent that the Governmental Entity objects to the participation of a party, or with paragraph (e) or (f) above to the extent that such disclosure may raise regulatory concerns (in which case, the disclosure may be
made on an outside counsel basis). 

  
  

 
 40 

	 	4.2.6	The Purchaser shall, and shall cause its Affiliates to use reasonable endeavours to procure the satisfaction of the conditions in Clauses 4.1.1 to 4.1.3 as soon as reasonably possible (and, in any event, not later than
the Longstop Date). Notwithstanding any other provision of this Agreement to the contrary, the Purchaser shall and, shall cause its Affiliates to use best endeavours to propose, negotiate, offer to commit and effect (and if such offer is accepted,
commit to and effect), by consent decree, undertaking, hold separate order, or otherwise, the sale, divestiture, licence or disposition of its Nimenrix and Mencevax products on a global basis (excluding existing manufacturing capabilities) as may be
required or desirable in order to procure the satisfaction of the conditions in Clauses 4.1.1 to 4.1.3 as soon as reasonably possible (and, in any event, not later than the Longstop Date) and to avoid the commencement of any Action or the issuing of
any Decision to prohibit the acquisition or any other transaction contemplated by this Agreement or, if such Action is already commenced, to avoid the entry of, or to effect the dissolution of, any injunction, temporary restraining order or other
order in any Action so as to enable the Closing to occur as soon as reasonably possible (and, in any event, not later than the Longstop Date): 

  

	 	4.2.7	The Seller shall, and shall cause the Vaccines Group to use reasonable endeavours to cooperate with the Purchaser in connection with procuring the satisfaction of the conditions in Clauses 4.1.1 to 4.1.3 as soon as
reasonably possible (and, in any event, not later than the Longstop Date), including providing to the Purchaser such information with respect to the Vaccines Group as the Purchaser may reasonably require in connection with satisfaction of its
obligations under this Clause. 

  

	 	4.2.8	The Purchaser and Seller shall cooperate to confirm, within 21 Business Days from signing of this Agreement, any additional merger notification requirements reasonably required or advisable in respect of the Transaction
in jurisdictions beyond those listed in Schedule 24, and shall cooperate with each other, within the meaning of Clause 4.2.6, in achieving any additional clearances, approvals and consents or waiting period expirations in such jurisdictions. For the
avoidance of doubt, Closing shall not be conditional upon such additional clearances, approvals and consents or waiting period expirations. 

  

	 	4.2.9	The Purchaser and Seller shall cooperate, in the manner contemplated in Clause 4.2.6, and use reasonable endeavours to ensure that no Governmental Entity shall enact, issue, promulgate, enforce or enter any Applicable
Law or Judgment as contemplated under Clause 4.1.5. In the event that any Governmental Entity enacts, issues, promulgates, enforces or enters any Applicable Law or Judgment as contemplated under Clause 4.1.5, the Seller and the Purchaser shall
cooperate and use reasonable endeavours to put in place arrangements that would allow the Transaction to complete to the greatest possible extent in compliance with the relevant Applicable Law or Judgment. 

  
  

 
 41 

	 	4.2.10	Without prejudice to the provisions of Schedule 3, each of the Seller and the Purchaser shall, and shall procure that each of its respective Affiliates shall, cooperate with each other in relation to the satisfaction of
the condition set out in Clause 4.1.8, and shall use its reasonable endeavours to ensure that the condition set out in Clause 4.1.8 is satisfied at Closing. 

  

	 	4.2.11	The Seller shall use best efforts to obtain the consents, amendments, waivers and approvals referred to in Clause 4.1.9 prior to the Closing Date. The cost of obtaining such consents, amendments, waivers and approvals
shall be borne by the Seller, including any payment or other incentive that may (whether required to be offered or not) be offered to [***] and/or [***] or any of their respective Affiliates in order to obtain such consents, amendments, waivers and
approvals. The Purchaser shall, and shall cause its Affiliates to cooperate with the Seller in connection with obtaining the consents, amendments, waivers and approvals referred to in Clause 4.1.9 and use its reasonable endeavours to ensure that
such conditions are satisfied at Closing, including providing to the Seller such information as the Seller may reasonably require in connection with the satisfaction of its obligations under this Clause 4.2.11. 

 

	4.3	Non-Satisfaction by the Long Stop Date 

  

	 	4.3.1	The Purchaser may at any time waive in whole or in part (and conditionally or unconditionally) the conditions set out in Clause 4.1.8 or 4.1.9 by notice in writing to the Seller. 

 

	 	4.3.2	If the conditions in Clause 4.1 are not satisfied (or waived in accordance with Clause 4.3.1) as of 22 October 2015 (the “Long Stop Date”), the Purchaser or the Seller may, in its sole discretion,
terminate this Agreement (other than Clauses 1, 13 and 16.2 to 16.14) and no party shall have any claim against the other under it, save for any claim arising from breach of any obligation contained in such Clauses or Clause 4.2. Neither the Seller
nor the Purchaser may terminate this Agreement after satisfaction or waiver of the conditions in Clause 4.1, except in accordance with this Agreement. 

  

	4.4	Termination 

  

	 	4.4.1	This Agreement may be terminated at any time prior to Closing: 

  

	 	(i)	by written consent of the Seller and the Purchaser; 

  

	 	(ii)	by either the Seller or the Purchaser by notice to the other party in the event that any Judgment restraining, enjoining or otherwise prohibiting the transactions contemplated by this Agreement shall have become final
and non-appealable, provided that the party seeking to terminate this Agreement pursuant to this Clause 4.4 has complied with the terms of the Implementation Agreement and this Agreement in connection with having such Judgment vacated or denied; or

  

	 	(iii)	by the Purchaser by notice to the Seller if: 

  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
  

 
 42 

	 	(a)	a Material Adverse Effect occurs prior to Closing (which shall include any breach or breaches of Clause 9.1 which alone or together constitute a Material Adverse Effect); or 

 

	 	(b)	the Seller fails to provide a Certificate immediately prior to Closing; or 

  

	 	(iv)	in accordance with the terms of the Implementation Agreement. 

  

	 	4.4.2	This Agreement shall terminate automatically at any time prior to Closing in the event that: 

  

	 	(i)	any other Target Asset Agreement terminates or is terminated in accordance with its terms; or 

  

	 	(ii)	the Novartis Break Fee and/or the GSK Break Fee becomes payable under clause 5.1 or clause 5.8 of the Implementation Agreement, respectively. 

 

	 	4.4.3	Save as provided in this Clause 4, neither party shall be entitled to terminate or rescind this Agreement (whether before or after Closing). If this Agreement is terminated pursuant to this Clause 4.4, this Agreement
shall be of no further force and effect and there shall be no further liability under this Agreement or any of the Ancillary Agreements on the part of any party, except that Clauses 1, 13 and 16.2 to 16.14, in each case, to the extent applicable,
shall survive any termination. 

  

	 	4.4.4	Nothing in this Clause 4.4 shall be deemed to release any party from any liability for any breach by such party of the terms and provisions of this Agreement prior to termination of this Agreement. 

 

	5	Pre-Closing 

  

	5.1	The Seller’s Obligations in Relation to the Business 

  

	 	5.1.1	The Seller undertakes to procure that between the date of this Agreement and Closing, it and the relevant members of the Seller’s Group shall, so far as permitted by Applicable Law, carry on the Business as carried
on by the Vaccines Group as a going concern in the ordinary course as carried on immediately prior to the date of this Agreement save in so far as agreed in writing by the Purchaser (such consent not to be unreasonably withheld or delayed).

  

	 	5.1.2	Without prejudice to the generality of Clause 5.1.1 and subject to Clause 5.2, the Seller undertakes to procure that, with respect to the Business as carried on by the Vaccines Group, between the date of this Agreement
and Closing, no member of the Seller’s Group shall, except as may be required to comply with this Agreement, without the prior written consent of the Purchaser (such consent not to be unreasonably withheld or delayed), take any of the actions
listed in Part 1 of Schedule 20. 

  

	 	5.1.3	Without prejudice to the generality of Clause 5.1.1, the Seller shall, in each case with respect to the Business as carried on by the Vaccines Group only: (i) undertake to procure the satisfaction of its
obligations listed in paragraph 1, Part 2 of Schedule 20; and (ii) procure that the Vaccines Group shall, between the date of this Agreement and Closing, comply with the requirements of paragraph 2, Part 2 of Schedule 20. 

  
  

 
 43 

	5.2	Exceptions to Seller’s Obligations in Relation to the Conduct of Business 

 Clause
5.1 shall not operate so as to prevent or restrict: 
  

	 	5.2.1	the disposal or transfer by one or more members of the Seller’s Group of any or all of the Non-strategic Assets; 

  

	 	5.2.2	any matter undertaken by any member of the Seller’s Group to facilitate or implement a Reorganisation in accordance with Clause 2.3.5; 

 

	 	5.2.3	any matter undertaken by any member of the Vaccines Group that is set out in Part 3 of Schedule 20; 

  

	 	5.2.4	any action to the extent it is required to be undertaken to comply with Applicable Law; or 

  

	 	5.2.5	any matter reasonably undertaken by any member of the Seller’s Group in an emergency or disaster situation with the intention of minimising any adverse effect of such situation in relation to the Vaccines
Group and where any delay arising by virtue of having to give notice to the Purchaser and await consent would materially prejudice the Vaccines Group, 

provided that the Seller shall notify the Purchaser as soon as reasonably practicable of any action taken or proposed to be taken as described
in Clause 5.2.4, shall provide to the Purchaser all such information as the Purchaser may reasonably request and shall use reasonable endeavours to consult with the Purchaser in respect of any such action. 

 

	5.3	The Seller’s obligations in relation to insurance 

 Without prejudice to the generality of
this Clause 5, between the date of this Agreement and Closing, the Seller shall or shall procure that the relevant members of the Seller’s Group shall maintain in force all Vaccines Group Insurance Policies and all Seller’s Group Insurance
Policies for the benefit of the Vaccines Group Businesses and Vaccines Group Companies. 
  

	5.4	The Seller’s obligations in relation to cash, Intra-Group Non-Trade Payables and Receivables and Third Party Indebtedness 

Prior to Closing, the Seller shall seek to minimise the amounts which would, but for this Clause 5.4, otherwise fall to be treated as: 

 

	 	(lix)	Intra-Group Non-Trade Payables; 

  

	 	(lx)	Intra-Group Non-Trade Receivables; 

  

	 	(lxi)	Vaccines Group Companies Cash Balances; and 

  

	 	(lxii)	Third Party Indebtedness, 

 in each case to the extent reasonably possible, taking into account
the consequences of any such reduction for the Seller’s Group. 
  

	5.5	Other Seller’s Obligations Prior to Closing 

 Without prejudice to the generality of this
Clause 5, prior to Closing the Seller shall, and shall procure that the relevant Vaccines Group Companies, the Seller and the Seller’s Affiliates shall allow the Purchaser and its respective agents, upon reasonable notice, reasonable access to,
and to take copies of, the books, records and documents of or relating in whole or in part to the Vaccines Group, provided that the obligations of the Seller under this Clause shall not extend to allowing access to information which is
(i) reasonably regarded as confidential to the activities of the Seller and the Seller’s Group otherwise than in relation to the Vaccines Group or (ii) commercially sensitive; or (iii) other information of the Vaccines Group if
such information cannot be shared with the Purchaser prior to Closing in compliance with Applicable Law (though the Seller shall seek to share such information with the Purchaser to the extent and in such a manner as would comply with Applicable
Law). 

  
  

 
 44 

	5.6	Affiliate Contracts 

  

	 	5.6.1	Other than as provided in the Ancillary Agreements and subject to Clauses 0 and 8.6, the Seller and the Purchaser shall procure that: 

 

	 	(i)	the Cash Pooling Arrangements; and 

  

	 	(ii)	each Affiliate Contract in force immediately prior to Closing, 

 shall terminate prior to
Closing and each counterparty thereto shall, effective as of Closing, settle all outstanding financial obligations arising out of such Affiliate Contracts and unconditionally release and irrevocably discharge each other party thereto from
(i) any and all further obligations to perform or any further performance of the various covenants, undertakings, warranties and other obligations contained in such Affiliate Contract and (ii) any and all claims and Liabilities whatsoever
arising out of, in any way connected with, as a result of or in respect of such Affiliate Contract. 
  

	 	5.6.2	As soon as practicable following the date of this Agreement, and in any event within one month of the date of this Agreement, the Seller shall provide a copy of each Affiliate Contract that is material to the Vaccines
Group and is in writing to the Purchaser. Within two months of the date of this Agreement, the Purchaser shall notify the Seller of the services provided under the Affiliate Contracts from the Seller’s Group which the Purchaser reasonably
requires in order to operate the business of the Vaccines Group as it is carried on at the date of this Agreement to continue to receive on the same terms as contained in the relevant Affiliate Contract for a maximum period of 6 months following
Closing provided that such services are not addressed by the Ancillary Agreements. 

  

	 	5.6.3	Any Affiliate Contract between or among Sandoz GmbH or Novartis Pharma Stein AG on the one hand, and any Vaccines Group Company on the other hand, and entered into after the date hereof with the written consent of the
Purchaser, shall not terminate prior to Closing in accordance with Clause 5.6.1, and shall transfer to the Purchaser upon Closing pursuant to Clause 2.3.1(viii). 

 

	5.7	Tax Groups 

  

	 	5.7.1	The Seller shall take all reasonable steps to procure that any Tax Consolidation existing between any member of the Seller’s Group Company and any Vaccines Group Company be terminated on or before Closing, so far
as permitted by the applicable law, or otherwise on the earliest date on which such termination is permitted under applicable law, and the Seller and the Purchaser shall take such action as is necessary to procure or effect this, including timely
submitting any necessary Tax documents. 

  
  

 
 45 

	 	5.7.2	Pending the taking effect of the action referred to in Clause 5.7.1, and for so long thereafter as may be necessary, the Purchaser shall (subject to the provisions of the Tax Indemnity) procure that such information is
provided to the Seller as may reasonably be required to enable any relevant member of the Seller’s Group to make all Tax Returns and other filings required of it in respect of the Tax Consolidation. 

 

	 	5.7.3	The Seller and the Purchaser shall cooperate in good faith to take, and procure that each member of the Seller’s Group and the Purchaser’s Group takes, all reasonable procedural or administrative steps
(including the making of elections and filings with relevant Tax Authorities) which are reasonably necessary to procure the minimisation of the extent to which Tax liabilities of members of the Seller’s Group (other than Vaccines Group
Companies) can be assessed on members of the Purchaser’s Group or on Vaccines Group Companies. 

  

	 	5.7.4	The Seller shall take all reasonable steps to procure that Chiron Panacea Vaccines Limited is finally liquidated and ceases to exist before Closing. 

 

	6	Closing 

  

	6.1	Date and Place 

 Closing shall take place simultaneously with closing under the other Target
Asset Agreements at 11.59 p.m. (Central European Time) at the offices of Freshfields Bruckhaus Deringer, 65 Fleet Street, London EC4Y 1HS (other than in respect of any Local Transfer Documents agreed between the parties to be executed in another
jurisdiction) on the last Business Day of the month in which fulfilment or waiver of the last of the condition(s) set out in Clause 4.1 to be fulfilled or waived takes place, except that: 

 

	 	6.1.1	where the last day of such month is not a Business Day, Closing shall instead take place on the first Business Day of the following month; and 

 

	 	6.1.2	where less than five Business Days remain between such fulfilment or waiver and the last Business Day of the month, Closing shall take place: 

 

	 	(i)	on the last Business Day of the following month; 

  

	 	(ii)	where the last day of such month is not a Business Day, Closing shall instead take place on the first Business Day of the month following the month referred to in Clause 6.1.2(i); or 

 

	 	(iii)	at such other location, time or date as may be agreed between the Purchaser and the Seller in writing. 

provided that: 
  

	 	(a)	Closing shall not take place and shall not be effective in any circumstances unless closing also takes place under and in accordance with the terms of the other Target Asset Agreements at the same time; and

  

	 	(b)	in determining the date on which the last of the conditions set out in Clause 4.1 is fulfilled or waived, the date shall be the date on which the last of the conditions set out in Clauses 4.1.1, 4.1.2, 4.1.3, 4.1.4,
4.1.6, 4.1.7 and 4.1.9 is fulfilled or waived unless any of the conditions set out in Clauses 4.1.5 and 4.1.8 is not fulfilled or waived on that date, in which case the date shall then be the first following date on which all of the conditions set
out in Clauses 4.1.5 and 4.1.8 are fulfilled or waived. 

  
  

 
 46 

	6.2	Closing Events 

  

	 	6.2.1	On Closing, the parties shall comply with their respective obligations specified in Schedule 15. The Seller may waive some or all of the obligations of the Purchaser as set out in Schedule 15 and the Purchaser may waive
some or all of the obligations of the Seller as set out in Schedule 15. 

  

	 	6.2.2	The parties acknowledge that the transfer of Product Approvals and Product Applications to the Purchaser or other members of the Purchaser’s Group may be subject to the approval of applicable Governmental Entities,
and that, notwithstanding anything in this Agreement to the contrary, each Product Approval and Product Application shall continue to be held by the relevant member of the Seller’s Group from the Closing Date until the relevant PA Transfer
Date. 

  

	 	6.2.3	The parties shall perform their respective obligations with respect to: 

  

	 	(i)	the transfer of the Product Approvals, Product Applications and Pipeline Product Approvals as set out in Schedule 8; 

  

	 	(ii)	the transfer of Contracts (other than Product Approvals, Product Applications and Pipeline Product Approvals) and the Transferred Intellectual Property Contracts as set out in Schedule 10 and the treatment of Shared
Business Contracts; and 

  

	 	(iii)	to the extent the Purchaser has elected to have the Relevant Part of a Shared Business Contract transferred to it, the separation of each Shared Business Contract as set out in Schedule 10. 

 

	6.3	Payment on Closing 

  

	 	6.3.1	On Closing the Purchaser shall pay (for itself and on behalf of each relevant member of the Purchaser’s Group in accordance with Clause 16.6) an amount in cleared funds, to the Seller to the Purchase Price Bank
Account, which is equal to the sum of: 

  

	 	(i)	the Headline Price; 

 plus 

 

	 	(ii)	the Estimated Vaccines Group Companies’ Cash Balances and the Estimated Intra-Group Non-Trade Receivables; 

minus 
  

	 	(iii)	the Estimated Third Party Indebtedness 

 minus 

 

	 	(iv)	the Estimated Intra-Group Non-Trade Payables; 

 minus 

 

	 	(v)	any Estimated Employee Benefit Adjustment; 

 minus 

  
  

 
 47 

	 	(vi)	the Estimated Tax Adjustment 

 plus 

 

	 	(vii)	the Estimated Working Capital Adjustment. 

  

	6.4	Notifications to determine payments on Closing 

  

	 	6.4.1	Five Business Days prior to Closing, the Seller shall notify the Purchaser of: 

  

	 	(i)	the Estimated Vaccines Group Companies’ Cash Balances; 

  

	 	(ii)	the Estimated Third Party Indebtedness; 

  

	 	(iii)	the Estimated Intra-Group Non-Trade Receivables; 

  

	 	(iv)	the Estimated Intra-Group Non-Trade Payables; 

  

	 	(v)	any Estimated Employee Benefit Adjustment; 

  

	 	(vi)	the Estimated Tax Adjustment; 

  

	 	(vii)	the Estimated Working Capital; and 

  

	 	(viii)	the Estimated Working Capital Adjustment, 

 and shall at the same time provide to the Purchaser
reasonable supporting calculations and information to enable the Purchaser to review the basis on which the estimates have been prepared. 
  

	 	6.4.2	The Seller’s notification pursuant to Clause 6.4.1 shall specify the relevant debtor and creditor for each Estimated Intra-Group Payable and Estimated Intra-Group Receivable. 

 

	 	6.4.3	Immediately following Closing: 

  

	 	(i)	the Purchaser shall procure that each Vaccines Group Company repays to the relevant member of the Seller’s Group the amount of any Estimated Intra-Group Non-Trade Payables and shall acknowledge on behalf of each
Group Company the payment of the Estimated Intra-Group Non-Trade Receivables in accordance with Clause 6.4.3(ii); and 

  

	 	(ii)	the Seller shall procure that each relevant member of the Seller’s Group repays to the relevant Vaccines Group Company the amount of any Estimated Intra-Group Non-Trade Receivables and shall acknowledge on behalf
of each relevant member of the Seller’s Group the payment of the Estimated Intra-Group Non-Trade Payables in accordance with Clause 6.4.3(i). 

  

	 	6.4.4	The repayments made pursuant to Clause 6.4.3 shall be adjusted in accordance with Clauses 7.3 and 7.4 when the Closing Statement becomes final and binding in accordance with Clause 7.2.1. 

 

	6.5	Breach of Closing Obligations 

 If any party fails to comply with any material obligation in
Clauses 6.2, 6.3 or 6.4, or Schedule 15 in relation to Closing, the Purchaser, in the case of non-compliance by the Seller, or the Seller, in the case of non-compliance by the Purchaser, shall be entitled (in addition to and without prejudice to all
other rights or remedies available) by written notice to the Seller or the Purchaser fix a new date for Closing which, except as agreed by the parties, shall be the last day of the month next ending or, if that day is not a Business Day, the first
Business Day falling after that day, in which case the provisions of Schedule 15 shall apply to Closing as so deferred, but provided such deferral may only occur once. 

  
  

 
 48 

 In all circumstances Closing shall only occur simultaneously with closing under the other Target
Asset Agreements. 
  

	7	Post-Closing Adjustments 

  

	7.1	Closing Statements 

  

	 	7.1.1	The Seller shall procure that as soon as practicable following Closing there shall be drawn up a draft of the Closing Statement (the “Draft Closing Statement”) in accordance with Schedule 16 in
relation to the Vaccines Group Companies and Vaccines Group Businesses, on a combined basis. 

  

	 	7.1.2	The Closing Statement shall be drawn up as at the Effective Time. 

  

	7.2	Determination of Closing Statement 

  

	 	7.2.1	The Draft Closing Statement as agreed or determined pursuant to paragraph 1 of Part 1 of Schedule 16: 

  

	 	(i)	shall constitute the Closing Statement for the purposes of this Agreement; and 

  

	 	(ii)	shall be final and binding on the parties. 

  

	 	7.2.2	The Working Capital, the Vaccines Group Companies’ Cash Balances, the Third Party Indebtedness, the Intra-Group Non-Trade Receivables, the Intra-Group Non-Trade Payables and the Tax Adjustment shall be derived from
the Closing Statement. 

  

	7.3	Adjustments to Purchase Price 

  

	 	7.3.1	Vaccines Group Companies’ Cash Balances: 

  

	 	(i)	if the Vaccines Group Companies’ Cash Balances are less than the Estimated Vaccines Group Companies’ Cash Balances, the Seller shall repay to the Purchaser an amount equal to the deficiency; or

  

	 	(ii)	if the Vaccines Group Companies’ Cash Balances are greater than the Estimated Vaccines Group Companies’ Cash Balances, the Purchaser shall pay to the Seller an additional amount equal to the excess.

  

	 	7.3.2	Intra-Group Non-Trade Receivables: 

  

	 	(i)	if the Intra-Group Non-Trade Receivables are less than the Estimated Intra-Group Non-Trade Receivables, the Seller shall repay to the Purchaser an amount equal to the deficiency; or 

 

	 	(ii)	if the Intra-Group Non-Trade Receivables are greater than the Estimated Intra-Group Non-Trade Receivables, the Purchaser shall pay to the Seller an additional amount equal to the excess. 

  
  

 
 49 

	 	7.3.3	Third Party Indebtedness: 

  

	 	(i)	if the Third Party Indebtedness is greater in magnitude than the Estimated Third Party Indebtedness, the Seller shall repay to the Purchaser an amount equal to the excess; or 

 

	 	(ii)	if the Third Party Indebtedness is less in magnitude than the Estimated Third Party Indebtedness, the Purchaser shall pay to the Seller an additional amount equal to the deficiency. 

 

	 	7.3.4	Intra-Group Non-Trade Payables: 

  

	 	(i)	if the Intra-Group Non-Trade Payables are greater in magnitude than the Estimated Intra-Group Non-Trade Payables, the Seller shall repay to the Purchaser an amount equal to the excess; or 

 

	 	(ii)	if the Intra-Group Non-Trade Payables are less in magnitude than the Estimated Intra-Group Non-Trade Payables, the Purchaser shall pay to the Seller an additional amount equal to the deficiency. 

 

	 	7.3.5	Tax Adjustment 

  

	 	(i)	if the Tax Adjustment is greater than the Estimated Tax Adjustment, the Seller shall repay to the Purchaser an amount equal to the difference; or 

 

	 	(ii)	if the Tax Adjustment is less than the Estimated Tax Adjustment, the Purchaser shall pay to the Seller an additional amount equal to the difference. 

 

	 	7.3.6	Working Capital: 

  

	 	(i)	if the Working Capital Adjustment is less than the Estimated Working Capital Adjustment, the Seller shall repay to the Purchaser an amount equal to the deficiency; or 

 

	 	(ii)	if the Working Capital Adjustment exceeds the Estimated Working Capital Adjustment, the Purchaser shall pay to the Seller an additional amount equal to the excess. 

 

	7.4	Adjustments to repayment of Intra-Group Non-Trade Payables and Intra-Group Non-Trade Receivables 

Following the determination of the Closing Statement pursuant to Clause 7.2 and paragraph 1 of Part 1 of Schedule 16, if the amount of any
Intra-Group Non-Trade Payable and/or any Intra-Group Non-Trade Receivable contained in the Closing Statement is greater or less than the amount of the corresponding Estimated Intra-Group Non-Trade Payable or Estimated Intra-Group Non-Trade
Receivable, then the Seller and the Purchaser shall procure that such adjustments to the repayments pursuant to Clause 6.4.3 are made as are necessary to ensure that (taking into account such adjustments) the actual amount of each Intra-Group
Non-Trade Payable and each Intra-Group Non-Trade Receivable has been repaid by each Group Company to the relevant member of the Seller’s Group or by the relevant member of the Seller’s Group to the relevant Group Company, as the case may
be. 
  

	7.5	Interest 

 Any payment to be made in accordance with Clause 7.3 shall include interest thereon
calculated from the Closing Date to the date of payment at a rate per annum of LIBOR. 

  
  

 
 50 

	7.6	Payment 

  

	 	7.6.1	Any payments pursuant to Clause 7.3 or 7.4, and any interest payable pursuant to Clause 7.5, shall be made on or before the Final Payment Date. 

 

	 	7.6.2	Where any payment is required to be made pursuant to Clause 7.3 or Clause 7.5 (in relation to a payment pursuant to Clause 7.3) the payment made on account of the Purchase Price shall be reduced or increased
accordingly. 

  

	 	7.6.3	Where any payment is required to be made pursuant to Schedule 12, the payment made shall be deemed to be a reduction to the Purchase Price. 

 

	8	Post-Closing Obligations 

  

	8.1	Indemnities 

  

	 	8.1.1	Indemnity by the Purchaser against Assumed Liabilities 

 The Purchaser hereby undertakes
to the Seller (for itself and on behalf of each other member of the Seller’s Group and their respective directors, officers, employees and agents) that, with effect from Closing, the Purchaser will indemnify on demand and hold harmless each
member of the Seller’s Group and their respective directors, officers, employees and agents against and in respect of any and all Assumed Liabilities. 
  

	 	8.1.2	Indemnities by Seller 

 Subject to Clause 8.1.3, the Seller hereby undertakes to the
Purchaser (for itself and on behalf of each other member of the Purchaser’s Group and their respective directors, officers, employees and agents) that, with effect from Closing, the Seller will indemnify on demand and hold harmless each member
of the Purchaser’s Group and their respective directors, officers, employees and agents against and in respect of any and all: 
  

	 	(i)	Excluded Liabilities; and 

  

	 	(ii)	Liabilities, including legal fees, to the extent they have arisen or arise (whether before or after Closing) as a result of or otherwise relate to any act, omission, fact, matter, circumstance or event undertaken,
occurring or in existence or arising before Closing so far as related to: (A) any breach of any anti-bribery warranty, including without limitation those set forth in paragraphs 9.1 through 9.6 of Schedule 18, not being true and correct when
made; (B) any government inquiries or investigations involving the Seller or its Affiliates or associated persons; (C) save to the extent in existence as at the date of this Agreement, any limitation, restriction or other reduction in drug
registrations, licenses, listings or marketing approvals, government pricing or reimbursement rates relating to the Products including specifically the value of lost future profits as a result of any such limitation, restriction or reduction; or
(D) any other claim, litigation, investigation or proceeding to the extent related to any of the foregoing (A) to (C), including but not limited to costs of investigation and defense and legal fees. 

  
  

 
 51 

	 	8.1.3	Limitations on Indemnities 

 Subject to Clause 8.1.4, the Seller shall not be liable
under Clause 8.1.2 in respect of: 
  

	 	(i)	any Time-Limited Excluded Liability unless a notice of claim in respect of the matter giving rise to such Liability is given by the Purchaser to the Seller within ten years of Closing, provided that this sub-Clause
(i) shall not apply in respect of any claim by the Purchaser which relates to: 

  

	 	(a)	a Product Liability; 

  

	 	(b)	a Governmental Liability; 

  

	 	(c)	a Clinical Trials/Data Liability; 

  

	 	(d)	an IP Liability; or 

  

	 	(e)	an Excluded Asset; 

  

	 	(ii)	any claim if and to the extent that the relevant Liability is included in the Closing Statement; or 

  

	 	(iii)	any individual claim (or a series of claims arising from similar or identical facts or circumstances) where the Liability (disregarding the provisions of this Clause 8.1.3(iii))) in respect of any such claim or series
of claims does not exceed US$10 million, provided that, for the avoidance of doubt, where the Liability in respect of any such claim or series of claims exceeds US$10 million, the Liability of the Seller shall be for the whole amount of such
claim(s) and not just the excess. 

  

	 	8.1.4	Disapplication of limitations 

 None of the limitations contained in Clause 8.1.3 shall
apply to any claim to the extent that such claim which arises or is increased, or to the extent to which it arises or is increased, as the consequence of, or which is delayed as a result of, fraud by any member of the Seller’s Group or any
director, officer or employee of any member of the Seller’s Group. 
  

	8.2	Conduct of Claims 

  

	 	8.2.1	Assumed Liabilities 

  

	 	(i)	If the Seller becomes aware after Closing of any claim by a third party which constitutes or may constitute an Assumed Liability, the Seller shall as soon as reasonably practicable: 

 

	 	(a)	give written notice thereof to the Purchaser, setting out such information as is available to the Seller as is reasonably necessary to enable the Purchaser to assess the merits of the potential claim; 

 

	 	(b)	take all appropriate actions to preserve evidence; and 

  

	 	(c)	provide the Purchaser with periodic updates on the status of the claim upon request and shall not admit, compromise, settle, discharge or otherwise deal with such claim without the prior written agreement of the
Purchaser (such agreement not to be unreasonably withheld or delayed). 

  
  

 
 52 

	 	(ii)	The Seller shall, and shall procure that each Share Seller and Business Seller shall, take such action as the Purchaser may reasonably request to avoid, dispute, resist, appeal, compromise, defend or mitigate any claim
which constitutes or may constitute an Assumed Liability subject to the Seller and each Share Seller and Business Seller being indemnified and secured to their reasonable satisfaction by the Purchaser against all Liabilities which may thereby be
incurred. In connection therewith, the Seller shall make or procure to be made available to the Purchaser or their duly authorised agents on reasonable notice during normal business hours all relevant books of account, records and correspondence
relating to the Vaccines Group Businesses which have been retained by the Seller’s Group (and shall permit the Purchaser to take copies thereof at its expense) for the purposes of enabling the Purchaser to ascertain or extract any information
relevant to the claim. 

  

	 	8.2.2	Excluded Liabilities 

  

	 	(i)	If the Purchaser becomes aware after Closing of any claim by a third party which constitutes or may constitute an Excluded Liability or relates to an Excluded Liability or any investigations related thereto, regardless
of whether the Purchaser believes that such claim would be made against a member of the Purchaser’s Group or a member of the Seller’s Group, the Purchaser shall as soon as reasonably practicable: 

 

	 	(a)	give written notice thereof to the Seller, setting out such information as is available to the Purchaser as is reasonably necessary to enable the Seller to assess the merits of the potential claim; 

 

	 	(b)	take all appropriate actions to preserve evidence; and 

  

	 	(c)	provide the Seller with periodic updates on the status upon request and shall not admit, compromise, settle, discharge or otherwise deal with such claim without the prior written agreement of the Seller (such agreement
not to be unreasonably withheld or delayed). 

  

	 	(ii)	The Purchaser shall take such action as the Seller may reasonably request to avoid, dispute, resist, appeal, compromise, defend or mitigate any claim which constitutes or may constitute an Excluded Liability subject to
the Purchaser being indemnified and secured to its reasonable satisfaction by the Seller against all Liabilities which may thereby be incurred. 

  

	 	(iii)	In addition, where any such claim or investigation involves a Governmental Entity, the Purchaser shall, subject to Applicable Law, the requirements of the Relevant Governmental Entity and the Seller providing an
appropriate confidentiality undertaking in favour of the Purchaser’s Group, provide to the Seller, at least five Business Days in advance (or, where not possible, as soon as reasonably possible), any analyses, appearances, presentations,
memoranda, briefs, arguments, opinions and proposals they or their agents make or submit to a Governmental Entity. Without limiting the foregoing, the parties agree, subject to the Applicable Law, and the requirements of the relevant Governmental
Entity, and the Seller providing an appropriate confidentiality undertaking in favour of the Purchaser’s Group, to: 

  
  

 
 53 

	 	(a)	give the Seller reasonable advance notice of all meetings with any Governmental Entity; 

  

	 	(b)	give the Seller an opportunity to participate in each of such meetings; 

  

	 	(c)	to the extent practicable, give the Seller reasonable advance notice of all substantive oral communications with any Governmental Entity; 

 

	 	(d)	if any Governmental Entity initiates a substantive oral communication, promptly notify the Seller of the substance of such communication; 

 

	 	(e)	provide the Seller with a reasonable advance opportunity to review and comment upon all substantive written communications (including any substantive correspondence, analyses, presentations, memoranda, briefs,
arguments, opinions and proposals) that the Purchaser or its agents intend to make or submit to a Governmental Entity in connection with such claim; 

  

	 	(f)	provide the Seller with copies of all substantive written communications to or from any Governmental Entity; and 

  

	 	(g)	not advance arguments with the Governmental Entity without prior agreement of the Seller that would reasonably be likely to have a significant adverse impact on the Seller, provided however, that the Purchaser shall not
be required to comply with paragraph (b) above to the extent that the Governmental Entity objects to the participation of a party, or with paragraph (e) or (f) above to the extent that such disclosure may raise regulatory concerns (in
which case, the disclosure may be made on an outside counsel basis). 

  

	 	(iv)	Other than in respect of any claim to the extent it relates to an IP Liability, a Commercial Practices Liability or a Governmental Liability (other than in respect of any Liability arising solely by virtue of a breach
of any Contract with any Governmental Entity which breach does not also constitute a breach of Applicable Law), the Seller shall be entitled at its own expense and in its absolute discretion, by notice in writing to the Purchaser, to take such
action as it shall deem necessary to avoid, dispute, deny, defend, resist, appeal, compromise or contest any such claim (including making counterclaims or other claims against third parties) in the name of and on behalf of the Purchaser or other
member of the Purchaser’s Group concerned and to have the conduct of any related proceedings, negotiations or appeals. In taking action on behalf of any member of the Purchaser’s Group as permitted by this Clause 8.2, the Seller shall, in
good faith, take into account and have due regard to any reputational matters or issues arising out of the claim for any member of the Purchaser’s Group or any of their respective directors, officers, employees or agents which are brought to
its attention by the Purchaser or a member of the Purchaser’s Group. 

  

	 	(v)	Without limitation to the Seller’s rights pursuant to Clause 8.10, the Purchaser shall make or procure to be made available to the Seller or its duly authorised agents on reasonable notice during normal business
hours full and free access to all relevant books of account, records and correspondence relating to the Vaccines Group which are in the possession of the Purchaser or any member of the Purchaser’s Group (and shall permit the Seller to take
copies thereof) for the purposes of enabling the Seller to ascertain or extract any information relevant to the claim. 

  
  

 
 54 

	 	(vi)	The Purchaser shall, and shall procure that each other member of the Purchaser’s Group shall, on reasonable notice from the Seller, give such assistance to the Seller as it may reasonably require in relation to the
claim including providing the Seller or any member of the Seller’s Group and its representative and advisers with access to and assistance from directors, officers, managers, employees, advisers, agents or consultants of the Purchaser and/or of
each other member of the Purchaser’s Group (collectively, the “Relevant Persons”) and the Purchaser will use its reasonable endeavours to procure that such Relevant Persons comply with any reasonable requests from the Seller
and generally co-operates with and assists the Seller and other members of the Seller’s Group. 

  

	 	(vii)	When seeking assistance under Clauses 8.2.2(v) and (vi), the Seller, or any other relevant member of the Seller’s Group, shall use reasonable endeavours to minimise interference with the Purchaser and the
Purchaser’s Group’s conduct of the relevant business or the performance by the Relevant Persons of their employment duties. 

  

	8.3	Release of Guarantees 

  

	 	8.3.1	The Purchaser shall use reasonable endeavours to procure as soon as reasonably practicable after Closing, the release of the Seller or any member of the Seller’s Group from any securities, guarantees or indemnities
given by or binding upon the Seller or any member of the Seller’s Group in respect of the Assumed Liabilities or in connection with a liability of any of the Vaccines Group Companies (other than an Excluded Liability). Pending such release, the
Purchaser shall indemnify the Seller and any member of the Seller’s Group against all amounts paid by any of them (acting reasonably) pursuant to any such securities, guarantees or indemnities in respect of such Assumed Liabilities or such
liability of the Vaccines Group Companies (other than an Excluded Liability). 

  

	 	8.3.2	The Seller shall use reasonable endeavours to procure by Closing or, to the extent not done by Closing, as soon as reasonably practicable after Closing, the release of the Vaccines Group Companies from any securities,
guarantees or indemnities given by or binding upon the Vaccines Group Companies in respect of any liability of the Seller or any member of the Seller’s Group. Pending such release, the Seller shall indemnify the Vaccines Group Companies against
all amounts paid by any of them (acting reasonably) pursuant to any such securities, guarantees or indemnities in respect of such liability of the Seller which arises after Closing. 

 

	8.4	Transferred Accounts Payable 

 If at any time after Closing, the Seller or any of its Affiliates
pays any monies in respect of any Transferred Accounts Payable, then the Purchaser shall pay or procure payment to the Seller (for the relevant Business Seller), as soon as reasonably practicable the amount paid, plus any Taxation suffered or
incurred by the Seller’s Group which would not have arisen but for the payment and receipt of such monies. 

  
  

 
 55 

	8.5	Transferred Accounts Receivable 

 If at any time after Closing, a Business Seller receives any
monies in respect of any Transferred Accounts Receivable, then the Business Seller shall pay or procure payment to the Purchaser, as soon as reasonably practicable the amount recovered, less any Taxation suffered or incurred by the Seller’s
Group which would not have arisen but for the receipt and payment of such monies. 
  

	8.6	Intra-Group Trading Balances 

 Any Intra-Group Trading Balances shall be settled after Closing
in the ordinary course of business and, in any event, within 60 days of Closing. 
  

	8.7	Transfer of Marketing Authorisations 

  

	 	8.7.1	The transfer of the Marketing Authorisations following Closing shall take place in accordance with Part 2 of Schedule 8 and the terms of the Manufacturing, Supply and Distribution Agreement. 

 

	 	8.7.2	Between the Closing Date and the Marketing Authorisation Transfer Date, the Seller agrees to assist the Purchaser in accordance with Part 4 of Schedule 8 in respect of any tenders relating to the Products.

  

	8.8	Wrong Pockets Obligations 

  

	 	8.8.1	Except as provided in Schedules 3, 8, 10, 11 and 12, if any property, right or asset forming part of the Vaccines Group (other than any property, right or asset expressly excluded from the sale under this Agreement) has
not been transferred to the Purchaser or to another member of the Purchaser’s Group and should have transferred pursuant to the terms of this Agreement, the Seller shall procure that such property, right or asset (and any related liability
which is an Assumed Liability) is transferred to the Purchaser, or to such other member of the Purchaser’s Group as the Purchaser may nominate reasonably acceptable to the Seller, as soon as practicable and at no cost to the Purchaser.

  

	 	8.8.2	If, following Closing, any property, right or asset not forming part of the Vaccines Group (other than any property, right or asset expressly included in the sale under this Agreement) is found to have been
transferred to the Purchaser or to another member of the Purchaser’s Group and should not have transferred pursuant to the terms of this Agreement, the Purchaser shall procure that such property, right or asset is transferred to the transferor
or another member of the Seller’s Group nominated by the Seller reasonably acceptable to the Purchaser as soon as practicable and at no cost to the Seller. 

  

	8.9	Covenant not to sue 

  

	 	8.9.1	 The Seller hereby undertakes not to enforce, at any time after Closing, any Out of Scope Patent against the Purchaser’s Group in relation
to the Purchaser’s Group carrying on the Business as at the date of Closing. 

  
  

 
 56 

	 	8.9.2	The Purchaser hereby undertakes not to enforce, at any time after Closing, any Vaccines Patent against the Seller’s Group in relation to the Seller’s Group carrying on the Seller’s Group Retained
Business as at the date of Closing. 

  

	8.10	The Purchaser’s Continuing Obligations 

  

	 	8.10.1	The Purchaser shall procure that as soon as practicable after Closing, each of the Vaccines Group Companies shall change its name so that it does not contain any of the Seller Restricted Marks or any name which is
likely to be confused with the same and shall provide the Seller with appropriate evidence of such change of name. 

  

	 	8.10.2	Except as provided in the Ancillary Agreements, the Purchaser shall not, and shall procure that no member of the Purchaser’s Group shall, after Closing, use the Seller Restricted Marks or any confusingly similar
name or mark, any extensions thereof or developments thereto in any business which competes with the Seller’s business, or any other business of the Seller or any member of the Seller’s Group in which the Seller Restricted Marks are used
for a minimum period of five (5) years following Closing and thereafter for so long as any member of the Seller’s Group continues to retain an interest in the relevant Seller Restricted Marks. 

 

	 	8.10.3	The Purchaser shall, and shall procure that the relevant Vaccines Group Companies shall, retain for a period of 10 years from Closing (and, upon notice from the Seller between 9 and 10 years from Closing, for a further
period of 5 years), and not dispose of or destroy, the books, records and documents of the Vaccines Group to the extent they relate to the period prior to Closing and shall, and shall procure that the relevant Vaccines Group Companies shall, if
reasonably requested by the Seller, allow the Seller reasonable access to such books, records and documents (including the right to take copies at the Seller’s expense) and to the employees of the Vaccines Group or former employees of the
Vaccines Group who are employees of any member of the Purchaser’s Group. 

  

	 	8.10.4	During the 90 days following the Closing Date, the Purchaser shall provide and cause to be provided to the Seller the information reasonably required to enable the Seller to prepare and audit the standard monthly
reporting forms of the Seller’s Group, to the extent that such financial reporting relates to the Vaccines Group, in respect of the period prior to the Closing and in respect of the calendar month in which the Closing occurs. The Purchaser
shall provide such financial reporting in respect of the calendar month in which Closing occurs to the Seller within six Business Days of the last day of the relevant month. 

 

	8.11	The Seller’s Continuing Obligations 

 For a period of 10 years from Closing (and, upon
notice from the Purchaser between 9 and 10 years from Closing, for a further period of 5 years), the Seller shall make or procure to be made available to the Purchaser or their duly authorised agents on reasonable notice during normal business
hours: 
  

	 	8.11.1	all relevant books, accounts, other records and correspondence relating to the Vaccines Group which have been retained by the Seller’s Group (and shall permit the Purchaser to take copies thereof);
and 

  
  

 
 57 

	 	8.11.2	reasonable access to employees of the Seller’s Group who have knowledge relating to any of the Products (including any inventor of the Products) for the purposes of the defence, prosecution or enforcement of
any Vaccines Group Intellectual Property Rights, or as required by law or a Governmental Entity, provided that the Purchaser shall promptly reimburse the Seller for expenses reasonably incurred by the Seller in relation to providing such access if
it exceeds 25 man hours in aggregate per annum. 

  

	8.12	Influenza Business 

  

	 	8.12.1	General 

  

	 	(i)	Without prejudice to Clauses 2.1, 2.2, 2.3.1 to 2.3.4, 3 and 4, the parties shall, acting reasonably and as soon as practicable, enter into such arrangements as are required to enable the Influenza Business (or parts
thereof) retained by the Seller, purchased by the Purchaser, or purchased by one or more third party purchasers (as applicable) to continue to operate the Influenza Business (or parts thereof) on substantially the same basis as it was operated by
the Seller immediately prior to the date of this Agreement. Such arrangements may include: 

  

	 	(a)	a transitional services agreement which, if required, will be on the same terms as the heads of terms relating to the Transitional Services Agreement in the Agreed Terms (with any necessary amendments) until such time
as the full form Transitional Services Agreement is agreed, in which case, the terms that will apply will be that full form agreement (with any necessary amendments); 

 

	 	(b)	a manufacturing, supply and distribution agreement which, if required, will be on the same terms as the heads of terms relating to the Manufacturing, Supply and Distribution Agreement in the Agreed Terms (with any
necessary amendments) until such time as the full form Manufacturing, Supply and Distribution Agreement is agreed, in which case, the terms that will apply will be that full form agreement (with any necessary amendments); and 

 

	 	(c)	a manufacturing and supply agreement which, if required, will be on the same terms as the heads of terms relating to the Influenza Business Manufacturing and Supply Agreement in the Agreed Terms (with any necessary
amendments) until such time as the full form Influenza Business Manufacturing and Supply Agreement is agreed, in which case, the terms that will apply will be that full form agreement (with any necessary amendments). 

 

	 	(ii)	Each party shall take all reasonable steps to cooperate with the other party to ensure that each relevant technology transfer takes place as soon as practicable. 

 

	 	(iii)	The Purchaser acknowledges that the Seller shall, at its option, be entitled to: 

  

	 	(a)	assign or novate the burden and benefit of the Influenza Business Manufacturing and Supply Agreement and any of the arrangements referred to in Clause 8.12.1(i) to any purchaser(s) of the Influenza Business (or parts
thereof) without the consent of the Purchaser; or 

  
  

 
 58 

	 	(b)	require the Purchaser to enter into separate agreements with any purchaser(s) of the Influenza Business (or parts thereof) on the same terms as the Influenza Business Manufacturing and Supply Agreement and any of the
arrangements referred to in Clause 8.12.1(i). 

  

	 	8.12.2	Influenza Business Manufacturing and Supply Agreement 

 If the Influenza Business
Manufacturing and Supply Agreement has not been entered into on the earlier of: (i) Closing; or (ii) the closing of any sale to the purchaser(s) of the Influenza Business (or parts thereof), the provisions of the heads of terms in relation
to the Influenza Business Manufacturing and Supply Agreement in the Agreed Terms shall be binding on the Seller and Purchaser until the earlier of: (i) the date on which the Manufacturing and Supply Agreement is entered into; and (ii) the
date specified in the heads of terms. 
  

	 	8.12.3	Confidential information 

 In connection with the services to be provided pursuant to
this Clause 8.12, where required by Applicable Law, the Seller and the Purchaser shall establish appropriate safe guards to maintain, and protect from improper disclosure, confidential information arising from the provision of such services. 

 

	8.13	Diagnostics TSA Liabilities 

 The Seller hereby undertakes to the Purchaser (for itself
and as trustee for each other member of the Purchaser’s Group) that, with effect from Closing, the Seller will indemnify on demand and hold harmless each member of the Purchaser’s Group, and any of their respective directors, officers and
employees, against and in respect of any and all Diagnostics TSA Liabilities (but excluding any Diagnostics TSA Liabilities which arise from the fraud, wilful default or negligence of the Purchaser, any member of the Purchaser’s Group, and any
of their respective directors, officers and employees, or where the Purchaser has not used commercially reasonable endeavours to procure that the Vaccines Group complies with its obligations under the Diagnostics TSA). 

 

	8.14	Seller’s Licence under the Out-Licensing Programme 

 The Seller grants (and shall procure
the grant) to the Purchaser of a non-exclusive, irrevocable, royalty-free, non-assignable, sub-licensable licence of the Out-Licensing Programme Intellectual Property Rights solely for use in relation to the Business which shall be sub-licensable by
the Purchaser solely (i) to members of the Purchaser’s Group and (ii) to third parties working with it on the development of the Products. 
  

	9	Warranties 

  

	9.1	The Seller’s Warranties 

  

	 	9.1.1	Subject to Clause 9.2, the Seller warrants (on behalf of the relevant Business Sellers or Share Sellers as applicable) to the Purchaser and each member of the Purchaser’s Group to which Shares or other assets are
transferred pursuant to this Agreement or any Local Transfer Document, that the statements set out in Schedule 18 are true and accurate as of the date of this Agreement. 

  
  

 
 59 

	 	9.1.2	Each of the Seller’s Warranties shall be separate and independent and shall not be limited by reference to any other paragraph of Schedule 18 or by anything in this Agreement or any Local Transfer Document
or in the Tax Indemnity. 

  

	 	9.1.3	The Seller does not give or make any warranty as to the accuracy of the forecasts, estimates, projections, statements of intent or statements of opinion provided to the Purchaser or any of its directors,
officers, employees, agents or advisers on or prior to the date of this Agreement. 

  

	 	9.1.4	Any Seller’s Warranty qualified by the expression “so far as the Seller is aware” or to the “Seller’s Knowledge” or any similar expression shall, unless otherwise stated, be deemed
to refer to the knowledge of the following persons: [***], such persons having made due and reasonable enquiry. 

 

	 	9.1.5	The Seller’s Warranties shall be deemed to be repeated immediately before Closing by reference to the facts, circumstances and knowledge then existing as if references in the Seller’s Warranties to the date of
this Agreement were references to the Closing Date. Without prejudice to the provisions of Clause 10, the Seller shall have no liability for any breach of any Seller’s Warranty where such Seller’s Warranty was true as at the date of this
Agreement unless the fact, event or circumstances giving rise to the breach constitutes a Material Adverse Effect. The Seller shall have no liability under this Clause 9.1.4 if the Purchaser has exercised its termination right in accordance with
Clause 4.4.1(iv). 

  

	 	9.1.6	Save insofar as they are specifically referred to in paragraphs 4.4 and 4.5 of Schedule 18, none of the Seller’s Warranties shall apply to any of the Beta Interferon Patent Rights. 

 

	9.2	Seller’s Disclosures 

  

	 	9.2.1	The Seller’s Warranties are subject to all matters which are fairly disclosed in this Agreement or in the Disclosure Letter. 

  

	 	9.2.2	References in the Disclosure Letter to paragraph numbers shall be to the paragraphs in Schedule 18 to which the disclosure is most likely to relate. Such references are given for convenience only and, shall not limit
the effect of any of the disclosures, all of which are made against the Seller’s Warranties as a whole. 

  

	9.3	The Purchaser’s Warranties 

 The Purchaser warrants to the Seller that the statements set
out in Schedule 19 are true and accurate as of the date of this Agreement. 
  

 

	*** 	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
  

 
 60 

	10	Limitation of Liability 

  

	10.1	Application 

  

	 	10.1.1	In respect of the Tax Indemnity, the provisions of this Clause 10 shall operate to limit the liability of the Seller only in so far as any provision in this Clause 10 is expressed to be applicable to the Tax Indemnity,
and the provisions of the Tax Indemnity shall further operate to limit the liability of the Seller in respect of any claims thereunder. 

  

	 	10.1.2	References to the Seller’s Warranties in Clauses 10.2 to 10.5 and 10.7 to 10.9 shall not include the Tax Warranties and the provisions of clause 3 of the Tax Indemnity shall operate to limit the liability of the
Seller and to govern the claims procedure in respect of any claim under the Tax Warranties in respect of a liability for Tax as if such claim had been a claim in respect of a Tax Liability (as defined in the Tax Indemnity) under the Tax Indemnity.

  

	10.2	Time Limitation for Claims 

 The Seller shall not be liable under this Agreement or any Local
Transfer Document for breach of any Seller’s Warranty or under the Tax Indemnity in respect of any claim unless a notice of the claim is given by the Purchaser to the Seller specifying the matters set out in Clause 11.2: 

 

	 	10.2.1	in the case of a claim under paragraph 1, 2.1, 2.2.1, 2.2.3 or 2.3 of Schedule 18, within the applicable statutory limitation period; 

 

	 	10.2.2	in the case of any claim under paragraphs 4.1 to 4.10 of Schedule 18, within 6 years of Closing; 

  

	 	10.2.3	in respect of claims under the Tax Warranties or the Tax Indemnity, before the date falling six months after the expiry of the period specified by statute during which an assessment of the relevant liability to Tax may
be issued by the relevant Tax Authority; and 

  

	 	10.2.4	in the case of any other claim, within two years of Closing. 

  

	10.3	Minimum Claims 

  

	 	10.3.1	The Seller shall not be liable under: 

  

	 	(i)	this Agreement or any Local Transfer Document for breach of any Seller’s Warranty in respect of any individual claim (or a series of claims arising from similar or identical facts or circumstances) where the
liability agreed or determined (disregarding the provisions of this Clause 10.3) in respect of any such claim or series of claims does not exceed 0.1 per cent. of the Headline Price; or 

 

	 	(ii)	this Agreement for breach of any Tax Warranty or under the Tax Indemnity in respect of any individual claim (or series of claims arising from similar or identical facts or circumstances) where the liability agreed or
determined (disregarding the provisions of this Clause 10.3) in respect of any such claim or series of claims does not exceed US$1 million; 

  

	 	10.3.2	Where the liability agreed or determined in respect of any such claim or series of claims exceeds (in the case of claims falling within Clause 10.3.1(i)) 0.1 per cent. of the Headline Price or, in the case of
claims falling within Clause 10.3.1(ii))) US$1 million, the liability of the Seller shall be for the whole amount of such claim(s) and not just the excess. 

  
  

 
 61 

	10.4	Aggregate Minimum Claims 

  

	 	10.4.1	The Seller shall not be liable under this Agreement or any Local Transfer Document for breach of any Seller’s Warranty in respect of any claim unless the aggregate amount of all claims for which the Seller would
otherwise be liable under this Agreement or any Local Transfer Document for breach of any Seller’s Warranty (disregarding the provisions of this Clause 10.4) exceeds one per cent. of the Headline Price. 

 

	 	10.4.2	Where the liability agreed or determined in respect of all claims exceeds one per cent. of the Headline Price, the Seller shall be liable for the aggregate amount of all claims as agreed or determined and not just the
excess. 

  

	 	10.4.3	For the avoidance of doubt, the Purchaser may give notice of any single claim in accordance with and for the purposes of Clause 10.2, irrespective of whether, at the time the notice is given, the amount set out in
Clause 10.4.2 has been exceeded. 

  

	10.5	Maximum Liability 

 The aggregate liability of the Seller in respect of: 

 

	 	10.5.1	any breaches of the Seller’s Warranties (other than the Seller’s Warranties contained in paragraphs 1, 2.1, 2.2.1, 2.2.3, 2.3 or 4.1 to 4.10 of Schedule 18) shall not exceed an amount equal to 30 per
cent. of the Headline Price; 

  

	 	10.5.2	any breaches of the Seller’s Warranties contained in paragraphs 4.1 to 4.10 of Schedule 18 shall not exceed an amount equal to 60 per cent. of the Headline Price; and 

 

	 	10.5.3	any breaches of the Seller’s Warranties contained in paragraphs 1, 2.1, 2.2.1, 2.2.3, or 2.3 of Schedule 18 shall not exceed the Headline Price. 

 

	10.6	Contingent Liabilities 

 The Seller shall not be liable under this Agreement or any Local
Transfer Document for breach of any Seller’s Warranties in respect of which the liability is contingent, unless and until such contingent liability becomes an actual liability and is due and payable (but the Purchaser has the right under Clause
11.1 to give notice of such claim before such time). For the avoidance of doubt, the fact that the liability may not have become an actual liability by the relevant date provided in Clause 10.2 shall not exonerate the Seller in respect of any claim
properly notified before that date. 
  

	10.7	Provisions 

 The Seller shall not be liable under this Agreement or any Local Transfer Document,
in either case, in respect of any claim for breach of any Seller’s Warranty, if and to the extent that any allowance, provision or reserve has been properly made in the Closing Statement or Statement of Net Assets for the matter giving rise to
the claim and the Seller can demonstrate that the allowance, provision or reserve so made was in respect of such matter. 

  
  

 
 62 

	10.8	Matters Arising Subsequent to this Agreement 

 Subject to Clause 8.1.2, the Seller shall not be
liable under this Agreement or any Local Transfer Document in either case in respect of any claim for breach of any Seller’s Warranty in respect of any matter, act, omission or circumstance (or any combination thereof), to the extent that the
same would not have occurred but for: 
  

	 	10.8.1	Agreed matters 

 any matter or thing done or omitted to be done by the Seller or any
member of the Seller’s Group before Closing pursuant to and in compliance with this Agreement or any Local Transfer Document or otherwise at the request in writing of the Purchaser; or 

 

	 	10.8.2	Changes in legislation 

 the passing of, or any change in, after the Closing Date, any
Applicable Law or administrative practice of any government, governmental department, agency or regulatory body having the force of the law including (without prejudice to the generality of the foregoing) any increase in the rates of Taxation or any
imposition of Taxation or any withdrawal of relief from Taxation not in force at the Closing Date. 
  

	10.9	Insurance 

 Without prejudice to Clause 14, the Seller’s Liability under this Agreement for
breach of any Seller’s Warranty shall be reduced by an amount equal to any loss or damage to which such claim related which has actually been recovered under a policy of insurance held by the Purchaser or a Vaccines Group Company (after
deducting any reasonable costs incurred in making such recovery including the amount of any excess or deductible). 
  

	10.10	Purchaser’s Right to Recover 

 If the Seller has paid an amount in discharge of any claim
under this Agreement for breach of any Seller’s Warranty and subsequently the Purchaser recovers (whether by payment, discount, credit, relief, insurance or otherwise) from a third party a sum which indemnifies or compensates the Purchaser (in
whole or in part) in respect of the loss or liability which is the subject matter of the claim, the Purchaser shall pay to the Seller as soon as practicable after receipt an amount equal to (i) the sum recovered from the third party less any
costs and expenses incurred in obtaining such recovery and any Tax on any amounts recovered (or Tax that would have been payable on such amounts but for the availability of any Tax relief), or if less (ii) the amount previously paid by the
Seller to the Purchaser. Any payment made by the Purchaser to the Seller under this Clause shall be made or procured by way of further adjustment of the consideration paid by the Purchaser and the provisions of Clause 3.3 shall apply mutatis
mutandis. 
  

	10.11	No Double Recovery and no Double Counting 

 A party shall be entitled to make more than one
claim under this Agreement arising out of the same subject matter, fact, event or circumstance but shall not be entitled to recover under this Agreement or any Local Transfer Document or the Tax Indemnity or otherwise more than once in respect of
the same Losses suffered or amount for which the party is otherwise entitled to claim (or part of such Losses or amount), regardless of whether more than one claim arises in respect of it. No amount (including any relief) (or part of any amount)
shall be taken into account, set off or credited more than once under this Agreement or any Local Transfer Document or the Tax Indemnity or otherwise, with the intent that there will be no double counting under this Agreement or any Local Transfer
Document and the Tax Indemnity or otherwise. 

  
  

 
 63 

	10.12	Fraud 

 None of the limitations contained in this Clause 10 shall apply to any claim to the
extent that such claim which arises or is increased, or to the extent to which it arises or is increased, as the consequence of, or which is delayed as a result of, fraud by any director or officer of any member of the Seller’s Group. 

 

	11	Claims 

  

	11.1	Notification of Potential Claims 

 Without prejudice to the obligations of the Purchaser under
Clause 11.2, if the Purchaser becomes aware of any fact, matter or circumstance that may give rise to a claim against the Seller under this Agreement or any Local Transfer Document for breach of any Seller’s Warranty other than a Tax Warranty
(ignoring for these purposes the application of Clause 11.2 or 11.3), the Purchaser shall as soon as reasonably practicable give a notice in writing to the Seller of such facts, matters or circumstances as are then available regarding the potential
claim. Failure to give notice within such period shall not affect the rights of the Purchaser to make a relevant claim under this Agreement or any Local Transfer Document for breach of any Seller’s Warranty, except that the failure shall be
taken into account in determining the liability of the Seller for such claim to the extent the Seller establishes that the amount of it is increased, or is not reduced, as a result of such failure. 

 

	11.2	Notification of Claims under this Agreement 

 Notices of claims under this Agreement or any
Local Transfer Document for breach of any Seller’s Warranty (other than a Tax Warranty) shall be given by the Purchaser to the Seller within the time limits specified in Clause 10.2 and shall specify information (giving reasonable detail) in
relation to the basis of the claim and setting out the Purchaser’s estimate of the amount of Losses which are, or are to be, the subject of the claim. 
  

	11.3	Commencement of Proceedings 

 Any claim notified pursuant to Clause 11.2 shall (if it has not
been previously satisfied, settled or withdrawn) be deemed to be irrevocably withdrawn 9 months after the relevant time limit set out in Clause 10.2 unless, at the relevant time, legal proceedings in respect of the relevant claim have been commenced
by being both issued and served except: 
  

	 	11.3.1	where the claim relates to a contingent liability, in which case it shall be deemed to have been withdrawn unless legal proceedings in respect of it have been commenced by being both issued and served with 9 months of
it having become an actual liability; or 

  

	 	11.3.2	where the claim is a claim for breach of a Seller’s Warranty of which notice is given for the purposes of Clause 10.2 at a time when the amount set out in Clause 10.4.2 has not been exceeded, in which case it shall
be deemed to have been withdrawn unless legal proceedings in respect of it have been commenced by being both issued and served within 9 months of the date of any subsequent notification to the Seller pursuant to Clause 11.1 of one or more claims
which result(s) in the total amount claimed in all claims notified to the Seller pursuant to Clause 10.2 exceeding the amount set out in Clause 10.4.2 for the first time. 

  
  

 
 64 

	11.4	Conduct of Third Party Claims 

 If the matter or circumstance that may give rise to a claim
against the Seller under this Agreement or any Local Transfer Document for breach of any Seller’s Warranty (other than a Tax Warranty) is a result of or in connection with a claim by a third party (a “Third Party Claim”) then: 

 

	 	11.4.1	the Purchaser shall as soon as reasonably practicable give written notice thereof to the Seller and thereafter shall provide the Seller with periodic updates upon reasonable request and shall consult with the Seller so
far as reasonably practicable in relation to the conduct of the Third Party Claim and shall take reasonable account of the views of the Seller in relation to the Third Party Claim; 

 

	 	11.4.2	the Third Party Claim shall not be admitted, compromised, disposed of or settled without the written consent of the Seller (such consent not to be unreasonably withheld or delayed); and 

 

	 	11.4.3	subject to the Seller indemnifying the Purchaser or other member of the Purchaser’s Group concerned against all reasonable costs and expenses (including legal and professional costs and expenses) that may be
incurred thereby, the Purchaser shall, or the Purchaser shall procure that any other members of the Purchaser’s Group shall, take such action as the Seller may reasonably request to avoid, dispute, deny, defend, resist, appeal, compromise or
contest the Third Party Claim, provided that this Clause 11.4.3 shall not apply where the claim by the third party relates to matters or circumstances referred to in paragraph 4 or 9 of Schedule 18 and the Purchaser shall then have the right to
conduct the claim at its discretion (subject to Clauses 11.4.1 and 11.4.2), 

 provided that failure to give notice in
accordance with Clause 11.4.1 shall not affect the rights of the Purchaser to make a relevant claim under this Agreement for breach of any Seller’s Warranty, except that the failure shall be taken into account in determining the liability of
the Seller for such claim to the extent the Seller establishes that the amount of it is increased, or is not reduced, as a result of such failure. 
  

	12	Restrictive Covenants 

  

	12.1	Non-compete 

 The Seller will not, and undertakes to procure that each member of the
Seller’s Group will not, for the period from Closing until three years after the Closing Date: 
  

	 	12.1.1	be engaged (directly or indirectly) in any business which competes with the Business as it is carried on at the Closing Date (the “Restricted Business”), provided that commercial transactions outside the
Restricted Business with a client, customer, supplier, licensor or distributor that is not a member of the Seller’s Group shall not be deemed to indirectly violate this Clause 12.1.1 by reason of such person being engaged in the Restricted
Business or taking any other action prohibited hereunder; or 

  
  

 
 65 

	 	12.1.2	solicit the custom of any person to whom goods or services have been sold by any member of the Vaccines Group in the course of its business during the two years before the Closing Date, in each case only to the extent
that such solicitation is in competition with the Business of the Vaccines Group as it is carried on at the Closing Date. 

  

	12.2	Exceptions to the non-compete 

  

	 	12.2.1	The restrictions in Clause 12.1 shall not apply to: 

  

	 	(i)	the Specified Excluded Businesses; 

  

	 	(ii)	the Influenza Business; 

  

	 	(iii)	any activities of any nature undertaken or developed by the Seller’s Group (other than the Vaccines Group) in relation to oncology; 

 

	 	(iv)	any activities of any nature (or any assets related thereto) contributed by the Seller’s Group pursuant to the Consumer Contribution Agreement; 

 

	 	(v)	any supply agreements between the Seller’s Group (other than the Vaccines Group) and the Business, the Influenza Business or Leo Constellation Limited (or its Affiliates); 

 

	 	(vi)	any person at such time as it is no longer a member of the Seller’s Group, and any person that purchases assets, operations, subsidiaries or businesses from the Seller’s Group if such Person is not a member of
the Seller’s Group after such transaction is consummated; 

  

	 	(vii)	any Affiliate of Seller in which a person who is not a member of the Seller’s Group holds equity interests and with respect to whom a member of the Seller’s Group has existing contractual or legal obligations
limiting its discretion to impose non-competition obligations; 

  

	 	(viii)	the holding of shares in a company or other entity for investment purposes provided the Seller does not exercise, directly or indirectly, Control over that company or entity; 

 

	 	(ix)	any business activity that would otherwise violate Clause 12.1 that is acquired in connection with an acquisition so long as the relevant member of the Seller’s Group divests all or substantially all of the
business activity that would otherwise violate Clause 12.1 or otherwise terminates or disposes of such business activity, product line or assets of such acquired business that would otherwise violate Clause 12.1 within nine months after the
consummation of the relevant acquisition, or such longer period as may reasonably be necessary to comply with Applicable Law (provided that in those circumstances the Seller shall procure that the Restricted Business is disposed of as soon as
reasonably practicable); 

  

	 	(x)	passive investments by a pension or employee benefit plan or trust for present or former employees; 

  

	 	(xi)	financial investments by the Novartis Venture Funds; 

  
  

 
 66 

	 	(xii)	investments by the Novartis Foundation for Sustainable Development, or a similar non-profit-based organization; 

  

	 	(xiii)	performance of any obligation of the Seller’s Group under the Transaction Documents, as amended from time to time in accordance with its their terms; or 

 

	 	(xiv)	provision of data or other content to or in connection with business conducted by any person, in each case as required by Applicable Law. 

 

	12.3	Non-solicit 

 The Seller will not, and undertakes to procure that each member of the
Seller’s Group will not, for a period of two years after the Closing Date, solicit or induce any Restricted Vaccines Group Employee to become employed or engaged whether as employee, consultant or otherwise by any member of the Seller’s
Group. 
  

	12.4	Exceptions to the non-solicit 

 The restrictions in Clause 12.3 shall not apply to the
solicitation, inducement or recruitment of any person: 
  

	 	12.4.1	through the placing of advertisements of posts available to the public generally; 

  

	 	12.4.2	through an employment agency, provided that no member of the Seller’s Group encourages or advises such agency to approach any such person; or 

 

	 	12.4.3	who is no longer employed by the Purchaser’s Group. 

  

	12.5	Reasonableness of Restrictions 

 Each undertaking contained in this Clause 12 shall be construed
as a separate undertaking and if one or more of the undertakings is held to be against the public interest or unlawful or in any way an unreasonable restraint of trade, the remaining undertakings shall continue to bind the Seller. 

 

	12.6	Definitions 

 For the purposes of this Clause: 

“Restricted Vaccines Group Employee” means any Transferred Employee who has access to trade secrets or other confidential
information of the Vaccines Group with an annual basic salary in excess of US$150,000; and 
 “Specified Excluded
Businesses” means the businesses and activities of: (i) Roche Holding AG and (ii) Novartis Institutes for BioMedical Research (and other activities of a similar type to those currently conducted by Novartis Institutes for
BioMedical Research). 
  

	13	Confidentiality 

  

	13.1	Announcements 

 No announcement, communication or circular concerning the existence or the
subject matter of this Agreement shall be made or issued by or on behalf of any member of the Seller’s Group or the Purchaser’s Group without the prior written approval of the Seller and the Purchaser (such consent not to be unreasonably
withheld or delayed). This shall not affect any announcement, communication or circular required by law or any governmental or regulatory body or the rules of any stock exchange on which the shares of any party (or its holding company) are listed
but the party with an obligation to make an announcement or communication or issue a circular (or whose holding company has such an obligation) shall consult with the other parties (or shall procure that its holding company consults with the other
parties) insofar as is reasonably practicable before complying with such an obligation. 

  
  

 
 67 

	13.2	Confidentiality 

  

	 	13.2.1	Subject to Clause 13.1 and Clause 13.2.2, each of the parties shall treat as strictly confidential and not disclose or use any information received or obtained as a result of entering into this Agreement, the Ancillary
Agreements or any agreement entered into pursuant to this Agreement which relates to: 

  

	 	(i)	the existence and provisions of this Agreement, the Ancillary Agreements and of any other agreement entered into pursuant to this Agreement; or 

 

	 	(ii)	the negotiations relating to this Agreement, the Ancillary Agreements and any such other agreement. 

  

	 	(iii)	(in the case of the Seller) any information relating to the Vaccines Group Companies and Vaccines Group Businesses following Closing and any other information relating to the business, financial or other affairs
(including future plans and targets) of the Purchaser’s Group. 

  

	 	(iv)	(in the case of the Purchaser) any information relating to the business, financial or other affairs (including future plans and targets) of the Seller’s Group including, prior to Closing, the Vaccines Group
Companies and Vaccines Group Businesses. 

  

	 	13.2.2	Clause 13.2.1 shall not prohibit disclosure or use of any information if and to the extent: 

  

	 	(i)	the disclosure or use is required by law, any governmental or regulatory body or any stock exchange on which the shares of any party (or its holding company) are listed; 

 

	 	(ii)	the disclosure or use is required to vest the full benefit of this Agreement or the Ancillary Agreements in any party; 

  

	 	(iii)	the disclosure or use is required for the purpose of any arbitral or judicial proceedings arising out of this Agreement, the Ancillary Agreements or any other agreement entered into under or pursuant to this Agreement
or to enable a determination to be made by the Reporting Accountants under this Agreement; 

  

	 	(iv)	the disclosure is made to a Tax Authority in connection with the Tax affairs of the disclosing party; 

  

	 	(v)	the disclosure is made to a ratings agency on a confidential basis in connection with the affairs of the disclosing party; 

  

	 	(vi)	the disclosure is made to professional advisers of any party on a need to know basis and on terms that such professional advisers undertake to comply with the provisions of Clause 13.2.1 in respect of such information
as if they were a party to this Agreement; 

  
  

 
 68 

	 	(vii)	the information was lawfully in the possession of that party without any obligation of secrecy prior to its being received or held, in either case as evidenced by written records; 

 

	 	(viii)	the information is or becomes publicly available (other than by breach of this Agreement); 

  

	 	(ix)	the other party has given prior written approval to the disclosure or use; or 

  

	 	(x)	the information is independently developed, 

 provided that prior to disclosure or use of any
information pursuant to Clause 13.2.2(i), (ii) or (iii), the party concerned shall, where not prohibited by law, promptly notify the other parties of such requirement with a view to providing the other parties with the opportunity to contest such
disclosure or use or otherwise to agree the timing and content of such disclosure or use. 
  

	14	Insurance 

  

	14.1	No cover under Seller’s Group Insurance Policies from Closing 

 The Purchaser acknowledges
and agrees that following Closing: 
  

	 	14.1.1	neither the Purchaser nor any Vaccines Group Company shall have or be entitled to the benefit of any Seller’s Group Insurance Policy in respect of any event, act or omission that takes place after Closing and it
shall be the sole responsibility of the Purchaser to ensure that adequate insurances are put in place for those Vaccines Group Companies and Vaccines Group Businesses with effect from Closing; 

 

	 	14.1.2	neither the Seller nor any member of the Seller’s Group shall be required to maintain any Seller’s Group Insurance Policy for the benefit of the Vaccines Group; 

 

	 	14.1.3	no Vaccines Group Company shall make or shall be entitled to make or notify a claim under any Seller’s Group Insurance Policy in respect of any event, act or omission that occurred prior to the Closing Date.

  

	14.2	Existing claims under Seller’s Group Insurance Policies 

 With respect to any claim made
before the Closing Date under any Seller’s Group Insurance Policy by or on behalf of any Vaccines Group Company or in relation to any Vaccines Group Business, to the extent that: 

 

	 	14.2.1	neither the Purchaser nor the Vaccines Group Companies have been indemnified by the Seller prior to the Closing Date in respect of the matter in respect of which the claim was made; or 

 

	 	14.2.2	the Liability in respect of which the claim was made has not been properly provided for in the Closing Statement and reduced the Working Capital accordingly, 

the Seller shall use reasonable endeavours after Closing to recover all monies due from insurers and shall pay any monies received (after
taking into account any deductible under the Seller’s Group Insurance Policies and less any Taxation suffered on the proceeds and any reasonable out of pocket expenses suffered or incurred by the Seller or any member of the Seller’s Group
in connection with the claim) to the Purchaser or, at the Purchaser’s written direction, the relevant Vaccines Group Company as soon as practicable after receipt. 

  
  

 
 69 

	15	France Business and Netherlands Business 

  

	15.1	France Business 

 Notwithstanding any other provision of this Agreement, this Agreement shall
not constitute a binding agreement to sell or purchase the France Business, provided that: 
  

	 	15.1.1	in the event that the France Put Option Exercise occurs before Closing, this Clause 15.1 (other than this Clause 15.1.1) shall terminate and shall cease to have effect, and the sale of the France Business shall be
subject to the provisions of this Agreement as if it were part of the Business to be sold as and from the date of this Agreement; 

  

	 	15.1.2	in the event that the France Put Option Exercise does not occur before Closing: 

  

	 	(i)	the provisions of Clauses 2 and 6 (the “Disapplied Provisions”) shall not apply to the France Business; 

  

	 	(ii)	prior to the France Closing, the provisions of Clause 12 and Schedules 11 and 12 (the “Suspended Provisions”) shall not apply to the France Business; and 

 

	 	(iii)	in respect of the Disapplied Provisions and, prior to the France Closing, the Suspended Provisions only: 

  

	 	(a)	the term “Business” shall be deemed to exclude the France Business; 

  

	 	(b)	the term “Companies” shall be deemed to exclude Novartis Vaccines and Diagnostics S.A.S.; 

  

	 	(c)	the term “Assumed Liabilities” shall be deemed to exclude the France Assumed Liabilities; and 

  

	 	(d)	the term “Employees” shall be deemed to exclude the France Employees; 

  

	 	15.1.3	with effect from the France Closing, the Suspended Provisions shall apply to the France Business mutatis mutandis save that in respect of the Suspended Provisions only (A) the term “Closing”
shall be deemed to refer to the France Closing and (B) the term “Closing Date” shall be deemed to refer to the date of the France Closing; and 

  

	 	15.1.4	the parties shall negotiate in good faith to agree any amendments to this Agreement and any of the Ancillary Agreements as are required in order to give effect to the principles set forth in this Clause 15.1 for the
purposes of complying with the information and consultation requirements in respect of the Comité d’enterprise de Novartis Vaccines and Diagnostics SAS (being the relevant works council in respect of the France Business); and

  

	 	15.1.5	the provisions of Clause 10 shall apply to the France Business as if the remaining provisions of this Clause 15.1 did not have any force or effect. 

  
  

 
 70 

	15.2	Netherlands Business 

 Notwithstanding any other provision of this Agreement, this Agreement
shall not constitute a binding agreement to sell or purchase the Netherlands Business, provided that: 
  

	 	15.2.1	in the event that the Netherlands Put Option Exercise occurs before Closing, this Clause 15.2 (other than this Clause 15.2.1) shall terminate and shall cease to have effect, and the sale of the Netherlands Business
shall be subject to the provisions of this Agreement as if it were part of the Business to be sold as and from the date of this Agreement; 

  

	 	15.2.2	in the event that the Netherlands Put Option Exercise does not occur before Closing: 

  

	 	(i)	the Disapplied Provisions shall not apply to the Netherlands Business; 

  

	 	(ii)	prior to the Netherlands Closing, the Suspended Provisions shall not apply to the Netherlands Business; and 

  

	 	(iii)	in respect of the Disapplied Provisions and, prior to the Netherlands Closing, the Suspended Provisions only: 

  

	 	(a)	the term “Business” shall be deemed to exclude the Netherlands Business; 

  

	 	(b)	the term “Vaccines Group Businesses” shall be deemed to exclude the Netherlands Business; 

  

	 	(c)	the term “Assumed Liabilities” shall be deemed to exclude the Netherlands Assumed Liabilities; and 

  

	 	(d)	the term “Employees” shall be deemed to exclude the Netherlands Employees; 

  

	 	15.2.3	with effect from the Netherlands Closing, the Suspended Provisions shall apply to the Netherlands Business mutatis mutandis save that in respect of the Suspended Provisions only (A) the term
“Closing” shall be deemed to refer to the Netherlands Closing and (B) the term “Closing Date” shall be deemed to refer to the date of the Netherlands Closing; and 

 

	 	15.2.4	the parties shall negotiate in good faith to agree any amendments to the Transaction Documents as are required in order to give effect to the principles set forth in this Clause 15.2 for the purposes of complying with
the information and consultation requirements in respect of Onderdeelcommissie NV (being the relevant works council in respect of the Netherlands Business); and 

  

	 	15.2.5	the provisions of Clause 10 shall apply to the Netherlands Business as if the remaining provisions of this Clause 15.2 did not have any force or effect. 

 

	16	Other Provisions 

  

	16.1	Further Assurances 

  

	 	16.1.1	Without prejudice to any restriction or limitation on the extent of any party’s obligations under this Agreement, each of the parties shall from time to time, so far as each is reasonably able, do or procure the
doing of all such acts and/or execute or procure the execution of all such documents in a form reasonably satisfactory to the party concerned as they may reasonably consider necessary to transfer the Vaccines Group to the Purchaser or otherwise to
give the other party the full benefit of this Agreement. 

  
  

 
 71 

	 	16.1.2	The parties shall negotiate in good faith to agree definitive and legally binding documentation in respect of each of the Ancillary Agreements for which heads of terms are in the Agreed Terms on the date of this
Agreement, and shall duly execute and deliver such definitive and legally binding documentation in respect of the Ancillary Agreements at Closing. 

  

	16.2	Whole Agreement 

  

	 	16.2.1	This Agreement and the Ancillary Agreements contain the whole agreement between the parties relating to the subject matter of this Agreement at the date hereof to the exclusion of any terms implied by law which may be
excluded by contract and supersedes any previous written or oral agreement between the parties in relation to the matters dealt with in this Agreement. 

  

	 	16.2.2	The Purchaser acknowledges that, in entering into this Agreement, it is not relying on any representation, warranty or undertaking not expressly incorporated into it. 

 

	 	16.2.3	Each of the parties agrees and acknowledges that its only right and remedy in relation to any representation, warranty or undertaking made or given in connection with this Agreement shall be for breach of the terms of
this Agreement and each of the parties waives all other rights and remedies (including those in tort or arising under statute) in relation to any such representation, warranty or undertaking. 

 

	 	16.2.4	In Clauses 16.2.1 to 16.2.3, “this Agreement” includes the Ancillary Agreements and all other documents entered into pursuant to this Agreement. 

 

	 	16.2.5	Nothing in this Clause 16.2 excludes or limits any liability for fraud. 

  

	16.3	No Assignment 

 No party may without the prior written consent of the other parties, assign,
grant any security interest over, hold on trust or otherwise transfer the benefit of the whole or any part of this Agreement. 
  

	16.4	Third Party Rights 

  

	 	16.4.1	Subject to Clause 16.4.2, the parties to this Agreement do not intend that any term of this Agreement should be enforceable, by virtue of the Contracts (Rights of Third Parties) Act 1999, by any person who is not a
party to this Agreement. 

  

	 	16.4.2	Certain provisions of this Agreement confer benefits on the Affiliates of the Purchaser and the Affiliates of the Seller (each such Affiliate being, for the purposes of this Clause 16.4, a “Third
Party”) and, subject to Clause 16.4.3, are intended to be enforceable by each Third Party by virtue of the Contracts (Rights of Third Parties) Act 1999. 

  

	 	16.4.3	Notwithstanding Clause 16.4.2, this Agreement may be varied in any way and at any time without the consent of any Third Party. 

  
  

 
 72 

	16.5	Variation or waiver 

  

	 	16.5.1	No variation of this Agreement shall be effective unless in writing and signed by or on behalf of each of the parties. 

  

	 	16.5.2	No failure or delay by a party in exercising any right or remedy provided by Applicable Law or under this Agreement or any Ancillary Agreement shall impair such right or remedy or operate or be construed as a waiver or
variation of it or preclude its exercise at any subsequent time and no single or partial exercise of any such right or remedy shall preclude any further exercise of it or the exercise of any other remedy. 

 

	16.6	Method of Payment and set off 

  

	 	16.6.1	Except as set out in Clause 16.6.2, payments (including payments pursuant to an indemnity, compensation or reimbursement provision) made or expressed to be made by the Purchaser and the Seller pursuant to this Agreement
or any claim for breach of this Agreement shall, insofar as the payment or claim relates to or affects any Shares (including the underlying Vaccines Group Companies transferred (directly or indirectly) by reason of the transfer of those Shares),
assets or liabilities, transferred pursuant to this Agreement and the Local Transfer Documents, be made or received (as the case may be) by: 

  

	 	(i)	the Seller, for itself or as agent on behalf of the relevant Share Seller or the Business Seller (each in respect of the Shares and/or assets and liabilities to be transferred by it pursuant to this Agreement and the
Local Transfer Documents); and 

  

	 	(ii)	the Purchaser, for itself or as agent on behalf of the relevant members of the Purchaser’s Group (each in respect of Shares and/or the assets and liabilities to be transferred by it pursuant to this Agreement and
the Local Transfer Documents). 

  

	 	16.6.2	The repayment of the Estimated Intra-Group Non-Trade Receivables and the Estimated Intra-Group Non-Trade Payables pursuant to Clause 6.4.3 and any adjustments to such repayment pursuant to Clause 7.4 shall be
settled by payments between the Seller, on behalf of the relevant members of the Seller’s Group, and the Purchaser, on behalf of the relevant Group Companies. 

 

	 	16.6.3	Any payments pursuant to this Agreement shall be made in full, without any set-off, counterclaim, restriction or condition and without any deduction or withholding (save as may be required by law or as otherwise
agreed), except that payments due between the Seller and the Purchaser: 

  

	 	(i)	in relation to repayments of the Estimated Intra-Group Non-Trade Payables and Estimated Intra-Group Non-Trade Receivables pursuant to Clause 6.4.3; or 

 

	 	(ii)	in relation to adjustments to those repayments pursuant to Clause 7.4, 

 respectively, shall be
discharged to the fullest extent possible by way of set-off against each other. 
  

	 	16.6.4	Any payments pursuant to this Agreement shall be effected by crediting for same day value the account specified by the Seller or the Purchaser (as the case may be) on behalf of the party entitled to the payment
(reasonably in advance and in sufficient detail to enable payment by telegraphic or other electronic means to be effected) on or before the due date for payment. 

  
  

 
 73 

	 	16.6.5	Payment of a sum in accordance with this Clause 16.6 shall constitute a payment in full of the sum payable and shall be a good discharge to the payer (and those on whose behalf such payment is made) of the payer’s
obligation to make such payment and the payer (and those on whose behalf such payment is made) shall not be obliged to see to the application of the payment as between those on whose behalf the payment is received. 

 

	16.7	Costs 

  

	 	16.7.1	Subject to Clause 16.8, the Seller shall bear all costs incurred by it and its Affiliates in connection with the preparation and negotiation of, and the entry into, this Agreement, the Local Transfer Documents, the Tax
Indemnity and the sale of the Vaccines Group. 

  

	 	16.7.2	The Purchaser shall bear all such costs incurred by it and its Affiliates in connection with the preparation and negotiation of, and the entry into, this Agreement, the Local Transfer Documents, the Tax Indemnity
and the purchase of the Vaccines Group. 

  

	16.8	Notarial Fees, Registration, Stamp and Transfer Taxes and Duties 

  

	 	16.8.1	Subject to Clauses 2.3.5, 2.3.6 and 16.8.2, the Purchaser or the relevant member of the Purchaser’s Group: 

  

	 	(i)	shall bear the cost half of all notarial fees and all registration, stamp and transfer taxes and duties or their equivalents in all jurisdictions where such fees, taxes and duties are payable as a result of the
transactions contemplated by this Agreement the other half of such cost to be borne by the Seller; 

  

	 	(ii)	shall be responsible for arranging the payment of all such fees, taxes and duties, including fulfilling any administrative or reporting obligation imposed by the jurisdiction in question in connection with such payment;
and 

  

	 	(iii)	shall indemnify the Sellers or any other member of the Seller’s Group against any Losses suffered by that Seller or member of the Seller’s Group as a result of the Purchaser failing to comply with its
obligations under this Clause 16.8. 

  

	 	16.8.2	The Purchaser and the Seller shall make or procure the making of such payments to each other (and to each other’s Affiliates) as are necessary to ensure the sharing of cost provided for under Clause 16.8.1.

  

	16.9	Interest 

 If any party defaults in the payment when due of any sum payable under this
Agreement, the Local Transfer Documents or the Tax Indemnity the liability of that party shall be increased to include interest on such sum from the date when such payment is due until the date of actual payment (as well after as before judgment) at
a rate per annum of two per cent. above LIBOR. Such interest shall accrue from day to day. 

  
  

 
 74 

	16.10	Grossing-up 

  

	 	16.10.1	All sums payable under this Agreement, the Local Transfer Documents and the Tax Indemnity shall be paid free and clear of all deductions, withholdings, set-offs or counterclaims whatsoever save only as may be permitted
by Clause 16.6.3 or required by law. Subject to Clauses 16.10.3 to 16.10.7 if any deductions or withholdings are required by law the party making the payment shall (except in the case of (i) any interest payable under Clause 7.5 or 16.9
(ii) or any amount payable under Schedule 17 which would not have been the subject of a deduction or withholding had it been paid to a company resident in Switzerland for the purposes of the double taxation treaty between Belgium and
Switzerland which was beneficially entitled to the payments and was not party to a conduit arrangement in respect of them) be obliged to pay to the other party such sum as will after such deduction or withholding has been made leave the other party
with the same amount as it would have been entitled to receive in the absence of any such requirement to make a deduction or withholding, provided that if either party to this Agreement shall have assigned or novated the benefit in whole or in part
of this Agreement or shall, after the date of this Agreement, have changed its tax residence or the permanent establishment to which the rights under this Agreement are allocated then the liability of the other party under this Clause 16.10.1 shall
be limited to that (if any) which it would have been had no such assignment, novation or change taken place. 

  

	 	16.10.2	If either party is or becomes aware of any facts making it reasonably likely that the Purchaser, or any relevant member of the Purchaser’s Group, will be required to deduct or withhold any amount in respect of the
Purchase Price (excluding any amount payable under Schedule 17) (a “Relevant Tax Deduction”), then that party shall, as soon as reasonably practicable, give notice to the other party (including details of the relevant facts and, so
far as possible, details of the rate and basis of such withholding) provided that for purposes of this Clause 16.10.2, the Seller may assume that the Purchase Price will be paid by (and for) a company resident for Tax purposes only in Belgium.

  

	 	16.10.3	The Seller and the Purchaser shall, and shall procure that the members of their respective groups shall (at the Seller’s cost), co-operate with each other in good faith and use all reasonable efforts to reduce or
mitigate any Relevant Tax Deduction (or its amount) and/or to enable the Seller or the relevant Share Seller or Business Seller to obtain any available credit or refund in respect of such Relevant Tax Deduction, including, without limitation, making
any available claim under an applicable double taxation treaty. 

  

	 	16.10.4	Without prejudice to the generality of Clause 16.10.3, the Seller and the Purchaser shall co-operate in good faith to establish or agree the amount or basis of calculation of any Relevant Tax Deduction prior to Closing
(and in this regard the Purchaser shall consider reasonably any relevant information or evidence provided or obtained by the Seller) including, if requested by the Seller and at the Seller’s expense, by seeking to obtain a ruling or
confirmation from a relevant Tax Authority, or obtaining an opinion from reputable local tax counsel or a firm of accountants of international standing satisfactory to the Purchaser (acting reasonably) and instructed jointly by the Seller and the
Purchaser. 

  
  

 
 75 

	 	16.10.5	The Purchaser shall, or shall procure that the relevant member of the Purchaser’s Group shall, make any Relevant Tax Deduction in the minimum amount required by Applicable Law, provided that: 

 

	 	(i)	if a double taxation treaty between the jurisdiction under the laws of which the Relevant Tax Deduction is required and the jurisdiction of residence of the Seller or the relevant Share Seller or Business Seller is in
force, the Purchaser shall (and shall procure that any relevant member of the Purchaser’s Group shall) make any Relevant Tax Deduction in an amount not exceeding the rate specified in such double taxation treaty (which may be nil), provided
that the Seller has provided the Purchaser with such evidence as is required under Applicable Law to establish the entitlement of the Seller (or relevant Share Seller or Business Seller) to the benefit of the applicable treaty; and

  

	 	(ii)	if an opinion from reputable local counsel or a firm of accountants of international standing has been obtained at the request of the Seller as envisaged by Clause 16.10.4, the Purchaser shall (and shall procure that
any relevant member of the Purchaser Group shall) make such Relevant Tax Deduction in an amount or on a basis which is consistent with that opinion (which may result in no withholding or deduction), provided that the Seller has indemnified the
Purchaser and any relevant member of the Purchaser’s Group, to the Purchaser’s reasonable satisfaction, against any Liabilities arising (including any interest and penalties) should such opinion be wholly or partly incorrect.

  

	 	16.10.6	The Purchaser shall promptly provide the Seller with evidence reasonably satisfactory to the Seller that a Relevant Tax Deduction has been made and an appropriate amount paid to the relevant Tax Authority.

  

	 	16.10.7	If any Relevant Tax Deduction is required an additional sum shall be payable in accordance with Clause 16.10.1 only if and to the extent that such deduction or withholding would not have been required had the Purchaser
and each member of the Purchaser’s Group making such payment or to which such payment relates been resident for Tax purposes only in Belgium. 

  

	16.11	Notices 

  

	 	16.11.1	Any notice or other communication in connection with this Agreement (each, a “Notice”) shall be: 

  

	 	(i)	in writing in English; and 

  

	 	(ii)	delivered by hand, fax, or by courier using an internationally recognised courier company. 

  

	 	16.11.2	A Notice to the Seller shall be sent to such party at the following address, or such other person or address as the Seller may notify to the Purchaser from time to time: 

Novartis AG 
 Postfach 

CH-4002 Basel 
 Switzerland 

  
  

 
 76 

 Fax: +41 613244300 

Attention: Head of M&A Legal 

with a copy to the Seller’s Lawyers, marked for the urgent attention of James Inglis (delivery of such copy shall not in itself
constitute valid notice). 
  

	 	16.11.3	A Notice to the Purchaser shall be sent to such party at the following address, or such other person or address as the Purchaser may notify to the Seller from time to time: 

GlaxoSmithKline plc 
 980 Great
West Road 
 Brentford 

Middlesex TW8 9GS 
 United
Kingdom 
 Fax: +44 (0)208 0476904 

Attention: The Company Secretary 

with a copy to the Purchaser’s Lawyers, marked for the urgent attention of Simon Nicholls (delivery of such copy shall not in itself
constitute valid notice). 
  

	 	16.11.4	A Notice shall be effective upon receipt and shall be deemed to have been received: 

  

	 	(i)	at the time of delivery, if delivered by hand or courier; 

  

	 	(ii)	at the time of transmission in legible form, if delivered by fax. 

  

	16.12	Invalidity or Conflict 

  

	 	16.12.1	If any provision in this Agreement shall be held to be illegal, invalid or unenforceable, in whole or in part, the provision shall apply with whatever deletion or modification is necessary so that the provision
is legal, valid and enforceable and gives effect to the commercial intention of the parties. 

  

	 	16.12.2	To the extent it is not possible to delete or modify the provision, in whole or in part, under Clause 16.12.1, then such provision or part of it shall, to the extent that it is illegal, invalid or unenforceable,
be deemed not to form part of this Agreement and the legality, validity and enforceability of the remainder of this Agreement shall, subject to any deletion or modification made under Clause 16.12.1, not be affected. 

 

	 	16.12.3	If there is any conflict between the terms of this Agreement and any of the Ancillary Agreements this Agreement shall prevail (as between the parties between this Agreement and as between any member of the Seller
Group and any member of the Purchaser Group) unless (i) such Ancillary Agreement expressly states that it overrides this Agreement in the relevant respect and (ii) the Seller and the Purchaser are either also parties to that Ancillary
Agreement or otherwise expressly agree in writing that such Ancillary Agreement shall override this Agreement in that respect. 

  
  

 
 77 

	16.13	Counterparts 

 This Agreement may be entered into in any number of counterparts, all of
which taken together shall constitute one and the same instrument. Any party may enter into this Agreement by executing any such counterpart. Delivery of a counterpart of this Agreement by email attachment shall be an effective mode of delivery.

  

	16.14	Governing Law and Submission to Jurisdiction 

  

	 	16.14.1	This Agreement and the documents to be entered into pursuant to it, save as expressly referred to therein, and any non-contractual obligations arising out of or in connection with the Agreement and such documents
shall be governed by and construed in accordance with English law. 

  

	 	16.14.2	Each of the parties irrevocably agrees that the courts of England and Wales are to have exclusive jurisdiction to settle any dispute which may arise out of or in connection with this Agreement and the documents
to be entered into pursuant to it, save as expressly referred to therein, and that accordingly any proceedings arising out of or in connection with this Agreement and the documents to be entered into pursuant to it shall be brought in such courts.
Each of the parties irrevocably submits to the jurisdiction of such courts and waives any objection to proceedings in any such court on the ground of venue or on the ground that proceedings have been brought in an inconvenient forum.

  

	16.15	Appointment of Process Agent 

  

	 	16.15.1	The Seller hereby irrevocably appoints Hackwood Secretaries Limited of One Silk Street, London EC2Y 8HQ as its agent to accept service of process in England and Wales in any legal action or proceedings arising
out of this Agreement, service upon whom shall be deemed completed whether or not forwarded to or received by the Seller. 

  

	 	16.15.2	The Seller agrees to inform the Purchaser in writing of any change of address of such process agent within 28 days of such change. 

 

	 	16.15.3	If such process agent ceases to be able to act as such or to have an address in England and Wales, the Seller irrevocably agrees to appoint a new process agent in England and Wales and to deliver to the Purchaser
within 14 days a copy of a written acceptance of appointment by the process agent. 

  

	 	16.15.4	Nothing in this Agreement shall affect the right to serve process in any other manner permitted by law. 

This Agreement has been entered into on the date stated at the beginning. 

  
  

 
 78 

			
	 SIGNED by
  

 
 AND
		 }

		
	 for and on behalf of

NOVARTIS AG:
		
	
	 SIGNED by
  

for and on behalf of

GLAXOSMITHKLINE PLC:

  
  

 
 79 

 Schedule 1 

Details of the Share Sellers, Shares etc. 

(Clause 2.1) 
  

					
	(1)	  	(2)	  	(3)
	Name
of Share Seller	  	Name of
Company/Minority Interest
Entity	  	Shares
			
	Novartis Deutschland GmbH	  	Novartis Vaccines and Diagnostics GmbH	  	2 shares (100%)
			
	Novartis Pharma AG	  	Novartis Vaccines and Diagnostics S.A.S	  	93,750 shares (100%)
			
	Novartis Farmaceutica S.A	  	Novartis Vaccines and Diagnostics S.L	  	150,100 shares (100%)
			
	Novartis Pharma AG	  	Novartis Vaccines and Diagnostics AG	  	1,600 shares (100%)
			
	Novartis Pharma AG	  	Novartis Vaccines and Diagnostics S.r.l.	  	1 quota of entire share capital (as defined under Italian law) (100%)
			
	Novartis Pharma AG	  	Novartis Vaccines and Diagnostics Pty Ltd	  	1,024,921 shares (100%)
			
	 (A) Novartis Pharma AG
 (B) Novartis Vaccines
and Diagnostics Inc.
	  	Chiron Behring Vaccines Private Limited	  	 (A) 4,900,000 shares (49%)
 (B) 5,100,000
shares (51%)
 TOTAL: 10,000,000 shares

			
	Novartis Overseas Investments AG	  	Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd	  	85%
			
	Novartis Pharma AG	  	Novartis Vaccines Institute for Global Health S.r.l.	  	1 quota of entire share capital (as defined under Italian law) (100%)
			
	(A) Novartis Pharma AG	  	Valneva SE	  	(A) 3,788,048 (6.63%)
			
	(B) Novartis Vaccines and Diagnostics Inc.	  		  	(B) 1,560,000 (2.73%)

  
  

 
 80 

 Schedule 2 

Companies, Subsidiaries and Minority Interest Entities 
  

	2	Particulars of the Companies 

  

					
	Name of Company:		Novartis Vaccines and Diagnostics GmbH
		
	Registered Number:		HRB 5629
		
	Registered Office:		Emil-von-Behring-Str. 76, 35041 Marburg, Germany
		
	Date and place of incorporation:		
		
	Issued share capital:		EUR 5,000,000.00 divided into 2 shares of 1 EUR and EUR 4,999,999 each
			
	Shareholders and shares held:		Novartis Deutschland GmbH		2 (100%)
		
	Name of Company:		Novartis Vaccines and Diagnostics SAS
		
	Registered Number:		423 697 168
		
	Registered Office:		10, rue Chevreul, 92150 Suresnes, France
		
	Date and place of incorporation:		22 July 1999, Nanterre
		
	Issued share capital:		EUR 1,500,000 divided into 93,750 shares of EUR 16 each
			
	Shareholders and shares held:		Novartis Pharma AG		93,750
					(100%)
		
	Name of Company:		Novartis Vaccines and Diagnostics S.L.
		
	Registered Number:		B58564808
		
	Registered Office:		Gran Vía de les Corts Catalanes, 764. 08013 Barcelona, Spain
		
	Date and place of incorporation:		19 September 1988, Barcelona
		
	Issued share capital:		EUR 675,450 divided into 150,100 shares of EUR 4.50 each
			
	Shareholders and shares held:		Novartis Farmaceutica S.A		150,100
					(100%)

  
  

 
 81 

					
	Name of Company:		Novartis Vaccines and Diagnostics AG
		
	Registered Number:		CHE-103.264.079
		
	Registered Office:		Basel, Switzerland
		
	Date and place of incorporation:		28 September 1953, Avenches
		
	Issued share capital:		CHF 800,000.00 divided into 1,600 shares of CHF 500 each
			
	Shareholders and shares held:		Novartis Pharma AG		1,600
shares
(100%)
		
	Name of Company:		Novartis Vaccines and Diagnostics S.r.l.
		
	Registered Number:		01392770465
		
	Registered Office:		Via Fiorentina 1, 53100, Siena, Italy
		
	Date and place of incorporation:		18 September 1990, Barga (LU)
		
	Issued share capital:		EUR 41,610,809.00 comprising 1 quota of entire share capital
			
	Shareholders and shares held:		Novartis Pharma AG		1 (100%)
		
	Name of Company:		Novartis Vaccines and Diagnostics Pty Limited
		
	ABN / ACN:		ABN 60 089 509 544; ACN 089 509 544
		
	Registered Office:		54 Waterloo Road, North Ryde NSW 2113, Australia
		
	Date and place of incorporation:		10 September 1999, Victoria
		
	Issued share capital:		ASD 1,024,921 divided into 1,024,921 shares of ASD 1 each
			
	Shareholders and shares held:		Novartis Pharma AG		1,024,921
					(100%)
		
	Name of Company:		Chiron Behring Vaccines Private Limited
		
	Registered Number:		U24230MH1997PTC111122
		
	Registered Office:		501 Shree Amba Shanti Chambers, Kurla Road, Andheri, Mumbai 400059, India
		
	Date and place of incorporation:		7 October 1997, Mumbai

  
  

 
 82 

					
	Name of Company:		Chiron Behring Vaccines Private Limited
		
	Issued share capital:		INR 100,000,000 divided into 10,000,000 shares of INR 10 each
			
	Shareholders and shares held:		Novartis Pharma AG		4,900,000
					(49%)
			
			Novartis Vaccines and Diagnostics Inc.		5,100,000
					(51%)
		
	Name of Company:		 Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.
 

		
	Registered Number:		330000000015616
		
	Registered/Principal Office:		No.56 Tian He Road, Yuhang Economic Development Zone, Hangzhou, Zhejiang Province, PRC.
		
	Date and place of incorporation:		
		
	Registered capital:		RMB 46,800,000
		
	Paid-in capital:		RMB 46,800,000
		
	Total investment amount:		RMB 117,000,000
			
	Shareholder and shares held:		Novartis Overseas Investments AG		85%
		
	Name of Company:		Novartis Vaccines Institute for Global Health S.r.l.
		
	Registered Number:		01204770521
		
	Registered/Principal Office:		Via Fiorentina 1, 53100, Siena, Italy
		
	Date and place of incorporation:		2 February 2007, Siena, Italy
		
	Issued share capital:		EUR 500,000.00 comprising 1 quota of entire share capital
			
	Shareholder and shares held:		Novartis Pharma AG		1 (100%)

  

	3	Particulars of the Subsidiaries 

  

					
	Name of Subsidiary:		Novartis Vaccines Vertriebs GmbH		 
			
	Registered Number:		HRB 193621		

  
  

 
 83 

					
	Name of Company:		Novartis Vaccines Vertriebs GmbH
		
	Registered Office:		Rudolf-Diesel-Ring 27, 83607 Holzkirchen, Germany
		
	Date and place of incorporation:		
		
	Issued share capital:		EUR 26,000.00 divided into 2 shares of EUR 25,600 and EUR 400 each
			
	Shareholders and shares held:		Novartis Vaccines and Diagnostics GmbH		2 (100%)

  

	4	Particulars of the Minority Interest Entities 

  

					
	Name of Company:		Valneva SE
		
	Registered Number:		422 497 560 RCS Lyon
		
	Registered Office:		70 Rue Saint Jean de Dieu, 69007 Lyon, France
		
	Date and place of incorporation:		 Initially incorporated on 26 January 2011, Commercial Court (greffe du Tribunal de Commerce) of Roussay, France

Incorporated with the Commercial Court (greffe du Tribunal de Commerce) of Lyon, France since change of registered office on 28 May 2013.

		
	Issued share capital:		€8,390,317.14, divided into 54,746,333 ordinary shares of €0.15 each and 17,836,719 preferred shares with a nominal value of €0.01 each
			
	Shareholders and shares held:		Novartis Vaccines & Diagostics Inc.		1,560,000
		Novartis Pharma AG		3,788,048
		
	Name of Company:		Chiron Panacea Vaccines Private Limited
		
	Registered Number:		U24230MH2004PTC147790
		
	Registered Office:		 7th Floor, A Wing, Sagar Tech Plaza

Sakinaka, Mumbai 400072, Maharashtra, India

		
	Date and place of incorporation:		13 July 2004, Mumbai, India

  
  

 
 84 

					
	Name of Company:		Chiron Panacea Vaccines Private Limited
		
	Issued share capital:		INR 45,918,200 (4,591,820 shares of INR 10 each)
			
	Shareholders and shares held:		Novartis Vaccines & Diagostic S.r.l.		2,295,910
					(50%)

  
  

 
 85 

 Schedule 3 

The Properties 
 Part 1

 (Company Real Property) 

Part A 
 Company Owned
Real Property 
 [***] 
  

 

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions, consisting of five pages, have been omitted from this filing and have been filed
separately with the Securities and Exchange Commission. 

  
  

 
 86 

 Part B 

Company Leased Real Property 
 [***] 

 
  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions, consisting of six pages, have been omitted from this filing and have been filed
separately with the Securities and Exchange Commission. 

  
  

 
 87 

 Schedule 3 

The Properties 
 Part 2

 (Transferred Real Property) 

Part A 
 Transferred
Owned Real Property 
 [***] 
  

 

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
  

 
 88 

 Part B 

Transferred Leased Real Property 
 [***]

  
  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions, consisting of three pages, have been omitted from this filing and have been filed
separately with the Securities and Exchange Commission. 

  
  

 
 89 

 Schedule 3 

The Properties 
 Part 3

 Terms relating to the Company Real Property 
  

	1	General Provisions relating to the Company Real Property 

  

	1.1	Interpretation 

 The following further definitions apply in this Part 3 of Schedule 3:

 “Company Landlord” means the person for the time being entitled to the reversion immediately expectant on the termination
of the term granted by a Company Lease; 
 “Company Leased Real Properties” means the leasehold properties identified in
Part B of Part 1 of this Schedule 3, and “Company Leased Real Property” means any one of them; 
 “Company
Leases” means the leases, licence documents or tenancy agreements under which the Company Leased Real Properties are held, including all documents supplemental to them, and “Company Lease” means any one of them; 

“Company Owned Real Properties” means the owned properties as identified in Part A of Part 1 of this Schedule 3 together with
all buildings, structures, fixed plant, fixed machinery and fixed equipment thereon (except as excluded in Clause 2.3.2), and “Company Owned Real Property” means any one of them; 

“Company Real Property Longstop Date” means the date on which a court of competent jurisdiction finally determines that a
Company Third Party Consent has been lawfully refused or cannot be obtained and/or that the Purchaser may not acquire (directly or indirectly, acting through a subsidiary) the relevant Company Real Property; 

“Company Third Party Consents” means all consents, licences, approvals, permits, authorisations or waivers required from any
Company Landlord, superior landlord and/or other third party, including any consents, licences, approvals, permits, authorisations or waivers required by any legislation or regulation or by any statutory, governmental, state, provincial or municipal
bodies or authorities which are required under a Company Lease or otherwise in relation to any change of control, shareholders or directors of the Vaccines Group Companies, and “Company Third Party Consent” means any one of them;

 “German Carve-out Leases” means the leases of the Company Leased Real Properties referred to at paragraphs 3.2 and 3.3 of
Part B of Part 1 of Schedule 3 and any other lease(s) of the Company Leased Real Properties at the Marburg Site where the premises demised by such lease(s) are occupied by both the Business and the German Flu Operations; 

“German Flu Lease(s)” has the meaning set out in paragraph 2.1 of this Part 3 of Schedule 3; and 

“German Vaccines Lease(s)” has the meaning set out in paragraph 2.1 of this Part 3 of Schedule 3. 

  
  

 
 90 

	1.2	Company Third Party Consents 

  

	1.2.1	This paragraph 1.2.1 of Part 3 of Schedule 3 applies to those Company Real Properties in relation to which a Company Third Party Consent is required and if such Company Third Party Consent remains to be obtained
as at the Closing Date this paragraph 1.2.1 of Part 3 of Schedule 3 shall continue to apply until the relevant Company Third Party Consent shall have been obtained or until the Company Real Property Longstop Date. If any Company Third Party Consents
are required: 

  

	 	(i)	the Seller shall make an application for, and shall use all reasonable endeavours to obtain each Company Third Party Consent as soon as reasonably practicable following the date of this Agreement and shall at all times
keep the Purchaser informed of progress in obtaining such Company Third Party Consents; 

  

	 	(ii)	the Purchaser shall supply such information and references as may reasonably be required by a Company Landlord, any superior landlord or other relevant third party in connection with a Company Third Party Consent;

  

	 	(iii)	the Purchaser shall be responsible for and undertake to pay, or procure the giving of undertakings to pay the professional and other fees of any Company Landlord, any superior landlord or other relevant person
(including any Tax or disbursements in respect of such fees but excluding any Tax on the actual net income, profit or gains of the Company Landlord, any superior landlord or any other relevant person) properly incurred in connection with any
application for Company Third Party Consents, whether or not such Company Third Party Consents are given; and 

  

	 	(iv)	in respect of the period after Closing only, the Purchaser shall enter into such covenants for the payment of the rent under the Company Lease and for the observance and performance of the covenants and conditions
contained in the Company Lease as may reasonably be required by the Company Landlord, any superior landlord or other relevant third party. 

  

	1.2.2	Each party shall give written notice to the other party as soon as reasonably practicable after obtaining any Company Third Party Consents which shall be accompanied by a copy of such consent. 

 

	1.2.3	Save as set out in paragraph 1.2.1(iii) of this Part 3 of Schedule 3, the Seller shall pay any moneys or provide or procure the giving of any guarantees or other security, in each case as may be lawfully required
by a Company Landlord, superior landlord or other relevant third party in connection with the obtaining of the Company Third Party Consents, provided that the Purchaser shall indemnify and keep indemnified the Seller in an amount equal to:

  

	 	(i)	any moneys required to be paid by the Seller pursuant to this paragraph; and 

  

	 	(ii)	any Liabilities under any guarantees or other security given or procured by the Seller pursuant to this paragraph and arising out of, or in connection with, an act or omission on the part of the Purchaser or (following
Closing) the relevant Vaccines Group Company, and where the Company Landlord, superior landlord or other relevant third party lawfully requires any guarantees or other security to be given by the person who is acquiring a membership interest in
respect of the relevant Vaccines Group Company, the Purchaser shall provide or procure the giving of any such guarantees or security. 

  
  

 
 91 

 Company Third Party Consent not obtained 

 

	 	1.2.4	If a Company Third Party Consent has been refused or otherwise not obtained within twelve months following the Closing Date, the Seller and the Purchaser may (acting reasonably) agree that an application is to be
made to a court of competent jurisdiction that the relevant Company Third Party Consent has been unreasonably withheld or delayed. 

  

	 	1.2.5	If an application is to be made to a court of competent jurisdiction pursuant to paragraph 1.2.4 of this Part 3 of Schedule 3: 

 

	 	(i)	the proceedings shall be brought by, and prosecuted at the expense of, the Purchaser; 

  

	 	(ii)	the Seller shall provide all such assistance in connection with such proceedings as the Purchaser (acting reasonably) may require in the interests of obtaining the Company Third Party Consent; and 

 

	 	(iii)	provided that the Seller has complied with its obligation under paragraph 1.2.1(i) of this Part 3 of Schedule 3, the Purchaser shall indemnify and keep indemnified the Seller for any costs and expenses properly incurred
in connection with any such assistance provided by the Seller. 

  

	 	1.2.6	If a Company Third Party Consent has not been obtained by the Company Real Property Longstop Date then the Seller and the Purchaser shall each bear fifty per cent. of any Losses of the Seller and the Purchaser
arising out of or in connection with the failure to obtain such Company Third Party Consent. 

  

	2	Specific provisions relating to the Marburg Site 

  

	2.1	The Seller agrees to procure that Novartis Vaccines and Diagnostics GmbH shall use reasonable efforts to procure the contemporaneous surrender of the German Carve-out Leases and the grant of replacement leases,
certain of which shall relate to those parts of the premises demised by the German Carve-out Leases which are used by the Business (the “German Vaccines Lease(s)”), and certain other of which shall relate to the balance of the premises
demised by the German Carve-out Leases (the “German Flu Lease(s)”). 

  

	2.2	If Novartis Vaccines and Diagnostics GmbH is able to procure the surrender of the German Carve-out Leases and the grant of the German Vaccines Lease(s) and the German Flu Lease(s) prior to Closing, it is
acknowledged that: 

  

	 	2.2.1	the German Flu Lease(s) shall be entered into by, or assigned prior to Closing to, an entity in the Seller’s Group Retained Business; 

 

	 	2.2.2	the German Flu Lease(s) shall not constitute lease(s) of Company Leased Real Property; and 

  

	 	2.2.3	the demise of the relevant Company Leased Real Property set out in Part B of Part 1 of this Schedule 3 shall be deemed amended to exclude the premises demised by the German Carve-out Leases and the German Flu
Lease(s) and to include reference to the premises demised by the German Vaccines Lease(s). 

  
  

 
 92 

	2.3	If Novartis Vaccines and Diagnostics GmbH is not able to procure the surrender of the German Carve-out Leases and the grant of the German Vaccines Lease(s) and the German Flu Lease(s) prior to Closing, the Seller
and the Purchaser shall use reasonable efforts to give practical effect to the above-described separation following Closing, and shall consider (without limitation): 

 

	 	2.3.1	continued negotiations with the relevant Company Landlords to achieve a separation of each German Carve-out Lease into a German Vaccines Lease and a German Flu Lease, the latter of which shall be entered into by,
or immediately assigned to, an entity in the Seller’s Group Retained Business; or 

  

	 	2.3.2	if a separation pursuant to paragraph 2.3.1 of this Part 3 of Schedule 3 is not achievable, a sub-lease of those parts of the premises demised by the German Carve-out Leases which are used by the German Flu
Operations to an entity in the Seller’s Group Retained Business. 

  

	2.4	The Seller agrees to procure that Novartis Vaccines and Diagnostics GmbH shall not agree to any terms of any German Vaccines Lease(s) which are not substantially similar to the equivalent terms of the relevant
underlying German Carve-out Lease without the consent of the Purchaser (not to be unreasonably withheld or delayed), and shall not agree to any terms of any German Flu Lease(s) which are not substantially similar to the equivalent terms of the
relevant underlying German Carve-out Lease without the consent of the Seller (not to be unreasonably withheld or delayed). 

  

	2.5	In connection with the implementation of the arrangements set out in this paragraph 2 of Part 3 of Schedule 3, the parties agree to work together prior to Closing (or, where paragraph 2.3 of this Part 3 of
Schedule 3 applies, after Closing) to agree the provision of any site engineering services reasonably required by the other in order to operate those premises demised by the German Vaccines Lease(s) or the German Flu Lease(s), as applicable, in
substantially the same manner as operated immediately prior to Closing. Such services may include, but are not limited to, supply of water, gas and electricity, the operation of clean utility systems (water for injection, clean steam, clean gases,
etc.), facility services contract management and administration, preventive and corrective maintenance, and shutdown coordination. 

  
  

 
 93 

 Schedule 3 

The Properties 
 Part 4

 Terms relating to the Transferred Real Property 
  

	1	General Provisions Relating to the Transferred Real Property 

  

	1.1	Interpretation 

 The following further definitions apply in this Part 4 of Schedule 3:

 “Landlord” means the person for the time being entitled to the reversion immediately expectant on the termination of the
term granted by a Lease; 
 “Leases” means the leases, licences or tenancy agreements under which the Transferred Leased
Real Properties are held by the relevant member of the Seller’s Group, including all documents supplemental to them, and “Lease” means any one of them; 

“Letting Document” means any lease, licence or tenancy agreement to which a Transferred Real Property is subject; 

“Licence” means a right in favour of the Purchaser and all persons authorised by it to occupy the Licensed Premises during the
Licence Period pursuant to this Part 4 of Schedule 3; 
 “Licence Fee” means the payments to be made by the Purchaser to the
Seller’s Group pursuant to paragraph 1.4.4 of this Part 4 of Schedule 3; 
 “Licence Period” means a period, which may
be different for each of the Licensed Premises, commencing on the Closing Date and ending on the earliest of the following dates: 
  

	 	(lxiii)	the date on which this Agreement is terminated by whatever means whether in whole or in relation to the relevant Licensed Premises; 

  

	 	(lxiv)	the date immediately preceding the date on which the term of the relevant Lease ends by whatever means; 

  

	 	(lxv)	the date of Property Transfer Completion in relation to the relevant Transferred Real Property; and 

  

	 	(lxvi)	the Property Longstop Date; 

 “Licensed Premises” means any of the Transferred
Real Properties for which all relevant Property Third Party Consents have not been obtained prior to, or at, the Closing Date; 

“Property Agreed Terms” means a transfer in the terms agreed between the relevant Business Seller, the Purchaser and any
relevant third party or determined pursuant to paragraph 1.3.2 of this Part 4 of Schedule 3 and signed for identification by or on behalf of the Business Sellers and by or on behalf of the Purchaser from time to time before or after the date of this
Agreement, with such alterations as may be agreed from time to time in writing between the relevant Business Seller, the Purchaser and any relevant third party; 

“Property Longstop Date” means the date on which a court of competent jurisdiction finally determines that a Property Third
Party Consent has been lawfully refused; 

  
  

 
 94 

 “Property Third Party Consents” means all consents, licences, approvals,
permits, authorisations or waivers required from any Landlord, superior landlord and/or other third party, including any consents, licences, approvals, permits, authorisations or waivers required by any legislation or regulation or by any statutory,
governmental, state, provincial or municipal bodies or authorities for or in connection with the transfer of a Transferred Real Property by the Business Sellers to the Purchaser and includes (where the context so admits) Sublease Consents; 

“Property Transfer Completion” means the completion of the transfer of a Transferred Real Property under this Agreement, where
such completion does not take place on the Closing Date because any relevant Property Third Party Consents have not been obtained on or prior to such date; 

“Property Transfer Completion Date” means the date of Property Transfer Completion in accordance with paragraph 1.7 of this
Part 4 of Schedule 3; 
 “Registered Title” means the registered title relating to a Transferred Real Property; 

“Sublease Consent” has the meaning given to it in paragraph 1.11.2 of this Part 4 of Schedule 3; 

“transfer”, for the purposes of this Part 4 of Schedule 3 only, means in respect of a Transferred Leased Real Property, the
transfer or assignment of the relevant Lease or Leases, and in the case of a Transferred Owned Real Property the transfer thereof, and “a transfer” means and includes any instruments, deeds or agreements effecting such transfer;

 “Transferred Leased Real Properties” means the leasehold properties held by a Business Seller and identified in Part B of
Part 2 of this Schedule 3 and “Transferred Leased Real Property” means any one of them; and 
 “Transferred Owned
Real Properties” means the owned properties identified in Part A of Part 2 of this Schedule 3 together with all buildings, structures, fixed plant, fixed machinery and fixed equipment thereon (except as excluded in Clause 2.3.2), and
“Transferred Owned Real Property” means any one of them. 
  

	1.2	Each of the Transferred Real Properties and/or the Leases thereof shall be transferred subject to the terms set out in this Part 4 of Schedule 3 and all other applicable terms of this Agreement.

  

	1.3	Pre-Closing 

  

	 	1.3.1	Prior to Closing, the Business Sellers and the Purchaser shall agree (acting reasonably) the form of all documents on Property Agreed Terms necessary for the transfer of each of the Transferred Real Properties
pursuant to the terms set out in this Part 4 of Schedule 3 and all other applicable terms of this Agreement. 

  

	 	1.3.2	Any dispute arising out of or connected with paragraph 1.3.1 of this Part 4 of Schedule 3 which is not resolved by agreement between the parties within nine months of such dispute arising shall be referred for
and resolved by expert determination as follows: 

  

	 	(i)	either the relevant Business Seller or the Purchaser may initiate an expert reference under this provision by proposing to the other party the appointment of an expert (the “Expert”); 

  
  

 
 95 

	 	(ii)	the Expert shall either be the nearest equivalent to a chartered surveyor in the relevant jurisdiction or (in relation to legal issues) a single QC (or equivalent), in each case with no less than 15 years’
post-qualification experience in commercial real estate in the relevant jurisdiction chosen by agreement between the relevant Business Seller and the Purchaser or, failing agreement within 14 days of the initiation of the reference, by the President
for the time being of the relevant professional body to which the Expert belongs (the “President”) on the application of either the relevant Business Seller or the Purchaser; 

 

	 	(iii)	the relevant Business Seller and the Purchaser shall request that the Expert determines the referred dispute within 10 days of receiving the reference; 

 

	 	(iv)	if the Expert has been appointed but is unable or unwilling to complete the reference, another Expert shall be appointed by agreement between the relevant Business Seller and the Purchaser or, failing agreement within 7
days of the parties being notified that the Expert is unable or unwilling to complete the reference, by the President on the application of either party; 

  

	 	(v)	the Expert shall act as an expert and not as an arbitrator; 

  

	 	(vi)	the relevant Business Seller and the Purchaser shall have the right to make representations and submissions to the Expert, but there will be no formal hearing; 

 

	 	(vii)	the relevant Business Seller and the Purchaser shall make all relevant documents and information within their control available to the Expert; 

 

	 	(viii)	the costs of the Expert shall be borne equally by the relevant Business Seller and the Purchaser; and 

  

	 	(ix)	the decision of the Expert shall, in the absence of fraud or manifest error, be final and binding on the parties. 

  

	 	1.3.3	This paragraph 1.3.3 of Part 4 of Schedule 3 applies to those Transferred Real Properties in relation to which a Property Third Party Consent is required and if such Property Third Party Consent remains to be
obtained as at the Closing Date this paragraph 1.3.3 of Part 4 of Schedule 3 shall continue to apply until the relevant Property Third Party Consent shall have been obtained or until the Property Longstop Date. If any Property Third Party Consents
are required: 

  

	 	(i)	the Seller or relevant Business Seller shall make an application for, and shall use all reasonable endeavours to obtain each Property Third Party Consent as soon as reasonably practicable following the date of this
Agreement for the transfer of the Transferred Real Property and shall, at all times, keep the Purchaser informed of progress in obtaining such Property Third Party Consents; 

 

	 	(ii)	the Purchaser shall: 

  

	 	(a)	supply such information and references as may reasonably be required by a Landlord, any superior landlord or other relevant third party in connection with a Property Third Party Consent; 

  
  

 
 96 

	 	(b)	in respect of the period after Closing only, enter into such covenants for the payment of the rent in respect of the Transferred Leased Real Properties and for the observance and performance of the covenants and
conditions on the part of the lessee contained in any Lease as may reasonably be required by the Landlord, any superior landlord or other relevant third party; 

  

	 	(c)	if reasonably required by the Landlord, any superior landlord or other relevant third party, provide a rent deposit or procure that a surety acceptable to such person guarantees the Purchaser’s obligations under
the Lease following the transfer of the relevant Transferred Leased Real Property; and 

  

	 	(d)	be responsible for and undertake to pay, or procure the giving of undertakings to pay the professional and other fees of any Landlord, any superior landlord or other relevant person (including any Tax or disbursements
in respect of such fees but excluding any Tax on the actual net income, profit or gains of the Landlord, any superior landlord or any other relevant person) properly in connection with any application for Property Third Party Consents, whether or
not such Property Third Party Consents are given. 

  

	 	1.3.4	Each party shall give written notice to the other party as soon as reasonably practicable after obtaining any Property Third Party Consents which shall be accompanied by a copy of such consent. 

 

	 	1.3.5	Subject to the Purchaser complying with its obligations under paragraphs 1.3.3(ii)(b) to (d) of this Part 4 of Schedule 3, the Seller shall pay, or shall procure that a member of the Seller’s Group pays, any
moneys or provide or procure the giving of any guarantees or other security, in each case as may be lawfully required by a Landlord, superior landlord or other relevant third party in connection with the obtaining of the Property Third Party
Consents, provided that the Purchaser shall indemnify and keep indemnified the Seller in an amount equal to: 

  

	 	(i)	any moneys required to be paid or procured to be paid by the Seller pursuant to this paragraph; and 

  

	 	(ii)	any Liabilities under any guarantees or other security given or procured by the Seller pursuant to this paragraph and arising out of, or in connection with, an act or omission on the part of the Purchaser.

  

	1.4	Licence 

  

	 	1.4.1	In the event that any Property Third Party Consents are not obtained on or before the Closing Date, notwithstanding the terms of the Leases, the Seller shall procure that the relevant Business Seller allows the
Purchaser to occupy the Licensed Premises for the Licence Period relating to the relevant Licensed Premises on the terms set out in this paragraph 1.4 of Part 4 of Schedule 3. 

 

	 	1.4.2	The Purchaser acknowledges that the grant of each Licence may amount to a breach of the terms of the relevant Lease. 

  

	 	1.4.3	The Licence of each Licensed Premises is granted: 

  
  

 
 97 

	 	(i)	subject to all of the matters to which the relevant Leases relating to the Transferred Leased Real Property are subject; 

  

	 	(ii)	subject to the matters referred to in the Registered Title and the Letting Documents; 

  

	 	(iii)	out of whatever right, title and interest that the relevant Business Seller has in the Licensed Premises and/or under the Leases; 

  

	 	(iv)	in such state of repair and condition as the Licensed Premises may be in as at the date on which the relevant Licence is granted; and 

 

	 	(v)	without making any statement or representation that the relevant Business Seller is entitled to grant it. 

  

	 	1.4.4	From Closing and pending Property Transfer Completion, the Purchaser shall pay to the relevant Business Seller a “Licence Fee” equivalent to: 

 

	 	(i)	all rents and other charges (including VAT due thereon under the relevant Lease where payable at the date of this Agreement by the relevant Business Seller) payable in respect of the Licensed Premises; and

  

	 	(ii)	all outgoings (including VAT due thereon under the relevant Lease) (including, but not limited to, rates, service charges, management charges, levies, air-conditioning charges, insurance, heating, electricity, gas,
telecommunications and other services and the cost of complying with fire and other statutory regulations) payable by the relevant Business Seller in respect of the Licensed Premises or charged upon the owner or occupier of the Licensed Premises,

 such payments to be made not less than 10 Business Days before any such sum falls due subject to the relevant Business
Seller giving the Purchaser not less than 10 Business Days’ prior written notice to that effect. To the extent that there has been a prepayment at the Closing Date of the amounts in paragraphs 1.4.4(i) and (ii) of this Part 4 of Schedule 3
by the Seller’s Group which is not otherwise accounted for in the Closing Statement, the Purchaser shall pay to the relevant member of the Seller’s Group within 10 Business Days of written demand an amount equal to the amount of such
prepayment in respect of any period after the Closing Date. 
  

	 	1.4.5	Throughout the Licence Period, the Purchaser shall, in respect of the Licensed Premises only: 

  

	 	(i)	keep the Licensed Premises in no worse a state of repair than they are in at the Closing Date, fair wear and tear excepted; 

  

	 	(ii)	observe and perform the covenants and conditions on the part of the lessee in the relevant Lease under which the relevant Business Seller holds the Licensed Premises (other than in relation to the payment of rent and
other charges paid to the relevant Business Seller as part of the Licence Fee and subject to paragraph 1.4.5(i) of this Part 4 of Schedule 3); and 

  

	 	(iii)	 use the Licensed Premises only in accordance with the terms of the Lease of the relevant Licensed Premises and in compliance with the law and
regulations where the relevant Licensed Premises is located (save for any 

  
  

 
 98 

	 	
such law or regulation that prohibits the use of the Licensed Premises without a Property Third Party Consent having been obtained). 

 

	 	1.4.6	The Purchaser and each Business Seller agree that: 

  

	 	(i)	the Licence is personal to the Purchaser and may only be exercised by the Purchaser and those authorised by it; 

  

	 	(ii)	(subject to paragraph 1.4.5 of this Part 4 of Schedule 3) the Purchaser and all persons authorised by it are permitted to have the unrestricted use and occupation of the Licensed Premises; and 

 

	 	(iii)	no relationship of landlord and tenant is created as a result of the Licence. 

  

	 	1.4.7	If a Landlord or any other relevant third party commences proceedings, raises any lawful objection or takes any other action in connection with the Purchaser’s occupation or use of any of the Licensed
Premises pending the obtaining of the relevant Property Third Party Consents, the Purchaser and the relevant Business Seller shall meet and negotiate in good faith in order to determine which steps should be taken in respect of the relevant
Transferred Real Property. 

  

	 	1.4.8	Throughout the Licence Period, the Purchaser shall, in respect of the Licensed Premises only, indemnify and keep indemnified each member of the Seller’s Group from and against any Licence Fee and any Losses
arising from the Licence and/or as a result of the occupation of the Licensed Premises by the Purchaser. 

  

	 	1.4.9	The Purchaser and the Business Sellers shall each inform the other forthwith of any notice received by it in relation to any of the Licensed Premises from the Landlord or any other third party. 

 

	1.5	Determination of Licence 

  

	 	1.5.1	The Licence in relation to any one or more of the Licensed Premises shall determine: 

  

	 	(i)	immediately if the Property Longstop Date occurs; or 

  

	 	(ii)	by the relevant Business Seller giving at least three months’ prior written notice to the Purchaser if the Purchaser fails to make the payment of the Licence Fee for a period of one month or is otherwise in
material breach of the provisions of the Licence for a continuous period of one month following written notification by the relevant Business Seller to the Purchaser of the same, and in either case the Purchaser has failed to remedy the relevant
failure to pay or to remedy the breach prior to the expiry of the three month notice period (or, if the breach is not capable of remedy within such three month period, the Purchaser has failed to commence to remedy the breach within that period and
thereafter failed diligently to continue with such remedy); or 

  

	 	(iii)	if the relevant Landlord in relation to a Transferred Leased Real Property prosecutes forfeiture proceedings (or the nearest local law equivalent) as a result of the occupation by the Purchaser of the Licensed
Premises then the parties shall either: 

  

	 	(a)	agree that the Licence shall determine on a date to be agreed between the parties (acting reasonably); or 

  
  

 
 99 

	 	(b)	in the absence of such agreement, either party may require a QC (or equivalent) with no less than 15 years’ post-qualification experience in commercial real estate in the relevant jurisdiction to be appointed (such
appointment to be by agreement between the Seller and the Purchaser or, failing agreement, within 14 days, by the President (as defined in paragraph 1.3.2(ii) of this Part 4 of Schedule 3)). Should the QC determine that there is more than a 50%
chance of the proceedings in question resulting in the Lease in question being forfeited (or equivalent), then the Licence shall determine on a date to be agreed between the parties (acting reasonably) in order to afford the Seller the opportunity
to apply for relief from forfeiture or otherwise challenge the proceedings in question on the basis that any breach resulting from the grant of the Licence has been cured, 

provided that this paragraph 1.5.1(iii) shall at all times operate without prejudice to paragraphs 1.4.7, 1.5.1(i) and 1.12. 

 

	 	1.5.2	If, for whatever reason, the Licence Period comes to an end in relation to any of the Licensed Premises then: 

  

	 	(i)	the Licence insofar as it relates to the relevant Licensed Premises shall be severable from the remainder of this Agreement and this Agreement shall otherwise remain in full force and effect; 

 

	 	(ii)	the Purchaser shall not be entitled to any refund, abatement or reduction of the Purchase Price but shall be entitled to a refund in respect of any Licence Fee prior to the termination of the Licence for the Licensed
Premises and which relates to the period following termination of the Licence; 

  

	 	(iii)	it shall not prejudice or affect any claim by any relevant Business Seller in respect of any prior breach of this Agreement by the Purchaser in respect of that Licensed Premises; and 

 

	 	(iv)	unless the Licence Period comes to an end due to Property Transfer Completion in respect of the relevant Licensed Premises taking place, the Purchaser shall: 

 

	 	(a)	vacate the Licensed Premises forthwith; 

  

	 	(b)	remove from the Licensed Premises all items belonging to it; 

  

	 	(c)	leave the Licensed Premises in a clean and tidy condition; and 

  

	 	(d)	at the request of the relevant Business Seller, reinstate the Licensed Premises or any part or parts thereof to at least as good a state of repair or condition as at Closing, fair wear and tear excepted.

  

	1.6	Closing 

  

	 	1.6.1	The transfer of the Transferred Real Property shall only take place on Closing to the extent that all necessary Property Third Party Consents in respect of the relevant transfer have been obtained prior to the
Closing Date. 

  

	 	1.6.2	Without prejudice to Clause 4.1.8, the Purchase Price shall be paid on the Closing Date in accordance with this Agreement even if any necessary Property Third Party Consents have not then been obtained and not
all the Transferred Real Property is transferred on the Closing Date. 

  
  

 
 100 

	 	1.6.3	Completion of the transfer of the Transferred Real Property shall take place at such place (or places) as the parties may agree. 

 

	1.7	Property Transfer Completion 

 Property Transfer Completion in respect of a Transferred
Real Property shall take place on the date falling 15 Business Days following the grant of all relevant Property Third Party Consents for such Transferred Real Property or on such other date as the parties shall agree acting reasonably (but not
before the Closing Date). 
  

	1.8	General Transfer Provisions 

  

	 	1.8.1	The Seller shall procure that the relevant members of the Seller’s Group shall transfer the Transferred Real Property to the Purchaser subject to the terms set out in this Part 4 of Schedule 3 and all other
applicable terms of this Agreement on the Closing Date or (if later) Property Transfer Completion. 

  

	 	1.8.2	The Transferred Real Property is sold subject to the Letting Documents (if any) but otherwise with vacant possession together with all buildings, structures, fixed plant, fixed machinery and fixed equipment
thereon except as excluded in Clause 2.3.2. 

  

	 	1.8.3	The transfer of each Transferred Real Property shall contain covenants with the relevant Business Seller by the Purchaser to comply with: 

 

	 	(i)	the obligations arising from the matters mentioned in the Registered Title; and 

  

	 	(ii)	obligations on the part of the landlord arising under the Letting Documents (if any), 

 insofar
as the relevant Business Seller may remain liable directly or indirectly for them after the Closing Date or Property Transfer Completion (as the case may be) and to indemnify the relevant member of the Seller’s Group against any non-compliance
and a further covenant by the Purchaser to indemnify the relevant Business Seller against any liability arising under an authorised guarantee agreement (or equivalent) entered into by the relevant member of the Seller’s Group. 

 

	 	1.8.4	The transfer of each Transferred Real Property shall be on the nearest equivalent terms that exist under local (national) law to a transfer of real property in England and Wales made with full title guarantee
save that where it is a Transferred Leased Real Property the covenant set out in Section 4(2)(b) of the Law of Property (Miscellaneous Provisions) Act 1994 shall not extend to the imposition on the transferor of liability for any subsisting
breach of obligation relating to the physical state of the Transferred Leased Real Property. 

  

	 	1.8.5	On the Closing Date or Property Transfer Completion (as the case may be) in respect of each of the Transferred Real Properties: 

 

	 	(i)	the Seller shall procure that the relevant Business Seller delivers to the Purchaser a duly executed transfer in respect of the relevant Transferred Real Property on Property Agreed Terms; and 

  
  

 
 101 

	 	(ii)	the Purchaser shall deliver to the Seller a duly executed transfer in respect of the relevant Transferred Real Property on Property Agreed Terms. 

 

	 	1.8.6	The Purchaser shall, at its own cost and expense, procure that all transfers are duly stamped, filed or registered at the relevant registries on a timely basis and within the statutory period (if any) and the
relevant Business Seller shall promptly assist the Purchaser with any requisitions or enquiries raised in relation thereto. 

  

	1.9	Subjections 

 Notwithstanding anything contained in this Agreement: 

 

	 	1.9.1	Each of the Transferred Real Properties is transferred subject to and (where appropriate) with the benefit of the following matters (to the extent applicable under the laws of the relevant jurisdiction):

  

	 	(i)	any unregistered interest which overrides first registration under Schedule 1 of the Land Registration Act 2002 (the “2002 Act”) and any interest which fall within Section 11(4)(c) of the 2002 Act
and any unregistered interests which override registered dispositions under Schedule 3 of the 2002 Act or their local jurisdiction equivalent (if any); 

  

	 	(ii)	such unregistered interests as may affect that Transferred Real Property to the extent and for so long as they are preserved by the transitional provisions of Schedule 12 of the 2002 Act or its local jurisdiction
equivalent (if any); 

  

	 	(iii)	all matters contained or referred to in the Letting Documents; 

  

	 	(iv)	all matters contained or referred to in the Property, Proprietorship and Charges registers (or equivalent entries and registers) of the Registered Title relating to that Transferred Real Property (except fixed and
floating charges securing money or liabilities); 

  

	 	(v)	all exceptions, reservations, rights, easements, quasi-easements, wayleaves, rent charges, covenants, conditions, declarations, leases, tenancies (including statutory tenancies), licences and agreements affecting the
same; 

  

	 	(vi)	(in the case of a leasehold property) the rents, covenants and conditions reserved by or contained in the Lease under which the same is respectively held; 

 

	 	(vii)	all local land charges (whether or not registered before the date of this Agreement) and all matters capable of registration as local land charges (whether or not actually registered) or their local jurisdiction
equivalent (if any); 

  

	 	(viii)	all notices served and orders, demands, proposals, or requirements made by any local or other public or competent authority; 

  

	 	(ix)	all actual or proposed orders, directions, plans, notices, instruments, charges, restrictions, conditions, agreements or other matters arising under any statute relating to town and country planning and any laws and
regulations intended to control or regulate the construction, demolition, alteration or change of use of land or buildings or to preserve or protect the environment; and 

  
  

 
 102 

	 	(x)	matters which are fairly disclosed by the Disclosure Letter. 

  

	 	1.9.2	The Purchaser is deemed to acquire with full knowledge of the matters referred to in paragraph 1.9.1 of this Part 4 of Schedule 3. 

 

	 	1.9.3	The Business Sellers shall procure that any and all financial charges affecting the Transferred Real Properties will be discharged on or before the date on which such Transferred Real Property is to be
transferred to the Purchaser, and shall provide to the Purchaser such evidence as the Purchaser may reasonably require in order to satisfy itself that such discharge has been effected and to remove any notices or entries in respect of such charges
from any relevant register. 

  

	 	1.9.4	The Business Sellers do not give any warranty as to the use or area of any of the Transferred Real Properties and shall not be required to define the boundaries of any of the Transferred Real Properties. The
transfer of the Transferred Real Properties shall not be annulled, nor shall any compensation be allowed or payable, in respect of any error in respect of any such matters. 

 

	 	1.9.5	On the date on which the transfer of each Transferred Real Property is completed, the Seller shall deliver, to the Purchaser (or such other third party as the Purchaser may reasonably direct) all of the original
documents in the possession of the Business Sellers or relevant member of the Seller’s Group in respect of each of the Transferred Real Properties. 

  

	 	1.9.6	The Purchaser shall not raise any requisition on matters arising after the date of this Agreement, except where the subject matter of the requisition is registered at the Land Registry (or equivalent local
registry) after the date of this Agreement and does not relate to any matter referred to in paragraph 1.9.1 of this Part 4 of Schedule 3. 

  

	 	1.9.7	To the extent that deposit guarantees have been given by the Seller’s Group in respect of any Transferred Real Property and/or insofar as the Seller’s Group retains any residual or ongoing liabilities
or obligations (including performance guarantees) in connection with the Transferred Real Property, the Purchaser shall use all reasonable endeavours procure that the Seller’s Group is released from all deposit guarantees and all other residual
or ongoing liabilities or obligations and, insofar as the counterparties thereto shall properly and lawfully refuse to give any such release, the Purchaser shall indemnify and keep indemnified the Seller (or the relevant member of the Seller’s
Group) in an amount equal to any Liabilities under any such residual or ongoing liabilities or obligations arising out of, or in connection with, an act or omission on the part of the Purchaser. 

 

	1.10	Insurance 

 The Business Sellers shall maintain their existing insurance (if any) on the
Transferred Real Properties and shall cancel such insurance with effect from the Closing Date or, if later, the date of Property Transfer Completion (as the case may be) unless agreed otherwise with the Purchaser. 

  
  

 
 103 

	1.11	Grant of Sublease 

 If a Business Seller is unable to obtain a Property Third Party
Consent from a Landlord for the transfer of a Transferred Leased Real Property the provisions of this paragraph 1.11 of Part 4 of Schedule 3 shall apply: 
  

	 	1.11.1	where a Lease permits a sublease to be granted without the requirement for any Property Third Party Consent from the Landlord, the relevant Business Seller shall grant to the Purchaser a sublease of the
Transferred Leased Real Property on the same rent and other terms and conditions as the Lease of the Transferred Leased Real Property with such changes as are appropriate and agreed between the relevant Business Seller and the Purchaser acting
reasonably and the term of the sublease shall be the term of such Lease less one day; and 

  

	 	1.11.2	where the Transferred Leased Real Property is held by the relevant Business Seller from a Landlord on terms which require the consent of the Landlord to: 

 

	 	(i)	the grant of a sublease; or 

  

	 	(ii)	the terms on which a sublease is granted, 

  

	 	 	the Seller or the relevant Business Seller shall use all reasonable endeavours to obtain such consent (“Sublease Consent”) from such Landlord. Where the relevant Business Seller is able to obtain the
appropriate Sublease Consent (or, where applicable, the court of competent jurisdiction referred to in paragraph 1.12.1 of this Part 4 of Schedule 3 declares that the Sublease Consent has been unreasonably withheld or delayed), the relevant Business
Seller shall grant to the Purchaser a sublease of the Transferred Leased Real Property on the same rent and other terms and conditions as the Lease of the Transferred Leased Real Property with such changes as are appropriate and agreed between the
relevant Business Seller and the Purchaser acting reasonably and the term of the sublease shall be the term of such Lease less one day. 

  

	1.12	Property Third Party Consent not obtained 

  

	 	1.12.1	If a Property Third Party Consent (and, where applicable, a Sublease Consent) has been refused or otherwise not obtained within twelve months following the Closing Date, the Seller and the Purchaser may (acting
reasonably) agree that an application is to be made to a court of competent jurisdiction that the relevant Property Third Party Consent has been unreasonably withheld or delayed. 

 

	 	1.12.2	If an application is to be made to a court of competent jurisdiction pursuant to paragraph 1.12.1 of this Part 4 of Schedule 3: 

 

	 	(i)	the proceedings shall be brought and prosecuted by the Seller; and 

  

	 	(ii)	the Purchaser shall provide all such assistance in connection with such proceedings as the Seller (acting reasonably) may require in the interests of obtaining the Property Third Party Consent; and 

 

	 	(iii)	provided that the Seller has complied with its obligations under paragraphs 1.3.3(i) and 1.11.2 of this Part 4 of Schedule 3, the Purchaser shall indemnify and keep indemnified the Seller for any costs and expenses
properly incurred by the Seller in bringing and prosecuting proceedings under this paragraph. 

  
  

 
 104 

	 	1.12.3	If a Property Third Party Consent has not been obtained by the Property Longstop Date then the Seller and the Purchaser shall each bear fifty per cent. of any Losses of the Seller and the Purchaser arising out of
or in connection with the failure to obtain such Property Third Party Consent. 

  

	1.13	Obligations on the Business Sellers 

  

	 	In this Part 4 of Schedule 3, any reference to an obligation on the part of the Business Sellers (or any of them, as the case may be) shall be read as if it were an obligation on the part of the Seller to procure
performance of such obligation by the Business Seller or Business Sellers in question. 

  

	1.14	Amsterdam Lease 

  

	 	1.14.1	The Seller shall keep the Purchaser fully informed of any discussions or negotiations with the Landlord in respect of the lease of premises at Hullenbergweg 81-135 (1011 CL), Amsterdam, The Netherlands (the
“Amsterdam Lease”), or any notices received by the Seller (or any member of the Seller’s Group) from the Landlord in respect of the Amsterdam Lease relating to the determination thereof or the yielding up of the premises demised
thereunder. 

  

	 	1.14.2	The Seller shall not, and shall procure that no member of the Seller’s Group shall, act independently of the Purchaser in relation to any discussions or negotiations relating to the extension or renewal of
the Amsterdam Lease, and shall not enter into any document or deed extending or renewing the term of the Amsterdam Lease without the prior written approval of the Purchaser (not to be unreasonably delayed). 

 

	 	1.14.3	The Seller shall, and shall procure that any relevant member of the Seller’s Group shall, take such action as the Purchaser may reasonably request in connection with the Amsterdam Lease, including taking
steps to extend or renew the same. 

  

	 	1.14.4	The Purchaser shall indemnify and keep indemnified the Seller against all costs properly incurred by the Seller (or any member of the Seller’s Group) arising out of or in connection with paragraph 1.14.3 of
this Part 4 of Schedule 3. 

  

	 	1.14.5	If the Amsterdam Lease is extended or renewed, the leasehold property as extended or renewed shall be a “Transferred Real Property” for the purposes of this Agreement and the provisions of this Part 4
of Schedule 3 shall apply to such lease as extended or renewed. 

  
  

 
 105 

 Schedule 4 

Vaccines Group Intellectual Property Rights and Vaccines Group Intellectual Property Contracts 

(Clause 2.3) 
 Part 1 

Vaccines Group Intellectual Property Rights 
 Part 2

 Vaccines Group Intellectual Property Contracts 

Part 3 
 Beta Interferon Patents 

  
  

 
 106 

 Schedule 5 

Excluded Employees 

(Clause 1.1) 
 [***] 

 
  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
  

 
 107 

 Schedule 6 

International Assignees 

(Clause 1.1) 
 [***] 

 
  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions, consisting of two pages, have been omitted from this filing and have been filed
separately with the Securities and Exchange Commission. 

  
  

 
 108 

 Schedule 7 

Permitted Encumbrances 

(Clause 1.1) 
  

	1.	Co-owned Vaccines Group Intellectual Property Rights. 

  
  

 
 109 

 Schedule 8 

Product Approvals and Product Applications 

Part 1 
 Terms relating to
the Product Approvals and Product Applications 
  

	1	General Provisions 

  

	1.1	The Purchaser shall do all things necessary to effect the transfer of each Product Approval and Product Application, including complying with requirements and requests of Governmental Entities with respect to the
transfer of each Product Approval and Product Application. 

  

	1.2	The Marketing Authorisations shall be transferred in accordance with Part 2 of this Schedule 8. 

  

	2	Product Applications 

  

	2.1	The Purchaser shall file or cause to be filed applications for the transfer of each Product Application in each country or territory in which such transfer is required to be submitted as soon as possible after the
Closing Date. 

  

	2.2	Pending the transfer of each Product Application each Seller shall, and shall cause the relevant members of its Group to: 

  

	 	2.2.1	upon reasonable request from the Purchaser and at the Purchaser’s expense, reasonably cooperate and coordinate with the Purchaser in relation to the transfer of the Product Applications, including by providing the
Purchaser with regulatory documentation concerning the Products owned or controlled by that Seller or any of its Affiliates; 

  

	 	2.2.2	perform such acts and services as may be requested by the Purchaser that are reasonably necessary or required by any Governmental Entity to maintain or renew any Product Application or are reasonably necessary for the
Purchaser to pursue the regulatory approval for any Product Application, including conducting any studies, including clinical and stability studies, concerning the Products; and 

 

	 	2.2.3	notify the Purchaser as soon as is reasonably practicable of any written communication received by such Seller or any member of its Group with respect to any Product Application and shall consult with the Purchaser with
respect to such communication and take into account the Purchaser’s views as to the form and content of any communication with any Governmental Entity concerning such Product Application. 

 

	3	Fees and expenses 

 From and after the Closing Date, the Purchaser shall promptly
reimburse the relevant members of the Seller’s Group for all maintenance and renewal fees and similar fees paid, and all out of pocket expenses reasonably incurred in connection with the satisfaction of any commitments or obligations by such
member of the Seller’s Group with respect to each Product Approval and each Product Application. 
  

	4	Notification 

 As soon as a Seller or the Purchaser or any of their respective Affiliates
receives notification, if any, of impending approval or approval of the transfer of a Product Application from a Governmental Entity, the notified party or the party whose Affiliate was notified shall inform the other party of the expected date of
appointment or transfer and actual date of appointment or transfer of that Product Application. 

  
  

 
 110 

	5	Responsibility for transfer 

 Notwithstanding any other provision of this Agreement, no
Seller nor any of its Affiliates shall have any Liability to the Purchaser in the event that the transfer of any Product Application alone results in any further obligations, commitments or Liabilities in relation to such Product Application. 

  
  

 
 111 

 Schedule 8 

Product Approvals and Product Applications 

Part 2 
 Transfer of
Marketing Authorisations 
  

	1	Marketing Authorisation Transfer and Marketing Authorisation Re-registration 

  

	1.1	The Seller and the Purchaser hereby agree they will each use, and will procure that their respective Affiliates will use, all reasonable endeavours to ensure that, as soon as reasonably practicable after the Closing
Date: 

  

	 	1.1.1	subject to paragraph 1.1.2, each Marketing Authorisation shall be transferred in accordance with Applicable Law by the Marketing Authorisation Holder to the Marketing Authorisation Transferee (“Marketing
Authorisation Transfer”); and 

  

	 	1.1.2	where Applicable Law does not permit Marketing Authorisation Transfer, a new marketing authorisation shall be registered in the name of the Marketing Authorisation Transferee to replace the existing Marketing
Authorisation (“Marketing Authorisation Re-registration”) and the Seller shall procure that the relevant Marketing Authorisation Holder takes all necessary steps to withdraw, abandon, cancel or allow to lapse the superseded
Marketing Authorisation as soon as practicable after the Marketing Authorisation Re-registration Date. 

  

	1.2	Any Marketing Authorisation Transfer or Marketing Authorisation Re-registration (as applicable) shall each be effected on a Market-by-Market basis (such that there shall not be any staggered Marketing Authorisation
Transfer or Marketing Authorisation Re-registration (as the case may be) on a Product-by-Product basis in any Market), unless otherwise agreed between the Seller and the Purchaser. 

 

	1.3	With effect from the Closing Date until the Marketing Authorisation Transfer Date or the Marketing Authorisation Re-registration Date (as applicable), the Seller shall procure that each Marketing Authorisation Holder
shall hold the Marketing Authorisation(s) in its name but for the account, risk and benefit of the relevant Marketing Authorisation Transferee. 

Submission of MA Documentation 
  

	1.4	Without prejudice to paragraph 1.5, the Purchaser shall be responsible for preparing and submitting, or for procuring that there is prepared and submitted (in any such case at the Purchaser’s cost and expense), all
notices, applications, submissions, reports and any other instruments, documents, correspondence or filings necessary to complete Marketing Authorisation Transfer or Marketing Authorisation Re-registration (as applicable) (the “MA
Documentation”). The MA Documentation shall be prepared in accordance with Applicable Law as soon as reasonably practicable. 

  

	1.5	At the Seller’s election, the Purchaser shall procure that advanced drafts of the MA Documentation are submitted to the Seller so as to allow the Seller and/or the Marketing Authorisation Holder a reasonable
opportunity to provide comments on such MA Documentation before it is submitted to the relevant Governmental Entity. The Purchaser shall incorporate all comments on such drafts as may reasonably be made by the Seller and/or the Marketing
Authorisation Holder PROVIDED THAT the Purchaser shall not be obliged to incorporate any comments if the Purchaser considers, acting reasonably that to do so would materially delay Marketing Authorisation Transfer or Marketing Authorisation
Re-registration (as applicable). 

  
  

 
 112 

	1.6	Where under Applicable Law the MA Documentation is required to be submitted to the relevant Governmental Entity: 

  

	 	1.6.1	by the Marketing Authorisation Holder, the Purchaser shall procure that the finalised MA Documentation is provided to the Seller after such MA Documentation is finalised in accordance with paragraph 1.5 above and the
Seller shall, in turn, procure that the Marketing Authorisation Holder submits such MA Documentation to the relevant Governmental Entity (the timing and date of such submission to be agreed with the Purchaser) and the Seller shall promptly
thereafter advise the Purchaser of such submission and provide a copy of the relevant MA Documentation (in the form submitted) to the Purchaser; and 

  

	 	1.6.2	by the Marketing Authorisation Transferee, the Purchaser shall procure that the relevant Marketing Authorisation Transferee submits the finalised MA Documentation to the relevant Governmental Entity as soon as
reasonably after such MA Documentation is finalised in accordance with paragraph 1.5 above and the Purchaser shall promptly thereafter advise the Seller of such submission and provide a copy of the relevant MA Documentation (in the form submitted)
to the Seller. 

  

	1.7	From the Closing Date, the Seller shall procure that the relevant Marketing Authorisation Holder shall, as soon as reasonably practicable, sign any notices, applications, submissions, reports and other instruments,
documents, correspondence or filings presented to it by the Purchaser or the relevant Marketing Authorisation Transferee that are necessary to effect Marketing Authorisation Transfer or Marketing Authorisation Re-registration (as applicable). The
Marketing Authorisation Holder shall: 

  

	 	1.7.1	provide notice of its consent to a Marketing Authorisation Transfer or Marketing Authorisation Re-registration if required by any Governmental Entity; and 

 

	 	1.7.2	provide to the Purchaser or the relevant Marketing Authorisation Transferee any information or other data or technical or other information in its possession that relates to the relevant Marketing Authorisation and that
is required by a relevant Governmental Entity or otherwise reasonably required by the Purchaser or the relevant Marketing Authorisation Transferee to assist the Purchaser or the relevant Marketing Authorisation Transferee to effect the relevant
Marketing Authorisation Transfer or Marketing Authorisation Re-registration; 

  

	 	1.7.3	in the event of any request for information or any query from any relevant Governmental Entity in respect of Marketing Authorisation Transfer or the Marketing Authorisation Re-registration (as applicable), the relevant
party receiving such request or query shall provide copies of any such request or query to the Seller or, as the case may be, to the Purchaser. The Purchaser shall be responsible for preparing, or shall be responsible for procuring that there is
prepared, (at the Purchaser’s cost and expense) any response to such a request or query with the intention that such request or query shall be dealt with as promptly and efficiently as possible. In advance of finalising any such response, the
Purchaser shall procure that the relevant response is submitted to the Seller so as to allow the Seller and/or the relevant Marketing Authorisation Holder a reasonable opportunity to provide comments on such response before it is submitted to the
Governmental Entity. The Purchaser shall procure that relevant Marketing Authorisation Transferee (i) shall submit the response to the relevant Governmental Entity as soon as reasonably practicable after the same has been finalised in
accordance with this paragraph 1.7.3 and (ii) shall provide a copy of the relevant response (in the form submitted) to the Seller. 

  
  

 
 113 

	2	Obligations Pending Marketing Authorisation Transfer or Marketing Authorisation Re-Registration 

  

	2.1	Unless otherwise required by Applicable Law or a relevant Governmental Entity (or unless otherwise agreed in writing by the Seller and the Purchaser), from the Closing Date until the applicable Marketing Authorisation
Transfer Date or Marketing Authorisation Re-registration Date: 

  

	 	2.1.1	the Seller shall: 

  

	 	(i)	maintain in force (or procure that there is maintained in force) each Marketing Authorisation, and shall not voluntarily amend, cancel or surrender any Marketing Authorisation unless requested to do so in writing by the
Purchaser or required to do so by any Applicable Law or any Governmental Entity; 

  

	 	(ii)	with the Purchaser’s consent (not to be unreasonably withheld or delayed) progress (or procure that there is progressed) any registrations, variations or renewals to Marketing Authorisations initiated by the Seller
(or any other member of the Seller’s Group) prior to the Closing Date or withdraw them upon the request of the Purchaser; 

  

	 	(iii)	procure that each Marketing Authorisation Holder shall comply with the terms of any Marketing Authorisation and shall notify the Purchaser as soon as reasonably practicable of the details of any variations or renewals
initiated following the Closing Date; 

  

	 	(iv)	inform the Purchaser of any impending renewals of Marketing Authorisations as at the Closing Date and the parties shall discuss in good faith to what extent any such renewal will be pursued or withdrawn (it being agreed
that the Purchaser shall have the final decision in any such matter); 

  

	 	(v)	not without the consent of the Purchaser, initiate any additional variations or amendments to the Marketing Authorisations, except to the extent required by any Governmental Entity or where failure to do so would breach
Applicable Law; and 

  

	 	(vi)	consider in good faith any request by the Purchaser to apply for a new marketing authorisation in respect of a Product PROVIDED THAT if the Seller agrees to submit such application, any costs or expenses incurred by the
Seller in making such application shall be for the Purchaser’s account and shall constitute MA Costs; 

  

	 	2.1.2	without prejudice to the generality of the foregoing paragraph 2.1.1(iii), the Purchaser acknowledges and agrees that each Marketing Authorisation Holder shall be entitled to do (or to procure that there is done) any or
all of the following (and the Purchaser acknowledges that, where the relevant Marketing Authorisation Holder so chooses and unless otherwise agreed, responsibility for each of the following activities shall rest with the relevant Marketing
Authorisation Holder): 

  

	 	(i)	pharmacovigilance activities related to the Marketing Authorisations, which activities shall be conducted in accordance with Applicable Law, the Pharmacovigilance Agreement, and the standards, policies and procedures of
the Seller’s Group from time to time in force; and 

  
  

 
 114 

	 	(ii)	conducting any and all communications with a Governmental Entity in respect of a Marketing Authorisation (including, without limitation to the generality of the foregoing, attending any meetings with relevant
Governmental Entities and filing and submitting all reports and other documents which it reasonably considers necessary to be submitted in order to comply with Applicable Law or its obligations under this Agreement), PROVIDED THAT responsibility for
(a) the costs of preparation of any such documents, reports and/or filings shall be borne by the Purchaser (or the relevant Marketing Authorisation Transferee) to the extent such costs are reasonably necessary, and (b) the submission of MA
Documentation shall be the responsibility of the Purchaser in accordance with paragraph 1.4 above, PROVIDED THAT the Seller shall ensure that the Purchaser is kept fully and promptly informed of any such communications or submissions in advance, to
the extent reasonably practicable; and 

  

	 	2.1.3	the Seller shall procure that each Marketing Authorisation Holder shall act in accordance with the reasonable instructions of the Purchaser or the Marketing Authorisation Transferee in respect of each Marketing
Authorisation in respect of which such Marketing Authorisation Holder is the holder, PROVIDED THAT no Marketing Authorisation Holder shall be obliged to comply with such instructions to the extent the same: (i) infringe the terms of the
relevant Marketing Authorisation(s); or (iii) are otherwise inconsistent with the provisions of the Pharmacovigilance Agreement relating to the Seller; 

  

	 	2.1.4	the Purchaser shall only request artwork changes to the extent such changes are required in order to comply with Applicable Law; 

  

	 	2.1.5	the Purchaser shall submit to the Seller (or shall procure that there is submitted) written details (in such form and with such supporting materials as the Seller may reasonably request) of any new, amended or proposed
advertising and promotional activity or training materials in respect of any Product Commercialised pursuant to any Marketing Authorisation (including (without limitation) any material reasonably requested by the Seller in order to validate new
and/or amended promotional or training materials), and the Purchaser acknowledges and agrees that no such advertising, promotional or training activity shall be implemented, undertaken or otherwise commenced without the prior written consent of the
Seller (for itself and on behalf of the relevant Marketing Authorisation Holder), such consent not to be unreasonably withheld. The Purchaser further agrees and acknowledges that, if it so chooses, the Seller shall be entitled to assume
responsibility for obtaining (or procuring that there is obtained) the consent(s) and approval(s) of any relevant Governmental Entity required for such new, amended or proposed advertising and promotional activity or training activity; and

  
  

 
 115 

	 	2.1.6	to the extent permitted by the terms of the relevant Marketing Authorisation, the Purchaser or any other member of the Purchaser’s Group shall Commercialise the Product(s) which are the subject of such Marketing
Authorisation (notwithstanding that such Marketing Authorisation is held in the name of the relevant Marketing Authorisation Holder and, for the avoidance of doubt, the proceeds of any such Commercialisation shall be for the benefit of the
Purchaser’s Group) and the Purchaser shall: 

  

	 	(i)	indemnify each member of the Seller’s Group against any and all actions, claims, demands, investigations, judgments, proceedings, liabilities, loss, damages, payments, costs and expenses arising in relation to the
Commercialisation of the Products by the Purchaser or any other member of the Purchaser’s Group under this paragraph (i); and 

  

	 	(ii)	procure that such Product(s) are Commercialised in compliance with the terms of the relevant Marketing Authorisation and/or the requirements of the relevant Governmental Entity. 

 

	3	New and Pending Marketing Authorisations in Respect of the Products 

  

	3.1	If, at any time prior to Closing, any member of the Seller’s Group is granted or otherwise comes to hold any marketing authorisation which relates exclusively to one or more Products (a “New Marketing
Authorisation”) then: 

  

	 	3.1.1	the Seller undertakes to the Purchaser to notify the Purchaser as soon as reasonably practicable following the date on which the relevant member of the Seller’s Group is granted, or becomes entitled to, the New
Marketing Authorisation; and 

  

	 	3.1.2	the provisions of paragraphs 1 and 2 above shall apply to that new Marketing Authorisation. 

  

	3.2	Where a member of the Seller’s Group has submitted to any Governmental Entity any application relating to the grant of a new marketing authorisation in respect of the Vaccines Group which is pending or in process
as at the date of this Agreement (a “Pending Marketing Authorisation”): 

  

	 	3.2.1	the Seller shall continue to be responsible for preparation and submission of all documents required to register such Pending Marketing Authorisation but, following Closing, it shall do so at the Purchaser’s cost
and shall pass responsibility for such Pending Marketing Authorisation to the Purchaser (or such member of the Purchaser’s Group as the Purchaser may nominate) as soon reasonably possible after Closing, subject to Applicable Law;

  

	 	3.2.2	from the Closing Date, the provisions of paragraph 1 shall apply mutatis mutandis to any registration process for any Pending Marketing Approval. 

 

	4	MA Costs 

 From the Closing Date, the Purchaser shall be responsible for all necessary
costs of preparation and submission of MA Documentation and, save as expressly provided in this Agreement, any other necessary costs incurred by the Seller or a member of the Seller’s Group in connection with the maintenance and any variations,
amendments and renewals of the Marketing Authorisations relating to the Products or for any matter requested by the Purchaser pursuant to this Part 2 of Schedule 8 and for all fees and costs reasonably incurred by the relevant member of the
Seller’s Group in complying with its obligations in respect of a Marketing Authorisation Transfer or Marketing Authorisation Re-registration (“MA Costs”). 

  
  

 
 116 

	5	Obligations following Marketing Authorisation Transfer or Marketing Authorisation Re-Registration 

  

	5.1	On and from the relevant Marketing Authorisation Transfer Date or Marketing Authorisation Re-registration Date (as applicable), the Purchaser shall procure that each Marketing Authorisation Transferee shall assume and
be solely responsible for: 

  

	 	5.1.1	all obligations as the holder of such Marketing Authorisation including (subject to the terms of the Pharmacovigilance Agreement) pharmacovigilance activities related to such Marketing Authorisation; 

 

	 	5.1.2	all activities and actions required by Applicable Law in connection with such Marketing Authorisation; and 

  

	 	5.1.3	any and all outstanding commitments and obligations to the relevant Governmental Entities with respect to the relevant Marketing Authorisation, save for any such commitments or obligations arising from a breach of this
Agreement by the Seller. 

  

	5.2	In the event that, following Marketing Authorisation Transfer or Marketing Authorisation Re-registration in respect of any Product, the Seller wishes to apply for a marketing authorisation in respect of a retained
product, the Purchaser shall (and shall procure that the relevant Marketing Authorisation Transferee shall) co-operate with and provide all reasonable assistance to the Seller (or the relevant member of the Seller’s Group) at the Seller’s
costs as may be reasonably required for the purposes of applying for such new marketing authorisation, including (without limitation) providing the Seller (or the relevant member of the Seller’s Group) and/or any Governmental Entity with such
access to Marketing Authorisation Data or such other data or technical or other information as is reasonably requested by the relevant Governmental Entity or is otherwise reasonably required by the Seller or the relevant member of the Seller’s
Group. 

  
  

 
 117 

 Schedule 8 

Product Approvals and Product Applications 

Part 3 
 List of Products,
Products Under Registration and Pipeline Products 
 PRODUCTS 
  

	1.	Adsorbed Diphtheria Vaccine Behring for Adults 

  

	2.	ANATETALL 

  

	3.	Bexsero 

  

	4.	Bivalent OPV 

  

	5.	Botulism Antitoxin Behring 

  

	6.	CRm-Hib bulk conc. 

  

	7.	Dif-Tet-All Adults 

  

	8.	DT Concentrate (preservative free) 

  

	9.	Encepur® adults 

  

	10.	Encepur® children 

  

	11.	MENJUGATE 

  

	12.	MENJUGATE KIT 

  

	13.	Menveo 

  

	14.	MONO OPV1 

  

	15.	MONO OPV3 

  

	16.	POLIORAL 

  

	17.	Poliovax-in 

  

	18.	QUATTVAXEM 

  

	19.	RabAvert® 

  

	20.	Rabipur® ex India 

  

	21.	Rabipur® ex Marburg 

  

	22.	Td-pur® 

  

	23.	Td-Virelon 

  

	24.	Tetanol pur 

  

	25.	TT Concentrate 

  

	26.	Vaxem Hib 

  

	27.	Vaxem Hib (Bulk) 

  
  

 
 118 

 PRODUCTS UNDER REGISTRATION 
  

	1.	Bexsero – in Argentina, Brazil, Chile, Colombia and Uruguay 

  

	2.	Menjugate Liquid – in Finland 

  

	3.	Menveo – in Egypt, South Africa, Thailand and Venezuela 

  

	4.	Rabipur® ex India – in Kazakhstan, Malaysia, Morocco and Zimbabwe 

 

	5.	Rabipur® ex Marburg – in India 

  

	6.	Tetanol pur – in Venezuela 

  

	7.	Vaxem Hib – in Vietnam 

 PIPELINE PRODUCTS 

[***] 
  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
  

 
 119 

 Schedule 8 

Product Approvals and Product Applications 

Part 4 
 Tenders 

From Closing until the Marketing Authorisation Transfer Date in any Market, the Seller shall, and shall procure that each member of the Seller’s Group
and the relevant Marketing Authorisation Holder shall, to the extent permitted by Applicable Law: 
  

	(a)	inform the Purchaser in writing of any Call for New Tender as soon as reasonably practicable following receipt; and 

  

	(b)	co-operate with and provide reasonable assistance to the Purchaser (or the relevant member of the Purchaser’s Group) for the purposes of responding to the Call for New Tender or otherwise applying for a new tender;
and 

  

	(c)	where Applicable Law requires such responses or applications to be made by the Marketing Authorisation Holder, the Seller shall procure that the Marketing Authorisation Holder submits such responses or applications on
behalf of the Purchaser PROVIDED THAT the Purchaser shall indemnify the Seller and/or the relevant Marketing Authorisation Holder (as the case may be) for any and all costs, expenses and liabilities suffered or reasonably incurred by the Seller
and/or the Marketing Authorisation Holder in complying with or as a result of the provisions of this paragraph. 

  
  

 
 120 

 Schedule 9 

Certificate 
 (Clause 1.1)

 To: GlaxoSmithKline plc 
 [Date] 

Certificate 
 This Certificate is issued in
accordance with clause 4.4.1(iii)(b) and paragraph 1.1.4 of Schedule 15 of the sale and purchase agreement between Novartis AG and GlaxoSmithKline plc dated 22 April 2014 (the “Agreement”). Unless otherwise defined, capitalised
words used in this Certificate shall have the meanings given to them in the Agreement. 
 We confirm that: 

1. no Material Adverse Effect has occurred between the date of the Agreement and the date of this Certificate; 

2. having made due and careful enquiry, we are not aware of any breach or breaches of Clause 9.1 which alone or together give rise to a Material Adverse
Effect; and 
 [either] 
 3. having made
due and careful enquiry, we are not aware of any breach or breaches of the Seller’s Warranties that would have occurred and that would, alone or together, have given rise to a Material Adverse Effect had the Seller’s Warranties been
repeated immediately before Closing by reference to the facts, circumstances and knowledge then existing as if references in the Seller’s Warranties to the date of this Agreement were references to the Closing Date. 

[or] 
 3. having made due and careful
enquiry, we are aware of the following material breaches of the Seller’s Warranties that would, alone or together, be material and have occurred had the Seller’s Warranties been repeated immediately before Closing by reference to the
facts, circumstances and knowledge then existing as if references in the Seller’s Warranties to the date of this Agreement were references to the Closing Date. 

[description of material breaches.] 

 
 For an on behalf of Novartis AG 

  
  

 
 121 

 Schedule 10 

Transferred Contracts 

(Clause 2.3) 
  

	1	Separation of Shared Business Contracts 

  

	1.1	Prior to Closing, the Seller and the Purchaser shall discuss and agree in good faith a process to identify all material Shared Business Contracts  

 

	1.2	The Seller shall use all reasonable efforts to maintain relationships under the Shared Business Contracts and continue to operate the Shared Business Contracts, including without limitation fulfilling all its
obligations under the Shared Business Contracts, in the same manner as it has for the twelve months prior to this Agreement. 

  

	1.3	The Purchaser may, by notice to the Seller at any time prior to the Marketing Authorisation Transfer Date in respect of the relevant Product in the relevant territory, elect to take the rights and obligation of
the Relevant Part of any Shared Business Contract. 

  

	1.4	If the Purchaser makes an election under paragraph 1.3 above, the Seller and the Purchaser shall use all reasonable endeavours to procure that an arrangement is entered into with the relevant counterparty to each
Shared Business Contract, the effect of which shall be that, with effect from whichever is the later of Marketing Authorisation Transfer Date and the date of the relevant arrangement, the benefit and burden of the Relevant Part is severed from such
Shared Business Contract and an agreement or arrangement equivalent to such Shared Business Contract is entered into between the relevant counterparty and a member of the Purchaser’s Group (or the Relevant Part of the Shared Business Contract
is sub-licensed to such Purchaser) (a “Separation”). For the avoidance of doubt, no part of any such Shared Business Contract shall be severed and transferred to any Purchaser in so far as it relates to the Seller’s Retained
Business, any product other than the Products or any Excluded Asset. 

  

	2	Obligation to obtain Third Party Consents 

  

	2.1	In relation to any Transferred Contract (excluding, for the purposes of this Schedule 10, any Product Approval or Product Application) or Transferred Intellectual Property Contract or Co-Owned Vaccines Group
Intellectual Property Right or Transferred Plant and Equipment which is not assignable or sub-licensable without a Third Party Consent or a Separation of a Shared Business Contract which is not separable without a Third Party Consent, this Agreement
shall not be construed as an assignment, an attempted assignment, a sub-licensing or an attempted sub-licensing and the Seller and the Purchaser shall each use reasonable endeavours both before and after Closing to obtain all necessary Third Party
Consents as soon as possible and shall keep the other informed of progress in obtaining such Third Party Consents. The Seller shall deliver to the Purchaser, on Closing or, if later, as soon as possible after receipt, any Third Party Consent.

  

	2.2	In connection with the obtaining of any Third Party Consent referred to in paragraph 2.1, the Purchaser shall supply to the Seller such information as may be reasonably requested by the Seller or any relevant
third party. 

  

	2.3	Save as otherwise provided in this Agreement, the cost of any fee demanded by the third party as consideration for giving the Third Party Consent shall be borne by the Purchaser, provided that: 

 

	 	2.3.1	the cost is agreed in advance by the Purchaser (such agreement not to be unreasonably withheld or delayed); and 

  
  

 
 122 

	 	2.3.2	no party shall be required to bear any internal or administrative costs of the other party in relation to any Third Party Consent. 

  

	3	Obligations until Third Party Consents are obtained/where Third Party Consents are refused 

  

	3.1	Subject to paragraph 3.2, the Purchaser shall assume, carry out, perform and discharge the Seller’s and the Business Seller’s obligations arising under the Transferred Contracts, Transferred
Intellectual Property Contracts, Co-Owned Vaccines Group Intellectual Property Rights, Transferred Plant and Equipment, and the Relevant Part of the Shared Business Contracts as from Closing. 

 

	3.2	In respect of any Transferred Contract, Transferred Intellectual Property Contract, Transferred Plant and Equipment, Relevant Part of Shared Business Contract or Co-Owned Vaccines Group Intellectual Property Right, from
Closing until the relevant Third Party Consent has been obtained as contemplated by paragraph 2.1 or where the Third Party Consent has been refused: 

  

	 	3.2.1	the relevant Business Seller shall hold on trust to the extent it is lawfully able to do so or, where it is not lawfully able to do so or where holding on trust is not possible under local law or otherwise
impracticable, the relevant Business Seller and the Purchaser shall make such other arrangements between themselves to provide to the Purchaser the benefits of the Contract (other than amounts corresponding to any Tax Liability by the relevant
Business Seller in respect of amounts due under or in respect of the Transferred Contract, Transferred Intellectual Property Contract, Relevant Part of Shared Business Contract, Transferred Plant and Equipment or Co-Owned Vaccines Group Intellectual
Property Right including the enforcement at the cost and for the account of the Purchaser of all rights of the relevant Business Seller against any other party thereto; 

 

	 	3.2.2	to the extent that the relevant Business Purchaser is lawfully able to do so, the Purchaser shall perform the relevant Business Seller’s obligations under the Contract as agent or sub-contractor and shall
indemnify the Seller and the relevant Business Seller if the Purchaser fails to do so. To the extent that the Purchaser is not lawfully able to perform such obligations, the Seller shall procure that relevant Business Seller shall, (subject to being
indemnified by the Purchaser for any Losses the Seller or the relevant Business Seller may incur in connection therewith) do all such things as the Purchaser may reasonably require to enable due performance of the Transferred Contract, Transferred
Intellectual Property Contract, Transferred Plant and Equipment or Relevant Part of the Shared Business Contract and the Purchaser shall indemnify the relevant Business Seller in respect thereof. 

 

	4	Failure to Obtain Third Party Consents 

  

	4.1	If a Third Party Consent is refused or otherwise not obtained on terms reasonably acceptable to the Purchaser within 18 months of Closing, or in the case of a Separation, 18 months of the Marketing Authorisation
Transfer Date: 

  

	 	4.1.1	the Seller shall be entitled to procure the termination of the Transferred Contract, Transferred Plant and Equipment, Transferred Intellectual Property Contract or Relevant Part of the Shared Business Contract and the
obligations of the parties under this Agreement in relation to such Transferred Contract, Transferred Intellectual Property Contract or Relevant Part of the Shared Business Contract shall cease forthwith; 

  
  

 
 123 

	 	4.1.2	references in this Agreement to the Transferred Contracts, Transferred Intellectual Property Contracts, Transferred Plant and Equipment or Relevant Part of the Shared Business Contract and the Vaccines Group Businesses
(other than in this paragraph 4) shall be construed as excluding such Transferred Contract, Transferred Intellectual Property Contract, Transferred Plant and Equipment or Relevant Part of the Shared Business Contract; and 

 

	 	4.1.3	the Seller and the Purchaser shall use all reasonable efforts to put in place alternative arrangements so as to give the Purchaser equivalent benefits or rights as would have been enjoyed under the terminated
Transferred Contract, Transferred Intellectual Property Contract, Relevant Part of the Shared Business Contract or Co-Owned Vaccines Group Intellectual Property Right. 

  
  

 
 124 

 Schedule 11 

Employees 
 (Clause 2.4.1)

  

	1	Information and consultation 

  

	1.1	At such time as the parties agree to be appropriate following the public announcement of the matters contemplated by this Agreement, the Seller and the Purchaser or the relevant member of the Purchaser’s
Group shall jointly communicate to the Employees an agreed notice which shall, other than to the extent the parties agree otherwise: 

  

	 	1.1.1	inform the Employees that following Closing those Employees who continue to be employed in the Business (as carried on by the Vaccines Group) would be employed by the Purchaser or relevant member of the Purchaser’s
Group; and 

  

	 	1.1.2	comply with the requirements of any applicable national law. 

 For the avoidance of doubt the
parties may agree to issue such notice to different Employees or categories of Employees at different times and in different forms. 
  

	1.2	Notwithstanding the operation of paragraph 1.1 above, the Seller and the Purchaser agree to comply with any more onerous notice requirements imposed by local laws. 

 

	1.3	The Purchaser (on its own behalf and on behalf of any relevant member of the Purchaser’s Group) shall provide the Seller (for itself and any relevant member of the Seller’s Group) with such information
and assistance at such times as the Seller may reasonably request or as may be reasonably necessary for the Seller or any other member of the Seller’s Group to comply with any formal or informal requirement to inform or consult with the
Employees, a relevant trade union, a relevant works council, or any other employee representatives in connection with the matters contemplated by this Agreement (which formal or informal requirements the Seller hereby undertakes to comply or procure
compliance with). Where reasonably necessary to ensure compliance with any formal or informal requirements or obligations to inform or consult with Employees, a relevant trade union, a relevant works council or any other employee representatives in
connection with the matters contemplated by this Agreement, the Seller (for itself and for each member of the Seller’s Group) and the Purchaser (for itself and for each member of the Purchaser’s Group) agree that the Purchaser or relevant
member of the Purchaser’s Group shall cooperate with and participate in any information, negotiation and/or consultation process as reasonably required by the Seller. 

 

	1.4	As soon as practicable following the date of this Agreement, the Purchaser agrees to provide on a timely basis such information, in writing, in respect of its existing terms and conditions of employment as may
reasonably be required by the Seller so as to facilitate the Seller’s information and consultation exercise with its Employees in respect of the matters set out in this Agreement. 

 

	2	Vaccines Business Employees 

  

	2.1	General 

  

	 	2.1.1	The Purchaser shall (or shall procure that the relevant member of the Purchaser’s Group shall) fulfil all its duties and obligations under Applicable Law in relation to the Vaccines Business Employees. Where
the provisions of local law do not provide for an automatic transfer of the employment of the Vaccines Business Employees to the Purchaser or a relevant member of the Purchaser’s Group with effect from (and including) the Closing Date, then
paragraph 2.2 below shall apply. Where the provisions of local law do provide for an automatic transfer of employment of the Relevant Vaccines Business Employees to the Purchaser or the relevant member of the Purchaser’s Group with effect from
(and including) the Closing Date, then paragraph 2.3 below shall apply. 

  
  

 
 125 

	 	2.1.2	The parties acknowledge and agree that: 

  

	 	(i)	any Deferred Employee shall be treated for all purposes under this Agreement as if such Deferred Employee were a Vaccines Business Employee or a Vaccines Group Company Employee (as appropriate); and 

 

	 	(ii)	the Purchaser’s obligations under this Schedule 11 shall apply in respect of each Deferred Employee in the same way as they do to each Vaccines Business Employee or Vaccines Group Company Employee (as appropriate);
and 

  

	 	(iii)	if any Deferred Employee accepts an offer of employment made by the Purchaser under paragraph 2.2.1 below or becomes an employee of a Vaccines Group Company after the Closing Date, such Deferred Employee shall further
be treated for all purposes under this Agreement as a Transferred Employee. 

  

	 	2.1.3	For the avoidance of doubt, this paragraph 2 shall not apply to any Excluded Employee, who will remain employed by the Seller or the relevant member of the Seller’s Group. 

 

	2.2	Where no automatic transfer of employment 

  

	 	2.2.1	In such timescale as the parties may agree, but in any event at least 30 Business Days prior to the Closing Date, the Purchaser or relevant member of the Purchaser’s Group shall make an offer to each Vaccines
Business Employee employed by the Seller or a member of the Seller’s Group to employ him or her under a new contract of employment to commence with effect from (and including) the Closing Date provided that such employee continues to be a
Vaccines Business Employee until the Closing Date. Save as otherwise agreed with the Seller (such agreement not to be unreasonably withheld), the offer to be made will be on the same terms and conditions (including as to period of continuous
employment) as were provided to that Vaccines Business Employee immediately prior to the Closing Date. The Purchaser shall keep the Seller updated throughout the offer process on when offers are made and accepted or rejected. 

 

	 	2.2.2	If the Vaccines Business Employee wishes to accept the offer of employment from the Purchaser or the relevant member of the Purchaser’s Group, then the Seller shall (or shall procure that the relevant member of
Seller’s Group shall), insofar as it is permitted by Applicable Law, waive the requirement on the Vaccines Business Employee concerned to give any period of notice of termination of his or her employment under the terms of his or her employment
so as to allow the Vaccines Business Employee to commence employment with the Purchaser or relevant member of the Purchaser’s Group with effect from (and including) the Closing Date. 

  
  

 
 126 

	2.3	Where automatic transfer of employment 

 If the Transfer Regulations do not or are found
not to or are alleged not to apply to any person who is a Relevant Vaccines Business Employee and to whom paragraph 2.2 does not apply, the Purchaser agrees that following Closing: 

 

	 	2.3.1	in consultation with the Seller, the Purchaser or relevant member of the Purchaser’s Group shall within 10 Business Days of being so requested by the Seller (as long as the request is made no later than 3
months after Closing) (or if the Purchaser so chooses), make such Relevant Vaccines Business Employee an offer in writing to employ him or her under a new contract of employment subject to, and to take effect upon, a date agreed between the parties
and such employee; and 

  

	 	2.3.2	save as otherwise agreed with the Seller (such agreement not to be unreasonably withheld) the offer to be made will be on the same terms and conditions (including as to period of continuous employment) as were
provided to that Relevant Vaccines Business Employee immediately prior to the Closing Date. 

  

	3	Wrong-pocket arrangements for persons other than Relevant Employees 

  

	3.1	If the contract of employment of any person other than a Relevant Employee is found or alleged to have effect upon Closing as if originally made with the Purchaser or another member of the Purchaser’s Group
(including any Vaccines Group Company) as a consequence of this Agreement, or if any Vaccines Group Company employs any person who does not work wholly or substantially in the Business (as carried on by the Vaccines Group), the Seller agrees that
following Closing: 

  

	 	3.1.1	in consultation with the Purchaser, the Seller or relevant member of the Seller’s Group may within 10 Business Days of being so requested by the Purchaser (as long as the request is made no later than 3 months
after Closing) (or if the Seller so chooses), make to that person an offer in writing to employ him or her under a new contract of employment subject to, and to take effect upon, the termination referred to below; and 

 

	 	3.1.2	the offer to be made will be on the same terms and conditions (including as to period of continuous employment) as were provided to that person immediately prior to the Closing Date. 

 

	3.2	After the expiry of the 10 Business Days referred to at paragraph 3.1 above, and provided that the relevant member of the Purchaser’s Group takes such steps as are legally possible to terminate the
employment of the person concerned as soon as reasonably practicable after becoming aware of the finding or allegation referred to at paragraph 3.1 above (either by giving notice or transferring the person by agreement to be concluded between the
relevant member of the Purchaser’s Group, the person concerned and the relevant member of the Seller’s Group), the Seller shall be responsible for and shall indemnify and keep indemnified the Purchaser (for itself and as trustee for any
relevant member of the Purchaser’s Group) against all Losses from time to time made, suffered or incurred by the Purchaser (or any other member of the Purchaser’s Group) as a result of: 

 

	 	3.2.1	the actual or alleged transfer to a member of the Purchaser’s Group and (regardless of whether there has been such a transfer) any employment liabilities relating to such person; 

 

	 	3.2.2	employing such person on and from the Closing Date until such termination (up to the time reasonably expected to have achieved such termination in accordance with the terms of the contract of employment and Applicable
Law) but subject to a maximum period of 6 months unless prevented by the terms of the contract of employment or Applicable Law; and 

  
  

 
 127 

	 	3.2.3	such termination. 

  

	3.3	The parties agree to co-operate in good faith to minimise the Losses which are subject to the indemnity referred to in paragraph 3.2 above.  

 

	4	Employment liabilities 

  

	4.1	All wages, salaries, employer’s liabilities in respect of associated Taxes and other periodic outgoings in respect of the Transferred Employees which relate to a period: 

 

	 	4.1.1	after the Closing Date shall be borne or discharged by the Purchaser or relevant member of the Purchaser’s Group; and 

  

	 	4.1.2	on or before the Closing Date shall be borne or discharged by the Seller or relevant member of the Seller’s Group. 

  

	4.2	The Seller shall (for itself and for each member of the Seller’s Group) indemnify and keep indemnified the Purchaser (for itself and as trustee for each other member of the Purchaser’s Group) against
all Losses (ignoring any amount in respect of Employee Benefits, as to which see Schedule 12) in respect of: 

  

	 	4.2.1	the employment of any Employee at any time prior to the Closing Date (excluding any Transferred Employee Benefit Liabilities (as defined in Schedule 12) which the Purchaser agrees to assume in accordance with Schedule
12); 

  

	 	4.2.2	any termination of the employment of any Employees prior to the Closing Date including, but not limited to, all claims relating to severance, termination pay, pay in lieu of notice of termination and similar obligations
(excluding any liability arising directly as a result of any breach of the commitments set out in paragraph 5 or 6 below by the Purchaser or a member of the Purchaser’s Group and any act or omission by the Purchaser or any member of the
Purchaser’s Group in relation to any Employee before Closing as a result of which that Employee treats his employment as having been terminated prior to the Closing Date); 

 

	 	4.2.3	any amount which becomes payable to any Employee or benefit to which any Employee becomes entitled by reason of this Agreement or the matters it contemplates, including any change of control or other payment or benefit
(and including any enhancement of severance terms on a subsequent termination of employment but excluding any Losses relating to any share-based incentive schemes, as to which see paragraph 11 below); 

 

	 	4.2.4	any failure by the Seller or any other member of the Seller’s Group to comply with any obligation to inform or consult with employee representatives in connection with the matters contemplated by this Agreement
(other than as a result of any failure set out in paragraph 4.3.3 below); and 

  

	 	4.2.5	any breach by the Seller or any other member of the Seller’s Group of paragraph 4.1.2 above or paragraph 4.4, 4.5 or 10 below. 

  
  

 
 128 

	4.3	The Purchaser shall (for itself and for each member of the Purchaser’s Group) indemnify and keep indemnified the Seller (for itself and as trustee for each other member of the Seller’s Group) against all
Losses (ignoring any amount in respect of Employee Benefits, as to which see Schedule 12) in respect of: 

  

	 	4.3.1	the employment of any of the Transferred Employees on and after the Closing Date (including, without limitation, any changes to terms and conditions of employment by the Purchaser or any other member of the
Purchaser’s Group); 

  

	 	4.3.2	any termination of the employment of any Transferred Employees on and after the Closing Date including, but not limited to, all claims relating to severance, termination pay, pay in lieu of notice of termination and
similar obligations except as contemplated under paragraph 3.2 above; 

  

	 	4.3.3	any failure by the Purchaser or any other member of the Purchaser’s Group to provide information and reasonable assistance to the Seller to enable the Seller or any other member of the Seller’s Group to comply
with any obligation to inform or consult with employee representatives in connection with the matters contemplated by this Agreement; 

  

	 	4.3.4	any breach by the Purchaser or any other member of the Purchaser’s Group of paragraph 4.1.1 above or paragraph 4.4 or 4.5 below; and 

 

	 	4.3.5	any act or omission by the Purchaser or any member of the Purchaser’s Group in relation to any Employee before Closing as a result of which that Employee treats his employment as having been terminated prior to the
Closing Date. 

  

	4.4	Any amount payable to or in respect of any Transferred Employee after Closing (including without limitation amounts paid under paragraph 4.5 below) which (ignoring vesting conditions and any amount payable in
respect of Employee Benefits or otherwise in accordance with Schedule 12) is referable to the period prior to Closing is payable by the Seller (for itself or on behalf of the relevant Share Seller or Business Seller). Responsibility for amounts
payable which are only partly referable to the period prior to Closing (again ignoring vesting conditions) is to be shared between the Seller (for itself or on behalf of the relevant Share Seller or Business Seller) and the Purchaser (for itself or
on behalf of the relevant member of the Purchaser’s Group) such that the Seller bears S per cent. of the cost and the Purchaser bears P per cent., where S is the percentage of the period by reference to which the amount was earned which fell on
or before the Closing Date and P is the percentage of that period which falls after the Closing Date. The Purchaser shall, or shall procure that such other member of the Purchaser’s Group shall, pay such amounts when due to the relevant
Transferred Employees on or after Closing and shall deduct and/or pay and account for any Tax payable or accountable for by the employer in respect of such amounts. The Seller covenants to reimburse the Purchaser in respect of any such amount (or S
per cent. of it where relevant), including any Tax payable or accountable for by the employer in respect of such amount, within 30 days of receiving notification that it has been paid to the extent such amounts are not reflected in the Closing
Statement. The Seller will provide the Purchaser with all information and documentation reasonably necessary to allow such payments to be made. 

  

	4.5	Following the Closing Date: 

  

	 	4.5.1	the Purchaser shall, or shall procure that a member of the Purchaser’s Group shall, pay a pro-rated cash bonus of an amount advised by the Seller to the Purchaser to each Transferred Employee who
participated in an annual cash bonus plan immediately before the Closing Date in their first payroll payment after the Closing Date; and 

  
  

 
 129 

	 	4.5.2	where the Seller is able to determine performance, any such bonus payment made to such eligible employees by the Purchaser or a member of the Purchaser’s Group will be based on the Seller’s
determination of performance to the Closing Date and pro-rated to the Closing Date; or 

  

	 	4.5.3	where the Seller is unable to determine performance (either business or individual), for example, because the Closing Date occurs near the start of the bonus year, the Seller shall calculate any such bonus payment based
on a deemed achievement of performance conditions at target level pro-rated to the Closing Date; and 

  

	 	4.5.4	as soon as reasonably practicable after the Closing Date, the Purchaser shall, or shall procure that such other member of the Purchaser’s Group shall, provide such information as the Seller requires in order for
the Seller to calculate the Tax payable or accountable for by the employer in respect of such bonus payments; and 

  

	 	4.5.5	the Purchaser shall, or shall procure that such other member of the Purchaser’s Group shall, deduct and/or account for any Tax payable or accountable for by the employer in respect of such bonus payments; and

  

	 	4.5.6	the Seller shall reimburse the Purchaser for the aggregate bonuses advised by the Seller to the Purchaser which are paid pursuant to this paragraph 4.5 along with the employer’s social security contributions due in
respect of such payments to the extent such amounts are not reflected in the Closing Statement. 

  

	5	Protection of terms and conditions and termination rights post-Closing 

  

	5.1	Without prejudice to paragraph 5.4 below, the Purchaser shall procure that for a period of 24 months following the Closing Date: 

 

	 	5.1.1	each Transferred Employee will (for so long as such Transferred Employee continues in the same role with any member of the Purchaser’s Group save that the Purchaser shall not seek to demote any Transferred Employee
to avoid the application of this provision) continue to receive at least the same basic salary; and 

  

	 	5.1.2	each Transferred Employee will continue to receive contractual benefits (but excluding Employee Benefits and any share-based incentive schemes or other long-term incentive plans) which the Purchaser reasonably considers
to be substantially comparable, taken as a whole, to the contractual benefits (but excluding Employee Benefits and any share-based incentive schemes or other long-term incentive plans) of such Transferred Employee immediately prior to the Closing
Date; and 

  

	 	5.1.3	no Transferred Employee will suffer a change to his overall employment terms (whether contractual or otherwise) and including, without limitation, any related to length of service (but excluding Employee Benefits and
any share-based incentive schemes or other long-term incentive plans), which, when taken as a whole viewed in the round (including to the extent relevant alongside any other changes being made at the same time to that Transferred Employee’s
employment terms), would in the Purchaser’s reasonable opinion acting in good faith, be regarded as materially detrimental. 

  

  
  

 
 130 

	5.2	The Purchaser confirms that, following the Closing Date and for so long as the Transferred Employees continue in the employment of any member of the Purchaser’s Group, the Transferred Employees will be
eligible to participate in those share-based incentive schemes or other long-term incentive plans that are operated by the Purchaser or relevant members of the Purchaser’s Group from time to time for employees of equivalent status, subject
always to the rules of such share-based incentive schemes or long-term incentive plans and any qualifying conditions. 

  

	5.3	The Seller shall provide or shall cause to be provided to any member of the Purchaser’s Group such information reasonably requested in writing by any member of the Purchaser’s Group to enable the
Purchaser to comply with its obligations in paragraph 5.1 above. 

  

	5.4	If the employment of any Transferred Employee is terminated by reason of redundancy within 24 months following the Closing Date, the Purchaser shall procure that there shall be provided to such Transferred
Employee benefits which are equivalent to those provided under such redundancy and severance policies and benefits (whether contractual or otherwise and giving due credit to the Transferred Employees for any additional service or earnings from the
Closing Date onwards) (but excluding Employee Benefits) as were applicable in respect of the particular Transferred Employee immediately prior to the Closing Date, to the extent that such policies and benefits are notified in writing to the
Purchaser prior to the Closing Date. If, at any time during the 24 month period immediately following the Closing Date, the Purchaser places any Transferred Employee into a redundancy selection process, the Purchaser undertakes that, in determining
such selection, it will or will procure that the relevant member of the Purchaser’s Group will take no account of the costs of dismissal of any person within the relevant selection pool (including such Transferred Employee).

  

	5.5	For the avoidance of doubt, the provisions of this paragraph 5 are without prejudice to the operation of any rule of law in relation to the terms and conditions of employment of the Transferred Employees.

  

	6	Benefits arrangements/service continuity 

  

	6.1	Each Transferred Employee shall have their service with the Seller’s Group and their respective predecessors recognised under any employee benefit plans or arrangements of the Purchaser’s Group for all
purposes of eligibility, vesting and accrual of benefits to the extent past service was recognised for such Transferred Employee under a comparable plan or arrangement immediately prior to the Closing Date. Notwithstanding the foregoing, nothing in
this paragraph 6.1 shall be construed to require recognition of service for the purposes of calculation of Employee Benefits or that would result in: 

  

	 	6.1.1	any additional liability being assumed by the Purchaser’s Group in respect of Employee Benefits other than subject to and in accordance with the provisions of Schedule 12; 

 

	 	6.1.2	duplication of benefit; 

  

	 	6.1.3	recognition of service for any purposes under any plan or arrangement for which participation, service and/or benefits accrual is frozen or any post-retirement medical plan; or 

 

	 	6.1.4	recognition of service under a newly established plan or arrangement for which prior service is not taken into account for employees of the Purchaser’s Group generally. 

  
  

 
 131 

	6.2	Without limiting the foregoing, with respect to the Transferred Employees, the Purchaser shall, or shall cause such other member of the Purchaser’s Group to, be responsible for all paid time off benefits,
including vacation pay, sick pay, banked leave, flexitime and other payments for time off of normal work hours accrued by the Transferred Employees up to the Closing Date, provided that, if the value of such matters (excluding normal accrued but
untaken annual leave for the year current as at Closing) would exceed US$7.5 million if accrued for in a balance sheet in accordance with IFRS, then the Seller shall compensate the Purchaser for such matters (again excluding normal accrued but
untaken annual leave for the year current as at Closing) by paying the Purchaser an amount equal to that value, less any amount actually accrued and transferred to the Purchaser for such matters. 

 

	6.3	With respect to any welfare plan maintained by the Purchaser or any other member of the Purchaser’s Group in which Transferred Employees are eligible to participate after the Closing Date, the Purchaser
shall: 

  

	 	6.3.1	waive all limitations as to pre-existing conditions, exclusions, evidence of insurability provisions, waiting periods with respect to such participation and coverage requirements or similar provisions under a
Purchaser’s benefit plans that are welfare plans (as defined in section 3(1) of ERISA or any equivalent Applicable Law) applicable to such employees to the extent such conditions, exclusions and waiting periods or other provisions were
satisfied or did not apply to such employees under welfare plans maintained by the Seller or other members of the Seller’s Group prior to the Closing Date; and 

 

	 	6.3.2	provide each Transferred Employee with credit for any co-payments and deductibles paid prior to the Closing Date in satisfying any analogous deductible or out-of-pocket requirements to the extent applicable under
any such plan in the year in which Closing occurs, to the extent credited under the welfare plans maintained by the Seller or other members of the Seller’s Group prior to the Closing Date. 

 

	7	US Transferred Employees 

  

	7.1	To the extent the Purchaser or any other member of the Purchaser’s Group maintains a health care and dependent care flexible spending account arrangement pursuant to section 125 or 129 of the Code
(collectively, “FSAs”), the Purchaser will use commercially reasonable efforts to honour the elections of all Transferred Employees who are employed in the United States and/or covered by US Benefit Plans (“US Transferred
Employees”) under the FSAs of any relevant member of the Seller’s Group (“Relevant Employer’s FSAs”), as in effect immediately prior to the Closing Date, and the Purchaser will use commercially reasonable efforts
to assume responsibility for administering all reimbursement claims of US Transferred Employees with respect to the calendar year in which the Closing Date occurs that are submitted for payment on or after the Closing Date, whether arising before,
on or after the Closing Date, under the Purchaser’s FSAs. As soon as practicable but no more than 45 days following the Closing Date, the Seller will cause to be transferred to the Purchaser an amount in cash equal to (i) the sum of all
contributions to the Relevant Employer’s FSAs with respect to the calendar year in which the Closing Date occurs by or on behalf of the US Transferred Employees prior to the Closing Date, reduced by (ii) the sum of all claims incurred in
the calendar year in which the Closing Date occurs that are submitted to the Relevant Employer for payment prior to the Closing Date and paid by the Relevant Employer’s FSAs with respect to such US Transferred Employees prior to the date of
such cash transfer to the Purchaser; provided, however, if this calculation results in a negative number, then the Purchaser will pay to the Seller (on behalf of the Relevant Employer) as soon as practicable following the end of the calendar year in
which the Closing Date occurs, the amount by which (ii) exceeds (i). 

  
  

 
 132 

	7.2	With effect on and from the Closing Date, the Purchaser shall, or shall procure that such other members of the Purchaser’s Group shall, assume the responsibility and obligation to provide COBRA continuation
coverage to all US Transferred Employees whose employment is terminated after the Closing Date and their eligible dependents. 

  

	8	Shared Employees 

 After the date of this Agreement, the Seller shall identify any Shared
Employees who work wholly or substantially in the Business (as carried on by the Vaccines Group) but who are not Vaccines Group Company Employees or Vaccines Business Employees. In consultation with the Purchaser, the Seller will procure that a
Vaccines Group Company will offer employment to any such employee before the Closing Date, to take effect from immediately before the Closing Date (provided that such employee continues to work wholly or substantially in the Business (as carried on
by the Vaccines Group) until the Closing Date) or, where that is not reasonably practicable or there is no Vaccines Group Company in the country in which the employee works, the Purchaser shall treat such employee as if he or she were a Vaccines
Business Employee (provided that such employee continues to work wholly or substantially in the Business (as carried on by the Vaccines Group) until the Closing Date) and the provisions of this Schedule 11 will apply to him or her and further
provided, however, that these arrangements will apply to no more than 10 full time equivalent employees. 
  

	9	International Assignees 

 Where Applicable Law does not provide for the automatic
transfer of employment of any International Assignee and/or the other terms governing their international assignment, the Purchaser shall assume and agree to be bound by the individual contract of employment and such other terms governing their
international assignment including any tax equalisation agreement entered into between an International Assignee and a member of the Seller’s Group provided that such employee becomes a Transferred Employee and the Seller has disclosed to the
Purchaser the template international assignment terms of the Seller’s Group prior to the Closing Date. 
  

	10	Liability for retention arrangements 

 The Seller or any other member of the
Seller’s Group has or will put in place certain retention arrangements (in the form of cash) to retain key employees in connection with the matters contemplated by this Agreement. To the extent that details of such retention arrangements are
disclosed to the Purchaser prior to the Closing Date, and in respect of arrangements put in place after the date of this Agreement, with the agreement of the Purchaser, the Purchaser shall, or shall procure that such other member of the
Purchaser’s Group shall, make the cash retention payments when due to the relevant Transferred Employees on or after Closing and shall deduct and/or pay and account for any Tax payable or accountable for by the employer in respect of such cash
payments. The Seller covenants to reimburse the Purchaser in respect of any cash retention payments, whether or not disclosed (including any Tax payable or accountable for by the employer in respect of such payments), which are put in place prior to
the Closing Date. The Seller acknowledges that the Purchaser may ask the Seller to put in place more generous retention arrangements than those proposed by the Seller (including, where practicable, putting in place retention arrangements which last
for a period of at least six months following Closing) and will not unreasonably withhold consent to such arrangements provided that any incremental cost of such arrangements over and above the cost of the Seller’s own proposals will be for the
Purchaser’s account. The Seller will provide the Purchaser with all information and documentation reasonably necessary to allow such payments to be made. 

  
  

 
 133 

	11	Share-based incentive schemes 

  

	11.1	This paragraph 11 applies notwithstanding any other provision of this Agreement. 

  

	11.2	Subject to paragraph 11.11, the Seller undertakes to use its best endeavours to ensure that share-based awards held by Transferred Employees pursuant to a share-based incentive scheme operated by the Seller or
another member of the Seller’s Group (“Relevant Awards”) shall be treated in a manner consistent with the “good leaver treatment” in the share-based incentive schemes operated by the Purchaser, to the extent possible
under the relevant plan rules and any Applicable Law. Where Relevant Awards are subject to performance (or other) conditions and it is not possible to determine whether or not such conditions have been met at the applicable early vesting date (or
within a reasonable period thereafter), the Seller and Purchaser agree that performance shall be deemed “on target”. 

For the avoidance of doubt: 
  

	 	(a)	where necessary and subject to (b), the Seller shall rely on the exercise of existing discretions in the relevant plan rules and (provided the approval of the Seller’s shareholders is not required) shall be
expected to amend the relevant plan rules to achieve the “good leaver treatment”; 

  

	 	(b)	the Seller (or relevant member of the Seller’s Group) shall not take any action which would require shareholder approval or which could trigger any significant legal, Tax or operational issues for the relevant
Transferred Employee (including the loss of any Tax-favourable treatment), the Seller’s Group or the Purchaser’s Group. 

For the purposes of this paragraph 11.2, the “good leaver treatment” shall be that: 

 

	 	(c)	Relevant Awards shall not lapse or be forfeited as a result of Closing except to the extent that they do not vest in accordance with (D) and/or (E) below; 

 

	 	(d)	Relevant Awards shall vest early as a result of Closing and shall be time pro-rated to take account of the reduced period of time, as a proportion of the original vesting period, that the relevant Transferred Employee
worked within the Seller’s Group (calculated on the basis of the number of years of service as at the Closing Date, where part years of service are rounded up); and 

 

	 	(e)	Relevant Awards that vest after the Closing Date shall remain subject to any relevant performance (or other) conditions, adjusted as necessary to take account of Closing and measured up to the applicable early vesting
date. 

 For the purposes of this paragraph 11.2, “on target” performance shall not be construed as permitting
share-based awards to vest in full. 

  
  

 
 134 

	11.3	The Seller agrees to indemnify the Purchaser (or relevant member of the Purchaser’s Group) for any Liabilities borne by the Purchaser’s Group in connection with the Relevant Awards, including any Tax. The
Purchaser agrees to use its best endeavours to seek any applicable Tax relief in respect of the Relevant Awards and to indemnify the Seller in respect of any Tax relief obtained, provided always that the Seller provides the Purchaser with any
information that the Purchaser may reasonably request in this respect in a timely manner. 

  

	11.4	Subject to paragraph 11.5, the Seller undertakes to inform the Purchaser of the vesting or exercise (as applicable) of the Relevant Awards and to provide, in a timely manner, details of the Relevant Awards that so vest
or are exercised so that the Purchaser’s Group can make any applicable withholdings for Tax and pay any Tax for which the Purchaser’s Group is liable in respect of the Relevant Awards to the relevant Tax Authority within any applicable
timescale. 

  

	11.5	To the extent permitted under the relevant plan rules and any Applicable Law, the Seller undertakes to sell such number of the shares underlying the Relevant Awards as may be necessary for the sale proceeds to
satisfy any applicable Tax withholdings and to pay such amounts to the Purchaser in sufficient time for the Purchaser to pay such Tax to the relevant Tax Authority within any applicable timescale, provided always that the Purchaser provides the
Seller with any information that the Seller may reasonably request in this respect in a timely manner. 

  

	11.6	The Seller undertakes to procure that each relevant member of the Seller’s Group will pay any Tax for which such member is liable in respect of the Relevant Awards to the relevant Tax Authority within any
applicable timescale. 

  

	11.7	The Seller undertakes to procure the completion of any relevant Tax Return in respect of the Relevant Awards and to procure the submission of any such Tax Return to the relevant Tax Authority within any
applicable timescale. 

  

	11.8	This paragraph shall apply where Relevant Awards lapse or are forfeited (or will lapse or be forfeited) either in whole or in part as a result of Closing. As soon as practicable following Closing (and, in any event, by
the later of 30 days from the Closing Date and 30 days from the first date after the Closing Date when the granting of share-based awards is not prevented by dealing restrictions, subject in both cases to the relevant plan rules and any Applicable
Law), the Purchaser (or member of the Purchaser’s Group) shall grant each relevant Transferred Employee a share-based award over shares in the capital of the Purchaser substantially equal in value (valued as at the date of grant) to the value
of the portion of their Relevant Awards which lapsed or was forfeited (or will lapse or be forfeited) as a result of Closing (valued as at the Closing Date), where relevant, disregarding any loss (or expected loss) of Tax-favourable treatment (each
a “Compensation Award”). To the extent that (i) it could reasonably have been expected that any related matching share award and/or free share award would have been granted to a Transferred Employee following Closing in
connection with any Relevant Award which lapsed or was forfeited (or will lapse or be forfeited) as a result of Closing (each a “Relevant Matching Award”), and (ii) such Relevant Matching Award has not been granted (or will not
be granted) as a result of Closing, on or around the date on which such Relevant Matching Award would, in the ordinary course of business, have been made by the Seller (or member of the Seller’s Group), the Purchaser (or member of the
Purchaser’s Group) shall grant each relevant Transferred Employee a share-based award over shares in the capital of the Purchaser substantially equal in value (valued as at the date of grant) to the value of such Relevant Matching Award (valued
as at the date of grant of the related Matching Award, defined below), where relevant, disregarding any loss (or expected loss) of Tax-favourable treatment (each a “Matching Award”), subject to the relevant plan rules and any
Applicable Law. 

  
  

 
 135 

 Such Compensation Awards and Matching Awards shall be granted pursuant to the rules of whichever
share-based incentive plan operated by the Purchaser’s Group at the time of grant the Purchaser considers most closely aligned to the share-based incentive plan operated by the Seller’s Group pursuant to which the related Relevant Award
had been granted (or related Relevant Matching Award would have been granted) but will vest according to a vesting schedule substantially similar to the vesting schedule that would have otherwise applied to the related Relevant Award or related
Relevant Matching Award if Closing had not occurred. In such cases: 
  

	 	(a)	the Purchaser undertakes to seek any applicable Tax relief in respect of the Compensation Awards and Matching Awards and to indemnify the Seller in respect of 50 per cent of any Tax relief obtained, provided always
that the Seller provides the Purchaser with any information that the Purchaser may reasonably request in this respect in a timely manner; 

  

	 	(b)	where a Compensation Award or Matching Award is granted in the form of a restricted share award, the Purchaser undertakes to obtain a valid election pursuant to section 431 of the Income Tax (Earnings and Pensions) Act
2003 (or, as applicable, any similar Tax election that is available pursuant to any Applicable Law in another jurisdiction), provided that, if either party makes representations to the other party to waive this obligation in respect of certain
Compensation Awards or certain Matching Awards and the other party consents to such waiver (such consent not to be unreasonably withheld), this paragraph (B) shall not apply in respect of such Compensation Awards or Matching Awards; and

  

	 	(c)	the Seller agrees to indemnify the Purchaser (or relevant member of the Purchaser’s Group) for any Liabilities borne by the Purchaser’s Group in connection with such Compensation Awards and Matching Awards,
including any Tax, provided that: 

  

	 	(i)	the Seller shall not indemnify the Purchaser (or relevant member of the Purchaser’s Group) to the extent that the Purchaser (or member of the Purchaser’s Group) compensates Transferred Employees for any loss
(or expected loss) of Tax-favourable treatment in respect of Relevant Awards or for any Liabilities to Tax as contemplated in paragraph 11.9 below; 

  

	 	(ii)	the Seller only agrees to indemnify the Purchaser (or member of the Purchaser’s Group) to a maximum of 50 per cent of the total of (i) the value of the portion of such Relevant Awards that lapsed or was
forfeited (or will lapse or be forfeited) as a result of Closing, (ii) the value of the Relevant Matching Awards, and (iii) any related Liabilities, including any Tax; and 

 

	 	(iii)	for the avoidance of doubt, the Seller shall not indemnify the Purchaser (or member of the Purchaser’s Group) for any lapse or forfeiture (or expected lapse or forfeiture) due to a failure to meet any applicable
performance (or other) conditions. 

  
  

 
 136 

 For these purposes, the compensation in respect of the portion of a Relevant Award which lapsed
or was forfeited (or will lapse or be forfeited) as a result of Closing shall not exceed the difference between (i) the value of the Relevant Award which could reasonably have been expected to vest on the normal vesting date but for Closing
(subject, where applicable, to performance (or other) conditions), and (ii) the value of the Relevant Award which actually vested (or will vest) as a result of Closing. 

For the purposes of this paragraph 11.8: 
  

	 	(a)	the portion of a Relevant Award which lapsed or was forfeited (or will lapse or be forfeited) as a result of Closing shall be valued on the basis of the average price of an ordinary share in the capital of the Seller
over the five trading days immediately prior to Closing; 

  

	 	(b)	the value of a Compensation Award to be granted shall be valued on the basis of the average price of an ordinary share in the capital of the Purchaser over the five trading days immediately prior to the date of grant;

  

	 	(c)	the value of a Relevant Matching Award shall be valued on the basis of the average price of an ordinary share in the capital of the Seller over the five trading days immediately prior to the date of grant of the related
Matching Award; 

  

	 	(d)	the value of a Matching Award to be granted shall be valued on the basis of the average price of an ordinary share in the capital of the Purchaser over the five trading days immediately prior to the date of grant; and

  

	 	(e)	any currency conversion shall be made in accordance with Clause 1.13.1 of this Agreement. 

  

	11.9	To the extent that any payment to a Transferred Employee (whether by the Seller’s Group or by the Purchaser’s Group) would trigger Liabilities to Tax under section 280G of the United States Internal Revenue
Code (“Section 280G”), the relevant Transferred Employee shall be allowed to choose whether to accept the full payment (and pay any relevant Section 280G Tax) or to receive such lower payment as may be necessary in order to
fall below the Section 280G threshold for Tax. To the extent that any similar Tax would arise pursuant to any Applicable Law in another jurisdiction, this paragraph 11.9 shall apply mutatis mutandis. 

 

	11.10	This paragraph shall apply where: (i) a Transferred Employee would, in the ordinary course of business, have been granted a share-based award pursuant to a share-based incentive scheme operated by the Seller
or another member of the Seller’s Group on the basis of performance criteria linked to the Seller’s Group’s 2014 financial year (which may, for the avoidance of doubt, be business and/or individual performance criteria and assessment)
(each a “2014 Performance Award”), and (ii) Closing occurs prior to the grant of such 2014 Performance Award. As soon as practicable following Closing (and, in any event, by the later of 30 days from the Closing Date and 30
days from the date when the value of each 2014 Performance Award has been determined), the Seller shall notify the Purchaser in writing of the value of each 2014 Performance Award and under which share-based incentive plan operated by the
Seller’s Group the related 2014 Performance Award would have been granted. As soon as practicable following the receipt of such notice (and, in any event, by the later of 30 days from the receipt of such notice and 30 days from the first date
following the receipt of such notice when the granting of share-based awards is not prevented by dealing restrictions, subject in both cases to the relevant plan rules and any Applicable Law), the Purchaser (or member of the Purchaser’s Group)
shall grant each relevant Transferred Employee a share-based award over shares in the capital of the Purchaser substantially equal in value (valued as at the date of grant) to the value of the 2014 Performance Award which would have been granted but
for the occurrence of Closing. Such 2014 Performance Awards shall be granted pursuant to the rules of whichever share-based incentive plan operated by the Purchaser’s Group at the time of grant the Purchaser considers most closely aligned to
the share-based incentive plan operated by the Seller’s Group pursuant to which the related 2014 Performance Award would have been granted. In such cases: 

  

	 	(a)	the Purchaser undertakes to seek any applicable Tax relief in respect of the 2014 Performance Awards and to indemnify the Seller in respect of any Tax relief obtained, provided always that the Seller provides the
Purchaser with any information that the Purchaser may reasonably request in this respect in a timely manner; 

  
  

 
 137 

	 	(b)	where a 2014 Performance Award is granted in the form of a restricted share award, the Purchaser undertakes to obtain a valid election pursuant to section 431 of the Income Tax (Earnings and Pensions) Act 2003 (or, as
applicable, any similar Tax election that is available pursuant to any Applicable Law in another jurisdiction), provided that, if either party makes representations to the other party to waive this obligation in respect of certain 2014 Performance
Awards and the other party consents to such waiver (such consent not to be unreasonably withheld), this paragraph (b) shall not apply in respect of such 2014 Performance Awards; and 

 

	 	(c)	the Seller agrees to indemnify the Purchaser (or relevant member of the Purchaser’s Group) for any Liabilities borne by the Purchaser’s Group in connection with such 2014 Performance Awards, including any Tax.

 The grant of a 2014 Performance Award to a Transferred Employee shall be taken into account by the Purchaser when
determining the extent to which that Transferred Employee shall participate in incentive arrangements (other than any Compensation Award or Matching Award) operated by the Purchaser’s Group following Closing. 

For the purposes of this paragraph 11.10: 
  

	 	(d)	the value of a 2014 Performance Award to be granted shall: (i) be determined by the Seller acting reasonably and in good faith, (ii) be consistent with past practice and with the level of similar awards
granted to employees remaining in service within the Seller’s Group, (iii) take into account the relevant business and/or individual performance criteria linked to the Seller’s Group’s 2014 financial year, and (iv) if
Closing occurs before 31 December 2014, be time pro-rated to take account of the reduced period of time, as a proportion of the Seller’s Group’s 2014 financial year, that the relevant Transferred Employee worked within the
Seller’s Group (calculated on the basis of the number of complete months of service as at the Closing Date); 

  

	 	(e)	the number of shares to be placed under a 2014 Performance Award shall be valued on the basis of the average price of an ordinary share in the capital of the Purchaser over the five trading days immediately prior to the
date of grant; and 

  
  

 
 138 

	 	(f)	any currency conversion shall be made in accordance with Clause 1.13.1 of this Agreement. 

  

	11.11	This paragraph shall apply if any member of the Seller’s Group’s corporate executive team (or similar body) is a Transferred Employee (each a “CET Member”). The treatment of share-based
awards held by CET members shall be determined by the remuneration committee of the board of directors of the Seller (acting reasonably and in good faith and following informal consultation with the Purchaser), subject to the rules of any relevant
share-based incentive scheme and any Applicable Law, and the provisions of paragraphs 11.8 and 11.10 shall apply. 

  
  

 
 139 

 Schedule 12 

Employee Benefits 

(Clause 2.4.2) 
 In this Schedule 12: 

“Employee Benefits” means benefits to or in respect of any current or former employee, including without limitation, any pension, early
retirement, disability, death benefit, long service awards, termination indemnity (such as Italian TFR) or post-retirement medical benefits or deferred compensation linked to retirement, disability or death benefits or old age part-time benefits
(such as German ATZ) and jubilee payments; 
 “Employee Benefit Liabilities” means liabilities and obligations (whether funded or
unfunded) in respect of any employee benefit promise, scheme, plan, fund, program, policy, practice or other individual or collective arrangement providing Employee Benefits; 

“Partial Liquidation Longstop Date” means, in relation to each of Novartis Pensionskasse 1, Novartis Pensionskasse 2, and Kaderkasse
Novartis, the earlier of (i) the date after Closing on which the plan undergoes partial liquidation, and (ii) 12 months after Closing; 

“Purchaser Funding Assumptions” means, in relation to any Transferred Employee Benefits, where a member of the Purchaser’s Group
provides, in the same country, a similar or comparable benefit programme to the programme to which the Transferred Employee Benefits relate (regardless of differences in the terms of entitlement of accrual etc), and there is a local obligation or
practice prior to the date of this Agreement to pre-fund or externally fund those similar or comparable benefits to a funding target which is determined by reference to a method and assumptions other than IFRS (such as would, for example, be the
case in relation to UK HMRC-registered defined benefit pension obligations), then that method and those assumptions as in force in relation to those similar or comparable benefits immediately prior to the date of this Agreement (so, taking the
example of UK defined benefit obligations, this would be the method and assumptions used to determine the relevant plan’s technical provisions as at the date of this Agreement – regardless of whether the plan is in fact fully funded on
that basis at any relevant time); 
 “Purchaser IFRS Assumptions” means, in relation to any Transferred Employee Benefits,
where a member of the Purchaser’s Group provides, in the same country, a similar or comparable benefit programme to the programme to which the Transferred Employee Benefits relate (regardless of differences in the terms of entitlement of
accrual etc), the method and assumptions used most recently prior to the date of this Agreement to value those similar or comparable benefits by the Purchaser’s Group (or any relevant member thereof) for IFRS accounting purposes; 

“Seller Funding Assumptions” means, in relation to any Transferred Employee Benefits, if there is a local obligation or practice prior
to the date of this Agreement to pre-fund or externally fund those Transferred Employee Benefits to a funding target which is determined by reference to a method and assumptions other than IFRS (such as would, for example, be the case in relation to
UK HMRC-registered defined benefit pension obligations), then that method and those assumptions as in force in relation to those Transferred Employee Benefits immediately prior to the date of this Agreement (so, taking the example of UK defined
benefit obligations, this would be the method and assumptions used to determine the relevant plan’s technical provisions as at the date of this Agreement – regardless of whether the plan is in fact fully funded on that basis at any
relevant time); 

  
  

 
 140 

 “Seller IFRS Assumptions” means, in relation to any Transferred Employee Benefits, the
method and assumptions used by the Seller’s Group (or the most relevant member thereof) most recently prior to the date of this Agreement to value those Transferred Employee Benefits for IFRS accounting purposes; 

“Swiss Actuary” means an actuary: (a) who can reasonably be viewed: (i) as independent of both the Purchaser and the Seller;
and (ii) as familiar with Swiss pension issues; and (b) whom the Purchaser and Seller have agreed should be jointly appointed by them for the purposes of determining the Swiss Assumptions or who in default of such agreement has been
appointed by the Swiss Association of Actuaries or other industry body of actuaries in Switzerland as agreed by the Seller and the Purchaser; and 

“Swiss Assumptions” means, in relation to any Transferred Employee Benefits in Switzerland, the Seller IFRS Assumptions adjusted:

  

	(a)	by replacing any assumed “cash balance” annuity conversion rate in the Seller IFRS Assumptions with a conversion rate which the Swiss Actuary certifies to the Purchaser and the Seller as representing a
reasonable estimate of the likely effective overall blended conversion rate which will apply in relation to the Transferred Employee Benefits in question, having regard to the changes to the rate which can (having regard to longevity projections,
legal and governance constraints around Swiss pension structures and such other matters as the Swiss Actuary considers relevant) in the Swiss Actuary’s opinion reasonably be expected to occur during the expected service lives of the Transferred
Employees to whom the Transferred Employee Benefits relate, and weighting the impact of those changes by reference to the ages of the relevant employees (and so the extent to which the changes will in fact operate to reduce the effective liability
on the Purchaser); and 

  

	(b)	by removing any reserve for death or disability benefits to the extent that the Swiss Actuary certifies to the Purchaser and the Seller that it constitutes a reserve for liabilities to and in respect of the relevant
Transferred Employees which could reasonably be externally insured by the Purchaser without introducing a new ongoing cost on the Purchaser which was not reflected in the Accounts. 

For the purposes of each of the Purchaser Funding Assumptions, the Purchaser IFRS Assumptions, the Seller Funding Assumptions, the Seller IFRS Assumptions and
the Swiss Assumptions, any economic and financial assumptions which are based (whether expressly or implicitly) on yields, rates or indices shall be updated for the purposes of such definitions to take account of those yields, rates or indices as at
Closing (or the latest practicable time prior to Closing). 
  

	1	Except to the extent otherwise requested by the Seller and expressly agreed by the Purchaser before Closing (such Purchaser agreement not to be unreasonably withheld to the extent that it is not reasonably possible for
the Seller or its Affiliates to retain the relevant Employee Benefit Liabilities – for example, where a Vaccines Group Company operates its own standalone arrangement, liability for which cannot lawfully be assumed by another member of the
Seller’s Group, or where liability unavoidably transfers by operation of law under European Council Directive 2001/23/EC or its local implementing legislation), any Employee Benefit Liabilities in respect of service in the Vaccines Group or
with any member of the Seller’s Group (including any Vaccines Group Company) or in any plan or arrangement in which any member of the Seller’s Group (including any Vaccines Group Company) participates or has participated:

  
  

 
 141 

	 	(a)	(in the case of a Transferred Employee) prior to Closing; or 

  

	 	(b)	(in the case of any other person) at any time, 

 (together, “Pre-Closing EB
Liabilities”) will stay with or be assumed by the Seller or its Affiliates (excluding any Vaccines Group Company) and the Seller shall fully indemnify the Purchaser and its Affiliates (which for the avoidance of doubt in the period from
Closing includes any Vaccines Group Company) against any such Employee Benefit Liabilities and against any liabilities and obligations to or in respect of any plan or arrangement for the provision of Employee Benefits in which any member of the
Seller’s Group (including any Vaccines Group Company) participates or participated prior to Closing. For the avoidance of doubt, the Purchaser’s agreement under this paragraph 1 may, if the Purchaser so determines, relate only to certain
specified categories or tranches of Pre-Closing EB Liabilities under a particular benefit programme (in other words, it does not need to be “all or nothing”), in which case it is only those specified Pre-Closing EB Liabilities which are
excluded from the scope of the Purchaser’s indemnity entitlement hereunder. 
  

	2	Where and to the extent that the Purchaser agrees under paragraph 1 that any Pre-Closing EB Liabilities may transfer to or remain with the Purchaser and/or its Affiliates (which for the avoidance of doubt in the period
from Closing includes any Vaccines Group Company) (such Pre-Closing EB Liabilities being the “Transferred Employee Benefit Liabilities” and the benefits to which they relate being the “Transferred Employee
Benefits”), the Purchaser will be compensated in respect of such Transferred Employee Benefit Liabilities as set out in the rest of this Schedule 12. Subject to being so compensated but without prejudice to paragraphs 9 and 11, the
Purchaser shall, or shall procure that its relevant Affiliate shall, assume, with a full discharge for the Seller and its Affiliates, the Transferred Employee Benefit Liabilities. Without limiting the Purchaser’s obligation not unreasonably to
withhold consent under paragraph 1 above, the parties hereby acknowledge that it would not be reasonably possible for the Seller or its Affiliates to retain those Pre-Closing EB Liabilities which attach to Vaccines Group Companies in Germany or
Switzerland. So subject to appropriate identification during the period before Closing of such liabilities and to the operation of the compensation mechanism set out in this Schedule 12, they will become Transferred Employee Benefit Liabilities. The
Purchaser also acknowledges its agreement to the principle that the post-retirement medical healthcare plan to which it admits US Transferred Employees who immediately before Closing were members of such a plan will take account of periods of
employment with the Seller’s Group to the extent previously recognised under the equivalent Seller’s Group plan for the purposes of determining eligibility, contributions, and vesting; again, therefore, subject to appropriate
identification during the period before Closing of such liabilities and to the operation of the compensation mechanism set out in this Schedule 12, they will become Transferred Employee Benefit Liabilities. 

United Kingdom 
 For the
avoidance of doubt, it is also agreed that no UK defined benefit pension liabilities are to be Transferred Employee Benefit Liabilities. 
  

	3	The value of the Transferred Employee Benefit Liabilities shall be determined on employee census data and plan provision as at Closing on: 

 

	3.1	in relation to any Transferred Employee Benefits in Switzerland, the Swiss Assumptions; and 

  
  

 
 142 

	3.2	in relation to any other Transferred Employee Benefits, the Seller IFRS Assumptions, PROVIDED that if any of the following values is available and is greater than the value derived using the Seller IFRS Assumptions then
that value will be used instead (and if more than one of these values is available then the one which would place the greatest value on the relevant Transferred Employee Benefit Liabilities will be used): 

 

	 	3.2.1	if a member of the Purchaser’s Group provides, in the same country, a similar or comparable benefit programme to the programme to which the Transferred Employee Benefits relate (regardless of differences in the
terms of entitlement of accrual etc), the value which is midway between the value based on the Seller IFRS Assumptions and the Purchaser IFRS Assumptions; 

  

	 	3.2.2	if there is a local obligation or practice prior to the date of this Agreement to pre-fund or externally fund the Transferred Employee Benefits to a funding target which is determined by reference to a method and
assumptions other than IFRS, the value derived using the Seller Funding Assumptions; and 

  

	 	3.2.3	if there is both: (i) a local obligation or practice prior to the date of this Agreement to pre-fund or externally fund the Transferred Employee Benefits to a funding target which is determined by reference to a
method and assumptions other than IFRS; and (ii) a member of the Purchaser’s Group provides, in the same country, a similar or comparable benefit programme to the programme to which the Transferred Employee Benefits relate (regardless of
differences in the terms of entitlement of accrual etc), the value which is midway between the value based on the Seller Funding Assumptions and the Purchaser Funding Assumptions. 

The market value as at Closing of any underlying assets related to the Transferred Employee Benefit Liabilities which are or are to be
transferred as per paragraph 8 below will be deducted from the value of the Transferred Employee Benefit Liabilities to the extent such assets are or will be available to the Purchaser or its Affiliates to meet such liabilities and the remaining
value of the Transferred Employee Benefit Liabilities (if any) is the “Employee Benefit Indemnification Amount”. Such determination shall be carried out on a country-by-country basis and, where necessary, on a plan-by-plan basis. For the
avoidance of doubt, in relation to Switzerland, the calculation shall, if partial liquidation occurs in relation to any of the Transferred Employee Benefit Liabilities by the Partial Liquidation Longstop Date, make allowance for the assets thereby
transferred assuming that they will be available to meet such liabilities. If any Employee Benefit Indemnification Amount is greater than the estimate of such amount determined for the purposes of the Estimated Employee Benefit Adjustment (or, where
no such estimate was made, greater than zero), the Seller shall pay or procure payment, by way of a reduction in the Purchase Price attributable to the relevant Shares or the particular part of the Vaccines Group to which the payment relates, an
amount equal to the difference (or, where no such estimate was made, such amount) to the Purchaser, or at the request of the Purchaser to an Affiliate of the Purchaser, as compensation for the Transferred Employee Benefit Liabilities. If any
Employee Benefit Indemnification Amount is less than the estimate of such amount determined for the purposes of the Estimated Employee Benefit Adjustment (if any), the Purchaser shall pay an amount equal to the difference to the Seller. 

  
  

 
 143 

	4	The Seller and its Affiliates shall, within 45 days after Closing (or, in the case of Switzerland, 45 days after the Partial Liquidation Longstop Date), provide its actuary, the Swiss Actuary and the actuary chosen by
the Purchaser with all relevant plan, asset, assumptions and employee census information needed to calculate the Employee Benefit Indemnification Amounts in respect of any Transferred Vaccines Business Employees. The actuary chosen by the Seller
shall provide the actuary chosen by the Purchaser with its calculation of the Employee Benefit Indemnification Amounts (including, but not limited to, any supporting documentation on which it relied as well as the methodologies it employed in
calculating the Employee Benefit Indemnification Amounts), on a plan-by-plan basis, within 90 days following Closing (or, in the case of Switzerland, 90 days after the Partial Liquidation Longstop Date). The actuary chosen by the Purchaser shall
review the calculation of the Employee Benefit Indemnification Amounts of the Seller’s actuary within 120 days following Closing (or, in the case of Switzerland, 120 days after the Partial Liquidation Longstop Date). The Employee Benefit
Indemnification Amounts shall be determined, on a plan-by-plan basis, by mutual agreement between the parties within 180 days following the Closing Date (or, in the case of Switzerland, 180 days after the Partial Liquidation Longstop Date).

  

	5	If the parties cannot agree on any Employee Benefit Indemnification Amount within the 180-day period referred to in paragraph 4, the parties shall appoint within 5 days an independent actuary acceptable to both parties,
or such actuary shall be selected by the President of the Institute and Faculty of Actuaries in the UK if they cannot agree, and the independent actuary thus appointed shall review their calculations and, within 75 days after appointment, render a
final and binding decision on the amount of that Employee Benefit Indemnification Amount, and, in making such decision, shall be limited to adopting the position taken by either one of the parties. The cost of any independent actuary shall be borne
jointly by the parties. 

  

	6	In connection with the procedures referred to in this Schedule 12, the parties shall provide each other and the actuaries referred to in this Schedule 12 with access to the relevant business records and other relevant
documents and information as may reasonably be requested. All documents, records and information provided for the purposes of this Schedule 12 must be accurate and complete in all material respects. 

 

	7	Each Employee Benefit Indemnification Amount shall be paid by the Seller (by way of a reduction in the Purchase Price attributable to the relevant Shares or the particular part of the Vaccines Group to which the payment
relates) within 14 days following its final determination. The Seller may make an accelerated or advance payment at its own discretion (which, for the avoidance of doubt, includes in relation to each Employee Benefit Indemnification Amount so much
(if any) of the Estimated Employee Benefit Adjustment as the Seller notified pursuant to Clause 6.4 was intended to relate to that Employee Benefit Indemnification Amount). Each Employee Benefit Indemnification Amount shall include interest
calculated from (and including) the Closing Date to (and including) the date of payment at a rate per annum of LIBOR (but where amounts are prepaid or paid in stages or treated as paid via inclusion in the Estimated Employee Benefit Adjustment then
the interest will cease to accrue on so much of the Employee Benefit Indemnification Amount as has been paid). Such interest shall accrue from day to day. Any such payment shall be made in US dollars (and any underlying values shall be expressed in
US dollars) and any currency other than US dollars shall be converted into US dollars at the exchange rates determined in accordance with Clause 1.13 of this Agreement on the Closing Date. 

 

	8	To the extent (if any) that there are any Transferred Employee Benefit Liabilities which prior to Closing were externally funded by assets held in a trust or other vehicle established for the purposes of meeting such
Transferred Employee Benefit Liabilities, the Purchaser will, if requested by the Seller before Closing and unless it is not reasonably practicable to do so, establish or nominate a trust or other vehicle which is capable of receiving a transfer of
assets from the pre-Closing trust or other vehicle to the extent that such assets relate to the Transferred Employee Benefit Liabilities. 

  
  

 
 144 

	9	If, within one year of Closing, the Seller or the Purchaser notifies the other that the membership or other benefit data (the “Data”) used for calculating any Employee Benefit Indemnification Amount may
be inaccurate, then a “Data Dispute” has arisen and the following provisions shall apply: 

  

	9.1	On such notification, the Seller shall procure that its actuary and the Purchaser shall procure that its actuary consult each other with a view to agreeing whether the Data is inaccurate and if so, what the accurate
Data should be. If the Seller’s actuary and the Purchaser’s actuary agree that the Data is inaccurate, they will jointly certify this to be the case and advise on what the accurate Data should be. The notification is deemed to have
occurred on the date of the certification. 

  

	9.2	If the Seller’s actuary and the Purchaser’s actuary fail to agree whether the Data is inaccurate within 60 days of the notification by one party to the other that the Data may be inaccurate, paragraph 5 shall
apply mutatis mutandis. The notification is deemed to have occurred when the independent actuary advises that the Data is inaccurate and what the accurate Data should be. 

 

	9.3	On the occurrence of the Data Dispute, the Seller and the Purchaser shall respectively procure that a valuation of the relevant Employee Benefit Indemnification Amount is carried out in accordance with paragraphs 3 and
4 (mutatis mutandis) but on the basis of the accurate Data as agreed under paragraph 9.1 or determined under paragraph 9.2. 

  

	9.4	If as a consequence of paragraph 9.3, the Seller has paid to the Purchaser an amount which on the basis of the further valuation is not payable, such amount (the “Overpayment”) shall be repaid within 21
days of the amount of the Overpayment being agreed or determined. Any such payment shall bear interest calculated from (and including) the date the Overpayment was made to (and including) the date the payment is made in full in accordance with this
paragraph 9.4 at a rate per annum of LIBOR. Such interest shall accrue from day to day. 

  

	9.5	If as a consequence of paragraph 9.3, the Seller has not paid to the Purchaser an amount which on the basis of the further valuation is payable, such amount (the “Outstanding Amount”) shall be paid
within 21 days of the amount of the Outstanding Amount being agreed or determined. Any such payment shall bear interest calculated from (and including) the Closing Date to (and including) the date the payment is made in full in accordance with this
paragraph 9.5 at a rate per annum of LIBOR. Such interest shall accrue from day to day. 

  

	10	Except as otherwise agreed by the Seller, the Purchaser shall where a trust or other vehicle has been established under paragraph 8, procure that all of the assets transferred as envisaged by paragraph 8 are paid into
such trust or other vehicle. If, after such payment or transfer, or after payment of an Employee Benefit Indemnification Amount or after making an Estimated Employee Benefit Adjustment, the Purchaser and/or its Affiliates achieves a reduction in its
liability to any Tax in respect of or in connection with the payment or transfer, the Purchaser shall pay to Seller (for itself or on behalf of the relevant Share Seller or Business Seller as applicable), within 30 days after the Purchaser would
otherwise have been liable to pay the saved Tax, a sum equal to the amount of that Tax reduction by way of an increase in the Purchase Price in respect of the relevant Shares or the particular part of the Vaccines Group. This paragraph 10 applies
for a period of four years following the later of the date on which a transfer of assets is made, or payment of any Employee Benefit Indemnification Amount or Estimated Employee Benefit Adjustment is made to the Purchaser. 

  
  

 
 145 

	11	The Seller covenants with the Purchaser to pay to the Purchaser an amount equal to any cost, claim or liability incurred by any member of the Purchaser’s Group which it is or becomes liable to make on or at any
time after Closing by reason of any change or purported change made to the terms of any Transferred Employee Benefits prior to Closing proving to be or have been legally ineffective or by reason of such terms and/or benefits failing to comply with
any mandatory legal requirements (excluding any obligation to equalise guaranteed minimum pensions in the United Kingdom). The Seller shall not be liable under this paragraph 11 in respect of any individual claim (or a series of claims arising from
similar or identical facts or circumstances) unless the liability in respect of such claim or series of claims exceeds US$100,000. If the Purchaser becomes aware of any fact, matter or circumstance that may give rise to a claim against the Seller
under this paragraph 11, the Purchaser shall as soon as reasonably practicable give notice in writing to the Seller of such facts, matters or circumstances as are then available regarding the potential claim. Failure to give such notice within such
period shall not affect the rights of the Purchaser to make a relevant claim under this paragraph 11, except that the Seller shall not be liable for any increase in the amount of such claim arising from such failure. The latest date on which the
Purchaser may give notice of a claim under this paragraph 11 is the fourth anniversary of the Closing Date. 

  

	12	Notwithstanding any general provision to the contrary in Schedule 11 and subject to being compensated in accordance with this Schedule 12, the Purchaser shall admit Transferred Employees in the United States who
participated in a post-retirement medical plan immediately prior to Closing to its own post-retirement medical plan. Subject to being compensated in accordance with this Schedule 12, periods of employment with the Seller’s Group (including,
without limitation, any current or former Affiliate of the Seller, to the extent previously recognised under the applicable benefit plan arrangement provided by the Seller’s Group), shall be taken into account for the purposes of determining,
as applicable, the eligibility for participation, contributions, and vesting for any employee under such post-retirement medical plan. 

  

	13	Notwithstanding any general provision to the contrary in Schedule 11, the US Transferred Employees shall, as of the Closing Date, become eligible to participate in a US tax-qualified defined contribution plan to the
extent such plan is sponsored by the Purchaser or a relevant member of the Purchaser’s Group. The Purchaser agrees that it will use commercially reasonable efforts to cause such plan to accept rollovers of the account balances of the US
Transferred Employees (including participant loan promissory notes) from the relevant employer’s tax-qualified retirement plans; provided that (i) the Purchaser will not be required to accept any such rollovers that might result in
material liability to the Purchaser or may otherwise cause the relevant plan to cease to qualify under Section 401(a) of the Code and (ii) the Purchaser will not be required to amend any plan to permit participant loans. 

 

	14	The parties agree that where any Transferred Employee has accrued defined contribution benefits prior to Closing in a Seller’s Group arrangement then: 

 

	14.1	the Seller shall use commercially reasonable efforts to procure the vesting of those benefits (if they would otherwise lapse as a result of Closing); 

  
  

 
 146 

	14.2	the parties shall, provided this will not impose unreasonable administrative burdens on the Purchaser’s Group, co-operate in good faith to procure a transfer of the account balances of such Transferred Employee
from the Seller’s Group arrangement to a Purchaser’s Group arrangement; and 

  

	14.3	for the avoidance of doubt, the Purchaser will comply with the provisions of paragraph 6.1 of Schedule 11. 

  
  

 
 147 

 Schedule 13 

Allocation of Purchase Price 

(Clauses 3.3 and 7.6) 
  

	1	The Seller and the Purchaser agree that the Purchase Price (and any adjustments thereto) and the Assumed Liabilities shall be allocated for Tax purposes among the Shares and the Vaccines Group Businesses in accordance
with Applicable Law (the “Allocation”). 

  

	2	Prior to the Closing Date and subject always to paragraph 1, the Seller and the Purchaser shall negotiate in good faith to reach an agreement as to the Allocation of the Purchase Price and the Assumed Liabilities
including by ascribing a value to that part of the Vaccines Group comprising the Products Encepur and Ixiaro (which, if disposed of by the Seller’s Group prior to the Closing Date shall be the amount payable by the Seller to the Purchaser
pursuant to Clause 3.6.1) to the Shares, and to any Vaccines Group Businesses that are subject to transfer Taxes or VAT, or where a valuation of a particular Vaccines Group Business prior to Closing is otherwise required by Applicable Law (each a
“Required Item”). 

  

	3	Failing agreement between the parties on the Allocation in respect of any Required Item in accordance with this Schedule 13, the Allocation shall be determined by the Reporting Accountants on the application of
the Seller or the Purchaser. Paragraphs 1.6 to 1.12 of Part 1 of Schedule 16 shall apply mutatis mutandis to the engagement and determination of the Reporting Accountants pursuant to this paragraph 3. 

 

	4	The Seller and the Purchaser shall negotiate in good faith to further allocate the Purchase Price and Assumed Liabilities among the Vaccines Group Businesses for which an allocation was not agreed prior to Closing
within 90 calendar days after the Closing Date. If the Seller and the Purchaser reach written agreement within such 90 day period, the Allocation, as so amended, shall become binding upon the Seller and the Purchaser as the “Final Allocation
Schedule”. 

  

	5	The Seller and the Purchaser shall, and shall procure that each of their Affiliates will, file all Tax Returns in a manner consistent with the Final Allocation Schedule, unless otherwise required by Applicable Law, and
shall take no position inconsistent with the Final Allocation Schedule in any proceedings before any Governmental Entity or otherwise. 

  

	6	If the Seller and the Purchaser are unable to agree to an Allocation pursuant to paragraph 4, the matter shall be determined by the Reporting Accountants on the application of the Seller or the Purchaser.
Paragraphs 1.6 to 1.12 of Part 1 of Schedule 16 shall apply mutatis mutandis to the engagement and determination of the Reporting Accountants pursuant to this paragraph 5. 

  
  

 
 148 

 Schedule 14 

VAT 
 (Clause 3.4)

  

	1	VAT: Records 

  

	1.1	The Seller may, on or before the date of Closing, obtain a direction from the relevant Tax Authority for the retention and preservation by it of any VAT records relating to its period of ownership of the relevant part
of the Vaccines Group and, where any such direction is obtained, the Seller shall: 

  

	 	1.1.1	preserve the records to which that direction relates in such a manner and for such period as may be required by the direction or by Applicable Law; and 

 

	 	1.1.2	allow the Purchaser, upon the Purchaser giving reasonable notice, reasonable access to and copies of such records where reasonably required by the Purchaser for its Tax purposes. 

 

	1.2	If no such direction as is referred to in paragraph 1.1 above is obtained or before the date of Closing and any documents in the possession or control of a member of the Seller’s Group are required by law to be
preserved by the Purchaser, the Seller shall, as soon as reasonably practicable after Closing, deliver such documents to the Purchaser. 

  

	2	VAT: Going Concern - EU Member States 

  

	2.1	The Seller and the Purchaser shall use reasonable endeavours (including, for the avoidance of doubt, the making of an election or application in respect of VAT to any Tax Authority or entering into a written agreement)
to secure that, to the extent reasonably possible, the sale of all or any part of the Vaccines Group Businesses, so far as carried on in the European Union, is treated as neither a supply of goods nor a supply of services for the purposes of the
laws governing VAT in each relevant member state. 

  

	2.2	Each Business Seller shall have the right to seek a ruling from the relevant Tax Authority as to whether the sale of all or part of the Vaccines Group Businesses, so far as carried on in the relevant member state,
should be treated as neither a supply of goods nor a supply of services for the purposes of the laws governing VAT in that member state and to account for VAT (and accordingly to seek an additional payment from the Purchaser under Clause 3.4.2) in
accordance with that ruling. The Seller shall not be obliged to challenge (or to procure that any relevant Business Seller challenges) that ruling unless required to do so by the Purchaser. If the Purchaser wishes to challenge, or to require the
relevant Business Seller to challenge, any such ruling it may do so, provided that it bears the full cost of, and agrees to indemnify the relevant Business Seller in respect of any loss arising from or in connection with, that challenge and that
such challenge shall not affect the date on which VAT must be paid to the Seller under paragraph 4 below. 

  

	2.3	Insofar as no ruling has been obtained from a relevant Tax Authority prior to Closing, the Seller shall determine in good faith if (or the extent to which) VAT is payable in respect of the sale of the Vaccines Group
Businesses and shall be entitled to charge (or not to charge) VAT to the Purchaser in accordance with such determination. 

  
  

 
 149 

	3	VAT: Going Concern - non-EU Jurisdictions 

  

	3.1	To the extent that any state outside the European Union provides for relief or exemption from VAT on the transfer of a business or a company or treats such a transaction as being non-taxable for VAT purposes, the Seller
and the Purchaser shall, use reasonable endeavours (including, for the avoidance of doubt, the making of an election or application in respect of VAT to any Tax Authority or entering into a written agreement) to secure such relief, exemption or
treatment, to the extent reasonably possible, as regards the sale of all or part of the Vaccines Group Businesses (insofar as the business of the Vaccines Group is carried on in the relevant state) under this Agreement. 

 

	3.2	The relevant Business Seller shall have the right to seek a ruling from the relevant Tax Authority as to whether the sale of all or part of the Vaccines Group Businesses, so far as the business of the Vaccines Group is
carried on in the relevant state, is eligible for a relief or exemption or is otherwise eligible to be treated as non-taxable for the purposes of the laws governing VAT in that state and to account for VAT and accordingly seek an additional payment
from the Purchaser under Clause 3.4.2) in accordance with that ruling. The Seller shall not be obliged to challenge (or to procure then the relevant Business Seller challenges) that ruling unless required to do so by the Purchaser. If the Purchaser
wishes to challenge, or to require the relevant Business Purchaser to challenge, any ruling it may do so, provided that it bears the full cost of, and agrees to indemnify the relevant Business Seller in respect of any loss arising from or in
connection with, that challenge and that such challenge shall not affect the date on which VAT must be paid to the Seller under paragraph 4 below. Insofar as no ruling has been obtained from a relevant Tax Authority prior to Closing, the Seller
shall determine in good faith if (or the extent to which) VAT is payable in respect of the sale of the Vaccines Group Businesses and shall be entitled to charge (or not to charge) VAT to the Purchaser in accordance with such determination.

  

	4	VAT: Time, Manner and Currency of Payment 

  

	4.1	Any amounts which the Purchaser is obliged to pay to the Seller under this Agreement in respect of VAT shall be paid by the Purchaser, on its own account or on behalf of another member of the Purchaser’s Group, to
the Seller or to such member of the Seller’s Group as the Seller may direct. Such amounts shall be paid in the currency in which the VAT in question must be accounted for to the relevant Tax Authority. 

 

	4.2	Subject to any provision or express agreement to the contrary, any amounts in respect of VAT payable in any jurisdiction in respect of the transfer at Closing of any of the Vaccines Group Businesses or Shares shall be
paid in accordance with paragraph 4.2 above at Closing against production of a valid VAT invoice (or equivalent, if any). 

  

	4.3	Notwithstanding any other provision of this Agreement, the Purchaser shall not be liable to account to the Seller or any member of the Seller’s Group for or in respect of penalties or interest arising solely from
the failure of the Seller or any other member of the Seller’s Group to account promptly for VAT to the relevant Tax Authority following the Seller having been placed in the appropriate amount of funds for that purpose by the Purchaser.

  
  

 
 150 

 Schedule 15 

Closing Obligations 

(Clause 6) 
  

	1	General Obligations 

  

	1.1	The Seller’s Obligations 

 On Closing, the Seller shall deliver or make available to
the Purchaser the following: 
  

	 	1.1.1	the Tax Indemnity duly executed by the Seller; 

  

	 	1.1.2	the Ancillary Agreements (other than the France SPA and the Netherlands APA and, if they have not been agreed, the Transitional Services Agreement, the Manufacturing, Supply and Distribution Agreement and the Influenza
Business Manufacturing and Supply Agreement) duly executed by the relevant members of the Seller’s Group; 

  

	 	1.1.3	a valid power of attorney or such other evidence reasonably satisfactory to the Purchaser that the Seller, and each of its relevant Affiliates, are authorised to execute this Agreement, the Tax Indemnity, the Ancillary
Agreements and the Local Transfer Documents (including, where relevant, any notarial deeds referred to in this Schedule 15), in each case to the extent that they are parties thereto; 

 

	 	1.1.4	the Certificate duly executed by the Seller; 

  

	 	1.1.5	the statutory books of the Vaccines Group Companies (which shall be written up to but not including the Closing Date), the certificate of incorporation (and certificate of incorporation on change of name) and common
seal (if any) of each Vaccines Group Company and share certificates (or other documents of title) in respect of all the issued share capital of each Vaccines Group Company; 

 

	 	1.1.6	In addition, the Seller shall, if requested by the Purchaser by notice in writing not less than five Business Days prior to the Closing Date: 

 

	 	(i)	procure any then present directors and officers (if any) of each Vaccines Group Company resign their offices to take effect at the Closing Date as such and to relinquish any rights which they may have under any contract
of employment with any Vaccines Group Company or under any statutory provisions (including any right to damages or compensation for breach of contract, loss of office, redundancy or unfair dismissal or on any other account whatsoever) and to confirm
that no agreement or arrangement is outstanding under which any Vaccines Group Company has or could have any obligation to any of them including in respect of remuneration or expenses; 

 

	 	(ii)	procure the present auditors of each Vaccines Group Company to resign their office as such, such resignations to take effect as at the Closing Date; and 

 

	 	(iii)	procure board meetings of the relevant Vaccines Group Companies are held, or written resolutions of the board are passed, at or by which: 

 

	 	(a)	it shall be resolved that each of the transfers relating to the Shares shall, so far as possible, be approved for registration and 

  
  

 
 151 

	 	(b)	any person nominated by the Purchaser shall be appointed director, such appointments to take effect on the Closing Date. 

  

	1.2	The Purchaser’s Obligations 

 On Closing, the Purchaser shall deliver or make
available to the Seller the following: 
  

	 	1.2.1	the Tax Indemnity duly executed by the Purchaser; 

  

	 	1.2.2	the Ancillary Agreements (other than the France SPA and the Netherlands APA and, if they have not been agreed, the Transitional Services Agreement, the Manufacturing, Supply and Distribution Agreement and the Influenza
Business Manufacturing and Supply Agreement) duly executed by the relevant members of the Purchaser’s Group; 

  

	 	1.2.3	evidence reasonably satisfactory to the Seller that the Purchaser, and each of its relevant Affiliates, are authorised to execute this Agreement, the Tax Indemnity, the Ancillary Agreements and the Local Transfer
Documents (including, where relevant, any notarial deeds referred to in this Schedule 15), in each case to the extent that they are parties thereto. 

  

	2	Transfer of the Shares and Vaccines Group Businesses 

  

	2.1	General Transfer Obligations 

 On Closing or such other date as agreed between the
parties, the Seller shall procure that the Share Sellers and Business Sellers shall, and the Purchaser shall, execute and/or deliver and/or make available Local Transfer Documents and take such steps as are required to transfer the Shares and
Vaccines Group Businesses in accordance with this Agreement. 
  

	2.2	Specific Transfer Obligations 

 For the purposes of compliance with paragraph 2.1, the
Seller and the Purchaser shall, between the date of this Agreement and Closing, negotiate in good faith any and all Local Transfer Documents and other such steps as are required to transfer the Shares and Vaccines Group Businesses in accordance with
this Agreement. 

  
  

 
 152 

 Schedule 16 

Post Closing Adjustments 

(Clause 7) 
 Part
1 
 Preparation of Closing Statement 
  

	1	Preparation 

  

	1.1	No later than 60 days following Closing, the Seller shall deliver to the Purchaser the Draft Closing Statement. Prior to such delivery, the Seller shall so far as is practicable consult with the Purchaser with a view to
reducing the potential areas of disagreement. 

  

	1.2	In order to enable the Seller to prepare the Draft Closing Statement, the Purchaser shall keep up-to-date and, subject to reasonable notice, make available to the Seller’s representatives and to the Seller’s
accountants all books and records relating to the Vaccines Group during normal office hours and co-operate with them with regard to the preparation, review and agreement or determination of the Draft Closing Statement. The Purchaser agrees to make
available the services of the employees of the Vaccines Group to assist the Seller in the preparation, review and agreement or determination of the Draft Closing Statement. 

In order to allow the Purchaser to review the Draft Closing Statement, the Seller shall, subject to reasonable notice, make available to the
Purchaser’s representatives and to the Purchaser’s accountants all books and records relating to the Vaccines Group during normal office hours and co-operate with them with regard to their review of the Draft Closing Statement. The Seller
agrees to make available the services of the employees of the Seller and its Affiliates to assist the Purchaser in its review of the Draft Closing Statement. 
  

	1.3	If the Purchaser does not within 60 days of presentation to it of the Draft Closing Statement give notice to the Seller that it disagrees with the Draft Closing Statement or any item thereof, such notice stating the
reasons for the disagreement in reasonable detail and specifying the adjustments which, in the Purchaser’s opinion should be made to the Draft Closing Statement (the “Purchaser’s Disagreement Notice”), the Draft Closing
Statement shall be final and binding on the parties for all purposes. If the Purchaser gives a valid Purchaser’s Disagreement Notice within such 60 days, the Seller and the Purchaser shall attempt in good faith to reach agreement in respect of
the Draft Closing Statement and, if they are unable to do so within 30 days of such notification, the Seller or the Purchaser may by notice to the other require that the Draft Closing Statement be referred to the Reporting Accountants (an
“Appointment Notice”). 

  

	1.4	Within 30 days of the giving of an Appointment Notice, the Seller may by notice to the Purchaser indicate that, in the light of the fact that the Purchaser has not accepted the Draft Closing Statement in its entirety,
it wishes the Reporting Accountants to consider matters relating to the Draft Closing Statement in addition to those specified in the Purchaser’s Disagreement Notice, provided that such matters as are related to the matters specified in the
Purchaser’s Disagreement Notice and that the notice states in reasonable detail the reasons why and in what respects the Seller believes that the Draft Closing Statement should be altered in respect of such matters (the “Seller’s
Disagreement Notice”). 

  
  

 
 153 

	1.5	The Reporting Accountants shall be engaged jointly by the Seller and the Purchaser on the terms set out in this paragraph 1 and otherwise on such terms as shall be agreed; provided that neither the Seller nor the
Purchaser shall unreasonably (having regard, inter alia, to the provisions of this paragraph 1) refuse its agreement to terms proposed by the Reporting Accountants or by the other party. If the terms of engagement of the Reporting Accountants have
not been settled within 45 days of their identity having been determined (or such longer period as the Seller and the Purchaser may agree) then, unless the Seller or the Purchaser is unreasonably refusing its agreement to those terms, those
accountants shall be deemed never to have become the Reporting Accountants and new Reporting Accountants shall be selected in accordance with the provisions of this Agreement. 

 

	1.6	Except to the extent that the Seller and the Purchaser agree otherwise, the Reporting Accountants shall determine their own procedure but: 

 

	 	1.6.1	apart from procedural matters and as otherwise set out in this Agreement shall determine only: 

  

	 	(i)	whether any of the arguments for an alteration to the Draft Closing Statement put forward in the Purchaser’s Disagreement Notice or the Seller’s Disagreement Notice is correct in whole or in part; and

  

	 	(ii)	if so, what alterations should be made to the Draft Closing Statement in order to correct the relevant inaccuracy in it; 

  

	 	1.6.2	shall apply the accounting principles, policies, procedures, practices and estimation techniques as set out in Part 2 of this Schedule; 

 

	 	1.6.3	shall make their determination pursuant to paragraph 1.6.1 as soon as is reasonably practicable; 

  

	 	1.6.4	the procedure of the Reporting Accountants shall: 

  

	 	(i)	give the Seller and Purchaser a reasonable opportunity to make written and oral representations to them; 

  

	 	(ii)	require that each party supply the other with a copy of any written representations at the same time as they are made to the Reporting Accountants; 

 

	 	(iii)	permit each party to be present while oral submissions are being made by the other party; and 

  

	 	(iv)	for the avoidance of doubt, the Reporting Accountants shall not be entitled to determine the scope of their own jurisdiction. 

  

	1.7	The Reporting Accountants shall send the Seller and the Purchaser a copy of their determination pursuant to paragraph 1.6.1 within one month of their appointment. Such determination: 

 

	 	1.7.1	shall be made available to the Seller and the Purchaser in writing; and 

  

	 	1.7.2	unless otherwise agreed by the Seller and the Purchaser, shall include reasons for each relevant determination. 

  

	1.8	The Reporting Accountants shall act as experts and not as arbitrators and their determination of any matter falling within their jurisdiction shall be final and binding on the Seller and the Purchaser save in the event
of manifest error (when the relevant part of their determination shall be void and the matter shall be remitted to the Reporting Accountants for correction). In particular, their determination shall be deemed to be incorporated into the Draft
Closing Statement. 

  
  

 
 154 

	1.9	The expenses (including amounts in respect of VAT) of the Reporting Accountants shall be borne as they shall direct at the time they make any determination under paragraph 1.6.1(i) or, failing such direction, equally
between the Purchaser and the Seller. 

  

	1.10	The Seller and the Purchaser shall co-operate with the Reporting Accountants and comply with their reasonable requests made in connection with the carrying out of their duties under this Agreement. In particular, the
Purchaser shall keep up-to-date and, subject to reasonable notice, make available to the Seller’s representatives, the Seller’s accountants and the Reporting Accountants all books and records relating to the Vaccines Group during normal
office hours as the Seller or the Reporting Accountants may reasonably request during the period from the appointment of the Reporting Accountants down to the making of the relevant determination. 

 

	1.11	Nothing in this Schedule 16 shall entitle a party or the Reporting Accountants access to any information or document which is protected by legal professional or litigation privilege, provided that neither the Seller nor
the Purchaser shall be entitled to refuse to supply such part or parts of documents as contain only the facts on which the relevant claim or argument is based. 

  

	1.12	Each party and the Reporting Accountants shall, and shall procure that its accountants and other advisers shall, keep all information and documents provided to them pursuant to this paragraph 1 confidential and shall
not use the same for any purpose, except for disclosure or use in connection with the preparation of the Draft Closing Statement, the proceedings of the Reporting Accountants or another matter arising out of this Agreement. 

  
  

 
 155 

 Part 2 

Closing Statement Principles 
 This Part 2
of Schedule 16 comprises the specific rules, principles, policies and practices, without limitation, for preparing the Closing Statement. 
 The Closing
Statement sets out the Working Capital, the Working Capital Adjustment, the Vaccines Group Companies’ Cash Balances, the Intra-Group Non-Trade Receivables, the Third Party Indebtedness, the Intra-Group Non-Trade Payables and the Tax Adjustment,
in each case as prepared in accordance with the specific rules, principles, policies and practices set forth in this Part 2 of Schedule 16. The Closing Statement shall be prepared in the form of the Illustrative Closing Statement in Part 3 of this
Schedule 16 which also sets forth, for illustrative purposes only, a computation of each of the components of the Closing Statement as of the close of business on 31 December 2013. 

For the avoidance of doubt, the Closing Statement as referred to in this Part 2 of Schedule 16 shall inclusively apply to each of the Draft Closing Statement
and the Closing Statement. 
  

	1	Closing Statement Rules 

  

	1.1	The Closing Statement shall be prepared as follows: 

  

	 	1.1.1	in accordance with the specific accounting treatments set out in paragraph 2 of this Part 2 of Schedule 16; and, subject thereto 

  

	 	1.1.2	adopting the same accounting principles, methods, procedures and practices utilized in preparing the Statement of Net Assets, as detailed in the Statement of Net Asset Rules, applied on a consistent basis using
consistent estimation methodologies and judgments and with consistent classifications as were used to prepare the Statement of Net Assets; and subject thereto 

  

	 	1.1.3	in accordance with IFRS. 

  

	1.2	For the avoidance of doubt, paragraph 1.1.1 shall take precedence over paragraphs 1.1.2 and 1.1.3, and paragraph 1.1.2 shall take precedence over paragraph 1.1.3. 

 

	2	Specific requirements 

  

	2.1	Cut-off 

 The Closing Statement (including the Draft Closing Statement) shall not take into
account any additional events and any additional information that becomes available after the Statement time up to the date that such Closing Statement is prepared. 
  

	2.2	Change of Ownership 

 The Closing Statement shall not be adjusted for any charges, provisions,
reserves or write-offs in respect of any costs, liabilities or charges that may be incurred by the Vaccines Group prior to or after the Closing as a consequence of the change of ownership of the Vaccines Group or any changes in the management
strategy, direction or priority or possible closure of any part of the Vaccines Group by the Purchaser after Closing, whether or not resulting from the change in ownership. 

  
  

 
 156 

	2.3	Deferred Tax 

 The Closing Statement (including the Draft Closing Statement) shall not take into
account or provide for deferred Tax. 
  

	2.4	Other Taxes 

 The Closing Statement (including the Draft Closing Statement) shall take account
of or provide for all income taxes and sales taxes, to which lines BS14_120 Taxes other than income taxes (Liability account) and BS13_108 Value added tax receivable apply. 
  

	3	Illustrative Working Capital Statement 

  

	3.1	Part 4 of this Schedule 16 sets forth, for illustrative purposes only a computation of the Working Capital as of the close of business on 31 December 2013 (the “Illustrative Working Capital Statement”).

  

	4	Base Working Capital 

  

	4.1	Base Working Capital is US$575 million to US$700 million and references in this Agreement to amounts being in excess of, greater than or less than Base Working Capital shall mean less than US$575 million and greater
than or in excess of US$700 million. 

  

	4.2	In relation to the France Business and the Netherlands Business, if one or both businesses is not transferred to the Purchaser under the terms of this Agreement at Closing, the Working Capital relating to such business
(or businesses) shall not be included in the determination of the Working Capital at the Effective Time. If one or both of the France Business or the Netherlands Business are transferred to the Purchaser after Closing, then a further adjustment
shall be made to the Closing Statement on the assumption that the France Business and/or the Netherlands Business were included in the Closing Statement taking the relevant items for the relevant business as of the date they are transferred to the
Purchaser. Any adjustment arising as a result of including the France Business or the Netherlands Business in the Closing Statement after the date of this Agreement shall be agreed and paid on the same basis as the Closing Statement was agreed and
paid in respect thereof made. 

  
  

 
 157 

 Part 3 

Illustrative Closing Statement 
 All
amounts in USD thousands 
  

					
	 	  	Vaccines Group (excl. Flu
business)
Illustrative Closing Statement
Dec 31, 2013	 
	 BS01_035 Financial Assets (Loans included in this line)
	  	 	[***]	  
	 BS01_511 Financial Debt – long term
	  	 	[***]	  
	 BS01_651 Financial Debt – short term
	  	 	[***]	  
	 Third Party Indebtedness
	  	 	[***]	  
	 BS01_180 Cash & cash equivalents
	  	 	[***]	  
	 Vaccines Group Companies’ Cash Balances
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 BS01_520 Total financing and loans from subsidiaries / JV
	  	 	[***]	  
	 Intra-Group Non-Trade Payables
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 BS01_050 Total financing and loans to subsidiaries / JV
	  	 	[***]	  
	 Intra-Group Non-Trade Receivables
	  	 	[***]	  
	 BS13_190 Current income tax receivables
	  	 	[***]	  
	 BS01_660 Income taxes payable
	  	 	[***]	  
	 Tax Adjustment
	  	 	[***]	  
	 Illustrative Net Working Capital (*)
	  	 	[***]	  

  

	(*)	The Illustrative Closing Date Net Working Capital is calculated in accordance with paragraph 4 of this Schedule 16. 

  

 

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
  

 
 158 

 Part 4 

Illustrative Working Capital Statement 
  

					
	 	  	Vaccines Group (excl. Flu business)
Illustrative Net Working Capital as
per December 31, 2013	 
	 BS01_110 Total inventories
	  	 	400,663	  
	 BS01_120 Trade receivables (3rd parties and AC)
	  	 	335,387	  
	 BS01_130 Receivables own BU
	  	 	22,683	  
	 BS01_140 Receivables other BU’s
	  	 	20,419	  
	 BS01_610 Trade payables (3rd parties and AC)
	  	 	(176,115	) 
	 BS01_620 Payables own BU
	  	 	(18,295	) 
	 BS01_630 Payables other BU’s
	  	 	(40,675	) 
	 Illustrative Net Working Capital
	  	 	544,067	  

  
  

 
 159 

 Schedule 17 

Milestone and Royalty Payments 
  

	1	Milestone Payments 

  

	1.1	MenABCWY Single Milestone Payment 

  

	 	1.1.1	The Purchaser shall promptly pay, or cause to be paid, to the Seller (or one of its Affiliates as designated by the Seller) a milestone payment in cash of US$450 million (the “MenABCWY Milestone
Payment”) upon issuance to the Purchaser or any of its Affiliates or their respective authorised sub-licensees or assignees (the “Relevant Parties”) on or before 31 December 2018 of a letter of approval of a Biologics
License Application or supplemental Biologics License Application (a “BLA”) issued by the FDA for any meningococcal vaccine (groups A, B, C, W-135 and Y) whether adjuvanted, combined or otherwise (the “MenABCWY Product”)
for use in, at a minimum, Adolescents. 

  

	 	1.1.2	The Purchaser shall not be obliged to make the MenABCWY Milestone Payment more than once under this paragraph 1.1 and its maximum aggregate liability under this paragraph 1.1 shall not exceed the amount of the MenABCWY
Milestone Payment. 

  

	1.2	Bexsero Single Milestone Payment 

 The Purchaser shall promptly pay, or cause to be paid, to the Seller
(or one of its Affiliates as designated by the Seller) a milestone payment in cash of US$450 million (the “Bexsero Milestone Payment”) following the first Calendar Year during which Net Sales of excluding the US in excess of [***]
are achieved. 
  

	 	1.2.1	The Purchaser shall not be obliged to make the Bexsero Milestone Payment more than once under this paragraph 1.2 and its maximum aggregate liability under this paragraph 1.2 shall not exceed the amount of the Bexsero
Milestone Payment. 

  

	1.3	ACIP Category A Single Milestone Payment 

  

	 	1.3.1	The Purchaser shall promptly pay, or cause to be paid, to the Seller (or one of its Affiliates as designated by the Seller) a milestone payment in cash of US$450 million (the “ACIP Category A Milestone
Payment”) upon any positive Category A recommendation by the Advisory Committee on Immunization Practices to the U.S. Centers for Disease Control and Prevention (or its successor) (“ACIP”), before 31 December 2019,
regardless of the population, sub-population, age group or risk-factor-based group to which the recommendation pertains, with respect to either (i) the MenABCWY Product; or (ii) Bexsero (whichever is earlier, and provided such milestone is
paid only once). 

  

	 	1.3.2	The Purchaser shall not be obliged to make the ACIP Category A Milestone Payment more than once under this paragraph 1.3 and its maximum aggregate liability under this paragraph 1.3 shall not exceed the amount of the
ACIP Category A Milestone Payment. 

  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
  

 
 160 

	1.4	GBS Single Milestone Payment 

  

	 	1.4.1	The Purchaser shall promptly pay, or cause to be paid, to the Seller (or one of its Affiliates as designated by the Seller) a milestone payment in cash of US$450 million (the “GBS Milestone Payment”)
upon any positive Category A or Category B recommendation by ACIP, regardless of the population, sub-population, age group or riskfactor-based group to which the recommendation pertains, with respect to any Group B streptococcus vaccine, whether
adjuvanted, combined or otherwise (the “GBS Product”). 

  

	 	1.4.2	The Purchaser shall not be obliged to make the GBS Milestone Payment more than once under this paragraph 1.4 and its maximum aggregate liability under this paragraph 1.4 shall not exceed the amount of the GBS Milestone
Payment. 

  

	2	Notification and Settlement of Milestone Payments 

  

	2.1	As promptly as practicable, but in any event within five days, the Purchaser shall notify the Seller in writing of any Milestone Payment becoming due. 

 

	2.2	The Purchaser shall pay each Milestone Payment within 30 days of achievement of the relevant Milestone. 

  

	2.3	All Milestone Payments due from the Purchaser to the Seller shall be made to the Seller or to an entity designated by the Seller by wire transfer of immediately available funds in US dollars to the credit of such bank
account or accounts as may be designated by the Seller from time to time. 

  

	3	Royalty Payments 

  

	3.1	GBS Worldwide Royalty Payments 

 Subject to paragraph 3.5, the Purchaser shall pay, or
cause to be paid, royalty payments to the Seller (or one of its Affiliates as designated by the Seller) on the aggregate Net Sales of the GBS Product and any adjuvanted or combined versions thereof, in the world in each Calendar Year, at the rate of
10% of such Net Sales in the world (the “GBS Royalty Payments”). 
  

	3.2	MenABCWY US Royalty Payments 

 Subject to paragraph 3.5, the Purchaser shall pay, or
cause to be paid, royalty payments to the Seller (or one of its Affiliates as designated by the Seller) on the aggregate Net Sales of the MenABCWY Product and any adjuvanted or combined versions thereof, in the US in each Calendar Year, at the rate
of 10% of such Net Sales in the US (the “MenABCWY US Royalty Payments”). 
  

	3.3	US Royalty Payments 

 Subject to paragraph 3.5, the Purchaser shall pay, or cause to be
paid, royalty payments to the Seller (or one of its Affiliates as designated by the Seller) on the aggregate Net Sales of Bexsero and any adjuvanted or combined versions (excluding, for the avoidance of doubt, MenABCWY) thereof, in the US in each
Calendar Year, at the rate of 10% of such Net Sales in the US (the “Bexsero US Royalty Payments”). 

  
  

 
 161 

	3.4	Bexsero Ex-US Royalty Payments 

 Subject to paragraph 3.5, the Purchaser shall pay, or
cause to be paid, royalty payments to the Seller (or one of its Affiliates as designated by the Seller) on the aggregate Net Sales of Bexsero and any adjuvanted or combined versions (excluding, for the avoidance of doubt, MenABCWY) thereof, in the
world (excluding the US) in each Calendar Year, at the rate of 10% of such Net Sales in the world (excluding the US) in excess of [***] in such Calendar Year (the “Bexsero Ex-US Royalty
Payments”). 
  

	3.5	Combinations 

 If the GBS Product, the MenABCWY Product or Bexsero is sold as part of the
combination (each a “Combination Product”) then, for the purposes of paragraph 3.1, 3.2, 3.3 or 3.4 (as applicable), the figure of Net Sales of the relevant Combination Product shall be calculated by multiplying the total amount of
Net Sales of that Combination product by the fraction A/(A+B), where A is the invoice price of the GBS Product, the MenABCWY Product or Bexsero (as applicable) sold separately and B is the invoice price of the other active ingredients and/or active
antigens and/or adjuvants in the Combination Product. 
  

	4	Settlement of Royalty Payments 

  

	4.1	Each Royalty Payment shall be an independent obligation of the Purchaser (not linked to any Royalty Payment in respect of another Applicable Product or Calendar Year) and shall continue to be due and payable
indefinitely in accordance with the terms of this Agreement. 

  

	4.2	Each Royalty Payment shall be payable on a Calendar Quarter basis in accordance with paragraph 5. 

  

	4.3	In respect of any period between the Closing Date and the start of the next Calendar Quarter (the “Stub Period”), the amount of any Royalty Payments due in respect of the Stub Period shall be adjusted
on a pro rata basis to reflect the number of days in the Stub Period as a proportion of the number of days in the Calendar Quarter in which Closing occurs. 

  

	5	Reporting of Royalty Payments 

  

	5.1	Within 10 Business Days of the end of: 

  

	 	5.1.1	each Calendar Quarter, the Purchaser shall provide to the Seller a Sales & Royalties Report; and 

  

	 	5.1.2	each Calendar Year, the Purchaser shall provide to the Seller an Annual Reconciliation Report. 

  

	5.2	The Seller shall submit an invoice to the Purchaser in a form agreed by the Seller and the Purchaser from time to time with respect to any Royalty Payment and/or Estimated Quarterly Bexsero Ex-US Royalty Payment shown
as due in a Sales & Royalties Report. 

  

	5.3	The Purchaser shall pay each Royalty Payment and/or Estimated Quarterly Bexsero Ex-US Royalty Payment due within 30 days of receipt of an invoice in respect of the same pursuant to paragraph 5.2. 

 

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
  

 
 162 

	5.4	All Royalty Payments due from the Purchaser to the Seller shall be made to the Seller or to an entity designated by the Seller by wire transfer of immediately available funds in US dollars to the credit of such bank
account or accounts as may be designated by the Seller from time to time. 

  

	6	Reconciliation of Bexsero Ex-US Royalty Payments 

  

	6.1	Following agreement or determination of the amount of the Bexsero Ex-US Royalty Payment due in respect of each Calendar Year (a “Final Bexsero Ex-US Royalty Payment”) either as set out in any Annual
Reconciliation Report or as subsequently agreed or determined in accordance with paragraphs 7 and 8: 

  

	 	6.1.1	if the Paid Bexsero Ex-US Royalty Payment is greater than the Final Bexsero Ex-US Royalty Payment, the Seller shall repay to the Purchaser an amount equal to the excess; or 

 

	 	6.1.2	if the Paid Bexsero Ex-US Royalty Payment is less than the Final Bexsero Ex-US Royalty Payment, the Purchaser shall pay to the Seller an additional amount equal to the deficiency. 

 

	6.2	The Seller or the Purchaser (as applicable) shall pay any amount due under paragraph 6.1 within 30 days of the agreement or determination of the Final Bexsero Ex-US Royalty Payment due in respect of such Calendar Year.

  

	6.3	Any payment to be made in accordance with paragraph 6.2 shall include interest thereon calculated from the date on which the amount would have been due for payment (had the Estimated Bexsero Ex-US Royalty Payments for
the Calendar Year been equal to the Bexsero Ex-US Royalty Payment for such Calendar Year) to the date of payment at a rate per annum of two per cent. above LIBOR. Such interest shall accrue from day to day. 

 

	7	Records and Audit 

  

	7.1	The Purchaser shall, and, so far as it is able to do so, shall cause the Relevant Parties to, keep in all material respects complete, true and accurate books and records in accordance with its Accounting Standards in
relation to this Agreement including in relation to Net Sales and Royalty Payments. The Purchaser shall, and, so far as it is able to do so, shall cause the Relevant Parties to, keep such books and records for at least five years following the
Calendar Year to which they pertain. 

  

	7.2	The Seller shall have the right, for a period of five years after receiving each Report, to audit such Report, whether by itself or through its Affiliates and/or to appoint an internationally-recognised independent
accounting firm to audit (whether the Seller, its Affiliates, or the accounting firm, the “Auditor”) such Report, and to inspect the relevant records of the Relevant Parties to verify such Report and the underlying statements,
records or books of accounts, as applicable. Where the Auditor is not the Seller, the Auditor shall have the right to disclose to the Seller and/or other Affiliates its conclusions regarding any payments owed hereunder to the Seller.

  

	7.3	The Purchaser shall, and shall cause the other Relevant Parties to, make their records available for inspection by the Auditor during regular business hours at such place or places where such records are customarily
kept upon receipt of reasonable advance notice from the Auditor to verify the accuracy of each Report and compliance with this Schedule 17. 

  
  

 
 163 

	7.4	The Seller shall bear the cost of any audit pursuant to this paragraph 7, as well as its own costs, fees and expenses associated with enforcing its rights with respect to any payments hereunder, except that, if it is
determined by the Auditor that the amounts set out in the Sales & Royalties Report for any Calendar Quarter are more than three per cent. below the amounts actually due pursuant to this Schedule 17, the reasonable costs, fees and expenses
charged or incurred by the Auditor shall be paid or reimbursed by the Purchaser. 

  

	7.5	In the event that the final result of the inspection reveals an undisputed underpayment or overpayment by the Purchaser, the underpaid or overpaid amount, as applicable, shall be settled promptly by the Seller or the
Purchaser (as applicable). 

  

	8	Disputes 

 In the event of any dispute between the parties in respect of whether a
Milestone Payment or a Royalty Payment is due, or the amount of any such payment due, in accordance with this Schedule 17, the dispute shall be determined by the Reporting Accountants on the application of the Seller or the Purchaser. Paragraphs 1.6
to 1.12 of Part 1 of Schedule 16 shall apply mutatis mutandis to the engagement and determination of the Reporting Accountants pursuant to this paragraph 8. 
  

	9	Covenants 

  

	9.1	The Purchaser agrees to procure that, following Closing, the Purchaser’s Group uses its commercially reasonable endeavours to satisfy each of the Milestones. 

 

	9.2	The Purchaser agrees that it will not, and it shall procure that no member of the Purchaser’s Group will, take any action or omit to take any action, in either case which is intended to frustrate the achievement of
any of the Milestones, or which is intended to reduce the amount of any Milestone Payment or Royalty Payment due pursuant to this Schedule 17. 

  

	10	Definitions 

 The following further definitions apply in this Schedule 17: 

“Accounting Standards” means, with respect to a Relevant Party, IFRS as generally and consistently applied by the Relevant
Party’s Group. The Purchaser shall promptly notify the Seller in writing in the event that it or its Group changes the Accounting Standards pursuant to which its records are maintained, it being understood that the Purchaser and its Group may
only use internationally recognised accounting principles; 
 “Adolescents” means individuals aged anywhere between 11 and
18 years old; 
 “Annual Reconciliation Report” means a written report or reports in a form to be agreed by the Seller and
the Purchaser from time to time showing a reconciliation of the amount of the Estimated Bexsero Ex-US Royalty Payment to the amount of the Bexsero Ex-US Royalty Payment due in respect of such Calendar Year; 

“Applicable Product(s)” means the GBS Product, the MenABCWY Product and Bexsero; 

“Calendar Quarter” means each of the four periods of 3 consecutive calendar months, starting on 1 January, 1 April,
1 July and 1 October; 

  
  

 
 164 

 “Calendar Year” means each period of 12 consecutive calendar months starting on
1 January and ending on 31 December; 
 “Estimated Bexsero Ex-US Royalty Payment” means the Purchaser’s reasonable
estimate of the Bexsero Ex-US Royalty Payment that will be payable pursuant to paragraph 3.4 in respect of the current Calendar Year; 

“Estimated Quarterly Bexsero Ex-US Royalty Payment” means one quarter of the Estimated Bexsero Ex-US Royalty Payment; 

“Milestone Payments” means the MenABCWY Milestone Payment, the Net Sales Milestone Payment, the ACIP Category A Milestone
Payment and the GBS Milestone Payment, and “Milestone Payment” means any one of them; 
 “Milestones” means the
facts, matters and circumstances giving rise to the requirement for the Purchaser to make the Milestone Payments; 
 “Net
Sales” means, in respect of an Applicable Product, the net sales by the Relevant Parties for the Applicable Product(s) sold to Third Parties other than sublicensees or assignees, as determined in accordance with Accounting Standards
consistently applied by the Purchaser. The deductions booked by the Relevant Parties to calculate the recorded net sales from gross sales shall include the following: 
  

	 	(lxvii)	normal trade, quantity and cash discounts; 

  

	 	(lxviii)	sales taxes, value added taxes and other taxes directly linked to the sale of Products to the extent included in the gross amount invoiced; 

 

	 	(lxix)	amounts repaid or credited by reasons of defects, rejections, recalls or returns; 

  

	 	(lxx)	rebates, commissions and chargebacks to customers and Third Parties; 

  

	 	(lxxi)	any amounts recorded in gross revenue associated with goods provided to customers for free, with the exception of samples; 

  

	 	(lxxii)	amounts provided or credited to customers through coupons, other discount programs and co-pay assistance programs; 

  

	 	(lxxiii)	delayed ship order credits, discounts or payments related to the impact of price increases between purchase and shipping dates; and 

  

	 	(lxxiv)	fees for service payments to customers for any non-separate services (including compensation for maintaining agreed inventory levels and providing information), 

and with respect to the calculation of Net Sales: 
  

	 	(a)	Net Sales only include the value charged or invoiced on the first sale to a Third Party and sales between or among Respective Parties shall be disregarded for purposes of calculating Net Sales; 

 

	 	(b)	if a Product is delivered to the Third Party before being invoiced (or is not invoiced), Net Sales will be calculated at the time all the revenue recognition criteria under Accounting Standards are met; and

  

	 	(c)	distributors shall not be considered as sublicensees/assignees; 

 “Paid Bexsero Ex-US
Royalty Payment” means the aggregate of all Estimated Quarterly Bexsero Ex-US Royalty Payments paid by the Purchaser in each Calendar Year; 

  
  

 
 165 

 “Report” means any Annual Reconciliation Report or Sales & Royalties
Report; 
 “Royalty Payments” means the GBS Royalty Payments, the MenABCWY US Royalty Payments, the Bexsero US Royalty
Payments and the Bexsero Ex-US Royalty Payments, and “Royalty Payment” means any one of them; 
 “Sales &
Royalties Report” means a written report or reports in a form to be agreed by the Seller and the Purchaser from time to time showing, on an Applicable Product-by-Applicable Product basis: 

 

	 	(lxxv)	each of (a) gross sales; (b) Net Sales; and (c) Royalty Payments (other than the Bexsero Ex-US Royalty Payments) payable, for each such Applicable Product in respect of the relevant Calendar Quarter;

  

	 	(lxxvi)	the Purchaser’s reasonable estimate of gross sales and Net Sales of the Bexsero Product in the world (excluding the US) in the current Calendar Year; 

 

	 	(lxxvii)	the Estimated Quarterly Bexsero Ex-US Royalty Payment; and 

  

	 	(lxxviii)	the information in paragraphs (i) to (iii) for (a) the equivalent Calendar Quarter in the prior Calendar Year; and (b) the cumulative totals for the current Calendar Year; 

“Third Party” means any person other than a party or an Affiliate of a party; and 

“US” means the United States of America, its territories and possessions, any state of the United States and the District of
Columbia; and “possessions” include Puerto Rico, the U.S. Virgin Islands, Guam, American Samoa, Wake Island and the Northern Mariana Islands. 

  
  

 
 166 

 Schedule 18 

Warranties given under Clause 9.1 
  

	1	Authority and Capacity 

  

	1.1	Incorporation 

 The Seller and each Share Seller and Business Seller is validly existing
and is a company duly incorporated and registered under the law of its jurisdiction of incorporation. 
  

	1.2	Authority to enter into Agreement 

  

	 	1.2.1	The Seller and each Share Seller and Business Seller has the legal right and full power and authority to enter into and perform this Agreement, any Ancillary Agreement to which it is a party and any other documents to
be executed by it pursuant to or in connection with this Agreement or any Ancillary Agreement. 

  

	 	1.2.2	The documents referred to in paragraph 1.2.1 will, when executed, constitute valid and binding obligations on the Seller and each Share Seller and Business Seller in accordance with their respective terms.

  

	 	1.2.3	Except as referred to in this Agreement, the Seller: 

  

	 	(i)	is not required to make any announcement, consultation, notice, report or filing; and 

  

	 	(ii)	does not require any consent, approval, registration, authorisation or permit, 

 in each case
in connection with the performance of this Agreement or any other document referred to in paragraph 1.2.1. 
  

	 	1.2.4	The execution and delivery of the documents referred to in paragraph 1.2.1 and the performance by the Seller, each Share Seller and each Business Seller of their respective obligations under them, will not:

  

	 	(i)	result in a breach of any provision of the memorandum or articles of association or by laws or equivalent constitutional document of the relevant member of the Seller’s Group; 

 

	 	(ii)	result in a breach of, or constitute a default under, any instrument or contract to which the relevant member of the Seller’s Group is party or by which the relevant member of the Seller’s Group is bound where
such breach is material to their ability to perform their obligations under such documents; 

  

	 	(iii)	result in a breach of any existing order, judgment or decree of any court, Governmental Entity by which the relevant member of the Seller’s Group is bound and where such breach is material to their ability to
perform their obligations under such documents. 

  

	1.3	Authorisation 

 The Seller and each Share Seller and Business Seller has taken, or will
have taken by Closing, all corporate action required by it to authorise it to enter into and to perform this Agreement, any Ancillary Agreement to which it is a party and any other documents to be executed by it pursuant to or in connection with
this Agreement or any Ancillary Agreement. 

  
  

 
 167 

	2	Vaccines Group 

  

	2.1	Organisation and Standing of the Vaccines Group Companies 

  

	 	2.1.1	Schedule 2 sets out a complete and accurate list of each of the Vaccines Group Companies, together with its jurisdiction of organisation, its authorised and outstanding capital stock or other equity interests, all of
which equity interests are held by the Seller or an Affiliate of the Seller unless otherwise stated in Schedule 2. 

  

	 	2.1.2	Each Vaccines Group Company is duly incorporated, validly existing and in good standing, under the laws of its jurisdiction of organisation and has all necessary corporate power under its constitutional documents to
conduct its portion of the Business as at the date of this Agreement. 

  

	2.2	The Shares 

  

	 	2.2.1	Either the Seller or one of its Affiliates is the legal and beneficial owner of the Shares. 

  

	 	2.2.2	There is no option, right to acquire, mortgage, charge, pledge, lien or other form of security or Encumbrance or equity on, over or affecting the Shares or the shares, capital stock or other equity interests in the
Subsidiaries or any of them and there is no agreement or commitment to give or create any. 

  

	 	2.2.3	All of the Shares and all of the shares, capital stock or other equity interests in the Subsidiaries have been duly authorised and validly issued and are fully paid and non-assessable. There are no options, warrants,
rights, convertible, exercisable or exchangeable securities, “phantom” stock rights, stock appreciation rights, stock-based performance units, commitments, Contracts, arrangements or undertakings of any kind to which any of the Vaccines
Group Companies is a party or by which it is bound obligating any of the Vaccines Group Companies to issue, deliver or sell, or cause to be issued, delivered or sold, additional shares of capital stock or other equity interests in, or any security
convertible into, or exercisable or exchangeable for, any capital stock of, or other equity interest in, such Vaccines Group Company. 

  

	 	2.2.4	There are no outstanding Contracts to which any of the Vaccines Group Companies is a party or is otherwise bound to repurchase, redeem or otherwise acquire any shares, capital stock or other equity interest of such
Vaccines Group Company. 

  

	 	2.2.5	None of the Shares, and the shares, capital stock and other equity interests in the Subsidiaries and Minority Interest Entities is subject to and was not issued in violation of any purchase option, call option, right of
first refusal, pre-emptive right, subscription right or similar right or any provision of Applicable Law or the constitutional documents of the Vaccines Group Companies. 

 

	2.3	The Assets 

 Save in relation to the Transferred Intellectual Property Rights, either the
Seller or another member of the Seller’s Group has good and valid title to the assets listed in Clause 2.3.1 free and clear of all Encumbrances other than Permitted Encumbrances. 

  
  

 
 168 

	2.4	Accounts 

 The Accounts of each Vaccines Group Company: 

 

	 	2.4.1	were prepared in accordance with accounting practices generally accepted in the jurisdiction of incorporation of the relevant Vaccines Group Company at the time they were audited; and 

 

	 	2.4.2	show in accordance with applicable legal requirements: 

  

	 	(i)	the assets and liabilities of the relevant Vaccines Group Company at the Accounts Date; and 

  

	 	(ii)	of the profits or losses of the relevant Vaccines Group Company for the accounting period ended on the Accounts Date. 

  

	2.5	Income Statements 

  

	 	2.5.1	The 2013 Income Statement: 

  

	 	(i)	is based on information properly extracted from the Seller’s Group accounting records without adjustment; and 

  

	 	(ii)	presents fairly in all material respects the results of operations of the Vaccines and Diagnostics division of the Seller’s Group as reported in the “Vaccines and Diagnostics” segment in the Novartis 2013
Annual Report for the period from and including 1 January 2013 up to and including 31 December 2013 excluding the Diagnostics Business but including the Influenza Business and the Out-Licensing Programme. 

 

	2.6	Statement of Net Assets 

  

	 	2.6.1	Schedule 23 sets out the Statement of Net Assets. 

  

	 	2.6.2	The Statement of Net Assets was prepared, in all material respects, in accordance with the Statement of Net Assets Rules, and on that basis fairly presents, in all material respects, the financial position of the
Vaccines Group as of the date thereof, subject to year-end audit adjustments and the absence of footnote discussions and similar presentation items therein. 

  

	2.7	Changes Since 31 December 2013 

 Except as a result of the execution and delivery of
this Agreement and, other than as contemplated by Clause 2.3.5 or Clause 5, from 31 December 2013 to the date of this Agreement: 
  

	 	2.7.1	the Business of the Vaccines Group has been conducted in all material respects in the ordinary and usual course; 

  

	 	2.7.2	the Vaccines Group has not entered into any material contract or commitment outside the ordinary course of business as conducted prior to 31 December 2013; and 

 

	 	2.7.3	to the Seller’s knowledge, there has been no event or circumstance arising which is reasonably likely to have had a Material Adverse Effect (as if reference in the definition of “Material Adverse Effect”
to the date of this Agreement were to 31 December 2013). 

  
  

 
 169 

	2.8	Third Party Indebtedness and financial instruments 

 None of the Vaccines Group
Companies: (i) has any Third Party Indebtedness exceeding $1 million (other than short-term bank borrowings in the ordinary course of business) or (ii) is a party to any financial instruments (including any swaps or derivatives) 

 

	2.9	Gross Profit and DCOGS 

  

	 	2.9.1	So far as the Seller is aware, based on management allocations and adjustments, and having regard to the purpose for which it was prepared, the 2013 Gross Profit does not materially misstate the gross profit of the
Vaccines Group for the period from and including 1 January 2013 up to and including 31 December 2013. 

  

	 	2.9.2	So far as the Seller is aware, the 2013 DCOGS: 

  

	 	(i)	is derived from information extracted from the Seller’s Group reporting systems with reasonable care and attention; and 

  

	 	(ii)	having regard to the purpose for which the 2013 DCOGS was prepared, does not materially misstate the direct cost of goods of each of the Products identified in the 2013 DCOGS for the period from and including
1 January 2013 up to and including 31 December 2013. 

  

	3	Real Property and Key Sites 

  

	3.1	Company Real Properties 

  

	 	3.1.1	The Company Real Properties are the only material freehold, leasehold or other immovable property in any part of the world owned, used or occupied by the Vaccines Group Companies or in respect of which any Vaccines
Group Company has any estate, or any material interest, right or liability. 

  

	 	3.1.2	Each of the Company Real Properties is used and occupied for the purpose of the business of a member of a Vaccines Group Company. 

  

	 	3.1.3	A member of the Seller’s Group is solely legally and beneficially entitled to such Company Real Property. 

  

	 	3.1.4	No person has or will have any right to possession, occupation or use of such Company Real Property in a manner that has or will have a material adverse effect on the use of, or operations at, such Company Real
Property. 

  

	 	3.1.5	There are no mortgages or charges affecting any of the Company Real Properties other than those registered in the relevant Land Register. 

 

	 	3.1.6	There are no material outstanding disputes, actions, claims or demands in respect of any Company Real Property, nor has the Seller or any member of the Seller’s Group received any notice threatening the same.

  

	 	3.1.7	In respect of each Company Leased Real Property, all material covenants and conditions contained in the Company Lease have been observed and performed to date. 

 

	3.2	Transferred Real Properties 

  

	 	3.2.1	The Transferred Real Properties are the only material freehold, leasehold or other immovable property in any part of the world owned or occupied by the Vaccines Group Businesses or in respect of which any Vaccines Group
Business has any estate, or any material interest, right or liability. 

  
  

 
 170 

	 	3.2.2	Each of the Transferred Real Properties is used and occupied for the purpose of the business of the Vaccines Group Business. 

  

	 	3.2.3	A member of the Seller’s Group is solely legally and beneficially entitled to such Transferred Real Property. 

  

	 	3.2.4	No person has or will have any right to possession, occupation or use of such Transferred Real Property in a manner that has or will have a material adverse effect on the use of, or operations at, such Transferred Real
Property. 

  

	 	3.2.5	There are no mortgages or charges affecting any of the Transferred Real Properties other than those registered in the relevant Land Register. 

 

	 	3.2.6	There are no material outstanding disputes, actions, claims or demands in respect of any Transferred Real Property, nor has the Seller or any member of the Seller’s Group received any notice threatening the same.

  

	 	3.2.7	In respect of each Transferred Leased Real Property, all material covenants and conditions contained in the Lease have been observed and performed to date. 

 

	3.3	Key Sites 

  

	 	3.3.1	The Key Sites are the only properties used or occupied by the Seller’s Group for the purpose of Manufacturing in respect of the Business. 

 

	 	3.3.2	No consents, licences, approvals, permits, authorisations or waivers are required from any Landlord, superior landlord or other third party to transfer any Key Site to the Purchaser (or any other member of the
Purchaser’s Group) indirectly (through the transfer of the Vaccines Group Companies). 

  

	 	3.3.3	There is no circumstance which would entitle any third party to exercise a right of power of entry or to take possession which would materially adversely restrict the continued possession, enjoyment or existing use of
each Key Site and there are no material restrictive conditions of servitude or public easements attaching to each Key Site. 

  

	 	3.3.4	No member of the Seller’s Group has had any notice from any competent authority to make any alteration, repair or addition to any Key Site, including with regards to the disposal of effluent or the state of
buildings or the number of legally required parking spaces which is presently outstanding. 

  

	4	Intellectual Property and Information Technology 

  

	4.1	Schedule 4 sets out, as of the date of this Agreement, complete and accurate details of Registered Vaccines Group Intellectual Property Rights, including for each such item, as applicable, (i) the identity of the
record owner, (ii) the registration or application number, and (iii) the jurisdiction of issuance or registration. 

  

	4.2	In relation to Products or Pipeline Products which are material to the Business, all documents and instruments necessary to maintain and preserve any extension of patent terms including Patent Term Extensions and patent
term adjustments in relation to: the (i) Registered Vaccines Group Intellectual Property Rights; and (ii) any Registered Intellectual Property Rights licensed under any Vaccines Group Intellectual Property Contracts for which the Seller
controls the prosecution and maintenance; and in each case, where such applications have a reasonable prospect of success, have been validly executed, delivered and filed in a timely manner with the appropriate Governmental Entity.

  
  

 
 171 

	4.3	Each of the Patents: (i) included within the Registered Vaccines Group Intellectual Property Rights for the Products or Pipeline Products which are material to the Business; and (ii) to the Seller’s
Knowledge, included within the Registered Intellectual Property Rights licensed under the Vaccines Group Intellectual Property Contracts for Products or Pipeline Products material to the Business, in each case, correctly identifies by name each
inventor thereof as determined in accordance with the Applicable Law of each jurisdiction in which such Patent issued and/or is pending. 

  

	4.4	To the Seller’s Knowledge, the Patents forming part of (i) the Registered Vaccines Group Intellectual Property Rights, and (ii) the Registered Intellectual Property Rights licensed under the Vaccines
Group Intellectual Property Contracts in each case for the Products or Pipeline Products which are material to the Business are subsisting, valid and enforceable and have not lapsed or been abandoned. 

 

	4.5	All renewal, application and other registry fees required for the maintenance, prosecution and enforcement of the Registered Vaccines Group Intellectual Property Rights relating to Products or Pipeline Products that are
material to the Business have been paid. 

  

	4.6	Schedule 4 sets out, a complete and accurate list of each material Vaccines Group Intellectual Property Contract. Neither the Seller nor any of its Affiliates has given, or received, written notice to terminate any
material Vaccines Group Intellectual Property Contract or the Merck 2012 Licence, and neither the Seller nor any Affiliate of the Seller is in default of any material Vaccines Group Intellectual Property Contract or the Merck 2012 Licence. To the
Seller’s Knowledge, no third party is in default under any material Vaccines Group Intellectual Property Contract or the Merck 2012 Licence. 

  

	4.7	The Seller and its Affiliates between them own all Registered Vaccines Group Intellectual Property Rights and the Beta Interferon Patent Rights free of all Encumbrances except Permitted Encumbrances. The Seller and its
Affiliates have taken reasonable steps to protect the confidentiality of Proprietary Information and Know-How relating to the Products. 

  

	4.8	To the Seller’s Knowledge: (i) the conduct of the Business as currently conducted does not infringe or misappropriate the Intellectual Property Rights of any third party; and (ii) there is no material
judicial, administrative or arbitral action, suit, hearing, inquiry, investigation or other proceeding (public or private) before any Governmental Entity pending against the Seller or any of its Affiliates in which it is alleged that the conduct of
the Business as currently conducted by the Seller and its Affiliates infringes or misappropriates any Intellectual Property Rights of any third party. Neither the Seller nor any of its Affiliates has received any written notice of such infringement
or misappropriation. 

  

	4.9	To the Seller’s Knowledge, no third party is infringing or misappropriating any Vaccines Group Intellectual Property Rights or Proprietary Information and neither the Seller nor its Affiliates have made any such
claims against any such persons, nor, to the Seller’s knowledge is there any basis for such a claim. 

  

	4.10	The Vaccines Group Intellectual Property Rights, the Intellectual Property Rights licensed under the Vaccines Group Intellectual Property Contracts, and the Intellectual Property Rights licensed under the Purchaser
Intellectual Property Licence Agreement constitute all the material Intellectual Property Rights used in the conduct of the Business as currently conducted by the Seller and its Affiliates on a worldwide basis; provided however, that the foregoing
is not a representation of non-infringement, non-misappropriation, or any other non-violation of Intellectual Property Rights of any third party, which representation is solely set out in paragraph 4.8 above. 

  
  

 
 172 

	4.11	All Information Technology necessary for the Business to be conducted in all material respects as it is carried on at the date of this Agreement is: (i) Owned Information Technology; (ii) is Transferred
Information Technology; or (iii) will be provided by the Seller and its Affiliates to the Purchaser and the Business under the Transitional Services Agreement. 

 

	4.12	The Business has not, in the 12 months prior to the date of this Agreement, experienced any material disruption in its operations as a result of any failure of its Information Technology. 

 

	5	Contracts 

  

	5.1	No Vaccines Group Company or Business Seller is a party to or subject to any Contract, transaction, arrangement, understanding or obligation (other than in relation to any Property, lease or contract of employment,
Information Technology or Intellectual Property Right) which is material to the business of the Vaccines Group and which: 

  

	 	5.1.1	is not in the ordinary course of business or is unduly onerous; 

  

	 	5.1.2	is not on an arm’s length basis; 

  

	 	5.1.3	has an unexpired term or likely duration of 10 years or more; 

  

	 	5.1.4	restricts its freedom to carry on its business in any part of the world in such manner as it thinks fit; 

  

	 	5.1.5	involves an aggregate outstanding expenditure by it of more than US$50 million, exclusive of VAT; 

  

	 	5.1.6	can be terminated in the event of a change of underlying ownership or control of a Vaccines Group Company; or 

  

	 	5.1.7	involves the supply of goods and services, the aggregate sales value of which (exclusive of VAT) will be more than 5 per cent of turnover of the Vaccines Group (exclusive of VAT) for the preceding financial year.

  

	5.2	Save in relation to any Vaccines Group Intellectual Property Contract, no Vaccines Group Company is in material default under any material Contract to which it is party and no third party is in material default under
any material Contract to which a Vaccines Group Company is party and, to the Seller’s knowledge, there are no circumstances in either case likely to give rise to such a material default. 

 

	5.3	Save in relation to any Vaccines Group Intellectual Property Contract, no Business Seller is in material default under any material Contract to which it is party and no third party is in material default under any
material Contract to which a Business Seller is party and, to the Seller’s knowledge, there are no circumstances in either case likely to give rise to such a material default. 

  
  

 
 173 

	6	Joint Ventures etc. 

 No Vaccines Group Company or Business Seller is, or has agreed to
become, a member of any joint venture, consortium, partnership or other unincorporated association (other than a recognised trade association in relation to which the Vaccines Group Company or Business Seller has no liability or obligation except
for the payment of annual subscription or membership fees). 
  

	7	Agreements with Connected Parties 

  

	7.1	There are no existing contracts or arrangements material to the business of the Vaccines Group between, on the one hand, any Business Seller or Vaccines Group Company and, on the other hand, the Seller, any Relevant
Seller other than on normal commercial terms in the ordinary course of business. 

  

	7.2	No Affiliate Contract is required to run the Business and the termination of any Affiliate Contract will not, when taken together with the rights and services under the Ancillary Agreements and for the respective terms
thereof, have a material effect on the Business. 

  

	7.3	The Vaccines Group Companies do not currently carry on any Seller’s Group Retained Business (other than the Influenza Business). 

 

	8	Sufficiency of Vaccines Group 

  

	8.1	Each of the assets listed in Clause 2.3.1 is owned both legally and beneficially by the Seller or its Affiliates and each of those assets capable of possession is, save where in the possession of third parties in the
ordinary course of business, in the possession of the Seller or its Affiliates. 

  

	8.2	Save for Permitted Encumbrances, no option, right to acquire, mortgage, charge, pledge, line or other form of security or Encumbrance (excluding licences of Intellectual Property or Know-How) or equity on, over or
affecting the whole or any part of the assets listed in Clause 2.3.1 is outstanding and, save in relation to Permitted Encumbrances, there is no agreement or commitment entered into by any member of the Seller’s Group to give or create any and
no claim has been made against any member of the Seller’s Group by any person entitled to any. 

  

	8.3	The Vaccines Group Businesses, assets of the Vaccines Group Companies and the assets of the Minority Interest Entities, when taken together with the rights and services under the Ancillary Agreements and for the
respective terms thereof: 

  

	 	(lxxix)	comprise all of the assets required to carry out the Business of the Vaccines Group in substantially the same manner as it has been during the twelve months prior to the date of this Agreement; and 

 

	 	(lxxx)	are sufficient in all material respects to carry out the Business of the Vaccines Group after the Closing substantially as conducted by the Seller and its Affiliates as of the date of this Agreement, 

provided however, that the foregoing is not a warranty of non-infringement, non-misappropriation or any other non-violation of Intellectual
Property Rights of any third party, which warranty is solely set out in paragraph 4.8. 

  
  

 
 174 

	9	Compliance with Laws, Permits and Anti-Bribery 

  

	9.1	None of the Seller or its Affiliates is in breach of any Applicable Law where such breach is reasonably likely to be material to the Vaccines Group. 

 

	9.2	Neither the Seller nor any of its Affiliates has received any written notice from any Governmental Entity that it is not in compliance (or any warning letter that it may not be in compliance) with any Applicable Law or
is not in possession of any permits, licences, certificates or other authorisations or consents of a Governmental Entity in each case as is necessary for the conduct of the Business of the Vaccines Group in all material respects as presently
conducted (each a “Permit” and, collectively, the “Permits”), except where such non-compliance or non-possession does not remain outstanding or uncured as of Closing or would not reasonably be expected to have a
material effect on the Business. 

  

	9.3	With respect to the Vaccines Group, since 1 January 2009, neither the Seller nor any of its Affiliates, nor any of their respective directors, officers or employees and, to the Seller’s Knowledge, no Seller
Partner has, directly or indirectly: (i) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity or to influence official action; (ii) made or offered to make any
unlawful payment to any foreign or domestic government official or employee, or agent, political party or any official of such party, or political candidate from corporate funds; (iii) made or offered to make any bribe, rebate, payoff,
influence payment, money laundering, kickback or other unlawful payment; or (iv) violated or is in violation of any provision of any applicable Anti-Bribery Law; and with respect to the Vaccines Group, the Seller and its relevant Affiliates
have instituted and maintain policies and procedures reasonably designed to ensure compliance with applicable Anti-Bribery Law. 

  

	9.4	With respect to the Vaccines Group, neither the Seller nor any of its Affiliates, nor any of their respective directors, officers or employees and, to the Seller’s Knowledge, no Seller Partner: (i) is
currently the subject of, nor has it been since 1 January 2009, the subject of, any action alleging a violation, or possible violation, of any Anti-Bribery Law, or been since 1 January 2009, the recipient of a subpoena, letter of
investigation or other document alleging a violation, or possible violation, of any Anti-Bribery Law, or (ii) has, since 1 January 2009, improperly or inaccurately recorded in any books and records (A) any payments, cash,
contributions, gifts, hospitalities or entertainment to a foreign or domestic government official, employee of an enterprise owned or controlled in whole or in part by any foreign government, official of a foreign or domestic political party or
campaign, or a foreign or domestic candidate for political office; or (B) other expenses related to political activity or lobbying. 

  

	9.5	With respect to the Vaccines Group, since 1 January 2009, neither the Seller nor any of its Affiliates, nor any of their respective directors or officers, and, to the Seller’s Knowledge, none of their
respective employees has received notice that any such person is or has been alleged to be in violation of any sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury or by the U.S. Department of State
or equivalent measures of the United Kingdom, European Union, or the United Nations (the “Sanctions Law”). With respect to the Vaccines Group, neither the Seller nor any of its Affiliates, nor any of their respective directors or
officers, and, to the Seller’s Knowledge, none of their respective employees has conducted any of their business activities whatsoever with, or for the benefit of, a government, national or legal entity to the extent such actions would violate
any Sanctions Law. None of the execution, delivery and performance of this Agreement and the direct or indirect use of proceeds from any transaction contemplated hereby or the fulfilment of the terms hereof will result in a violation by any person
of any Sanctions Law. 

  
  

 
 175 

	9.6	Each member of the Seller’s Group, in connection with the Products, the Product Approvals, the Product Applications, the Transferred Contracts and the Transferred Intellectual Property Contracts requires its
Service Providers to act in accordance with the requirements of applicable Anti-Bribery Law and uses all reasonable endeavours to procure that they do so. Each such Service Provider has in place policies, systems, controls and procedures designed to
prevent, and which are reasonably expected to continue to prevent, it and its Associated Persons from violating applicable Anti-Bribery Law. 

  

	10	Product Approvals 

  

	10.1	The Seller or one of its Affiliates is the registered holder of each of the Product Approvals. All material Product Approvals held by Seller or its Affiliates are in full force and effect. No material deficiencies have
been asserted by any applicable Government Entity with respect to any Product Approval or Product Filing, nor, to the Seller’s knowledge, are there any facts or circumstances that would be likely to lead to such assertions being made.

  

	10.2	Each Product was and is being researched, developed, manufactured, marketed or sold in all material respects in accordance with the specifications and standards contained in the relevant Product Approval and the related
Marketing Authorisation Data and in accordance with Applicable Law. 

  

	10.3	Neither the Seller or any of its Affiliates has received any written notice that any Governmental Entity with jurisdiction over the Products has commenced or will commence any action: (i) to withdraw the approval
of any Product or otherwise revoke or materially amend any Product Approval or Marketing Authorisation Data; or (ii) enjoin production, marketing or sale of any Product and, to the Seller’s knowledge, no such action has been threatened.

  

	10.4	All application and renewal fees due and payable with respect to all material Product Approvals have been paid. 

  

	10.5	All preclinical and clinical investigations with respect to the Products are being and have been conducted in compliance with Applicable Law in all material respects. The Seller and its Affiliates have not, and to the
Seller’s Knowledge, none of its Product Partners or any other third party under any Licensed Intellectual Property Contract has received since 1 January 2009, any written notices or other correspondence from any Governmental Entity with
respect to any on-going clinical or pre-clinical studies or tests of any Product requiring the termination, suspension or material modification of such studies or tests. 

 

	10.6	None of the Seller or its Affiliates or, to the Seller’s Knowledge, any Product Partner or any other third parties pursuant to any Licensed Intellectual Property Contract, has any knowledge of any adverse event,
arising since the date three years prior to the date of this Agreement, reportable with respect to the safety or efficacy of any Product which is expected to be material. 

 

	11	Product Recall 

  

	11.1	No Product (or any component thereof) has been recalled, suspended, withdrawn, seized, discontinued or the subject of a refusal to file, clinical hold, deficiency or similar action letter (including any correspondence
questioning data integrity) as a result of any action by any Governmental Entity, by the Seller or any of its Affiliates; nor are any such actions pending or under consideration (or any facts, conditions, or circumstance known) by the Seller or any
of its Affiliates, or, to the Seller’s Knowledge, by any Governmental Entity. There is not, to the Seller’s Knowledge, pending or threatened litigation anywhere in the world seeking the recall, withdrawal, suspension, seizure or
discontinuance of any of the Products. 

  
  

 
 176 

	12	Product Liability 

 The Products sold by the Business during the Relevant Period have
complied in all material respects with all applicable product specifications and have been Manufactured in all material respects in accordance with applicable requirements of then current GMP and any Applicable Law, except for any such
non-compliance that has not had, and would not reasonably be expected to have, a materially adverse impact on the relevant Product. 
  

	13	Taxes 

  

	13.1	Each Vaccines Group Company and each Tax Group to which it belongs has, and every member of the Seller’s Group with an interest in the Vaccines Group has in respect of the Vaccines Group, duly, and within any
appropriate time limits, filed all Tax Returns required to be filed and has maintained all records required to be maintained for tax purposes in relation to the assets comprised in the Vaccines Group; all such information was and remains complete
and accurate in all material respects and all such Tax Returns were complete and accurate in all material respects and were made on the proper basis. 

  

	13.2	There are no Tax liens on any asset comprised in the Vaccines Group Businesses (other than Permitted Encumbrances). 

  

	13.3	No Vaccines Group Company and no Tax Group to which a Vaccines Group Company belongs is currently under audit or examination by a Tax Authority that could result in the assessment of a material amount of Tax and neither
the Seller nor any Vaccines Group Company (nor any Tax Group to which a Vaccines Group Company belongs) has received notice from a Tax Authority of any dispute or disagreement outstanding or contemplated at the date of this Agreement with any Tax
Authority regarding liability or potential liability to any Tax recoverable from any Vaccines Group Company or regarding the availability of any relief from Tax to any Vaccines Group Company and, so far as the Seller is aware, there are no
circumstances which make it likely that any such dispute or disagreement will commence. 

  

	13.4	The Disclosure Letter lists every written agreement that a Vaccines Group Company has entered into, in each case, which is currently in force, to have its Tax affairs dealt with on a consolidated basis and for any Tax
sharing arrangement (including without limitation any arrangement under which Tax losses or Tax reliefs are surrendered or agreed to be surrendered or claimed) in respect of the profits, gains or losses of that Vaccines Group Company with any
company not being another Vaccines Group Company. 

  

	13.5	No Vaccines Group Company, and no Tax Group to which a Vaccines Group Company belongs, has received or requested any extension of time to file a Tax Return that remains unfiled or has granted or requested a waiver or
extension of a limitation on any period for audit and examination or assessment and collection of Tax for any taxable period as to which Tax could be assessed. 

  

	13.6	No member of the Seller’s Group with an interest in the Vaccines Group has received notice from a Tax Authority of, and so far as the Seller is aware, there is not any dispute or disagreement outstanding at the
date of this Agreement with any Tax Authority regarding the proper method of computing the profits of the Vaccines Group (or any part of it) for Tax purposes or the proper treatment for VAT purposes of any supplies of goods or services made (or
treated as made) in the course of the Vaccines Group and, so far as the Seller is aware, there are no circumstances which make it likely that any such dispute or disagreement will commence. 

  
  

 
 177 

	13.7	So far as the Seller is aware, no Vaccines Group Company benefits from any preferential Tax regime, granted by law or by special authorisation issued by any Tax Authority or by any other authority, which would in whole
or in part be withdrawn as a result of the signature of this Agreement. 

  

	13.8	So far as the Seller is aware, no Tax Authority has within the past three years operated or agreed to operate any special arrangement (being an arrangement which is not based on relevant legislation or any
published practice) in relation to any assets comprised in the Vaccines Group. 

  

	13.9	In respect of all documents which establish or are necessary to establish the title of the relevant member of the Seller’s Group to each material asset comprised in the Vaccines Group, or by virtue of which the
relevant member of the Seller’s Group has any right in respect of each such asset, all applicable stamp duties, transfer taxes, registration charges or similar duties or charges have been duly paid. 

 

	13.10	So far as the Seller is aware, other than any payments which are of a nature or type (such as expenditure on business entertainment or marketing) which are not deductible for Tax purposes by reason of a general
restriction on deductibility applicable to payments of that nature or type under the laws of the jurisdiction in which the relevant Vaccines Group Company is resident for Tax purposes or carries on its business, no Vaccines Group Company is under
any obligation to make any future payment which will not be deductible for Tax purposes in an amount which, if the payment were deductible for Tax purposes, would reduce the Tax liability of the relevant Vaccines Group Company by an amount exceeding
US$5 million. 

  

	13.11	The country of incorporation which is given in Schedule 2 for each Vaccines Group Company is also the Tax residence of each Vaccines Group Company, and is the only country whose Tax Authorities seek to charge Tax on the
worldwide profits or gains of that Vaccines Group Company and no Vaccines Group Company has, within the past three years, carried on the Business of the Vaccines Group through a permanent establishment in any other country. 

 

	14	Environmental Matters 

  

	14.1	To the Seller’s Knowledge, each Business Seller (with respect to its conduct of the Business and any Transferred Real Property) and Vaccines Group Company is in compliance in all material respects with all
Environmental Laws. 

  

	14.2	To the Seller’s Knowledge, each Vaccines Group Company and each Business Seller (with respect to its conduct of the Business and any Transferred Real Property) possesses all material Permits required under
applicable Environmental Laws necessary to conduct its portion of the Business. 

  

	14.3	To the Seller’s Knowledge, no Vaccines Group Company nor any Business Seller (with respect to its conduct of the Business and any Transferred Real Property) has received any written notice alleging a material
violation of any Environmental Laws, other than matters that have been resolved in all material respects. 

  
  

 
 178 

	14.4	To the Seller’s Knowledge, no Vaccines Group Company nor any Business Seller (with respect to its conduct of the Business and any Transferred Real Property) has received any written notice or claim alleging that it
is or may be liable to any person in any material respect under any applicable Environmental Law as a result of a release or threatened release of any Hazardous Substance at any Transferred Real Property, other than matters that have been resolved
in all material respects. 

  

	14.5	To the Seller’s Knowledge, no Vaccines Group Company nor any Business Seller (with respect to its conduct of the Business and any Transferred Real Property) is a party to any pending proceedings relating to any
Environmental Laws, other than proceedings that would not reasonably be expected to have a Material Adverse Effect. 

  

	15	Employees 

  

	15.1	The Employees are all employed by a Vaccines Group Company or a Business Seller and work wholly or substantially in the Business (as carried on by the Vaccines Group). 

 

	15.2	The Disclosure Letter contains a true, complete and correct list of the following information in respect of each Vaccines Business Employee and each Vaccines Group Company Employee as of 17 April 2014 (organised by
country and, in relation to any Vaccines Group Company, by legal employer): (A) employee identification details; (B) date of birth; (C) employment status (part-time or full-time); (D) employment start date; (E) base salary;
(F) target annual incentive for 2014 (and actual bonus for 2013); and (G) target long-term incentive for 2014 (and actual long-term incentive for 2013). 

 

	15.3	In each of the Material Employee Jurisdictions except as would not be reasonably expected to have a Material Adverse Effect: 

  

	 	15.3.1	as of the date of this Agreement there is not, and in the two years prior to the date of this Agreement there has not been, nor to the Seller’s Knowledge is there pending or threatened, any labour strike, dispute,
work stoppage or lockout by any group of either Vaccines Business Employees or Vaccines Group Company Employees; 

  

	 	15.3.2	no trade union or works council is recognised in any way for bargaining, information or consultation purposes in relation to any of the Vaccines Business Employees or Vaccines Group Company Employees and no collective
bargaining negotiations, whether voluntary or mandatory, are currently taking place with respect to any of the Vaccines Business Employees or Vaccines Group Company Employees and, as of the date of this Agreement, no Vaccines Group Company or
Business Seller is a party to any agreement (whether legally binding or not) with any trade union or works council affecting any Vaccines Business Employee or Vaccines Group Company Employee and there is no existing dispute with any such
representative body (or, to the Seller’s Knowledge, pending or threatened) in relation to the Business (as carried on by the Vaccines Group); 

  

	 	15.3.3	there is no material litigation, claim or other dispute existing, nor to the Seller’s Knowledge, pending or threatened by or in respect of any Employees (or any former employees of the Vaccines Group Companies) in
respect of their employment or any matter arising from their employment; and 

  
  

 
 179 

	 	15.3.4	no Vaccines Group Company or Business Seller has, within the 2 years prior to the date of this Agreement, closed any plant or facility, effectuated any layoffs of employees or implemented any early retirement,
separation or similar programme in each case in violation of the WARN Act, nor has any Vaccines Group Company or Business Seller announced any such action or programme for the future. 

 

	15.4	No Key Personnel has given notice terminating his or her contract of employment, nor is under notice of dismissal. 

  

	15.5	To the Seller’s Knowledge, and subject to the next sentence, no Vaccines Group Company Employee will, as a result of the entering into of this Agreement or Closing, be entitled to receive any payment or benefit
which he would not otherwise be entitled to receive (including, without limitation, an enhanced severance package on a subsequent termination) or be entitled to treat either such event as amounting to a breach of his terms and conditions of
employment or to treat himself as redundant or dismissed or released from any obligation. This warranty shall not apply to any retention arrangements (in the form of cash or shares) put in place by the Seller or any member of the Seller’s Group
to retain key employees in connection with the matters contemplated by this Agreement as described in paragraphs 10 and 11 of Schedule 11, or any arrangement relating to the share-based incentive schemes of the Seller’s Group pursuant to
paragraph 11 of Schedule 11. 

  

	15.6	Since the Statement of Net Assets Date, no material change has been made, announced or proposed to the emoluments or other terms of employment of any Employee, and no such change, and no negotiation or request
for such a change, is due or expected within 12 months from the date of this Agreement, and the employing company is under no obligation to make such a change (with or without retrospective operation) other than any arrangement relating to the
share-based incentive schemes of the Seller’s Group pursuant to paragraph 11 of Schedule 11. 

  

	15.7	All the employees needed to carry on the Business (as carried on by the Vaccines Group) at the date of this Agreement at the Key Sites are employed by a Vaccines Group Company and, to the Seller’s Knowledge
(other than insofar as would not reasonably be expected to have a Material Adverse Effect) have not resigned and are not expected to resign their employment as a result of this Agreement or the transactions it contemplates. 

 

	16	Employee Benefits 

  

	16.1	The Disclosure Letter contains a true, complete and correct list of all bonus, staff incentives (including any share-based incentive schemes), redundancy or other benefits payable on termination of employment (whether
voluntary or involuntary but excluding arrangements required in accordance with Applicable Law), ill-health, Employee Benefits or other benefits which are the material benefits available to the Vaccines Business Employees and the Vaccines Group
Company Employees in the Material Employee Jurisdictions. To the Seller’s Knowledge, other than any arrangement relating to the share-based incentive schemes of the Seller’s Group pursuant to paragraph 11 of Schedule 11, no Vaccines Group
Company or Business Seller has made any promises or commitments to make available any additional benefits to the Vaccines Business Employees and the Vaccines Group Company Employees in the Material Employee Jurisdictions, or to modify or change in
any material way any existing benefits in the Material Employee Jurisdictions, or to continue or maintain the level of any existing benefits generally for any period, which in each case could reasonably be expected to have a Material Adverse Effect.

  
  

 
 180 

	16.2	The Disclosure Letter contains true and complete copies of all documents of any written benefit schemes, plans or arrangements referred to in paragraph 16.1 above applicable to either Vaccines Business Employees or
Vaccines Group Company Employees in the Material Employee Jurisdictions containing material terms (including governing documents, and for benefit plans that are not share-based incentive schemes, related trust agreements or other funding documents)
and a true, complete and correct summary of the material terms of any unwritten benefit schemes, plans or arrangements referred to in paragraph 16.1 above. 

  

	16.3	Benefit Plans 

  

	 	16.3.1	In the Material Employee Jurisdictions all benefit and compensation schemes, plans, funds, contracts, policies, agreements or arrangements (other than the US Benefit Plans and any schemes, plans, funds, contracts,
policies, agreements or arrangements operated by any Governmental Entity) (A) operated by or on behalf of a Vaccines Group Company or Business Seller, with respect to Vaccines Group Company Employees or Vaccines Business Employees or current or
former employees or directors of a Vaccines Group Company, (B) in respect of which any Vaccines Group Company or Business Seller, with respect to Vaccines Group Company Employees or Vaccines Business Employees, the Seller or any member of the
Seller’s Group contributes or has contributed or (C) in respect of which any Vaccines Group Company or Business Seller, with respect to Vaccines Group Company Employees or Vaccines Business Employees, has any liability (whether actual or
contingent), including, but not limited to, plans providing Employee Benefits or during periods of sickness or disablement, or any deferred or incentive compensation, welfare, healthcare, medical, stock or stock-related award plans, including
individual pension commitments, “jubilee” pension benefits and retirement and termination indemnity arrangements, and in relation to Switzerland, all plans, funds, contracts, policies, agreements or arrangements providing pension or other
benefits on retirement (such schemes, plans, funds, contracts, policies, agreements and arrangements hereinafter being referred to as “Non-US Benefit Plans”) and the US Benefit Plans have been administered in accordance with their terms
and are in compliance with Applicable Law, except for any failures to so administer or be in compliance that, individually and in the aggregate, would not reasonably be expected to have a Material Adverse Effect. All required filings for all Benefit
Plans have been made on time and with the appropriate Governmental Entity, except for any failures to timely file that, individually and in the aggregate, would not reasonably be expected to have a Material Adverse Effect. As of the date of this
Agreement, there is no existing, pending or, to the Seller’s Knowledge, threatened material litigation, claim or other dispute relating to Benefit Plans. 

  

	 	16.3.2	The Vaccines Group Companies or Business Sellers, with respect to Vaccines Group Company Employees or Vaccines Business Employees in each Material Employee Jurisdiction, (A) are in material compliance with all
Applicable Law respecting employment, employment practices, terms and conditions of employment, occupational health, safety, wages and hours, (B) have withheld all amounts required by Applicable Law, collective bargaining agreements or the
Benefit Plans to be withheld from the wages, salaries or other payments to the Vaccines Group Company Employees or the Vaccines Business Employees and former employees of the Vaccines Group Companies, (C) in respect of the Vaccines Group
Company Employees or Vaccines Business Employees or former employees of the Vaccines Group Companies, are not liable under any applicable provisions of the Benefit Plans and any Applicable Law for any arrears, wages, Taxes, other than payments not
yet due, or any penalty for failure to comply with the foregoing and (D) are not liable under any applicable provisions of the Benefit Plans and any Applicable Law for any payment to any trust or other fund or to any Governmental Entity with
respect to unemployment compensation benefits, workers compensation, social security or other benefits for Vaccines Group Company Employees or Vaccines Business Employees or former employees of the Vaccines Group Companies, other than payments not
yet due, except, in each case, for any failures to comply, failures to withhold or liabilities that, individually and in the aggregate, would not reasonably be expected to have a Material Adverse Effect. 

  
  

 
 181 

	 	16.3.3	All material contributions that the Vaccines Group Companies or Business Sellers, with respect to Vaccines Business Employees or the Vaccines Group Company Employees in a Material Employee Jurisdiction and Switzerland,
are required to make to any Benefit Plan in respect of the period on or before the date of this Agreement have been fully and timely paid when due. 

  

	17	Litigation 

  

	17.1	No Vaccines Group Company or Business Seller is involved whether as claimant or defendant or other party in any claim or Proceeding (other than as claimant in the collection of debts arising in the ordinary course of
its business none of which exceeds US$5 million) which is material to the Business. 

  

	17.2	To the Seller’s Knowledge, no such claim or Proceeding of material importance is pending or threatened by or against any Vaccines Group Company or Business Seller. 

 

	18	Insolvency 

  

	18.1	No order has been made and no resolution has been passed for the winding up of any Share Seller or any Business Seller, or for the appointment of any administrator, receiver (including administrative receiver) or
liquidator (provisional or otherwise) over the whole or any part of the property, assets and/or undertaking of any Share Seller or any Business Seller. 

  

	18.2	No petition has been presented or meeting convened for the purpose of considering a resolution or resolution circulated for the winding up of any Share Seller or any Business Seller, or for the appointment of any
administrator, receiver (including administrative receiver) or liquidator (provisional or otherwise) over the whole or any part of the property, assets and/or undertaking of any Share Seller or any Business Seller. 

 

	18.3	Neither any Share Seller nor any Business Seller has stopped payment or suspended payment of its debts generally, is insolvent or deemed unable to pay its debts as they fall due. 

 

	19	Insurance 

 All material insurance policies relating to the Vaccines Group are in full
force and effect and, to the Seller’s Knowledge, no notice of cancellation, termination or default has been received with respect to any such insurance policy. All premiums due and payable on such policies covering periods up to Closing have
been paid in full or accrued. 

  
  

 
 182 

	20	Consents and Licences 

  

	20.1	All governmental and quasi-governmental licences, consents, permissions, waivers, exceptions and approvals required for carrying on the Business of the Vaccines Group, the absence of which, individually or in the
aggregate, would be material to the Vaccines Group, are in force and, to the Seller’s Knowledge, no written notice has been received by the Seller or any member of the Seller’s Group which indicates that any such licence, consent,
permission, waiver, exception or approval is likely to be revoked or which may confer a right of revocation. 

  

	21	Delinquent and Wrongful Acts 

  

	21.1	To the Seller’s Knowledge, no member of the Seller’s Group has, during the Relevant Period, committed any criminal or illegal act which relates to the Vaccines Group Companies or the Vaccines Group Businesses.

  

	21.2	No member of the Seller’s Group has, during the Relevant Period, received notification that any investigation or inquiry is being or has been conducted by any supranational, national or local authority or
governmental agency specifically related to the Vaccines Group, which is material in respect of the Vaccines Group. 

  

	22	Compliance 

  

	22.1	No member of the Seller’s Group has received in the Relevant Period any written notification or written claim (in each case, which remains outstanding) that it has conducted the Business of the Vaccines Group with
respect to the research, development, manufacturing, distribution and sale of the Products in a manner which does not in any respect comply with all Applicable Law, or which in any respect is defective or dangerous, where the pursuit of any such
notification or claim is, or would reasonably be expected to be, material in respect of the Vaccines Group. 

  

	22.2	So far as the Seller is aware, the Vaccines Group has, and has during the Relevant Period been, operated in all material respects in compliance with all Applicable Law or standards and to the Seller’s Knowledge
there are no circumstances that could involve or lead to a material violation of any material Applicable Law or standards. 

  

	23	Pipeline Products 

  

	23.1	The Seller or one of its Affiliates is the registered holder of each of the Pipeline Product Approvals, and the benefit of each Pipeline Product Approval can be transferred to the Purchaser (or another member of the
Purchaser’s Group) regardless as to whether such transfer occurs directly (whether by way of transfer, reissuance or any other equivalent mechanism under Applicable Law of the relevant jurisdiction) or indirectly (through the transfer of the
Vaccines Group Companies). 

  

	23.2	All development activities in relation to the Pipeline Products have been conducted in the ordinary course and in accordance with all Applicable Law and standards and to the Seller’s Knowledge there are no
circumstances relating to the development of the Pipeline Products that could involve or lead to a material violation of any material Applicable Law or standards. 

 

	23.3	No material regulatory, clinical or safety event has occurred in relation to the Pipeline Products and no member of the Seller’s Group has received any notification or claim from any person of any such event (or
the possibility of any such event). 

  
  

 
 183 

	24	Manufacturing Licences and Manufacture 

  

	24.1	All Manufacturing Licences which are material to the Vaccines Group, are in effect and are validly held by a member of the Seller’s Group and during the Relevant Period, to the Seller’s Knowledge, no member of
the Seller’s Group has received any written notice of any suit, action or proceeding regarding the revocation or modification of any such Manufacturing Licence. 

 

	24.2	No directive, order or notice has been given to the Seller or any member of the Seller’s Group by any relevant regulatory authority to update, modify, amend, vary, supplement or delete any process and/or
methodology relevant to the manufacture at the Sites of any Product currently manufactured at the Sites and, so far as the Seller is aware, no such directive, order or notice is pending. 

 

	25	No Industrial Action 

 To the Seller’s Knowledge, there is no industrial action
currently taking place, threatened or expected which is, or is expected to be, material to the Business. 
  

	26	Ongoing Clinical Trials 

 Schedule 22 contains a complete list of all Ongoing Clinical
Trails. 

  
  

 
 184 

 Schedule 19 

Warranties given by the Purchaser under Clause 9.3 
  

	1	Authority and Capacity 

  

	1.1	Incorporation 

 The Purchaser is validly existing and is a company duly incorporated and
registered under the law of its jurisdiction of incorporation. 
  

	1.2	Authority to enter into Agreement 

  

	 	1.2.1	The Purchaser and each member of its Group has the legal right and full power and authority to enter into and perform this Agreement, any Ancillary Agreement to which it is a party and any other documents to be executed
by it pursuant to or in connection with this Agreement or any Ancillary Agreement. 

  

	 	1.2.2	The documents referred to in paragraph 1.2.1 will, when executed, constitute valid and binding obligations on the Purchaser and each member of its Group in accordance with their respective terms. 

 

	 	1.2.3	Except as referred to in this Agreement, the Purchaser: 

  

	 	(i)	is not required to make any announcement, consultation, notice, report or filing; and 

  

	 	(ii)	does not require any consent, approval, registration, authorisation or permit, 

 in each case
in connection with the performance of this Agreement or any other document referred to in paragraph 1.2.1. 
  

	 	1.2.4	The execution and delivery of the documents referred to in paragraph 1.2.1 and the performance by the Purchaser and each member of its Group of their respective obligations under them, will not: 

 

	 	(i)	result in a breach of any provision of the memorandum or articles of association or by laws or equivalent constitutional document of the relevant member of the Purchaser’s Group; 

 

	 	(ii)	result in a breach of, or constitute a default under, any instrument or contract to which the relevant member of the Purchaser’s Group is party or by which the relevant member of the Purchaser’s Group is bound
where such breach is material to their ability to perform their obligations under such documents; 

  

	 	(iii)	result in a breach of any existing order, judgment or decree of any court, Governmental Entity by which the relevant member of the Purchaser’s Group is bound and where such breach is material to their ability to
perform their obligations under such documents. 

  
  

 
 185 

	1.3	Authorisation 

 The Purchaser has taken, or will have taken by Closing, all corporate
action required by it to authorise it to enter into and to perform this Agreement, any Ancillary Agreement to which it is a party and any other documents to be executed by it pursuant to or in connection with this Agreement or any Ancillary
Agreement. 

  
  

 
 186 

 Schedule 20 

Pre-Closing Obligations 

(Clause 5.2) 
 Part 1

 Seller Restrictions 
 The actions
for the purposes of Clause 5.1.2 are: 
  

	1	amend or otherwise modify the constitutional documents of any Vaccines Group Company other than minor or administrative amendments or modifications which are not adverse to the Business or to the Purchaser of any member
of the Purchaser’s Group; 

  

	2	create, allot or issue, or grant an option or right to subscribe for or purchase, any share capital or other securities or loan capital of any Vaccines Group Company; 

 

	3	repay, redeem or repurchase any share capital, or other securities of any Vaccines Group Company; 

  

	4	make any acquisition or disposal which has a value in excess of US$10 million, exclusive of VAT; 

  

	5	grant any guarantee or indemnity for the obligations of any person which has a value in excess of US$5 million (other than in the ordinary course of trading); 

 

	6	dispose of, or agree to dispose of, any material asset or material stock at below market value other than in the ordinary course of business; 

 

	7	acquire or agree to acquire any share, shares or other interest in any company, partnership or other venture, other than an investment of 5 per cent or less of the total shares or interest in such company,
partnership or venture and provided the investment is not more than US$5 million; 

  

	8	enter into, extend, amend, give notice to terminate or vary in any material respect any lease of real property or change the existing use of such property which is material to the Vaccines Group; 

 

	9	cease, compromise or settle any dispute including litigation, arbitration or administrative proceedings in relation to (or otherwise compromise or settle) any claim by Pfizer which relates to any form of meningococcal
vaccine (Group B) whether adjuvanted, combined or otherwise (or any similar product) of Pfizer or enter into any licensing arrangements with Pfizer in relation to such products or Intellectual Property Rights relevant to them; 

 

	10	enter into any borrowing facility which has a value in excess of US$10 million; 

  

	11	enter into any off-balance sheet finance arrangements; 

  

	12	sell, lease, license, transfer or dispose of, or create any Encumbrance over, any material assets of the Vaccines Group other than (i) in the ordinary course of business (including any sale of inventory); or
(ii) any Permitted Encumbrance; 

  

	13	(a) terminate, materially amend (or amend in any respect in relation to a Product or Pipeline Product which is material to the Business) or grant any material waiver under (or any waiver in relation to a Product or
Pipeline Product which is material to the Business) any Vaccines Group Intellectual Property Contract or the Merck 2012 Licence or (b) terminate any Transferred Contract other than in the ordinary course of business or terminate any Contract
held by the Vaccines Group Companies other than in the ordinary course of business; 

  
  

 
 187 

	14	fail to comply in all material respects with all Applicable Law, Product Approvals, Pipeline Product Approvals and Marketing Authorisations applicable to the operation of the Business; 

 

	15	assign, dispose of, license (save in respect of non-exclusive licences relating to the Seller’s research, development or Commercialisation of the Products) abandon any material Vaccines Group Intellectual Property
Rights (or any Vaccines Group Intellectual Property Rights in respect of a Product or Pipeline Product which is material to the Business), or cease to prosecute or otherwise dispose of, fail to maintain, defend or pursue applications for any
material Registered Vaccines Group Intellectual Property Rights (or any Registered Vaccines Group Intellectual Property Rights in respect of a Product or Pipeline Product which is material to the Business); 

 

	16	save where requested in writing by the Purchaser or required by any applicable Governmental Entity, cancel, surrender or materially amend (or amend in any respect in relation to a Product or Pipeline Product which is
material to the Business) any applications, submissions or filings with respect to Registered Vaccines Group Intellectual Property Rights; 

  

	17	instigate, cease, compromise or settle any litigation or arbitration proceedings related to the Vaccines Group in relation to a claim for which the potential liability attaching thereto is in excess of US$5
million; 

  

	18	make any material amendment to any Marketing Authorisation, Manufacturing Licence or Environmental Permit, in each case except to the extent required by: (a) Applicable Law; (b) any Governmental Entity, or
(c) the standards, policies and procedures of the Seller’s Group as then in force; 

  

	19	enter into or amend in any material respect any Transferred Contract, or incur any commitment, which is not capable of being terminated without compensation at any time with twelve months’ notice or less or which
is not in the ordinary course of business, or which involves or may involve total annual expenditure in excess of US$10 million, exclusive of VAT; 

  

	20	enter into any contract which would materially restrict the freedom of the Vaccines Group to operate in any part of the world; 

  

	21	terminate (except for good cause) the employment of any Key Personnel; 

  

	22	take any steps to increase or reduce the proportion of time spent working in the Business (as carried on by the Vaccines Group) by any employee of any member of the Seller’s Group or to transfer the employment of
any Employee to another member of the Seller’s Group or to employ or offer to employ or engage any new persons in the Business (as carried on by the Vaccines Group) other than in the ordinary course of business consistent with past practice and
subject to an aggregate increase of not more than 2.5 per cent. in total staff costs of the Business (as carried on by the Vaccines Group) per annum, provided that this restriction shall not apply to the redeployment of any Vaccines Group
Company Employee who is not wholly or substantially engaged in the Business (as carried on by the Vaccines Group) before the Closing Date to employment with another member of the Seller’s Group; 

  
  

 
 188 

	23	make, or commit to make, any changes to the terms and conditions of employment (including pension fund commitments or any increase to remuneration) or to any employee benefit plan of any Employee, other than
(a) those required by Applicable Law or (b) pursuant to normal annual pay reviews in the ordinary course of business consistent with past practice and subject to an aggregate increase of not more than five per cent. in total staff costs of
the Business (as carried on by the Vaccines Group) per annum or (c) retention arrangements in the form of cash or shares to retain key employees in connection with the matters contemplated by this Agreement as described in paragraphs 10 and 11
of Schedule 11, or (d) those changes to the share-based incentive schemes made for the purpose of complying with paragraph 11 of Schedule 11; 

  

	24	make any promises or commitment to any Employees or employee representative body concerning the matters contemplated by this Agreement or offer or otherwise give any assurances to any Employees as to the possibility of
continued employment with the Purchaser’s Group after Closing; 

  

	25	make any change or commitment to make any change to the terms of any redundancy policy or practice applying to the Employees (including amounts payable on redundancy); 

 

	26	enter into (where there is no existing agreement) or materially amend any collective bargaining agreement or other contract with a labour organisation, works council or employee organisation to create new or additional
obligations for any member of the Seller’s Group, in each case in relation to the Business (as carried on by the Vaccines Group); and 

  

	27	undertake any recall or withdrawal of any Product (other than in the ordinary course of business or to comply with Applicable Law). 

  
  

 
 189 

 Part 2 

Seller Obligations 
  

	1	Obligations Prior to be Satisfied prior to the Closing 

 At least five Business Days
prior to the Closing Date, the Seller shall provide the Purchaser with a list of any required actions that must be taken within three (3) months after Closing with respect to the payment of any registration, maintenance, or renewal fees or the
filing of any documents, applications or certificates in order to maintain any Registered Vaccines Group Intellectual Property Rights in full force and effect. Upon the Purchaser’s reasonable request, the Seller shall execute and deliver
assignment agreements and other transfer documentation, including, where applicable, duly executed assignments of such Registered Vaccines Group Intellectual Property Rights for recording with the applicable Governmental Entity, and to take such
further actions, in each case at the Purchaser’s reasonable cost and expense and as may be required, to give effect to the foregoing assignments. 
  

	2	Obligations from the Date of the Agreement to the Closing 

 The requirements for the
purposes of Clause 5.1.3 are: 
  

	2.1	so far as permitted by Applicable Law, the Seller shall procure that each member of the Seller’s Group informs the Purchaser promptly if the Seller becomes aware of, or has reasonable grounds for suspecting any
violation of Anti-Bribery Law which is reasonably likely to have an impact on the Vaccines Group, and 

  

	2.2	carry out capital expenditure in relation to any site operated by the Vaccines Group where the Products are manufactured in a manner materially consistent (and within a variance of 10 per cent. in aggregate) with
the Seller’s capital expenditure programme for the Business as at the date of this Agreement; 

  

	2.3	maintain and keep any Registered Vaccines Group Intellectual Property Rights and ensure that all filings and notifications required to be made in respect of the same are made in accordance with past practice;

  

	2.4	progress, in accordance with past practice any applications, submissions, filings or other correspondence relating to the grant of new Registered Vaccines Group Intellectual Property Rights; 

 

	2.5	progress, in accordance with past practice during the Relevant Period, any applications, submissions, filings or other correspondence initiated by such member of the Seller’s Group relating to the grant of new
Manufacturing Licences and Environmental Permits in respect of the Vaccines Group; 

  

	2.6	continue to promote, market and Commercialise the Products in accordance with past practice during the Relevant Period and do not materially accelerate or increase the quantity of Products distributed to the relevant
distributors and/or wholesalers, in each case except in respect of a bona fide increase in demand for the relevant Product by the relevant distributor and/or wholesaler which has not been stimulated in any way by discounts, rebates, claw-backs or
the like outside of the ordinary course of business or the grant of preferred terms offered by the Seller’s Group outside of the ordinary course; 

  
  

 
 190 

	2.7	not discontinue or cease to operate or materially reduce the resources applied to any part of the Business; 

  

	2.8	maintain the level of Manufacturing Stocks and Manufacturing Inventory held for use in the Business materially in accordance with the Seller’s Group’s operating policies as applied to the Vaccines Group from
time to time in force; 

  

	2.9	maintain the level of In-Market Inventory held for use in the Business materially in accordance with the Seller’s Group’s operating policies as applied to the Vaccines Group from time to time in force;

  

	2.10	use all reasonable endeavours to ensure that the manufacture of the Products by the Seller’s Group comply with Applicable Law; 

  

	2.11	use all reasonable endeavours to ensure that the Products sold by the Business comply with Applicable Law; 

  

	2.12	continue to conduct the Ongoing Clinical Trials in accordance with GCP and the Seller Group’s policies and procedures; and 

  

	2.13	notify the Purchaser in writing of any actual safety or quality issue in respect of any Product or the manufacture of any Product (as soon as reasonably practicable after becoming aware of the same) which issue the
relevant member of the Seller’s Group, acting reasonably and in good faith, considers material in the context of the manufacture or commercialisation of such Product. 

 

	2.14	so far as permitted by Applicable Law, report periodically to the Purchaser concerning the status of the Business, including delivering to the Purchaser as soon as reasonably practicable each month: 

 

	 	2.14.1	an update on material commercial developments in relation to the Business and the Products during the previous month; 

  

	 	2.14.2	the gross profit for each Product in respect of the previous month; and 

  

	2.15	a report on the month-end in-trade inventory in respect of each Product for the previous month prepared in the ordinary course of business consistent with past practice, together with a comparison against the comparable
period of trading for the prior year; 

  

	2.16	use all reasonable endeavours to obtain a waiver in relation to the Transaction from the joint venture partner in Zhejiang Tianyuan Bio-Pharmaceutical Co. Ltd in respect of the joint venture partner’s rights of
first refusal; and 

  

	2.17	shall or shall procure that each member of the Seller’s Group continues to respond to any Calls For Tender in accordance with past practices in the relevant market. 

  
  

 
 191 

 Part 3 

Exceptions 
 Clause 5.1 shall not operate
so as to prevent or restrict the declaration, making or payment of any dividend or other distribution to shareholders. 

  
  

 
 192 

 Schedule 21 

Key Employees 
 (Clause
1.1) 
 [***] 
  

 

	*** 	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
  

 
 193 

 Schedule 22 

Ongoing Clinical Trials 

(Clause 1.1) 
  

	3	Ongoing interventional trials 

 [***] 

 

	4	Ongoing observational Trials 

 [***] 

 
  

	*** 	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
  

 
 194 

 Schedule 23 

Statement of Net Assets 

(Clause 1.1) 
 Part 1

 Statement of Net Assets Rules 

Part 1 of Schedule 23 comprises the Statement of Net Assets Rules. 

Part 2 of Schedule 23 sets forth, for illustrative purposes only, a computation of the Statement of Net Assets as of the close of business on 31 December
2013 (the “Statement of Net Assets”). 
  

	1	Preparation of the Statement of Net Assets 

  

	1.1	Period 

 The Statements of Net Assets is prepared as of the close of business on the
final day of the relevant calendar month. 
  

	1.2	Translation of Reporting Entity’s Statements of Net Assets 

 A reporting entity
reports in local currency. All reports are translated into US dollars by the Seller for reporting purposes. The Statement of Net Assets is translated with the period-end exchange rates which are the rates provided by Novartis Group Treasury and are
based on Bloomberg’s mid-morning CET exchange rates and are published in the Group Treasury section of the Novartis intranet. 
  

	1.3	Novartis Reporting System and Materiality: 

  

	 	1.3.1	Financial information is obtained from the Financial Consolidation & Reporting System of Novartis and the supporting general ledgers are prepared in accordance with Novartis’ Accounting Manual (the
“NAM”). The Financial Consolidation & Reporting System is the system of record for Novartis external reporting. References in the Statement of Net Assets included as part 2 of this Schedule 23 shown as “BS01 lines
010-671” relate to the groupings shown in Novartis’ monthly reporting form “BS01 – Balance sheet”. 

  

	 	1.3.2	For the Seller’s reporting purposes, the financial reporting of a legal entity is separated into a divisional part, which includes operating items and a corporate part, which mainly captures the amounts
related to taxes, post-employment benefit obligations and most of the financial assets and liabilities. The Statement of Net Assets contains the business of the Vaccines division (including the Influenza Business) as included in Novartis’
segment reporting (column C - “Vaccines Divisional Reported Statement of Net Assets”), and items of the corporate Statement of Net Assets for the Vaccines Group Companies (Column D – “Vaccines Statement of Net Assets of the
Corporate part of the Vaccines Group Companies” and items related to the Statement of Net Assets for the Novartis Vaccines Institute for Global Health (column E – “Statement of Net Assets of the part of Novartis Vaccines Institute for
Global Health”) as well as adjustments for certain items which are either excluded from or added to the transaction (columns F -“Excluded items”). A US$10 million threshold was applied. Column H shows the impact of the Influenza
Business which is excluded from the transaction. For the purpose of the carve out of the Influenza Business allocations have been made based on management’s best estimate of the contribution of the Influenza Business. For Receivables own BU
(BS01_130) and Payables own BU (BS01_620) items related to the entity in Liverpool, which will not transfer have been added back into the statement of net assets. For other entities amounts related to the Influenza Business have not been added back
in as they are offsetting each other. Payables and Receivables to Other BU’s related to the Influenza Business have been left in the statement of net assets as they are not expected to be material on a net basis. A materiality threshold of US$
50million applies to the Influenza Business. 

  
  

 
 195 

	 	1.3.3	The Statement of Net Assets has been prepared as follows: 

  

	 	(i)	in accordance with the specific accounting treatments set out below; and, subject thereto, 

  

	 	(ii)	adopting the same accounting principles, methods, procedures and practices utilized in preparing the consolidated financial statements of Novartis AG as described in the Novartis Accounting Manual applied on a
consistent basis using consistent estimation methodologies and judgments and with consistent classifications and, subject thereto, 

  

	 	(iii)	in accordance with IFRS. 

  

	 	1.3.4	For the avoidance of doubt, paragraph 1.3.3(i) shall take precedence over paragraphs 1.3.3(ii) and 1.3.3(iii), and paragraph 1.3.3(ii) shall take precedence over paragraph 1.3.3(iii). 

 

	2	Specific Policies 

 The following supplement the description in the NAM for certain items
included in the Vaccines Group Statement of Net Assets: 
  

	2.1	Non-Current assets 

  

	 	2.1.1	Property, plant and equipment (BS01_010) 

 For the purpose of the Vaccines Divisional
Statement of Net Assets an amount of US$122 million is included for assets which are not dedicated to the Vaccines Group and will not transfer to the Purchaser (as reflected in Column F). These assets comprise all property, plant and equipment
located in Emeryville, California and in Pernambuco, Brazil. 
  

	 	2.1.2	Financial assets &– subsidiaries/JV (BS01_040) 

 This line reflects equity
investments that Vaccines Group Companies hold in other Vaccines Group Companies. These relationships have been eliminated in the Statement of Net Assets (as reflected in Column F). 

 

	 	2.1.3	Total financing and loans to subsidiaries/JV (BS01_050) 

 This line represents financing
owed by any member of the Seller’s Group to a Transferred Subsidiary. For the purpose of the Statement of Net Assets balances within the Vaccines Group have been excluded (as reflected in Column F). 

  
  

 
 196 

	2.2	Current Assets: 

  

	 	2.2.1	Trade receivables (BS01_120) 

 An amount of US$51 million of trade receivables is
excluded from this Statement of Net Assets (as reflected in Column F) as it relates to non-Vaccines business activity such as licence fee receivables related to HCV and HIV patents. 

 

	 	2.2.2	Receivables own BU (BS01_130) 

 Column C of the Statement of Net Assets represents
receivables against other entities within the Vaccines division, which are offset by an equivalent amount in the line Payables own BU. These amounts have been eliminated in Column F of the Statement of Net Assets. 

 

	 	2.2.3	Receivables own BU – Corporate and Institute for Global Health (BS01_130) 

 Columns
D and E of the Statement of Net Assets represent receivables against other members of the Seller’s Group as well as other Vaccines Group Companies. The receivables against other Vaccines Group Companies have been eliminated in Column F of the
Statement of Net Assets. 
  

	 	2.2.4	Receivables other BU’s (BS01_140) 

 Receivables recognized on this line are due
from members of the Seller’s Group operating in the Pharmaceuticals and Sandoz segments which are selling vaccines in markets where the Vaccines Group is not represented. The receivable of the Vaccines Institute for Global Health relates to a
Transferred Subsidiary and has therefore been eliminated. 
  

	 	2.2.5	Other current assets (BS01_160) 

 An amount of US$5 million is related to current assets
of the divested Diagnostics business, which did not transfer to the purchaser of the Diagnostics business. They are excluded from the Statement of Net Assets as they do not relate to the activities of the Vaccines Group (as reflected in Column F).
Furthermore, an amount of US$1 million is related to assets of the plant in Pernambuco, Brazil which will not be transferred and has therefore been excluded (as reflected in Column F) from the Statement of Net Assets. 

 

	 	2.2.6	Prepaid share-based payments (BS01_161) 

 An asset for prepaid share-based compensation
is recognized to reflect Novartis’ internal charge-out mechanism for its equity settled share-based compensation plans. For entities settling the charge for the shares at the beginning of the vesting period, it reflects the expense yet to be
recognized for the unvested part of a share-based compensation plan. This asset has been excluded (as reflected in Column F) and is not reflected in the Statement of Net Assets. 

 

	2.3	Long-term Liabilities: 

  

	 	2.3.1	Total financing and loans from subsidiaries/JV (BS01_520) 

 This line represents
financing received from any member of the Seller’s Group. For the purpose of the Statement of Net Assets, balances within the Vaccines Group have been excluded (as reflected in Column F). 

  
  

 
 197 

	 	2.3.2	Other non-current liabilities (BS01_540) 

 Column F excludes net liabilities for
post-employment benefits of US$90 million included in the corporate part of the Vaccines Group Companies as their treatment is addressed separately in Schedule 12. 
  

	2.4	Current Liabilities: 

  

	 	2.4.1	Trade payables (BS01_610) 

 An amount of US$11 million included in this line relates to
the construction of the plant in Pernambuco, Brazil which will not be transferred and has therefore been excluded (as reflected in Column F) from the Statement of Net Assets. 
  

	 	2.4.2	Payables own BU (BS01_620) 

 Column C of the Statement of Net Assets represents payables
against other entities within the Vaccines division, which are offset by an equivalent amount in the line Receivables own BU. These amounts have been eliminated in the Statement of Net Assets. 

 

	 	2.4.3	Payables own BU – Corporate (BS01_620) 

 Column D of the Statement of Net Assets
represents payables against other Vaccines Group Companies as well as payables against other members of the Seller’s Group. The corporate payables against Vaccines Group Companies have been eliminated in Column F of the Statement of Net Assets.

  

	 	2.4.4	Payables other BU’s (BS01_630) 

 Payables recognized on this line are due to
members of the Sellers’ Group, except for a payable recognized by the Vaccines Institute for Global Health, which is owed to a Vaccines Group Company and has therefore been eliminated. 

 

	 	2.4.5	Accrued and other current liabilities (BS01_670) 

 An amount of US$35 million is related
to short term liabilities of the divested Diagnostics business, which did not transfer to the purchaser of this Diagnostics business. They are excluded from the Statement of Net Assets (as reflected in Column F) as they do not relate to the
activities of the Vaccines Group. Furthermore, an amount of US$3 million relates to the construction of the plant in Pernambuco, Brazil, which will not be transferred and has therefore also been excluded (as reflected in Column F) from the Statement
of Net Assets. An amount of US$1 million relates to legal fees for litigation not related to the Vaccines Group. 
  

	 	2.4.6	Accrued share-based payments (BS01_671) 

 A liability for share-based compensation is
recognized to reflect Novartis’ internal charge-out mechanism for its equity-settled share-based compensation plans. For entities settling the charge for the shares after the vesting period, it reflects the expense recognized for the vested
part of a share based compensation plan. This liability has been excluded (as reflected in Column F) and is not reflected in the Statement of Net Assets. 

  
  

 
 198 

 Part 2 

Statement of Net Assets 
 All amounts in $
thousands 
  

																																					
	 	  	Column A	 	  	Column B	 	  	Column C	 	  	Column D	 	  	Column E	 	  	Column F	 	  	Column G	 	  	Column H	 	  	Column I	 
	 	  	Vaccines
Dataroom
balance
sheet
Dec 31,
2013	 	  	Adjustments*	 	  	Vaccines
Divisional
Reported
Statement
of Net
Assets at
Dec 31,
2013	 	  	Vaccines
Statement
of Net
Assets of
the
Corporate
part of the
Vaccines
Group
Companies	 	  	Statement
of Net
Assets of
the part of
Novartis
Vaccines
Institute
for Global
Health	 	  	Excluded
items	 	  	Vaccines
Group
Statement
of Net
Assets
Dec 31,
2013	 	  	Influenza
business	 	  	Vaccines
Group
(excl.
Influenza
business)
Statement
of Net
Assets
Dec 31,
2013	 
	 BS01_010 Property, plant and equipment
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	729,492	  
	 BS01_020 Intangible assets
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	1,853,635	  
	 BS01_034 Financial assets_ associated companies
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	777	  
	 BS01_035 Financial assets - 3rd parties and loans to AC
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	17,981	  
	 BS01_040 Financial assets & subsidiaries//JV
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	0	  
	 BS01_042 Deferred tax assets
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	78,951	  
	 BS01_044 Other non-current non-financial assets
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	23,129	  
	 BS01_050 Total financing and loans to subsidiaries / JV
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	58,563	  
	 BS01_110 Total inventories
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	400,663	  
	 BS01_120 Trade receivables (3rd parties and AC)
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	335,387	  
	 BS01_130 Receivables own BU
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	21,818	  

  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
  

 
 199 

																																					
	 	  	Column A	 	  	Column B	 	  	Column C	 	  	Column D	 	  	Column E	 	  	Column F	 	  	Column G	 	  	Column H	 	  	Column I	 
	 BS01_130 Receivables own BU – Corporate and Institute for Global Health
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	865	  
	 BS01_140 Receivables other BU’s
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	20,419	  
	 BS01_160 Other current assets (3rd parties and AC)
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	70,207	  
	 BS01_161 Prepaid share-based payments
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  				  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	0	  
	 BS01_180 Cash & cash equivalents
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  				  	 	4,393	  
	 Total Assets
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	3,616,280	  
	 Bs01_511 Financial debt – long-term
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  				  	 	8	  
	 BS01_520 Total financing and loans from subsidiaries// JV
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	680,633	  
	 BS01_535 Deferred tax liabilities
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	92,072	  
	 BS01_540 Other non-current liabilities (3rd parties and AC)
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	54,071	  
	 BS01_610 Trade payables (3rd parties and AC)
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	176,115	  
	 BS01_620 Payables own BU
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	15,056	  
	 BS01_620 Payables own BU – Corporate
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	3,239	  
	 BS01_630 Payables other BU’s
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	40,675	  
	 BS01_651 Financial debt – Short-term (3rd parties and AC)
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	1,395	  

  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
  

 
 200 

																																					
	 	  	Column A	 	  	Column B	 	  	Column C	 	  	Column D	 	  	Column E	 	  	Column F	 	  	Column G	 	  	Column H	 	  	Column I	 
	 BS01_660 Income taxes payable
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	55,060	  
	 BS01_670 Accrued and other current liabilities (3rd parties and AC)
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	238,671	  
	 BS01_671 Accrued share-based payments
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	0	  
	 Total Liabilities
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	1,356,995	  
	 Net Assets
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	2,259,285	  

  

	*	The difference for BS01_010 Property, plant and equipment relates to the plant built in Pernambuco Brazil, which had been excluded in the dataroom balance sheet. 

The difference for BS01_160 Other current assets is composed of other current assets related to the Diagnostics Business, but which have not been transferred
to Grifols; these were excluded in the dataroom balance sheet. 
 Line BS01_620 and Line BS01_630 have been combined into the line Intercompany payable in
the dataroom balance sheet and items related to Pernambuco have been excluded. 
 The difference for BS01_670 Accrued and other current liabilities is
composed of items related to the Diagnostics business, which have not been transferred to Grifols and were therefore excluded in the dataroom balance and items related to the Plant in Pernambuco, which have also been excluded in the dataroom balance
sheet. 
  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
  

 
 201 

 Schedule 24 

Regulatory Approvals 
 The following table
provides the additional jurisdictions and applicable antitrust, merger control, or foreign investment rules referenced in Clause 4.1.3. 
 This list of
jurisdictions and statutes is not meant to be indicative of a known filing or approval requirement in these jurisdictions. To the extent that clearances, approvals, waivers, no action letters or consents are not required to be obtained or not
otherwise agreed by the parties to be appropriate, and waiting periods are not required to have expired in these jurisdictions, prior to Closing, such clearances, approvals, waivers, no action letters, consents, and waiting period expirations will
not be conditions precedent to Closing 
  

			
	Country		Statute Under Which Filing/Approval is Required
		
	Australia		The Competition and Consumer Act of 2010
		
	Brazil		Law No. 12,529 of November 30, 2011
		
	Canada		The Competition Act
		
	China		The Chinese Anti-Monopoly Law
		
	India		The Competition Act of 2002, as amended by The Competition (Amendment) Act of 2007
		
	Israel		The Restrictive Trade Practices Law, 5748-1988
		
	Japan		The Act on Prohibition of Private Monopolisation and Maintenance of Fair Trade No. 54 of 1947
		
	Mexico		The Federal Law on Economic Competition
		
	New Zealand		The Commerce Act of 1986
		
	Russia		Federal Law No. 135-FZ of July 16, 2006 on Protection of Competition
		
	South Africa		The Competition Act 89 of 1998
		
	South Korea		The Monopoly Regulation and Fair Trade Act
		
	Taiwan		The Fair Trade Law of 1991
		
	Turkey		The Law on Protection of Competition No. 4054 of 1994

  
  

 
 202 

 Table of Contents 

 
  

							
	Contents	  	Page	 
			
	 1
	 	Interpretation	  	 	1	  
			
	 2
	 	Sale and Purchase of the Vaccines Group	  	 	29	  
			
	 3
	 	Consideration	  	 	35	  
			
	 4
	 	Conditions	  	 	37	  
			
	 5
	 	Pre-Closing	  	 	43	  
			
	 6
	 	Closing	  	 	46	  
			
	 7
	 	Post-Closing Adjustments	  	 	49	  
			
	 8
	 	Post-Closing Obligations	  	 	51	  
			
	 9
	 	Warranties	  	 	59	  
			
	 10
	 	Limitation of Liability	  	 	61	  
			
	 11
	 	Claims	  	 	64	  
			
	 12
	 	Restrictive Covenants	  	 	65	  
			
	 13
	 	Confidentiality	  	 	67	  
			
	 14
	 	Insurance	  	 	69	  
			
	 15
	 	France Business and Netherlands Business	  	 	70	  
			
	 16
	 	Other Provisions	  	 	71	  
		
	 Schedule 1 Details of the Share Sellers, Shares etc. (Clause 2.1)
	  	 	80	  
		
	 Schedule 2 Companies, Subsidiaries and Minority Interest Entities
	  	 	81	  
		
	 Schedule 3 The Properties Part 1 (Company Real Property)
	  	 	86	  
		
	 Schedule 3 The Properties Part 2 (Transferred Real Property)
	  	 	88	  
		
	 Part B Transferred Leased Real Property
	  	 	89	  
		
	 Schedule 3 The Properties Part 3 Terms relating to the Company Real Property
	  	 	90	  
		
	 Schedule 3 The Properties Part 4 Terms relating to the Transferred Real Property
	  	 	94	  

  
  

 
 1 

			
		
	 Schedule 4 Vaccines Group Intellectual Property Rights and Vaccines Group Intellectual Property Contracts (Clause 2.3)
		106
		
	 Schedule 5 Excluded Employees (Clause 1.1)
		107
		
	 Schedule 6 International Assignees (Clause 1.1)
		108
		
	 Schedule 7 Permitted Encumbrances (Clause 1.1)
		109
		
	 Schedule 8 Product Approvals and Product Applications Part 1 Terms relating to the Product Approvals and Product Applications
		110
		
	 Schedule 8 Product Approvals and Product Applications Part 2 Transfer of Marketing Authorisations
		112
		
	 Schedule 8 Product Approvals and Product Applications Part 3 List of Products, Products Under Registration and Pipeline
Products
		118
		
	 Schedule 8 Product Approvals and Product Applications Part 4 Tenders
		120
		
	 Schedule 9 Certificate (Clause 1.1)
		121
		
	 Schedule 10 Transferred Contracts (Clause 2.3)
		122
		
	 Schedule 11 Employees (Clause 2.4.1)
		125
		
	 Schedule 12 Employee Benefits (Clause 2.4.2)
		140
		
	 Schedule 13 Allocation of Purchase Price (Clauses 3.3 and 7.6)
		148
		
	 Schedule 14 VAT (Clause 3.4)
		149
		
	 Schedule 15 Closing Obligations (Clause 6)
		151
		
	 Schedule 16 Post Closing Adjustments (Clause 7)
		153
		
	 Schedule 17 Milestone and Royalty Payments
		160
		
	 Schedule 18 Warranties given under Clause 9.1
		167
		
	 Schedule 19 Warranties given by the Purchaser under Clause 9.3
		185
		
	 Schedule 20 Pre-Closing Obligations (Clause 5.2)
		187
		
	 Schedule 21 Key Employees (Clause 1.1)
		193
		
	 Schedule 22 Ongoing Clinical Trials (Clause 1.1)
		194
		
	 Schedule 23 Statement of Net Assets (Clause 1.1)
		195
		
	 Schedule 24 Regulatory Approvals
		202

  
  

 
 2 

 Schedule 2 

Amended Disclosure Letter 
 [***] 

 

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions, consisting of 91 pages, have been omitted from this filing and have been filed
separately with the Securities and Exchange Commission 

  
  

 
 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}]]